FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Rho, M Camacho-Soto, A Cheng, A Havran, M Morone, NE Rodriguez, E Shega, J Weiner, DK AF Rho, Monica Camacho-Soto, Alejandra Cheng, Abby Havran, Mark Morone, Natalia E. Rodriguez, Eric Shega, Joseph Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment. Part VIII: Lateral Hip and Thigh Pain SO PAIN MEDICINE LA English DT Article DE Lateral Hip Pain; Greater Trochanteric Pain Syndrome; Chronic Low Back Pain; Thigh Pain; Iliotibial Band Pain; Lumbar Radiculopathy; Lumbar Radiculitis; Hip Osteoarthritis; Lumbar Spinal Stenosis; Meralgia Paresthetica; Diagnostic Algorithm; Elderly ID LUMBAR DISC HERNIATION; NERVE STRETCH TEST; ILIOTIBIAL BAND; NONOPERATIVE TREATMENT; MERALGIA-PARESTHETICA; OSTEOARTHRITIS; RUNNERS; RADICULOPATHY; IMPINGEMENT; FLEXIBILITY AB Objective. This article presents an evidence-based algorithm to assist primary care providers with the diagnosis and management of lateral hip and thigh pain in older adults. It is part of a series that focuses on coexisting pain patterns and contributors to chronic low back pain (CLBP) in the aging population. The objective of the series is to encourage clinicians to take a holistic approach when evaluating and treating CLBP in older adults. Methods. A content expert panel and a primary care panel collaboratively used the modified Delphi approach to iteratively develop an evidence-based diagnostic and treatment algorithm. The panelists included physiatrists, geriatricians, internists, and physical therapists who treat both civilians and Veterans, and the algorithm was developed so that all required resources are available within the Veterans Health Administration system. An illustrative patient case was chosen from one of the author's clinical practices to demonstrate the reasoning behind principles presented in the algorithm. Results. An algorithm was developed which logically outlines evidence-based diagnostic and therapeutic recommendations for lateral hip and thigh pain in older adults. A case is presented which highlights the potential complexities of identifying the true pain generator and the importance of implementing proper treatment. Conclusions. Lateral hip and thigh pain in older adults can contribute to and coexist with CLBP. Distinguishing the true cause(s) of pain from potentially a myriad of asymptomatic degenerative changes can be challenging, but a systematic approach can assist in identifying and treating some of the most common causes. C1 [Rho, Monica; Cheng, Abby] Northwestern Univ, McGaw Med Ctr, Rehabil Inst Chicago, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. [Camacho-Soto, Alejandra] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Havran, Mark] VA Cent Iowa Hlth Care Syst, Extended Care & Rehab, Des Moines, IA USA. [Havran, Mark] Des Moines Univ, Des Moines, IA USA. [Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Rodriguez, Eric; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Shega, Joseph] VITAS Healthcare, Miami, FL USA. [Weiner, Debra K.] Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Dept Anesthesiol, Pittsburgh, PA USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. Drs. Monica Rho and Alejandra Camacho-Soto are co-first authors. NR 45 TC 1 Z9 1 U1 9 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JUL PY 2016 VL 17 IS 7 BP 1249 EP 1260 DI 10.1093/pm/pnw111 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DZ1WK UT WOS:000385632100008 ER PT J AU Liu, J Wang, PP Douglas, SL Tate, JM Sham, S Lloyd, SG AF Liu, Jian Wang, Peipei Douglas, Samuel L. Tate, Joshua M. Sham, Simon Lloyd, Steven G. TI Impact of high-fat, low-carbohydrate diet on myocardial substrate oxidation, insulin sensitivity, and cardiac function after ischemia-reperfusion SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE diet; myocardial ischemia-reperfusion injury; insulin; metabolism ID KETONE-BODY METABOLISM; PERFUSED RAT-HEART; LOW-FLOW ISCHEMIA; ACID OXIDATION; MITOCHONDRIAL METABOLISM; GLUCOSE-TOLERANCE; KETOGENIC DIET; OBESE RATS; INJURY; RESISTANCE AB High-fat, low-carbohydrate Diet (HFLCD) impairs the myocardial response to ischemia-reperfusion, but the underlying mechanisms remain elusive. We sought to determine the magnitude of diet-induced alterations in intrinsic properties of the myocardium (including insulin sensitivity and substrate oxidation) and circulating substrate and insulin differences resulting from diet, leading to this impaired response. Rats were fed HFLCD (60% kcal from fat/30% protein/10% carbohydrate) or control diet (CONT) (16%/19%/65%) for 2 wk. Isolated hearts underwent global low-flow ischemia followed by reperfusion (I/R). Carbon-13 NMR spectroscopy was used to determine myocardial substrate TCA cycle entry. Myocardial insulin sensitivity was assessed as dose-response of Akt phosphorylation. There was a significant effect of HFLCD and I/R with both these factors leading to an increase in free fatty acid (FFA) oxidation and a decrease in carbohydrate or ketone oxidation. Following I/R, HFLCD led to decreased ketone and increased FFA oxidation; the recovery of left ventricular (LV) function was decreased in HFLCD and was negatively correlated with FFA oxidation and positively associated with ketone oxidation. HFLCD also resulted in reduced insulin sensitivity. Under physiologic ranges, there were no direct effects of buffer insulin and ketone levels on oxidation of any substrate and recovery of cardiac function after I/R. An insulinketone interaction exists for myocardial substrate oxidation characteristics. We conclude that the impaired recovery of function after ischemia-reperfusion with HFLCD is largely due to intrinsic diet effects on myocardial properties, rather than to diet effect on circulating insulin or substrate levels. C1 [Liu, Jian; Douglas, Samuel L.; Tate, Joshua M.; Sham, Simon; Lloyd, Steven G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Wang, Peipei] Natl Univ Singapore, Natl Univ Hlth Syst, Cardiovasc Res Inst, Singapore, Singapore. [Lloyd, Steven G.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Lloyd, SG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, D-101 Cardiac MRI,1808 7th Ave South, Birmingham, AL 35294 USA. EM slloyd@uabmc.edu FU American Heart Association [0735212N]; National Institute of Diabetes and Digestive and Kidney Diseases [P30 DK-056336] FX This work was supported in part by American Heart Association Scientist Development Grant 0735212N and by National Institute of Diabetes and Digestive and Kidney Diseases P30 DK-056336. NR 48 TC 0 Z9 0 U1 5 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUL PY 2016 VL 311 IS 1 BP H1 EP H10 DI 10.1152/ajpheart.00809.2015 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA DY3CZ UT WOS:000384969700001 PM 27199129 ER PT J AU McClatchey, PM Schafer, M Hunter, KS Reusch, JEB AF McClatchey, P. Mason Schafer, Michal Hunter, Kendall S. Reusch, Jane E. B. TI The endothelial glycocalyx promotes homogenous blood flow distribution within the microvasculature SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE glycocalyx; microvascular perfusion; perfusion heterogeneity; oxygen delivery ID CHRONIC HEART-FAILURE; TRANSIT-TIME HETEROGENEITY; SKELETAL-MUSCLE; METABOLIC SYNDROME; PERFUSION HETEROGENEITY; EXERCISE CAPACITY; IN-VIVO; CAPILLARY HEMODYNAMICS; INSULIN-RESISTANCE; BARRIER PROPERTIES AB Many common diseases involve impaired tissue perfusion, and heterogeneous distribution of blood flow in the microvasculature contributes to this pathology. The physiological mechanisms regulating homogeneity/heterogeneity of microvascular perfusion are presently unknown. Using established empirical formulations for blood viscosity modeling in vivo (blood vessels) and in vitro (glass tubes), we showed that the in vivo formulation predicts more homogenous perfusion of microvascular networks at the arteriolar and capillary levels. Next, we showed that the more homogeneous blood flow under simulated in vivo conditions can be explained by changes in red blood cell interactions with the vessel wall. Finally, we demonstrated that the presence of a spacefilling, semipermeable layer (such as the endothelial glycocalyx) at the vessel wall can account for the changes of red blood cell interactions with the vessel wall that promote homogenous microvascular perfusion. Collectively, our results indicate that the mechanical properties of the endothelial glycocalyx promote homogeneous microvascular perfusion. Preservation or restoration of normal glycocalyx properties may be a viable strategy for improving tissue perfusion in a variety of diseases. C1 [McClatchey, P. Mason; Reusch, Jane E. B.] Univ Colorado, Div Endocrinol, Anschutz Med Campus, Aurora, CO USA. [McClatchey, P. Mason; Reusch, Jane E. B.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [McClatchey, P. Mason; Schafer, Michal; Hunter, Kendall S.; Reusch, Jane E. B.] Univ Colorado, Dept Bioengn, Anschutz Med Campus, Aurora, CO USA. [Schafer, Michal; Hunter, Kendall S.] Childrens Hosp Colorado, Div Cardiol, Dept Pediat, Aurora, CO USA. [Reusch, Jane E. B.] Univ Colorado, Sch Med, Ctr Womens Hlth Res, Aurora, CO USA. RP Reusch, JEB (reprint author), 12801 E 17th Ave,MS 8106, Aurora, CO 80045 USA. EM jane.reusch@ucdenver.edu FU Colorado Clinical and Translational Sciences Institute [UL1-RR-025780]; Center for Women's Health Research; Veterans Affairs Merit Review; Department of Bioengineering FX This work was supported by Colorado Clinical and Translational Sciences Institute-UL1-RR-025780 (to J. E. B. Reusch, M. Schafer, K. S. Hunter, and P. M. McClatchey), the Center for Women's Health Research (to J. E. B. Reusch), Veterans Affairs Merit Review (to J. E. B. Reusch), and the Department of Bioengineering (to P. M. McClatchey). NR 63 TC 0 Z9 0 U1 2 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD JUL PY 2016 VL 311 IS 1 BP H168 EP H176 DI 10.1152/ajpheart.00132.2016 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA DY3CZ UT WOS:000384969700017 PM 27199117 ER PT J AU Han, F Zhou, ZW Rapacchi, S Nguyen, KL Finn, JP Hu, P AF Han, Fei Zhou, Ziwu Rapacchi, Stanislas Nguyen, Kim-Lien Finn, J. Paul Hu, Peng TI Segmented Golden Ratio Radial Reordering with Variable Temporal Resolution for Dynamic Cardiac MRI SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE golden ratio; cardiac MRI; RF golden angle radial; segmented k-space ID RETROSPECTIVE RECONSTRUCTION; CINE IMAGES; K-SPACE; ANGIOGRAPHY; MOTION AB Purpose: Golden ratio (GR) radial reordering allows for retrospective choice of temporal resolution by providing a near-uniform k-space sampling within any reconstruction window. However, when applying GR to electrocardiogram (ECG)-gated cardiac imaging, the k-space coverage may not be as uniform because a single reconstruction window is broken into several temporally isolated ones. The goal of this study was to investigate the image artifacts caused by applying GR to ECG-gated cardiac imaging and to propose a segmented GR method to address this issue. Methods: Computer simulation and phantom experiments were used to evaluate the image artifacts resulting from three k-space sampling patterns (ie, uniform radial, conventional GR, and segmented GR). Two-and three-dimensional cardiac cine images were acquired in seven healthy subjects. Imaging artifacts due to k-space sampling nonuniformity were graded on a 5-point scale by an experienced cardiac imaging reader. Results: Segmented GR provides more uniform k-space sampling that is independent of heart-rate variation than conventional GR. Cardiac cine images using segmented GR have significantly higher and more reliable image quality than conventional GR. Conclusion: Segmented GR successfully addresses the non-uniform sampling that occurs with combining conventional GR with ECG gating. This technique can potentially be applied to any ECG-gated cardiac imaging application to allow for retrospective selection of a reconstruction window. (C) 2015 Wiley Periodicals, Inc. C1 [Han, Fei; Zhou, Ziwu; Rapacchi, Stanislas; Nguyen, Kim-Lien; Finn, J. Paul; Hu, Peng] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA. [Han, Fei; Zhou, Ziwu] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Hu, Peng] Univ Calif Los Angeles, Biomed Phys Interdept Grad Program, Los Angeles, CA USA. [Nguyen, Kim-Lien] VA Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA. [Nguyen, Kim-Lien] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Hu, P (reprint author), Dept Radiol Sci, 300 UCLA Med Plaza Suite B119, Los Angeles, CA 90095 USA. EM penghu@mednet.ucla.edu OI Nguyen, Kim-Lien/0000-0002-8854-2976 FU National Institutes of Health [1R01HL127153] FX Grant sponsor: National Institutes of Health; Grant number: 1R01HL127153. NR 20 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD JUL PY 2016 VL 76 IS 1 BP 94 EP 103 DI 10.1002/mrm.25861 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DY3MK UT WOS:000384996900008 PM 26243442 ER PT J AU Barnett, PG Schmitt, SK Yu, W Goetz, MB Ohl, ME Asch, SM AF Barnett, Paul G. Schmitt, Susan K. Yu, Wei Goetz, Matthew Bidwell Ohl, Michael E. Asch, Steven M. TI How Will New Guidelines Affect CD4 Testing in Veterans With HIV? SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HIV; CD4 testing; veterans; guidelines; cost ID ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; CELL COUNT; SUPPRESSION AB Background. Guidelines now recommend limited use of routine CD4 cell count testing in human immunodeficiency virus (HIV)-infected patients with successful viral control who are not immunocompromised. Methods. CD4 and viral load tests for patients receiving HIV care from the US Department of Veterans Affairs during 2009-2013 were evaluated to determine trends in CD4 testing frequency and the number, cost, and results of CD4 tests considered optional under the guidelines. Results. There were 28 530 individuals with sufficient testing to be included. At the time of the last CD4 test, 19.8% of the cohort was eligible for optional monitoring and 15.6% for minimal monitoring. CD4 testing frequency declined by 10.8% over 4 years, reducing the direct cost of testing by US$196 000 per year. Full implementation of new treatment guidelines could reduce CD4 testing a further 28.9%, an additional annual savings of US$600 000. CD4 tests conducted during periods of potentially reduced monitoring were rarely <200 cells/mu L: 1.1% of the tests conducted when minimal monitoring was recommended and just 0.3% of tests conducted when optional monitoring was recommended were less than this value. Conclusions. Reduced CD4 monitoring of HIV-infected patients would result in modest cost savings and likely reduce patient anxiety, with little or no impact on the quality of care. Veterans Affairs has made substantial progress in reducing the frequency of optional CD4 testing, but further reductions may still be warranted. C1 [Barnett, Paul G.; Schmitt, Susan K.; Yu, Wei] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA. [Barnett, Paul G.] Univ Calif San Francisco, Dept Psychiat, Treatment Res Ctr, San Francisco, CA USA. [Barnett, Paul G.; Yu, Wei; Asch, Steven M.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, Infect Dis Sect, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Ohl, Michael E.] Univ Iowa, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City Vet Affairs Med Ctr, Dept Internal Med,Carver Coll Med, Iowa City, IA 52242 USA. [Asch, Steven M.] Stanford Univ, Sch Med, Dept Gen Med Disciplines, Stanford, CA 94305 USA. RP Barnett, PG (reprint author), VA Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM paul.barnett@va.gov FU Quality Enhancement Research Initiative; Health Services Research and Development Service of the US Department of Veterans Affairs FX This work was supported by the Quality Enhancement Research Initiative and the Health Services Research and Development Service of the US Department of Veterans Affairs. NR 18 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 1 PY 2016 VL 63 IS 1 BP 96 EP 100 DI 10.1093/cid/ciw194 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DT1FH UT WOS:000381226600019 PM 27045125 ER PT J AU Garvey, WT Mechanick, JI Brett, EM Garber, AJ Hurley, DL Jastreboff, AM Nadolsky, K Pessah-Pollack, R Plodkowski, R AF Garvey, W. Timothy Mechanick, Jeffrey I. Brett, Elise M. Garber, Alan J. Hurley, Daniel L. Jastreboff, Ania M. Nadolsky, Karl Pessah-Pollack, Rachel Plodkowski, Raymond CA AACE ACE Obesity Clinical Practice TI AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY SO ENDOCRINE PRACTICE LA English DT Article ID BODY-MASS INDEX; POLYCYSTIC-OVARY-SYNDROME; NONALCOHOLIC FATTY-LIVER; RANDOMIZED-CONTROLLED-TRIAL; TYPE-2 DIABETES-MELLITUS; GASTROESOPHAGEAL-REFLUX DISEASE; BINGE-EATING DISORDER; OBSTRUCTIVE SLEEP-APNEA; PLACEBO-CONTROLLED TRIAL; LIFE-STYLE INTERVENTION AB Objective: Development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and the American College of Endocrinology (ACE) Board of Trustees and adheres to published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent review of clinical evidence with transparent incorporation of subjective factors. Results: There are 9 broad clinical questions with 123 recommendation numbers that include 160 specific statements (85 [53.1%] strong [Grade A]; 48 [30.0%] intermediate [Grade B], and 11 [6.9%] weak [Grade C], with 16 [10.0%] based on expert opinion [Grade D]) that build a comprehensive medical care plan for obesity. There were 133 (83.1%) statements based on strong (best evidence level [BEL] 1 = 79 [49.4%]) or intermediate (BEL 2 = 54 [33.7%]) levels of scientific substantiation. There were 34 (23.6%) evidence-based recommendation grades (Grades A-C = 144) that were adjusted based on subjective factors. Among the 1,790 reference citations used in this CPG, 524 (29.3%) were based on strong (evidence level [EL] 1), 605 (33.8%) were based on intermediate (EL 2), and 308 (17.2%) were based on weak (EL 3) scientific studies, with 353 (19.7%) based on reviews and opinions (EL 4). Conclusion: The final recommendations recognize that obesity is a complex, adiposity-based chronic disease, where management targets both weight-related complications and adiposity to improve overall health and quality of life. The detailed evidence-based recommendations allow for nuanced clinical decision-making that addresses real-world medical care of patients with obesity, including screening, diagnosis, evaluation, selection of therapy, treatment goals, and individualization of care. The goal is to facilitate high-quality care of patients with obesity and provide a rational, scientific approach to management that optimizes health outcomes and safety. C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] UAB Diabet Res Ctr, Birmingham, AL USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, Metab Support, New York, NY 10029 USA. [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, Med, New York, NY 10029 USA. [Brett, Elise M.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Garber, Alan J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Garber, Alan J.] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA. [Garber, Alan J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Hurley, Daniel L.] Mayo Clin, Med, Rochester, MN USA. [Jastreboff, Ania M.] Yale Univ, Sch Med, Internal Med, Endocrinol,Pediat,Pediat Endocrinol, New Haven, CT USA. [Nadolsky, Karl] Walter Reed Natl Mil Med Ctr, Diabet Obes & Metab Inst, Bethesda, MD USA. [Pessah-Pollack, Rachel] Mt Sinai Sch Med, ProHlth Care Associates, Div Endocrinol, Lake Success, NY USA. [Plodkowski, Raymond] Scripps Clin, Ctr Weight Management, Div Endocrinol Diabet & Metab, San Diego, CA USA. RP Garvey, WT (reprint author), Amer Assoc Clin Endocrinologists, 245 Riverside Ave,Suite 200, Jacksonville, FL 32202 USA. EM publications@aace.com NR 1790 TC 11 Z9 11 U1 29 U2 30 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JUL PY 2016 VL 22 SU 3 BP 1 EP 203 DI 10.4158/EP161365.GL PG 203 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX3NJ UT WOS:000384279500001 PM 27219496 ER PT J AU Garvey, WT Mechanick, JI Brett, EM Garber, AJ Hurley, DL Jastreboff, AM Nadolsky, K Pessah-Pollack, R Plodkowski, R AF Garvey, W. Timothy Mechanick, Jeffrey I. Brett, Elise M. Garber, Alan J. Hurley, Daniel L. Jastreboff, Ania M. Nadolsky, Karl Pessah-Pollack, Rachel Plodkowski, Raymond CA AACE ACE Obesity Clinical Practice TI AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY SO ENDOCRINE PRACTICE LA English DT Article ID CARDIOVASCULAR-DISEASE RISK; WEIGHT-LOSS DIETS; RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; BODY-MASS INDEX; MEDITERRANEAN DIET; METABOLIC SYNDROME; MACRONUTRIENT COMPOSITION; STANDARDIZED PRODUCTION; INSULIN SENSITIVITY AB Objective: Development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and the American College of Endocrinology (ACE) Board of Trustees and adheres to published AACE protocols for the standardized production of clinical practice guidelines (CPGs). Methods: Recommendations are based on diligent review of clinical evidence with transparent incorporation of subjective factors. Results: There are 9 broad clinical questions with 123 recommendation numbers that include 160 specific statements (85 [53.1%] strong [Grade A], 48 [30.0%] intermediate [Grade B], and 11 [6.9%] weak [Grade C], with 16 [10.0%] based on expert opinion [Grade D]) that build a comprehensive medical care plan for obesity. There were 133 (83.1%) statements based on strong (best evidence level [BEL] 1 = 79 [49.4%]) or intermediate (BEL 2 = 54 [33.7%]) levels of scientific substantiation. There were 34 (23.6%) evidence-based recommendation grades (Grades A-C = 144) that were adjusted based on subjective factors. Among the 1,788 reference citations used in this CPG, 524 (29.3%) were based on strong (evidence level [EL] 1), 605 (33.8%) were based on intermediate (EL 2), and 308 (17.2%) were based on weak (EL 3) scientific studies, with 351 (19.6%) based on reviews and opinions (EL 4). Conclusion: The final recommendations recognize that obesity is a complex, adiposity-based chronic disease, where management targets both weight-related complications and adiposity to improve overall health and quality of life. The detailed evidence-based recommendations allow for nuanced clinical decision-making that addresses real-world medical care of patients with obesity, including screening, diagnosis, evaluation, selection of therapy, treatment goals, and individualization of care. The goal is to facilitate high-quality care of patients with obesity and provide a rational, scientific approach to management that optimizes health outcomes and safety. C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] UAB Diabet Res Ctr, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, Metab Support, New York, NY 10029 USA. [Mechanick, Jeffrey I.] Icahn Sch Med Mt Sinai, Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Brett, Elise M.] Icahn Sch Med Mt Sinai, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Garber, Alan J.] Baylor Coll Med, Dept Med Biochem & Mol Biol, Houston, TX 77030 USA. [Garber, Alan J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Hurley, Daniel L.] Mayo Clin, Med, Rochester, MN USA. [Jastreboff, Ania M.] Yale Univ, Sch Med, Internal Med Endocrinol Pediat Pediat Endocrinol, New Haven, CT USA. [Nadolsky, Karl] Walter Reed Natl Mil Med Ctr, Diabet Obes & Metab Inst, Bethesda, MD USA. [Pessah-Pollack, Rachel] Mt Sinai Sch Med, New York, NY USA. [Pessah-Pollack, Rachel] ProHealth Care Associates, Div Endocrinol, Lake Success, NY USA. [Plodkowski, Raymond] Scripps Clin, Div Endocrinol Diabet & Metab, Ctr Weight Management, San Diego, CA USA. RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), UAB Diabet Res Ctr, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA. EM publications@aace.com NR 75 TC 6 Z9 6 U1 5 U2 5 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JUL PY 2016 VL 22 IS 7 BP 842 EP 884 DI 10.4158/EP161356.ESGL PG 43 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DX3NI UT WOS:000384279400011 PM 27472012 ER PT J AU Heidenreich, PA Sahay, A Oliva, N Gholami, P Lin, S Mittman, BS Rumsfeld, JS AF Heidenreich, Paul A. Sahay, Anju Oliva, Nancy Gholami, Parisa Lin, Shoutzu Mittman, Brian S. Rumsfeld, John S. TI Impact of the Hospital to Home Initiative on Readmissions in the VA Health Care System SO QUALITY MANAGEMENT IN HEALTH CARE LA English DT Article DE heart failure; quality of care; readmission; transition of care ID HEART-FAILURE; INTERVENTIONS; METAANALYSIS; RATES AB Background: Hospital to Home (H2H) is a national quality improvement initiative sponsored by the Institute for Healthcare Improvement and the American College of Cardiology, with the goal of reducing readmission for patients hospitalized with heart disease. We sought to determine the impact of H2H within the Veterans Affairs (VA) health care system. Methods: Using a controlled interrupted time series, we determined the association of VA hospital enrollment in H2H with the primary outcome of 30-day all-cause readmission following a heart failure hospitalization. VA heart failure providers were surveyed to determine quality improvement projects initiated in response to H2H. Secondary outcomes included initiation of recommended H2H projects, follow-up within 7 days, and total hospital days at 30 days and 1 year. Results: Sixty-five of 104 VA hospitals (66%) enrolled in the national H2H initiative. Hospital characteristic associated with H2H enrollment included provision of tertiary care, academic affiliation, and greater use of home monitoring. There was no significant difference in mean 30-day readmission rates (20.0% 5.0% for H2H vs 19.3% +/- 5.9% for non-H2H hospitals; P = .48) The mean fraction of patients with a cardiology visit within 7 days was slightly higher for H2H hospitals (3.0% +/- 2.4% for H2H vs 2.0% +/- 1.9% for non-H2H hospitals; P = .05). Patients discharged from H2H hospitals had fewer mean hospitals days during the following year (7.6% +/- 2.6% for H2H vs 9.2% +/- 3.0 for non-H2H; P = .01) early after launch of H2H, but the effect did not persist. Conclusions: VA hospitals enrolling in H2H had slightly more early follow-up in cardiology clinic but no difference in 30-day readmission rates compared with hospitals not enrolling in H2H. C1 [Heidenreich, Paul A.; Sahay, Anju; Oliva, Nancy; Gholami, Parisa; Lin, Shoutzu] Vet Adm Palo Alto Hlth Care Syst, 111C,3801 Ave, Palo Alto, CA 94303 USA. [Mittman, Brian S.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA. [Rumsfeld, John S.] Eastern Colorado VA Hlth Care Syst, Denver, CO USA. RP Heidenreich, PA (reprint author), Vet Adm Palo Alto Hlth Care Syst, 111C,3801 Ave, Palo Alto, CA 94303 USA. EM heiden@stanford.edu FU Veterans Administration's Quality Enhancement and Research Initiative [04-326, SDP 09-160] FX This study was supported by grants from the Veterans Administration's Quality Enhancement and Research Initiative 04-326 and SDP 09-160. NR 11 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1063-8628 EI 1550-5154 J9 QUAL MANAG HEALTH CA JI Qual. Manag. Health Care PD JUL-SEP PY 2016 VL 25 IS 3 BP 129 EP 133 DI 10.1097/QMH.0000000000000105 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DX1OI UT WOS:000384136300002 PM 27367213 ER PT J AU Cefalu, WT Buse, JB Tuomilehto, J Fleming, GA Ferrannini, E Gerstein, HC Bennett, PH Ramachandran, A Raz, I Rosenstock, J Kahn, SE AF Cefalu, William T. Buse, John B. Tuomilehto, Jaakko Fleming, G. Alexander Ferrannini, Ele Gerstein, Hertzel C. Bennett, Peter H. Ramachandran, Ambady Raz, Itamar Rosenstock, Julio Kahn, Steven E. TI Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; RANDOMIZED-CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; 10-YEAR FOLLOW-UP; BETA-CELL FUNCTION; DA QING IGT; FASTING GLUCOSE; INSULIN-SECRETION; PROGRAM OUTCOMES AB The International Diabetes Federation estimates that 415 million adults worldwide now have diabetes and 318 million have impaired glucose tolerance. These numbers are expected to increase to 642 million and 482 million, respectively, by 2040. This burgeoning pandemic places an enormous burden on countries worldwide, particularly resource-poor regions. Numerous landmark trials evaluating both intensive lifestyle modification and pharmacological interventions have persuasively demonstrated that type 2 diabetes can be prevented or its onset can be delayed in high-risk individuals with impaired glucose tolerance. However, key challenges remain, including how to scale up such approaches for widespread translation and implementation, how to select appropriately from various interventions and tailor them for different populations and settings, and how to ensure that preventive interventions yield clinically meaningful, cost-effective outcomes. In June 2015, a Diabetes Care Editors' Expert Forum convened to discuss these issues. This article, an outgrowth of the forum, begins with a summary of seminal prevention trials, followed by a discussion of considerations for selecting appropriate populations for intervention and the clinical implications of the various diagnostic criteria for prediabetes. The authors outline knowledge gaps in need of elucidation and explore a possible new avenue for securing regulatory approval of a prevention-related indication for metformin, as well as specific considerations for future pharmacological interventions to delay the onset of type 2 diabetes. They conclude with descriptions of some innovative, pragmatic translational initiatives already under way around the world. C1 [Cefalu, William T.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Buse, John B.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland. [Tuomilehto, Jaakko] Dasman Diabet Inst, Dasman, Kuwait. [Tuomilehto, Jaakko] King Abdulaziz Univ, Saudi Diabet Res Grp, Jeddah, Saudi Arabia. [Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria. [Fleming, G. Alexander] Kinexum, Harpers Ferry, WV USA. [Ferrannini, Ele] CNR, Inst Clin Physiol, Pisa, Italy. [Gerstein, Hertzel C.] McMaster Univ, Hamilton, ON, Canada. [Gerstein, Hertzel C.] Hamilton Hlth Sci, Hamilton, ON, Canada. [Bennett, Peter H.] NIH, Phoenix, AZ USA. [Ramachandran, Ambady] India Diabet Res Fdn, Madras, Tamil Nadu, India. [Bennett, Peter H.] Dr A Ramachandrans Diabet Hosp, Madras, Tamil Nadu, India. [Raz, Itamar] Hadassah Hebrew Univ Hosp, Dept Internal Med, Diabet Unit, Jerusalem, Israel. [Rosenstock, Julio] Med City, Dallas Diabet & Endocrine Ctr, Dallas, TX USA. [Rosenstock, Julio] Univ Texas Southwestern Med Ctr, Dallas, TX USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. RP Cefalu, WT (reprint author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. EM william.cefalu@pbrc.edu OI Kahn, Steven/0000-0001-7307-9002 FU National Institutes of Health (NIH) [1U54-GM-104940]; NIH [P50-AT-002776] FX Writing and editing support services for this article were provided by Debbie Kendall of Kendall Editorial in Richmond, VA. The Editorial Committee recognizes that the work of the journal and contributions such as this Expert Forum would not be possible without the dedicated work and continued support of many individuals. Specifically, the planning, logistics, and funding of the meeting and the incredible editorial support would not have been possible without the tireless efforts of Chris Kohler and his staff at the ADA Publishing office. In addition, the Editorial Committee thanks Lyn Reynolds and her staff in the ADA editorial office for support and Anne Gooch at the Pennington Biomedical Research Center for her valuable assistance in helping to organize the Expert Forum. W.T.C. is supported in part by National Institutes of Health (NIH) grant 1U54-GM-104940, which funds the Louisiana Clinical and Translational Science Center, and NIH grant P50-AT-002776. NR 138 TC 5 Z9 5 U1 1 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2016 VL 39 IS 7 BP 1186 EP 1201 DI 10.2337/dc16-0873 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DT3YG UT WOS:000381416500027 PM 27631469 ER PT J AU Gracious, BL Fontanella, CA Phillips, GS Bridge, JA Marcus, SC Campo, JV AF Gracious, Barbara L. Fontanella, Cynthia A. Phillips, Gary S. Bridge, Jeffrey A. Marcus, Steven C. Campo, John V. TI Antidepressant Exposure and Risk of Fracture Among Medicaid-Covered Youth SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article DE Antidepressants; Child and Adolescent Psychiatry ID SEROTONIN-REUPTAKE INHIBITORS; BONE-MINERAL DENSITY; PEDIATRIC OFFICIAL POSITIONS; DEPRESSIVE SYMPTOMS; ADOLESCENTS; CHILDREN; WOMEN; GROWTH; RECOMMENDATIONS; OSTEOPOROSIS AB Objective: This study examines the association between antidepressant use and risk of fracture in depressed youth and assesses whether fracture incidence varies over the course of antidepressant treatment. Method: A retrospective cohort analysis of Ohio Medicaid claims data was conducted for youth ages 6-17 years with a new episode of ICD-9-diagnosed depression from 2001-2009. The primary outcome variable was time to fracture. Fracture rates were compared between depressed youth treated with antidepressant medication and untreated depressed youth. Time categories of no use, past use, and current use were compared. Results: Of 50,673 depressed youths, 5,872 (11.6%) experienced a fracture. Of those who had a fracture, 2,228 (37.9%) were exposed to antidepressants, 80% of which were selective serotonin reuptake inhibitors. The adjusted hazard ratio (HR) was 3% higher in those currently prescribed antidepressants (HR = 1.03; 95% CI, 1.00-1.06; P = .03). The risk ratio (RR) for adjusted fracture rates per 10,000 persons was twice as high during the first 30 days of antidepressant use compared to the other time periods (RR = 2.0; 95% CI, 1.2-3.3; P = .007). The number of fractures for those with past antidepressant use did not differ from those with no history of antidepressant use. Conclusions: Antidepressant use may be associated with a small but significant increase in fracture risk, particularly within the first 30 days of treatment. Findings underscore a need for additional prospective and mechanistic research. Prescribers should consider other risks for fracture in antidepressant-treated youth, particularly disability and the concomitant use of other medications that increase fracture risk. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Gracious, Barbara L.; Fontanella, Cynthia A.; Campo, John V.] Ohio State Univ, Dept Psychiat & Behav Hlth, Wexner Med Ctr, Columbus, OH 43210 USA. [Gracious, Barbara L.; Bridge, Jeffrey A.] Nationwide Childrens Hosp, Res Inst, Ctr Innovat Pediat Practice, Columbus, OH USA. [Phillips, Gary S.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA. [Bridge, Jeffrey A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. [Marcus, Steven C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Gracious, BL (reprint author), Nationwide Childrens Hosp, 700 Childrens Dr,J West 4923, Columbus, OH 43205 USA. EM Barbara.Gracious@nationwidechildrens.org FU National Center for Research Resources [UL1RR025755]; Jeffrey Research Fellowship at the Department of Psychiatry and Behavioral Health; Nationwide Children's Hospital; Ohio State University FX This project was supported by Award Number UL1RR025755 from the National Center for Research Resources, for the statistical support by Mr Phillips. Dr Gracious' salary for the project was supported by The Jeffrey Research Fellowship at the Department of Psychiatry and Behavioral Health, Nationwide Children's Hospital and The Ohio State University. NR 37 TC 0 Z9 0 U1 3 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUL PY 2016 VL 77 IS 7 BP 950 EP + DI 10.4088/JCP.15m09828 PG 11 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DW6XY UT WOS:000383795900023 ER PT J AU Frey, LJ Bernstam, EV Denny, JC AF Frey, Lewis J. Bernstam, Elmer V. Denny, Joshua C. TI Precision medicine informatics SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Editorial Material ID ELECTRONIC HEALTH RECORDS; GENOME-WIDE ASSOCIATION; GENOTYPE; DISEASE; SYSTEMS; IMPLEMENTATION; MELANOMA; THERAPY; NETWORK; SUPPORT C1 [Frey, Lewis J.] Med Univ South Carolina, Biomed Informat Ctr, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Frey, Lewis J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC 29401 USA. [Bernstam, Elmer V.] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA. [Bernstam, Elmer V.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Gen Internal Med, Sch Med, Houston, TX 77030 USA. [Denny, Joshua C.] Vanderbilt Univ, Dept Biomed Informat, 221 Kirkland Hall, Nashville, TN 37235 USA. [Denny, Joshua C.] Vanderbilt Univ, Dept Med, Nashville, TN USA. RP Frey, LJ (reprint author), Med Univ South Carolina, Biomed Informat Ctr, Dept Publ Hlth Sci, Charleston, SC 29425 USA.; Frey, LJ (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC 29401 USA. FU National Institutes of Health (NIH) [1R01GM108346-01, U54-GM104941]; Health Equity and Rural Outreach Innovation Center [CIN 13-418]; Hollings Cancer Center at the Medical University of South Carolina [P30 CA138313]; National Cancer Institute (NCI) [U01 CA180964]; Sheikh Bin Zayed Al Nahyan Foundation; Cancer Prevention Research Institute of Texas Precision Oncology Decision Support Core [RP150535]; National Center for Advancing Translational Sciences (NCATS) [UL1 TR000371]; Bosarge Foundation; MD Anderson Cancer Center [NCI P30 CA016672]; NIH [R01 LM 010685, R01 GM 103859, R01 GM 105688] FX The work of L.J.F. was supported in part by National Institutes of Health (NIH) grants 1R01GM108346-01 and U54-GM104941, Health Equity and Rural Outreach Innovation Center grant CIN 13-418, and funding from the Hollings Cancer Center's support grant P30 CA138313 at the Medical University of South Carolina. The work of E.V.B. was supported by National Cancer Institute (NCI) U01 CA180964, the Sheikh Bin Zayed Al Nahyan Foundation, the Cancer Prevention Research Institute of Texas Precision Oncology Decision Support Core RP150535, National Center for Advancing Translational Sciences (NCATS) grant UL1 TR000371 (Center for Clinical and Translational Sciences), the Bosarge Foundation, and an MD Anderson Cancer Center support grant (NCI P30 CA016672). The work of J.C.D. was supported by R01 LM 010685, R01 GM 103859, and R01 GM 105688 from the NIH. NR 72 TC 1 Z9 2 U1 5 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JUL PY 2016 VL 23 IS 4 BP 668 EP 670 DI 10.1093/jamia/ocw053 PG 3 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA DW6SS UT WOS:000383782100002 PM 27274018 ER PT J AU Williams, JS Egede, LE AF Williams, Joni S. Egede, Leonard E. TI The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Multimorbidity; Quality of life; Health status; Functional disability; Chronic disease ID MULTIPLE CHRONIC CONDITIONS; PRIMARY-CARE; COMMUNITY SETTINGS; MANAGING PATIENTS; PREVALENCE; VALIDITY; RELIABILITY; MANAGEMENT; ADULTS; SCALES AB Introduction: Approximately 50% of adults have multimorbidity (MM) that is associated with greater disability, poorer quality of life (QOL) and increased psychological distress. This study assessed the association between MM and QOL, health status and functional disability in U.S. adults. Methods: Cross-sectional study of 23,789 patients from 2011 Medical Expenditure Panel Survey was conducted. Mean scores were calculated for QOL (physical component score [PCS] and mental component score [MCS]) and proportions for functional limitation (activities of daily living [ADL]; instrumental ADL [IADL] and physical functioning). Health status was assessed by depression and serious psychological distress. Regression models evaluated associations between MM and QOL, functional health status and functional limitations, while adjusting for confounders. Results: Approximately 53% of 45-64-year-olds and 84% of those =65-years-old had MM. In adjusted models, =3 conditions were significantly associated with poorer outcomes-PCS QOL (b = -9.15; 95% CI: -9.69 to -8.61), MCS QOL ( = -1.98; 95% CI: -2.43 to -1.52), ADL (odds ratio [OR] = 5.80; 95% CI: 2.27-14.8), IADL (OR = 3.99; 95% CI: 2.31-6.88) and physical functioning (OR = 16.8; 95% CI: 12.0-23.6) compared with 1-2 conditions. Depression (PCS QOL: b = -4.02; 95% CI: -4.89 to -3.15; MCS QOL: b = -12.5; 95% CI: -13.2 to -10.9; ADL: OR = 2.49; 95% CI: 1.65-3.76; IADL: OR = 2.65; 95% CI: 1.88-3.72; physical functioning: OR = 2.44; 95% CI: 1.99-2.99) and serious psychological distress (PCS QOL: b = -3.16; 95% CI: -4.30 to -2.03; MCS QOL: b = -11.8; 95% CI: -12.8 to -10.8; ADL: OR = 1.57; 95% CI: 0.95-2.60; IADL: OR = 1.13; 95% CI: 0.80-1.59 and physical functioning: OR = 1.41; 95% CI: 1.11-1.78) were significantly associated with adverse outcomes. Conclusions: In this nationally representative sample of U.S. adults, MM was significantly associated with poorer QOL, functional health status and physical functioning, when adjusting for relevant confounders. A holistic view of the complexities associated with MM must dictate comprehensive care. C1 [Williams, Joni S.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC USA. [Williams, Joni S.; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC USA. [Egede, Leonard E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Hlth Equ & Rural Outreach Innovat Ctr, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699] FX This study was supported by Grant no. K24DK093699 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 22 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD JUL PY 2016 VL 352 IS 1 BP 45 EP 52 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DV1GB UT WOS:000382667400006 PM 27432034 ER PT J AU Mingrone, G Cummings, DE AF Mingrone, Geltrude Cummings, David E. TI Changes of insulin sensitivity and secretion after bariatric/metabolic surgery SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article ID Y GASTRIC BYPASS; BETA-CELL FUNCTION; TYPE-2 DIABETES-MELLITUS; NORMAL GLUCOSE-TOLERANCE; SEVERELY OBESE-PATIENTS; BARIATRIC SURGERY; WEIGHT-LOSS; SLEEVE GASTRECTOMY; BILIOPANCREATIC DIVERSION; GLYCEMIC CONTROL AB Type 2 diabetes (T2D) is classically characterized by failure of pancreatic beta-cell function and insulin secretion to compensate for a prevailing level of insulin resistance, typically associated with visceral obesity. Although this is usually a chronic, progressive disease in which delay of end-organ complications is the primary therapeutic goal for medical and behavioral approaches, several types of bariatric surgery, especially those that include intestinal bypass components, exert powerful anti diabetes effects to yield remission of T2D in most cases. It has become increasingly clear that in addition to the known benefits of acute caloric restriction and chronic weight loss to ameliorate T2D, bariatric/metabolic operations also engage a variety of weight-independent mechanisms to improve glucose homeostasis, enhancing insulin sensitivity and secretion to varying degrees depending on the specific operation. In this paper, we review the effects of Roux-en-Y gastric bypass, biliopancreatic diversion, and vertical sleeve gastrectomy on the primary determinants of glucose homeostasis: insulin sensitivity, insulin secretion, and, to the lesser extent that it is known, insulin independent glucose disposal. A full understanding of these effects should help optimize surgical and device-based designs' to provide maximal antidiabetes impact, and it holds the promise to identify targets for possible novel diabetes pharmacotherapeutics. These insights also contribute to the conceptual rationale for use of bariatric operations as "metabolic surgery," employed primarily to treat T2D, including among patients not obese enough to qualify for surgery based on traditional criteria related to high body mass index. (C) 2016 American Society for Metabolic and Bariatric Surgery. All rights reserved. C1 [Mingrone, Geltrude] Univ Cattolica Sacro Cuore, Dept Internal Med, Rome, Italy. [Cummings, David E.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Cummings, David E.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. RP Cummings, DE (reprint author), Univ Washington, Dept Med, Box 358280,Mail Stop 111, Seattle, WA 98195 USA. EM davidec@u.washington.edu RI DE SOUZA, AGLECIO/Q-4056-2016 NR 68 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD JUL PY 2016 VL 12 IS 6 BP 1199 EP 1205 DI 10.1016/j.soard.2016.05.013 PG 7 WC Surgery SC Surgery GA DV8VU UT WOS:000383215600008 PM 27568471 ER PT J AU Schlosser, RJ Gage, SE Kohli, P Soler, ZM AF Schlosser, Rodney J. Gage, Selby E. Kohli, Preeti Soler, Zachary M. TI Burden of illness: A systematic review of depression in chronic rhinosinusitis SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Review ID QUALITY-OF-LIFE; ENDOSCOPIC SINUS SURGERY; DISEASE SEVERITY; OUTCOMES; ANXIETY; HEALTH; IMPACT; SYMPTOMS; COHORT AB Background: Depression has been reported in patients with chronic rhinosinusitis (CRS), but its prevalence varies across studies, and uncertainty remains regarding the association with baseline disease severity and treatment outcomes. Objective: To systematically assess the prevalence of depression in CRS and to review its relationship to baseline disease severity and outcomes after treatment. Methods: A systematic review of the prevalence of possible depression was performed by using the available methods to diagnose depression, and the results were pooled. Studies that examined the relationship of depression on baseline disease severity and treatment outcomes were organized and reported individually. Results: Thirteen studies met inclusion criteria for prevalence analysis. The prevalence of possible or likely depression in patients with CRS ranged from 11.0 to 40.0%, depending on the method of diagnosis and sensitivity of various depression instruments. Positive depression screening was consistently associated with worse CRS-specific quality of life (QOL), medication usage, and health care utilization, but there were no reliable CRS-specific factors to predict the presence of depression. Patients with possible depression who underwent medical or surgical treatment for CRS tended to have improvements in CRS-specific QOL but did not achieve the same degree of QOL as patients who were not depressed. Depression-specific QOL seemed to improve after treatment for CRS. Conclusion: Positive depression screening was common in patients with CRS and had a negative association on the entire spectrum of QOL, health care utilization, and productivity. CRS-specific treatments were still beneficial in patients who seemed to be depressed and improved both depression-specific and CRS-specific QOL. C1 [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Schlosser, Rodney J.; Gage, Selby E.; Kohli, Preeti; Soler, Zachary M.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. RP Soler, ZM (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM solerz@musc.edu FU Flight Attendant Medical Research Institute [113042 CIA]; National Institute on Deafness and Other Communication Disorders, the National Institutes of Health, Bethesda, Maryland [R01 DC005805, R03 DC013651-01] FX Supported by a grant from the Flight Attendant Medical Research Institute (ID 113042 CIA). Z.M. Soler is also supported by grants from the National Institute on Deafness and Other Communication Disorders, the National Institutes of Health, Bethesda, Maryland (R01 DC005805; R03 DC013651-01) NR 27 TC 2 Z9 2 U1 1 U2 1 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JUL-AUG PY 2016 VL 30 IS 4 BP 250 EP 256 DI 10.2500/ajra.2016.30.4343 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DU3IN UT WOS:000382104100012 PM 27456594 ER PT J AU Chalmers, JR Simpson, E Apfelbacher, CJ Thomas, KS von Kobyletzki, L Schmitt, J Singh, JA Svensson, A Williams, HC Abuabara, K Aoki, V Ardeleanu, M Awici-Rasmussen, M Barbarot, S Berents, TL Block, J Bragg, A Burton, T Clemmensen, KKB Creswell-Melville, A Dinesen, M Drucker, A Eckert, L Flohr, C Garg, M Gerbens, LAA Graff, ALB Hanifin, J Heinl, D Humphreys, R Ishii, HA Kataoka, Y Leshem, YA Marquort, B Massuel, MA Merhand, S Mizutani, H Murota, H Murrell, DF Nakahara, T Nasr, I Nograles, K Ohya, Y Osterloh, I Pander, J Prinsen, C Purkins, L Ridd, M Sach, T Schuttelaar, MLA Shindo, S Smirnova, J Sulzer, A Gjerde, ES Takaoka, R Talmo, HV Tauber, M Torchet, F Volke, A Wahlgren, CF Weidinger, S Weisshaar, E Wollenberg, A Yamaga, K Zhao, CY Spuls, PI AF Chalmers, J. R. Simpson, E. Apfelbacher, C. J. Thomas, K. S. von Kobyletzki, L. Schmitt, J. Singh, J. A. Svensson, A. Williams, H. C. Abuabara, K. Aoki, V. Ardeleanu, M. Awici-Rasmussen, M. Barbarot, S. Berents, T. L. Block, J. Bragg, A. Burton, T. Clemmensen, K. K. Bjerring Creswell-Melville, A. Dinesen, M. Drucker, A. Eckert, L. Flohr, C. Garg, M. Gerbens, L. A. A. Graff, A. L. B. Hanifin, J. Heinl, D. Humphreys, R. Ishii, H. A. Kataoka, Y. Leshem, Y. A. Marquort, B. Massuel, M. -A. Merhand, S. Mizutani, H. Murota, H. Murrell, D. F. Nakahara, T. Nasr, I. Nograles, K. Ohya, Y. Osterloh, I. Pander, J. Prinsen, C. Purkins, L. Ridd, M. Sach, T. Schuttelaar, M. -L. A. Shindo, S. Smirnova, J. Sulzer, A. Gjerde, E. Synnove Takaoka, R. Talmo, H. Vestby Tauber, M. Torchet, F. Volke, A. Wahlgren, C. -F. Weidinger, S. Weisshaar, E. Wollenberg, A. Yamaga, K. Zhao, C. Y. Spuls, P. I. TI Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID MEASUREMENT INSTRUMENTS; ECZEMA; QUALITY; DELPHI; COSMIN; SIGNS AB This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmo, Sweden on 23-24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [ including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms. C1 [Chalmers, J. R.; Thomas, K. S.; Williams, H. C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England. [Simpson, E.; Hanifin, J.; Leshem, Y. A.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA. [Apfelbacher, C. J.; Heinl, D.] Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, D-93053 Regensburg, Germany. [von Kobyletzki, L.] Lund Univ, Skane Univ Hospital, Dept Dermatol, Malmo, Sweden. [von Kobyletzki, L.; Smirnova, J.] Karlstad Univ, Dept Publ Hlth Sci, Karlstad, Sweden. [Schmitt, J.] Univ Dresden, Ctr Lvidence Based Hlthcare, Dresden, Germany. [Schmitt, J.] Tech Univ Dresden, Dept Occupat & Social Med, D-01062 Dresden, Germany. [Singh, J. A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, J. A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Svensson, A.] Malmo Univ Hosp, Dept Dermatol & Venerol, Malmo, Sweden. [Abuabara, K.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Aoki, V.; Takaoka, R.] Univ Sao Paulo, Sch Med, Dept Dermatol, Sao Paulo, Brazil. [Ardeleanu, M.] Regeneron Pharmaceut Inc, Immunol & Inflammat, New York, NY USA. [Awici-Rasmussen, M.; Gjerde, E. Synnove] Psoriasis & Eczema Assoc Norway, Oslo, Norway. [Barbarot, S.] CHU Nantes, Dept Dermatol, F-44035 Nantes 01, France. [Berents, T. L.] Univ Oslo, Inst Clin Med, Oslo 3, Norway. [Berents, T. L.] Oslo Univ Hosp, Dept Dermatol, Oslo, Norway. [Block, J.] Natl Eczema Assoc, Natl Eczema Org, San Rafael, CA USA. [Bragg, A.] Chugai Pharma Europe Ltd, London, England. [Clemmensen, K. K. Bjerring] Univ Copenhagen, Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark. [Creswell-Melville, A.] Soc Canadienne IEczema, Keswick, ON, Canada. [Dinesen, M.] LEO Pharma AS, Industriparken 55, Ballerup, Denmark. [Drucker, A.] Univ Hlth Nem ork, Div Dermatol, Toronto, ON, Canada. [Eckert, L.] Hlth Econ & Outcomes Res, Sanofi, France. [Flohr, C.] Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England. [Flohr, C.] Kings Coll London, London, England. [Garg, M.] LEO Pharma, Copenhagen, Denmark. [Gerbens, L. A. A.; Spuls, P. I.] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands. [Graff, A. L. B.; Humphreys, R.] Natl Eczema Soc, London, England. [Ishii, H. A.] Brazilian Atop Dermatitis Assoc AADA, Sao Paulo, Brazil. [Kataoka, Y.] Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan. [Massuel, M. -A.] Sanofi Aventis, Paris, France. [Merhand, S.] Assoc Francaise Eczema, Redon, France. [Mizutani, H.; Torchet, F.] Mie Univ, Grad Sch Med, Tsu, Mie, Japan. [Mizutani, H.; Torchet, F.] Mie Univ, Hosp Tsu, Tsu, Mie, Japan. [Murota, H.; Shindo, S.; Yamaga, K.] Osaka Univ, Dept Dermatol, Osaka, Japan. [Murrell, D. F.; Zhao, C. Y.] St George Hosp, Dept Dermatol, Sydney, NSW, Australia. [Murrell, D. F.; Zhao, C. Y.] Univ New S Wales, Sydney, NSW, Australia. [Nakahara, T.] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan. [Nograles, K.] Greater New York City Area Pharmaceut, Celgene Corp, New York, NY USA. [Ohya, Y.] Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Allergy, Tokyo, Japan. [Osterloh, I.] Ostermed Ltd, Kent, OH USA. [Pander, J.] Celgene BV, Utrecht, Netherlands. [Prinsen, C.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Dept Epidemiol & Biostat, Amsterdam, Netherlands. [Purkins, L.] Ziarco Pharma Ltd, Canterbury, Kent, England. [Ridd, M.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England. [Sach, T.] Univ E Anglia, Hlth Econ Grp, Norwich, Norfolk, England. [Schuttelaar, M. -L. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, Groningen, Netherlands. [Sulzer, A.; Talmo, H. Vestby] Sanofi Aventis, Montpellier, France. [Tauber, M.] Toulouse Univ, Toulouse, France. [Volke, A.] Univ Tartu, Dept Dermatol, Tartu, Estonia. [Wahlgren, C. -F.] Karolinska Inst, Dept Med, Dermatol Unit, Solna, Sweden. [Wahlgren, C. -F.] Karolinska Univ Hosp, Stockholm, Sweden. [Weidinger, S.] Venereol & Allergy Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany. [Weisshaar, E.] Heidelberg Univ, Dept Social Med, Occupat & Environm Dermatol, Heidelberg, Germany. [Wollenberg, A.] Univ Munich, Dept Dermatol & Allergy, Munich, Germany. RP Chalmers, JR (reprint author), Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham, England. RI Weidinger, Stephan/C-8461-2011; Aoki, Valeria/H-1415-2012 OI Apfelbacher, Christian/0000-0003-3805-8219; Ridd, Matthew/0000-0002-7954-8823; Schuttelaar, Marie-Louise/0000-0002-0766-4382 FU Department of Health [CDF-2014-07-006] NR 19 TC 6 Z9 6 U1 4 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD JUL PY 2016 VL 175 IS 1 BP 69 EP 79 DI 10.1111/bjd.14773 PG 11 WC Dermatology SC Dermatology GA DS6UF UT WOS:000380917600017 PM 27436240 ER PT J AU Apelo, SIA Lamming, DW AF Apelo, Sebastian I. Arriola Lamming, Dudley W. TI Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Review DE Intermittent rapamycin; Lifespan; Mouse; Rapamycin analogs ID EXTENDS LIFE-SPAN; KIDNEY-TRANSPLANT RECIPIENTS; GENETICALLY HETEROGENEOUS MICE; INDUCED INSULIN-RESISTANCE; STEM-CELL TRANSPLANTATION; DIETARY RESTRICTION; ADIPOSE-TISSUE; MYCOPHENOLATE-MOFETIL; GLUCOSE-HOMEOSTASIS; COGNITIVE DEFICITS AB Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice. Although rapamycin is an FDA-approved drug for select indications, a diverse set of negative side effects may preclude its wide-scale deployment as an antiaging therapy. mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo. Over the past decade, it has become clear that although genetic and pharmacological inhibition of mTORC1 extends lifespan and delays aging, inhibition of mTORC2 has negative effects on mammalian health and longevity and is responsible for many of the negative side effects of rapamycin. In this review, we discuss recent advances in understanding the molecular and physiological effects of rapamycin treatment, and we discuss how the use of alternative rapamycin treatment regimens or rapamycin analogs has the potential to mitigate the deleterious side effects of rapamycin treatment by more specifically targeting mTORC1. Although the side effects of rapamycin are still of significant concern, rapid progress is being made in realizing the revolutionary potential of rapamycin-based therapies for the treatment of diseases of aging. C1 Univ Wisconsin, Dept Med, Madison, WI USA. [Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu FU National Institute on Aging at the National Institutes of Health [R00 AG041765]; University of Wisconsin-Madison School of Medicine and Public Health; University of Wisconsin-Madison Department of Medicine; American Diabetes Association [1-16-PMF-001]; Glenn Award for Research in the Biological Mechanisms of Aging; AFAR Research Grant from American Federation for Aging Research; William S. Middleton Memorial Veterans Hospital FX This work was supported by the National Institute on Aging at the National Institutes of Health (R00 AG041765 to D.W.L.); the University of Wisconsin-Madison School of Medicine and Public Health; and the University of Wisconsin-Madison Department of Medicine. S.I.A.A is supported by a fellowship from the American Diabetes Association (1-16-PMF-001). The Lamming Laboratory is supported in part by a Glenn Award for Research in the Biological Mechanisms of Aging and an AFAR Research Grant from the American Federation for Aging Research. This work was supported using facilities and resources at the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 126 TC 8 Z9 8 U1 5 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JUL PY 2016 VL 71 IS 7 BP 841 EP 849 DI 10.1093/gerona/glw090 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DT0YW UT WOS:000381209900001 ER PT J AU Apelo, SIA Pumper, CP Baar, EL Cummings, NE Lamming, DW AF Apelo, Sebastian I. Arriola Pumper, Cassidy P. Baar, Emma L. Cummings, Nicole E. Lamming, Dudley W. TI Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Anti-aging; Life span; Mice; mTOR; Rapamycin ID INDUCED INSULIN-RESISTANCE; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; MAMMALIAN TARGET; MTOR INHIBITION; RESTRICTION; ACTIVATION; LONGEVITY; COMPLEX; DIET AB Inhibition of the mTOR (mechanistic target of rapamycin) signaling pathway by the FDA-approved drug rapamycin promotes life span in numerous model organisms and delays age-related disease in mice. However, the utilization of rapamycin as a therapy for age-related diseases will likely prove challenging due to the serious metabolic and immunological side effects of rapamycin in humans. We recently identified an intermittent rapamycin treatment regimen-2 mg/kg administered every 5 days-with a reduced impact on glucose homeostasis and the immune system as compared with chronic treatment; however, the ability of this regimen to extend life span has not been determined. Here, we report for the first time that an intermittent rapamycin treatment regimen starting as late as 20 months of age can extend the life span of female C57BL/6J mice. Our work demonstrates that the anti-aging potential of rapamycin is separable from many of its negative side effects and suggests that carefully designed dosing regimens may permit the safer use of rapamycin and its analogs for the treatment of age-related diseases in humans. C1 [Apelo, Sebastian I. Arriola; Pumper, Cassidy P.; Baar, Emma L.; Cummings, Nicole E.; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI USA. [Apelo, Sebastian I. Arriola; Pumper, Cassidy P.; Baar, Emma L.; Cummings, Nicole E.; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. [Cummings, Nicole E.; Lamming, Dudley W.] Univ Wisconsin, Endocrinol & Reprod Physiol Grad Training Program, Madison, WI 53706 USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu FU National Institute on Aging at the National Institutes of Health [R00 AG041765]; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; American Diabetes Association [1-16-PMF-001] FX This work was supported by the National Institute on Aging at the National Institutes of Health (R00 AG041765 to D.W.L.); the UW-Madison School of Medicine and Public Health; and the UW-Madison Department of Medicine. S.I.A.A is supported by a fellowship from the American Diabetes Association (1-16-PMF-001). This work was supported using facilities and resources at the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 44 TC 5 Z9 5 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JUL PY 2016 VL 71 IS 7 BP 876 EP 881 DI 10.1093/gerona/glw064 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DT0YW UT WOS:000381209900005 ER PT J AU Klein, E Solomon, AJ Corboy, J Bernat, J AF Klein, E. Solomon, A. J. Corboy, J. Bernat, J. TI Physician compensation for industry-sponsored clinical trials in multiple sclerosis influences patient trust SO MULTIPLE SCLEROSIS AND RELATED DISORDERS LA English DT Article DE Multiple sclerosis; Trust; Clinical trials; Conflict of interest; Professional conduct and ethics; Industry-sponsored clinical trials ID CONFLICTS-OF-INTEREST; POTENTIAL RESEARCH PARTICIPANTS; CARE; VIEWS AB Background: Perceived physician financial conflicts of interest of can affect patient trust. Payment to physicians for industry sponsored clinical trials in multiple sclerosis is a relatively new potential source of physician conflict of interest. There is limited available data on how physician payment for trial involvement in multiple sclerosis clinical trials may influence patient trust. Objective: To understand how patient trust is influenced by information about physician payment for multiple sclerosis clinical trials. Methods: An anonymous online instrument was developed. Results: 597 people with multiple sclerosis participated in the study. The study found that 61% of patients who had not previously participated in a clinical trial estimated that they would have lower levels of trust in their physician if the physician was paid for involvement in their clinical trial. Among former clinical trial participants, 38% self-reported a lower level of trust. Other potential physician-industry relationships, such as industry consulting or giving industry-sponsored talks, also adversely affected trust, though to a lesser extent than physician payment for subject participation in clinical trials. Conclusions: Results of this study demonstrate that physician payment for study participation in multiple sclerosis clinical trials is a potential conflict that can adversely affect patient trust. (C) 2016 Elsevier B.V. All rights reserved. C1 [Klein, E.] Portland VA Med Ctr, Neurol Serv, POB 1034,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. [Klein, E.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Klein, E.] Univ Washington, Ctr Sensorimotor Neural Engn, Seattle, WA 98195 USA. [Klein, E.] Univ Washington, Dept Philosophy, Seattle, WA 98195 USA. [Solomon, A. J.] Univ Vermont, Dept Neurol Sci, Burlington, VT 05405 USA. [Corboy, J.] Univ Colorado, Dept Neurol, Boulder, CO 80309 USA. [Bernat, J.] Geisel Sch Med Dartmouth, Dept Neurol, Hanover, NH USA. RP Klein, E (reprint author), Portland VA Med Ctr, Neurol Serv, POB 1034,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM kleine@ohsu.edu NR 20 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2211-0348 EI 2211-0356 J9 MULT SCLER RELAT DIS JI Mult. Scler. Relat. Disord. PD JUL PY 2016 VL 8 BP 4 EP 8 DI 10.1016/j.msard.2016.04.001 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA DU6SP UT WOS:000382345200004 PM 27456867 ER PT J AU Nagami, GT AF Nagami, Glenn T. TI Hyperchloremia - Why and how SO NEFROLOGIA LA English DT Review DE Hyperchloremia; Electrolyte disorder; Serum bicarbonate ID CRITICALLY-ILL PATIENTS; THICK ASCENDING LIMB; RENAL BLOOD-FLOW; PROXIMAL TUBULE; METABOLIC-ACIDOSIS; CHLORIDE; SODIUM; KIDNEY; NACL; MORTALITY AB Hyperchloremia is a common electrolyte disorder that is associated with a diverse group of clinical conditions. The kidney plays an important role in the regulation of chloride concentration through a variety of transporters that are present along the nephron. Nevertheless, hyperchloremia can occur when water losses exceed sodium and chloride losses, when the capacity to handle excessive chloride is overwhelmed, or when the serum bicarbonate is low with a concomitant rise in chloride as occurs with a normal anion gap metabolic acidosis or respiratory alkalosis. The varied nature of the underlying causes of the hyperchloremia will, to a large extent, determine how to treat this electrolyte disturbance. Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Nefrologia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Nagami, Glenn T.] VA Greater Los Angeles Healthcare Syst, Dept Med, Nephrol Sect, Los Angeles, CA 90073 USA. [Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Nagami, GT (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Nephrol Sect, Los Angeles, CA 90073 USA.; Nagami, GT (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. EM glenn.nagami@va.gov FU U.S. Department of Veterans Affairs FX This work was supported, in part, by the U.S. Department of Veterans Affairs. NR 35 TC 0 Z9 0 U1 0 U2 0 PU SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ PI MADRID PA HOSPITAL RAMON Y CAJAL CTR DE COLMENAR, KM 9,100, 28034 MADRID, SPAIN SN 0211-6995 EI 1989-2284 J9 NEFROLOGIA JI Nefrologia PD JUL-AUG PY 2016 VL 36 IS 4 BP 347 EP 353 DI 10.1016/j.nefro.2016.04.001 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DU1GU UT WOS:000381957000003 PM 27267918 ER PT J AU Altawalbeh, SM Thorpe, JM Thorpe, CT Smith, KJ AF Altawalbeh, Shoroq M. Thorpe, Joshua M. Thorpe, Carolyn T. Smith, Kenneth J. TI Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy SO VALUE IN HEALTH LA English DT Article DE asthma treatment; cost-utility analysis; hospitalization; older adults ID QUALITY-OF-LIFE; ADD-ON THERAPY; ELDERLY-PATIENTS; PLUS SALMETEROL; UNITED-STATES; MONTELUKAST; EXACERBATIONS; METAANALYSIS; MEDICATIONS; MANAGEMENT AB Background: Long-acting beta agonists (LABA) and leukotriene receptor antagonists (LTRA) are the major add-on treatments in older adults with persistent asthma when inhaled corticosteroids (ICS) fail to achieve adequate asthma control. Objectives: To evaluate the cost utility of ICS + LABA treatment compared with ICS + LTRA treatment in older adults with asthma. Methods: A Markov model was used to estimate the incremental costs and quality-adjusted life expectancy associated with ICS + LABA treatment versus ICS + LTRA treatment in older adults with asthma in the United States from the health system perspective. The HCUPnet 2010 national statistics were used to extract the costs associated with asthma and cardiovascular hospitalizations, and inpatient mortality associated with these events. Event probabilities were predicted using Medicare 2009-2010 claims for older adults with asthma. Treatment costs were estimated on the basis of average wholesale drug price listings, and utility estimates were extracted from the literature. To account for uncertainty, oneway sensitivity analysis and probabilistic sensitivity analysis were performed. Results: The model predicted that, compared with ICS + LTRA treatment, ICS + LABA treatment costs $5,823 more while gaining 0.03 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio of $209,090 per QALY. Hospitalization probabilities and posthospitalization utilities were the most influential parameters in the one-way sensitivity analysis. Probabilistic uncertainty analysis using Monte-Carlo simulations showed that the probabilities that ICS + LTRA treatment is cost-effective compared with ICS + LABA treatment are 77% and 62% at $50,000 and $100,000 per QALY gained willingness-to-pay thresholds, respectively. Conclusions: The cost-effectiveness of ICS + LABA treatment is economically unfavorable in older adults when compared with LTRA as addon treatment. C1 [Altawalbeh, Shoroq M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Altawalbeh, Shoroq M.] Jordan Univ Sci & Technol, Sch Pharm, Dept Clin Pharm, Irbid, Jordan. [Thorpe, Joshua M.; Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Thorpe, Joshua M.; Thorpe, Carolyn T.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Dept Med, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA 15213 USA. RP Altawalbeh, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM sha55@pitt.edu FU University of Pittsburgh School of Pharmacy; Pittsburgh Claude D. Pepper Older Americans Independence Center [NIA P30 AGAG024827] FX This study was supported by the University of Pittsburgh School of Pharmacy and the Pittsburgh Claude D. Pepper Older Americans Independence Center (NIA P30 AGAG024827). NR 48 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD JUL-AUG PY 2016 VL 19 IS 5 BP 537 EP 543 DI 10.1016/j.jval.2016.02.004 PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DU5MA UT WOS:000382254600007 PM 27565270 ER PT J AU Kohli, P Soler, ZM Nguyen, SA Muus, JS Schlosser, RJ AF Kohli, Preeti Soler, Zachary M. Nguyen, Shaun A. Muus, John S. Schlosser, Rodney J. TI The Association Between Olfaction and Depression: A Systematic Review SO CHEMICAL SENSES LA English DT Review DE anosmia; BDI; hyposmia; normosmia; SIT-40; Sniffin' Sticks ID QUALITY-OF-LIFE; CHRONIC RHINOSINUSITIS; MAJOR DEPRESSION; ODOR IDENTIFICATION; DISORDERS; DYSFUNCTION; SCHIZOPHRENIA; SENSITIVITY; MEMORY; MOOD AB Previous studies on the relationship between olfaction and depression have revealed mixed results. In addition, few have focused on the reciprocity of this association. The aim of this study is to combine depression and olfactory data in two separate patient populations to further understand their association. A systematic literature review was conducted using 3 online databases to identify studies correlating olfaction and depression in patients presenting with either primary depression or primary olfactory dysfunction. For the depressed population, weighted means and standard deviations for the Sniffin' Sticks Test and the 40-item Smell Identification Test were combined using 10 studies. For the olfactory dysfunction population, weighted means of Beck's Depression Inventory were combined using 3 studies. Independent t-tests were used to compare differences between groups. Comparing primary depressed patients with controls, depressed patients showed decreased scores in olfactory threshold (6.31 +/- 1.38 vs. 6.78 +/- 0.88, P = 0.0005), discrimination (12.05 +/- 1.44 vs. 12.66 +/- 1.36, P = 0.0073), identification (12.57 +/- 0.74 vs. 12.98 +/- 0.90, P < 0.0001), and 40-Item Smell Identification Test (35.31 +/- 1.91 vs. 37.41 +/- 1.45, P < 0.0001). In patients with primary olfactory dysfunction, Beck's Depression Inventory scores were significantly different between patients classified as normosmics, hyposmics and anosmics (5.21 +/- 4.73 vs. 10.93 +/- 9.25 vs. 14.15 +/- 5.39, P a parts per thousand currency sign 0.0274 for all 3 comparisons). In conclusion, patients with depression have reduced olfactory performance when compared with the healthy controls and conversely, patients with olfactory dysfunction, have symptoms of depression that worsen with severity of smell loss. C1 [Kohli, Preeti; Soler, Zachary M.; Nguyen, Shaun A.; Muus, John S.; Schlosser, Rodney J.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. RP Kohli, P (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM pkohli89@gmail.com NR 38 TC 2 Z9 2 U1 8 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0379-864X EI 1464-3553 J9 CHEM SENSES JI Chem. Senses PD JUL PY 2016 VL 41 IS 6 BP 479 EP 486 DI 10.1093/chemse/bjw061 PG 8 WC Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology SC Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology GA DT1BE UT WOS:000381215900001 PM 27170667 ER PT J AU Pandey, N Herrera, HH Johnson, CM MacCarthy, AA Copeland, LA AF Pandey, Nivedita Herrera, Henry H. Johnson, Christopher M. MacCarthy, Andrea A. Copeland, Laurel A. TI Preventative care for patients with inflammatory bowel disease in the Veterans Health Administration SO MEDICINE LA English DT Article DE inflammatory bowel disease; preventative health; veterans health administration ID INCREASED RISK; METAANALYSIS; GUIDELINES; DIAGNOSES; THERAPY; AFFAIRS; CANCER AB Patients with inflammatory bowel disease (IBD) have underlying immune dysregulation. Immunosuppressive medications put them at risk of infection. This study assessed rates of recommended vaccinations and preventative screening in patients with IBD. Nationwide data on patients diagnosed with IBD in the Veterans Health Administration (VHA) October 2004 to September 2014 were extracted. Variation in vaccination, screenings, and risk of death by demographic factors (age group, gender) were estimated in bivariate and multivariable analyses. During the 10-year study period, 62,002 patients were treated for IBD. Nonmelanoma skin cancer was found in 2.6%, and these patients more commonly accessed dermatology clinic (22.5% vs 15.2%; chi-square = 66.6; df = 1; P < 0.0001). In total, 15% received DEXA scans, especially women (34.7% vs 13.2% men; chi-square = 1415.5; df = 1; P < 0.0001). Eye manifestations were noted in 38.3% yet only 31% were referred to ophthalmology. Abnormal Pap smears were found for 15% of women < 65 (compared to 5% among normal patient populations); 34% had no record of Pap smear in VHA data. Vaccination rates were modest: pneumococcal 39%; TDAP 23%; hepatitis B 3%; varicella and PPD <0.5%. In an adjusted logistic regression model, 5-year mortality was lower among those using primary care prior to IBD diagnosis (odds ratio [OR] = 0.61; 95% CI 0.55-0.68). Despite the current IBD guidelines, vaccination and preventative screening rates were unacceptably low among patients diagnosed with IBD. Interventions such as education and increased awareness may be needed to improve these rates. C1 [Pandey, Nivedita] Cent Texas Vet Hlth Care Syst, Gastroenterol Serv, Temple, TX USA. [Herrera, Henry H.; Johnson, Christopher M.] Scott & White Mem Hosp & Clin, Dept Med, Div Gastroenterol, Temple, TX 76508 USA. [MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Copeland, Laurel A.] Scott & White Mem Hosp & Clin, Dept Med, Ctr Appl Hlth Res, Cent Texas Vet Hlth Care Syst, Temple, TX 76508 USA. [Copeland, Laurel A.] UT Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX USA. RP Pandey, N (reprint author), Vet Mem Dr, Temple, TX USA. EM nainidel@gmail.com OI Copeland, Laurel/0000-0002-9478-0209 FU Veterans Health Administration HSRD Award [09-335]; Gastroenterology division of Central Texas Veterans Health Care System; Veterans Health Administration; Scott & White Healthcare; NIMH FX This study was supported by the Veterans Health Administration HSR&D Award #09-335 with additional support from Gastroenterology division of Central Texas Veterans Health Care System. LAC received grant funds from Veterans Health Administration, Scott & White Healthcare, and NIMH. NR 28 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD JUL PY 2016 VL 95 IS 27 AR e4012 DI 10.1097/MD.0000000000004012 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DS1QW UT WOS:000380372400027 PM 27399081 ER PT J AU Biegus, J Hillege, HL Postmus, D Valente, MAE Bloomfield, DM Cleland, JGF Cotter, G Davison, BA Dittrich, HC Fiuzat, M Givertz, MM Massie, BM Metra, M Teerlink, JR Voors, AA O'Connor, CM Ponikowski, P AF Biegus, Jan Hillege, Hans L. Postmus, Douwe Valente, Mattia. A. E. Bloomfield, Daniel M. Cleland, John G. F. Cotter, Gad Davison, Beth A. Dittrich, Howard C. Fiuzat, Mona Givertz, Michael M. Massie, Barry M. Metra, Marco Teerlink, John R. Voors, Adriaan A. O'Connor, Christopher M. Ponikowski, Piotr TI Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Liver dysfunction; Prognosis; Liver function tests ID LEVELS PREDICT SURVIVAL; EJECTION FRACTION; RENAL-FUNCTION; MORTALITY; ADMISSION; TROPONIN; PROGRAM; TRIAL AB Aims Episodes of acute heart failure (AHF) unfavourably affect multiple organs, which may have an adverse impact on the outcomes. We investigated the prevalence and clinical consequences of abnormal liver function tests (LFTs) in AHF patients enrolled in the PROTECT study. Methods and results The LFTs comprised serial assessment of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and albumin at baseline and during follow-up (daily until discharge, on days 7 and 14). The prevalence of abnormal LFTs (above upper limit of normal for AST and ALT or below lower limit of normal for albumin) was: at baseline AST 20%, ALT 12%, albumin 40%; and at day 14: AST 15%, ALT 9%, albumin 26%. Abnormal LFTs at baseline were associated with a higher risk of in-hospital death with odds ratios [95% confidence interval (CI)] of 3.5 (1.7-7.3) for AST, 3.9 (1.8-8.4) for ALT, and 2.8 (1.3-5.9) for albumin (all P < 0.01). Abnormal baseline and discharge LFTs had an unfavourable impact on 180-day mortality with hazard ratios (95% CI) for baseline AST, ALT, and albumin of 1.3 (1.0-1.7), 1.1 (1.0-1.2), 1.4 (1.1-1.8), respectively, and 1.5 (1.1-2.0), 1.5 (1.0-2.2), and 1.6 (1.2-2.1), for discharge AST, ALT, albumin, respectively (all P < 0.05). Analysis of LFTs trajectories (calculated as changes in LFTs over time) revealed that increasing AST and ALT on day 3 as well as decreasing albumin on day 4 were independent prognosticators of 180-day outcome (all P < 0.05). Conclusions Abnormal LFTs are frequent in AHF at baseline and during hospital stay and predict worse outcomes. Whether this association is causal and what are the underlying mechanisms involved require further study. C1 [Biegus, Jan; Ponikowski, Piotr] Med Univ, Dept Heart Dis, Wroclaw, Poland. [Biegus, Jan; Ponikowski, Piotr] Clin Mil Hosp, Dept Cardiol, Ctr Heart Dis, Wroclaw, Poland. [Hillege, Hans L.; Postmus, Douwe; Valente, Mattia. A. E.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Cleland, John G. F.] Univ Hull, Castle Hill Hosp, Dept Cardiol, Natl Heart & Lung Inst,Imperial Coll London,Royal, Kingston Upon Hull HU6 7RX, N Humberside, England. [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Fiuzat, Mona; O'Connor, Christopher M.] Duke Univ, Med Ctr, Div Cardiovasc Med, Duke Clin Res Inst, Durham, NC USA. [Givertz, Michael M.] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA USA. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Sect Cardiol, San Francisco, CA 94143 USA. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Metra, Marco] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Cardiol, Brescia, Italy. RP Ponikowski, P (reprint author), Med Univ, Wroclaw Ctr Heart Dis, Dept Heart Dis, Clin Mil Hosp, Weigla 5, PL-53114 Wroclaw, Poland. EM piotrponikowski@4wsk.pl NR 21 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JUL PY 2016 VL 18 IS 7 BP 830 EP 839 DI 10.1002/ejhf.532 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DS8DG UT WOS:000381012700013 PM 27170455 ER PT J AU Mallipattu, SK He, JC AF Mallipattu, Sandeep K. He, John C. TI The podocyte as a direct target for treatment of glomerular disease? SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE abatacept; calcineurin inhibitors; glucocorticoids; podocyte; rituximab ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; ENDOTHELIAL GROWTH-FACTOR; TRANSGENIC REN2 RAT; END-ORGAN DAMAGE; NEPHROTIC-SYNDROME; RETINOIC ACID; PUROMYCIN AMINONUCLEOSIDE; COSTIMULATORY BLOCKADE; MOLECULAR-MECHANISMS; PROTECTS PODOCYTES AB The Centers for Disease Control and Prevention estimates more than 10% of adults in the United States, over 20 million Americans, have chronic kidney disease (CKD). A failure to maintain the glomerular filtration barrier directly contributes to the onset of CKD. The visceral epithelial cells, podocytes, are integral to the maintenance of this renal filtration barrier. Direct podocyte injury contributes to the onset and progression of glomerular diseases such as minimal change disease (MCD), focal segmental glomerular sclerosis (FSGS), diabetic nephropathy, and HIV-associated nephropathy (HIVAN). Since podocytes are terminally differentiated with minimal capacity to self-replicate, they are extremely sensitive to cellular injury. In the past two decades, our understanding of the mechanism(s) by which podocyte injury occurs has greatly expanded. With this newfound knowledge, therapeutic strategies have shifted to identifying targets directed specifically at the podocyte. Although the systemic effects of these agents are important, their direct effect on the podocyte proves to be essential in ameliorating glomerular disease. In this review, we highlight the mechanisms by which these agents directly target the podocyte independent of its systemic effects. C1 [Mallipattu, Sandeep K.] SUNY Stony Brook, Dept Med, Div Nephrol, Stony Brook, NY 11794 USA. [He, John C.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [He, John C.] James J Peters VA Med Ctr, Renal Sect, New York, NY USA. RP He, JC (reprint author), Icahn Sch Med Mt Sinai, Dept Med Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM cijiang.he@mssm.edu FU National Institutes of Health (NIH) [1K08DK-102519]; NIH [1R01DK-078897]; Chinese 973 Fund [2012CB51760] FX S. K. Mallipattu is supported by National Institutes of Health (NIH) Grant 1K08DK-102519. J. C. He is supported by NIH 1R01DK-078897, and Chinese 973 Fund 2012CB51760. NR 63 TC 3 Z9 3 U1 4 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUL 1 PY 2016 VL 311 IS 1 BP F46 EP F51 DI 10.1152/ajprenal.00184.2016 PG 6 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA DS5MS UT WOS:000380826900006 PM 27097894 ER PT J AU Wagner, B Drel, V Gorin, Y AF Wagner, Brent Drel, Viktor Gorin, Yves TI Pathophysiology of gadolinium-associated systemic fibrosis SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Review DE fibrosis; gadolinium; nephrogenic fibrosing dermopathy; NADPH oxidase; skin diseases ID RESONANCE-IMAGING CONTRAST; STAGE RENAL-DISEASE; IN-VIVO; MYOFIBROBLAST DIFFERENTIATION; CIRCULATING FIBROCYTES; DIABETIC-NEPHROPATHY; KIDNEY-DISEASE; LIVER FIBROSIS; NADPH OXIDASES; CASE SERIES AB Systemic fibrosis from gadoliniumbased magnetic resonance imaging contrast is a scourge for the afflicted. Although gadolinium-associated systemic fibrosis is a rare condition, the threat of litigation has vastly altered clinical practice. Most theories concerning the etiology of the fibrosis are grounded in case reports rather than experiment. This has led to the widely accepted conjecture that the relative affinity of certain contrast agents for the gadolinium ion inversely correlates with the risk of succumbing to the disease. How gadolinium-containing contrast agents trigger widespread and site-specific systemic fibrosis and how chronicity is maintained are largely unknown. This review highlights experimentally-derived information from our laboratory and others that pertain to our understanding of the pathophysiology of gadolinium-associated systemic fibrosis. C1 [Wagner, Brent] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Wagner, Brent; Drel, Viktor; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. RP Wagner, B (reprint author), Univ Texas Hlth Sci Ctr, South Texas Vet Hlth Care Syst, Dept Med, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wagnerb@uthscsa.edu FU Veterans Administration Merit Award [I01 BX001958]; National Institutes of Health [R01 DK-102085, UL1 TR-001120, R01 DK-079996, R01 DK-78971]; National Priorities Research Program [NPRP8-1750-3-360]; Qatar National Research Fund FX The research was funded by the Veterans Administration Merit Award (I01 BX001958, B. Wagner); the National Institutes of Health through Grants R01 DK-102085 (B. Wagner), UL1 TR-001120 (Y. Gorin), R01 DK-079996 (Y. Gorin), and R01 DK-78971 (Y. Gorin); and an award from the Qatar National Research Fund, National Priorities Research Program (NPRP8-1750-3-360) (Y. Gorin). NR 105 TC 1 Z9 1 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JUL 1 PY 2016 VL 311 IS 1 BP F1 EP F11 DI 10.1152/ajprenal.00166.2016 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA DS5MS UT WOS:000380826900001 PM 27147669 ER PT J AU Meyer, JD Koltyn, KF Stegner, AJ Kim, JS Cook, DB AF Meyer, Jacob D. Koltyn, Kelli F. Stegner, Aaron J. Kim, Jee-Seon Cook, Dane B. TI Influence of Exercise Intensity for Improving Depressed Mood in Depression: A Dose-Response Study SO BEHAVIOR THERAPY LA English DT Article DE depression; exercise; antidepressant response; exercise optimization; symptom management ID RANDOMIZED CONTROLLED-TRIALS; PHYSICAL-ACTIVITY; DSM-IV; ANXIETY; VALIDATION; DISORDERS; VALIDITY; ADULTS; STATES AB Introduction: Exercise effectively improves mood in major depressive disorder (MDD), but the optimal exercise stimulus to improve depressed mood is unknown. Purpose: To determine the dose-response relationship of acute exercise intensity with depressed mood responses to exercise in MDD. We hypothesized that the acute response to exercise would differ between light, moderate, and hard intensity exercise with higher intensities yielding more beneficial responses. Methods: Once weekly, 24 women (age: 38.6 +/- 14.0) diagnosed with MDD underwent a 30-minute session at one of three steady-state exercise intensities (light, moderate, hard; rating of perceived exertion 11, 13 or 15) or quiet rest on a stationary bicycle. Depressed mood was evaluated with the Profile of Mood States before, 10 and 30 minutes post-exercise. Results: Exercise reduced depressed mood 10 and 30 minutes following exercise, but this effect was not influenced by exercise intensity. Participants not currently taking antidepressants (n = 10) had higher baseline depression scores, but did not demonstrate a different antidepressant response to exercise compared to those taking antidepressants. Conclusions: To acutely improve depressed mood, exercise of any intensity significantly improved feelings of depression with no differential effect following light, moderate, or hard exercise. Pharmacological antidepressant usage did not limit the mood-enhancing effect of acute exercise. Acute exercise should be used as a symptom management tool to improve mood in depression, with even light exercise an effective recommendation. These results need to be replicated and extended to other components of exercise prescription (e.g., duration, frequency, mode) to optimize exercise guidelines for improving depression. C1 [Meyer, Jacob D.; Koltyn, Kelli F.; Stegner, Aaron J.; Kim, Jee-Seon; Cook, Dane B.] Univ Wisconsin, Madison, WI 53706 USA. [Stegner, Aaron J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Meyer, JD (reprint author), 2000 Observ Dr, Madison, WI 53706 USA. EM jdmeyer3@wisc.edu FU Virginia Home Henry Gift Fund; University of Wisconsin-Madison Graduate School; Wisconsin Center for Education Research; National Research Service Award from the Health Resources and Services Administration [T32HP10010] FX This project was funded, in part, by the Virginia Home Henry Gift Fund, the University of Wisconsin-Madison Graduate School and the Wisconsin Center for Education Research. Jacob Meyer was partially supported by a National Research Service Award from the Health Resources and Services Administration T32HP10010 to the University of Wisconsin Department of Family Medicine and Community Health. None of the funding sources were involved in the study design, collection, analysis or interpretation of the data. The authors would like to thank Lauren Schlapman, Hannah Feinstein, Shawn Tipple, Matthew Patton, Caroline Wickler and Rachel Prince for their contributions during data collection and processing. NR 38 TC 2 Z9 2 U1 20 U2 31 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD JUL PY 2016 VL 47 IS 4 BP 527 EP 537 PG 11 WC Psychology, Clinical SC Psychology GA DS7NR UT WOS:000380970700008 PM 27423168 ER PT J AU Barnes, GD Stanislawski, MA Liu, WH Baron, AE Armstrong, EJ Ho, PM Klein, A Maddox, TM Nallamothu, BK Rumsfeld, JS Tsai, TT Bradley, SM AF Barnes, Geoffrey D. Stanislawski, Maggie A. Liu, Wenhui Baron, Anna E. Armstrong, Ehrin J. Ho, P. Michael Klein, Andrew Maddox, Thomas M. Nallamothu, Brahmajee K. Rumsfeld, John S. Tsai, Thomas T. Bradley, Steven M. TI Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE abciximab; eptifibatide; mortality; medication errors; percutaneous coronary intervention ID DECISION-SUPPORT-SYSTEMS; CART PROGRAM; PRASUGREL; REGISTRY; RISK; THROMBOCYTOPENIA; EPTIFIBATIDE; CLOPIDOGREL; ABCIXIMAB; QUALITY AB Background-Several antiplatelet medications used during and after percutaneous coronary intervention (PCI) are contraindicated for specific patient groups. A broad assessment of contraindicated medication use and associated clinical outcomes is not well described. Methods and Results-Using national Veterans Affairs Clinical Assessment, Reporting, and Tracking Program data for all PCI between 2007 and 2013, we evaluated patients with contraindications to commonly used antiplatelet medications during and after PCI, defined in accordance with package inserts. Adjusted association between contraindicated medication use and outcomes of periprocedural bleeding and 30-day mortality were assessed using Cox proportional hazards with inverse probability weighting. Among 64 294 patients undergoing PCI, 11 315(17.6%) had a contraindication to a common antiplatelet medication and 737 (6.5%) of these patients received a contraindicated medication. In unadjusted analyses, any contraindicated medication use was associated with both increased bleeding and 30-day mortality. In adjusted models, contraindicated abciximab use in patients with thrombocytopenia (hazard ratio, 2.23; 95% confidence interval, 1.58-3.16) and in patients with a previous stroke (hazard ratio, 1.93; 95% confidence interval, 1.37-2.71) remained significantly associated with increased bleeding. Contraindicated abciximab use was not significantly associated with 30-day mortality in adjusted models. Use of eptifibatide in dialysis patients was not significantly associated with an increased risk of bleeding or mortality. Conclusions-In this national cohort, approximate to 18% of patients undergoing PCI had contraindications to common antiplatelet medications. Approximately 6% of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality. Continued efforts to reduce contraindicated medication use may help avoid periprocedural complications. C1 [Barnes, Geoffrey D.; Nallamothu, Brahmajee K.] Univ Michigan, Ann Arbor VA Med Ctr, Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA. [Stanislawski, Maggie A.; Liu, Wenhui; Armstrong, Ehrin J.; Ho, P. Michael; Maddox, Thomas M.; Rumsfeld, John S.; Bradley, Steven M.] Denver VA Med Ctr, Denver, CO USA. [Baron, Anna E.] Univ Colorado, Sch Publ Hlth, Denver, CO 80202 USA. [Klein, Andrew] St Louis VA Med Ctr, St Louis, MO USA. [Tsai, Thomas T.] Kaiser Permanente Colorado, Inst Heath Res, Denver, CO USA. RP Barnes, GD (reprint author), Univ Michigan, Frankel Cardiovasc Ctr, 2800 Plymouth Rd,Bldg 14 G101, Ann Arbor, MI 48109 USA. EM gbarnes@umich.edu FU National Heart, Lung, and Blood Institute [T32-HL007853]; Veterans Affairs Health Services Research and Development [HSRD-CDA2 10-199, HSRD-CDA2 08-021] FX Dr Barnes is supported by National Heart, Lung, and Blood Institute grant T32-HL007853. Drs Bradley and Maddox are supported by Career Development Awards (HSR&D-CDA2 10-199 and HSR&D-CDA2 08-021, respectively) from Veterans Affairs Health Services Research and Development. NR 27 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JUL PY 2016 VL 9 IS 4 BP 406 EP + DI 10.1161/CIRCOUTCOMES.115.002043 PG 19 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DS2MY UT WOS:000380609700010 PM 27245070 ER PT J AU Covert, KL Fleming, JN Staino, C Casale, JP Boyle, KM Pilch, NA Meadows, HB Mardis, CR McGillicuddy, JW Nadig, S Bratton, CF Chavin, KD Baliga, PK Taber, DJ AF Covert, Kelly L. Fleming, James N. Staino, Carmelina Casale, Jillian P. Boyle, Kimberly M. Pilch, Nicole A. Meadows, Holly B. Mardis, Caitlin R. McGillicuddy, John W. Nadig, Satish Bratton, Charles F. Chavin, Kenneth D. Baliga, Prabhakar K. Taber, David J. TI Predicting and preventing readmissions in kidney transplant recipients SO CLINICAL TRANSPLANTATION LA English DT Article DE healthcare quality; hospital readmission; kidney transplantation; medication adherence; pharmacy ID EARLY HOSPITAL READMISSION; PATIENT; REHOSPITALIZATION; CRITERIA; OUTCOMES AB A lack of research exploring post-transplant process optimization to reduce readmissions and increasing readmission rates at our center from 2009 to 2013 led to this study, aimed at assessing the effect of patient and process factors on 30-d readmission rates after kidney transplantation. This was a retrospective case-control study in adult kidney transplant recipients. Univariate and multivariate analyses were utilized to assess patient and process determinants of 30-d readmissions. 384 patients were included; 30-d readmissions were significantly associated with graft loss and death (p = 0.001). Diabetes (p = 0.049), pharmacist identification of poor understanding or adherence, and prolonged time on hemodialysis prior to transplant were associated with an increased risk of 30-d readmissions. After controlling for risk factors, readmission rates were only independently predicted by pharmacist identification of patient lack of understanding or adherence regarding post-transplant medications and dialysis exposure for more than three yr (OR 2.3, 95% CI 1.10-4.71, p = 0.026 and OR 2.1, 95% CI 1.22, 3.70, respectively), both of which were significantly modified by history of diabetes. Thirty-d readmissions are attributable to both patient and process-level factors. These data suggest that a lack of post-transplant medication knowledge in high-risk patients drives early hospital readmission. C1 [Covert, Kelly L.; Fleming, James N.; Staino, Carmelina; Casale, Jillian P.; Boyle, Kimberly M.; Pilch, Nicole A.; Meadows, Holly B.; Mardis, Caitlin R.] Med Univ South Carolina, Dept Pharm Serv, 280 Calhoun St,MSC 132, Charleston, SC 29425 USA. [McGillicuddy, John W.; Nadig, Satish; Bratton, Charles F.; Chavin, Kenneth D.; Baliga, Prabhakar K.; Taber, David J.] Med Univ South Carolina, Dept Surg, Charleston, SC USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. RP Covert, KL (reprint author), Med Univ South Carolina, Dept Pharm Serv, 280 Calhoun St,MSC 132, Charleston, SC 29425 USA. EM kelly.covert@outlook.com NR 16 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 EI 1399-0012 J9 CLIN TRANSPLANT JI Clin. Transplant. PD JUL PY 2016 VL 30 IS 7 BP 779 EP 786 DI 10.1111/ctr.12748 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA DR5PS UT WOS:000379955500006 PM 27101090 ER PT J AU Subhash, SS Baracco, G Miller, SL Eagan, A Radonovich, LJ AF Subhash, Shobha S. Baracco, Gio Miller, Shelly L. Eagan, Aaron Radonovich, Lewis J. TI ESTIMATION OF NEEDED ISOLATION CAPACITY FOR AN AIRBORNE INFLUENZA PANDEMIC SO HEALTH SECURITY LA English DT Article ID EXPEDIENT PATIENT ISOLATION; SARS; CONTAINMENT; EPIDEMIC; CARE AB We estimated the number of isolation beds needed to care for a surge in patients during an airborne-transmissible influenza pandemic. Based on US health system data, the amount of available airborne isolation beds needed for ill patients will be exceeded early in the course of a moderate or severe influenza pandemic, requiring medical facilities to find ways to further expand isolation bed capacity. Rather than building large numbers of permanent airborne infection isolation rooms to increase surge capacity, an investment that would come at great financial cost, it may be more prudent to prepare for wide-scale creation of just-in-time temporary negative-pressure wards. C1 [Subhash, Shobha S.; Eagan, Aaron; Radonovich, Lewis J.] US Dept Vet Affairs, VA Natl Ctr Occupat Hlth & Infect Control, Gainesville, FL USA. [Baracco, Gio] Miami VA Healthcare Syst, Infect Dis, Miami, FL USA. [Baracco, Gio] Miami VA Healthcare Syst, Infect Control Program, Miami, FL USA. [Baracco, Gio] Univ Miami, Miller Sch Med, Div Infect Dis, Med Clin, Miami, FL 33136 USA. [Miller, Shelly L.] Univ Colorado, Mech Engn, Boulder, CO 80309 USA. RP Subhash, SS (reprint author), Natl Ctr Occupat Hlth & Infect Control, Vet Hlth Adm, Off Patient Care Serv Publ Hlth, 1601 SW Archer Rd 151E, Gainesville, FL 32608 USA. EM Shobsubhash@gmail.com NR 28 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2326-5094 EI 2326-5108 J9 HEALTH SECUR JI Health Secur. PD JUL-AUG PY 2016 VL 14 IS 4 BP 258 EP 263 DI 10.1089/hs.2016.0015 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DS4SS UT WOS:000380772200008 PM 27447336 ER PT J AU Ellis, MKM Sally, MB Malinoski, D AF Ellis, Margaret Kathleen Menzel Sally, Mitchell Brett Malinoski, Darren TI The development and current status of Intensive Care Unit management of prospective organ donors SO INDIAN JOURNAL OF UROLOGY LA English DT Review DE Critical care; donor management; kidney transplant; renal transplant ID DELAYED GRAFT FUNCTION; HEART-BEATING DONORS; KIDNEY-TRANSPLANT RECIPIENTS; RENAL-FUNCTION; DECEASED DONORS; POTENTIAL DONORS; GOALS WORKGROUP; DONATION RATES; TRAUMA CENTER; HEPATITIS-B AB Introduction: Despite continuous advances in transplant medicine, there is a persistent worldwide shortage of organs available for donation. There is a growing body of research that supports that optimal management of deceased organ donors in Intensive Care Unit can substantially increase the availability of organs for transplant and improve outcomes in transplant recipients. Methods: A systematic literature review was performed, comprising a comprehensive search of the PubMed database for relevant terms, as well as individual assessment of references included in large original investigations, and comprehensive society guidelines. Results: In addition to overall adherence to catastrophic brain injury guidelines, optimization of physiologic state in accordance with established donor management goals (DMGs), and establishment of system-wide processes for ensuring early referral to organ procurement organizations (OPOs), several specific critical care management strategies have been associated with improved rates and outcomes of renal transplantation from deceased donors. These include vasoactive medication selection, maintenance of euvolemia, avoidance of hydroxyethyl starch, glycemic control, targeted temperature management, and blood transfusions if indicated. Conclusions: Management of deceased organ donors should focus first on maintaining adequate perfusion to all organ systems through adherence to standard critical care guidelines, early referral to OPOs, and family support. Furthermore, several specific DMGs and strategies have been recently shown to improve both the rates and outcomes of organ transplantation. C1 [Ellis, Margaret Kathleen Menzel] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Anesthesiol, Sect Anesthesiol, Portland, OR 97201 USA. [Ellis, Margaret Kathleen Menzel] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Anesthesiol, Sect Surg Crit Care, Portland, OR 97201 USA. [Sally, Mitchell Brett; Malinoski, Darren] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Trauma Crit Care & Acute Care Surg, Sect Surg Crit Care, Portland, OR 97201 USA. RP Ellis, MKM (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,Mail Code P3 Anes, Portland, OR 97239 USA. EM menzel@ohsu.edu NR 63 TC 0 Z9 0 U1 3 U2 3 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0970-1591 EI 1998-3824 J9 INDIAN J UROL JI Indian J. Urol. PD JUL-SEP PY 2016 VL 32 IS 3 BP 178 EP 185 DI 10.4103/0970-1591.185103 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DS9NZ UT WOS:000381111500004 PM 27555674 ER PT J AU Jang, JH Lee, JH Chand, HS Lee, JS Lin, Y Weathington, N Mallampalli, R Jeon, YJ Nyunoya, T AF Jang, Jun-Ho Lee, Ji-Hyeok Chand, Hitendra S. Lee, Jong-Soo Lin, Yong Weathington, Nathaniel Mallampalli, Rama Jeon, You-Jin Nyunoya, Toru TI APO-9 '-Fucoxanthinone Extracted from Undariopsis peteseniana Protects Oxidative Stress-Mediated Apoptosis in Cigarette Smoke-Exposed Human Airway Epithelial Cells SO MARINE DRUGS LA English DT Article DE brown algae; apo-9 '-fucoxanthinone; cigarette smoke; airway epithelial cells; DNA damage; apoptosis; oxidative stress ID WERNERS-SYNDROME PROTEIN; HUMAN LUNG FIBROBLASTS; ALGA EISENIA-BICYCLIS; ECKLONIA-CAVA; BROWN ALGA; DNA-DAMAGE; CELLULAR SENESCENCE; MARINE-ALGAE; PELVETIA-SILIQUOSA; SARGASSUM-MUTICUM AB Long-term cigarette smoking increases the risk for chronic obstructive pulmonary disease (COPD), characterized by irreversible expiratory airflow limitation. The pathogenesis of COPD involves oxidative stress and chronic inflammation. Various natural marine compounds possess both anti-oxidant and anti-inflammatory properties, but few have been tested for their efficacy in COPD models. In this study, we conducted an in vitro screening test to identify natural compounds isolated from various brown algae species that might provide protection against cigarette smoke extract (CSE)-induced cytotoxicity. Among nine selected natural compounds, apo-9'-fucoxanthinone (Apo9F) exhibited the highest protection against CSE-induced cytotoxicity in immortalized human bronchial epithelial cells (HBEC2). Furthermore, the protective effects of Apo9F were observed to be associated with a significant reduction in apoptotic cell death, DNA damage, and the levels of mitochondrial reactive oxygen species (ROS) released from CSE-exposed HBEC2 cells. These results suggest that Apo9F protects against CSE-induced DNA damage and apoptosis by regulating mitochondrial ROS production. C1 [Jang, Jun-Ho; Weathington, Nathaniel; Mallampalli, Rama; Nyunoya, Toru] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA. [Jang, Jun-Ho; Mallampalli, Rama; Nyunoya, Toru] VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. [Lee, Ji-Hyeok; Jeon, You-Jin] Jeju Natl Univ, Dept Marine Sci, Jeju 690756, South Korea. [Chand, Hitendra S.; Lin, Yong] Lovelace Resp Res Inst, Albuquerque, NM 87108 USA. [Lee, Jong-Soo] Gyeongsang Natl Univ, Inst Marine Ind, Dept Seafood Sci & Technol, Tongyeong 650160, South Korea. RP Nyunoya, T (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA.; Nyunoya, T (reprint author), VA Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. EM jangj2@upmc.edu; lee198186@daum.net; hchand@lrri.org; legs@gnu.ac.kr; ylin@lrri.org; weathingtonnm@upmc.edu; mallampallir@upmc.edu; youjin2014@gmail.com; nyunoyat@upmc.edu OI Chand, Hitendra/0000-0002-0574-9307 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and the Development; US Department of Veterans Affairs [CX001048]; Flight Attendant Medical Research Institute; National Institute of Health [AI117560]; American Lung Association [RG306208] FX This manuscript was supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and the Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs (CX001048) to T.N.; Flight Attendant Medical Research Institute to R.M.; National Institute of Health (AI117560) and American Lung Association (RG306208) to H.C. NR 54 TC 0 Z9 0 U1 1 U2 2 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1660-3397 J9 MAR DRUGS JI Mar. Drugs PD JUL PY 2016 VL 14 IS 7 AR 140 DI 10.3390/md14070140 PG 14 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DS4PJ UT WOS:000380762700019 ER PT J AU Kales, HC Kavanagh, J Chiang, C Kim, HM Bishop, T Valenstein, M Blow, FC AF Kales, Helen C. Kavanagh, Janet Chiang, Claire Kim, H. Myra Bishop, Tiffany Valenstein, Marcia Blow, Frederic C. TI Predictors of Antidepressant Nonadherence Among Older Veterans With Depression SO PSYCHIATRIC SERVICES LA English DT Article ID PRIMARY-CARE; PERCEIVED STIGMA; ADHERENCE; PATIENT; SEVERITY; SERVICES; RECEIPT; ANXIETY; RISK; RACE AB Objective: Most depression among older adults is treated in primary care, and many patients do not adhere to medication treatment. The U.S. Department of Veterans Affairs (VA) has recently introduced initiatives to address such treatment gaps. This study examined patient-reported antidepressant nonadherence during the acute treatment period (first four months after a prescription) and identified predictors of nonadherence in a sample of older veterans. Methods: This was a prospective, observational study of 311 participants ages 60 and older who received care at three VA medical centers and who had a diagnosis of clinically significant depression and were given a new outpatient antidepressant prescription. Participants completed an initial interview and a follow-up interview at four months after treatment recommendation. Antidepressant adherence was measured with a well-validated self-report measure. Results: At four months, 29% of participants reported nonadherence to their antidepressant medication. In unadjusted analyses, nonadherence was significantly associated with being African American, having no spouse or significant other, having greater general medical comorbidity, and receiving the prescription in a primary care setting (versus a specialty mental health setting). In logistic regression models controlling for several variables (demographic, illness, and functional status variables; type of antidepressant; contact with a therapist; medical setting; and site of recruitment), two predictors remained significantly associated with nonadherence: African-American race (odds ratio [OR] = 4.23, p < .001) and general medical comorbidity (OR = 1.33, p = .002). Conclusions: The two main predictors of nonadherence among older adults with depression were African-American race and general medical comorbidity. Results suggest that significant needs remain for important patient subgroups to improve antidepressant adherence. C1 [Kales, Helen C.; Kavanagh, Janet; Bishop, Tiffany; Valenstein, Marcia; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Kim, H. Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA. [Kales, Helen C.; Chiang, Claire; Valenstein, Marcia; Blow, Frederic C.] US Dept Vet Affairs, Ctr Clin Management Res Hlth Serv Res & Dev, Ann Arbor, MI USA. RP Kales, HC (reprint author), Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. EM kales@med.umich.edu FU Health Services Research and Development, U.S. Department of Veterans Affairs [IIR 04-104-2] FX This research was supported by grant IIR 04-104-2 from Health Services Research and Development, U.S. Department of Veterans Affairs. The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 28 TC 0 Z9 0 U1 6 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL 1 PY 2016 VL 67 IS 7 BP 728 EP 734 DI 10.1176/appi.ps.201500120 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DT7NA UT WOS:000381672300006 PM 27032656 ER PT J AU Coleman, KJ Stewart, C Waitzfelder, BE Zeber, JE Morales, LS Ahmed, AT Ahmedani, BK Beck, A Copeland, LA Cummings, JR Hunkeler, EM Lindberg, NM Lynch, F Lu, CY Owen-Smith, AA Trinacty, CM Whitebird, RR Simon, GE AF Coleman, Karen J. Stewart, Christine Waitzfelder, Beth E. Zeber, John E. Morales, Leo S. Ahmed, Ameena T. Ahmedani, Brian K. Beck, Arne Copeland, Laurel A. Cummings, Janet R. Hunkeler, Enid M. Lindberg, Nangel M. Lynch, Frances Lu, Christine Y. Owen-Smith, Ashli A. Trinacty, Connie Mah Whitebird, Robin R. Simon, Gregory E. TI Racial-Ethnic Differences in Psychiatric Diagnoses and Treatment Across 11 Health Care Systems in the Mental Health Research Network SO PSYCHIATRIC SERVICES LA English DT Article ID AFFECTIVE-DISORDERS; UNITED-STATES; ANTIPSYCHOTIC MEDICATIONS; ANTIDEPRESSANT TREATMENT; MEDICAID POPULATION; DEPRESSION CARE; NATIONAL TRENDS; CHART AUDIT; SELF-REPORT; SCHIZOPHRENIA AB Objective: The objective of this study was to characterize racial-ethnic variation in diagnoses and treatment of mental disorders in large not-for-profit health care systems. Methods: Participating systems were 11 private, not-forprofit health care organizations constituting the Mental Health Research Network, with a combined 7,523,956 patients age 18 or older who received care during 2011. Rates of diagnoses, prescription of psychotropic medications, and total formal psychotherapy sessions received were obtained from insurance claims and electronic medical record databases across all health care settings. Results: Of the 7.5 million patients in the study, 1.2 million (15.6%) received a psychiatric diagnosis in 2011. This varied significantly by race-ethnicity, with Native American/Alaskan Native patients having the highest rates of any diagnosis (20.6%) and Asians having the lowest rates (7.5%). Among patients with a psychiatric diagnosis, 73% (N = 850,585) received a psychotropic medication. Non-Hispanic white patients were significantly more likely (77.8%) than other racial-ethnic groups (odds ratio [OR] range.48-.81) to receive medication. In contrast, only 34% of patients with a psychiatric diagnosis (N=548,837) received formal psychotherapy. Racial-ethnic differences were most pronounced for depression and schizophrenia; compared with whites, non-Hispanic blacks were more likely to receive formal psychotherapy for their depression (OR=1.20) or for their schizophrenia (OR=2.64). Conclusions: There were significant racial-ethnic differences in diagnosis and treatment of psychiatric conditions across 11 U.S. health care systems. Further study is needed to understand underlying causes of these observed differences and whether processes and outcomes of care are equitable across these diverse patient populations. C1 [Coleman, Karen J.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Stewart, Christine; Simon, Gregory E.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA. [Waitzfelder, Beth E.; Trinacty, Connie Mah] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. [Zeber, John E.; Copeland, Laurel A.] US Dept Vet Affairs, Hlth Serv Res & Dev, Temple, TX USA. [Zeber, John E.; Copeland, Laurel A.] Baylor Scott & White Hlth, Ctr Appl Hlth Res, Temple, TX USA. [Morales, Leo S.] Univ Washington, Ctr Hlth Equ Divers & Inclus, Seattle, WA 98195 USA. [Ahmed, Ameena T.] Kaiser Permanente Northern Calif, Permanente Med Grp, San Francisco, CA USA. [Ahmedani, Brian K.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Beck, Arne] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Cummings, Janet R.] Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hunkeler, Enid M.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Lindberg, Nangel M.; Lynch, Frances] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Lu, Christine Y.] Harvard Med Sch, Boston, MA USA. [Lu, Christine Y.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Owen-Smith, Ashli A.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA. [Whitebird, Robin R.] St Catherine Univ, Univ St Thomas, Sch Social Work, St Paul, MN USA. RP Coleman, KJ (reprint author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. EM karen.j.coleman@kp.org OI Copeland, Laurel/0000-0002-9478-0209 FU National Institute of Mental Health award - Mental Health Research Network [U19MH092201] FX Funding was provided by National Institute of Mental Health award U19MH092201 in support of the Mental Health Research Network. NR 47 TC 1 Z9 1 U1 1 U2 4 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL 1 PY 2016 VL 67 IS 7 BP 749 EP 757 DI 10.1176/appi.ps.201500217 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DT7NA UT WOS:000381672300009 PM 27079987 ER PT J AU Leggett, A Ganoczy, D Zivin, K Valenstein, M AF Leggett, Amanda Ganoczy, Dara Zivin, Kara Valenstein, Marcia TI Predictors of Pharmacy-Based Measurement and Self-Report of Antidepressant Adherence: Are Individuals Overestimating Adherence? SO PSYCHIATRIC SERVICES LA English DT Article ID PATIENT ADHERENCE; DEPRESSION; PHARMACOTHERAPY; QUALITY; RISK AB Objective: This study considered various factors as predictors of antidepressant adherence over time as assessed by self-report and medication possession ratios (MPRs) derived from administrative pharmacy data. Methods: Adherence was assessed at six and 12 months among 443 veterans in ongoing treatment for depression in a trial of peer support. Logistic regression models were utilized to consider predictors of adequate adherence. Results: At six and 12 months, respectively, 36% and 35% of patients had poor adherence on the basis of MPRs and 24% and 18% had poor adherence on the basis of self-report. MPRs indicating poor adherence were more likely among men, members of racial groups other than white, and patients with Hispanic ethnicity. Poor self-reported adherence was associated with increased depressive symptoms and unemployment. Conclusions: These adherence measures may be complementary. Strategies to improve adherence might target specific demographic groups, unemployed persons, and persons with higher levels of depressive symptoms. C1 [Leggett, Amanda; Zivin, Kara; Valenstein, Marcia] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Ganoczy, Dara; Zivin, Kara; Valenstein, Marcia] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA. RP Leggett, A (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. EM leggetta@med.umich.edu FU Health Services Research and Development Service, U.S. Department of Veterans Affairs [IIR-08-325]; National Institute of Mental Health geriatric mental health services fellowship [T32 MH073553] FX Support for this work was provided by the Health Services Research and Development Service, U.S. Department of Veterans Affairs (IIR-08-325). Dr. Leggett is funded by a National Institute of Mental Health geriatric mental health services fellowship (T32 MH073553). NR 15 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL 1 PY 2016 VL 67 IS 7 BP 803 EP 806 DI 10.1176/appi.ps.201400568 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DT7NA UT WOS:000381672300019 PM 26876656 ER PT J AU Kopacz, MS Kane, CP Stephens, B Pigeon, WR AF Kopacz, Marek S. Kane, Cathleen P. Stephens, Brady Pigeon, Wilfred R. TI Use of ICD-9-CM Diagnosis Code V62.89 (Other Psychological or Physical Stress, Not Elsewhere Classified) Following a Suicide Attempt SO PSYCHIATRIC SERVICES LA English DT Article ID RISK AB Objective: This study examined the demographic, diagnostic, and service characteristics of veterans who received services for "other psychological or physical stress, not elsewhere classified" (ICD-9-CM V62.89) in the month following a suicide attempt. Methods: An electronic search of a Veterans Health Administration (VHA) suicide event reporting system identified 22,701 veterans who were survivors of a suicide attempt. Their clinical service encounter records were extracted from a VHA administrative database to identify those who received services related to V62.89. Results: Services related to V62.89 were provided to N=2,173 (9.6%) of the sample. Chaplains were the predominant service provider, identified in N=1,745 (80%) of the service encounters. Differences were noted between those who received services related to V62.89 from a chaplain or from another service provider. Conclusions: V62.89 appears to be a focus of clinical concern for some veteran suicide attempt survivors. Additional research is needed to better understand any implications for suicide "postvention." C1 [Kopacz, Marek S.; Kane, Cathleen P.; Stephens, Brady; Pigeon, Wilfred R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. [Pigeon, Wilfred R.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov FU U.S. Department of Veterans Affairs (VA) VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, New York; Merck; Sharp; Dohme FX This work was funded in part by the U.S. Department of Veterans Affairs (VA) VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, New York. The views expressed are those of the authors and do not reflect the official policy or position of the VA or the U.S. government.; Dr. Pigeon reports receipt of speaker fees from Merck, Sharp, and Dohme. The other authors report no financial relationships with commercial interests. NR 15 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUL 1 PY 2016 VL 67 IS 7 BP 807 EP 810 DI 10.1176/appi.ps.201500302 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DT7NA UT WOS:000381672300020 PM 26876664 ER PT J AU Mitchell, MA Hedayati, DO Rodriguez, KL Gordon, AJ Broyles, LM True, G Balbale, SN Conley, JW AF Mitchell, Michael A. Hedayati, Daniel O. Rodriguez, Keri L. Gordon, Adam J. Broyles, Lauren M. True, Gala Balbale, Salva N. Conley, James W. TI Logistical Lessons Learned in Designing and Executing a Photo-Elicitation Study in the Veterans Health Administration SO QUALITATIVE REPORT LA English DT Article DE Homeless Persons; Photography; Qualitative Research; Veterans; Veterans' Health ID PATIENT-CENTERED CARE; ILLNESS AB Participatory photography research methods have been used to successfully engage and collect in-depth information from individuals whose voices have been traditionally marginalized in clinical or research arenas. However, participatory photography methods can introduce unique challenges and considerations regarding study design, human subject protections, and other regulatory barriers, particularly with vulnerable patient populations and in highly regulated institutions. Practical guidance on navigating these complex, interrelated methodological, logistical, and ethical issues is limited. Using a case exemplar, we describe our experiences with the planning, refinement, and initiation of a research study that used photo-elicitation interviews to assess the healthcare experiences of homeless and marginally housed United States Veterans. We discuss practical issues and recommendations related to study design, logistical "pitfalls" during study execution, and ensuring human subjects protections in the context of a study with a highly vulnerable patient population taking place in a highly risk-averse research environment. C1 [Mitchell, Michael A.] Allegheny Cty Dept Human Serv, Off Data Anal Res & Evaluat, Pittsburgh, PA 15222 USA. [Mitchell, Michael A.; Gordon, Adam J.; Broyles, Lauren M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA. [Hedayati, Daniel O.; Rodriguez, Keri L.; Gordon, Adam J.; Broyles, Lauren M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Rodriguez, Keri L.; Conley, James W.] VA Pittsburgh Healthcare System, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. [Rodriguez, Keri L.] VA Pittsburgh Healthcare System, Vet Engn Resource Ctr, Pittsburgh, PA USA. [True, Gala] Southeast Louisiana Vet Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 16, New Orleans, LA USA. [True, Gala] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA. [Balbale, Salva N.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Balbale, Salva N.] Dept Vet Affairs, Washington, DC USA. [Conley, James W.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA 15261 USA. RP Mitchell, MA (reprint author), Allegheny Cty Dept Human Serv, Off Data Anal Res & Evaluat, Pittsburgh, PA 15222 USA.; Mitchell, MA; Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.; Hedayati, DO; Broyles, LM (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.; Conley, JW (reprint author), VA Pittsburgh Healthcare System, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA.; Conley, JW (reprint author), VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA 15261 USA. EM mike.mitchell@alleghenycounty.us; daniel@medstudent.pitt.edu; lauren.broyles@va.gov; james.conley@va.gov NR 25 TC 0 Z9 0 U1 2 U2 2 PU NOVA SOUTHEASTERN UNIV PI FORT LAUDERDALE-DAVIE PA 3301 COLLEGE AVE, FORT LAUDERDALE-DAVIE, FL 33314 USA SN 2160-3715 J9 QUAL REP JI Qual. Rep. PD JUL PY 2016 VL 21 IS 7 BP 1303 EP 1315 PG 13 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA DT6VQ UT WOS:000381623100008 ER PT J AU Koyama, AK Tworoger, SS Eliassen, AH Okereke, OI Weisskopf, MG Rosner, B Yaffe, K Grodstein, F AF Koyama, Alain K. Tworoger, Shelley S. Eliassen, A. Heather Okereke, Olivia I. Weisskopf, Marc G. Rosner, Bernard Yaffe, Kristine Grodstein, Francine TI Endogenous sex hormones and cognitive function in older women SO Alzheimers & Dementia LA English DT Article DE Hormones; Subjective cognitive complaints; Cognition; Dementia; Alzheimer's disease ID SUBJECTIVE MEMORY COMPLAINTS; ALZHEIMERS-DISEASE; POSTMENOPAUSAL WOMEN; RISK; INDIVIDUALS; HIPPOCAMPUS; IMPAIRMENT; COMMUNITY; DEMENTIA; THERAPY AB Introduction: We examined the association between endogenous sex hormones and both objective and subjective measures of cognitive function. Methods: We followed 3044 women up to 23 years in a prospective cohort study. We measured plasma levels of estrone, estrone sulfate, estradiol, androstenedione, testosterone, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEA-S) in 1989-1990, conducted neuropsychologic testing in 1999-2008, and inquired about subjective cognition in 2012. Results: Overall, we observed little relation between plasma levels of hormones and either neuropsychologic test performance or subjective cognition. However, after adjustment for age and education, we observed a borderline significant association of higher levels of plasma estrone with higher scores for both overall cognition (P trend = .10) and verbal memory (P trend = .08). Discussion: There were no clear associations of endogenous hormone levels at midlife and cognition in later life, although a suggested finding of higher levels of plasma estrone associated with better cognitive function merits further research. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Koyama, Alain K.; Tworoger, Shelley S.; Eliassen, A. Heather; Okereke, Olivia I.; Rosner, Bernard; Grodstein, Francine] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Koyama, Alain K.; Tworoger, Shelley S.; Eliassen, A. Heather; Okereke, Olivia I.; Rosner, Bernard; Grodstein, Francine] Harvard Med Sch, Boston, MA 02115 USA. [Koyama, Alain K.; Tworoger, Shelley S.; Eliassen, A. Heather; Okereke, Olivia I.; Weisskopf, Marc G.; Grodstein, Francine] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Weisskopf, Marc G.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Rosner, Bernard] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Koyama, AK (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.; Koyama, AK (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Koyama, AK (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. EM akoyama@post.harvard.edu RI Okereke, Olivia/R-9934-2016 FU National Institute of Health [UM1 CA186107, R01 CA49449, T32 MH017119] FX This work was supported by the National Institute of Health (UM1 CA186107, R01 CA49449, T32 MH017119). NR 37 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD JUL PY 2016 VL 12 IS 7 BP 758 EP 765 DI 10.1016/j.jalz.2015.12.010 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DS2EL UT WOS:000380561100002 PM 26806389 ER PT J AU Walton, RG Zhu, XL Tian, L Heywood, EB Liu, J Hill, HS Liu, JR Bruemmer, D Yang, QL Fu, YC Garvey, WT AF Walton, R. Grace Zhu, Xiaolin Tian, Ling Heywood, Elizabeth B. Liu, Jian Hill, Helliner S. Liu, Jiarong Bruemmer, Dennis Yang, Qinglin Fu, Yuchang Garvey, W. Timothy TI AP2-NR4A3 transgenic mice display reduced serum epinephrine because of increased catecholamine catabolism in adipose tissue SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE nuclear receptor 4A3 transgenic mice; nuclear receptor 4A3; type 2 diabetes; lipolysis; monoamine oxidase ID GLUCOSE-TRANSPORT SYSTEM; LOW-DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; CAROTID ARTERIES; LIPID-METABOLISM; GENE-EXPRESSION; ADIPOCYTES; SECRETION; NOREPINEPHRINE; NORADRENALINE AB The NR4A orphan nuclear receptors function as early response genes to numerous stimuli. Our laboratory has previously demonstrated that overexpression of NR4A3 (NOR-1, MINOR) in 3T3-L1 adipocytes enhances insulin-stimulated glucose uptake. To assess the in vivo effect of NR4A3 on adipocytes, we generated transgenic mice with NR4A3 overexpression driven by the adipocyte fatty acid-binding protein (AP2) promoter (AP2-NR4A3 mice). We hypothesized that AP2-NR4A3 mice would display enhanced glucose tolerance and insulin sensitivity. However, AP2-NR4A3 mice exhibit metabolic impairment, including increased fasting glucose and insulin, impaired glucose tolerance, insulin resistance, decreased serum free fatty acids, and increased low-density lipoprotein-cholesterol. AP2-NR4A3 mice also display a significant reduction in serum epinephrine due to increased expression of catecholamine-catabolizing enzymes in adipose tissue, including monoamine oxidase-A. Furthermore, enhanced expression of monoamine oxidase-A is due to direct transcriptional activation by NR4A3. Finally, AP2-NR4A3 mice display cardiac and behavioral alterations consistent with chronically low circulating epinephrine levels. In conclusion, overexpression of NR4A3 in adipocytes produces a complex phenotype characterized by impaired glucose metabolism and low serum catecholamines due to enhanced degradation by adipose tissue. C1 [Walton, R. Grace; Zhu, Xiaolin; Tian, Ling; Liu, Jian; Hill, Helliner S.; Yang, Qinglin; Fu, Yuchang; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Heywood, Elizabeth B.; Bruemmer, Dennis] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY USA. [Heywood, Elizabeth B.; Bruemmer, Dennis] Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY USA. [Liu, Jiarong] Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Walton, RG (reprint author), Univ Kentucky, Coll Hlth Sci, 900 S Limestone,CTW 433, Lexington, KY 40536 USA. EM r.grace.walton@uky.edu FU National Institutes of Health (NIH) [RO1-DK-083562]; Department of Veterans Affairs Merit Review research award; UAB Diabetes Research Center [P60-DK-079626]; NIH [RO1-HL-084611, RO1-HL-084611-S1]; UAB core facilities FX We received research support from a number of UAB core facilities. As such, we would like to thank Dr. David Allison (UAB Nutrition Obesity Research Center), Dr. Barbara A. Gower and Maryellen Williams (UAB Diabetes Research and Treatment Center Human Physiology Core), Dr. Maria Johnson and Dr. Timothy R. Nagy (UAB Diabetes Research and Treatment Center Animal Physiology Core), Dr. Kevin A. Roth and Dr. Terry Lewis (UAB Neuroscience Molecular Detection Core, P30 NS47466), Dr. Elliot J. Lefkowitz (Molecular and Genetic Bioinformatics Facility, 5UL1-RR-025777), and Dr. Thomas Van Groen (UAB Small Animal Behavioral Core, P30-NS-47466). This work was funded by National Institutes of Health (NIH) Grant RO1-DK-083562 (W. T. Garvey), a Department of Veterans Affairs Merit Review research award (W. T. Garvey), the UAB Diabetes Research Center, P60-DK-079626 (W. T. Garvey), and NIH Grants RO1-HL-084611 (D. Bruemmer) and RO1-HL-084611-S1 (D. Bruemmer). NR 42 TC 0 Z9 0 U1 4 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUL 1 PY 2016 VL 311 IS 1 BP E69 EP E81 DI 10.1152/ajpendo.00330.2015 PG 13 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA DS1QS UT WOS:000380372000005 PM 27166283 ER PT J AU McCubbrey, AL Barthel, L Mould, KJ Mohning, MP Redente, EF Janssen, WJ AF McCubbrey, Alexandra L. Barthel, Lea Mould, Kara J. Mohning, Michael P. Redente, Elizabeth F. Janssen, William J. TI Selective and inducible targeting of CD11b(+) mononuclear phagocytes in the murine lung with hCD68-rtTA transgenic systems SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE CD11b(+) macrophages; hCD68-rtTA; mouse model; recruited macrophages; transgenic mice ID MACROPHAGES IN-VITRO; ALVEOLAR MACROPHAGES; TISSUE MACROPHAGES; INTERSTITIAL MACROPHAGES; CIRCULATING MONOCYTES; EXUDATE MACROPHAGES; GENE-EXPRESSION; DENDRITIC CELLS; LYMPH-NODES; MOUSE AB Selective and inducible targeting of CD11b(+) mononuclear phagocytes in the murine lung with hCD68-rtTA transgenic systems. Am J Physiol Lung Cell Mol Physiol 311:L87-L100, 2016. First published May 17, 2016; doi:10.1152/ajplung.00141.2016.-During homeostasis two distinct macrophage (Mo) populations inhabit the lungs: tissue Mo (often called interstitial Mo) and resident alveolar Mo (re-sAMo). During acute lung inflammation, monocytes from the circulation migrate to areas of injury where they mature into a third Mo population: recruited Mo. Resident AMo uniquely express low levels of CD11b and high levels of CD11c. In comparison, recruited Mo and tissue Mo express high levels of CD11b and low levels of CD11c. It is likely that these three Mo subpopulations play distinct roles in injury and disease states; however, tools with which to individually target or track these populations are lacking. Here we demonstrate the utility of an hCD68-rtTA transgenic system for specific, robust, and inducible targeting of CD11b(+) recruited Mo and tissue Mo in the murine lung with negligible activation in resAMo. Using hCD68rtTA-GFP reporter mice, we show both during homeostasis and inflammation that administration of doxycycline induces tet-On reporter expression in recruited Mo and tissue Mo but not in resident AMo. We further demonstrate how hCD68-rtTA can be effectively combined with tet-On Cre to target these same recMo and tissue Mo. Accordingly, the hCD68-rtTA system is a powerful new tool that can be used for lineage tracing, fate mapping, and gene deletion in a variety of murine models, thereby enabling sophisticated investigation of the unique role of these CD11b(+) Mo during lung heath and disease. C1 [McCubbrey, Alexandra L.; Barthel, Lea; Mould, Kara J.; Mohning, Michael P.; Janssen, William J.] Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA. [Redente, Elizabeth F.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA. [Mould, Kara J.; Mohning, Michael P.; Janssen, William J.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Redente, Elizabeth F.] Denver Vet Affairs Med Ctr, Dept Res, Denver, CO USA. RP McCubbrey, AL (reprint author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA. EM mccubbreya@njhealth.org FU National Heart, Lung, and Blood Institute [HL-109517, HL-114381, HL-126333, HL-007085-41]; Parker B. Francis Foundation Fellowship; Pulmonary Fibrosis Foundation Fellowship FX This work was supported by National Heart, Lung, and Blood Institute Grants HL-109517 (to W. Janssen), HL-114381 (to W. Janssen), HL-126333 (to M. Mohning), HL-007085-41 (to K. Mould), a Parker B. Francis Foundation Fellowship (to E. Redente), and a Pulmonary Fibrosis Foundation Fellowship (to Redente). NR 52 TC 0 Z9 0 U1 1 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD JUL 1 PY 2016 VL 311 IS 1 BP L87 EP L100 DI 10.1152/ajplung.00141.2016 PG 14 WC Physiology; Respiratory System SC Physiology; Respiratory System GA DS4RE UT WOS:000380767700009 PM 27190063 ER PT J AU Skorin, L Dailey, KH AF Skorin, Leonid, Jr. Dailey, Kathryn H. TI Clicking Eyelids: A New Finding of Prostaglandin-Associated Periorbitopathy SO OPTOMETRY AND VISION SCIENCE LA English DT Article DE prostaglandin-associated periorbitopathy; prostaglandin; eyelids; bimatoprost; clicking; orbital fat atrophy; tight orbits ID TOPICAL BIMATOPROST; CILIARY MUSCLE; IN-VITRO; LATANOPROST; TRAVOPROST; THERAPY; SULCUS AB Purpose To present and discuss a case representing both a new sign and symptom of prostaglandin-associated periorbitopathy. Case Report An 83-year-old female patient presented for a 6-month glaucoma follow-up in July 2013 with no specific visual or comfort complaints. The patient had a 14-year history of bilateral primary open angle glaucoma and a 13-year history of once daily bimatoprost use in both eyes. Evaluation at previous examinations revealed long eyelashes, tight eyelids, small palpebral fissures, and deepening of the upper eyelid sulcus. During slit-lamp examination of the anterior segment, it was noted that the patient's eyelids clicked intermittently when she blinked. The patient had not previously noticed the clicking and it was determined to be present in each eye individually. The eyelid clicking has been noted to be present in every follow-up examination since it was discovered in July 2013. Conclusions Prostaglandin-associated periorbitopathy and the resulting cosmetic effects noticed visually by patients are well documented. Our case represents a new audible sign and symptom that may be found with prostaglandin-associated periorbitopathy but has not to our knowledge been reported in the literature. C1 [Skorin, Leonid, Jr.] Mayo Clin Hlth Syst, Dept Ophthalmol, Albert Lea, MN USA. [Dailey, Kathryn H.] VA Puget Sound Hlth Care Syst, Amer Lake Div, Tacoma, WA USA. RP Skorin, L (reprint author), Mayo Clin Hlth Syst, 404 W Fountain St, Albert Lea, MN 56007 USA. EM skorin.leonid@mayo.edu NR 13 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-5488 EI 1538-9235 J9 OPTOMETRY VISION SCI JI Optom. Vis. Sci. PD JUL PY 2016 VL 93 IS 7 BP 779 EP 781 DI 10.1097/OPX.0000000000000862 PG 3 WC Ophthalmology SC Ophthalmology GA DR9UJ UT WOS:000380241300016 PM 27055061 ER PT J AU Kittiskulnam, P Sheshadri, A Johansen, KL AF Kittiskulnam, Piyawan Sheshadri, Anoop Johansen, Kirsten L. TI Consequences of CKD on Functioning SO SEMINARS IN NEPHROLOGY LA English DT Review DE Chronic kidney disease; physical function; frailty; cognitive function; depression; health-related quality of life ID CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; STAGE RENAL-DISEASE; PERITONEAL-DIALYSIS PATIENTS; COMORBIDITY SURVEY REPLICATION; RECEIVING CHRONIC-HEMODIALYSIS; BLOOD-PRESSURE VARIABILITY; IN-CENTER HEMODIALYSIS; MINI-MENTAL-STATE; COGNITIVE IMPAIRMENT AB Chronic kidney disease (CKD) is highly prevalent in the United States and throughout the world,(1) with approximately 13% of adults affected.(2) In addition, according to recent estimates, almost half of patients with CKD stages 3 to 5 are 70 years of age and older.(2) In the United States, the number of prevalent end-stage renal disease cases continues to increase in patients older than age 65. In light of the demographic characteristics of patients with CKD and ESRD, there has been considerable focus on associations between CKD and cardiovascular outcomes.(3) Until recently, less attention had been paid to other consequences of CKD in general and among older individuals with CKD in particular, but there is now solid evidence linking CKD with impairments of physical function, cognitive function, and emotional function and quality of life. This review summarizes available literature on these topics, focusing specifically on physical functioning and frailty, cognitive function, emotional health, including depression and anxiety, and health-related quality of life. Published by Elsevier Inc. C1 [Kittiskulnam, Piyawan; Sheshadri, Anoop; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Kittiskulnam, Piyawan] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Dept Med, Thai Red Cross Soc, Bangkok, Thailand. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Box 111J,4150 Clement St, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU International Society of Nephrology Fellowship; National Institute of Diabetes and Digestive and Kidney Diseases [K24 DK085153]; Veterans Health Administration FX This work was supported in part by an International Society of Nephrology Fellowship (P.K.), by a grant (K24 DK085153) from the National Institute of Diabetes and Digestive and Kidney Diseases (K.L.J.), and by fellowship funding from the Veterans Health Administration (A.S.). NR 151 TC 0 Z9 0 U1 3 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 EI 1558-4488 J9 SEMIN NEPHROL JI Semin. Nephrol. PD JUL PY 2016 VL 36 IS 4 BP 305 EP 318 DI 10.1016/j.semnephrol.2016.05.007 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA DT1IG UT WOS:000381234300007 PM 27475661 ER PT J AU Pena-Polanco, JE Fried, LF AF Pena-Polanco, Julio E. Fried, Linda F. TI Established and Emerging Strategies in the Treatment of Chronic Kidney Disease SO SEMINARS IN NEPHROLOGY LA English DT Review DE Chronic kidney disease; progression; renin-angiotensin system ID CHRONIC RENAL-INSUFFICIENCY; RANDOMIZED CLINICAL-TRIAL; BLOOD-PRESSURE CONTROL; CONVERTING ENZYME-INHIBITION; TYPE-2 DIABETIC-NEPHROPATHY; DOUBLE-BLIND; URIC-ACID; RECEPTOR ANTAGONIST; CARDIOVASCULAR OUTCOMES; MICROVASCULAR OUTCOMES AB Chronic kidney disease (CKD) is a common condition that has become a significant public health concern. The mainstay therapeutic approach to CKD is based on renin-angiotensin system blockade as well as blood pressure and glycemic control. Despite these interventions, the management of CKD remains suboptimal, with a large proportion of the CKD population progressing to end-stage renal disease. Newer strategies for the treatment of CKD have emerged over the past years focusing on decreasing inflammation and delaying the development of fibrosis. Despite promising results in experimental models and small randomized studies, adequately powered randomized trials are required to evaluate the benefits and risks of these therapies in the CKD population. In this review, we discuss the evidence behind, and gaps in our knowledge of, established therapies as well as newer potential strategies for managing CKD, concentrating on interventions that currently are being evaluated in randomized studies. (C) 2016 Elsevier Inc. All rights reserved. C1 [Pena-Polanco, Julio E.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Fried, Linda F.] Univ Pittsburgh, Epidemiol & Clin & Translat Sci, Pittsburgh, PA USA. RP Pena-Polanco, JE (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. NR 95 TC 0 Z9 0 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 EI 1558-4488 J9 SEMIN NEPHROL JI Semin. Nephrol. PD JUL PY 2016 VL 36 IS 4 BP 331 EP 342 DI 10.1016/j.semnephrol.2016.05.009 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA DT1IG UT WOS:000381234300009 PM 27475663 ER PT J AU Carter, A Borrero, S Wessel, C Washington, DL Bean-Mayberry, B Corbelli, J AF Carter, Andrea Borrero, Sonya Wessel, Charles Washington, Donna L. Bean-Mayberry, Bevanne Corbelli, Jennifer CA VA Women's Hlth Disparities Res Wo TI Racial and Ethnic Health Care Disparities Among Women in the Veterans Affairs Healthcare System: A Systematic Review SO WOMENS HEALTH ISSUES LA English DT Article ID UNITED-STATES; SATISFACTION; MILITARY; TRAUMA; RATES AB Background: Women are a rapidly growing segment of patients who seek care in the Veterans Affairs (VA) Healthcare System, yet many questions regarding their health care experiences and outcomes remain unanswered. Racial and ethnic disparities have been well-documented in the general population and among veterans; however, prior disparities research conducted in the VA focused primarily on male veterans. We sought to characterize the findings and gaps in the literature on racial and ethnic disparities among women using the VA. Methods: We systematically reviewed the literature on racial and ethnic health care disparities exclusively among women using the VA Healthcare System. We included studies that examined health care use, satisfaction, and/or quality, and stratified data by race or ethnicity. Results: Nine studies of the 2,591 searched met our inclusion criteria. The included studies examined contraception provision/access (n = 3), treatment of low bone mass (n = 1), hormone therapy (n = 1), use of mental health or substance abuse-related services (n = 2), trauma exposure and use of various services (n = 1), and satisfaction with primary care (n = 1). Five of nine studies showed evidence of a significant racial or ethnic difference. Conclusion: In contrast with the wealth of literature examining disparities both among the male veterans and women in non VA settings, only nine studies examine racial and ethnic disparities specifically among women in the VA Healthcare System. These results demonstrate that there is an unmet need to further assess health care disparities among female VA users. Published by Elsevier Inc. on behalf of Jacobs Institute of Women's Health. C1 [Carter, Andrea; Borrero, Sonya; Corbelli, Jennifer] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Wessel, Charles] Univ Pittsburgh, Hlth Sci Lib Syst, Pittsburgh, PA USA. [Washington, Donna L.; Bean-Mayberry, Bevanne] Vet Affairs Greater Los Angeles Healthcare Syst, Vet Affairs Hlth Serv Res & Dev, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Washington, Donna L.; Bean-Mayberry, Bevanne] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Borrero, S (reprint author), 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu RI Wessel, Charles/B-2318-2013 OI Wessel, Charles/0000-0002-5018-0156 FU VA Women's Health Research Network [VA HSRD SDR 10-012] FX This work was supported in part by the VA Women's Health Research Network (VA HSR&D SDR 10-012). The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. To the best of our knowledge, there are no conflicts of interest. NR 38 TC 1 Z9 1 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JUL-AUG PY 2016 VL 26 IS 4 BP 401 EP 409 DI 10.1016/j.whi.2016.03.009 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DS4KB UT WOS:000380748900007 PM 27138241 ER PT J AU Goodrich, DE Klingaman, EA Verchinina, L Goldberg, RW Littman, AJ Janney, CA Kim, HM Maguen, S Hoerster, KD Owen, RR Holleman, RG Roman, P Lai, ZS Bowersox, NW AF Goodrich, David E. Klingaman, Elizabeth A. Verchinina, Lilia Goldberg, Richard W. Littman, Alyson J. Janney, Carol A. Kim, Hyungjin Myra Maguen, Shira Hoerster, Katherine D. Owen, Richard R. Holleman, Robert G. Roman, Pia Lai, Zongshan Bowersox, Nicholas W. TI Sex Differences in Weight Loss among Veterans with Serious Mental Illness: Observational Study of a National Weight Management Program SO WOMENS HEALTH ISSUES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; LIFE-STYLE INTERVENTIONS; BODY-MASS INDEX; BIPOLAR DISORDER; HEALTH-CARE; RISK-FACTORS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; GENDER-DIFFERENCES; WOMEN VETERANS AB Purpose: Obesity disproportionately burdens individuals with serious mental illness (SMI), especially women. This observational study investigated whether there were sex differences in weight loss and program participation among veterans with SMI enrolled in the Veterans Health Administration's (VHA) MOVE! weight management program. Procedures: Participants were identified from a national cohort of 148,254 veterans enrolled in MOVE! during fiscal years 2008 through 2012 who attended two or more sessions within 12 months of enrollment. The cohort included those with International Classification of Disease, 9th Edition, Clinical Modification (ICD-9-CM) diagnoses for SMI, age less than 70 years, and weight data at baseline and one or more follow-up timepoints within approximately 1 year of enrollment (n = 8,943 men; n = 2,245 women). Linear mixed models assessed associations of sex with 6-and 12-month weight change from baseline, adjusting for demographic-and site-level variables. Findings: Both sexes averaged 6.4 (standard deviation, 4.6) sessions within 12 months; however, women with and without SMI participated at rates double their respective proportion rates among all VHA users. Participants averaged statistically significant weight loss at 6 months (men, -2.5 lb [95% CI, - 2.8 to -2.1]; women, -2.4 lb [95% CI, -3.1 to -1.7]) and 12 months (men, -2.5 lb [95% CI, -2.8 to -2.2]; women, -2.9 lb [95% CI, -3.6 to -2.2]), but no sex-based difference in absolute weight loss at either timepoint. Slightly more women achieved 5% or greater (clinically significant) weight loss at the 12-month follow-up than did men (25.7% vs. 23.0%; p < .05). Conclusions: Women with SMI participated in MOVE! at rates equivalent to or greater than men with SMI, with comparable weight loss. More women were Black, single, had bipolar and posttraumatic stress disorder, and higher service-connected disability, suggesting areas for program customization. Published by Elsevier Inc. on behalf of Jacobs Institute of Women's Health. Published by Elsevier Inc. on behalf of Jacobs Institute of Women's Health. C1 [Goodrich, David E.; Verchinina, Lilia; Janney, Carol A.; Kim, Hyungjin Myra; Holleman, Robert G.; Roman, Pia; Lai, Zongshan; Bowersox, Nicholas W.] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI USA. [Klingaman, Elizabeth A.; Goldberg, Richard W.] VA Maryland Hlth Care Syst, Baltimore VA Med Ctr, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA. [Klingaman, Elizabeth A.; Goldberg, Richard W.] Univ Maryland, Sch Med, Div Psychiat Serv Res, Dept Psychiat, Baltimore, MD USA. [Littman, Alyson J.] VA Puget Sound Med Ctr, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA USA. [Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI USA. [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Owen, Richard R.] Cent Arkansas Vet Healthcare Syst, VA Ctr Mental Healthcare & Outcomes Res, North Little Rock, AR USA. [Owen, Richard R.] Univ Arkansas Med Sci, Coll Med, Dept Psychiat, Inst Psychiat Res, Little Rock, AR 72205 USA. [Bowersox, Nicholas W.] VA Serious Mental Illness Treatment Resource & Ev, Ann Arbor, MI USA. RP Klingaman, EA (reprint author), VA Maryland Hlth Care Syst, Baltimore VA Med Ctr, 10 North Greene St,Annex Suite 720, Baltimore, MD 21201 USA. EM Elizabeth.klingaman@va.gov OI Goodrich, David/0000-0003-3232-2189 FU VA Health Services Research and Development Quality Enhancement Research Initiative (QUERI) programs for Diabetes and Mental Health research as a locally initiated project [QLP 55-017]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; VA Rehabilitation R&D Career Development Award [6982] FX Funding was provided by the VA Health Services Research and Development Quality Enhancement Research Initiative (QUERI) programs for Diabetes and Mental Health research as a locally initiated project (QLP 55-017). Dr. Klingaman's time was supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment and is the result of work supported with resources and the use of facilities at the VA Capitol Health Care Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC). Dr. Littman's time was supported by a VA Rehabilitation R&D Career Development Award (#6982). NR 74 TC 0 Z9 0 U1 4 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JUL-AUG PY 2016 VL 26 IS 4 BP 410 EP 419 DI 10.1016/j.whi.2016.05.001 PG 10 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DS4KB UT WOS:000380748900008 PM 27365284 ER PT J AU Rosenbaum, DL Kimerling, R Pomernacki, A Goldstein, KM Yano, EM Sadler, AG Carney, D Bastian, LA Bean-Mayberry, BA Frayne, SM AF Rosenbaum, Diane L. Kimerling, Rachel Pomernacki, Alyssa Goldstein, Karen M. Yano, Elizabeth M. Sadler, Anne G. Carney, Diane Bastian, Lori A. Bean-Mayberry, Bevanne A. Frayne, Susan M. TI Binge Eating among Women Veterans in Primary Care: Comorbidities and Treatment Priorities SO WOMENS HEALTH ISSUES LA English DT Article ID MENTAL-HEALTH-SERVICES; DIALECTICAL BEHAVIOR-THERAPY; FEMALE VETERANS; OBESE-PATIENTS; PSYCHIATRIC COMORBIDITY; AFGHANISTAN VETERANS; SURVEY REPLICATION; COMMUNITY SAMPLE; UNITED-STATES; WEIGHT-GAIN AB Background: Little is known about the clinical profile and treatment priorities of women with binge eating disorder (BED), a diagnosis new to the fifth edition of Diagnostic and Statistical Manual of Mental Disorders. We identified comorbidities and patients' treatment priorities, because these may inform implementation of clinical services. Methods: Data were collected from women veteran primary care patients. Analyses compared those who screened positive for BED (BED+), and those without any binge eating symptoms (BED-). Results: Frequencies of comorbid medical and psychological disorders were high in the BED+ group. The BED+ group's self-identified most common treatment priorities were mood concerns (72.2%), weight loss (66.7%), and body image/food issues (50%). Among those with obesity, a greater proportion of the BED+ group indicated body image/food issues was their top treatment priority (12.9% vs. 2.8%; p < .01), suggesting that these patients may be more apt to seek treatment beyond weight management for their problematic eating patterns. Conclusions: Women primary care patients with BED demonstrate high medical and psychological complexity; their subjective treatment priorities often match objective needs. These findings may inform the development of targeted BED screening practices for women with obesity in primary care settings, and the eventual adoption of patient-centered BED treatment resources. Published by Elsevier Inc. on behalf of Jacobs Institute of Women's Health. C1 [Rosenbaum, Diane L.; Kimerling, Rachel; Pomernacki, Alyssa; Carney, Diane; Frayne, Susan M.] VA Palo Alto Hlth Care Syst, Hlth Serv Res & Dev, Ctr Innovat Implementat, Palo Alto, CA USA. [Rosenbaum, Diane L.] Drexel Univ, Dept Psychol, 3141 Chestnut St, Philadelphia, PA 19104 USA. [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Palo Alto, CA USA. [Goldstein, Karen M.] Durham VA Med Ctr, Hlth Serv Res & Dev, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Goldstein, Karen M.] Duke Univ, Dept Med, Durham, NC USA. [Yano, Elizabeth M.; Bean-Mayberry, Bevanne A.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Sadler, Anne G.] Iowa City VA Hlth Care Syst, Hlth Serv Res & Dev, Ctr Comprehens Access & Delivery Res & Evaluat, Iowa City, IA USA. [Sadler, Anne G.] Univ Iowa Hosp & Clin, Dept Psychiat, Iowa City, IA 52242 USA. [Bastian, Lori A.] VA Connecticut Healthcare Syst, Hlth Serv Res & Dev, Pain Res Informat Multimorbid & Educ Ctr, West Haven, CT USA. [Bastian, Lori A.] Yale Sch Med, Internal Med, New Haven, CT USA. [Bean-Mayberry, Bevanne A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Frayne, Susan M.] Stanford Univ, Div Gen Med Disciplines, Stanford, CA 94305 USA. RP Rosenbaum, DL (reprint author), Drexel Univ, Dept Psychol, 3141 Chestnut St, Philadelphia, PA 19104 USA. EM diane.rosenbaum@drexel.edu FU VA HSRD [SDR 10-012]; VA HSR&D Service Senior Research Career Scientist Award [RCS 05-195] FX This study was funded by the VA HSR&D (Project SDR 10-012). Dr. Yano's effort was funded by a VA HSR&D Service Senior Research Career Scientist Award (RCS 05-195). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government. NR 74 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JUL-AUG PY 2016 VL 26 IS 4 BP 420 EP 428 DI 10.1016/j.whi.2016.02.004 PG 9 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DS4KB UT WOS:000380748900009 PM 26972486 ER PT J AU Breland, JY Donalson, R Dinh, J Nevedal, A Maguen, S AF Breland, Jessica Y. Donalson, Rosemary Dinh, Julie Nevedal, Andrea Maguen, Shira TI Women Veterans' Treatment Preferences for Disordered Eating SO WOMENS HEALTH ISSUES LA English DT Article ID WEIGHT-LOSS; BINGE; MILITARY; PREVALENCE; SYMPTOMS; OUTCOMES; PTSD; MEN AB Objective: Disordered eating, which includes subclinical and clinical maladaptive eating behaviors, is common among women, including those served by the Veterans Health Administration (VA). We used qualitative methods to determine whether and how women veterans want to receive treatment for disordered eating. Method: Women veterans participated in one of seven focus groups/interviews and completed in-person demographic and psychological questionnaires. We used thematic analysis of focus groups/interviews to understand preferences for disordered eating treatment. Results: Participants (n = 20) were mostly women of color (55%); mean age was 48 (SD = 15) and 65% had significant psychological symptoms. Few participants described being assessed for disordered eating, but all thought VA should provide treatment for disordered eating. Through thematic analysis, we identified six preferences: 1) treatment for disordered eating should be provided in groups, 2) treatment for disordered eating should provide concrete skills to facilitate the transition out of structured military environments, 3) treatment for disordered eating should address the relationship between eating and mental health, 4) disordered eating can be treated with mindfulness and cognitive-behavioral therapy, 5) disordered eating treatment providers should be experienced and take an interactive approach to care, but can come from diverse disciplines, and 6) referrals to treatment for disordered eating should be open ended, occur early, and allow for ongoing, flexible access to treatment. Conclusions: Women veterans are interested in treatment for disordered eating. Preferred treatments align with existing treatments, could be offered in conjunction with weight loss or primary care services, and should provide social support and interactive learning. Published by Elsevier Inc. on behalf of Jacobs Institute of Women's Health. C1 [Breland, Jessica Y.; Nevedal, Andrea] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,MPD-152, Menlo Pk, CA 94025 USA. [Breland, Jessica Y.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Donalson, Rosemary; Dinh, Julie; Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA. [Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Dinh, Julie] Rice Univ, Dept Psychol, Houston, TX 77251 USA. RP Breland, JY (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd,MPD-152, Menlo Pk, CA 94025 USA. EM breland@stanford.edu OI Breland, Jessica/0000-0003-0024-3478 FU Veterans Health and Integration Program (VHIP); VA Office of Academic Affiliations; VA Health Services Research and Development Service; VA HSR&D Advanced Fellowship Program FX This research was supported by the Veterans Health and Integration Program (VHIP; PI: Maguen). Dr. Breland is supported by the VA Office of Academic Affiliations and VA Health Services Research and Development Service in conjunction with a VA HSR&D Advanced Fellowship Program. Sponsors had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors report no conflicts of interest. NR 29 TC 0 Z9 0 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 EI 1878-4321 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD JUL-AUG PY 2016 VL 26 IS 4 BP 429 EP 436 DI 10.1016/j.whi.2016.04.006 PG 8 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DS4KB UT WOS:000380748900010 PM 27264912 ER PT J AU Thirumalai, A Cooper, LA Rubinow, KB Amory, JK Lin, DW Wright, JL Marck, BT Matsumoto, AM Page, ST AF Thirumalai, Arthi Cooper, Lori A. Rubinow, Katya B. Amory, John K. Lin, Daniel W. Wright, Jonathan L. Marck, Brett T. Matsumoto, Alvin M. Page, Stephanie T. TI Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PROSTATE-CANCER; HYPOGONADAL MEN; OLDER MEN; SERUM TESTOSTERONE; SEXUAL FUNCTION; REPLACEMENT THERAPY; BODY-COMPOSITION; CONTROLLED-TRIAL; YOUNG MEN; ANDROGENS AB Context: Concern exists that T replacement therapy (TRT) might increase the risk of prostate disease. There are limited data regarding the impact of TRT on prostate androgen concentrations. Objective: Determine the dose-dependent effects of exogenous T administration on intraprostatic androgen concentrations. Design: Twelve-week, double-blinded, randomized, placebo-controlled trial. Setting: Academic medical center. Participants: Sixty-two healthy eugonadal men, aged 25-55 years. Interventions: Subjects were randomly assigned to receive injections of acyline, a GnRH antagonist (used to achieve medical castration), every 2 weeks plus transdermal T gel (1.25 g, 2.5 g, 5.0 g, 10 g, or 15 g daily), or placebo injections and transdermal gel for 12 weeks. Main Outcomes: Serum T and dihydrotestosterone (DHT) were measured at baseline and every 2 weeks during treatment. Intraprostatic T and DHT concentrations were assessed from tissue obtained through ultrasound-guided prostate needle biopsies at week 12. Androgens were quantified by liquid chromatography-tandem mass spectrometry. Results: 51 men completed the study and were included in the analysis. There were no significant adverse events. Exogenous T resulted in a dose-dependent increase in serum T and DHT concentrations (190-770 and 60-180 ng/dL, respectively). Although intraprostatic T differed among dose groups (P = .01), intraprostatic DHT was comparable regardless of T dose (P = .11) and was 10- to 20-fold greater than intraprostatic T. Conclusions: In healthy, medically castrate men receiving exogenous T, the total intraprostatic androgen concentration (predominantly DHT) remained stable across serum T concentrations within the physiological range. These findings further our knowledge of the relationship between serum and intraprostatic androgens and suggest that physiological serum T achieved by TRT is unlikely to alter the prostate hormonal milieu. C1 [Thirumalai, Arthi; Rubinow, Katya B.; Amory, John K.; Matsumoto, Alvin M.; Page, Stephanie T.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Cooper, Lori A.] Polyclinic, Endocrinol, Seattle, WA 98122 USA. [Lin, Daniel W.; Wright, Jonathan L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [Lin, Daniel W.; Wright, Jonathan L.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Marck, Brett T.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Thirumalai, A (reprint author), Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Box 357138,1959 NE Pacific St, Seattle, WA 98195 USA. EM arthidoc@u.washington.edu FU National Institute of Aging, National Institutes of Health (NIH) [RO1AG037603]; NIH [5T32DK007247-37]; Robert B. McMillen Professorship; University of Washington Nutrition Obesity Research Center [P30 DK035816]; American Heart Association Clinical Research Program; Eunice Kennedy Shriver National Institute of Child Health and Development Grant [6K12 HD053984]; VA Advanced Fellowship in Geriatrics FX This work was supported by the National Institute of Aging, National Institutes of Health (NIH) through Grant RO1AG037603 (to S.T.P.). Additional support was received as follows: NIH Grant 5T32DK007247-37 (to A.T.), the Robert B. McMillen Professorship (to S.T.P.), University of Washington Nutrition Obesity Research Center Pilot and Feasibility Award P30 DK035816, the American Heart Association Clinical Research Program, and the Eunice Kennedy Shriver National Institute of Child Health and Development Grant 6K12 HD053984(all to K.B.R.). The work was also supported by a VA Advanced Fellowship in Geriatrics (to L.A.C.) and resource and facilities use at VA Puget Sound Health Care System in Seattle, Washington (to B.T.M. and A.M.M.). NR 40 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUL PY 2016 VL 101 IS 7 BP 2937 EP 2944 DI 10.1210/jc.2016-1483 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DR9OA UT WOS:000380224800039 PM 27172434 ER PT J AU Holmes, B Lee, J Landon, KA Benavides-Serrato, A Bashir, T Jung, ME Lichtenstein, A Gera, J AF Holmes, Brent Lee, Jihye Landon, Kenna A. Benavides-Serrato, Angelica Bashir, Tariq Jung, Michael E. Lichtenstein, Alan Gera, Joseph TI Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE cyclin D1; glioblastoma; heterogeneous nuclear ribonucleoprotein (hnRNP); mechanistic target of rapamycin (mTOR); Myc (c-Myc); translation; IRES; ITAF; mRNA translation ID NUCLEAR RIBONUCLEOPROTEIN A1; TRANS-ACTING FACTOR; HNRNP A1; MAMMALIAN TARGET; GROWTH; IRES; RESISTANCE; SENSITIVITY; MULTIFORME; INITIATION AB Our previous work has demonstrated an intrinsic mRNA-specific protein synthesis salvage pathway operative in glioblastoma (GBM) tumor cells that is resistant to mechanistic target of rapamycin (mTOR) inhibitors. The activation of this internal ribosome entry site (IRES)-dependent mRNA translation initiation pathway results in continued translation of critical transcripts involved in cell cycle progression in the face of global eIF-4E-mediated translation inhibition. Recently we identified compound 11 (C11), a small molecule capable of inhibiting c-MYC IRES translation as a consequence of blocking the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. Here we demonstrate that C11 also blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-GBM properties when combined with the mechanistic target of rapamycin kinase inhibitor PP242. The structure-activity relationship of C11 was investigated and resulted in the identification of IRES-J007, which displayed improved IRES-dependent initiation blockade and synergistic anti-GBM effects with PP242. Mechanistic studies with C11 and IRES-J007 revealed binding of the inhibitors within the UP1 fragment of heterogeneous nuclear ribonucleoprotein A1, and docking analysis suggested a small pocket within close proximity to RRM2 as the potential binding site. We further demonstrate that co-therapy with IRES-J007 and PP242 significantly reduces tumor growth of GBM xenografts in mice and that combined inhibitor treatments markedly reduce the mRNA translational state of cyclin D1 and c-MYC transcripts in these tumors. These data support the combined use of IRES-J007 and PP242 to achieve synergistic antitumor responses in GBM. C1 [Holmes, Brent; Lichtenstein, Alan; Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA. [Jung, Michael E.; Lichtenstein, Alan; Gera, Joseph] Univ Calif Los Angeles, Jonnson Comprehens Canc Ctr, Los Angeles, CA 90048 USA. [Jung, Michael E.; Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90048 USA. [Lee, Jihye; Jung, Michael E.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90048 USA. [Holmes, Brent; Landon, Kenna A.; Benavides-Serrato, Angelica; Bashir, Tariq; Lichtenstein, Alan; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. RP Gera, J (reprint author), 16111 Plummer St 151,Bldg 1,Rm C111A, Los Angeles, CA 91343 USA. EM jgera@mednet.ucla.edu FU National Institutes of Health [R01CA168700]; Department of Veterans Affairs MERIT Grant [I01BX002665] FX This work was supported by National Institutes of Health Grant R01CA168700 and by Department of Veterans Affairs MERIT Grant I01BX002665. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 39 TC 2 Z9 2 U1 4 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUL 1 PY 2016 VL 291 IS 27 BP 14146 EP 14159 DI 10.1074/jbc.M116.726927 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DR5XG UT WOS:000379975100022 PM 27226604 ER PT J AU Brody, AA Edelman, L Siegel, EO Foster, V Bailey, DE Bryant, AL Bond, SM AF Brody, Abraham A. Edelman, Linda Siegel, Elena O. Foster, Victoria Bailey, Donald E., Jr. Bryant, Ashley Leak Bond, Stewart M. TI Evaluation of a peer mentoring program for early career gerontological nursing faculty and its potential for application to other fields in nursing and health sciences SO NURSING OUTLOOK LA English DT Article DE Mentoring; Peer mentorship; Gerontological nursing; Leadership; Professional development; Faculty ID JUNIOR FACULTY; EDUCATION; MODEL AB Background: As the retirement rate of senior nursing faculty increases, the need to implement new models for providing mentorship to early career academics will become key to developing and maintaining an experienced faculty. Purpose: This evaluation of a peer mentorship program for predoctoral and postdoctoral gerontological nurses examined its efficacy, utility, and potential for improvement. Methods: A web-based survey was developed, implemented, and completed by 22 mentees and 17 mentors (71% and 61% response rates, respectively) as part of the evaluation. Discussion: The peer mentorship program was found to be valuable by both mentors (64.7%) and mentees (72.7%) in helping mentees further develop their careers and networks and providing mentors with supported mentorship experience. Conclusion: The peer mentorship program could serve as a model for other professional organizations, academic institutions:and consortiums to enhance and extend the formal vertical mentorship provided to early academic career individuals. C1 [Brody, Abraham A.] NYU, Coll Nursing, Hartford Inst Geriatr Nursing, 433 First Ave,Room 504, New York, NY 10010 USA. [Brody, Abraham A.] James J Peters Bronx VA Med Ctr, Bronx, NY USA. [Edelman, Linda] Univ Utah, Sch Nursing, Hartford Ctr Geriatr Nursing Excellence, Salt Lake City, UT USA. [Siegel, Elena O.] Univ Calif Davis, Betty Irene Moore Sch Nursing, Sacramento, CA 95817 USA. [Foster, Victoria] Clayton State Univ, Sch Nursing, Morrow, GA USA. [Bailey, Donald E., Jr.] Duke Univ, Sch Nursing, Durham, NC USA. [Bryant, Ashley Leak] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA. [Bond, Stewart M.] Boston Coll, Connell Sch Nursing, Chestnut Hill, MA 02167 USA. RP Brody, AA (reprint author), NYU, Coll Nursing, Hartford Inst Geriatr Nursing, 433 First Ave,Room 504, New York, NY 10010 USA. EM Ab.Brody@nyu.edu OI Brody, Abraham/0000-0002-3405-7043 FU John A Hartford Foundation FX The authors would like to acknowledge the John A Hartford Foundation for its generous funding of this program, and the administrative support provided by the National Hartford Center of Gerontological Nursing Excellence. NR 26 TC 0 Z9 0 U1 6 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD JUL-AUG PY 2016 VL 64 IS 4 BP 332 EP 338 DI 10.1016/j.outlook.2016.03.004 PG 7 WC Nursing SC Nursing GA DR8YB UT WOS:000380183200008 PM 27156778 ER PT J AU Cunningham, FE Hur, K Dong, DA Miller, DR Zhang, RP Wei, XM McCarren, M Mosholder, AD Graham, DJ Aspinall, SL Good, CB AF Cunningham, Francesca E. Hur, Kwan Dong, Diane Miller, Donald R. Zhang, Rongping Wei, Xiangming McCarren, Madeline Mosholder, Andrew D. Graham, David J. Aspinall, Sherrie L. Good, Chester B. TI A comparison of neuropsychiatric adverse events during early treatment with varenicline or a nicotine patch SO ADDICTION LA English DT Article DE Adverse drug events; mental health disorder; nicotine replacement therapy; varenicline ID RECEPTOR PARTIAL AGONIST; RANDOMIZED CONTROLLED-TRIAL; SUSTAINED-RELEASE BUPROPION; SMOKING-CESSATION; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; PROSPECTIVE COHORT; SUICIDAL-BEHAVIOR; BIPOLAR DISORDER; MAJOR DEPRESSION AB Aims We compared the risk of mental health episodes requiring hospitalization (primary aim) or out-patient clinic visits (secondary aim) associated with varenicline versus the nicotine patch (NP) in an era prior to psychiatric boxed warnings. Design Retrospective cohort. Setting Department of Veterans Affairs (VA), USA. Participants VA patients with or without psychiatric comorbidities and a new prescription for varenicline (15 255) were propensity score-matched (1 : 2) to new users of NP (123 054) between 1 May 2006 and 30 September 2007, resulting in 11 774 and 23 548 patients in the varenicline and NP groups, respectively. Measurements The primary outcomes were hospitalizations with a primary discharge diagnosis of a range of mental health disorders: depression, schizophrenia, bipolar disorder, suicide attempt, post-traumatic stress disorder, other psychosis and drug-induced mental disorders. Secondary outcomes were out-patient clinic visits with a primary diagnosis of the above list of mental health disorders. Findings Background characteristics of the treatment groups were similar after matching. There was no statistically significant difference in risk of hospitalization for any of the studied mental health disorders with varenicline compared with NP. Among secondary outcomes there was an increased risk of out-patient clinic visits for schizophrenia among patients who received varenicline [hazard ratio (HR) = 1.27; 95% confidence interval (CI) = 1.07, 1.51], this increase being evident only in those with a pre-existing mental health disorder. Conclusion In US VA patients studied prior to the boxed warning being implemented, use of varenicline for smoking cessation was not associated with a detectable increase compared with nicotine patches in hospitalization for any mental health outcomes. There was an increased rate of out-patient attendances with a primary diagnosis of schizophrenia amounting to five per 100 person years of treatment. This increase was found only in patients with a pre-existing mental health disorder. C1 [Cunningham, Francesca E.; Hur, Kwan; Dong, Diane; Zhang, Rongping; Wei, Xiangming; McCarren, Madeline; Aspinall, Sherrie L.; Good, Chester B.] VA Ctr Medicat Safety, Hines, IL USA. [Miller, Donald R.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Miller, Donald R.] Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Mosholder, Andrew D.; Graham, David J.] US FDA, Silver Spring, MD USA. [Aspinall, Sherrie L.; Good, Chester B.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Aspinall, Sherrie L.; Good, Chester B.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. RP Cunningham, FE (reprint author), Ctr Medicat Safety, PBM Serv, Dept Vet Affairs, 1st Ave,1 Block,N Cermak Rd,Bldg 37,Room 139, Hines, IL 60141 USA. EM fran.cunningham@va.gov FU FDA FX Funds from the FDA were used to support this study under an interagency agreement between the FDA and the Veterans Health Administration. The authors do not have a relevant financial interest in this paper or any connections with the tobacco, alcohol, pharmaceutical or gaming industries. The views expressed in this paper are those of the authors, and no official endorsement by the United States Food and Drug Administration, Department of Veteran Affairs or the United States Government is intended or should be inferred. NR 65 TC 1 Z9 1 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JUL PY 2016 VL 111 IS 7 BP 1283 EP 1292 DI 10.1111/add.13329 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DR5OG UT WOS:000379951700026 PM 26826702 ER PT J AU Post, RM Altshuler, LL Kupka, RW McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, R. M. Altshuler, L. L. Kupka, R. W. McElroy, S. L. Frye, M. A. Rowe, M. Grunze, H. Suppes, T. Keck, P. E., Jr. Leverich, G. S. Nolen, W. A. TI Offspring of parents with bipolar illness from the US are more ill than those from the Netherlands and Germany SO BIPOLAR DISORDERS LA English DT Meeting Abstract CT 18th Annual Conference of the International-Society-for-Bipolar-Disorders / 8th Biennial Conference of the International-Society-for-Affective-Disorders CY JUL 13-16, 2016 CL Amsterdam, NETHERLANDS SP Int Soc Bipolar Disorders, Int Soc Affect Disorders C1 [Post, R. M.; Rowe, M.; Leverich, G. S.] Bipolar Collaborat Network, Bethesda, MD USA. [Post, R. M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, L. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, L. L.] VA Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA. [Kupka, R. W.; Keck, P. E., Jr.] VU Med Ctr Amsterdam, Dept Psychiat, Amsterdam, Netherlands. [McElroy, S. L.; Keck, P. E., Jr.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, S. L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, M. A.] Mayo Clin, Dept Psychiat, Rochester, MN USA. [Grunze, H.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England. [Suppes, T.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, T.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, W. A.] Univ Groningen, Univ Med Ctr, Dept Psychiat, Groningen, Netherlands. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-5647 EI 1399-5618 J9 BIPOLAR DISORD JI Bipolar Disord. PD JUL PY 2016 VL 18 SU 1 SI SI MA S-058 BP 35 EP 35 PG 1 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DR5KI UT WOS:000379941500066 ER PT J AU Wrape, ER Jenkins, SR Callahan, JL Nowlin, RB AF Wrape, Elizabeth R. Jenkins, Sharon Rae Callahan, Jennifer L. Nowlin, Rachel B. TI Emotional and Cognitive Coping in Relationship Dissolution SO JOURNAL OF COLLEGE COUNSELING LA English DT Article DE relationship dissolution; repetitive negative thinking; avoidance ID POSTTRAUMATIC STRESS-SYMPTOMS; COLLEGE-STUDENTS; ROMANTIC RELATIONSHIPS; MENTAL-HEALTH; EXPERIENTIAL AVOIDANCE; RELATIONSHIP BREAKUP; DATING COUPLES; DEPRESSED MOOD; EVENT SCALE; RUMINATION AB Dissolution of a romantic relationship can adversely affect functioning among college students and represents one primary reason for seeking campus counseling. This study examined the associations among common coping strategies and distress following relationship dissolution. Avoidance and repetitive negative thinking (RNT) were significantly associated with distress, and gender was found to moderate the relationship between RNT and distress. Findings suggest that college counselors should consider emotional coping strategies following relationship dissolutions. C1 [Wrape, Elizabeth R.; Jenkins, Sharon Rae; Callahan, Jennifer L.; Nowlin, Rachel B.] Univ North Texas, Dept Psychol, Denton, TX USA. [Wrape, Elizabeth R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, 1660 South Columbian Way, Seattle, WA 98108 USA. RP Wrape, ER (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, 1660 South Columbian Way, Seattle, WA 98108 USA. EM elizabeth.wrape2@va.gov NR 62 TC 0 Z9 0 U1 3 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1099-0399 EI 2161-1882 J9 J COLL COUNS JI J. Coll. Couns. PD JUL PY 2016 VL 19 IS 2 BP 110 EP 123 DI 10.1002/jocc.12035 PG 14 WC Psychology, Applied SC Psychology GA DR4KV UT WOS:000379871300002 ER PT J AU Bachhuber, MA Bradley, KA AF Bachhuber, Marcus A. Bradley, Katharine A. TI Evidence-Based Care for People with Unhealthy Alcohol Use-Still Elusive SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID INTERVENTION; METAANALYSIS; MISUSE C1 [Bachhuber, Marcus A.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, 3300 Kossuth Ave, Bronx, NY 10467 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bradley, Katharine A.] VA Puget Sound, HSR&D Ctr Innovat, Seattle, WA USA. RP Bachhuber, MA (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, 3300 Kossuth Ave, Bronx, NY 10467 USA. EM mbachhub@montefiore.org OI Bachhuber, Marcus/0000-0002-5610-8382 FU NCATS NIH HHS [UL1 TR001073]; NIAAA NIH HHS [K24 AA022128] NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2016 VL 31 IS 7 BP 710 EP 711 DI 10.1007/s11606-016-3695-1 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DR4KS UT WOS:000379871000004 PM 27071398 ER PT J AU Al-Helou, G Anklesaria, Z Kohlwes, J Ahari, J Dhaliwal, G AF Al-Helou, Georges Anklesaria, Zafia Kohlwes, Jeffrey Ahari, Jalil Dhaliwal, Gurpreet TI When the Illness Goes Off Script-An Exercise in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE systemic inflammatory response; sepsis; illness scripts ID LANGERHANS CELL HISTIOCYTOSIS; HEMOPHAGOCYTIC SYNDROME; ABDOMINAL-PAIN; WOMAN C1 [Al-Helou, Georges; Ahari, Jalil] George Washington Univ Hosp, Pulm & Crit Care Div, Washington, DC 20037 USA. [Anklesaria, Zafia] Univ Calif Los Angeles, Pulm & Crit Care Div, Los Angeles, CA USA. [Kohlwes, Jeffrey; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kohlwes, Jeffrey; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Al-Helou, G (reprint author), George Washington Univ Hosp, Pulm & Crit Care Div, Washington, DC 20037 USA. EM gre05@email.gwu.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUL PY 2016 VL 31 IS 7 BP 803 EP 807 DI 10.1007/s11606-016-3632-3 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DR4KS UT WOS:000379871000021 PM 26976289 ER PT J AU Tsan, JY Stock, EM Greenawalt, DS Zeber, JE Copeland, LA AF Tsan, Jack Y. Stock, Eileen M. Greenawalt, David S. Zeber, John E. Copeland, Laurel A. TI Mental health treatment after major surgery among Vietnam-era Veterans with posttraumatic stress disorder SO JOURNAL OF HEALTH PSYCHOLOGY LA English DT Article DE mental health treatment; posttraumatic stress disorder; surgery; Veterans ID QUALITY-OF-LIFE; ADMINISTRATIVE DATA; PHYSICAL HEALTH; OLDER-ADULTS; MILITARY; AFFAIRS; PTSD AB The purpose of this study was to examine mental health treatment use among Vietnam Veterans with posttraumatic stress disorder and determine whether undergoing major surgery interrupted mental health treatment or increased the risk of psychiatric hospitalization. Using retrospective data from Veterans Health Administration's electronic medical record system, a total of 3320 Vietnam-era surgery patients with preoperative posttraumatic stress disorder were identified and matched 1:4 with non-surgical patients with posttraumatic stress disorder. The receipt of surgery was associated with a decline in overall mental health treatment and posttraumatic stress disorder-specific treatment 1month following surgery but not during any subsequent month thereafter. Additionally, surgery was not associated with psychiatric admission. C1 [Tsan, Jack Y.; Zeber, John E.; Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Austin, TX USA. [Tsan, Jack Y.; Stock, Eileen M.; Zeber, John E.; Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst Jointly Scott & Whi, Ctr Appl Hlth Res, Temple, TX USA. [Greenawalt, David S.] Albany Stratton VA Med Ctr, Albany, NY USA. RP Tsan, JY (reprint author), US Dept Vet Affairs, Cent Texas Vet Hlth Care Syst, Austin Outpatient Clin, 7901 Metropolis Dr,O11A-2, Austin, TX 78744 USA. EM jack.tsan@va.gov OI Copeland, Laurel/0000-0002-9478-0209 FU Veterans Health Administration [HSRD IIR-09-335]; VISN 17 Center of Excellence for Research on Returning War Veterans; Center for Applied Health Research; Central Texas Veterans Health Care System; Scott & White Healthcare FX This study was supported by the Veterans Health Administration including HSR&D IIR-09-335 (Copeland-PI), the VISN 17 Center of Excellence for Research on Returning War Veterans, and the Center for Applied Health Research, jointly sponsored by Central Texas Veterans Health Care System and Scott & White Healthcare. NR 25 TC 0 Z9 0 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1359-1053 EI 1461-7277 J9 J HEALTH PSYCHOL JI J. Health Psychol. PD JUL PY 2016 VL 21 IS 7 BP 1249 EP 1260 DI 10.1177/1359105314551620 PG 12 WC Psychology, Clinical SC Psychology GA DR3SX UT WOS:000379824000006 PM 25305191 ER PT J AU Doyle, BJ Ettner, SL Nuckols, TK AF Doyle, Brian J. Ettner, Susan L. Nuckols, Teryl K. TI Supplemental insurance reduces out-of-pocket costs in medicare observation services SO JOURNAL OF HOSPITAL MEDICINE LA English DT Letter C1 [Doyle, Brian J.; Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Doyle, Brian J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ettner, Susan L.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Nuckols, Teryl K.] Cedar Sinai Med Ctr, Dept Med, Div Gen Internal Med, Los Angeles, CA USA. [Nuckols, Teryl K.] RAND Corp, Santa Monica, CA USA. RP Doyle, BJ (reprint author), 911 Broxton Plaza, Los Angeles, CA 90024 USA. EM bdoyle@mednet.ucla.edu OI Doyle, Brian/0000-0003-2782-2306 NR 11 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JUL PY 2016 VL 11 IS 7 BP 502 EP 504 DI 10.1002/jhm.2588 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DR6VI UT WOS:000380039000008 PM 27373701 ER PT J AU Prahl, M Dhaliwal, G Shulman, ST Doshi, N Monash, B AF Prahl, Mary Dhaliwal, Gurpreet Shulman, Stanford T. Doshi, Neeti Monash, Bradley TI Another spin SO JOURNAL OF HOSPITAL MEDICINE LA English DT Editorial Material ID TOXIC-SHOCK-SYNDROME; STAPHYLOCOCCUS-AUREUS C1 [Prahl, Mary; Doshi, Neeti; Monash, Bradley] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Dhaliwal, Gurpreet; Monash, Bradley] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shulman, Stanford T.] Northwestern Univ, Dept Pediat, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. RP Monash, B (reprint author), 505 Parnassus Ave,Box 0131, San Francisco, CA 94143 USA. EM bradley.monash@ucsf.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JUL PY 2016 VL 11 IS 7 BP 509 EP 512 DI 10.1002/jhm.2574 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DR6VI UT WOS:000380039000010 PM 27018991 ER PT J AU Foss, MH Pou, S Davidson, PM Dunaj, JL Winter, RW Pou, S Licon, MH Doh, JK Li, YX Kelly, JX Dodean, RA Koop, DR Riscoe, MK Purdy, GE AF Foss, Marie H. Pou, Sovitj Davidson, Patrick M. Dunaj, Jennifer L. Winter, Rolf W. Pou, Sovijja Licon, Meredith H. Doh, Julia K. Li, Yuexin Kelly, Jane X. Dodean, Rozalia A. Koop, Dennis R. Riscoe, Michael K. Purdy, Georgiana E. TI Diphenylether-Modified 1,2-Diamines with Improved Drug Properties for Development against Mycobacterium tuberculosis SO ACS INFECTIOUS DISEASES LA English DT Article DE antibiotic; drug development; tuberculosis; proton motive force; MmpL3 ID SPONTANEOUS MUTATION; ANTITUBERCULAR DRUG; TRANSPORTER ACRB; SQ109; DISCOVERY; OPTIMIZATION; INHIBITION; MECHANISM; BINDING; MMPL3 AB New treatments for tuberculosis infection are critical to combat the emergence of multidrug- and extensively drug-resistant Mycobacterium tuberculosis (Mtb). We report the characterization of a diphenylether-modified adamantyl 1,2-diamine that we refer to as TBL-140, which has a minimal inhibitory concentration (MIC99) of 1.2 mu g/mL. TBL-140 is effective against drug-resistant Mtb and nonreplicating bacteria. In addition, TBL-140 eliminates expansion of Mtb in cell culture infection assays at its MIC. To define the mechanism of action of this compound, we performed a spontaneous mutant screen and biochemical assays. We determined that TBL-140 treatment affects the proton motive force (PMF) by perturbing the transmembrane potential (Delta Psi), consistent with a target in the electron transport chain (ETC). As a result, treated bacteria have reduced intracellular ATP levels. We show that TBL-140 exhibits greater metabolic stability than SQ109, a structurally similar compound in clinical trials for treatment of MDR-TB infections. Combined, these results suggest that TBL-140 should be investigated further to assess its potential as an improved therapeutic lead against Mtb. C1 [Foss, Marie H.; Davidson, Patrick M.; Dunaj, Jennifer L.; Licon, Meredith H.; Doh, Julia K.; Riscoe, Michael K.; Purdy, Georgiana E.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Pou, Sovitj; Winter, Rolf W.; Pou, Sovijja; Li, Yuexin; Kelly, Jane X.; Dodean, Rozalia A.; Riscoe, Michael K.] Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Koop, Dennis R.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. RP Purdy, GE (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM purdyg@ohsu.edu FU Medical Research Foundation of Oregon Early Clinical Investigator grant; NIH [T32 AI 007472]; U.S. Department of Veterans Affairs; National Science Foundation [0741993] FX M.H.F. was supported by a Medical Research Foundation of Oregon Early Clinical Investigator grant and NIH T32 AI 007472. This project was supported with funds from the U.S. Department of Veterans Affairs (MKR). The National Science Foundation (Grant 0741993) supported the purchase of the LTQ-Orbitrap Discovery MS system used for analysis of our samples. We thank Dr. Karen Dobos at Colorado State University for sharing the clinical susceptible and monoresistant Mtb pairs. NR 29 TC 3 Z9 3 U1 3 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 2373-8227 J9 ACS INFECT DIS JI ACS Infect. Dis. PD JUL PY 2016 VL 2 IS 7 BP 500 EP 508 DI 10.1021/acsinfecdis.6b00052 PG 9 WC Chemistry, Medicinal; Infectious Diseases SC Pharmacology & Pharmacy; Infectious Diseases GA DR1AP UT WOS:000379638600008 PM 27626102 ER PT J AU Petersen, T Lee, YJ Osinusi, A Amorosa, VK Wang, C Kang, M Matining, R Zhang, X Dou, DN Umbleja, T Kottilil, S Peters, MG AF Petersen, Tess Lee, Yu-Jin Osinusi, Anu Amorosa, Valerianna K. Wang, Crystal Kang, Minhee Matining, Roy Zhang, Xiao Dou, Diana Umbleja, Triin Kottilil, Shyam Peters, Marion G. TI Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; NITAZOXANIDE; TIZOXANIDE; PHARMACOKINETICS; INFECTION; HCV AB A combination of nitazoxanide (NTZ), peginterferon (PegIFN), and ribavirin (RBV) may result in higher sustained virologic response (SVR) rates in hepatitis C virus (HCV) monoinfected patients. This study evaluated the effect of NTZ on interferon-stimulated gene (ISG) expression in vitro and in vivo among HIV/HCV genotype-1 (GT-1) treatment-naive patients. The ability of NTZ to enhance host response to interferon (IFN) signaling using the HCV cell culture system was initially evaluated. Second, ISG expression in 53 patients with treatment outcomes [21 SVR and 32 nonresponders (NR)] in the ACTG A5269 trial, a phase-II study (4-week lead in of NTZ 500mg daily followed by 48 weeks of NTZ, PegIFN, and weight-based RBV), was assessed. The relative expression of 48 ISGs in peripheral blood mononuclear cells (PBMCs) was measured at baseline, week 4, and week 8 of treatment in a blinded manner. In vitro NTZ produced a direct and additive antiviral effect with IFN-alfa, with pretreatment of NTZ resulting in maximal HCV suppression. NTZ augmented IFN-mediated ISG induction in PBMCs from relapsers and SVRs (p < 0.05), but not NR. In ACTG A5269, baseline expression of most ISGs was similar between NR and SVR. NTZ minimally induced 17 genes in NR and 13 genes in SVR after 4 weeks of therapy. However, after initiation of PegIFN and RBV, ISG induction was predominantly observed in the SVR group and not NR group. NTZ treatment facilitates IFN-induced suppression of HCV replication. Inability to achieve SVR with IFN-based therapy in this clinical trial is associated with diminished ISG response to therapy that is refractory to NTZ. C1 [Petersen, Tess; Lee, Yu-Jin; Osinusi, Anu; Wang, Crystal; Zhang, Xiao; Dou, Diana; Kottilil, Shyam] NIAID, Immunoregulat Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. [Osinusi, Anu; Kottilil, Shyam] Univ Maryland, Sch Med, Inst Human Virol, Div Clin Care & Res, 725 West Lombard St,Room S222, Baltimore, MD 21201 USA. [Osinusi, Anu] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Amorosa, Valerianna K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Amorosa, Valerianna K.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kang, Minhee; Matining, Roy; Umbleja, Triin] Harvard Sch Publ Hlth, Boston, MA USA. [Peters, Marion G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Kottilil, S (reprint author), Univ Maryland, Sch Med, Inst Human Virol, Div Clin Care & Res, 725 West Lombard St,Room S222, Baltimore, MD 21201 USA. EM Skottilil@ihv.umaryland.edu FU ACTG Network Leadership Grant [1U01AI068636]; ACTG Statistical and Data Management Center Grant [1U01AI068634]; UAB VSL grant [NIH/NIAID 7UM1AI068636]; Intramural Research Program of the NIAID, National Institutes of Health [AI000390] FX ACTG A5269 members and funding: ACTG Network Leadership Grant 1U01AI068636. ACTG Statistical and Data Management Center Grant 1U01AI068634. For HCV RNA and HCV genotyping efforts performed at Dr. Victoria A. Johnson's UAB Virology Laboratory 54: James Darren Hazelwood. UAB VSL grant (NIH/NIAID 7UM1AI068636).; This research was supported in part with federal funds from the Intramural Research Program of the NIAID, National Institutes of Health (AI000390). NR 21 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JUL PY 2016 VL 32 IS 7 BP 660 EP 667 DI 10.1089/aid.2015.0236 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DR0PJ UT WOS:000379609100007 PM 26974581 ER PT J AU Yoon, J Fonarow, GC Groeneveld, PW Teerlink, JR Whooley, MA Sahay, A Heidenreich, PA AF Yoon, Jean Fonarow, Gregg C. Groeneveld, Peter W. Teerlink, John R. Whooley, Mary A. Sahay, Anju Heidenreich, Paul A. TI Patient and Facility Variation in Costs of VA Heart Failure Patients SO JACC-HEART FAILURE LA English DT Article DE costs; heart failure; veterans ID MEDICARE BENEFICIARIES; ELDERLY-PATIENTS; OLDER PATIENTS; UNITED-STATES; AVERAGE COST; HEALTH-CARE; RISK; READMISSION; VETERANS; HOSPITALIZATION AB OBJECTIVES This study sought to determine the variation in annual health care costs among patients with heart failure in the Veterans Affairs (VA) system. BACKGROUND Heart failure is associated with considerable use of health care resources, but Little is known about patterns in patient characteristics related to higher costs. METHODS We obtained VA utilization and cost records for all patients with a diagnosis of heart failure in fiscal year 2010. We compared total VA costs by patient demographic factors, comorbid conditions, and facility where they were treated in bivariate analyses. We regressed total costs on patient factors alone, VA facility alone, and all factors combined to determine the relative contribution of patient factors and facility to explaining cost differences. RESULTS There were 117,870 patients with heart failure, and their mean annual VA costs were $30,719 (SD 49,180) with more than one-half of their costs from inpatient care. Patients at younger ages, of Hispanic or black race/ethnicity, diagnosed with comorbid drug use disorders, or who died during the year had the highest costs (all p < 0.01). There was variation in costs by facility as mean adjusted costs ranged from approximately $15,000 to $48,000. In adjusted analyses, patient factors atone explained more of the variation in health care costs (R-2=0.116) compared with the facility where the patient was treated (R-2=0.018). CONCLUSIONS A large variation in costs of heart failure patients was observed across facilities, although this was explained largely by patient factors. Improving the efficiency of VA resource utilization may require increased scrutiny of high-cost patients to determine if adequate value is being delivered to those patients. (C) 2016 by the American College of Cardiology Foundation. C1 [Yoon, Jean] Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Groeneveld, Peter W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Teerlink, John R.; Whooley, Mary A.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. [Teerlink, John R.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Sahay, Anju; Heidenreich, Paul A.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Menlo Pk, CA USA. [Heidenreich, Paul A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Yoon, J (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Hlth Econ Resource Ctr, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM jean.yoon@va.gov NR 30 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD JUL PY 2016 VL 4 IS 7 BP 551 EP 558 DI 10.1016/j.jchf.2016.01.003 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DQ5YY UT WOS:000379282400005 PM 26970829 ER PT J AU Pang, PS Teerlink, JR Voors, AA Ponikowski, P Greenberg, BH Filippatos, G Felker, GM Davison, BA Cotter, G Kriger, J Prescott, MF Hua, TA Severin, T Metra, M AF Pang, Peter S. Teerlink, John R. Voors, Adriaan A. Ponikowski, Piotr Greenberg, Barry H. Filippatos, Gerasimos Felker, G. Michael Davison, Beth A. Cotter, Gad Kriger, Joshua Prescott, Margaret F. Hua, Tsushung A. Severin, Thomas Metra, Marco TI Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes An Exploratory Analysis From the RELAX-AHF Trial SO JACC-HEART FAILURE LA English DT Article DE acute heart failure; emergency department; risk stratification; serelaxin ID EMERGENCY-DEPARTMENT; CARDIAC TROPONIN; MORTALITY; HOSPITALIZATION; STRATIFICATION; PREDICTION; DESIGN; VALIDATION; BIOMARKERS; ADMISSIONS AB OBJECTIVES The aim of this study was to determine if a baseline high-sensitivity troponin T (hsTnT) value <= 99th percentile upper reference limit (0.014 mu g/l ["low hsTnT"]) identifies patients at tow risk for adverse outcomes. BACKGROUND Approximately 85% of patients who present to emergency departments with acute heart failure are admitted. Identification of patients at low risk might decrease unnecessary admissions. METHODS A post-hoc analysis was conducted from the RELAX-AHF (Serelaxin, Recombinant Human Relaxin-2, for Treatment of Acute Heart Failure) trial, which randomized patients within 16 h of presentation who had systolic blood pressure >125 mm Hg, mild to moderate renal impairment, and N-terminal pro-brain natriuretic peptide >= 1,600 ng/l to serelaxin versus placebo. Linear regression models for continuous endpoints and Cox models for time-to-event endpoints were used. RESULTS Of the 1,076 patients with available baseline hsTnT values, 107 (9.9%) had low hsTnT. No cardiovascular (CV) deaths through day 180 were observed in the low-hsTnT group compared with 79 CV deaths (7.3%) in patients with higher hsTnT. By univariate analyses, low hsTnT was associated with lower risk for all 5 primary outcomes: 1) days alive and out of the hospital by day 60; 2) CV death or rehospitalization for heart failure or renal failure by day 60; 3) length of stay; 4) worsening heart failure through day 5; and 5) CV death through day 180. After multivariate adjustment, only 180-day CV mortality remained significant (hazard ratio: 0.0; 95% confidence interval: 0.0 to 0.736; p = 0.0234; C-index = 0.838 [95% confidence interval: 0.798 to 0.878]). CONCLUSIONS No CV deaths through day 180 were observed in patients with hsTnT levels <= 0.014 mu g/l despite high N-terminal pro-brain natriuretic peptide levels. Low baseline hsTnT may identify patients with acute heart faiLure at very Low risk for CV mortality. (C) 2016 by the American College of Cardiology Foundation. C1 [Pang, Peter S.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Pang, Peter S.] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Greenberg, Barry H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece. [Felker, G. Michael] Duke Univ, Sch Med, Durham, NC USA. [Felker, G. Michael] Duke Clin Res Inst, Durham, NC USA. [Davison, Beth A.; Cotter, Gad] Momentum Res, Durham, NC USA. [Kriger, Joshua] Columbia Univ, New York, NY USA. [Prescott, Margaret F.; Hua, Tsushung A.] Novartis Pharmaceut, New Hanover, NJ USA. [Severin, Thomas] Novartis Pharmaceut, Basel, Switzerland. [Metra, Marco] Univ Brescia, Brescia, Italy. RP Pang, PS (reprint author), Indiana Univ, Dept Emergency Med, 640 Eskenazi Ave,FOB 3rd Floor, Indianapolis, IN 46202 USA. EM ppang@iu.edu RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 NR 36 TC 7 Z9 7 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1779 EI 2213-1787 J9 JACC-HEART FAIL JI JACC-Heart Fail. PD JUL PY 2016 VL 4 IS 7 BP 591 EP 599 DI 10.1016/j.jchf.2016.02.009 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DQ5YY UT WOS:000379282400012 PM 27039129 ER PT J AU Tuepker, A Zickmund, SL Nicolajski, CE Hahm, B Butler, J Weir, C Post, L Hickam, DH AF Tuepker, Anais Zickmund, Susan L. Nicolajski, Cara E. Hahm, Bridget Butler, Jorie Weir, Charlene Post, Lori Hickam, David H. TI Providers' Note-Writing Practices for Post-traumatic Stress Disorder at Five United States Veterans Affairs Facilities SO JOURNAL OF BEHAVIORAL HEALTH SERVICES & RESEARCH LA English DT Article ID ELECTRONIC HEALTH RECORDS; MEDICAL-RECORD; PTSD; INFORMATION; EXPERIENCES; THERAPY; DOCTORS; PATIENT AB The capacity of electronic health records (EHRs) to capture desired information depends on the practices of health care providers. These practices have not been well studied in relation to post-traumatic stress disorder (PTSD). This qualitative study investigated how providers write EHR notes on PTSD through 38 interviews with providers working at five Veterans Affairs (VA) hospitals across the United States of America. Two overarching themes were prominent in the results. Providers used progress notes primarily to remember and access details for direct patient care, but only rarely for care coordination. Providers infrequently recorded information not judged to directly contribute to improved care, sometimes deliberately omitting information perceived to jeopardize patients' access to, or quality of, care. Omitted information frequently included sexual or non-military trauma. Understanding providers' thought processes can help clinicians be aware of the limitations of EHR notes as a tool for learning the histories of new patients. Similarly, researchers relying on EHR data for PTSD research should be aware of likely areas of missing data. C1 [Tuepker, Anais] VA Portland Hlth Care Syst, CIVIC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Tuepker, Anais] Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97201 USA. [Zickmund, Susan L.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Nicolajski, Cara E.] UPMC Ctr High Value Hlth Care, Pittsburgh, PA USA. [Hahm, Bridget] James A Haley Vet Hosp, Tampa, FL USA. [Butler, Jorie; Weir, Charlene] VA Salt Lake City Healthcare Syst, Consortium Healthcare Informat Res, Salt Lake City, UT USA. [Post, Lori] Yale Univ, Dept Emergency Med, New Haven, CT USA. [Hickam, David H.] PCORI, Washington, DC USA. RP Tuepker, A (reprint author), VA Portland Hlth Care Syst, CIVIC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.; Tuepker, A (reprint author), Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97201 USA. EM tuepker@ohsu.edu FU VA's Health Services Research and Development Service through its Consortium for Health Informatics Research (CHIR) FX Funding for this research was provided by the VA's Health Services Research and Development Service through its Consortium for Health Informatics Research (CHIR). The views expressed are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors would like to thank all members of the Consortium for Health Informatics Research (CHIR) PTSD research team, with particular thanks to Jessica Robb for project coordination. NR 26 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1094-3412 EI 1556-3308 J9 J BEHAV HEALTH SER R JI J. Behav. Health Serv. Res. PD JUL PY 2016 VL 43 IS 3 BP 428 EP 442 DI 10.1007/s11414-015-9472-9 PG 15 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DQ2NZ UT WOS:000379040600007 PM 26228929 ER PT J AU Dawson, AZ Walker, RJ Campbell, JA Egede, LE AF Dawson, Aprill Z. Walker, Rebekah J. Campbell, Jennifer A. Egede, Leonard E. TI Validation of theoretical pathway between discrimination, diabetes self-care and glycemic control SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Discrimination; Glycemic control; Self-care; Pathways; Stress ID PERCEIVED RACIAL-DISCRIMINATION; AFRICAN-AMERICANS; RATED HEALTH; STRESS; ADULTS; RESILIENCY; BEHAVIORS; SERVICES; MELLITUS; VALIDITY AB Aims: This study examined the mechanisms through which discrimination influences diabetes self-care and glycemic control in patients with diabetes by using structured equation modeling. Methods: 615 patients were recruited from two adult primary care clinics in the southeastern United States. Measures were based on a theoretical model and included perceived discrimination, social support, social cohesion, and perceived stress. Structured equation modeling examined the relationship with diabetes self-care and glycemic control. Results: The final model (chi2(211) = 328.82, p < 0.0001, R-2 = 0.99, RMSEA = 0.03 and CFI = 0.98) shows that higher stress is directly significantly related to a decreased self-care (r = -0.59, p <0.001) and increased HbA1c (r = 0.27, p < 0.05). There was no significant direct association between discrimination, social support or social cohesion, and glycemic control or self-care. There was, however, a direct significant association between increased discrimination (r = 0.46, p < 0.001), decreased social support (r = -0.34, p < 0.001), increased social cohesion (r = 0.14, p < 0.05) and increased stress. Conclusions: These results support the hypothesized pathway of discrimination on health outcomes, showing both a direct and indirect influence through stress on HbA1c in adults with diabetes. Understanding the pathways through which discrimination influences diabetes outcomes is important for providing more comprehensive and effective care. These results suggest future interventions targeting patients with diabetes should take discrimination-induced stress into account. (C) 2016 Elsevier Inc. All rights reserved. C1 [Dawson, Aprill Z.; Walker, Rebekah J.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VAMC, Charleston VA HSR&D COIN, HEROIC, 109 Bee St, Charleston, SC USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, 135 Rutledge Ave, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280, Charleston, SC 29425 USA. EM dawson@musc.edu; walkerrj@musc.edu; campbja@musc.edu; egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease [K24DK093699-01] FX This study was supported by Grant K24DK093699-01 from The National Institute of Diabetes and Digestive and Kidney Disease (PI: Leonard Egede). NR 38 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD JUL PY 2016 VL 30 IS 5 BP 858 EP 863 DI 10.1016/j.jdiacomp.2016.03.014 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP8PI UT WOS:000378759700018 PM 27068266 ER PT J AU Meyer, AND Murphy, DR Singh, H AF Meyer, Ashley N. D. Murphy, Daniel R. Singh, Hardeep TI Communicating Findings of Delayed Diagnostic Evaluation to Primary Care Providers SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Algorithms; Ambulatory Care Facilities; Communication; Control Groups; Electronic Health Records; Electronic Mail; Follow-Up Studies; Humans; Neoplasms; Primary Care Providers; Telephone ID ELECTRONIC HEALTH RECORDS; INFORMATION OVERLOAD; PATIENT; COMMON AB Background: We previously found that an intervention involving electronic algorithms to detect delays in follow-up of cancer-related abnormal or "red-flag" findings and communicating this information to primary care providers (PCPs) led to more timely diagnostic evaluation. In this study, we examined the effectiveness of various communication strategies to inform PCPs about the delayed follow-up. Methods: After identifying follow-up delays through electronic health record-based algorithms and record reviews, we communicated this information to PCPs using 3 escalating steps. First, we sent secure E-mails. If no evidence of follow-up was found in a medical record review after 1 week, we made up to 3 attempts to reach the PCPs or their nurses via telephone. If they could not be reached, we informed clinic directors as the third and final step. In this analysis, we evaluate PCPs' follow-up in response to these methods of communication. Results: A total of 733 patients with follow-up delays were identified (369 patients in the intervention group and 364 patients in the control group). Communicating information to PCPs about possible follow-up delays led to decreased times to diagnostic evaluation, but communication related to delays did not always lead to follow-up for the patients in the intervention group. Specifically, secure E-mails led to follow-up in 11.1% of cases (41 of 369), telephone calls led to follow-up in 68.6% of cases (225 of 328), and contacting clinic directors led to follow-up in 5 of 11 cases in which communication escalated to this level. Conclusion: Strategies to communicate to PCPs information on delayed follow-up of findings suspicious for cancer were useful, but not fail-safe. Additional back-up strategies, such as using case coordinators, might be needed. C1 Michael E De Bakey Vet Affairs Med Ctr, Houston Vet Affairs Ctr Innovat Qual Effectivenes, Houston, TX USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX USA. RP Meyer, AND (reprint author), Ctr Innovat Qual Effectiveness & Safety 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM ameyer@bcm.edu FU Agency for Health Care Research and Quality [R18HS017820, K08-HS022901, R01HS022087]; Houston Veterans Affairs Health Services Research & Development Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413]; VA Health Services Research and Development Service [CRE 12-033, USA 14274]; VA National Center for Patient Safety FX This work was supported by the Agency for Health Care Research and Quality (grant no. R18HS017820) and the Houston Veterans Affairs Health Services Research & Development Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). DRM is supported by a Mentored Career Development Award (grant K08-HS022901) from the Agency for Healthcare Research and Quality. HS is also supported by the VA Health Services Research and Development Service (CRE 12-033; Presidential Early Career Award for Scientists and Engineers USA 14274), the VA National Center for Patient Safety, and the Agency for Health Care Research and Quality (grant R01HS022087). NR 14 TC 1 Z9 1 U1 3 U2 3 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 EI 1558-7118 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD JUL-AUG PY 2016 VL 29 IS 4 BP 469 EP 473 DI 10.3122/jabfm.2016.04.150363 PG 5 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA DR0MC UT WOS:000379600600008 PM 27390378 ER PT J AU Sweet, RA MacDonald, ML Kirkwood, CM Ding, Y Schempf, T Jones-Laughner, J Kofler, J Ikonomovic, MD Lopez, OL Garver, ME Fitz, NF Koldamova, R Yates, NA AF Sweet, Robert A. MacDonald, Matthew L. Kirkwood, Caitlin M. Ding, Ying Schempf, Tadhg Jones-Laughner, Jackie Kofler, Julia Ikonomovic, Milos D. Lopez, Oscar L. Garver, Megan E. Fitz, Nicholas F. Koldamova, Radosveta Yates, Nathan A. TI Apolipoprotein E*4 (APOE*4) Genotype Is Associated with Altered Levels of Glutamate Signaling Proteins and Synaptic Coexpression Networks in the Prefrontal Cortex in Mild to Moderate Alzheimer Disease SO MOLECULAR & CELLULAR PROTEOMICS LA English DT Article ID AMYLOID-BETA; COGNITIVE IMPAIRMENT; ELDERLY SUBJECTS; TRANSGENIC MICE; FRONTAL-CORTEX; EXPRESSION; PATHOLOGY; DEFICITS; ISOFORM; BRAIN AB It has been hypothesized that Alzheimer disease (AD) is primarily a disorder of the synapse. However, assessment of the synaptic proteome in AD subjects has been limited to a small number of proteins and often included subjects with end-stage pathology. Protein from prefrontal cortex gray matter of 59 AD subjects with mild to moderate dementia and 12 normal elderly subjects was assayed using targeted mass spectrometry to quantify 191 synaptically expressed proteins. The profile of synaptic protein expression clustered AD subjects into two groups. One of these was characterized by reduced expression of glutamate receptor proteins, significantly increased synaptic protein network coexpression, and associated with Apolipoprotein E*4 (APOE*4) carrier status. The second group, by contrast, showed few differences from control subjects. A subset of AD subjects had altered prefrontal cortex synaptic proteostasis for glutamate receptors and their signaling partners. Efforts to therapeutically target glutamate receptors in AD may have outcomes dependent on APOE*4 genotype. C1 [Sweet, Robert A.; MacDonald, Matthew L.; Kirkwood, Caitlin M.; Schempf, Tadhg; Lopez, Oscar L.; Garver, Megan E.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Jones-Laughner, Jackie; Yates, Nathan A.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA. [Kofler, Julia] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Sweet, Robert A.; Ikonomovic, Milos D.; Lopez, Oscar L.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Fitz, Nicholas F.; Koldamova, Radosveta] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA. [Sweet, Robert A.] VISN 4 Mental Illness Res Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomedical Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA.; Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,Lothrop & Terrace St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU VAPHS [BX000452]; [MH16804]; [AG05133]; [AG014449]; [AG027224]; [AG037481]; [AG044490]; [P30CA047904] FX This work was supported by grants MH16804 (MLM), AG05133 (OLL), AG014449 (MDI), AG027224 (RAS), AG037481 (RK), AG044490 (NFF), and VAPHS grant BX000452 (RAS). The Biomedical Mass Spectrometry Center and UPCI Cancer Proteomics Facility are supported in part by award P30CA047904. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 53 TC 0 Z9 0 U1 3 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 1535-9476 EI 1535-9484 J9 MOL CELL PROTEOMICS JI Mol. Cell. Proteomics PD JUL PY 2016 VL 15 IS 7 BP 2252 EP 2262 DI 10.1074/mcp.M115.056580 PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA DQ9SS UT WOS:000379550200005 PM 27103636 ER PT J AU Richards, DJ Tan, Y Coyle, R Li, Y Xu, RY Yeung, N Parker, A Menick, DR Tian, BZ Mei, Y AF Richards, Dylan J. Tan, Yu Coyle, Robert Li, Yang Xu, Ruoyu Yeung, Nelson Parker, Arran Menick, Donald R. Tian, Bozhi Mei, Ying TI Nanowires and Electrical Stimulation Synergistically Improve Functions of hiPSC Cardiac Spheroids SO NANO LETTERS LA English DT Article DE Silicon nanowires; electrical stimulation; cardiac spheroids; human induced pluripotent stem cell-derived cardiomyocytes ID CELL-DERIVED CARDIOMYOCYTES; PLURIPOTENT STEM-CELLS; MYOCARDIAL-INFARCTION; HEART-FAILURE; IN-VITRO; GAP-JUNCTIONS; RAT HEARTS; MATURATION; TISSUE; EXPRESSION AB The advancement of human induced pluripotent stem-cell-derived cardiomyocyte (hiPSC-CM) technology has shown promising potential to provide a patient-specific, regenerative cell therapy strategy to treat cardiovascular disease. Despite the progress, the unspecific, underdeveloped phenotype of hiPSC-CMs has shown arrhythmogenic risk and limited functional improvements after transplantation. To address this, tissue engineering strategies have utilized both exogenous and endogenous stimuli to accelerate the development of hiPSC-CMs. Exogenous electrical stimulation provides a biomimetic pacemaker-like stimuli that has been shown to advance the electrical properties of tissue engineered cardiac constructs. Recently, we demonstrated that the incorporation of electrically conductive silicon nanowires to hiPSC cardiac spheroids led to advanced structural and functional development of hiPSC-CMs by improving the endogenous electrical microenvironment. Here, we reasoned that the enhanced endogenous electrical microenvironment of nanowired hiPSC cardiac spheroids would synergize with exogenous electrical stimulation to further advance the functional development of nanowired hiPSC cardiac spheroids. For the first time, we report that the combination of nanowires and electrical stimulation enhanced cell cell junction formation, improved development of contractile machinery, and led to a significant decrease in the spontaneous beat rate of hiPSC cardiac spheroids. The advancements made here address critical challenges for the use of hiPSC-CMs in cardiac developmental and translational research and provide an advanced cell delivery vehicle for the next generation of cardiac repair. C1 [Richards, Dylan J.; Tan, Yu; Coyle, Robert; Li, Yang; Yeung, Nelson; Parker, Arran; Mei, Ying] Clemson Univ, Bioengn Dept, Clemson, SC 29634 USA. [Xu, Ruoyu; Tian, Bozhi] Univ Chicago, James Franck Inst, Dept Chem, Chicago, IL 60637 USA. [Xu, Ruoyu; Tian, Bozhi] Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA. [Menick, Donald R.] Med Univ South Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29425 USA. [Mei, Ying] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Menick, Donald R.] Med Univ South Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Mei, Y (reprint author), Clemson Univ, Bioengn Dept, Clemson, SC 29634 USA.; Mei, Y (reprint author), Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. EM mei@clemson.edu FU National Institutes of Health [8P20 GM103444, U54 GM104941]; Clemson University; National Science Foundation [NSF - EPS-0903795]; NIH Cardiovascular Training Grant [T32 HL007260]; US Department of Veterans Affairs Merit Review [I01 BX002327]; NIH-NIGMS [P30 GM103342] FX The work is supported by the National Institutes of Health (8P20 GM103444, U54 GM104941), the startup funds from Clemson University, the National Science Foundation (NSF - EPS-0903795), the NIH Cardiovascular Training Grant (T32 HL007260), and US Department of Veterans Affairs Merit Review (I01 BX002327). This study used the services of the Morphology, Imaging, and Instrumentation Core, which is supported by NIH-NIGMS P30 GM103342 to the South Carolina COBRE for Developmentally Based Cardiovascular Diseases. NR 56 TC 1 Z9 1 U1 17 U2 22 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1530-6984 EI 1530-6992 J9 NANO LETT JI Nano Lett. PD JUL PY 2016 VL 16 IS 7 BP 4670 EP 4678 DI 10.1021/acs.nanolett.6b02093 PG 9 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA DR3HL UT WOS:000379794200101 PM 27328393 ER PT J AU Hardiman, G Savage, SJ Hazard, ES Wilson, RC Courtney, SM Smith, MT Hollis, BW Halbert, CH Gattoni-Celli, S AF Hardiman, Gary Savage, Stephen J. Hazard, E. Starr Wilson, Robert C. Courtney, Sean M. Smith, Michael T. Hollis, Bruce W. Halbert, Chanita Hughes Gattoni-Celli, Sebastiano TI Systems analysis of the prostate transcriptome in African-American men compared with European-American men SO PHARMACOGENOMICS LA English DT Article DE African-American; health disparities; prostate; RNA-seq; transcription; vitamin D ID VITAMIN-D-RECEPTOR; DIFFERENTIAL EXPRESSION ANALYSIS; CANCER PREVENTION TRIAL; 1,25-DIHYDROXYVITAMIN D-3; 25-HYDROXYVITAMIN D; WHITE MEN; SUPPLEMENTATION; CELLS; RISK; GENE AB Aim: African-Americans (AA) have increased prostate cancer risk and a greater mortality rate than European-Americans (EA). AA exhibit a high prevalence of vitamin D deficiency. We examined the global prostate transcriptome in AA and EA, and the effect of vitamin D-3 supplementation. Patients & methods: Twenty-seven male subjects (ten AA and 17 EA), slated to undergo prostatectomy were enrolled in the study. Fourteen subjects received vitamin D-3 (4000 IU daily) and 13 subjects received placebo for 2 months prior to surgery. Results: AA show higher expression of genes associated with immune response and inflammation. Conclusion: Systems level analyses support the concept that Inflammatory processes may contribute to disease progression in AA. These transcripts can be modulated by a short course of vitamin D-3 supplementation. C1 [Hardiman, Gary] Med Univ South Carolina, Dept Med & Publ Hlth, Charleston, SC 29425 USA. [Hardiman, Gary; Hazard, E. Starr; Wilson, Robert C.; Courtney, Sean M.] Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA. [Hazard, E. Starr] Med Univ South Carolina, Lib Sci & Informat, Charleston, SC USA. [Savage, Stephen J.] Ralph H Johnson VA Med Ctr, Dept Urol, Charleston, SC USA. [Savage, Stephen J.; Halbert, Chanita Hughes; Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Wilson, Robert C.; Smith, Michael T.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC USA. [Hollis, Bruce W.] Med Univ South Carolina, Dept Pediat, Charleston, SC USA. [Halbert, Chanita Hughes] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Gattoni-Celli, Sebastiano] Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. RP Hardiman, G (reprint author), Med Univ South Carolina, Dept Med & Publ Hlth, Charleston, SC 29425 USA.; Hardiman, G (reprint author), Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA.; Gattoni-Celli, S (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.; Gattoni-Celli, S (reprint author), Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. EM hardiman@musc.edu; gattonis@musc.edu FU Veterans Administration (VA) CSRD Merit Award [CX000753]; MUSC Center for Genomic Medicine; MUSCCOM; Genomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; Hollings Cancer Center, Medical University of South Carolina [P30 CA 138313] FX This research was funded by Veterans Administration (VA) CSR&D Merit Award CX000753 and a Pilot Project grant from the MUSC Center for Genomic Medicine to SG-C and MUSCCOM start-up funds to GTH. The authors also acknowledge support from the Genomics Shared Resource, Hollings Cancer Center, Medical University of South Carolina. This shared resource is supported in part by the Hollings Cancer Center, Medical University of South Carolina Support Grant (P30 CA 138313). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 46 TC 2 Z9 2 U1 0 U2 1 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1462-2416 EI 1744-8042 J9 PHARMACOGENOMICS JI Pharmacogenomics PD JUL PY 2016 VL 17 IS 10 BP 1129 EP 1143 DI 10.2217/pgs-2016-0025 PG 15 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DR3XC UT WOS:000379835000003 PM 27359067 ER PT J AU Gassman, AA Lewis, MS Lee, JC AF Gassman, Andrew A. Lewis, Michael S. Lee, Justine C. TI Remote Ischemic Preconditioning Recipient Tissues Improves the Viability of Murine Fat Transfer SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID REPERFUSION INJURY; RAT MODEL; BREAST; RECONSTRUCTION; TRANSPLANTATION; SURVIVAL; HARVEST; CELLS; HEART; SIZE AB Background: Local ischemia before the development of recipient circulation may contribute to the highly variable long-term results of fat grafting. Remote ischemic preconditioning before adipose procurement augments the retention of fat grafts and limits subsequent liposclerosis. However, there is no literature examining what role remote ischemic preconditioning has on the fat graft recipient site. Methods: Subcutaneous adipose tissue from transgenic mice expressing green fluorescent protein/luciferase was injected into skin folds of wild-type mice. Donors and recipients experienced intermittent temporary hindlimb tourniquet application before harvest and transfer, respectively. The viability of the transferred tissue was examined over 28 days by luciferin bioluminescence and subsequent histologic analysis. Results: There was a difference in bioluminescence at days 0, 14, and 28. The remote ischemic preconditioning donor or recipient mouse-alone groups demonstrated an approximately 2- to 3-fold increase in bioluminescence. Donor and recipient remote ischemic preconditioning had a 9-fold increase in bioluminescence. Histologic analysis at 28 days confirmed the presence of donor adipocytes, and they were gradually replaced by recipient inflammation and scar tissue. However, the amount of interstitial fibrosis was substantially less in the remote ischemic preconditioning groups. These findings were more pronounced when remote ischemic preconditioning was used for both donor and recipient mice. Conclusions: Remote ischemic preconditioning has the ability to increase the viability of donor adipocytes and limit interstitial fibrosis. More specifically, remote ischemic preconditioning treatment of both donated adipose tissue and recipient wound beds demonstrates the greatest overall adipose cellular viability and native architecture. C1 [Gassman, Andrew A.] Univ Texas Southwestern Med Ctr, Dept Plast Surg, 1801 Inwood Rd, Dallas, TX 75390 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Plast & Reconstruct Surg, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Dept Pathol, Los Angeles, CA USA. RP Gassman, AA (reprint author), Univ Texas Southwestern Med Ctr, Dept Plast Surg, 1801 Inwood Rd, Dallas, TX 75390 USA. EM andrew.gassman@utsouthwestern.edu FU Plastic Surgery Foundation [274376]; Jean Perkins Foundation FX This work was supported by the Plastic Surgery Foundation (Pilot Research Grant number 274376) (to A.A.G.) and the Jean Perkins Foundation (to J.C.L.). NR 24 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD JUL PY 2016 VL 138 IS 1 BP 55E EP 63E DI 10.1097/PRS.0000000000002295 PG 9 WC Surgery SC Surgery GA DQ6RG UT WOS:000379332200008 PM 27348686 ER PT J AU Nagpal, A Xu, R Pangarkar, S Dworkin, I Singh, JR AF Nagpal, Ameet Xu, Rachel Pangarkar, Sanjog Dworkin, Ian Singh, Jaspal R. TI Driving Under the Influence of Opioids SO PM&R LA English DT Editorial Material ID CHRONIC NONMALIGNANT PAIN; DRUG-ABUSING VOLUNTEERS; NEUROPSYCHOLOGICAL PERFORMANCE; PRESCRIPTION OPIOIDS; ORAL OXYCODONE; NONCANCER PAIN; UNITED-STATES; MORPHINE; PSYCHOMOTOR; THERAPY C1 [Nagpal, Ameet; Xu, Rachel] Univ Texas Hlth Sci Ctr San Antonio, Dept Anesthesiol, San Antonio, TX 78229 USA. [Pangarkar, Sanjog] Vet Hlth Serv, Inpatient Pain Serv, Dept Phys Med & Rehabil, Los Angeles, CA USA. [Dworkin, Ian] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA. [Singh, Jaspal R.] Weill Cornell Med Coll, Phys Med & Rehabil, 525 E 68th St,Baker 16, New York, NY 10065 USA. RP Singh, JR (reprint author), Weill Cornell Med Coll, Phys Med & Rehabil, 525 E 68th St,Baker 16, New York, NY 10065 USA. EM jrs9012@med.cornell.edu NR 43 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD JUL PY 2016 VL 8 IS 7 BP 698 EP 705 DI 10.1016/j.pmrj.2016.05.010 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DR1RB UT WOS:000379681500011 PM 27406008 ER PT J AU Schapira, MM Imbert, D Oh, E Byhoff, E Shea, JA AF Schapira, Marilyn M. Imbert, Diana Oh, Eric Byhoff, Elena Shea, Judy A. TI Public engagement with scientific evidence in health: A qualitative study among primary-care patients in an urban population SO PUBLIC UNDERSTANDING OF SCIENCE LA English DT Article DE decision making in science; health communication; patients; public understanding of science ID STATISTICAL LITERACY; INFORMATION; NUMERACY; RISK; COMMUNICATION; MEDICINE; PERCEPTIONS; CONFIDENCE; EXPERIENCE; CHOICE AB The purpose of this study is to explore the experience and perspective of patients regarding scientific evidence in health and the degree that this information impacts health behavior and medical decision making. A focus group study was conducted. Participants were recruited from an urban primary-care practice. The focus group discussions were audio-recorded, transcribed verbatim, and coded by two independent investigators. Emergent themes were identified. Participants (n=30) ranged in age from 30 to 79years, 60% were female, 77% were black, and 50% had at least some college experience. Three thematic areas informed a wide range in level of interest regarding scientific study design and result information: (1) scientific literacy, (2) medical decision making style, and (3) impact of culture and community on decision making. Our findings indicate that communication strategies that incorporate key elements of scientific study design, methods, and results will most effectively translate findings from comparative effectiveness research to patient-informed decision making regarding evidence-based health interventions. C1 [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Schapira, Marilyn M.; Imbert, Diana; Byhoff, Elena; Shea, Judy A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Oh, Eric] Swarthmore Coll, Swarthmore, PA 19081 USA. RP Schapira, MM (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mschap@upenn.edu FU Robert Wood Johnson Foundation Health & Society Scholars program at the University of Pennsylvania FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from the Robert Wood Johnson Foundation Health & Society Scholars program at the University of Pennsylvania. NR 40 TC 0 Z9 0 U1 4 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0963-6625 EI 1361-6609 J9 PUBLIC UNDERST SCI JI Public Underst. Sci. PD JUL PY 2016 VL 25 IS 5 BP 612 EP 626 DI 10.1177/0963662514560489 PG 15 WC Communication; History & Philosophy Of Science SC Communication; History & Philosophy of Science GA DR3EW UT WOS:000379786400008 PM 25491359 ER PT J AU Grandhige, AP Timmer, M O'Neill, MJ Binney, ZO Quest, TE AF Grandhige, Anjali P. Timmer, Marjorie O'Neill, Michael J. Binney, Zachary O. Quest, Tammie E. TI Respiratory Therapists' Experiences and Attitudes Regarding Terminal Extubations and End-of-Life Care SO RESPIRATORY CARE LA English DT Article DE palliative care; respiratory therapist; ventilator; end of life ID WITHDRAWAL; SUPPORT; OUTCOMES; UNIT AB BACKGROUND: Respiratory therapists (RTs) routinely care for patients with life- limiting illnesses and in some hospitals are responsible for terminal extubations. Data on how such experiences affect RTs are scarce. The objective of this work was to survey RTs at 2 academic medical centers about their experiences caring for patients with terminal extubations. METHODS: An online survey was distributed to the hospitals' RTs. Survey data included demographics and experiences with end-of-life care and terminal extubations. The survey was derived from previously published questionnaires plus input from hospital RT leaders. RESULTS: Sixty-five of 173 RTs (37.6%) responded. Of these, 42.4% were >= 50 y old, and 62.7% were female. 20.3% had <= 5 y experience; 52.5% had >= 16 y. 93.8% self-reported being involved in at least one terminal extubation; of those, 36.1% reported performing >= 20. Nearly half (47.5%) wanted to be involved in family meetings discussing terminal extubations, but just 6.6% were frequently involved. Only 32.3% felt that they received adequate education regarding terminal illness in RT school; 32.3% reported gathering this knowledge while working. 60.0% wanted more formal education around terminal patient care. 27.9% reported sometimes being uncomfortable with performing a terminal extubation; most of these rarely felt that they had the option not to perform the extubation. CONCLUSIONS: RTs are rarely involved in end-of-life discussions despite a desire to be, and they experience situations that generate discomfort. There is demand for more formal RT training around care for terminal patients. Clinical protocols that involve RTs in meetings before ventilator withdrawal should be considered. C1 [Grandhige, Anjali P.; O'Neill, Michael J.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Timmer, Marjorie] Emory Univ Hosp, Dept Resp Care, Atlanta, GA USA. [Grandhige, Anjali P.; O'Neill, Michael J.; Binney, Zachary O.; Quest, Tammie E.] Emory Univ, Emory Palliat Care Ctr, Atlanta, GA USA. [Binney, Zachary O.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA. [Quest, Tammie E.] US Dept Vet Affairs, Med Ctr, Atlanta, GA USA. [Quest, Tammie E.] Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA. RP Grandhige, AP (reprint author), Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.; Grandhige, AP (reprint author), Emory Univ, Emory Palliat Care Ctr, Atlanta, GA USA. EM anjali.grandhige@emory.edu NR 14 TC 1 Z9 1 U1 3 U2 4 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JUL PY 2016 VL 61 IS 7 BP 891 EP 896 DI 10.4187/respcare.04168 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DQ5EU UT WOS:000379228600002 PM 27274094 ER PT J AU McConnell, RA Kerlin, MP Schweickert, WD Ahmad, F Patel, MS Fuchs, BD AF McConnell, Ryan A. Kerlin, Meeta Prasad Schweickert, William D. Ahmad, Faraz Patel, Mitesh S. Fuchs, Barry D. TI Using a Post-Intubation Checklist and Time Out to Expedite Mechanical Ventilation Monitoring: Observational Study of a Quality Improvement Intervention SO RESPIRATORY CARE LA English DT Article DE blood gas analysis; acidosis; artificial respiration; mechanical ventilators; checklist; quality improvement ID SURGICAL SAFETY CHECKLIST; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; BLOOD-GAS-ANALYSIS; INTRAHOSPITAL TRANSPORT; HOSPITAL MORTALITY; MEDICAL TEAM; ARTERIAL; COMMUNICATION; OXYGEN AB BACKGROUND: Delayed mechanical ventilation monitoring may impede recognition of life-threatening acidemia. Coordination of multidisciplinary processes can be improved by using a checklist and time-out procedure. The study objective was to evaluate process-related outcomes after implementation of a post-intubation checklist and time out. METHODS: An observational study of a 24-bed medical ICU in Philadelphia, Pennsylvania, was conducted from January to December 2011. A random sample of mechanically ventilated adults was selected from the pre-intervention (n = 80) and post-intervention (n = 144) periods. The primary outcome was the proportion of subjects with an arterial blood gas (ABG) result within 60 min of mechanical ventilation initiation. Secondary outcomes included rates of respiratory acidosis, moderate-severe acidemia (pH < 7.25), checklist initiation, and project sustainability. Chi-square analysis was used to evaluate differences in outcomes between time periods. RESULTS: After the intervention, the proportion of subjects with an ABG result within 60 min increased (56% vs 37%, P = .01), and time to ABG result improved (58 min vs 79 min, P = .004). Adjusting for illness severity, the proportion with an ABG result within 60 min remained significantly higher in the post-intervention period (odds ratio 2.42, 95% CI 1.25-4.68, P = .009). Checklist adherence was higher with ICU intubations than for intubations performed outside the ICU (71% vs 27% checklist initiation rate, P < .001). Transfer from referring institutions (23% checklist initiation rate, P = .006) negatively impacted checklist use. Implementation challenges included frequent stakeholder turnover, undefined process ownership, and lack of real-time performance feedback. CONCLUSIONS: A post-intubation checklist and time out improved the timeliness of mechanical ventilation monitoring through more rapid assessment of arterial blood gases. Implementing this peri-intubation procedure may reduce the risks associated with transitioning to full mechanical ventilatory support. Optimal implementation necessitates strategies to surmount organizational and behavioral barriers to change. C1 [McConnell, Ryan A.] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA. [Kerlin, Meeta Prasad; Schweickert, William D.; Fuchs, Barry D.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA. [Ahmad, Faraz] Northwestern Univ, Dept Med, Div Cardiol, Chicago, IL 60611 USA. [Patel, Mitesh S.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Patel, Mitesh S.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP McConnell, RA (reprint author), Univ Calif San Francisco, Div Gastroenterol, 513 Parnassus Ave,S-357, San Francisco, CA 94143 USA. EM ryan.mcconnell@ucsf.edu NR 38 TC 1 Z9 1 U1 2 U2 2 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD JUL PY 2016 VL 61 IS 7 BP 902 EP 912 DI 10.4187/respcare.04191 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DQ5EU UT WOS:000379228600004 PM 26932381 ER PT J AU Winter, CC Katiyar, KS Hernandez, NS Song, YJ Struzyna, LA Harris, JP Cullen, DK AF Winter, Carla C. Katiyar, Kritika S. Hernandez, Nicole S. Song, Yeri J. Struzyna, Laura A. Harris, James P. Cullen, D. Kacy TI Transplantable living scaffolds comprised of micro-tissue engineered aligned astrocyte networks to facilitate central nervous system regeneration SO ACTA BIOMATERIALIA LA English DT Article DE Tissue engineering; Living scaffold; Glial cell transplant; Biomaterials; Regeneration; Neurotrauma; Neurodegeneration; Traumatic brain injury; Cell migration; Axon pathfinding; Neural stem cells ID SPINAL-CORD-INJURY; ROSTRAL MIGRATORY STREAM; NEURAL STEM-CELLS; NEURITE OUTGROWTH; IN-VITRO; SUBSTRATE CURVATURE; SUBVENTRICULAR ZONE; NEURONAL MIGRATION; BRAIN-INJURY; TRACT AXONS AB Neurotrauma, stroke, and neurodegenerative disease may result in widespread loss of neural cells as well as the complex interconnectivity necessary for proper central nervous system function, generally resulting in permanent functional deficits. Potential regenerative strategies involve the recruitment of endogenous neural stem cells and/or directed axonal regeneration through the use of tissue engineered "living scaffolds" built to mimic features of three-dimensional (3-D) in vivo migratory or guidance pathways. Accordingly, we devised a novel biomaterial encasement scheme using tubular hydrogel-collagen micro-columns that facilitated the self-assembly of seeded astrocytes into 3-D living scaffolds consisting of long, cable-like aligned astrocytic networks. Here, robust astrocyte alignment was achieved within a micro-column inner diameter (ID) of 180 mu m or 300-350 mu m but not 1.0 mm, suggesting that radius of curvature dictated the extent of alignment. Moreover, within small ID micro-columns, >70% of the astrocytes assumed a bi-polar morphology, versus similar to 10% in larger micro-columns or planar surfaces. Cell-cell interactions also influenced the aligned architecture, as extensive astrocyte-collagen contraction was achieved at high (9-12 x 10(5) cells/mL) but not lower (2-6 x 10(5) cells/mL) seeding densities. This high density micro-column seeding led to the formation of ultra-dense 3-D "bundles" of aligned bi-polar astrocytes within collagen measuring up to 150 mu m in diameter yet extending to a remarkable length of over 2.5 cm. Importantly, co-seeded neurons extended neurites directly along the aligned astrocytic bundles, demonstrating permissive cues for neurite extension. These transplantable cable-like astrocytic networks structurally mimic the glial tube that guides neuronal progenitor migration in vivo along the rostral migratory stream, and therefore may be useful to guide progenitor cells to repopulate sites of widespread neurodegeneration. Statement of Significance This manuscript details our development of novel micro-tissue engineering techniques to generate robust networks of longitudinally aligned astrocytes within transplantable micro-column hydrogels. We report a novel biomaterial encasement scheme that facilitated the self-assembly of seeded astrocytes into long, aligned regenerative pathways. These miniature "living scaffold" constructs physically emulate the glial tube - a pathway in the brain consisting of aligned astrocytes that guide the migration of neuronal progenitor cells - and therefore may facilitate directed neuronal migration for central nervous system repair. The small size and self-contained design of these aligned astrocyte constructs will permit minimally invasive transplantation in models of central nervous system injury in future studies. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. C1 [Winter, Carla C.; Katiyar, Kritika S.; Hernandez, Nicole S.; Song, Yeri J.; Struzyna, Laura A.; Harris, James P.; Cullen, D. Kacy] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA. [Winter, Carla C.; Struzyna, Laura A.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. [Winter, Carla C.; Katiyar, Kritika S.; Struzyna, Laura A.; Harris, James P.; Cullen, D. Kacy] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Katiyar, Kritika S.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA. [Hernandez, Nicole S.; Song, Yeri J.; Cullen, D. Kacy] Univ Penn, Perelman Sch Med, Neurosci Grad Grp, Philadelphia, PA 19104 USA. RP Cullen, DK (reprint author), 105E Hayden Hall 3320 Smith Walk, Philadelphia, PA 19104 USA. EM dkacy@mail.med.upenn.edu FU Penn Medicine Neuroscience Center; National Science Foundation [DGE-1321851]; National Institutes of Health [T32-NS043126, F31-NS090746]; Michael J. Fox Foundation (Therapeutic Pipeline Program) [9998]; Department of Veterans Affairs (RRD Merit Review) [B1097-I]; U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-207004]; Penn's Center for Undergraduate Research Fellowships FX Financial support was provided by the Penn Medicine Neuroscience Center, National Science Foundation (Graduate Research Fellowship DGE-1321851), National Institutes of Health (T32-NS043126; F31-NS090746), Michael J. Fox Foundation (Therapeutic Pipeline Program #9998), Department of Veterans Affairs (RR&D Merit Review #B1097-I), U.S. Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-207004), and Penn's Center for Undergraduate Research & Fellowships. We thank Patricia Murphy for technical assistance in these studies. NR 56 TC 2 Z9 2 U1 17 U2 32 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1742-7061 EI 1878-7568 J9 ACTA BIOMATER JI Acta Biomater. PD JUL 1 PY 2016 VL 38 BP 44 EP 58 DI 10.1016/j.actbio.2016.04.021 PG 15 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA DQ1LZ UT WOS:000378963800005 PM 27090594 ER PT J AU Vijayan, A Faubel, S Askenazi, DJ Cerda, J Fissell, WH Heung, M Humphreys, BD Koyner, JL Liu, KD Mour, G Nolin, TD Bihorac, A AF Vijayan, Anitha Faubel, Sarah Askenazi, David J. Cerda, Jorge Fissell, William H. Heung, Michael Humphreys, Benjamin D. Koyner, Jay L. Liu, Kathleen D. Mour, Girish Nolin, Thomas D. Bihorac, Azra CA Amer Soc Nephrology Acute Kidney Injury Advisory Grp TI Clinical Use of the Urine Biomarker [TIMP-2] x [ IGFBP7] for Acute Kidney Injury Risk Assessment SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Acute kidney injury (AKI); biomarker; [TIMP-2] x [IGFBP7]; diagnosis; critically ill; tissue inhibitor of metalloproteinase 2; insulin-like growth factor binding protein 7; NephroCheck; early detection; risk assessment; renal dysfunction; decreased kidney function ID ACUTE-RENAL-FAILURE; CYCLE ARREST BIOMARKERS; CRITICALLY-ILL PATIENTS; FUROSEMIDE STRESS TEST; ACID-BINDING PROTEIN; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; TISSUE INHIBITOR; NEPHROLOGY CONSULTATION; POOR OUTCOMES AB Acute kidney injury (AKI) is a serious complication, commonly occurring in the critically ill population, with devastating short- and long-term consequences. Despite standardization of the definition and staging of AKI, early recognition remains challenging given that serum creatinine level is a marker, albeit imperfect, of kidney function and not kidney injury. Furthermore, the delay in increase in serum creatinine level after loss of glomerular filtration also prevents timely detection of decreased kidney function in patients with AKI. During the past decade, numerous clinical investigations have evaluated the utility of several biomarkers in the early diagnosis and risk stratification of AKI. In 2014, the US Food and Drug Administration approved the marketing of a test based on the combination of urine concentrations of tissue inhibitor of metalloproteinase 2 and insulinlike growth factor binding protein 7 ([TIMP-2] 3 [ IGFBP7]) to determine whether certain critically ill patients are at risk for developing moderate to severe AKI. The optimal role of this biomarker in the diagnosis, management, and prognosis of AKI in different clinical settings requires further clarification. In this perspective, we summarize the biological actions of these 2 cell-cycle arrest biomarkers and present important considerations regarding the clinical application, interpretation, and limitations of this novel test for the early detection of AKI. Am J Kidney Dis. 68(1): 19-28. (C) 2016 by the National Kidney Foundation, Inc. C1 [Vijayan, Anitha; Humphreys, Benjamin D.] Washington Univ, Dept Med, Div Renal, St Louis, MO USA. [Faubel, Sarah] Univ Colorado, Div Renal, Denver, CO 80202 USA. [Faubel, Sarah] Denver VA Med Ctr, Denver, CO USA. [Askenazi, David J.] Univ Alabama Birmingham, Div Pediat Nephrol, Birmingham, AL USA. [Cerda, Jorge] Albany Med Coll, Albany, NY 12208 USA. [Fissell, William H.] Vanderbilt Univ, Dept Med, Div Nephrol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Heung, Michael] Univ Michigan, Dept Med, Div Nephrol, Ann Arbor, MI 48109 USA. [Koyner, Jay L.] Univ Chicago, Dept Med, Sect Nephrol, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Liu, Kathleen D.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA. [Mour, Girish] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15260 USA. [Nolin, Thomas D.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Bihorac, Azra] Univ Florida, Dept Med, Gainesville, FL USA. [Bihorac, Azra] Univ Florida, Dept Anesthesiol, Gainesville, FL USA. [Bihorac, Azra] Univ Florida, Dept Surg, Gainesville, FL USA. RP Vijayan, A (reprint author), Washington Univ, Div Renal, Campus Box 8129,660 S Euclid Ave, St Louis, MO 63110 USA. EM avijayan@dom.wustl.edu FU Spectral Medical Inc and AM-Pharma; Astute Medical Inc; NIH [U01DK104308, U01DK085649]; Abbott; Achaogen Inc; Chemocentryx Inc; Durect Corporation; Center for Sepsis and Critical Illness Award from the National Institute of General Medical Sciences [P50 GM-111152]; Society of Critical Care Medicine FX Dr Vijayan was a clinical adjudicator for the Topaz trial and has research support from Spectral Medical Inc and AM-Pharma. Dr Askenazi is a speaker for the AKI Foundation. Dr Heung reports receiving grant funding from Astute Medical Inc, the manufacturer of NEPHROCHECK. Dr Humphreys is a Co-Principal Investigator on an NIH grant to develop novel biomarkers of chronic kidney disease (CKD) (U01DK104308). Dr Koyner reports receiving grant funding from Abbott and Astute Medical Inc for enrolling patients in observational AKI biomarker studies and consulting fees from Astute Medical Inc. Dr Liu was a clinical adjudicator for the Topaz trial and reports consultancy agreements with Achaogen Inc, Astute Medical Inc, Chemocentryx Inc, and Durect Corporation. She is a Co-Principal Investigator on an NIH grant to test novel biomarkers of CKD (U01DK085649). Dr Nolin is member of the Independent Data Monitoring Committee for Thrasos Innovation Inc. Dr Bihorac is supported by Center for Sepsis and Critical Illness Award P50 GM-111152 from the National Institute of General Medical Sciences and has received research grants from the Society of Critical Care Medicine, Astute Medical Inc, and the I. Heermann Anesthesia Foundation Inc. The remaining authors declare that they have no relevant financial interests. NR 74 TC 11 Z9 11 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2016 VL 68 IS 1 BP 19 EP 28 DI 10.1053/j.ajkd.2015.12.033 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA DP6VB UT WOS:000378636100010 PM 26948834 ER PT J AU Kraut, JA AF Kraut, Jeffrey A. TI Approach to the Treatment of Methanol Intoxication SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Toxic alcohols; serum osmolal gap; serum anion gap; fomepizole; methanol; methanol intoxication; ethanol; hemodialysis ID ETHYLENE-GLYCOL; OSMOLAL GAP; FORMATE KINETICS; ANION-GAP; EXTRACORPOREAL TREATMENTS; METABOLIC-ACIDOSIS; SERUM OSMOLALITY; DIAGNOSIS; FOMEPIZOLE; HEMODIALYSIS AB Methanol intoxication is an uncommon but serious poisoning. Its adverse effects are due primarily to the impact of its major metabolite formic acid and lactic acid resulting from cellular hypoxia. Symptoms including abdominal pain and loss of vision can appear a few hours to a few days after exposure, reflecting the time necessary for accumulation of the toxic byproducts. In addition to a history of exposure, increases in serum osmolal and anion gaps can be clues to its presence. However, increments in both parameters can be absent depending on the nature of the toxic alcohol, time of exposure, and coingestion of ethanol. Definitive diagnosis requires measurement with gas or liquid chromatography, which are laborious and expensive procedures. Tests under study to detect methanol or its metabolite formate might facilitate the diagnosis of this poisoning. Treatment can include administration of ethanol or fomepizole, both inhibitors of the enzyme alcohol dehydrogenase to prevent formation of its metabolites, and hemodialysis to remove methanol and formate. In this Acid-Base and Electrolyte Teaching Case, a patient with methanol intoxication due to ingestion of model airplane fuel is described, and the value and limitations of current and new diagnostic and treatment measures are discussed. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Kraut, Jeffrey A.] UCLA Membrane Biol Lab, Med & Res Serv Vet Adm Greater Los Angeles Health, Los Angeles, CA USA. [Kraut, Jeffrey A.] Vet Adm Greater Los Angeles Healthcare Syst, Div Nephrol, Los Angeles, CA USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Kraut, JA (reprint author), VHAGLA Healthcare Syst, Div Nephrol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkraut@ucla.edu FU UCLA Academic Senate; Veterans Administration FX Support: The manuscript was supported by funds from the UCLA Academic Senate and Veterans Administration. NR 55 TC 1 Z9 1 U1 3 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2016 VL 68 IS 1 BP 161 EP 167 DI 10.1053/j.ajkd.2016.02.058 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DP6VB UT WOS:000378636100026 PM 27180631 ER PT J AU Kamaraj, DC Dicianno, BE Mahajan, HP Buhari, AM Cooper, RA AF Kamaraj, Deepan C. Dicianno, Brad E. Mahajan, Harshal P. Buhari, Alhaji M. Cooper, Rory A. TI Interrater Reliability of the Power Mobility Road Test in the Virtual Reality-Based Simulator-2 SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Durable medical equipment; Neurological rehabilitation; Process assessment (health care); Rehabilitation; Reproducibility of results; Simulation training; Virtual reality exposure therapy; Wheelchairs ID WHEELCHAIR DRIVING PERFORMANCE; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; COMMUNITY; USERS; AGREEMENT; VALIDITY; JOYSTICK; PEOPLE; SKILLS AB Objective: To assess interrater reliability of the Power Mobility Road Test (PMRT) when administered through the Virtual Reality based SIMulator-version 2 (VRSIM-2). Design: Within-subjects repeated-measures design. Setting: Participants interacted with VRSIM-2 through 2 display options (desktop monitor vs immersive virtual reality screens) using 2 control interfaces (roller system vs conventional movement-sensing joystick), providing 4 different driving scenarios (driving conditions 1-4). Participants performed 3 virtual driving sessions for each of the 2 display screens and 1 session through a real-world driving course (driving condition 5). The virtual PMRT was conducted in a simulated indoor office space, and an equivalent course was charted in an open space for the real-world assessment. After every change in driving condition, participants completed a self-reported workload assessment questionnaire, the Task Load Index, developed by the National Aeronautics and Space Administration. Participants: A convenience sample of electric-powered wheelchair (EPW) athletes (N=21) recruited at the 31st National Veterans Wheelchair Games. Interventions: Not applicable. Main Outcome Measures: Total composite PMRT score. Results: The PMRT had high interrater reliability (intraclass correlation coefficient [ICC]>.75) between the 2 raters in all 5 driving conditions. Post hoc analyses revealed that the reliability analyses had >80% power to detect high ICCs in driving conditions 1 and 4. Conclusions: The PMRT has high interrater reliability in conditions 1 and 4 and could be used to assess EPW driving performance virtually in VRSIM-2. However, further psychometric assessment is necessary to assess the feasibility of administering the PMRT using the different interfaces of VRSIM-2. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Kamaraj, Deepan C.; Dicianno, Brad E.; Mahajan, Harshal P.; Buhari, Alhaji M.; Cooper, Rory A.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA 15206 USA. [Kamaraj, Deepan C.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu OI Kamaraj, Dr.C/0000-0003-0639-8518; Kamaraj, Deepan C/0000-0003-1241-1723 FU Department of Veteran Affairs Research and Development Merit Review Award [A6035R] FX Supported by the Department of Veteran Affairs Research and Development Merit Review Award (grant no. A6035R) with resources and facilities at the Human Engineering Research Laboratories, VA Pittsburgh HealthCare System The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government. NR 50 TC 0 Z9 0 U1 4 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2016 VL 97 IS 7 BP 1078 EP 1084 DI 10.1016/j.apmr.2016.02.005 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DQ1RZ UT WOS:000378979400005 PM 26921680 ER PT J AU Kamaraj, DC Dicianno, BE Mahajan, HP Buhari, AM Cooper, RA AF Kamaraj, Deepan C. Dicianno, Brad E. Mahajan, Harshal P. Buhari, Alhaji M. Cooper, Rory A. TI Stability and Workload of the Virtual Reality-Based Simulator-2 SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Durable medical equipment; Process assessment (health care); Rehabilitation; Reproducibility of results; Simulation training; Virtual reality exposure therapy; Wheelchairs ID SPINAL-CORD-INJURY; WHEELCHAIR SKILLS; ADVERSE CONSEQUENCES; MOBILITY DEVICES; PEOPLE; RELIABILITY; PERFORMANCE; VALIDITY; REPAIRS; PROGRAM AB Objective: To assess the stability of clinicians' and users' rating of electric-powered wheelchair (EPW) driving while using 4 different human machine interfaces (HMIs) within the Virtual Reality-based SIMulator-version 2 (VRSIM-2) and in the real world (accounting for a total of 5 unique driving conditions). Design: Within-subjects repeated-measures design. Setting: Simulation-based assessment in a research laboratory. Participants: A convenience sample of EPW athletes (N=21) recruited at the 31st National Veterans Wheelchair Games. Interventions: Not applicable. Main Outcome Measures: Composite PMRT scores from the Power Mobility Road Test (PMRT); Raw Task Load Index; and the 6 subscale scores from the Task Load Index developed by the National Aeronautics and Space Administration (NASA-TLX). Results: There was moderate stability (intraclass correlation coefficient between .50 and .75) in the total composite PMRT scores (P<001) and the users' self-reported performance scores (P<.001) among the 5 driving conditions. There was a significant difference in the workload among the 5 different driving conditions as reflected by the Raw Task Load Index (P=.009). Subanalyses revealed this difference was due to the difference in the mental demand (P=.007) and frustration (P=.007) subscales. Post hoc analyses revealed that these differences in the NASA-TLX subscale scores were due to the differences between real-world and virtual driving scores, particularly attributable to the conditions (1 and 3) that lacked the rollers as a part of the simulation. Conclusions: Further design improvements in the simulator to increase immersion experienced by the EPW user, along with a standardized training program for clinicians to deliver PMRT in VRSIM-2, could improve the stability between the different HMIs and real-world driving. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Kamaraj, Deepan C.; Dicianno, Brad E.; Mahajan, Harshal P.; Buhari, Alhaji M.; Cooper, Rory A.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Related Technol, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. [Kamaraj, Deepan C.; Dicianno, Brad E.; Mahajan, Harshal P.; Buhari, Alhaji M.; Cooper, Rory A.] Human Engn Res Labs, Pittsburgh, PA USA. [Kamaraj, Deepan C.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Related Technol, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. EM dicianno@pitt.edu OI Kamaraj, Dr.C/0000-0003-0639-8518; Kamaraj, Deepan C/0000-0003-1241-1723 FU Department of Veteran Affairs Research and Development Merit Review Award [A6035R] FX Supported by the Department of Veteran Affairs Research and Development Merit Review Award (grant no. A6035R) with resources and facilities at the Human Engineering Research Laboratories, VA Pittsburgh HealthCare System The contents of this publication do not represent the views of the Department of Veterans Affairs or the United States Government. NR 31 TC 0 Z9 0 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2016 VL 97 IS 7 BP 1085 EP 1092 DI 10.1016/j.apmr.2016.01.032 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DQ1RZ UT WOS:000378979400006 PM 26921682 ER PT J AU Hiremath, SV Intille, SS Kelleher, A Cooper, RA Ding, D AF Hiremath, Shivayogi V. Intille, Stephen S. Kelleher, Annmarie Cooper, Rory A. Ding, Dan TI Estimation of Energy Expenditure for Wheelchair Users Using a Physical Activity Monitoring System SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Energy metabolism; Estimation; Exercise test; Motor activity; Rehabilitation; Smartphone; Spinal cord injuries; Wheelchairs ID SPINAL-CORD-INJURY; RANDOMIZED CONTROLLED-TRIAL; WEIGHT-LOSS; VALIDATION; ACCELEROMETERS; INTERVENTION; DISABILITIES; PARAPLEGIA; PEOPLE AB Objective: To develop and evaluate energy expenditure (EE) estimation models for a physical activity monitoring system (PAMS) in manual wheelchair users with spinal cord injury (SCI). Design: Cross-sectional study. Setting: University-based laboratory environment, a semistructured environment at the National Veterans Wheelchair Games, and the participants' home environments. Participants: Volunteer sample of manual wheelchair users with SCI (N=45). Intervention: Participants were asked to perform 10 physical activities (PAs) of various intensities from a list. The PAMS consists of a gyroscope-based wheel rotation monitor (G-WRM) and an accelerometer device worn on the upper arm or on the wrist. Criterion EE using a portable metabolic cart and raw sensor data from PAMS were collected during each of these activities. Main Outcome Measures: Estimated EE using custom models for manual wheelchair users based on either the G-WRM and arm accelerometer (PAMS-Arm) or the G-WRM and wrist accelerometer (PAMS-Wrist). Results: EE estimation performance for the PAMS-Arm (average error +/- SD: -9.82%+/- 37.03%) and PAMS-Wrist (-5.65%+/- 32.61%) on the validation dataset indicated that both PAMS-Arm and PAMS-Wrist were able to estimate EE for a range of PAs with <10% error. Moderate to high intraclass correlation coefficients (ICCs) indicated that the EE estimated by PAMS-Arm (ICC3,1 = .82, P<.05) and PAMS-Wrist (ICC3,1 = .89, P<.05) are consistent with the criterion EE. Conclusions: Availability of PA monitors can assist wheelchair users to track PA levels, leading toward a healthier lifestyle. The new models we developed can estimate PA levels in manual wheelchair users with SCI in laboratory and community settings. (C) 2016 by the American Congress of Rehabilitation Medicine C1 [Hiremath, Shivayogi V.; Kelleher, Annmarie; Cooper, Rory A.; Ding, Dan] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, US Dept Vet Affairs, Pittsburgh, PA USA. [Hiremath, Shivayogi V.; Kelleher, Annmarie; Cooper, Rory A.; Ding, Dan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Hiremath, Shivayogi V.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Hiremath, Shivayogi V.] Temple Univ, Dept Phys Therapy, Philadelphia, PA 19140 USA. [Intille, Stephen S.] Northeastern Univ, Coll Comp & Informat Sci, Boston, MA 02115 USA. [Intille, Stephen S.] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA. [Cooper, Rory A.; Ding, Dan] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Hiremath, SV (reprint author), Temple Univ, Dept Phys Therapy, Coll Publ Hlth, 3307 N Broad St,Jones Hall,Ste 623, Philadelphia, PA 19140 USA. EM Shiv.Hiremath@temple.edu RI Emchi, Karma/Q-1952-2016 FU Department of Defense [W81XWH-10-1-0816]; Switzer Research Fellowship [H133F110032]; National Institute on Disability and Rehabilitation Research, Department of Education; Human Engineering Research Laboratories, Veterans Affairs Pittsburgh Healthcare System FX Supported by the Department of Defense (grant no. W81XWH-10-1-0816); the Switzer Research Fellowship (grant no. H133F110032), awarded by the National Institute on Disability and Rehabilitation Research, Department of Education; and the Human Engineering Research Laboratories, Veterans Affairs Pittsburgh Healthcare System. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 30 TC 0 Z9 0 U1 3 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD JUL PY 2016 VL 97 IS 7 BP 1146 EP 1153 DI 10.1016/j.apmr.2016.02.016 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DQ1RZ UT WOS:000378979400014 PM 26976800 ER PT J AU Bourge, RC Waxman, AB Gomberg-Maitland, M Shapiro, SM Tarver, JH Zwicke, DL Feldman, JP Chakinala, MM Frantz, RP Torres, F Cerkvenik, J Morris, M Thalin, M Peterson, L Rubin, LJ AF Bourge, Robert C. Waxman, Aaron B. Gomberg-Maitland, Mardi Shapiro, Shelley M. Tarver, James H., III Zwicke, Dianne L. Feldman, Jeremy P. Chakinala, Murali M. Frantz, Robert P. Torres, Fernando Cerkvenik, Jeffrey Morris, Marty Thalin, Melissa Peterson, Leigh Rubin, Lewis J. TI Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System Results of the DelIVery for PAH Trial SO CHEST LA English DT Article DE central venous catheters; drugs; health-related quality of life; pulmonary arterial hypertension; pulmonary hypertension; treprostinil ID QUALITY-OF-LIFE; CATHETERS; INFUSION; INFECTIONS; SAFETY AB BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often limited by patient/physician dissatisfaction with the delivery methods. Complications associated with external pump-delivered continuous therapy include IV catheter-related bloodstream infections and subcutaneous infusion site pain. We therefore investigated a fully implantable intravascular delivery system for treprostinil infusion. METHODS: A multicenter, prospective, single-arm, clinical trial (DelIVery for Pulmonary Arterial Hypertension) was conducted by using an implantable intravascular delivery system. The implanted pumps were refilled percutaneously at least every 12 weeks. The primary end point was the rate of catheter-related complications using the new model 10642 catheter compared with a predefined objective performance criterion of 2.5 per 1,000 patient-days based on the literature. RESULTS: Patients (n = 60) with severe PAH (World Health Organization group 1) receiving a stable dose of IV treprostinil for at least 4 weeks received an implant device and were followed up for 12.1 +/- 4.4 months. Six catheter-related complications occurred, corresponding to a complication rate of 0.27 per 1,000 patient-days. The 97.5% upper one-sided confidence bound of 0.59 was less than the predefined criterion of 2.5 per 1,000 patient-days (P < .0001). Plasma treprostinil levels at 1 week postimplantation were highly correlated with baseline levels (r = 0.91; P < .0001). The delivery system management time as reported by the patients was 2.5 +/- 1.7 hours per week preimplantation, and this time decreased to 0.6 +/- 0.8 hour per week at 6 months' postimplantation (P < .0001). All patients rated overall satisfaction with the implantable system as good, very good, or excellent at 6 weeks and 6 months. There were no catheter-related bloodstream infections or catheter occlusions. CONCLUSIONS: The implantable intravascular delivery system delivered treprostinil to patients with PAH with a low rate of catheter-related complications and a high rate of patient satisfaction. C1 [Bourge, Robert C.] Univ Alabama Birmingham, 321k Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA. [Waxman, Aaron B.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Gomberg-Maitland, Mardi] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Shapiro, Shelley M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shapiro, Shelley M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Tarver, James H., III] Orlando Reg Med Ctr Inc, Orlando, FL USA. [Zwicke, Dianne L.] Aurora St Lukes Med Ctr, Milwaukee, WI USA. [Feldman, Jeremy P.] Arizona Pulm Specialists Ltd, Scottsdale, AZ USA. [Chakinala, Murali M.] Washington Univ, Sch Med, St Louis, MO USA. [Frantz, Robert P.] Mayo Clin, Rochester, MN USA. [Torres, Fernando] Univ Texas Southwestern Med Ctr, Rochester, MN USA. [Cerkvenik, Jeffrey; Morris, Marty; Thalin, Melissa] Medtronic Inc, Minneapolis, MN USA. [Peterson, Leigh] United Therapeut Corp, Res Triangle Pk, NC USA. [Rubin, Lewis J.] Univ Calif San Diego, Div Pulm & Crit Care Med, La Jolla, CA USA. RP Bourge, RC (reprint author), Univ Alabama Birmingham, 321k Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA. EM bbourge@uab.edu FU Medtronic, Inc; United Therapeutics Corporation FX The sponsor of this study was Medtronic, Inc, and the funding for this study came from United Therapeutics Corporation. NR 20 TC 4 Z9 5 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD JUL PY 2016 VL 150 IS 1 BP 27 EP 34 DI 10.1016/j.chest.2015.11.005 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DQ5BS UT WOS:000379220000016 PM 27396777 ER PT J AU Cadoni, S Falt, P Sanna, S Argiolas, M Fanari, V Gallittu, P Liggi, M Mura, D Porcedda, ML Smajstrla, V Erriu, M Leung, FW AF Cadoni, Sergio Falt, Premysl Sanna, Stefano Argiolas, Mariangela Fanari, Viviana Gallittu, Paolo Liggi, Mauro Mura, Donatella Porcedda, Maria L. Smajstrla, Vit Erriu, Matteo Leung, Felix W. TI Impact of Colonoscopy Insertion Techniques on Adenoma Detection SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Bowel cleanliness; Colon lesion detection; Interval cancer; Small adenomas; Water-aided colonoscopy ID INTERVAL COLORECTAL CANCERS; BOWEL PREPARATION QUALITY; WATER EXCHANGE; NEGATIVE COLONOSCOPY; MISS RATE; RISK; IMMERSION; POLYPS; RATES; METAANALYSIS AB Low adenoma detection rate (ADR) predicts development of interval cancers, found mainly in the right (cecum-ascending) colon, where poor bowel preparation is an associated factor. Single-site studies reported increased detection of adenomas in the proximal colon segments by water exchange (WE). Data about colon cleansing revealed that WE had the greatest impact in the right colon. To test the hypothesis that WE had the greatest impact on ADR in colon segments with the most favorable bowel cleanliness scores, namely the right colon. We pooled right colon and overall ADR data of three similarly designed colonoscopy trials that compared WE, water immersion (WI) and insufflation of air or carbon dioxide (AICD) in a mixed gender European population. In this study, 1200 (704 males) subjects and were included. 288 were screening cases. Demographic and procedural data were comparable. Water exchange achieved significantly higher right colon < 10 mm ADR (11.9 %, vs WI 6.9 %, p = 0.016; vs AICD 7.2 %, p = 0.025). Water exchange achieved the lowest proportions of poor bowel preparation and the highest right colon and overall Boston bowel preparation scale scores (p range 0.003, < 0.0005). In patients with right colon excellent bowel cleanliness, water exchange was the only method significantly associated with right colon adenoma detection. One of the limitations is unblinded colonoscopists. In a mixed gender European population, water exchange is confirmed to be a superior insertion technique showing a significant increase in < 10 mm right colon adenoma detection, achieving the cleanest colon and lowest proportions of poor bowel preparation requiring repeat procedures. NCT01781650, 01954862, 01780818. C1 [Cadoni, Sergio; Gallittu, Paolo; Liggi, Mauro; Mura, Donatella] St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. [Falt, Premysl; Smajstrla, Vit] Vitkovice Hosp, Ctr Digest Dis, Zaluzanskeho 1192-15, Ostrava 70384, Czech Republic. [Sanna, Stefano; Argiolas, Mariangela; Fanari, Viviana; Porcedda, Maria L.] NS Bonaria Hosp, Digest Endoscopy Unit, I-09037 San Gavino Monreale, VS, Italy. [Erriu, Matteo] Univ Cagliari, Dept Surg Sci, I-09121 Cagliari, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. EM cadonisergio@gmail.com; faltprem@centrum.cz; endo.sangav@tiscali.it; Margiolas2003@tiscali.it; mavivi@tiscali.it; paologallittu@gmail.com; liggim@gmail.com; muradonatella@live.it; toniolaura@tiscali.it; bormed1@volny.cz; matteoerr@gmail.com; felixleung@socal.rr.com NR 44 TC 3 Z9 3 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUL PY 2016 VL 61 IS 7 BP 2068 EP 2075 DI 10.1007/s10620-016-4053-1 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DQ2EA UT WOS:000379013300037 PM 26846118 ER PT J AU Swiderska-Syn, M Xie, GH Michelotti, GA Jewell, ML Premont, RT Syn, WK Diehl, AM AF Swiderska-Syn, Marzena Xie, Guanhua Michelotti, Gregory A. Jewell, Mark L. Premont, Richard T. Syn, Wing-Kin Diehl, Anna Mae TI Hedgehog Regulates Yes-Associated Protein 1 in Regenerating Mouse Liver SO HEPATOLOGY LA English DT Article ID HEPATIC-FIBROSIS; HEPATOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; PARTIAL-HEPATECTOMY; ACTIVATION; PATHWAY; CELLS; YAP; TUMORIGENESIS; CANCER AB Adult liver regeneration requires induction and suppression of proliferative activity in multiple types of liver cells. The mechanisms that orchestrate the global changes in gene expression that are required for proliferative activity to change within individual liver cells, and that coordinate proliferative activity among different types of liver cells, are not well understood. Morphogenic signaling pathways that are active during fetal development, including Hedgehog and Hippo/Yes-associated protein 1 (Yap1), regulate liver regeneration in adulthood. Cirrhosis and liver cancer result when these pathways become dysregulated, but relatively little is known about the mechanisms that coordinate and control morphogenic signaling during effective liver regeneration. We evaluated the hypothesis that the Hedgehog pathway controls Yap1 activation during liver regeneration by studying intact mice and cultured liver cells. In cultured hepatic stellate cells (HSCs), disrupting Hedgehog signaling blocked activation of Yap1, and knocking down Yap1 inhibited induction of both Yap1- and Hedgehog-regulated genes that enable HSC to become myofibroblasts (MFs). In mice, disrupting Hedgehog signaling in MFs inhibited liver regeneration after partial hepactectomy (PH). Reduced proliferative activity in the liver epithelial compartment resulted from loss of stroma-derived paracrine signals that activate Yap1 and the Hedgehog pathway in hepatocytes. This prevented hepatocytes from up-regulating Yap1- and Hedgehog-regulated transcription factors that normally promote their proliferation. Conclusions: Morphogenic signaling in HSCs is necessary to reprogram hepatocytes to regenerate the liver epithelial compartment post-PH. This discovery identifies novel molecules that might be targeted to correct defective repair during cirrhosis and liver cancer. C1 [Swiderska-Syn, Marzena; Xie, Guanhua; Michelotti, Gregory A.; Jewell, Mark L.; Premont, Richard T.; Diehl, Anna Mae] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC USA. [Syn, Wing-Kin] Fdn Liver Res, Inst Hepatol, Regenerat & Repair, London, England. [Syn, Wing-Kin] Med Univ South Carolina, Dept Med, Div Gastroenterol & Hepatol, Charleston, SC USA. [Syn, Wing-Kin] Ralph H Johnson VAMC, Gastroenterol Sect, Charleston, SC USA. RP Diehl, AM (reprint author), Duke Univ, Med Ctr, Div Gastroenterol, 595 LaSalle St,Snyderman Bldg,Suite 1073, Durham, NC 27710 USA. EM diehl004@mc.duke.edu FU National Institute of Health (NIH) - NIDDK [R37 AA010154, R56 DK106633, R01 DK077794] FX This work was supported by the following grants: National Institute of Health (NIH) - NIDDK, R37 AA010154, R56 DK106633, and R01 DK077794 (to A.M.D.). NR 31 TC 3 Z9 3 U1 4 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD JUL PY 2016 VL 64 IS 1 BP 232 EP 244 DI 10.1002/hep.28542 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DQ5GP UT WOS:000379233400027 PM 26970079 ER PT J AU Fitzpatrick, MA Suda, KJ Safdar, N Goldstein, B Jones, MM Poggensee, L Ramanathan, S LeWan, R Evans, CT AF Fitzpatrick, Margaret A. Suda, Katie J. Safdar, Nasia Goldstein, Barry Jones, Makoto M. Poggensee, Linda Ramanathan, Swetha LeWan, Ryan Evans, Charlesnika T. TI Unique Risks and Clinical Outcomes Associated With Extended-Spectrum beta-Lactamase Enterobacteriaceae in Veterans With Spinal Cord Injury or Disorder: A Case-Case-Control Study SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID RESISTANT STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI BACTEREMIA; ACUTE REHABILITATION UNIT; NOSOCOMIAL INFECTIONS; URINARY-TRACT; ADMINISTRATIVE DATA; IMPACT; PREVALENCE; ORGANISMS; SUSCEPTIBILITY AB OBJECTIVES. To describe the burden of extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in veterans with spinal cord injury or disorder (SCI/D), to identify risk factors for ESBL acquisition, and to assess impact on clinical outcomes DESIGN. Retrospective case-case-control study PATIENTS AND SETTING. Veterans with SCI/D and utilization at a Veterans' Affairs medical center from January 1, 2012, to December 31, 2013. METHODS. Patients with a positive culture for ESBL Klebsiella pneumoniae, Escherichia coli, or Proteus mirabilis were matched with patients with non-ESBL organisms by organism, facility, and level of care and to uninfected controls by facility and level of care. Inpatients were also matched by time at risk. Univariate and multivariate matched models were assessed for differences in risk factors and outcomes. RESULTS. A total of 492 cases (62.6% outpatients) were matched 1:1 with each comparison group. Recent prior use of fluoroquinolones and prior use of third- and fourth-generation cephalosporins were independently associated with ESBL compared to the non-ESBL group (adjusted odds ratio [aOR], 2.61; 95% confidence interval [CI], 1.77-3.84; P < .001 for fluoroquinolones and aOR, 3.86; 95% CI, 2.06-7.25; P < .001 for third- and fourth-generation cephalosporins) and the control group (aOR, 2.10; 95% CI, 1.29-3.43; P = .003 for fluoroquinolones; and aOR, 3.31; 95% CI, 1.56-7.06; P = .002 for third- and fourth-generation cephalosporins). Although there were no differences in mortality rate, the ESBL group had a longer post-culture length of stay (LOS) than the non-ESBL group (incidence rate ratio, 1.36; 95% CI, 1.13-1.63; P = .001). CONCLUSIONS. All SCI/D patients with ESBL were more likely to have had recent exposure to fluoroquinolones or third- and fourth generation cephalosporins, and hospitalized patients were more likely to have increased post-culture LOS. Programs targeted toward reduced antibiotic use in SCI/D patients may prevent subsequent ESBL acquisition. C1 [Fitzpatrick, Margaret A.; Suda, Katie J.; Poggensee, Linda; Ramanathan, Swetha; LeWan, Ryan; Evans, Charlesnika T.] Dept Vet Affairs, Ctr Innovat Complex Chron Healthcare, Hines, IL USA. [Fitzpatrick, Margaret A.; Suda, Katie J.; Poggensee, Linda; Ramanathan, Swetha; LeWan, Ryan; Evans, Charlesnika T.] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Fitzpatrick, Margaret A.] Loyola Univ, Stritch Sch Med, Dept Med, Div Infect Dis, Maywood, IL 60153 USA. [Suda, Katie J.] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA. [Safdar, Nasia] Dept Vet Affairs, William S Middleton VA Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Div Infect Dis, Madison, WI USA. [Goldstein, Barry] VA Puget Sound Healthcare Syst, Dept Vet Affairs, Off Spinal Cord Injury & Disorders Serv, Seattle, WA USA. [Goldstein, Barry] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Jones, Makoto M.] VA Salt Lake City Healthcare Syst, Dept Vet Affairs, Salt Lake City, UT USA. [Jones, Makoto M.] Univ Utah, Dept Med, Div Epidemiol, Salt Lake City, UT 84112 USA. [Ramanathan, Swetha] Edward Hines Jr VA Hosp, Dept Vet Affairs, Dept Pharm, Hines, IL USA. [Evans, Charlesnika T.] Northwestern Univ, Ctr Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Evans, Charlesnika T.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Inst Publ Hlth & Med, Chicago, IL 60611 USA. RP Fitzpatrick, MA (reprint author), 5000 S 5th Ave, Hines, IL 60141 USA. EM Margaret.fitzpatrick@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service Merit Review Award [B-1583-P]; Health Services Research and Development Service Post-Doctoral Fellowship Award [TPR 42-005]; Spinal Cord Injury Quality Enhancement Research Initiative [SCI-98-001]; VA FX We would like to thank Scott Miskevics for his assistance with programming and data analysis. This work was supported by The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service Merit Review Award (grant no. B-1583-P), Health Services Research and Development Service Post-Doctoral Fellowship Award (grant no. TPR 42-005), and the Spinal Cord Injury Quality Enhancement Research Initiative (grant no. SCI-98-001). Dr. Nasia Safdar is additionally supported by a VA-funded Patient Safety Center of Inquiry. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. NR 37 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUL PY 2016 VL 37 IS 7 BP 768 EP 776 DI 10.1017/ice.2016.60 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DQ3KL UT WOS:000379101100004 PM 27025908 ER PT J AU Llerena, K Wynn, JK Hajcak, G Green, MF Horan, WP AF Llerena, Katiah Wynn, Jonathan K. Hajcak, Greg Green, Michael F. Horan, William P. TI Patterns and reliability of EEG during error monitoring for internal versus external feedback in schizophrenia SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY LA English DT Article DE Event related potentials; Schizophrenia; Principal component analysis; Reward; Electroencephalography; Performance monitoring ID EVENT-RELATED POTENTIALS; TIME-ESTIMATION TASK; BRAIN ACTIVITY; HEALTHY-VOLUNTEERS; ANTISACCADE TASK; REWARD MAGNITUDE; NEURAL SYSTEM; NEGATIVITY; ERP; STATE AB Background: Accurately monitoring one's performance on daily life tasks, and integrating internal and external performance feedback are necessary for guiding productive behavior. Although internal feedback processing, as indexed by the error-related negativity (ERN), is consistently impaired in schizophrenia, initial findings suggest that external performance feedback processing, as indexed by the feedback negativity (FN), may actually be intact. The current study evaluated internal and external feedback processing task performance and test-retest reliability in schizophrenia. Methods: 92 schizophrenia outpatients and 63 healthy controls completed a flanker task (ERN) and a time estimation task (FN). Analyses examined the Delta ERN and Delta FN defined as difference waves between correct/positive versus error/negative feedback conditions. A temporal principal component analysis was conducted to distinguish the Delta ERN and Delta FN from overlapping neural responses. We also assessed test-retest reliability of Delta ERN and Delta FN in patients over a 4-week interval. Results: Patients showed reduced Delta ERN accompanied by intact Delta FN. In patients, test-retest reliability for both Delta ERN and Delta FN over a four-week period was fair to good. Conclusion: Individuals with schizophrenia show a pattern of impaired internal, but intact external, feedback processing. This pattern has implications for understanding the nature and neural correlates of impaired feedback processing in schizophrenia. Published by Elsevier B.V. C1 [Llerena, Katiah; Wynn, Jonathan K.; Green, Michael F.; Horan, William P.] VISN 22 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, 11301 Wilshire Blvd,Bldg 210, Los Angeles, CA 90073 USA. [Llerena, Katiah; Wynn, Jonathan K.; Green, Michael F.; Horan, William P.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Hajcak, Greg] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA. RP Llerena, K (reprint author), VA Greater Los Angeles, Healthcare Syst, MIRECC, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM kllerena@ucla.edu FU AbbVie; DSP; Forum; Mnemosyne (scientific board); Takeda; Roche; Amgen FX Dr. Green reports having received consulting fees from AbbVie, DSP, Forum, Mnemosyne (scientific board), Takeda, Roche. He has received grant funding from Amgen and Forum. The rest of the authors report no biomedical financial interests or potential conflicts of interest. NR 59 TC 1 Z9 1 U1 3 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-8760 EI 1872-7697 J9 INT J PSYCHOPHYSIOL JI Int. J. Psychophysiol. PD JUL PY 2016 VL 105 BP 39 EP 46 DI 10.1016/j.ijpsycho.2016.04.012 PG 8 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA DQ3MQ UT WOS:000379106800006 PM 27166742 ER PT J AU Kirkpatrick, JN Hauptman, PJ Swetz, KM Blume, ED Gauvreau, K Maurer, M Goodlin, SJ AF Kirkpatrick, James N. Hauptman, Paul J. Swetz, Keith M. Blume, Elizabeth D. Gauvreau, Kimberlee Maurer, Mathew Goodlin, Sarah J. TI Palliative Care for Patients With End-Stage Cardiovascular Disease and Devices: A Report From the Palliative Care Working Group of the Geriatrics Section of the American College of Cardiology SO JAMA INTERNAL MEDICINE LA English DT Letter ID VENTRICULAR ASSIST DEVICES C1 [Kirkpatrick, James N.] Univ Washington, Div Cardiol, Eth Consultat Serv, 1959 NE Pacific St, Seattle, WA 98125 USA. [Hauptman, Paul J.] St Louis Univ, Div Cardiol, Dept Med, St Louis, MO 63103 USA. [Swetz, Keith M.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Blume, Elizabeth D.; Gauvreau, Kimberlee] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA. [Maurer, Mathew] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA. [Goodlin, Sarah J.] Portland VA Med Ctr, Portland, OR USA. [Goodlin, Sarah J.] Patient Ctr Educ & Res, Portland, OR USA. RP Kirkpatrick, JN (reprint author), Univ Washington, Div Cardiol, Eth Consultat Serv, 1959 NE Pacific St, Seattle, WA 98125 USA. EM kirkpatj@uw.edu NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2016 VL 176 IS 7 BP 1017 EP 1019 DI 10.1001/jamainternmed.2016.2096 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DQ2NR UT WOS:000379039700032 PM 27214624 ER PT J AU Talebreza, S Widera, E AF Talebreza, Shaida Widera, Eric TI A Perspective on Hospice Reform and Additional Caregiver Support Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Talebreza, Shaida] Univ Utah, Div Geriatr, Sch Med, Salt Lake City, UT USA. [Talebreza, Shaida] Home Based Primary Care, Salt Lake City, UT USA. [Talebreza, Shaida] George E Wahlen Salt Lake City Vet Affairs Med Ct, Salt Lake City, UT USA. [Talebreza, Shaida] Inspirat Hosp, Salt Lake City, UT USA. [Widera, Eric] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Widera, Eric] San Francisco VA Med Ctr, Hosp & Palliat Care, 4150 Clement St, San Francisco, CA 94121 USA. RP Widera, E (reprint author), San Francisco VA Med Ctr, Hosp & Palliat Care, 4150 Clement St, San Francisco, CA 94121 USA.; Widera, E (reprint author), UCSF, Div Geriatr & Geriatr Med Fellowship, San Francisco, CA 94121 USA. EM eric.widera@ucsf.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2016 VL 176 IS 7 BP 1032 EP 1033 DI 10.1001/jamainternmed.2016.2742 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DQ2NR UT WOS:000379039700041 PM 27379480 ER PT J AU Ong, MK Romano, PS Fonarow, GC AF Ong, Michael K. Romano, Patrick S. Fonarow, Gregg C. TI Telemedicine in Heart Failure-Ineffective or Just Ill Used? Reply SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Ong, Michael K.; Fonarow, Gregg C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10940 Wilshire Blvd,Ste 700, Los Angeles, CA 90024 USA. [Ong, Michael K.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Romano, Patrick S.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA. [Romano, Patrick S.] Univ Calif Davis, Dept Pediat, Davis, CA 95616 USA. RP Ong, MK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 10940 Wilshire Blvd,Ste 700, Los Angeles, CA 90024 USA. EM michael.ong@ucla.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUL PY 2016 VL 176 IS 7 BP 1035 EP 1036 DI 10.1001/jamainternmed.2016.2860 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DQ2NR UT WOS:000379039700046 PM 27379485 ER PT J AU Kudler, H Day, K Schnurr, PP AF Kudler, Harold Day, Kristine Schnurr, Paula P. TI Treatment Options for Veterans With Posttraumatic Stress Disorder SO JAMA PSYCHIATRY LA English DT Letter C1 [Kudler, Harold] US Dept Vet Affairs, Mental Hlth Serv, Washington, DC 20420 USA. [Day, Kristine] US Dept Vet Affairs, Natl Evidence Based Psychotherapy Program, Washington, DC 20420 USA. [Schnurr, Paula P.] US Dept Vet Affairs, Natl Ctr PTSD, Washington, DC 20420 USA. RP Kudler, H (reprint author), US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM harold.kudler@va.gov NR 4 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JUL PY 2016 VL 73 IS 7 BP 756 EP 757 DI 10.1001/jamapsychiatry.2016.0746 PG 2 WC Psychiatry SC Psychiatry GA DQ2OT UT WOS:000379042700019 PM 27191547 ER PT J AU Yehuda, R Hoge, CW AF Yehuda, Rachel Hoge, Charles W. TI Treatment Options for Veterans With Posttraumatic Stress Disorder Reply SO JAMA PSYCHIATRY LA English DT Letter ID MENTAL-HEALTH-CARE; PSYCHOTHERAPY; SOLDIERS; DROPOUT; PTSD; IRAQ C1 [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, 1 Gustave L Levy Pl, New York, NY 10029 USA. [Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM rachel.yehuda@mssm.edu NR 6 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JUL PY 2016 VL 73 IS 7 BP 758 EP 758 DI 10.1001/jamapsychiatry.2016.0572 PG 1 WC Psychiatry SC Psychiatry GA DQ2OT UT WOS:000379042700021 PM 27191824 ER PT J AU Won, OJ Zhang, L Wang, JH Su, QT Feng, Q Zhang, XHF Mani, SA Paulter, R Creighton, CJ Ittmann, MM Xin, L AF Won, Oh-Joon Zhang, Li Wang, Jianghua Su, Qingtai Feng, Qin Zhang, Xiang H. F. Mani, Sendurai A. Paulter, Robia Creighton, Chad J. Ittmann, Michael M. Xin, Li TI Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID TO-MESENCHYMAL TRANSITION; CELL-GROWTH INHIBITION; CANCER-CELLS; DOWN-REGULATION; ANDROGEN RECEPTOR; SEMINAL-VESICLE; BREAST-CANCER; SIGNALING PATHWAYS; ORGANOID CULTURES; EPITHELIAL-CELLS AB Although Notch signaling is deregulated in prostate cancer, the role of this pathway in disease development and progression is not fully understood. Here, we analyzed 2 human prostate cancer data sets and found that higher Notch signaling correlates with increased metastatic potential and worse disease survival rates. We used the Pten-null mouse prostate cancer model to investigate the function of Notch signaling in the initiation and progression of prostate cancer. Disruption of the transcription factor RBPJ in Pten-null mice revealed that endogenous canonical Notch signaling is not required for disease initiation and progression. However, augmentation of Notch activity in this model promoted both proliferation and apoptosis of prostate epithelial cells, which collectively reduced the primary tumor burden. The increase in cellular apoptosis was linked to DNA damage-induced p53 activation. Despite a reduced primary tumor burden, Notch activation in Pten-null mice promoted epithelial-mesenchymal transition and FOXC2-dependent tumor metastases but did not confer resistance to androgen deprivation. Notch activation also resulted in transformation of seminal vesicle epithelial cells in Pten-null mice. Our study highlights a multifaceted role for Notch signaling in distinct aspects of prostate cancer biology and supports Notch as a potential therapeutic target for metastatic prostate cancer. C1 [Won, Oh-Joon; Zhang, Li; Su, Qingtai; Feng, Qin; Zhang, Xiang H. F.; Xin, Li] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Wang, Jianghua; Ittmann, Michael M.; Xin, Li] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Zhang, Xiang H. F.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA. [Zhang, Xiang H. F.; Creighton, Chad J.; Ittmann, Michael M.; Xin, Li] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Translat Mol Pathol, Houston, TX 77030 USA. [Paulter, Robia] Baylor Coll Med, Dept Mol Physiol, Houston, TX 77030 USA. [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Ittmann, Michael M.] Baylor Coll Med, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Xin, L (reprint author), Baylor Coll Med, M533 DeBakey Bldg,BCM MS130,One Baylor Plaza, Houston, TX 77030 USA. EM xin@bcm.edu RI Mani, Sendurai/A-7244-2009 OI Mani, Sendurai/0000-0002-5918-4276 FU NIH [P30-AI036211, P30-CA125123, S10-RR024574, R01-CA190378, R21-CA196570, U01-CA141497] FX We thank Joseph Valdez for initiating some early studies, Boyu Zhang for technical help, Yiqun Zhang for analyzing expression microarray analyses, the Small Animal Imaging Facilities at Baylor College of Medicine and Texas Children's Hospital, the Cytometry and Cell Sorting Core at Baylor College of Medicine for technical support with funding from the NIH (P30-AI036211, P30-CA125123, and S10-RR024574), and Joel M. Sederstrom for expert assistance. This work is supported by NIH R01-CA190378 and R21-CA196570 (to L. Xin), NIH U01-CA141497 (to M.M. Ittmann), and NIH P30-CA125123 (the Cancer Center Shared Resources Grant). NR 63 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD JUL PY 2016 VL 126 IS 7 BP 2626 EP 2641 DI 10.1172/JCI84637 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DQ3IA UT WOS:000379094800026 ER PT J AU Li, PL Kaiser, P Lampiris, HW Kim, P Yukl, SA Havlir, DV Greene, WC Wong, JK AF Li, Peilin Kaiser, Philipp Lampiris, Harry W. Kim, Peggy Yukl, Steven A. Havlir, Diane V. Greene, Warner C. Wong, Joseph K. TI Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation SO NATURE MEDICINE LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; RETINOIC ACID; SIGNAL-ACTIVATION; T-CELL; RNA; RECOGNITION; ACITRETIN; INFECTION; REPLICATION; RECEPTORS AB The persistence of latent HIV proviruses in long-lived CD4(+) T cells despite antiretroviral therapy (ART)(1-3) is a major obstacle to viral eradication(4-6). Because current candidate latency reversing agents (LRAs) induce HIV transcription, but fail to clear these cellular reservoirs(7,8), new approaches for killing these reactivated latent HIV reservoir cells are urgently needed. HIV latency depends upon the transcriptional quiescence of the integrated provirus and the circumvention of immune defense mechanisms(4-6,9). These defenses include cell-intrinsic innate responses that use pattern-recognition receptors (PRRs) to detect viral pathogens, and that subsequently induce apoptosis of the infected cell(10). Retinoic acid (RA)-inducible gene I (RIG-I, encoded by DDX58) forms one class of PRRs that mediates apoptosis and the elimination of infected cells after recognition of viral RNA(11-14). Here we show that acitretin, an RA derivative approved by the US Food and Drug Administration (FDA), enhances RIG-I signaling ex vivo, increases HIV transcription, and induces preferential apoptosis of HIV-infected cells. These effects are abrogated by DDX58 knockdown. Acitretin also decreases proviral DNA levels in CD4(+) T cells from HIV-positive subjects on suppressive ART, an effect that is amplified when combined with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Pharmacological enhancement of an innate cellular-defense network could provide a means by which to eliminate reactivated cells in the latent HIV reservoir. C1 [Li, Peilin; Kaiser, Philipp; Lampiris, Harry W.; Kim, Peggy; Yukl, Steven A.; Wong, Joseph K.] San Francisco VA Med Ctr, Med Serv, Infect Dis Sect, San Francisco, CA 94121 USA. [Li, Peilin; Lampiris, Harry W.; Yukl, Steven A.; Havlir, Diane V.; Greene, Warner C.; Wong, Joseph K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Havlir, Diane V.] San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94110 USA. [Greene, Warner C.] Univ Calif San Francisco, Dept Microbiol & Biol, San Francisco, CA 94143 USA. [Greene, Warner C.] Gladstone Inst Virol & Immunol, San Francisco, CA USA. RP Li, PL (reprint author), San Francisco VA Med Ctr, Med Serv, Infect Dis Sect, San Francisco, CA 94121 USA.; Li, PL (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM peilin.li@ucsf.edu FU NIH [1R21AI104445-01A1, R56 AI116342, R21 AI116218]; Department of Veterans Affairs Merit Review Award [5101 BX001048]; UCSF-Gladstone Center for AIDS Research Virology Core [P30AI027763, U19 AI096113]; amfAR Institute for HIV Cure Research [109301] FX We thank the study participants, without whom this research could not have been performed. We thank S. Deeks, H. Gunthard, C. Lopez, and H. Hatano for their helpful comments and support, and M. Vu for assistance with participant recruitment. We thank J.C.W. Carroll for graphics arts, S. Ordway for editorial assistance, and S. Wilcox for administrative assistance. We thank the US National Institutes of Health (NIH) AIDS Reagent Program, Division of AIDS, NIAID, NIH for cell lines, plasmid, and reagents. This work was supported by the NIH (grants 1R21AI104445-01A1 (P.L.), R56 AI116342 and R21 AI116218 (J.K.W.)), the Department of Veterans Affairs Merit Review Award 5101 BX001048 (J.K.W.), the UCSF-Gladstone Center for AIDS Research Virology Core P30AI027763 (W.C.G. and J.K.W.), U19 AI096113 (W.C.G.) and research supported as part of the amfAR Institute for HIV Cure Research with grant number 109301(W.G., J.K.W., and P.L.). NR 39 TC 4 Z9 4 U1 4 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 EI 1546-170X J9 NAT MED JI Nat. Med. PD JUL PY 2016 VL 22 IS 7 BP 807 EP 811 DI 10.1038/nm.4124 PG 5 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA DQ7DK UT WOS:000379366900020 PM 27294875 ER PT J AU Cardenas, DP Muir, ER Duong, TQ AF Cardenas, Damon P. Muir, Eric R. Duong, Timothy Q. TI MRI of cerebral blood flow under hyperbaric conditions in rats SO NMR IN BIOMEDICINE LA English DT Article DE arterial spin labeling; CBF; oxygen therapy; BOLD; magnetic susceptibility ID LONGITUDINAL RELAXATION-TIME; OXYGEN-TENSION; MAGNETIC-FIELD; FUNCTIONAL MRI; TRANSIT-TIME; BOLD FMRI; BRAIN; HYPEROXIA; HYPOXIA; CBF AB Hyperbaric oxygen (HBO) therapy has a number of clinical applications. However, the effects of acute HBO on basal cerebral blood flow (CBF) and neurovascular coupling are not well understood. This study explored the use of arterial spin labeling MRI to evaluate changes in baseline and forepaw stimulus-evoked CBF responses in rats (n = 8) during normobaric air (NB), normobaric oxygen (NBO) (100% O-2), 3 atm absolute (ATA) hyperbaric air (HB) and 3 ATA HBO conditions. T-1 was also measured, and the effects of changes in T-1 caused by increasing oxygen on the CBF calculation were investigated. The major findings were as follows: (i) increased inhaled oxygen concentrations led to a reduced respiration rate; (ii) increased dissolved paramagnetic oxygen had significant effects on blood and tissue T-1, which affected the CBF calculation using the arterial spin labeling method; (iii) the differences in blood T-1 had a larger effect than the differences in tissue T-1 on CBF calculation; (iv) if oxygen-induced changes in blood and tissue T-1 were not taken into account, CBF was underestimated by 33% at 3 ATA HBO, 10% at NBO and <5% at HB; (v) with correction, CBF values under HBO, HB and NBO were similar (p > 0.05) and all were higher than CBF under NB by similar to 40% (p < 0.05), indicating that hypercapnia from the reduced respiration rate masks oxygen-induced vasoconstriction, although blood gas was not measured; and (vi) substantial stimulus-evoked CBF increases were detected under HBO, similar to NB, supporting the notion that activation-induced CBF regulation in the brain does not operate through an oxygen-sensing mechanism. CBF MRI provides valuable insights into the effects of oxygen on basal CBF and neurovascular coupling under hyperbaric conditions. Copyright (c) 2016 John Wiley & Sons, Ltd. C1 [Cardenas, Damon P.; Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Cardenas, Damon P.] Univ Texas San Antonio, Grad Sch Biomed Sci, San Antonio, TX USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Muir, ER; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM muire@uthscsa.edu; duongt@uthscsa.edu FU National Institute of General Medical Sciences, Minority Biomedical Research Support, Research Initiative for Scientific Enhancement fellowship [GM060655] FX This work was supported in part by a National Institute of General Medical Sciences, Minority Biomedical Research Support, Research Initiative for Scientific Enhancement GM060655 fellowship to D.P.C. NR 37 TC 0 Z9 0 U1 8 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0952-3480 EI 1099-1492 J9 NMR BIOMED JI NMR Biomed. PD JUL PY 2016 VL 29 IS 7 BP 961 EP 968 DI 10.1002/nbm.3555 PG 8 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA DQ2JM UT WOS:000379028600012 PM 27192391 ER PT J AU Bai, XY Oberley-Deegan, RE Bai, A Ovrutsky, AR Kinney, WH Weaver, M Zhang, G Honda, JR Chan, ED AF Bai, Xiyuan Oberley-Deegan, Rebecca E. Bai, An Ovrutsky, Alida R. Kinney, William H. Weaver, Michael Zhang, Gong Honda, Jennifer R. Chan, Edward D. TI Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection SO RESPIROLOGY LA English DT Article DE apoptosis; autophagy; curcumin; nuclear-factor kappa B; tuberculosis ID NF-KAPPA-B; MULTIDRUG-RESISTANT TUBERCULOSIS; NITRIC-OXIDE; IN-VIVO; APOPTOSIS; CANCER; ACTIVATION; PATHWAY; LIPOARABINOMANNAN; AUTOPHAGOSOME AB Background and objectiveWith the worldwide emergence of highly drug-resistant tuberculosis (TB), novel agents that have direct antimycobacterial effects or that enhance host immunity are urgently needed. Curcumin is a polyphenol responsible for the bright yellow-orange colour of turmeric, a spice derived from the root of the perennial herb Curcuma longa. Curcumin is a potent inducer of apoptosisan effector mechanism used by macrophages to kill intracellular Mycobacterium tuberculosis (MTB). MethodsAn in vitro human macrophage infection model was used to determine the effects of curcumin on MTB survival. ResultsWe found that curcumin enhanced the clearance of MTB in differentiated THP-1 human monocytes and in primary human alveolar macrophages. We also found that curcumin was an inducer of caspase-3-dependent apoptosis and autophagy. Curcumin mediated these anti-MTB cellular functions, in part, via inhibition of nuclear factor-kappa B (NFB) activation. ConclusionCurcumin protects against MTB infection in human macrophages. The host-protective role of curcumin against MTB in macrophages needs confirmation in an animal model; if validated, the immunomodulatory anti-TB effects of curcumin would be less prone to drug resistance development. The effects of curcumin (a polyphenol of tumeric) on Mycobacterium tuberculosis (MTB) infection using human macrophages were investigated in this study. Curcumin reduced the intracellular burden of MTB in infected macrophages through inhibition of NFB activation resulting in the induction of caspase-3-dependent apoptosis and autophagy. C1 [Bai, Xiyuan; Bai, An; Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. [Bai, Xiyuan; Oberley-Deegan, Rebecca E.; Bai, An; Ovrutsky, Alida R.; Kinney, William H.; Weaver, Michael; Honda, Jennifer R.; Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO USA. [Bai, Xiyuan; Ovrutsky, Alida R.; Kinney, William H.; Honda, Jennifer R.; Chan, Edward D.] Univ Colorado, Sch Med, Dept Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Oberley-Deegan, Rebecca E.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA. [Zhang, Gong] Shaanxi Univ Chinese Med, Coll Pharm, Xianyang, Shaanxi, Peoples R China. RP Bai, XY (reprint author), Natl Jewish Hlth, D509 Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM baix@njhealth.org NR 45 TC 2 Z9 2 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD JUL PY 2016 VL 21 IS 5 BP 951 EP 957 DI 10.1111/resp.12762 PG 7 WC Respiratory System SC Respiratory System GA DQ2VQ UT WOS:000379061900024 PM 27012592 ER PT J AU Jones, JA AF Jones, Jeffrey A. TI Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb" SO TRENDS IN CARDIOVASCULAR MEDICINE LA English DT Editorial Material ID SMOOTH-MUSCLE-CELLS; II TYPE-1 RECEPTOR; AORTIC-ANEURYSM; BETA RECEPTOR; MOUSE MODEL; ACTIVATION; MUTATIONS; LOSARTAN; MICE; ALPHA-V-BETA-3 C1 [Jones, Jeffrey A.] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg Res, Strom Thurmond Res Bldg, Charleston, SC 29425 USA. [Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Strom Thurmond Res Bldg, Charleston, SC 29425 USA. RP Jones, JA (reprint author), Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg Res, Strom Thurmond Res Bldg, Charleston, SC 29425 USA.; Jones, JA (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Strom Thurmond Res Bldg, Charleston, SC 29425 USA. EM jonesja@musc.edu FU BLRD VA [I01 BX000904] NR 35 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1050-1738 J9 TRENDS CARDIOVAS MED JI Trends Cardiovasc. Med. PD JUL PY 2016 VL 26 IS 5 BP 429 EP 432 DI 10.1016/j.tcm.2016.02.005 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DP7FD UT WOS:000378663700006 PM 27013137 ER PT J AU Sher, L AF Sher, L. TI Buprenorphine and the treatment of depression, anxiety, non-suicidal self-injury, and suicidality SO ACTA PSYCHIATRICA SCANDINAVICA LA English DT Letter C1 [Sher, L.] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, L.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA.; Sher, L (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. EM leo.sher@mssm.edu NR 5 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-690X EI 1600-0447 J9 ACTA PSYCHIAT SCAND JI Acta Psychiatr. Scand. PD JUL PY 2016 VL 134 IS 1 BP 84 EP 85 DI 10.1111/acps.12577 PG 2 WC Psychiatry SC Psychiatry GA DP7UZ UT WOS:000378706000011 PM 27009622 ER PT J AU Johnson, SD Levingston, C Young, MRI AF Johnson, Sara D. Levingston, Corinne Young, M. Rita I. TI Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells SO ANTICANCER RESEARCH LA English DT Article DE head and neck cancer; premalignant oral lesions; cytokines; T cell activation ID UPPER AERODIGESTIVE TRACT; NECK-CANCER; HEAD; CARCINOMA; MECHANISMS; IL-6; CARCINOGENESIS; PROGRESSION; DISEASE; CAVITY AB Background: Head and neck squamous cell carcinomas (HNSCC) are known to evade the host immune response. How premalignant oral lesions modulate the immune response, however, has yet to be elucidated. Materials and Methods: A mouse model of oral carcinogenesis was used to determine how mediators from premalignant oral lesion cells vs. HNSCC cells impact on immune cytokine production and activation. Results: Media conditioned by premalignant lesion cells elicited an increased production of T cell-associated cytokines and proinflammatory mediators from cervical lymph node cells compared to media conditioned by HNSCC cells or media alone. In the presence of premalignant lesion cell-conditioned media, CD4(+) T cell expression of the IL-2 receptor CD25 and CD8(+) T cell expression of the activation marker CD69 was greater, compared to what was induced in HNSCC cell-conditioned media or media alone. Conclusion: Premalignant lesion cells promote a proinflammatory environment and induce immune changes before HNSCC tumors are established. C1 [Johnson, Sara D.; Levingston, Corinne; Young, M. Rita I.] Res Serv 151 Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Johnson, Sara D.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Johnson, Sara D.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. EM rita.young@va.gov FU Clinical Sciences Research and Development Program of the Department of Veterans Affairs [I01-CX000851]; National Institutes of Health [RO1-CA128837] FX This work was supported by the Clinical Sciences Research and Development Program (I01-CX000851) of the Department of Veterans Affairs and by grants from the National Institutes of Health (RO1-CA128837) (MRIY). NR 39 TC 2 Z9 2 U1 0 U2 1 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 EI 1791-7530 J9 ANTICANCER RES JI Anticancer Res. PD JUL PY 2016 VL 36 IS 7 BP 3261 EP 3270 PG 10 WC Oncology SC Oncology GA DQ0DC UT WOS:000378867600004 PM 27354582 ER PT J AU Flowers, CR Costa, LJ Pasquini, MC Le-Rademacher, J Lill, M Shore, TB Vaughan, W Craig, M Freytes, CO Shea, TC Horwitz, ME Fay, JW Mineishi, S Rondelli, D Mason, J Braunschweig, I Ai, WY Yeh, RF Rodriguez, TE Flinn, I Comeau, T Yeager, AM Pulsipher, MA Bence-Bruckler, I Laneuyille, P Bierman, P Chen, AI Kato, K Wang, YL Xu, C Smith, AJ Waller, EK AF Flowers, Christopher R. Costa, Luciano J. Pasquini, Marcelo C. Le-Rademacher, Jennifer Lill, Michael Shore, Tsiporah B. Vaughan, William Craig, Michael Freytes, Cesar O. Shea, Thomas C. Horwitz, Mitchell E. Fay, Joseph W. Mineishi, Shin Rondelli, Damiano Mason, James Braunschweig, Ira Ai, Weiyun Yeh, Rosa F. Rodriguez, Tulio E. Flinn, Ian Comeau, Terrance Yeager, Andrew M. Pulsipher, Michael A. Bence-Bruckler, Isabelle Laneuyille, Pierre Bierman, Philip Chen, Andy I. Kato, Kazunobu Wang, Yanlin Xu, Cong Smith, Angela J. Waller, Edmund K. TI Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Non-Hodgkin lymphoma; Hodgkin lymphoma; Busulfan; Autologous stem cell transplantation; Stem cell transplantation; Lymphoma; Chemotherapy ID HIGH-DOSE CHEMOTHERAPY; NON-HODGKINS-LYMPHOMA; BONE-MARROW-TRANSPLANTATION; DAILY INTRAVENOUS BUSULFAN; HIGH-RISK PATIENTS; DAILY IV BUSULFAN; PREPARATIVE REGIMENS; AGGRESSIVE LYMPHOMA; BEAM CHEMOTHERAPY; RANDOMIZED-TRIAL AB Busulfan, cyclophosphamide, and etoposide (BuCyE) is a commonly used conditioning regimen for autologous stem cell transplantation (ASCT). This multicenter, phase II study examined the safety and efficacy of BuCyE with individually adjusted busulfan based on preconditioning pharmacokinetics. The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended, due to high early treatment-related mortality (TRM) in patients > 65 years. BuCyE outcomes were compared with contemporaneous recipients of carmustine, etoposide, cytarabine, and melphalan (BEAM) from the Center for International Blood and Marrow Transplant Research. Two hundred seven subjects with HL (n = 66) or NHL (n = 141) were enrolled from 32 centers in North America, and 203 underwent ASCT. Day 100 TRM for all subjects (n = 203), patients > 65 years (n = 17), and patients <= 65 years (n = 186) were 4.5%, 23.5%, and 2.7%, respectively. The estimated rates of 2-year progression-free survival (PFS) were 33% for HL and 58%, 77%, and 43% for diffuse large B cell lymphoma (DLBCL; n = 63), mantle cell lymphoma (Ma; n = 29), and follicular lymphoma (FL; n = 23), respectively. The estimated rates of 2-year overall survival (OS) were 76% for HL and 65%, 89%, and 89% for DLBCL, MCL, and FL, respectively. In the matched analysis rates of 2-year TRM were 3.3% for BuCyE and 3.9% for BEAM, and there were no differences in outcomes for NHL. Patients with HL had lower rates of 2-year PFS with BuCyE, 33% (95% CI, 21% to 46%), than with BEAM, 59% (95% CI, 52% to 66%), with no differences in TRM or OS. BuCyE provided adequate disease control and safety in B cell NHL patients <= 65 years but produced worse PFS in HL patients when compared with BEAM. (C) 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Flowers, Christopher R.; Waller, Edmund K.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Div BMT, 1365B Clifton Rd,Suite B5119, Atlanta, GA 30322 USA. [Costa, Luciano J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Pasquini, Marcelo C.; Le-Rademacher, Jennifer] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Lill, Michael] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Shore, Tsiporah B.] New York Hosp, Weill Cornell Med Ctr Hematol Oncol, New York, NY 10021 USA. [Vaughan, William] Univ Alabaman Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA. [Craig, Michael] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Shea, Thomas C.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA. [Horwitz, Mitchell E.] Duke Univ, Med Ctr, Dept Med, Adult Stem Cell Transplant Program,Div Cellular T, Durham, NC 27710 USA. [Fay, Joseph W.] Baylor Univ, Med Ctr, Dallas, TX USA. [Mineishi, Shin] Univ Michigan, Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA. [Rondelli, Damiano] Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL USA. [Mason, James] Scripps Clin, La Jolla, CA USA. [Braunschweig, Ira] Montefiore Med Ctr, Dept Oncol, 111 E 210Th St, Bronx, NY 10467 USA. [Ai, Weiyun] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA. [Yeh, Rosa F.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Rodriguez, Tulio E.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Maywood, IL USA. [Flinn, Ian] Sarah Cannon Res Inst, Nashville, TN USA. [Comeau, Terrance] New Brunswick Stem Cell Transplant Program, St John, NB, Canada. [Yeager, Andrew M.] Univ Arizona, Ctr Canc, Blood & Marrow Transplantat Program, Tucson, AZ USA. [Pulsipher, Michael A.] Childrens Hosp Los Angeles, Keck Sch Med, Div Hematol Oncol & Blood & Marrow Transplant, Los Angeles, CA 90027 USA. [Pulsipher, Michael A.] Univ So Calif, Los Angeles, CA USA. [Bence-Bruckler, Isabelle] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada. [Laneuyille, Pierre] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Montreal, PQ, Canada. [Bierman, Philip] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA. [Chen, Andy I.] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Portland, OR 97201 USA. [Kato, Kazunobu; Wang, Yanlin; Xu, Cong; Smith, Angela J.] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. [Costa, Luciano J.; Mineishi, Shin] Univ Alabama Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA. [Le-Rademacher, Jennifer] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Kato, Kazunobu] Bristol Myers Squibb, Princeton, NJ USA. RP Waller, EK (reprint author), Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Div BMT, 1365B Clifton Rd,Suite B5119, Atlanta, GA 30322 USA.; Waller, EK (reprint author), Emory Univ, Winship Canc Inst, 1365B Clifton Rd,Suite B5119, Atlanta, GA 30322 USA. EM ewaller@emory.edu RI Flowers, Christopher/F-1953-2010 OI Flowers, Christopher/0000-0002-9524-3990 FU Otsuka Pharmaceutical Development & Commercialization, Inc. FX Otsuka Pharmaceutical Development & Commercialization, Inc. sponsored this study and provided the i.v. Bu for the analyses. NR 51 TC 3 Z9 3 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD JUL PY 2016 VL 22 IS 7 BP 1197 EP 1205 DI 10.1016/j.bbmt.2016.03.018 PG 9 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA DP4JR UT WOS:000378462700008 PM 27040394 ER PT J AU Khalil, HA Lei, NY Brinkley, G Scott, A Wang, JF Kar, UK Jabaji, ZB Lewis, M Martin, MG Dunn, JCY Stelzner, MG AF Khalil, Hassan A. Lei, Nan Ye Brinkley, Garrett Scott, Andrew Wang, Jiafang Kar, Upendra K. Jabaji, Ziyad B. Lewis, Michael Martin, Martin G. Dunn, James C. Y. Stelzner, Matthias G. TI A novel culture system for adult porcine intestinal crypts SO CELL AND TISSUE RESEARCH LA English DT Article DE Porcine intestinal culture; Enteroid; Intestinal spheroid; Intestinal subepithelial myofibroblast; Transduction of intestinal epithelium ID STEM-CELL; IN-VITRO; ANIMAL-MODELS; TRANSPLANTATION; EPITHELIUM; ORGANOIDS; COLON; DIFFERENTIATION; PROGENITORS; ENGRAFTMENT AB Porcine models are useful for investigating therapeutic approaches to short bowel syndrome and potentially to intestinal stem cell (ISC) transplantation. Whereas techniques for the culture and genetic manipulation of ISCs from mice and humans are well established, similar methods for porcine stem cells have not been reported. Jejunal crypts were isolated from murine, human, and juvenile and adult porcine small intestine, suspended in Matrigel, and co-cultured with syngeneic intestinal subepithelial myofibroblasts (ISEMFs) or cultured without feeder cells in various culture media. Media containing epidermal growth factor, noggin, and R-spondin 1 (ENR medium) were supplemented with various combinations of Wnt3a- or ISEMF-conditioned medium (CM) and with glycogen synthase kinase 3 inhibitor (GSK3i), and their effects were studied on cultured crypts. Cell lineage differentiation was assessed by immunohistochemistry and quantitative polymerase chain reaction. Cultured porcine cells were serially passaged and transduced with a lentiviral vector. Whereas ENR medium supported murine enteroid growth, it did not sustain porcine crypts beyond 5 days. Supplementation of Wnt3a-CM and GSK3i resulted in the formation of complex porcine enteroids with budding extensions. These enteroids contained a mixture of stem and differentiated cells and were successfully passaged in the presence of GSK3i. Crypts grown in media supplemented with porcine ISEMF-CM formed spheroids that were less well differentiated than enteroids. Enteroids and spheroids were transfected with a lentivirus with high efficiency. Thus, our method maintains juvenile and adult porcine crypt cells long-term in culture. Porcine enteroids and spheroids can be successfully passaged and transduced by using lentiviral vectors. C1 [Khalil, Hassan A.; Lei, Nan Ye; Scott, Andrew; Jabaji, Ziyad B.; Dunn, James C. Y.; Stelzner, Matthias G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Brinkley, Garrett; Wang, Jiafang; Kar, Upendra K.; Martin, Martin G.] Mattel Childrens Hosp, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA USA. [Brinkley, Garrett; Wang, Jiafang; Kar, Upendra K.; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lewis, Michael] VA Greater Los Angeles Hlth Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Stelzner, Matthias G.] VA Greater Los Angeles Hlth Syst, Dept Surg, Los Angeles, CA USA. RP Stelzner, MG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.; Stelzner, MG (reprint author), VA Greater Los Angeles Hlth Syst, Dept Surg, Los Angeles, CA USA. EM stelzner@ucla.edu OI Khalil, Hassan/0000-0002-3835-1290 FU National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infections Diseases [DK085535-01, DK085535-02S2]; California Institute of Regenerative Medicine [RT2-01985]; [CURE/P30 DK041301] FX The UCLA Vectorcore is supported by CURE/P30 DK041301. This research was performed as a project of the Intestinal Stem Cell Consortium, a collaborative research project funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infections Diseases (DK085535-01 and DK085535-02S2) and was supported in part by the California Institute of Regenerative Medicine (RT2-01985). NR 36 TC 2 Z9 2 U1 6 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0302-766X EI 1432-0878 J9 CELL TISSUE RES JI Cell Tissue Res. PD JUL PY 2016 VL 365 IS 1 BP 123 EP 134 DI 10.1007/s00441-016-2367-0 PG 12 WC Cell Biology SC Cell Biology GA DQ0GR UT WOS:000378877600011 PM 26928041 ER PT J AU Morrison, K Winter, L Gitlin, LN AF Morrison, Karen Winter, Laraine Gitlin, Laura N. TI Recruiting Community-Based Dementia Patients and Caregivers in a Nonpharmacologic Randomized Trial: What Works and How Much Does It Cost? SO JOURNAL OF APPLIED GERONTOLOGY LA English DT Article DE caregiving; dementia care; home care; clinical trials ID ALZHEIMER-DISEASE RESEARCH; OLDER-ADULTS; INTERVENTION RESEARCH; AFRICAN-AMERICAN; AGING RESEARCH; RETENTION; MANAGEMENT; PARTICIPATION; PREVENTION; ATTITUDES AB Objectives: The aim of this study was to evaluate the yield and cost of three recruitment strategiesdirect mail, newspaper advertisements, and community outreachfor identifying and enrolling dementia caregivers into a randomized trial testing a nonpharmacologic approach to enhancing quality of life of patients and caregivers (dyads). Method: Enrollment occurred between 2006 and 2008. The number of recruitment inquiries, number and race of enrollees, and costs for each recruitment strategy were recorded. Results: Of 284 inquiries, 237 (83%) dyads enrolled. Total cost for recruitment across methodologies was US$154 per dyad. Direct mailings resulted in the most enrollees (n = 135, 57%) and was the least costly method (US$63 per dyad) compared with newspaper ads (US$224 per dyad) and community outreach (US$350 per dyad). Although enrollees were predominately White, mailings yielded the highest number of non-Whites (n = 37). Discussion: Direct mailings was the most effective and least costly method for enrolling dyads in a nonpharmacologic dementia trial. C1 [Morrison, Karen] Bayada Home Hlth Care, 190 N Independence Mall West,Suite 700, Philadelphia, PA 19106 USA. [Winter, Laraine] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Gitlin, Laura N.] Johns Hopkins Univ, Ctr Innovat Care Aging, Baltimore, MD USA. RP Morrison, K (reprint author), Bayada Home Hlth Care, 190 N Independence Mall West,Suite 700, Philadelphia, PA 19106 USA. EM morrisonkk49@gmail.com FU National Institute on Aging; National Institute on Nursing Research [RO1 AG22254]; PA Department of Health, Tobacco Settlement [SAP 100027298] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research reported in this article was supported by funds from the National Institute on Aging and the National Institute on Nursing Research (Grant RO1 AG22254) and the PA Department of Health, Tobacco Settlement (SAP 100027298). NR 40 TC 3 Z9 3 U1 3 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0733-4648 EI 1552-4523 J9 J APPL GERONTOL JI J. Appl. Gerontol. PD JUL PY 2016 VL 35 IS 7 BP 788 EP 800 DI 10.1177/0733464814532012 PG 13 WC Gerontology SC Geriatrics & Gerontology GA DP7PM UT WOS:000378691300006 PM 24799354 ER PT J AU Dixon, CE Carlson, SW AF Dixon, C. Edward Carlson, Shaun W. TI FUNCTIONAL DEFICITS ARE ATTENUATED IN HUMAN ALPHA SYNUCLEIN TRANSGENIC RATS AFTER TBI SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 34th Annual National Neurotrauma Symposium CY JUN 26-29, 2016 CL Lexington, KY DE alpha synuclein; transgenic; CCI; function C1 [Dixon, C. Edward; Carlson, Shaun W.] Univ Pittsburgh, Neurosurg, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Neurosurg, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 1 PY 2016 VL 33 IS 13 MA PSB-190 BP A80 EP A81 PG 2 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DP2QY UT WOS:000378336200219 ER PT J AU Grovola, M Harris, JP Brown, DP Wolf, JA Cullen, DK AF Grovola, Michael Harris, James P. Brown, Daniel P. Wolf, John A. Cullen, D. Kacy TI NEUROPATHOLOGICAL ALTERATIONS IN THE HILUS AFTER DIFFUSE BRAIN INJURY SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 34th Annual National Neurotrauma Symposium CY JUN 26-29, 2016 CL Lexington, KY DE large animal models; mossy cell; diffuse brain injury; synaptic changes C1 [Grovola, Michael; Harris, James P.; Brown, Daniel P.; Wolf, John A.; Cullen, D. Kacy] Univ Penn, Neurosurg, Philadelphia, PA 19104 USA. [Grovola, Michael; Harris, James P.; Brown, Daniel P.; Wolf, John A.; Cullen, D. Kacy] Philadelphia VA Med Ctr, Neurosurg, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 1 PY 2016 VL 33 IS 13 MA PSB-247 BP A101 EP A101 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DP2QY UT WOS:000378336200276 ER PT J AU Haghighi, F Carr, W LoPresti, M Yarnell, A Karmakar, M Mendelev, N Umali, M McCarron, R Elder, G Ahlers, S AF Haghighi, Fatemeh Carr, Walter LoPresti, Matthew Yarnell, Angela Karmakar, Moumita Mendelev, Natalia Umali, Michelle McCarron, Richard Elder, Gregory Ahlers, Stephen TI EPIGENETIC AND TRANSCRIPTIONAL SIGNATURES OF BLAST EXPOSURE SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 34th Annual National Neurotrauma Symposium CY JUN 26-29, 2016 CL Lexington, KY DE epigenetics; methylation; blast C1 [Haghighi, Fatemeh; Karmakar, Moumita; Mendelev, Natalia] Icahn Sch Med Mt Sinai, Neurosci, New York, NY 10029 USA. [Haghighi, Fatemeh; Umali, Michelle; Elder, Gregory] James J Peters VA Med Ctr, Med Epigen, New York, NY USA. [Carr, Walter; LoPresti, Matthew; Yarnell, Angela] Walter Reed Army Inst Res, Rockville, MD USA. [McCarron, Richard; Ahlers, Stephen] Naval Med Res Ctr, Silver Spring, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 1 PY 2016 VL 33 IS 13 MA PSB-183 BP A78 EP A78 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DP2QY UT WOS:000378336200212 ER PT J AU Harel, N Yung, L Romero, A Santiago, T Guber, K Kastuar, S Nguyen, N Wu, YK Carmel, J Spungen, A Bauman, W AF Harel, Noam Yung, Lok Romero, Angelica Santiago, Tiffany Guber, Kenneth Kastuar, Shivani Nhuquynh Nguyen Wu, Yu-Kuang Carmel, Jason Spungen, Ann Bauman, William TI PAIRED MAGNETIC AND ELECTRICAL STIMULATION FOR CERVICAL SCI SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 34th Annual National Neurotrauma Symposium CY JUN 26-29, 2016 CL Lexington, KY DE non-invasive brain stimulation; TMS; cervical electrical stimulation; spike timing-dependent plasticity C1 [Harel, Noam; Yung, Lok; Romero, Angelica; Santiago, Tiffany; Guber, Kenneth; Nhuquynh Nguyen; Wu, Yu-Kuang; Spungen, Ann; Bauman, William] James J Peters VA Med Ctr, Neurol, Spinal Cord Injury, Bronx, NY USA. [Harel, Noam; Kastuar, Shivani; Spungen, Ann; Bauman, William] Icahn Sch Med Mt Sinai, Neurol, Rehabil Med, New York, NY 10029 USA. [Carmel, Jason] Cornell Univ, Coll Med, Burke Med Res Inst, Neurol, White Plains, NY 10605 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 1 PY 2016 VL 33 IS 13 MA AANS03-02 BP A3 EP A3 PG 1 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DP2QY UT WOS:000378336200006 ER PT J AU Wofford, KL Browne, K Harris, JP Mietus, C Brown, DP Grovola, M Kuo, E Wolf, JA Duda, JE Spiller, KL Cullen, DK AF Wofford, Kathryn L. Browne, Kevin Harris, James P. Mietus, Constance Brown, Daniel P. Grovola, Michael Kuo, Emory Wolf, John A. Duda, John E. Spiller, Kara L. Cullen, D. Kacy TI RAPID MICROGLIAL ACTIVATION NEAR INJURED NEURONS FOLLOWING DIFFUSE BRAIN INJURY IN SWINE SO JOURNAL OF NEUROTRAUMA LA English DT Meeting Abstract CT 34th Annual National Neurotrauma Symposium CY JUN 26-29, 2016 CL Lexington, KY DE diffuse brain injury; plasmalemmal disruption; glial reactivity C1 [Wofford, Kathryn L.; Browne, Kevin; Harris, James P.; Brown, Daniel P.; Grovola, Michael; Kuo, Emory; Wolf, John A.; Duda, John E.; Cullen, D. Kacy] Vet Affairs Med Ctr, Philadelphia, PA USA. [Wofford, Kathryn L.; Browne, Kevin; Harris, James P.; Mietus, Constance; Brown, Daniel P.; Grovola, Michael; Kuo, Emory; Wolf, John A.; Cullen, D. Kacy] Univ Penn, Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA. [Wofford, Kathryn L.; Spiller, Kara L.] Drexel Univ, Biomed Engn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUL 1 PY 2016 VL 33 IS 13 MA PSB-295 BP A118 EP A119 PG 2 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DP2QY UT WOS:000378336200324 ER PT J AU McCauley, JL Hyer, JM Ramakrishnan, VR Leite, R Melvin, CL Fillingim, RB Frick, C Brady, KT AF McCauley, Jenna L. Hyer, J. Madison Ramakrishnan, V. Ramesh Leite, Renata Melvin, Cathy L. Fillingim, Roger B. Frick, Christie Brady, Kathleen T. TI Dental opioid prescribing and multiple opioid prescriptions among dental patients Administrative data from the South Carolina prescription drug monitoring program SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Oxycodone; patient education; prescriptions; drug ID UNITED-STATES; NONMEDICAL USE; OVERDOSE; PAIN; ABUSE; GUIDELINES; THERAPY; RISK; PHARMACOGENETICS; HYDROCODONE AB Background. Despite increased attention to dentists' roles in curbing opioid misuse, abuse, and diversion, information regarding prescribing practices and the frequency of multiple concurrent opioid prescriptions among dental patients is limited. Methods. The authors reviewed South Carolina prescription drug monitoring program data representing dispensed medication for patients prescribed at least 1 opioid by a dentist during the most recently available 2-year time frame (2012-2013). The authors used descriptive analyses to examine the types and frequency of dental opioid prescriptions and the frequency of existing multiple concurrent opioid prescriptions among dental patients. Results. Nearly all dispensed dental opioid prescriptions (99.9%; n = 653,650) were for immediate-release opioids and were initial prescription fills (96.2%). Hydrocodone (76.1%) and oxycodone (12.2%) combination products were the most frequently dispensed opioids prescribed by dentists. People younger than 21 years received 11.2% of dentist-prescribed opioids dispensed. Patients with multiple concurrent opioid prescriptions were identified within 30-day (n = 113,818), 90-day (n = 166,124), and 180-day (n = 205,576) time frames. Conclusions. Dentists prescribed a high volume of the immediate-release opioids dispensed in South Carolina. A notable minority of dental patients had incidents of multiple preexisting opioid prescriptions, a factor implicated in patient misuse, abuse, overdose, and diversion. Practical Implications. Use of a prescription drug monitoring program before prescribing provides a record of controlled substances dispensed to a patient and may inform prescribing, coordination of care, and addiction screening or referral. Patients should receive information regarding misuse behaviors and their risks, as well as the importance of secure storage and disposal of leftover opioid medications. C1 [McCauley, Jenna L.] Med Univ S Carolina, Addict Sci Div, Dept Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA. [Hyer, J. Madison; Ramakrishnan, V. Ramesh; Melvin, Cathy L.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Leite, Renata] Med Univ S Carolina, Dept Periodont, Charleston, SC 29425 USA. [Fillingim, Roger B.] Univ Florida, Dept Community Dent & Behav Sci, Gainesville, FL USA. [Frick, Christie] S Carolina Dept Hlth & Environm Control, Prescript Drug Monitoring Program, Columbia, SC 29201 USA. [Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP McCauley, JL (reprint author), Med Univ S Carolina, Addict Sci Div, Dept Psychiat & Behav Sci, 67 President St, Charleston, SC 29425 USA. EM mccaule@musc.edu FU National Institute on Drug Abuse [K12-DA031794, K23-DA036566]; South Carolina Clinical and Translational Research Institute; National Institutes of Health [UL1-TR000062] FX This research was supported by grants K12-DA031794 and K23-DA036566 from the National Institute on Drug Abuse and by the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina, through grant UL1-TR000062 from the National Institutes of Health. NR 46 TC 1 Z9 1 U1 2 U2 2 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 EI 1943-4723 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD JUL PY 2016 VL 147 IS 7 BP 537 EP 544 DI 10.1016/j.adaj.2016.02.017 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DP5ON UT WOS:000378547000007 PM 27055600 ER PT J AU Kenagy, RD Civelek, M Kikuchi, S Chen, LH Grieff, A Sobel, M Lusis, AJ Clowes, AW AF Kenagy, Richard D. Civelek, Mete Kikuchi, Shinsuke Chen, Lihua Grieff, Anthony Sobel, Michael Lusis, Aldons J. Clowes, Alexander W. TI Scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN) are hub genes of coexpression network modules associated with peripheral vein graft patency SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID SMOOTH-MUSCLE-CELLS; INTERMEDIATE-LAYER PROTEIN; EPIDERMAL-GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; NUCLEOTIDE EXCHANGE FACTOR; EX-VIVO EXPANSION; SAPHENOUS-VEIN; FACTOR-XA; ENDOTHELIAL-CELLS; SELENOPROTEIN P AB Objective: Approximately 30% of autogenous vein grafts develop luminal narrowing and fail because of intimal hyperplasia or negative remodeling. We previously found that vein graft cells from patients who later develop stenosis proliferate more in vitro in response to growth factors than cells from patients who maintain patent grafts. To discover novel determinants of vein graft outcome, we have analyzed gene expression profiles of these cells using a systems biology approach to cluster the genes into modules by their coexpression patterns and to correlate the results with growth data from our prior study and with new studies of migration and matrix remodeling. Methods: RNA from 4-hour serum-or platelet-derived growth factor (PDGF)-BB-stimulated human saphenous vein cells obtained from the outer vein wall (20 cell lines) was used for microarray analysis of gene expression, followed by weighted gene coexpression network analysis. Cell migration in microchemotaxis chambers in response to PDGF-BB and cell-mediated collagen gel contraction in response to serum were also determined. Gene function was determined using short-interfering RNA to inhibit gene expression before subjecting cells to growth or collagen gel contraction assays. These cells were derived from samples of the vein grafts obtained at surgery, and the long-term fate of these bypass grafts was known. Results: Neither migration nor cell-mediated collagen gel contraction showed a correlation with graft outcome. Although 1188 and 1340 genes were differentially expressed in response to treatment with serum and PDGF, respectively, no single gene was differentially expressed in cells isolated from patients whose grafts stenosed compared with those that remained patent. Network analysis revealed four unique groups of genes, which we term modules, associated with PDGF responses, and 20 unique modules associated with serum responses. The "yellow" and "skyblue" modules, from PDGF and serum analyses, respectively, correlated with later graft stenosis (P=.005 and P=.02, respectively). In response to PDGF, yellow was also associated with increased cell growth. For serum, skyblue was also associated with inhibition of collagen gel contraction. The hub genes for yellow and skyblue (ie, the gene most connected to other genes in the module), scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN), respectively, were tested for effects on proliferation and collagen contraction. Knockdown of SCARA5 increased proliferation by 29.9% +/- 7.8% (P<.01), whereas knockdown of SBSN had no effect. Knockdown of SBSN increased collagen gel contraction by 24.2% +/- 8.6% (P<.05), whereas knockdown of SCARA5 had no effect. Conclusions: Using weighted gene coexpression network analysis of cultured vein graft cell gene expression, we have discovered two small gene modules, which comprise 42 genes, that are associated with vein graft failure. Further experiments are needed to delineate the venous cells that express these genes in vivo and the roles these genes play in vein graft healing, starting with the module hub genes SCARA5 and SBSN, which have been shown to have modest effects on cell proliferation or collagen gel contraction. C1 [Kenagy, Richard D.; Kikuchi, Shinsuke; Chen, Lihua; Grieff, Anthony; Sobel, Michael; Clowes, Alexander W.] Univ Washington, Dept Surg, Seattle, WA 98109 USA. [Civelek, Mete; Lusis, Aldons J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Kikuchi, Shinsuke] Asahikawa Med Univ, Dept Vasc Surg, Asahikawa, Hokkaido, Japan. [Sobel, Michael] VA Puget Sound Hlth Care Syst, Div Vasc Surg, Seattle, WA USA. [Sobel, Michael] Univ Washington, Seattle, WA 98109 USA. [Lusis, Aldons J.] Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90024 USA. [Lusis, Aldons J.] Univ Calif Los Angeles, Dept Immunol & Mol Genet, Los Angeles, CA USA. [Lusis, Aldons J.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA. RP Kenagy, RD (reprint author), Univ Washington, Ctr Cardiovasc Biol, POB 358050,850 Republican St, Seattle, WA 98109 USA. EM rkenagy@u.washington.edu OI Civelek, Mete/0000-0002-8141-0284 FU CSRD VA [I01 CX000712]; NHLBI NIH HHS [K99 HL121172, P01 HL030568, R01 HL030946, T32 HL069766] NR 111 TC 0 Z9 0 U1 3 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUL PY 2016 VL 64 IS 1 BP 202 EP + DI 10.1016/j.jvs.2014.12.052 PG 14 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DP5UI UT WOS:000378562900028 PM 25935274 ER PT J AU Julius, A Longfellow, K AF Julius, Anthony Longfellow, Katelan TI Movement Disorders A Brief Guide in Medication Management SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Movement disorders; Parkinson's disease; Nonmotor symptoms; Essential tremor; Restless leg syndrome ID RESTLESS LEGS SYNDROME; PLACEBO-CONTROLLED TRIAL; SLEEP BEHAVIOR DISORDER; AGONIST WITHDRAWAL SYNDROME; QUALITY STANDARDS SUBCOMMITTEE; EARLY PARKINSONS-DISEASE; DOUBLE-BLIND TRIAL; TOXIN TYPE-A; ESSENTIAL TREMOR; ORTHOSTATIC HYPOTENSION AB Movement disorders can be challenging to manage and often use a specific set of medications. Because it is a complex and broad field within neurology, many providers are unfamiliar with the classes of medications. This article details medications used for specific conditions, explains why these medications are helpful, and shares pearls and pitfalls related to each agent, focusing on parameters such as dose titration, side effect profiles, and specific drug-drug interactions and challenges. We focus on the most commonly encountered movement disorders, including essential tremor, Parkinson's disease, rapid eye movement sleep behavior disorder, and restless leg syndrome. C1 [Julius, Anthony; Longfellow, Katelan] Univ Washington, Med Ctr, VA Puget Sound, 1660 S Columbian Way, Seattle, WA 98108 USA. RP Longfellow, K (reprint author), Univ Washington, Med Ctr, VA Puget Sound, 1660 S Columbian Way, Seattle, WA 98108 USA. EM katelanlongfellow@catholichealth.net NR 137 TC 0 Z9 0 U1 1 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JUL PY 2016 VL 100 IS 4 BP 733 EP + DI 10.1016/j.mcna.2016.03.002 PG 30 WC Medicine, General & Internal SC General & Internal Medicine GA DP6BK UT WOS:000378581700007 PM 27235613 ER PT J AU Allen, C Evans, G Sutton, EL AF Allen, Caitlin Evans, Ginger Sutton, Eliza L. TI Pharmacologic Therapies in Women's Health Contraception and Menopause Treatment SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Long-acting reversible contraception; Combined hormonal contraception; Emergency contraception; Menopause transition; Genitourinary syndrome of menopause; Estrogen therapy ID ACTING REVERSIBLE CONTRACEPTION; RANDOMIZED CONTROLLED-TRIAL; EMERGENCY CONTRACEPTION; INTRAUTERINE-DEVICE; VASOMOTOR SYMPTOMS; ORAL-CONTRACEPTIVES; VENOUS THROMBOEMBOLISM; ULIPRISTAL ACETATE; CLINICAL-TRIAL; HORMONAL CONTRACEPTIVES AB Female hormones play a significant role in the etiology and treatment of many women's health conditions. This article focuses on the common uses of hormonal therapy. When prescribing estrogen-containing regimens throughout the span of a woman's life, the risks are similar (ie, cardiovascular risk and venous thromboembolism), but the degree of risk varies significantly depending on a woman's particular set of risk factors and the details of the hormone regimen. In addition to estrogens and progestogens, this article also touches on the use of selective steroid receptor modulators in emergency contraception and in treatment of menopause symptoms. C1 [Allen, Caitlin] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, MFCB 5120, 1685 Highland Ave, Madison, WI 53705 USA. [Evans, Ginger] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,S-123 PCC, Seattle, WA 98108 USA. [Sutton, Eliza L.] Univ Washington, Dept Med, Womens Hlth Care Ctr, 4245 Roosevelt Way Northeast,Box 354765, Seattle, WA 98105 USA. RP Allen, C (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, MFCB 5120, 1685 Highland Ave, Madison, WI 53705 USA. EM callen@uwhealth.org NR 94 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD JUL PY 2016 VL 100 IS 4 BP 763 EP + DI 10.1016/j.mcna.2016.03.008 PG 28 WC Medicine, General & Internal SC General & Internal Medicine GA DP6BK UT WOS:000378581700008 PM 27235614 ER PT J AU Malakhov, A Wen, J Zhang, BX Wang, H Geng, H Chen, XD Sun, Y Yeh, CK AF Malakhov, A. Wen, J. Zhang, B-X Wang, H. Geng, H. Chen, X-D Sun, Y. Yeh, C-K TI Rechargeable anticandidal denture material with sustained release in saliva SO ORAL DISEASES LA English DT Article DE Candida-associated denture stomatitis; antifungal treatment; drug delivery; rechargeable biomaterial ID CANDIDA-ALBICANS; BIOFILM FORMATION; IN-VITRO; TISSUE CONDITIONERS; ANTIFUNGAL ACTIVITY; SILVER-ZEOLITE; DRUG-RELEASE; STOMATITIS; MICONAZOLE; RESISTANCE AB ObjectiveCandida-induced denture stomatitis is a common debilitating problem among denture wearers. Previously, we described the fabrication of a new denture material that released antifungal drugs when immersed in phosphate buffered saline. Here, we use more clinically relevant immersion conditions (human saliva; 37 degrees C) and measure miconazole release and bioactivity. Materials and MethodsDisks were prepared by grafting PNVP [poly(N-vinyl-2-pyrrolidinone)] onto PMMA [poly(methylmethacrylate)] using plasma initiation (PMMA-g-PNVP) and then loaded with miconazole. Drug-loaded disks were immersed in 10-100% human saliva (1-30days). Miconazole release was measured and then tested for bioactivity vs miconazole-sensitive and miconazole-resistant Candida isolates. ResultsHPLC was used to quantify miconazole levels in saliva. Miconazole-loaded disks released antifungal drug for up to 30days. Higher drug release was found with higher concentrations of saliva, and, interestingly, miconazole solubility was increased with higher saliva concentrations. The released miconazole retained its anticandidal activity. After immersion, the residual miconazole could be quenched and the disks recharged. Freshly recharged disks displayed the same release kinetics and bioactivity as the original disks. Quenched disks could also be charged with chlorhexidine that displayed anticandidal activity. ConclusionsThese results suggest that PMMA-g-PNVP is a promising new denture material for long-term management of denture stomatitis. C1 [Malakhov, A.; Zhang, B-X; Wang, H.; Chen, X-D; Yeh, C-K] South Texas Vet Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, San Antonio, TX 78229 USA. [Malakhov, A.; Zhang, B-X; Wang, H.; Chen, X-D; Yeh, C-K] South Texas Vet Hlth Care Syst, Res Serv, Audie L Murphy Div, San Antonio, TX 78229 USA. [Malakhov, A.; Zhang, B-X; Wang, H.; Chen, X-D; Yeh, C-K] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Wen, J.; Sun, Y.] Univ Massachusetts, Dept Chem, Lowell, MA USA. [Geng, H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. RP Yeh, CK (reprint author), South Texas Vet Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, San Antonio, TX 78229 USA.; Yeh, CK (reprint author), South Texas Vet Hlth Care Syst, Res Serv, Audie L Murphy Div, San Antonio, TX 78229 USA. EM yeh@uthscsa.edu FU NIH; NIDCR T-32 [DE021084, DE014318]; COSTAR Program; VA Merit Review [1I01BX001103] FX This study was supported by NIH and NIDCR T-32 grants DE021084, DE014318, the COSTAR Program, and a VA Merit Review (1I01BX001103). We are grateful to Dr. Nathan Wiederhold, Director of the Fungal Testing Laboratory (UTHSCSA), for kindly providing the Candida isolates used in this study and to Dr. David Dean (Professor, Comprehensive Dentistry, UTHSCSA) for his scientific input and careful editing of the manuscript. The authors declared no potential conflict of interests with respect to the authorship and/or publication of this article. NR 33 TC 1 Z9 1 U1 5 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1354-523X EI 1601-0825 J9 ORAL DIS JI Oral Dis. PD JUL PY 2016 VL 22 IS 5 BP 391 EP 398 DI 10.1111/odi.12456 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DP6WA UT WOS:000378638800007 PM 26855200 ER PT J AU Poston, CJ Pierce, TC Li, Y Brinson, CW Lu, Z Lauer, AW Leite, RS Huang, Y AF Poston, C. J. Pierce, T. C. Li, Y. Brinson, C. W. Lu, Z. Lauer, A. W. Leite, R. S. Huang, Y. TI Statin intake is associated with MMP-1 level in gingival crevicular fluid of patients with periodontitis SO ORAL DISEASES LA English DT Article DE statin; periodontitis; diabetes mellitus; matrix metalloproteinase-1 ID MATRIX METALLOPROTEINASE-1 EXPRESSION; U937 MONONUCLEAR-CELLS; ALVEOLAR BONE LOSS; HIGH GLUCOSE; CARDIOVASCULAR-DISEASE; INFLAMMATORY RESPONSES; INTERFERON-GAMMA; LIPOPOLYSACCHARIDE; THERAPY; ROSUVASTATIN AB BackgroundThis study was conducted to assess whether statin intake is associated with clinical parameters of periodontitis and matrix metalloproteinase (MMP) levels in gingival crevicular fluid (GCF) of non-diabetic and diabetic patients. MethodsWe first determined the effect of simvastatin on MMP expression in mononuclear cells. We then recruited 117 non-diabetic and diabetic patients, who all had periodontitis and took or did not take statin, and measured periodontal probing depth (PPD) and clinical attachment level (CAL), and collected gingival crevicular fluid (GCF) to quantify MMPs. ResultsThe invitro studies showed that simvastatin potently inhibited the expression of MMP-1, MMP-8, and MMP-9 upregulated by lipopolysaccharide (LPS) and high glucose in mononuclear cells. The patient study showed that, after adjusting for age and smoking status, PPD in diabetic patients on statin was significantly less than that in diabetic patients not on statin. MMP-1 level in GCF of non-diabetic and diabetic patients on statin was lower than that of non-diabetic and diabetic patients not on statin, respectively. No difference was found for MMP-8 and -9 levels in GCF. ConclusionStatin intake is associated with reduced PPD in diabetic patients and MMP-1 level in GCF in either non-diabetic or diabetic patients. C1 [Poston, C. J.; Pierce, T. C.; Leite, R. S.] Med Univ S Carolina, Coll Dent Med, Div Periodont, Dept Stomatol, Charleston, SC 29425 USA. [Li, Y.; Brinson, C. W.; Huang, Y.] Med Univ S Carolina, Coll Med, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA. [Lu, Z.; Huang, Y.] Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29425 USA. [Lauer, A. W.] Med Univ S Carolina, Coll Med, Dept Publ Hlth Sci, Div Biostat, Charleston, SC 29425 USA. RP Huang, Y (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29425 USA.; Huang, Y (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 114 Doughty St, Charleston, SC 29425 USA. EM huangyan@musc.edu FU NIH [DE016353]; Merit Review Grant from Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs FX This work was supported by NIH grant DE016353 and Merit Review Grant from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs (to Y.H.). NR 45 TC 0 Z9 0 U1 0 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1354-523X EI 1601-0825 J9 ORAL DIS JI Oral Dis. PD JUL PY 2016 VL 22 IS 5 BP 438 EP 444 DI 10.1111/odi.12474 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DP6WA UT WOS:000378638800013 PM 26988924 ER PT J AU Mazzoni, M Bombardi, C Vallorani, C Sirri, F De Giorgio, R Caio, G Grandis, A Sternini, C Clavenzani, P AF Mazzoni, M. Bombardi, C. Vallorani, C. Sirri, F. De Giorgio, R. Caio, G. Grandis, A. Sternini, C. Clavenzani, P. TI Distribution of alpha-transducin and alpha-gustducin immunoreactive cells in the chicken (Gallus domesticus) gastrointestinal tract SO POULTRY SCIENCE LA English DT Article DE chemosensing; alpha-transducin; alpha-gustducin; gastrointestinal tract; chicken ID BITTER TASTE RECEPTORS; SMALL-INTESTINE; SIGNALING MECHANISMS; CHROMOGRANIN-A; EXPRESSION; GUT; ENDOCRINE; COLOCALIZATION; NUTRIENTS; ONTOGENY AB The expression and distribution patterns of the taste signaling molecules, alpha-gustducin (G(alpha gust)) and alpha-transducin (G(alpha tran)) G-protein subunits, were studied in the gastrointestinal tract of the chicken (Gallus domesticus) using the immunohistochemical method. G(alpha gust) and G(alpha tran) immunoreactive (-IR) cells were observed in the mucosal layer of all examined segments, except the esophagus, crop, and the saccus cranialis of the gizzard. The highest numbers of G(alpha gus)t and G(alpha tran)-IR cells were found in the proventriculus glands and along the villi of the pyloric, duodenum, and rectal mucosa. G(alpha gust) and G(alpha tran)-IR cells located in the villi of the jejunum, ileum, and cloaca were much less numerous, while only a few G(alpha gus)t and G(alpha tran)-IR cells were detected in the mucosa of the proventriculus and cecum. In the crypts, IR cells were observed in the small and large intestine as well as in the cloaca. G(alpha gust) and G(alpha tran)-IR cells displayed elongated ("bottle-" or "pearlike") or rounded shape. The demonstration of G(alpha gust) and G(alpha tran) expression provides evidence for taste receptor mediated mucosal chemosensitivity in the chicken gastrointestinal tract. C1 [Mazzoni, M.; Bombardi, C.; Vallorani, C.; Grandis, A.; Clavenzani, P.] Univ Bologna, Dept Vet Med Sci, Ozzano Dell Emilia, BO, Italy. [Sirri, F.] Univ Bologna, Dept Agr & Food Sci, Ozzano Dell Emilia, BO, Italy. [De Giorgio, R.; Caio, G.] Univ Bologna, Dept Med & Surg Sci, Ozzano Dell Emilia, BO, Italy. [Sternini, C.] Univ Calif Los Angeles, David Geffen Sch Med, CURE DDRC, Div Digest Dis,Dept Med, Los Angeles, CA 90095 USA. [Sternini, C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. [Sternini, C.] Vet Adm Greater Los Angeles Hlth Syst, Los Angeles, CA USA. RP Mazzoni, M (reprint author), Univ Bologna, Dept Vet Med Sci, Ozzano Dell Emilia, BO, Italy. EM m.mazzoni@unibo.it RI Mazzoni, Maurizio/J-1918-2016 OI Mazzoni, Maurizio/0000-0002-7384-5990 FU Department of Veterinary Medical Science, University of Bologna; National Institute of Health [P30DK41301, R01DK98447] FX This study was financed by the Department of Veterinary Medical Science, University of Bologna. CS is supported by the National Institute of Health grants, P30DK41301 and R01DK98447. NR 34 TC 1 Z9 1 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0032-5791 EI 1525-3171 J9 POULTRY SCI JI Poult. Sci. PD JUL PY 2016 VL 95 IS 7 BP 1624 EP 1630 DI 10.3382/ps/pew057 PG 7 WC Agriculture, Dairy & Animal Science SC Agriculture GA DP6PI UT WOS:000378619000018 PM 26957624 ER PT J AU Kishan, AU Wang, PC Upadhyaya, SK Hauswald, H Demanes, DJ Nickols, NG Kamrava, M Sadeghi, A Kupelian, PA Steinberg, ML Prionas, ND Buyyounouski, MK King, CR AF Kishan, Amar U. Wang, Pin-Chieh Upadhyaya, Shrinivasa K. Hauswald, Henrik Demanes, D. Jeffrey Nickols, Nicholas G. Kamrava, Mitchell Sadeghi, Ahmad Kupelian, Patrick A. Steinberg, Michael L. Prionas, Nicolas D. Buyyounouski, Mark K. King, Christopher R. TI SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer SO PRACTICAL RADIATION ONCOLOGY LA English DT Article ID STEREOTACTIC BODY RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; DOSE-RATE BRACHYTHERAPY; RADIATION-THERAPY; MULTIINSTITUTIONAL ANALYSIS; ANTIGEN BOUNCE; KINETICS; MONOTHERAPY; FAILURE; LEVEL AB Purpose: To compare patterns of prostate-specific antigen (PSA) response following stereotactic body radiation therapy (SBRT), high-dose-rate (HDR) brachytherapy, and conventionally fractionated intensity modulated radiation therapy (IMRT) in patients with low-or intermediate-risk prostate cancer (CaP). Methods and materials: Eligible study patients included 439 patients with low-or intermediate-risk prostate cancer who were treated with radiation therapy (RT) alone between 2003 and 2013, remained free of biochemical recurrence, and had at least 2 PSA values within the first year following RT. Of these, 130 were treated with SBRT, 220 with HDR brachytherapy, and 89 with IMRT. Multivariate regression analysis was used to compare PSA nadirs (nPSA), time to nPSA, and PSA bounce parameters among the 3 modalities. Indicator variable analysis was used to develop empirical models of PSA decay using the treatment modalities as indicator variables. Results: Significantly more patients treated with SBRT or HDR brachytherapy achieved raw nPSAs of <0.5 ng/mL compared with patients treated with IMRT (76.2% and 75.9% vs 44.9%, respectively; P < .0001 for SBRT or HDR brachytherapy vs IMRT). On multivariate analysis, nPSA was significantly lower with SBRT and HDR compared with IMRT (P < .0001). Time to nPSA and bounce parameters was not significantly different among IMRT, SBRT, and HDR. Overall, SBRT and HDR brachytherapy caused significantly larger PSA decay rates (P < .001). When truncating follow-up at 1000 days, the corresponding decay rates were larger for all 3 modalities, with no significant differences between them. Conclusions: Stereotactic body radiation therapy and HDR brachytherapy produce lower nPSAs than IMRT. Within 1000 days of follow-up, the modalities produce similar rates of PSA decay; subsequently, decay continues (albeit at a slower pace) after SBRT and HDR brachytherapy but plateaus with IMRT. Because nPSA is a validated predictor of long-term outcome, these data not only suggest a distinct radiobiological effect with SBRT and HDR brachytherapy, but also predict for clinical outcomes that might equal or surpass those of IMRT. (C) 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved. C1 [Kishan, Amar U.; Wang, Pin-Chieh; Demanes, D. Jeffrey; Nickols, Nicholas G.; Kamrava, Mitchell; Kupelian, Patrick A.; Steinberg, Michael L.; King, Christopher R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA. [Upadhyaya, Shrinivasa K.] Univ Calif Davis, Dept Biol & Agr Engn, Davis, CA 95616 USA. [Hauswald, Henrik] Univ Heidelberg Hosp, Dept Radiat Oncol & Radiat Therapy, Heidelberg, Germany. [Nickols, Nicholas G.; Prionas, Nicolas D.; Buyyounouski, Mark K.] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA. [Sadeghi, Ahmad] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA. RP Kishan, AU (reprint author), Dept Radiat Oncol, 200 UCLA Med Plaza,B265, Los Angeles, CA 90095 USA. EM aukishan@gmail.com NR 31 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1879-8500 J9 PRACT RADIAT ONCOL JI Pract. Radiat. Oncol. PD JUL-AUG PY 2016 VL 6 IS 4 BP 268 EP 275 DI 10.1016/j.prro.2015.11.002 PG 8 WC Oncology SC Oncology GA DP6RQ UT WOS:000378626600018 PM 26850649 ER PT J AU Woolley, JD Arcuni, PA Stauffer, CS Fulford, D Carson, DS Batki, S Vinogradov, S AF Woolley, Josh D. Arcuni, Peter A. Stauffer, Christopher S. Fulford, Daniel Carson, Dean S. Batki, Steve Vinogradov, Sophia TI The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study SO PSYCHOPHARMACOLOGY LA English DT Article DE Oxytocin; Heroin; Opioid; Addiction; Tolerability; Craving; Implicit; Social; RMET; Clinical ID SOCIAL COGNITION; NEURAL SYSTEMS; WITHDRAWAL; TOLERANCE; ADDICTION; HUMANS; ALCOHOLICS; METHADONE; IMPLICIT; RELAPSE AB Rationale There has been an explosion of research on the potential benefits of the social neuropeptide oxytocin for a number of mental disorders including substance use disorders. Recent evidence suggests that intranasal oxytocin has both direct anti-addiction effects and pro-social effects that may facilitate engagement in psychosocial treatment for substance use disorders. Objectives We aimed to assess the tolerability of intranasal oxytocin and its effects on heroin craving, implicit association with heroin and social perceptual ability in opioid-dependent patients receiving opioid replacement therapy (ORT) and healthy control participants. Methods We performed a randomized, double-blind, placebo-controlled, within-and between-subjects, crossover, proof-of-concept trial to examine the effects of oxytocin (40 international units) on a cue-induced craving task (ORT patients only), an Implicit Association Task (IAT), and two social perception tasks: the Reading the Mind in the Eyes Task (RMET) and The Awareness of Social Inference Test (TASIT). Results Oxytocin was well tolerated by patients receiving ORT but had no significant effects on craving or IAT scores. There was a significant reduction in RMET performance after oxytocin administration versus placebo in the patient group only, and a significant reduction in TASIT performance after oxytocin in both the patient and healthy control groups. Conclusions A single dose of intranasal oxytocin is well tolerated by patients receiving ORT, paving the way for future investigations. Despite no significant improvement in craving or IAT scores after a single dose of oxytocin and some evidence that social perception was worsened, further investigation is required to determine the role oxytocin may play in the treatment of opioid use disorder. C1 [Woolley, Josh D.; Stauffer, Christopher S.; Batki, Steve; Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA. [Woolley, Josh D.; Arcuni, Peter A.; Stauffer, Christopher S.; Batki, Steve; Vinogradov, Sophia] San Francisco VA Med Ctr, Dept Mental Hlth, 4150 Clement St 116C-1, San Francisco, CA 94121 USA. [Fulford, Daniel] Boston Univ, Sargent Coll Hlth & Rehabil Sci, 635 Commonwealth Ave,SAR 512, Boston, MA 02215 USA. [Carson, Dean S.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Woolley, JD (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA.; Woolley, JD (reprint author), San Francisco VA Med Ctr, Dept Mental Hlth, 4150 Clement St 116C-1, San Francisco, CA 94121 USA. EM Josh.Woolley@ucsf.edu FU San Francisco Treatment Research Center at the University of California, San Francisco from the National Institute on Drug Abuse [P50 DA009253] FX This project was supported by the San Francisco Treatment Research Center at the University of California, San Francisco, via grant number P50 DA009253 from the National Institute on Drug Abuse. NR 62 TC 1 Z9 1 U1 4 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JUL PY 2016 VL 233 IS 13 BP 2571 EP 2580 DI 10.1007/s00213-016-4308-8 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DP5ZE UT WOS:000378575900015 PM 27137199 ER PT J AU Ware, JB Biester, RC Whipple, E Robinson, KM Ross, RJ Nucifora, PG AF Ware, Jeffrey B. Biester, Rosette C. Whipple, Elizabeth Robinson, Keith M. Ross, Richard J. Nucifora, Paolo G. TI Combat-related Mild Traumatic Brain Injury: Association between Baseline Diffusion-Tensor Imaging Findings and Long-term Outcomes SO RADIOLOGY LA English DT Article ID AXONAL INJURY; SYMPTOMS; VETERANS; RETURN; MODEL; WORK; PTSD; IRAQ AB Purpose: To determine whether functional outcomes of veterans who sustained combat-related mild traumatic brain injury (TBI) are associated with scalar metrics derived from diffusion- tensor (DT) imaging at their initial postdeployment evaluation. Materials and Methods: This HIPAA-compliant retrospective study was approved by the institutional review board, and the requirement to obtain informed consent was waived. From 2010 to 2013, initial postdeployment evaluation, including clinical assessment and brain magnetic resonance (MR) examination with DT imaging, was performed in combat veterans who sustained mild TBI while deployed. Outcomes from chart review encompassed initial postdeployment clinical assessment as well as later functional status, including evaluation of occupational status and health care utilization. Scalar diffusion metrics from the initial postdeployment evaluation were compared with outcomes by using multivariate analysis. Veterans who did and did not return to work were also compared for differences in clinical variables by using t and x(2) tests. Results: Postdeployment evaluation was performed a mean of 3.8 years after injury (range, 0.5-9 years; standard deviation, 2.5 years). After a mean follow-up of 1.4 years (range, 0.5-2.5 years; standard deviation, 0.8 year), 34 of 57 veterans (60%) had returned to work. Return to work was associated with diffusion metrics in multiple regions of white matter, particularly in the left internal capsule and the left frontal lobe (P = .02-.05). Overall, veterans had a mean of 46 health care visits per year during the follow-up period (range, 3-196 visits per year; standard deviation, 41 visits per year). Cumulative health care visits over time were inversely correlated with diffusion anisotropy of the splenium of the corpus callosum and adjacent parietal white matter (P < .05). Clinical measures obtained during initial postdeployment evaluation were not predictive of later functional status (P = .12-.8). Conclusion: Differences in white matter microstructure may partially account for the variance in functional outcomes among veterans who sustained combat-related mild TBI. (C) RSNA, 2016 C1 [Ware, Jeffrey B.; Nucifora, Paolo G.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA USA. [Biester, Rosette C.; Whipple, Elizabeth; Robinson, Keith M.] Philadelphia VA Med Ctr, Dept Rehabil Med, Philadelphia, PA USA. [Ross, Richard J.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA. [Ware, Jeffrey B.; Nucifora, Paolo G.] Univ Penn, Perelman Sch Med, Dept Radiol, Philadelphia, PA 19104 USA. [Ross, Richard J.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Nucifora, PG (reprint author), Loyola Univ, Med Ctr, Dept Radiol, Maywood, IL 60153 USA.; Nucifora, PG (reprint author), Loyola Univ, Med Ctr, Dept Neurol, 2160 S 1st Ave, Maywood, IL 60153 USA. EM paolo.nucifora@lumc.edu NR 30 TC 2 Z9 2 U1 4 U2 7 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD JUL PY 2016 VL 280 IS 1 BP 212 EP 219 DI 10.1148/radiol.2016151013 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DP8BC UT WOS:000378721900023 PM 27022770 ER PT J AU Martin, JL AF Martin, Jennifer L. TI What to do about the Growing Number of Veterans with Diagnosed Sleep Disorders SO SLEEP LA English DT Editorial Material ID DISSEMINATION C1 [Martin, Jennifer L.] Univ Calif Los Angeles, Geriat Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Martin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Martin, JL (reprint author), VAGLAHS GRECC 11E,16111 Plummer St, North Hills, CA 91343 USA. EM Jennifer.Martin@va.gov NR 11 TC 0 Z9 0 U1 1 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JUL 1 PY 2016 VL 39 IS 7 BP 1331 EP 1332 DI 10.5665/sleep.5956 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DP9SJ UT WOS:000378837000001 PM 27306268 ER PT J AU Graham, ZA Qin, W Harlow, LC Ross, NH Bauman, WA Gallagher, PM Cardozo, CP AF Graham, Z. A. Qin, W. Harlow, L. C. Ross, N. H. Bauman, W. A. Gallagher, P. M. Cardozo, C. P. TI Focal adhesion kinase signaling is decreased 56 days following spinal cord injury in rat gastrocnemius SO SPINAL CORD LA English DT Article ID INDUCED MUSCLE ATROPHY; SKELETAL-MUSCLE; PROTEIN-SYNTHESIS; GENE-EXPRESSION; FIBER-TYPE; PHOSPHORYLATION; EXERCISE; RESISTANCE; MASS; MEN AB Study design: Descriptive study. Objectives: The goal of this study was to determine the effects of spinal cord injury (SCI) on aspects of the focal adhesion kinase (FAK) signaling pathway 56 days post injury in rat gastrocnemius. Setting: This study was conducted in Bronx, NY, USA. Methods: Three-month-old male Wistar rats were exposed to either a sham surgery (n=10) or complete T4 spinal cord transection (n=10). Rats were killed 56 days following surgery and the muscle was collected. Following homogenization, proteins of the FAK pathway were analyzed by western immunoblotting or reverse transcription-qPCR. In addition, cellular markers for proteins that target the degradation of FAK were investigated. Results: SCI resulted in significantly lower levels of total and phosphorylated FAK, cSrc and p70S6k, and a trend for increased FRNK protein expression. SCI did not change levels of the alpha 7 or beta 1 integrin subunits, total or phosphorylated ERK1/2, phosphorylated Akt and TSC2 or total p70S6k. SCI resulted in a greater expression of total Akt. mRNA expression of FAK and the alpha 7 or beta 1 integrins remained unchanged between sham and SCI groups. Caspase-3/7 activity and Trim72 mRNA and protein expression remained unchanged following SCI. Conclusion: SCI results in diminished FAK signaling and is independent of ERK1/2 and Akt. SCI has no effect on mRNA levels for genes encoding components of the focal adhesion 56 days after injury. C1 [Graham, Z. A.; Qin, W.; Harlow, L. C.; Ross, N. H.; Bauman, W. A.; Cardozo, C. P.] Natl Ctr Excellence Med Consequences Spinal Cord, James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Graham, Z. A.; Qin, W.; Bauman, W. A.; Cardozo, C. P.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY USA. [Bauman, W. A.; Cardozo, C. P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY USA. [Gallagher, P. M.] Univ Kansas, Appl Physiol Lab, Lawrence, KS USA. [Cardozo, C. P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY USA. RP Cardozo, CP (reprint author), Natl Ctr Excellence Med Consequences Spinal Cord, James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM christopher.cardozo@mssm.edu RI Gallagher, Philip/R-9937-2016 OI Gallagher, Philip/0000-0003-4563-4536 FU Department of Veterans Affairs Rehabilitation Research and Development Service [B1313R, B0687R, B9212C]; University of Kansas FX This work was supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (B1313R and B0687R) to WQ, (B9212C) to WAB and CPC, and a University of Kansas General Research Grant to PMG. NR 40 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD JUL PY 2016 VL 54 IS 7 BP 502 EP 509 DI 10.1038/sc.2015.183 PG 8 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DQ0FA UT WOS:000378872700003 PM 26481700 ER PT J AU Lee, SJ Jacobson, MA Johnston, CB AF Lee, Sei J. Jacobson, Margaret A. Johnston, C. Bree TI Improving Diabetes Care for Hospice Patients SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Editorial Material DE diabetes mellitus; hospice; hypoglycemia; glycemic control; glucose lowering medication; hyperglycemia ID PALLIATIVE CARE; BLOOD-GLUCOSE; MANAGEMENT; HYPERGLYCEMIA AB Although type 2 diabetes guidelines recommend less aggressive glycemic control for patients with limited life expectancy, many hospice patients continue their glucose-lowering medications, resulting in an increased risk of hypoglycemia. Three common reasons for overly tight glycemic control in hospice patients include (1) discussions about reducing or stopping chronic medications are uncomfortable; (2) many patients and families believe that mild hyperglycemia can cause symptoms; and (3) until 2014, Healthcare Information and Data Information Set (HEDIS) quality indicators for glycemic control included hospice patients. To address these issues, we recommend (1) providers discuss with patients and families upon hospice enrollment that diabetes medications can be reduced or discontinued as their life-limiting disease progresses; (2) keeping blood glucose levels between 200 and 300 mg/dL; and (3) educate providers that HEDIS measures now exclude hospice patients. Implementing these recommendations should decrease the risk of hypoglycemia in hospice patients and improve their quality of life. C1 [Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Bldg 1,Rm 220F, San Francisco, CA 94121 USA. [Lee, Sei J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Jacobson, Margaret A.] Whatcom Hosp, Bellingham, WA USA. [Johnston, C. Bree] PeaceHlth Med Syst, Bellingham, WA USA. RP Lee, SJ (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St,Bldg 1,Rm 220F, San Francisco, CA 94121 USA. EM sei.lee@ucsf.edu NR 9 TC 0 Z9 0 U1 4 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD JUL PY 2016 VL 33 IS 6 BP 517 EP 519 DI 10.1177/1049909115578386 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DP3NJ UT WOS:000378401100001 PM 25852204 ER PT J AU Cruz-Oliver, DM Malmstrom, TK Fernandez, N Parikh, M Garcia, J Sanchez-Reilly, S AF Cruz-Oliver, Dulce M. Malmstrom, Theodore K. Fernandez, Natalia Parikh, Manas Garcia, Jessica Sanchez-Reilly, Sandra TI Education Intervention "Caregivers Like Me" for Latino Family Caregivers Improved Attitudes Toward Professional Assistance at End-of-life Care SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE family caregivers; Latino; culture; end of life; hospice; palliative; education intervention; pretest-posttest ID UNITED-STATES; CANCER-PATIENTS; ETHNIC-DIFFERENCES; OLDER LATINOS; HOSPICE; HEALTH; DEATH; EXPERIENCE; BURDEN; PLACE AB Objective: This study explores the ability of a culturally sensitive and case-based education intervention, Caregivers Like Me, to improve knowledge and attitudes regarding end-of-life (EOL) resources among Latino caregivers. Methods: A multicentered, cross-sectional study of Latino communities from different geographical regions and cultural backgrounds. An educational intervention was administered to family caregivers of Latino elders using a case-based video telenovela and pretest-posttest questionnaires. Results: Participants (N = 145) were mostly females (79%) with mean age of 56 15 years. They reported active learning from intervention (91%) and high satisfaction (92%) with educational experience. Both caregiver stress self-awareness and willingness to accept professional help improved significantly from pretest to posttest. Conclusion: A culturally sensitive educational intervention increased Latino caregivers' self-awareness about caregiver stress and the need to consider professional assistance for EOL care. C1 [Cruz-Oliver, Dulce M.] St Louis Univ, Div Geriatr Med, South Grand Blvd, St Louis, MO 63104 USA. [Malmstrom, Theodore K.] St Louis Univ, Sch Med, Dept Neurol & Psychiat, 1402 South Grand Blvd M238, St Louis, MO 63104 USA. [Fernandez, Natalia] Univ Puerto Rico, Med Sci Campus, San Juan, PR 00936 USA. [Parikh, Manas] St Louis Univ, Sch Med, Div Geriatr Med, 1402 South Grand Blvd M238, St Louis, MO 63104 USA. [Garcia, Jessica] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Med, San Antonio, TX 78229 USA. [Garcia, Jessica; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, GEC, San Antonio, TX USA. [Garcia, Jessica; Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Cruz-Oliver, DM (reprint author), St Louis Univ, Dept Internal Med, Div Geriatr, 1402 South Grand Blvd M238, St Louis, MO 63104 USA. EM dcruzoli@slu.edu FU Health Resources and Services Administration (HRSA) Geriatric Academic Career Award [K01HP20479-03-00] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Health Resources and Services Administration (HRSA) Geriatric Academic Career Award K01HP20479-03-00. NR 44 TC 0 Z9 0 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD JUL PY 2016 VL 33 IS 6 BP 527 EP 536 DI 10.1177/1049909115584315 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DP3NJ UT WOS:000378401100003 PM 26019262 ER PT J AU Duncan, MD Vazirani, SS AF Duncan, Mark D. Vazirani, Sondra S. TI An Unusual Rapid Response Call: Malignant Catatonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Editorial Material ID ELECTROCONVULSIVE-THERAPY; LORAZEPAM C1 [Duncan, Mark D.; Vazirani, Sondra S.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, 757 Westwood Plaza,B7-111, Los Angeles, CA 90095 USA. [Vazirani, Sondra S.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Duncan, MD (reprint author), Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, 757 Westwood Plaza,B7-111, Los Angeles, CA 90095 USA. EM mduncan@mednet.ucla.edu NR 10 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD JUL PY 2016 VL 129 IS 7 BP 678 EP 680 DI 10.1016/j.amjmed.2016.03.005 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DO8WJ UT WOS:000378065800036 PM 27046246 ER PT J AU Gaffo, AL Mikuls, TR Stamp, LK Neogi, T AF Gaffo, Angelo L. Mikuls, Ted R. Stamp, Lisa K. Neogi, Tuhina TI Allopurinol Dose Reductions Based on Creatinine Alert Redesign System SO AMERICAN JOURNAL OF MEDICINE LA English DT Letter ID HYPERURICEMIA; CLEARANCE C1 [Gaffo, Angelo L.] Univ Alabama Birmingham, Dept Med, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Div Rheumatol, Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Stamp, Lisa K.] Univ Otago, Dept Med, Christchurch, New Zealand. [Neogi, Tuhina] Boston Univ, Dept Med, Med Sch Med, Boston, MA 02215 USA. RP Gaffo, AL (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. NR 5 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD JUL PY 2016 VL 129 IS 7 BP E95 EP E95 DI 10.1016/j.amjmed.2015.12.035 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DO8WJ UT WOS:000378065800021 PM 27320718 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry? SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Editorial Material ID BIOLOGICS REGISTER; FACTOR THERAPY; BRITISH SOCIETY; MALIGNANCY; DIAGNOSIS; LYMPHOMA; TIME C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] UAB, Sch Publ Hlth, Sch Med, Dept Med,Div Epidemiol, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com NR 18 TC 0 Z9 0 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUL PY 2016 VL 75 IS 7 BP 1265 EP 1267 DI 10.1136/annrheumdis-2015-208526 PG 3 WC Rheumatology SC Rheumatology GA DO8SZ UT WOS:000378055400013 PM 26951640 ER PT J AU Norrholm, SD Jovanovic, T Gerardi, M Breazeale, KG Price, M Davis, M Duncan, E Ressler, KJ Bradley, B Rizzo, A Tuerk, PW Rothbaum, BO AF Norrholm, Seth Davin Jovanovic, Tanja Gerardi, Maryrose Breazeale, Kathryn G. Price, Matthew Davis, Michael Duncan, Erica Ressler, Kerry J. Bradley, Bekh Rizzo, Albert Tuerk, Peter W. Rothbaum, Barbara O. TI Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Acoustic startle; Posttraumatic stress disorder; Virtual reality; Psychophysiology; Exposure therapy; Cortisol ID POSTTRAUMATIC-STRESS-DISORDER; CONDITIONED FEAR EXTINCTION; COGNITIVE-BEHAVIORAL TREATMENT; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CLINICAL-TRIAL; SOCIAL ANXIETY DISORDER; D-CYCLOSERINE; POTENTIATED STARTLE; PROLONGED EXPOSURE; TREATMENT RESPONSE AB Baseline cue-dependent physiological reactivity may serve as an objective measure of posttraumatic stress disorder (PTSD) symptoms. Additionally, prior animal model and psychological studies would suggest that subjects with greatest symptoms at baseline may have the greatest violation of expectancy to danger when undergoing exposure based psychotherapy; thus treatment approaches which enhanced the learning under these conditions would be optimal for those with maximal baseline cue-dependent reactivity. However methods to study this hypothesis objectively are lacking. Virtual reality (VR) methodologies have been successfully employed as an enhanced form of imaginal prolonged exposure therapy for the treatment of PTSD. Our goal was to examine the predictive nature of initial psychophysiological (e.g., startle, skin conductance, heart rate) and stress hormone responses (e.g., cortisol) during presentation of VR-based combat-related stimuli on PTSD treatment outcome. Combat veterans with PTSD underwent 6 weeks of VR exposure therapy combined with either D-cycloserine (DCS), alprazolam (ALP), or placebo (PBO). In the DCS group, startle response to VR scenes prior to initiation of treatment accounted for 76% of the variance in CAPS change scores, p < 0.001, in that higher responses predicted greater changes in symptom severity over time. Additionally, baseline cortisol reactivity was inversely associated with treatment response in the ALP group, p = 0.04. We propose that baseline cue-activated physiological measures will be sensitive to predicting patients' level of response to exposure therapy, in particular in the presence of enhancement (e.g., DCS). Published by Elsevier Ltd. C1 [Norrholm, Seth Davin; Duncan, Erica; Bradley, Bekh] Mental Hlth Serv, Atlanta Vet Affairs Med Ctr, Washington, DC USA. [Norrholm, Seth Davin; Jovanovic, Tanja; Gerardi, Maryrose; Breazeale, Kathryn G.; Davis, Michael; Duncan, Erica; Ressler, Kerry J.; Bradley, Bekh; Rothbaum, Barbara O.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA. [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Rizzo, Albert] Univ So Calif, Dept Psychiat, Inst Creat Technol, Los Angeles, CA 90089 USA. [Rizzo, Albert] Univ So Calif, Sch Gerontol, Los Angeles, CA 90089 USA. [Tuerk, Peter W.] Ralph H Johnson VAMC, Charleston, SC USA. [Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Norrholm, SD (reprint author), Atlanta VAMC, MHSL 116A,1670 Clairmont Rd, Decatur, GA 30033 USA. EM seth.norrholm@va.gov FU Department of Defense Clinical Trial Grant [W81XWH-10-1-1045]; NIMH [U19 MH-069056, R01 MH-70880, R01 MH-094757]; Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Grant ("Optimal Dose of Early Intervention to Prevent PTSD"); McCormick Foundation ("BraveHeart: MLB's Welcome Back Veterans Southeast Initiative"); Genentech; Posit Science Corporation; National Institute on Drug Abuse FX Dr. Rothbaum is a consultant to and owns equity in Virtually Better, Inc., which creates virtual environments; however, Virtually Better did not create the Virtual Iraq environment tested in this study; the terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Dr. Rothbaum also has funding from Department of Defense Clinical Trial Grant W81XWH-10-1-1045 ("Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer"), from NIMH grant U19 MH-069056 ("The Emory-MSSM-GSK-NIMH Collaborative Mood and Anxiety Disorders Initiative"), from NIMH grant R01 MH-70880 ("A Cognitive Enhancer May Facilitate Behavioral Exposure Therapy"), from NIMH grant R01 MH-094757 ("Prospective Determination of Psychobiological Risk Factors for Posttraumatic Stress"), from a Brain and Behavior Research Foundation (NARSAD) Distinguished Investigator Grant ("Optimal Dose of Early Intervention to Prevent PTSD"), and from the McCormick Foundation ("BraveHeart: MLB's Welcome Back Veterans Southeast Initiative"); she has received previous support from Transcept Pharmaceuticals ("A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Low-Dose Ondansetron for Adjunctive Therapy in Adult Patients With Obsessive Compulsive Disorder Who Have Not Adequately Responded to Treatment With a Serotonin Reuptake Inhibitor"); she receives royalties from Oxford University Press, Guilford, American Psychiatric Publishing, and Emory University; and she received one advisory board payment from Genentech. Drs. Ressler and Davis are founding members of Extinction Pharmaceuticals/Therapade Technologies, which seek to develop D-cycloserine and other compounds for use to augment the effectiveness of psychotherapy; they have received no equity or income from this relationship within the last 3 years; the terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Dr. Duncan has received research support from the Posit Science Corporation and grant support from NIMH and the National Institute on Drug Abuse. The remaining authors report no financial relationships with commercial interests. NR 80 TC 2 Z9 2 U1 18 U2 37 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD JUL PY 2016 VL 82 BP 28 EP 37 DI 10.1016/j.brat.2016.05.002 PG 10 WC Psychology, Clinical SC Psychology GA DP0PD UT WOS:000378190800004 PM 27183343 ER PT J AU Philip, NS Dunner, DL Dowd, SM Aaronson, ST Brock, DG Carpenter, LL Demitrack, MA Hovav, S Janicak, PG George, MS AF Philip, Noah S. Dunner, David L. Dowd, Sheila M. Aaronson, Scott T. Brock, David G. Carpenter, Linda L. Demitrack, Mark A. Hovav, Sarit Janicak, Philip G. George, Mark S. TI Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study (vol 9, pg 251, 2016) SO BRAIN STIMULATION LA English DT Correction C1 [Philip, Noah S.] Providence VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI USA. [Philip, Noah S.; Carpenter, Linda L.] Butler Hosp, Providence, RI 02906 USA. [Dunner, David L.] Ctr Anxiety & Depress, Mercer Isl, WA USA. [Dowd, Sheila M.; Janicak, Philip G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Aaronson, Scott T.] Sheppard Pratt Hlth Syst, Baltimore, MD USA. [Brock, David G.; Demitrack, Mark A.] Neuronetics Inc, Malvern, PA USA. [Hovav, Sarit] Univ Nebraska Med Ctr, Creighton Univ, Omaha, NE USA. [George, Mark S.] Med Univ S Carolina, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Philip, NS (reprint author), Providence VA Med Ctr, Ctr Neurorestorat & Neurotechnol, Providence, RI USA.; Philip, NS (reprint author), Butler Hosp, Providence, RI 02906 USA. EM Noah_Philip@Brown.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD JUL-AUG PY 2016 VL 9 IS 4 BP 639 EP 639 DI 10.1016/j.brs.2016.03.015 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DO8VL UT WOS:000378063000027 ER PT J AU Ge, L AF Ge, Liang TI A Characteristic-Based Constitutive Law for Dispersed Fibers SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article ID HUMAN CORONARY-ARTERIES; MECHANICAL-PROPERTIES; COLLAGENOUS TISSUES; WALL MECHANICS; MODEL; ORIENTATION; KINEMATICS; FRAMEWORK; ANEURYSMS; BEHAVIOR AB Biological tissues are typically constituted of dispersed fibers. Modeling the constitutive laws of such tissues remains a challenge. Direct integration over all fibers is considered to be accurate but requires very expensive numerical integration. A general structure tensor (GST) model was previously developed to bypass this costly numerical integration step, but there are concerns about the model's accuracy. Here we estimate the approximation error of the GST model. We further reveal that the GST model ignores strain energy induced by shearing motions. Subsequently, we propose a new characteristic-based constitutive law to better approximate the direct integration model. The new model is very cost-effective and closely approximates the "true" strain energy as calculated by the direct integration when stress-strain nonlinearity or fiber dispersion angle is small. C1 [Ge, Liang] Univ Calif San Francisco, Dept Surg, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. RP Ge, L (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. EM liang.ge@va.gov FU National Institutes of Health [R01 HL119857, HL063348, HL128278, HL118627] FX This work was supported by the National Institutes of Health (Grant Nos. R01 HL119857, HL063348, HL128278, and HL118627). NR 30 TC 0 Z9 0 U1 1 U2 2 PU ASME PI NEW YORK PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 EI 1528-8951 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD JUL PY 2016 VL 138 IS 7 AR 071006-1 DI 10.1115/1.4033517 PG 8 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA DP1FV UT WOS:000378236800011 ER PT J AU Aldridge, MD Epstein, AJ Brody, AA Lee, EJ Cherlin, E Bradley, EH AF Aldridge, Melissa D. Epstein, Andrew J. Brody, Abraham A. Lee, Eric J. Cherlin, Emily Bradley, Elizabeth H. TI The Impact of Reported Hospice Preferred Practices on Hospital Utilization at the End of Life SO MEDICAL CARE LA English DT Article DE end of life care; hospice preferred practices; end of life hospitalization; transitions; end of life intensity; hospice ID OF-LIFE; UNITED-STATES; PROFIT STATUS; FOR-PROFIT; CARE; CANCER; MEDICARE; HEALTH; PLACE; INTENSITY AB Background: The Affordable Care Act requires hospices to report quality measures across a range of processes and practices. Yet uncertainties exist regarding the impact of hospice preferred practices on patient outcomes. Objective: Assess the impact of 6 hospice preferred practices and hospice organizational characteristics on hospital utilization and death using the first national data on hospice preferred practices. Design: Longitudinal cohort study (2008-2011) of Medicare beneficiaries (N = 149,814) newly enrolled in a national random sample of hospices (N = 577) from the National Hospice Survey (84% response rate) and followed until death. Outcome Measures: The proportion of patients at each hospice admitted to the hospital, emergency department (ED), and intensive care unit (ICU), and who died in the hospital after hospice enrollment. Results: Hospices that reported assessing patient preferences for site of death at admission had lower odds of being in the highest quartile for hospital death (AOR = 0.36; 95% CI, 0.14-0.93) and ED visits (AOR = 0.27; 95% CI, 0.10-0.76). Hospices that reported more frequently monitoring symptoms had lower odds of being in the highest quartile for ICU stays (AOR = 0.48; 95% CI, 0.24-0.94). In adjusted analyses, a higher proportion of patients at for-profit compared with nonprofit hospices experienced a hospital admission (15.3% vs. 10.9%, P < 0.001), ED visit (21.8% vs. 15.6%, P < 0.001), and ICU stay (5.1% vs. 3.0%, P < 0.001). Conclusions: Hospitalization of patients following hospice enrollment varies substantially across hospices. Two of the 6 preferred practices examined were associated with hospitalization rates and for-profit hospices had persistently high hospitalization rates regardless of preferred practice implementation. C1 [Aldridge, Melissa D.; Lee, Eric J.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,POB 1070, New York, NY 10029 USA. [Aldridge, Melissa D.; Brody, Abraham A.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Epstein, Andrew J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Brody, Abraham A.] NYU, Coll Nursing, New York, NY USA. [Cherlin, Emily; Bradley, Elizabeth H.] Yale Univ, Dept Epidemiol & Publ Hlth, Sch Publ Hlth, New Haven, CT 06520 USA. RP Aldridge, MD (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,POB 1070, New York, NY 10029 USA. EM melissa.aldridge@mssm.edu OI Brody, Abraham/0000-0002-3405-7043 FU National Institute of Nursing Research [5R01NR013499]; National Cancer Institute [1R01CA116398-01A2]; John D. Thompson Foundation FX Supported by the National Institute of Nursing Research 5R01NR013499 (M.D.A.), the National Cancer Institute 1R01CA116398-01A2 (E.B.), and the John D. Thompson Foundation (E.B.). NR 36 TC 1 Z9 1 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUL PY 2016 VL 54 IS 7 BP 657 EP 663 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DO8UW UT WOS:000378061000004 PM 27299952 ER PT J AU Wang, SY Aldridge, MD Gross, CP Canavan, M Cherlin, E Johnson-Hurzeler, R Bradley, E AF Wang, Shi-Yi Aldridge, Melissa D. Gross, Cary P. Canavan, Maureen Cherlin, Emily Johnson-Hurzeler, Rosemary Bradley, Elizabeth TI End-of-Life Care Intensity and Hospice Use A Regional-level Analysis SO MEDICAL CARE LA English DT Article DE Medicare hospice benefit; health services research; geographic variation; end-of-life care ID MEDICARE BENEFICIARIES; LAST YEAR; HEALTH; DEATH; PATTERNS; FAMILIES; PAYMENTS; QUALITY; CANCER; TRENDS AB Objectives: Despite increased hospice use over the last decade, end-of-life care intensity continues to increase. To understand this puzzle, we sought to examine regional variation in intensive end-of life care and determine its associations with hospice use patterns. Methods: Using Medicare claims for decedents aged 66 years and above in 2011, we assessed end-of-life care intensity in the last 6 months of life across hospital referral regions (HRRs) as measured by proportion of decedents per HRR experiencing hospitalization, emergency department use, intensive care unit (ICU) admission, and number of days spent in hospital (hospital-days) and ICU (ICU days). Using hierarchical generalized linear models and adjusting for patient characteristics, we examined whether these measures were associated with overall hospice use, very short (<7 d), medium (8-179 d), or very long (> 180 d) hospice enrollment, focusing on very short stay. Results: End-of-life care intensity and hospice use patterns varied substantially across HRRs. Regional-level end-of-life care intensity was positively correlated with very short hospice enrollment. Comparing HRRs in the highest versus the lowest quintiles of intensity in end-of-life care, regions with more intensive care had higher rates of very short hospice enrollment, with adjusted odds ratios (AOR) 1.14 [99% confidence interval (CI), 1.04-1.25] for hospitalization; AOR, 1.23 (CI, 1.12-1.36) for emergency department use; AOR, 1.25 (CI, 1.14-1.38) for ICU admission; AOR, 1.10 (CI, 1.00-1.21) for hospital -days; and AOR, 1.20 (CI, 1.08-1.32) for ICU-days. Conclusions: At the regional level, increased end-of-life care intensity was consistently associated with very short hospice use. C1 [Wang, Shi-Yi] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St, New Haven, CT 06520 USA. [Wang, Shi-Yi; Gross, Cary P.] Yale Canc Ctr, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT USA. [Wang, Shi-Yi; Gross, Cary P.] Yale Univ, Sch Med, 60 Coll St, New Haven, CT 06520 USA. [Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Aldridge, Melissa D.] James J Peters VA Med Ctr, Bronx, NY USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, Sect Gen Internal Med, 60 Coll St, New Haven, CT 06520 USA. [Canavan, Maureen; Cherlin, Emily; Bradley, Elizabeth] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 60 Coll St, New Haven, CT 06520 USA. [Johnson-Hurzeler, Rosemary] John D Thompson Hosp Inst Educ Training & Res Inc, Branford, CT USA. RP Wang, SY (reprint author), Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St, New Haven, CT 06520 USA. EM shiyi.wang@yale.edu FU National Cancer Institute [1R01CA116398-01A2]; John D. Thompson Foundation; National Institute of Nursing Research [1R01NR013499-01A1]; Agency for Healthcare Research and Quality [1K01HS023900-01] FX Supported by grant 1R01CA116398-01A2 from the National Cancer Institute (M.D.A. and E.B.); the John D. Thompson Foundation (E.B.); grant 1R01NR013499-01A1 from the National Institute of Nursing Research (M.D.A.); and grant 1K01HS023900-01 from the Agency for Healthcare Research and Quality (S.-Y.W.). These sources of support were not used for any portion of the current manuscript. NR 20 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUL PY 2016 VL 54 IS 7 BP 672 EP 678 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DO8UW UT WOS:000378061000006 PM 27111747 ER PT J AU Lo-Ciganic, WH Gellad, WF Huskamp, HA Choudhry, NK Chang, CCH Zhang, R Jones, BL Guclu, H Richards-Shubik, S Donohue, JM AF Lo-Ciganic, Wei-Hsuan Gellad, Walid F. Huskamp, Haiden A. Choudhry, Niteesh K. Chang, Chung-Chou H. Zhang, Ruoxin Jones, Bobby L. Guclu, Hasan Richards-Shubik, Seth Donohue, Julie M. TI Who Were the Early Adopters of Dabigatran? An Application of Group-based Trajectory Models SO MEDICAL CARE LA English DT Article DE anticoagulants; direct thrombin inhibitor; physician prescribing behavior; dabigatran; group-based trajectory models ID NONVALVULAR ATRIAL-FIBRILLATION; GENERAL-PRACTITIONERS; ORAL ANTICOAGULANTS; UNITED-STATES; RISK-FACTORS; DRUGS; PHYSICIAN; ADOPTION; WARFARIN; PATIENT AB Background: Variation in physician adoption of new medications is poorly understood. Traditional approaches (eg, measuring time to first prescription) may mask substantial heterogeneity in technology adoption. Objective: Apply group-based trajectory models to examine the physician adoption of dabigratran, a novel anticoagulant. Methods: A retrospective cohort study using prescribing data from IMS Xponenem on all Pennsylvania physicians regularly prescribing anticoagulants (n=3911) and data on their characteristics from the American Medical Association Masterfile. We examined time to first dabigatran prescription and group-based trajectory models to identify adoption trajectories in the first 15 months. Factors associated with rapid adoption were examined using multivariate logistic regressions. Outcomes: Trajectories of monthly share of oral anticoagulant prescriptions for dabigatran. Results: We identified 5 distinct adoption trajectories: 3.7% rapidly and extensively adopted dabigatran (adopting in <3 mo with 45% of prescriptions) and 13.4% were rapid and moderate adopters (< 3 mo with 20% share). Two groups accounting for 21.6% and 16.1% of physicians, respectively, were slower to adopt (6-10 mo post-introduction) and dabigatran accounted for <10% share. Nearly half (45.2%) of anticoagulant prescribers did not adopt dabigatran. Cardiologists were much more likely than primary care physicians to rapidly adopt [odds ratio (OR) = 12.2; 95% confidence interval (CI), 9.27-16.1] as were younger prescribers (age 36-45 y: OR= 1.49, 95% CI, 1.13-1.95; age 46-55: OR = 1.34, 95% CI, 1.07-1.69 vs. >55 y). Conclusions: Trajectories of physician adoption of dabigatran were highly variable with significant differences across specialties. Heterogeneity in physician adoption has potential implications for the cost and effectiveness of treatment. C1 [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Drachman Hall Room B307E,1295N Martin Ave, Tucson, AZ 85719 USA. [Lo-Ciganic, Wei-Hsuan; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Hlth Policy Inst, Pittsburgh, PA 15260 USA. [Gellad, Walid F.; Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Huskamp, Haiden A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA. [Choudhry, Niteesh K.] Harvard Univ, Sch Med, Boston, MA USA. [Chang, Chung-Chou H.] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Zhang, Ruoxin; Guclu, Hasan] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA. [Jones, Bobby L.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. [Guclu, Hasan] Istanbul Medeniyet Univ, Stat Dept, Istanbul, Turkey. [Richards-Shubik, Seth] Lehigh Univ, Coll Business & Econ, Dept Econ, Bethlehem, PA 18015 USA. RP Lo-Ciganic, WH (reprint author), Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Drachman Hall Room B307E,1295N Martin Ave, Tucson, AZ 85719 USA. EM lociganic@pharmacy.arizona.edu FU National Heart, Lung, and Blood Institute [R01HL119246]; University of Pittsburgh Health Policy Institute, Center for Pharmaceutical Policy and Prescribing FX Supported by National Heart, Lung, and Blood Institute (R01HL119246). W.-H.L.-C. was funded by a post-doctoral fellowship through the University of Pittsburgh Health Policy Institute, Center for Pharmaceutical Policy and Prescribing. NR 49 TC 1 Z9 1 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUL PY 2016 VL 54 IS 7 BP 725 EP 732 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DO8UW UT WOS:000378061000013 PM 27116109 ER PT J AU Balaratnasingam, C Freund, KB Tan, AM Mrejen, S Hunyor, AP Keegan, DJ Dansingani, KK Dayani, PN Barbazetto, IA Sarraf, D Jampol, LM Yannuzzi, LA AF Balaratnasingam, Chandrakumar Freund, K. Bailey Tan, Anna M. Mrejen, Sarah Hunyor, Alex P. Keegan, David J. Dansingani, Kunal K. Dayani, Pouya N. Barbazetto, Irene A. Sarraf, David Jampol, Lee M. Yannuzzi, Lawrence A. TI Bullous Variant of Central Serous Chorioretinopathy Expansion of Phenotypic Features Using Multimethod Imaging SO OPHTHALMOLOGY LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; RETINAL-DETACHMENT; ORGAN-TRANSPLANTATION; NEOVASCULARIZATION; THERAPY AB Purpose: To define the phenotypic characteristics of the bullous variant of central serous chorioretinopathy (CSC) using multimethod imaging. Design: Retrospective, observational case series. Participants: Twenty-one eyes of 14 patients with bullous retinal detachment resulting from CSC (bullous CSC group) and 122 eyes of 84 patients with chronic CSC without bullous retinal detachment (nonbullous CSC group). Methods: We performed a retrospective review of clinical and multimethod imaging data of patients who sought treatment from the authors with bullous retinal detachment resulting from CSC between January 2010 and November 2015. Multimethod imaging comprised color photography, fluorescein angiography, fundus autofluorescence, and high-resolution optical coherence tomography. Consecutive cases of chronic CSC without bullous retinal detachment, seen during the same period, comprised a comparative group. Main Outcome Measures: Qualitative and quantitative characteristics of the choroid, retinal pigment epithelium, and retina were compared between the 2 groups. Results: Mean age of the bullous CSC group was 53.8 years. There was no difference in age, visual acuity, corticosteroid use, or the proportion of white patients and men between the 2 groups (all P > 0.132). Peripheral nonperfusion occurred only in eyes with bullous retinal detachment (38% of cases). Retinal pigment epithelial tears were seen in 95% of eyes in the bullous group and none of the eyes in the nonbullous CSC group. The bullous CSC group demonstrated a greater number of pigment epithelial detachments (PEDs) and more eyes demonstrated PEDs with internal hyperreflectivity (both P < 0.016). Mean subfoveal choroidal thickness in the bullous CSC group (463.1 +/- 83.1 mm) was not different compared with that of the nonbullous CSC group (400.6 +/- 100.6 mm; P = 0.993). More eyes in the bullous CSC group demonstrated hyperreflectivity around large choroidal vessels and at the level of the choriocapillaris on OCT (P < 0.001). Retinal folds and subretinal fibrin were identified in a greater proportion of eyes in the bullous CSC group (both P < 0.001). Conclusions: Bullous retinal detachment is a rare manifestation of chronic CSC and is characterized by a unique constellation of phenotypic and multimethod imaging features. (C) 2016 by the American Academy of Ophthalmology. C1 [Balaratnasingam, Chandrakumar; Freund, K. Bailey; Tan, Anna M.; Mrejen, Sarah; Dansingani, Kunal K.; Barbazetto, Irene A.; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10022 USA. [Balaratnasingam, Chandrakumar; Freund, K. Bailey; Tan, Anna M.; Mrejen, Sarah; Dansingani, Kunal K.; Barbazetto, Irene A.; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA. [Balaratnasingam, Chandrakumar; Freund, K. Bailey; Barbazetto, Irene A.] NYU, Dept Ophthalmol, Sch Med, 550 1St Ave, New York, NY 10016 USA. [Balaratnasingam, Chandrakumar] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia. [Hunyor, Alex P.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2006, Australia. [Hunyor, Alex P.] Retina Associates, Chatswood, NSW, Australia. [Keegan, David J.] Mater Misericordiae Univ Hosp, Dublin, Ireland. [Dayani, Pouya N.] Retina Vitreous Associated Med Grp, Los Angeles, CA USA. [Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90024 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Jampol, Lee M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Yannuzzi, LA (reprint author), Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10022 USA. EM layannuzzi@gmail.com OI Freund, K. Bailey/0000-0002-7888-9773 FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York; Macula Foundation, Inc, New York, New York; RANZCO Eye Foundation, NSW, Australia FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York; The Macula Foundation, Inc, New York, New York; and RANZCO Eye Foundation, NSW, Australia. The funding organizations had no role in the design or conduct of this research. NR 36 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD JUL PY 2016 VL 123 IS 7 BP 1541 EP 1552 DI 10.1016/j.ophtha.2016.03.017 PG 12 WC Ophthalmology SC Ophthalmology GA DP3KC UT WOS:000378391100026 PM 27084564 ER PT J AU Taber, DJ Hamedi, M Rodrigue, JR Gebregziabher, MG Srinivas, TR Baliga, PK Egede, LE AF Taber, David J. Hamedi, Mahsa Rodrigue, James R. Gebregziabher, Mulugeta G. Srinivas, Titte R. Baliga, Prabhakar K. Egede, Leonard E. TI Quantifying the Race Stratified Impact of Socioeconomics on Graft Outcomes in Kidney Transplant Recipients SO TRANSPLANTATION LA English DT Article ID SOCIAL ADAPTABILITY INDEX; RENAL-ALLOGRAFT RECIPIENTS; EVENT TIME DATA; RACIAL DISPARITIES; AFRICAN-AMERICANS; RISK-FACTORS; SURVIVAL; DISEASE; MORTALITY; PREDICTS AB Background. Socioeconomic status (SES) is a significant determinant of health outcomes and may be an important component of the causal chain surrounding racial disparities in kidney transplantation. The social adaptability index (SAI) is a validated and quantifiable measure of SES, with a lack of studies analyzing this measure longitudinally or between races. Methods. Longitudinal cohort study in adult kidney transplantation transplanted at a single-center between 2005 and 2012. The SAI score includes 5 domains (employment, education, marital status, substance abuse and income), each with a minimum of 0 and maximum of 3 for an aggregate of 0 to 15 (higher score. better SES). Results. One thousand one hundred seventy-one patients were included; 624 (53%) were African American (AA) and 547 were non-AA. African Americans had significantly lower mean baseline SAI scores (AAs 6.5 vs non-AAs 7.8; P < 0.001). Cox regression analysis demonstrated that there was no association between baseline SAI and acute rejection in non-AAs (hazard ratio [HR], 0.92; 95% confidence interval [95% CI], 0.81-1.05), whereas it was a significant predictor of acute rejection in AAs (HR, 0.89; 95% CI, 0.80-0.99). Similarly, a 2-stage approach to joint modelling of time to graft loss and longitudinal SAI did not predict graft loss in non-AAs (HR, 1.01; 95% CI, 0.28-3.62), whereas it was a significant predictor of graft loss in AAs (HR, 0.23; 95% CI, 0.06-0.93). Conclusions. After controlling for confounders, SAI scores were associated with a lower risk of acute rejection and graft loss in AA kidney transplant recipients, whereas neither baseline nor follow-up SAI predicted outcomes in non-AA kidney transplant recipients. C1 [Taber, David J.; Baliga, Prabhakar K.] Med Univ S Carolina, Coll Med, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Taber, David J.] Ralph H Johnson VAMC, Dept Pharm, Charleston, SC USA. [Hamedi, Mahsa] Med Univ S Carolina, Coll Med, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Rodrigue, James R.] Harvard Univ, Beth Israel Deaconess Med Ctr, Transplant Inst, Sch Med, Boston, MA 02215 USA. [Gebregziabher, Mulugeta G.] Med Univ S Carolina, Dept Publ Hlth Sci, Coll Med, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Srinivas, Titte R.] Med Univ S Carolina, Div Transplant Nephrol, Coll Med, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VAMC, Vet Affairs HSR&D Hlth Equ & Rural Outreach In, Charleston, SC USA. RP Taber, DJ (reprint author), Med Univ S Carolina, Div Transplant Surg, 96 Jonathan Lucas St,MSC 611, Charleston, SC 29425 USA. EM taberd@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU NIDDK NIH HHS [K23 DK099440, T35 DK007431] NR 35 TC 5 Z9 5 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD JUL PY 2016 VL 100 IS 7 BP 1550 EP 1557 DI 10.1097/TP.0000000000000931 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DP0AG UT WOS:000378149300030 PM 26425875 ER PT J AU Gleason, CE Dowling, NM Benton, SF Kaseroff, A Gunn, W Edwards, DF AF Gleason, Carey E. Dowling, N. Maritza Benton, Susan Flowers Kaseroff, Ashley Gunn, Wade Edwards, Dorothy Farrar TI Common Sense Model Factors Affecting African Americans' Willingness to Consult a Healthcare Provider Regarding Symptoms of Mild Cognitive Impairment SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE timely diagnosis; mild cognitive impairment; common sense model; health disparities; structural equation modeling ID ALZHEIMERS ASSOCIATION WORKGROUPS; NURSING-HOME PLACEMENT; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DEMENTIA DIAGNOSIS; TIMELY DIAGNOSIS; OLDER-ADULTS; DISEASE; SAMPLE; REPRESENTATIONS AB Objective: Although at increased risk for developing dementia compared with white patients, older African Americans are diagnosed later in the course of dementia. Using the common sense model (CSM) of illness perception, we sought to clarify processes promoting timely diagnosis of mild cognitive impairment (MCI) for African American patients. Design, Setting, Participants: In-person, cross-sectional survey data were obtained from 187 African American (mean age: 60.44 years). Data were collected at social and health-focused community events in three southern Wisconsin cities. Measurements: The survey represented a compilation of published surveys querying CSM constructs focused on early detection of memory disorders, and willingness to discuss concerns about memory loss with healthcare providers. Derived CSM variables measuring perceived causes, consequences, and controllability of MCI were included in a structural equation model predicting the primary outcome: Willingness to discuss symptoms of MCI with a provider. Results: Two CSM factors influenced willingness to discuss symptoms of MCI with providers: Anticipation of beneficial consequences and perception of low harm associated with an MCI diagnosis predicted participants' willingness to discuss concerns about cognitive changes. No association was found between perceived controllability and causes of MCI, and willingness to discuss symptoms with providers. Conclusions: These data suggest that allaying concerns about the deleterious effects of a diagnosis, and raising awareness of potential benefits, could influence an African American patient's willingness to discuss symptoms of MCI with a provider. The findings offer guidance to designers of culturally congruent MCI education materials, and healthcare providers caring for older African Americans. C1 [Gleason, Carey E.; Dowling, N. Maritza; Edwards, Dorothy Farrar] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Gleason, Carey E.; Edwards, Dorothy Farrar] Univ Wisconsin, Dept Med, Div Geriatr, Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Benton, Susan Flowers; Kaseroff, Ashley] Univ Wisconsin, Sch Educ, Dept Rehabil Psychol & Special Educ, Madison, WI USA. [Gunn, Wade; Edwards, Dorothy Farrar] Univ Wisconsin, Sch Educ, Kinesiol & Occupat Therapy, Madison, WI USA. RP Gleason, CE (reprint author), William S Middleton Mem VA Hosp, 2500 Overlook Terrace,GRECC 11G,D4223, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu RI Edwards, Dorothy/L-6720-2016 FU Wisconsin ADRC Minority Recruitment Satellite Program; Education, Clinical, and Administrative Cores of the Wisconsin ADRC; Community-Academic Aging Research Network (CAARN); Wisconsin Partnership Program of the University of Wisconsin School of Medicine and Public Health; Wisconsin Alzheimer's Disease Research Center (ADRC; NIH-NIA) [P50-AG033514]; Madison VA Geriatric Research, Education, and Clinical Center (GRECC); Community-Academic Aging Research Network; National Institute on Aging [RC4AG038175]; NCATS via the UW Clinical and Translational Science Award (CTSA) [UL1TR000427] FX The authors acknowledge support from the Wisconsin ADRC Minority Recruitment Satellite Program, and the Education, Clinical, and Administrative Cores of the Wisconsin ADRC, and the Community-Academic Aging Research Network (CAARN). Finally, we are grateful for the dedication and support from our Community Partners, Charlestine Daniel, MS, and Paul Rusk from the Alzheimer's and Dementia Alliance; staff Ornella Hills, and Tyrone Dickson from the Wisconsin Alzheimer's Disease Research Center; project assistants Paul Izard and Brianna Harris; and our participants.; This project was funded by the Wisconsin Partnership Program of the University of Wisconsin School of Medicine and Public Health and the Wisconsin Alzheimer's Disease Research Center (ADRC; NIH-NIA grant P50-AG033514), and supported by the Madison VA Geriatric Research, Education, and Clinical Center (GRECC), and the Community-Academic Aging Research Network, award number RC4AG038175 from the National Institute on Aging. Additional support was provided by NCATS grant UL1TR000427 (PI: M. Drezner) via the UW Clinical and Translational Science Award (CTSA) and resources and use of facilities at the UW School of Medicine and Public Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging, the National Institutes of Health, or any other funding agency. This is GRECC manuscript number: 2014-027. NR 34 TC 0 Z9 0 U1 5 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUL PY 2016 VL 24 IS 7 BP 537 EP 546 DI 10.1016/j.jagp.2015.08.005 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DO6BH UT WOS:000377866800005 PM 26809602 ER PT J AU Becerra, MB Becerra, BJ Hassija, CM Safdar, N AF Becerra, Monideepa B. Becerra, Benjamin J. Hassija, Christina M. Safdar, Nasia TI Unmet Mental Healthcare Need and Suicidal Ideation Among US Veterans SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSION; WAR VETERANS; RISK; AFGHANISTAN; SERVICES; DEATH; IRAQ; ASSOCIATION; SYMPTOMS AB Introduction: Suicide prevention remains a national priority, especially among vulnerable populations. With increasing trends in suicide among Veterans, understanding the underlying factors associated with such an outcome is imperative. In this study, the association between unmet mental healthcare need and suicidal ideation among U.S. Veterans was evaluated. Methods: The National Survey on Drug Use and Health, 2008-2013, was used to identify those with mental illness, resulting in a total sample of 2,015 Veterans. Data were analyzed in July 2015. Survey-weighted descriptive and logistic regression analyses were conducted with p<0.05 used to establish significance. Results: Sixteen percent of Veterans reported unmet mental healthcare need and 18% had past-year suicidal ideation. After adjusting for confounders, unmet mental healthcare need was associated with increased likelihood of suicidal ideation (AOR=4.11) in the study population. Other characteristics, such as participating in a governmental assistance program and alcohol dependency in the past year, demonstrated 66% and 103% increased odds of suicidal ideation, respectively. Conclusions: Unmet mental healthcare need is a critical aspect of suicidal ideation among Veterans. Improved access to care for such at-risk populations through means of integrated care is needed to ensure reduced burden of suicide among Veterans. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Becerra, Monideepa B.] Calif State Univ San Bernardino, Dept Hlth Sci & Human Ecol, San Bernardino, CA 92407 USA. [Becerra, Monideepa B.; Becerra, Benjamin J.; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Becerra, Benjamin J.] Loma Linda Univ, Sch Allied Hlth Profess, Loma Linda, CA 92350 USA. [Hassija, Christina M.] Calif State Univ San Bernardino, Dept Psychol, San Bernardino, CA 92407 USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI USA. RP Becerra, MB (reprint author), 5500 Univ Pkwy, San Bernardino, CA 92407 USA. EM mbecerra@csusb.edu FU U.S. Department of Veterans Affairs (VA) Merit grant; VA National Center for Patient Safety FX Nasia Safdar is supported by a U.S. Department of Veterans Affairs (VA) Merit grant and by the VA National Center for Patient Safety. NR 33 TC 0 Z9 0 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUL PY 2016 VL 51 IS 1 BP 90 EP 94 DI 10.1016/j.amepre.2016.01.015 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DO8VR UT WOS:000378063800013 PM 26927480 ER PT J AU Coulon, SM Monroe, CM West, DS AF Coulon, Sandra M. Monroe, Courtney M. West, Delia S. TI A Systematic, Multi-domain Review of Mobile Smartphone Apps for Evidence-Based Stress Management SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEALTH-CARE PROVIDERS; GOOD MEDICAL-ETHICS; SOCIOECONOMIC-STATUS; MENTAL-HEALTH; ANXIETY; DEPRESSION; ADHERENCE; QUALITY; TOOLS; PRINCIPLES AB Contex: Chronic stress presents a growing, pervasive burden in healthcare, and mobile smartphone applications (apps) have the potential to deliver evidence-based stress management strategies. This review identified and evaluated stress management apps across domains of (1) evidence-based content; (2) transparency in app development; and (3) functionality of the app interface. Evidence acquisition: The iOS App Store was systematically searched. Apps with descriptions indicating that they targeted the intended audience and included evidence-related terminology, at least one evidence-based stress management strategy, and behavior change components were downloaded and evaluated by two independent raters across the three domains of evidence-based content, transparency, and functionality. Evidence synthesis: A total of 902 apps were identified based on 21 searches. Of these, 60 met study criteria and were downloaded and evaluated between April and June 2015. Twenty (33%) ultimately did not deliver an evidence-based strategy. Of the delivered strategies, the most common were mindfulness and meditation (73%) and diaphragmatic breathing (25%). On average, apps addressed half of the transparency criteria, and nearly all (85%) were acceptable across usability criteria. A total of 32 apps included both evidence-based content and exhibited no problems with usability or functionality; apps affiliated with a non-profit, research-engaged institution comprised 31% of these. Conclusions: This review evaluated 60 iOS apps for stress management across domains of evidence-based content, transparency, and functionality; these apps have the potential to effectively supplement medical care. Findings further indicate that a comprehensive, multi-domain approach can distinguish apps that use evidence-based strategies from those that do not. (C) 2016 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Coulon, Sandra M.; Monroe, Courtney M.; West, Delia S.] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. RP Coulon, SM (reprint author), Ralph H Johnson Vet Affairs Med Ctr, 109 Bee St,Mental Hlth Serv 116, Charleston, SC 29401 USA. EM coulon@mailbox.sc.edu FU Technology Center to Promote Healthy Lifestyles (TecHealth), Arnold School of Public Health, University of South Carolina FX This work was funded in part by the Technology Center to Promote Healthy Lifestyles (TecHealth), Arnold School of Public Health, University of South Carolina. SMC, CMM, and DSW contributed to the manuscript in its conception and writing. SMC and DSW developed the app screening and evaluation methods. SMC and CMM each evaluated the downloaded stress management apps. SMC screened app descriptions and CMM assessed the reliability of the screening. SMC developed data collection tools; extracted, cleaned, and analyzed the data; and wrote the initial drafts of the manuscript. CMM and DSW revised the drafts. The work was performed while SMC was at the University of South Carolina. All authors had full access to all of the data, and read and approved the final manuscript. NR 49 TC 1 Z9 1 U1 10 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUL PY 2016 VL 51 IS 1 BP 95 EP 105 DI 10.1016/j.amepre.2016.01.026 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DO8VR UT WOS:000378063800014 PM 26993534 ER PT J AU Pham, H Hui, HX Morvaridi, S Cai, JN Zhang, SQ Tan, J Wu, V Levin, N Knudsen, B Goddard, WA Pandol, SJ Abrol, R AF Hung Pham Hui, Hongxiang Morvaridi, Susan Cai, Jiena Zhang, Sanqi Tan, Jun Wu, Vincent Levin, Nancy Knudsen, Beatrice Goddard, William A., III Pandol, Stephen J. Abrol, Ravinder TI A bitter pill for type 2 diabetes? The activation of bitter taste receptor TAS2R38 can stimulate GLP-1 release from enteroendocrine L-cells SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE GLP-1; Diabetes; Enteroendocrine L-cell; GPCR structure prediction; Virtual ligand screening; Gut receptors ID CHAIN FATTY-ACID; DIPEPTIDYL-PEPTIDASE-IV; GLUCAGON-LIKE PEPTIDE-1; GASTROINTESTINAL-TRACT; STC-1 CELLS; HUMAN COLON; GUT; SECRETION; EXPRESSION; GUSTDUCIN AB The bitter taste receptor TAS2R38 is a G protein coupled receptor (GPCR) that has been found in many extra-oral locations like the gastrointestinal (GI) system, respiratory system, and brain, though its function at these locations is only beginning to be understood. To probe the receptor's potential metabolic role, immunohistochemistry of human ileum tissues was performed, which showed that the receptor was co-localized with glucagon-like peptide 1 (GLP-1) in L-cells. In a previous study, we had modeled the structure of this receptor for its many taste-variant haplotypes (Tan et al. 2011), including the taster haplotype PAV. The structure of this haplotype was then used in a virtual ligand screening pipeline using a collection of similar to 2.5 million purchasable molecules from the ZINC database. Three compounds (Z7, Z3, Z1) were purchased from the top hits and tested along with PTU (known TAS2R38 agonist) in in vitro and in vivo assays. The dose-response study of the effect of PTU and Z7 on GLP-1 release using wild-type and TAS2R38 knockout HuTu-80 cells showed that the receptor TAS2R38 plays a major role in GLP-1 release due to these molecules. In vivo studies of PTU and the three compounds showed that they each increase GLP-1 release. PTU was also chemical linked to cellulose to slow its absorption and when tested in vivo, it showed an enhanced and prolonged GLP-1 release. These results suggest that the GI lumen location of TAS2R38 on the L-cell makes it a relatively safe drug target as systemic absorption is not needed for a TAS2R38 agonist drug to effect GLP-1 release. (C) 2016 Elsevier Inc. All rights reserved. C1 [Hung Pham; Morvaridi, Susan; Knudsen, Beatrice; Pandol, Stephen J.; Abrol, Ravinder] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA. [Hung Pham; Morvaridi, Susan; Knudsen, Beatrice; Pandol, Stephen J.; Abrol, Ravinder] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Hui, Hongxiang; Knudsen, Beatrice; Pandol, Stephen J.; Abrol, Ravinder] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hui, Hongxiang; Cai, Jiena] Southern Med Univ, Int Ctr Metab Dis, Guangzhou, Guangdong, Peoples R China. [Zhang, Sanqi] Xi An Jiao Tong Univ, Dept Med Chem, Xian 710061, Peoples R China. [Tan, Jun; Goddard, William A., III; Abrol, Ravinder] CALTECH, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA. [Tan, Jun] Chongqing Univ, Bioengn Coll, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400030, Peoples R China. [Wu, Vincent; Pandol, Stephen J.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Levin, Nancy; Pandol, Stephen J.; Abrol, Ravinder] GIRx Metab Inc, Los Angeles, CA USA. RP Pandol, SJ; Abrol, R (reprint author), Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA.; Pandol, SJ; Abrol, R (reprint author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Hui, HX; Pandol, SJ; Abrol, R (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Hui, HX (reprint author), Southern Med Univ, Int Ctr Metab Dis, Guangzhou, Guangdong, Peoples R China. EM abrolr@csmc.edu FU Materials and Process Simulation Center at Caltech; Cedars-Sinai Medical Center; NIH [P01CA163200]; Department of Veterans Affairs FX RA acknowledges support in part from Materials and Process Simulation Center at Caltech when this project started and from start-up funds provided by Cedars-Sinai Medical Center. SJP acknowledges partial support for this project from NIH P01CA163200 and the Department of Veterans Affairs. NR 40 TC 2 Z9 2 U1 6 U2 13 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD JUL 1 PY 2016 VL 475 IS 3 BP 295 EP 300 DI 10.1016/j.bbrc.2016.04.149 PG 6 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA DO6XH UT WOS:000377926300009 PM 27208775 ER PT J AU Keay, SK Zhang, CO AF Keay, Susan K. Zhang, Chen-Ou TI Abnormal Akt signalling in bladder epithelial cell explants from patients with interstitial cystitis/bladder pain syndrome can be induced by antiproliferative factor treatment of normal bladder cells SO BJU INTERNATIONAL LA English DT Article DE bladder epithelial cells; Akt; Wnt/frizzled; antiproliferative factor; interstitial cystitis/bladder pain syndrome ID EPIDERMAL-GROWTH-FACTOR; SYNDROME/INTERSTITIAL CYSTITIS; GENE-EXPRESSION; URINE MARKERS; PATHWAY; PROTEIN; CANCER; DIFFERENTIATION; UROTHELIUM; ACTIVATION AB Objectives To determine whether protein kinase B (Akt) signalling and secretion of specific downstream effector proteins are abnormal in specific cell fractions of bladder epithelial cells from patients with interstitial cystitis/bladder pain syndrome (IC/BPS), as explanted bladder epithelial cells from patients with IC/BPS produce a frizzled 8-related glycopeptide antiproliferative factor (APF) that inhibits normal bladder epithelial cell proliferation and expression of several proteins known to be regulated by Akt signalling. A related secondary objective was to determine whether treatment of normal bladder epithelial cells with active synthetic asialo-antiproliferative factor (as-APF) induces similar changes in Akt signalling and specific downstream effector proteins/mRNAs. Patients and Methods Cell proteins were extracted into four subcellular fractions from primary bladder epithelial explants of six patients who fulfilled modified National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) criteria for IC/BPS and six age-and gender-matched controls. Total and/or phosphorylated cellular Akt, glycogen synthase kinase 3 beta (GSK3 beta), and beta-catenin; total cellular JunB; and secreted matrix metalloproteinase 2 (MMP2) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) levels were determined by Western blot. MMP2, JunB, p53, uroplakin 3 (UPK3), and beta-actin mRNAs were quantified by quantitative reverse transcriptase-polymerase chain reaction. Akt activity was determined by nonradioactive assay. Results IC/BPS cells had lower Akt activity, along with lower Akt ser473- and GSK3 beta ser9-phosphorylation and higher beta-catenin ser33,37/thr41-phosphorylation in specific fractions as compared with matched control cells. IC/BPS explants also had evidence of additional downstream abnormalities compared with control cells, including lower nuclear JunB; lower secreted MMP2 and HB-EGF; plus lower MMP2, JunB, and UPK3 mRNAs but higher p53 mRNA relative to beta-actin. Each of these IC/BPS cell abnormalities was also induced in normal cells by as-APF. Conclusion These findings indicate that IC/BPS cells have abnormal Akt activity with downstream protein expression abnormalities including decreased MMP2 and HB-EGF secretion. They also support the hypothesis that APF plays a role in the pathogenesis of IC/BPS via its effects on cell Akt signalling and HB-EGF production. C1 [Keay, Susan K.] Univ Maryland, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA. [Keay, Susan K.] US Dept Vet Affairs, Med Ctr, Med Serv, Baltimore, MD USA. [Zhang, Chen-Ou] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA. RP Keay, SK (reprint author), Vet Affairs Maryland Hlth Care Syst, Room 3B-184,10 N Green St, Baltimore, MD 21201 USA. EM susan.keay2@va.gov FU Office of Research and Development (Medical Research Service), Department of Veterans Affairs; NIH [R01 DK52596] FX The authors thank Toby Chai, MD, for providing the patient biopsies from which the explanted cells were originally propagated. This work was supported by the Office of Research and Development (Medical Research Service), Department of Veterans Affairs, and by NIH R01 DK52596. Chen-Ou Zhang carried out major experiments and prepared the figures for these studies. Susan K. Keay designed the research, supervised performance of the experiments and interpretation of the data, and prepared the manuscript, which was reviewed by Chen-Ou Zhang before submission. NR 54 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1464-4096 EI 1464-410X J9 BJU INT JI BJU Int. PD JUL PY 2016 VL 118 IS 1 BP 161 EP 172 DI 10.1111/bju.13457 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA DO8OK UT WOS:000378042700026 PM 26919663 ER PT J AU Kagan, VE Jiang, J Huang, Z Tyurina, YY Desbourdes, C Cottet-Rousselle, C Dar, HH Verma, M Tyurin, VA Kapralov, AA Cheikhi, A Mao, G Stolz, D Croix, CMS Watkins, S Shen, Z Li, Y Greenberg, ML Tokarska-Schlattner, M Boissan, M Lacombe, ML Epand, RM Chu, CT Mallampalli, RK Bayir, H Schlattner, U AF Kagan, V. E. Jiang, J. Huang, Z. Tyurina, Y. Y. Desbourdes, C. Cottet-Rousselle, C. Dar, H. H. Verma, M. Tyurin, V. A. Kapralov, A. A. Cheikhi, A. Mao, G. Stolz, D. Croix, C. M. St. Watkins, S. Shen, Z. Li, Y. Greenberg, M. L. Tokarska-Schlattner, M. Boissan, M. Lacombe, M-L Epand, R. M. Chu, C. T. Mallampalli, R. K. Bayir, H. Schlattner, U. TI NDPK-D (NM23-H4)-mediated externalization of cardiolipin enables elimination of depolarized mitochondria by mitophagy SO CELL DEATH AND DIFFERENTIATION LA English DT Article ID NUCLEOSIDE-DIPHOSPHATE-KINASE; SACCHAROMYCES-CEREVISIAE; ESSENTIAL REQUIREMENT; SELECTIVE AUTOPHAGY; INTERMEMBRANE SPACE; HEART MITOCHONDRIA; MAMMALIAN-CELLS; FUNCTIONAL-ROLE; MEMBRANE; PROTEIN AB Mitophagy is critical for cell homeostasis. Externalization of the inner mitochondrial membrane phospholipid, cardiolipin (CL), to the surface of the outer mitochondrial membrane (OMM) was identified as a mitophageal signal recognized by the microtubule-associated protein 1 light chain 3. However, the CL-translocating machinery remains unknown. Here we demonstrate that a hexameric intermembrane space protein, NDPK-D (or NM23-H4), binds CL and facilitates its redistribution to the OMM. We found that mitophagy induced by a protonophoric uncoupler, carbonyl cyanide m-chlorophenylhydrazone (CCCP), caused externalization of CL to the surface of mitochondria in murine lung epithelial MLE-12 cells and human cervical adenocarcinoma HeLa cells. RNAi knockdown of endogenous NDPK-D decreased CCCP-induced CL externalization and mitochondrial degradation. A R90D NDPK-D mutant that does not bind CL was inactive in promoting mitophagy. Similarly, rotenone and 6-hydroxydopamine triggered mitophagy in SH-SY5Y cells was also suppressed by knocking down of NDPK-D. In situ proximity ligation assay (PLA) showed that mitophagy-inducing CL-transfer activity of NDPK-D is closely associated with the dynamin-like GTPase OPA1, implicating fission-fusion dynamics in mitophagy regulation. C1 [Kagan, V. E.; Jiang, J.; Huang, Z.; Tyurina, Y. Y.; Dar, H. H.; Tyurin, V. A.; Kapralov, A. A.; Cheikhi, A.; Mao, G.] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Dept Environm & Occupat Hlth, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA. [Desbourdes, C.; Cottet-Rousselle, C.; Tokarska-Schlattner, M.; Schlattner, U.] Univ Grenoble Alpes UJF, LBFA, BP 53, F-38041 Grenoble 9, France. [Desbourdes, C.; Cottet-Rousselle, C.; Tokarska-Schlattner, M.; Schlattner, U.] Univ Grenoble Alpes UJF, SFR Environm & Syst Biol BEeSy, U1055, BP 53, F-38041 Grenoble 9, France. [Desbourdes, C.; Cottet-Rousselle, C.; Tokarska-Schlattner, M.; Schlattner, U.] INSERM, U1055, Grenoble, France. [Verma, M.; Chu, C. T.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Stolz, D.; Croix, C. M. St.; Watkins, S.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA. [Shen, Z.; Li, Y.; Greenberg, M. L.] Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA. [Boissan, M.; Lacombe, M-L] Univ Paris 06, Sorbonne Univ, St Antoine Res Ctr, INSERM,UMR S 938, Paris, France. [Boissan, M.] Hop Tenon, AP HP, Serv Biochim & Hormonol, F-75970 Paris, France. [Epand, R. M.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada. [Mallampalli, R. K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA. [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Bayir, H.] Univ Pittsburgh, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA. RP Kagan, VE (reprint author), Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Dept Environm & Occupat Hlth, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA.; Schlattner, U (reprint author), Univ Grenoble Alpes UJF, LBFA, BP 53, F-38041 Grenoble 9, France.; Schlattner, U (reprint author), Univ Grenoble Alpes UJF, SFR Environm & Syst Biol BEeSy, U1055, BP 53, F-38041 Grenoble 9, France.; Bayir, H (reprint author), Univ Pittsburgh, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM Kagan@pitt.edu; hub22@pitt.edu; uwe.schlattner@ujf-grenoble.fr OI Kapralov, Oleksandr/0000-0002-3006-916X; Tyurin, Vladimir/0000-0002-3474-1697 FU National Institutes of Health [P01HL114453, U19AI068021, NS076511, NS061817, ES020693, NS065789, AG026389, HL117880]; National Institute of Occupational Safety and Health [OH008282]; Human Frontier Science Program [HFSP-RGP0013/2014]; Barth Syndrome Foundation of Canada; Barth Syndrome Foundation of United States; Fondation pour la Recherche Medicale (FRM) [DPM20121125557]; CMIRA Explo'ra doc fellowship of the Region Rhone Alpes; GEFLUC; Natural Sciences and Engineering Council of Canada [9848] FX This study was supported in part by the National Institutes of Health P01HL114453, U19AI068021, NS076511, NS061817, ES020693, NS065789, AG026389, HL117880, National Institute of Occupational Safety and Health OH008282, Human Frontier Science Program HFSP-RGP0013/2014, and the Barth Syndrome Foundation of Canada and United States. This work was also supported by the Fondation pour la Recherche Medicale (FRM; DPM20121125557), a CMIRA Explo'ra doc fellowship of the Region Rhone Alpes, GEFLUC and the Natural Sciences and Engineering Council of Canada, grant 9848. NR 63 TC 7 Z9 7 U1 4 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1350-9047 EI 1476-5403 J9 CELL DEATH DIFFER JI Cell Death Differ. PD JUL PY 2016 VL 23 IS 7 BP 1140 EP 1151 DI 10.1038/cdd.2015.160 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DO6YN UT WOS:000377929500006 PM 26742431 ER PT J AU Patel, NR Tamara, LA Lee, H AF Patel, Niraj R. Tamara, Luis A. Lee, Ho TI Tc-99m Sestamibi Thyroid Scan in Amiodarone-Induced Thyrotoxicosis Type I SO CLINICAL NUCLEAR MEDICINE LA English DT Editorial Material DE Tc-99m sestamibi; amiodarone-induced thyrotoxicosis; Graves disease; hyperthyroidism AB Amiodarone-induced thyrotoxicosis (AIT) type I describes inducement of clinical hyperthyroidism by excessive thyroidal iodine in the setting of latent Graves disease, and therapy differs from that used for AIT type II. A 65-year-old man previously on amiodarone for atrial fibrillation developed clinical hyperthyroidism. Diagnosis of AIT was made, but the type was not clear. Tc-99m sestamibi thyroid scan showed diffusely increased uptake and retention in an enlarged thyroid gland, a pattern consistent with AIT type I. Methimazole was initiated and controlled the thyrotoxicosis. I-123 iodide thyroid scan and uptake study performed later was consistent with Graves disease. C1 Baylor Coll Med, Div Nucl Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Patel, NR (reprint author), 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Niraj.Patel2@va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0363-9762 EI 1536-0229 J9 CLIN NUCL MED JI Clin. Nucl. Med. PD JUL PY 2016 VL 41 IS 7 BP 566 EP 567 DI 10.1097/RLU.0000000000001243 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DO3QJ UT WOS:000377695800018 PM 27163459 ER PT J AU Salinsky, M Storzbach, D Goy, E Kellogg, M Boudreau, E AF Salinsky, Martin Storzbach, Daniel Goy, Elizabeth Kellogg, Marissa Boudreau, Eilis TI Health care utilization following diagnosis of psychogenic nonepileptic seizures SO EPILEPSY & BEHAVIOR LA English DT Article DE Psychogenic nonepileptic seizures; Epilepsy; Health care utilization; Veterans ID VIDEO-EEG; VETERANS; EPILEPSY; ADMISSION AB Objectives: The long-term outcome of patients with psychogenic nonepileptic seizures (PNES) is of importance given the disabling symptoms and tendency to affect patients early in their productive years. Health care utilization (HCU) is an important outcome measure reflecting overall health status and costs. There is little information regarding long-term HCU following diagnosis of PNES. Methods: We retrospectively reviewed records of Veterans diagnosed with PNES during epilepsy monitoring unit (EMU) evaluation. For the three-year period following diagnosis of PNES, we reviewed emergency department (ED) visits, hospitalizations, outpatient clinic visits, and radiology procedures. We compared the three years following PNES diagnosis with the three years preceding diagnosis. We also compared patients with PNES and patients with epileptic seizures (ES). Results: Emergency department visits and hospitalizations were more frequent in patients with PNES compared with those in patients with ES (p = 0.01). There was no overall improvement in HCU during the three-year interval following diagnosis of PNES. A transient decrease during the year following diagnosis was not sustained over three-year follow-up. Pain complaints rather than seizures were the most common reason for presentation, whereas the opposite was true for patients with ES (p < 0.01). There was a sharp decrease in neurology outpatient visits (p < 0.001) and a decrease in primary care visits (p < 0.05) after PNES was diagnosed. Total outpatient visits were unchanged. Conclusions: Overall HCU did not improve during the three years following diagnosis of PNES, compared with three years preceding diagnosis. The results add to studies documenting poor seizure outcomes following diagnosis of PNES and underscore the need for more effective and comprehensive treatments, addressing comorbid symptoms. Published by Elsevier Inc. C1 [Salinsky, Martin; Boudreau, Eilis] Portland VA Med Ctr, Portland, OR USA. [Salinsky, Martin; Storzbach, Daniel; Goy, Elizabeth; Kellogg, Marissa; Boudreau, Eilis] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Kellogg, Marissa] Stanford Univ, Med Ctr, Dept Neurol, Stanford, CA 94305 USA. RP Salinsky, M (reprint author), Portland VAMC Epilepsy Ctr, 3710 SW US Vet Hosp Rd P3ECOE, Portland, OR 97239 USA. EM Salinsky@ohsu.edu FU Department of Veterans Affairs [5101CX00071] FX This study was supported by grant # 5101CX00071 from the Department of Veterans Affairs. NR 30 TC 0 Z9 0 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 EI 1525-5069 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD JUL PY 2016 VL 60 BP 107 EP 111 DI 10.1016/j.yebeh.2016.04.007 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA DO7WA UT WOS:000377992500018 PM 27206227 ER PT J AU Andrikopoulou, E AlJaroudi, WA Farag, A Lester, D Patel, H Iskandrian, AE Hage, FG AF Andrikopoulou, Efstathia AlJaroudi, Wael A. Farag, Ayman Lester, Davis Patel, Hiren Iskandrian, Ami E. Hage, Fadi G. TI The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Article DE Heart rate response; Regadenoson; Vasodilator stress; Myocardial perfusion imaging; Coronary artery disease ID POSITRON-EMISSION-TOMOGRAPHY; CORONARY-ARTERY-DISEASE; DIABETES-MELLITUS; ASYMPTOMATIC PATIENTS; NUCLEAR CARDIOLOGY; DEFECT SIZE; STRESS; ADENOSINE; RISK; ISCHEMIA AB The heart rate response (HRR, percentage change from baseline) to regadenoson during myocardial perfusion imaging (MPI) can provide incremental prognostic value in patients with known or suspected coronary artery disease. Our purpose was to evaluate the variability and prognostic value of HRR on serial measurements. We studied 648 consecutive patients (61 +/- 11 years, 48 % with diabetes) who underwent two regadenoson MPI studies (16 +/- 9 months between studies). HRR < 30 % was defined as abnormal. All-cause mortality was determined by chart review and verified using the US Social Security Death Master File. HRR was well correlated between the two studies (intraclass correlation coefficient 0.72, 95 % CI 0.67 -aEuro parts per thousand 0.76) with no systematic bias (mean difference 0.88 %, p = 0.2) or proportional bias (p = 0.5) by Bland-Altman analysis in all patients and in those with normal MPI on both studies. Of the 308 patients (48 %) with normal baseline HRR (HRR-1), 33 % had developed a blunted HRR on the second MPI study (HRR-2). Older age, male gender, end-stage renal disease, and abnormal baseline left ventricular ejection fraction were independent predictors of a new-onset abnormal HRR. During a mean follow-up of 2.4 +/- 1.2 years, 55 patients (8.5 %) died. Patients with a blunted HRR-1 had increased mortality risk irrespective of their HRR-2 (p = 0.9, log-rank test). Among patients with normal HRR-1, a blunted HRR-2 was an independent predictor of all-cause mortality beyond clinical and traditional MPI data (hazard ratio 2.83, 95 % CI 1.14 -aEuro parts per thousand 7.03). Finally, patients with a normal HRR-1 and HRR-2 had the lowest event rate, while those with any abnormal HRR had an increased risk of death (hazard ratio 2.5, 95 % CI 1.2 -aEuro parts per thousand 5.4). There was good correlation in the HRR to regadenoson on serial measurements without systematic or proportional biases. Patients with consistently normal HRR had the best prognosis. C1 [Andrikopoulou, Efstathia; Farag, Ayman; Lester, Davis; Patel, Hiren; Iskandrian, Ami E.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Andrikopoulou, Efstathia; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL 35233 USA. [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.; Hage, FG (reprint author), Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL 35233 USA.; Hage, FG (reprint author), Univ Alabama Birmingham, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 32 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD JUL PY 2016 VL 43 IS 8 BP 1493 EP 1502 DI 10.1007/s00259-016-3380-y PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DO8AS UT WOS:000378005000015 PM 27079736 ER PT J AU Rosenfeld, EA Marx, J Terry, MA Stall, R Pallatino, C Borrero, S Miller, E AF Rosenfeld, Elian A. Marx, John Terry, Martha A. Stall, Ronald Pallatino, Chelsea Borrero, Sonya Miller, Elizabeth TI Intimate partner violence, partner notification, and expedited partner therapy: a qualitative study SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Intimate partner violence; sexually transmitted infections; treatment; sexual violence; partner notification; expedited partner therapy ID SEXUALLY-TRANSMITTED INFECTIONS; FEMALE ADOLESCENTS; DOMESTIC VIOLENCE; SERVICES; GIRLS; RISK AB Over one-third of women experience intimate partner violence (IPV) in their lifetime. IPV increases the risk of infection and re-infection with sexually transmitted infections (STIs). The extent to which health care providers consider IPV when recommending partner notification and expedited partner therapy is unknown. The objective of this qualitative study was to understand health care providers' views on IPV and STIs when recommending partner treatment to patients with chlamydia. Using a purposive sampling strategy to include health care providers who treat young women at risk for chlamydia, 23 semi-structured, in-depth interviews were conducted. While some health care providers expressed concern for their patients' safety and believed assessing for IPV was needed before provision of expedited partner therapy, nearly a third had not considered the links between IPV and STIs. Strategies used by health care providers to assess for IPV did not include inquiry about specific behaviours related to IPV, STI risk, and sexual coercion. Many health care providers understand the risk for IPV in the setting of STI treatment, yet a significant portion of those interviewed failed to recognise the link between IPV and STIs. Provider education is necessary to increase knowledge and implement more effective inquiry and counselling about IPV to more safely recommend expedited partner therapy. C1 [Rosenfeld, Elian A.] VA Pittsburgh Healthcare Syst, VA Womens Hlth, Univ Dr C 151C Bldg 30, Pittsburgh, PA 15240 USA. [Marx, John; Terry, Martha A.; Stall, Ronald; Pallatino, Chelsea] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Borrero, Sonya] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Miller, Elizabeth] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Adolescent Med, Pittsburgh, PA 15213 USA. RP Rosenfeld, EA (reprint author), VA Pittsburgh Healthcare Syst, VA Womens Hlth, Univ Dr C 151C Bldg 30, Pittsburgh, PA 15240 USA. EM elian.rosenfeld@va.gov FU University of Pittsburgh FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study received funding from the Myrna Silverman Award and William Green Award from the University of Pittsburgh. NR 26 TC 1 Z9 1 U1 4 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD JUL PY 2016 VL 27 IS 8 BP 656 EP 661 DI 10.1177/0956462415591938 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DO4RZ UT WOS:000377772100009 PM 26088259 ER PT J AU Katagira, W Walter, ND Den Boon, S Kalema, N Ayakaka, I Vittinghoff, E Worodria, W Cattamanchi, A Huang, L Davis, JL AF Katagira, Winceslaus Walter, Nicholas D. Den Boon, Saskia Kalema, Nelson Ayakaka, Irene Vittinghoff, Eric Worodria, William Cattamanchi, Adithya Huang, Laurence Davis, John Lucian TI Empiric TB Treatment of Severely Ill Patients With HIV and Presumed Pulmonary TB Improves Survival SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE pulmonary tuberculosis; treatment; danger signs; survival; HIV; sub-Saharan Africa ID SMEAR-NEGATIVE TUBERCULOSIS; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; IMMUNODEFICIENCY; DIAGNOSIS; ALGORITHM; COHORT; UGANDA AB Rationale: In 2007, World Health Organization (WHO) issued emergency recommendations on empiric treatment of sputum acid-fast bacillus smear-negative patients with possible tuberculosis (TB) in HIV-prevalent areas, and called for operational research to evaluate their effectiveness. We sought to determine if early, empiric TB treatment of possible TB patients with abnormal chest radiography or severe illness as suggested by the 2007 WHO guidelines, is associated with improved survival. Methods: We prospectively enrolled consecutive HIV-seropositive inpatients at Mulago Hospital in Kampala, Uganda, from 2007 to 2011 with cough for >= 2 weeks. We retrospectively examined the effect of empiric TB treatment before discharge on 8-week survival among those with and without a WHO-defined "danger sign," including fever >39 degrees C, tachycardia >120 beats per minute, or tachypnea >30 breaths per minute. We modeled the interaction between empiric TB treatment and danger signs, and their combined effect on 8-week survival, and adjusted for relevant covariates. Results: Among 631 sputum smear-negative patients, 322 (51%) had danger signs. Cumulative 8-week survival of patients with danger signs was significantly higher with empiric TB treatment (80%) than without treatment (64%, P < 0.001). After adjusting for duration of cough and concurrent hypoxemia, patients with danger signs who received empiric TB treatment had a 44% reduction in 8-week mortality (risk ratio 0.56, 95% confidence interval: 0.34-0.91, P = 0.020). Conclusions: Empiric TB treatment of HIV-seropositive, smear-negative, presumed pulmonary TB patients with 1 or more danger signs is associated with improved 8-week survival. Enhanced implementation of the 2007 WHO empiric treatment recommendations should be encouraged whenever and wherever rapid and highly sensitive diagnostic tests for TB are unavailable. C1 [Katagira, Winceslaus; Walter, Nicholas D.; Den Boon, Saskia; Kalema, Nelson; Ayakaka, Irene; Worodria, William; Cattamanchi, Adithya] Makerere Univ Univ Calif San Francisco MU UCSF Re, Kampala, Uganda. [Walter, Nicholas D.; Huang, Laurence] Denver Vet Affairs Med Ctr, Pulm Sect, Denver, CO USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Worodria, William] Makerere Univ, Dept Med, Coll Hlth Sci, Kampala, Uganda. [Cattamanchi, Adithya] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA. [Huang, Laurence] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA USA. [Davis, John Lucian] Yale Univ, Dept Epidemiol Microbial Dis, Sch Publ Hlth, New Haven, CT USA. [Davis, John Lucian] Yale Univ, Sch Med, Pulm Crit Care & Sleep Med Sect, New Haven, CT USA. RP Davis, JL (reprint author), Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis, 60 Coll St, New Haven, CT 06520 USA. EM Lucian.Davis@yale.edu FU NIH [K24HL087713, R01HL090335, K23HL094141, R21AI101714]; NIH/NHLBI [K12 HL090147-04, CDA1IK2CX000914-01A1, K23AI080147] FX Supported by NIH K24HL087713 (L.H.), R01HL090335 (L.H.), K23HL094141 (A.C.), NIH/NHLBI K12 HL090147-04 (N.D.W.), CDA1IK2CX000914-01A1 (N.D.W.), K23AI080147 (J.L.D.), and NIH R21AI101714 (J.L.D.). NR 27 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUL 1 PY 2016 VL 72 IS 3 BP 297 EP 303 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DO8UM UT WOS:000378059800016 PM 26918546 ER PT J AU Graber, CJ Goetz, MB AF Graber, Christopher J. Goetz, Matthew Bidwell TI Next steps for antimicrobial stewardship SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material C1 [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. EM matthew.goetz@va.gov NR 8 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD JUL PY 2016 VL 16 IS 7 BP 764 EP 765 DI 10.1016/S1473-3099(16)00099-2 PG 3 WC Infectious Diseases SC Infectious Diseases GA DP2LH UT WOS:000378319600012 PM 26947616 ER PT J AU Watkins, LE Han, SZ Harpaz-Rotem, I Mota, NP Southwick, SM Krystal, JH Gelernter, J Pietrzak, RH AF Watkins, Laura E. Han, Shizhong Harpaz-Rotem, Ilan Mota, Natalie P. Southwick, Steven M. Krystal, John H. Gelernter, Joel Pietrzak, Robert H. TI FKBP5 polymorphisms, childhood abuse, and PTSD symptoms: Results from the National Health and Resilience in Veterans Study SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Posttraumatic stress disorder; FKBP5; Childhood abuse; Gene environment interaction; HPA axis ID POSTTRAUMATIC-STRESS-DISORDER; DSM-IV; ASSOCIATION; VALIDATION; CHILDREN; ADULTS; RISK AB Polymorphisms in the FK506 Binding Protein 5 (FKBP5) gene may interact with childhood abuse to increase risk of developing posttraumatic stress disorder (PTSD) symptoms. The objective of this study was to examine the relationship of four previously identified FKBP5 putative risk SNP5 (rs9296158, rs3800373, rs1360780, rs947008), childhood abuse, and lifetime PTSD symptoms, including contemporary phenotypic models of PTSD symptoms, in two nationally representative samples of European-American (EA) U.S. military veterans. The main sample included 1585 EA veterans who participated in the National Health and Resilience in Veterans Study (NHRVS), and the replication sample included 577 EA veterans who participated in a second baseline cohort survey of the NHRVS. Outcome variables were lifetime PTSD symptom severity and a 4-factor phenotypic model of PTSD symptoms that included re-experiencing, avoidance, emotional numbing/negative cognitions and mood, and hyperarousal/alterations in arousal and reactivity symptoms. Results revealed that the four FKBP5 SNPs were associated with PTSD symptom severity in both samples (p values ranged from 0.001 to 0.012). Further, SNP rs9470080 in the main sample, and all four SNP5 in the replication sample interacted with childhood abuse to predict PTSD severity (p values ranged from 0.002 to 0.006). In both samples, all four FKBP5 SNPs predicted hyperarousal/alterations in arousal and reactivity (p values ranged from <0.001 to 0.002). Results of this study suggest that FKBP5 polymorphisms, directly and interactively with childhood abuse, predict severity of lifetime PTSD symptoms, most notably hyperarousal symptoms, in two nationally representative samples of EA veterans. They further indicate that FKBP5 polymorphisms and childhood abuse may contribute to vulnerability for PTSD symptoms and may be most strongly associated with trauma-related hyperarousal symptoms that comprise this phenotype. Published by Elsevier Ltd. C1 [Watkins, Laura E.; Harpaz-Rotem, Ilan; Southwick, Steven M.; Krystal, John H.; Gelernter, Joel; Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT USA. [Watkins, Laura E.; Harpaz-Rotem, Ilan; Southwick, Steven M.; Krystal, John H.; Gelernter, Joel; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave 151D, New Haven, CT USA. [Han, Shizhong] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA. [Mota, Natalie P.] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada. RP Watkins, LE (reprint author), US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, VA Connecticut Healthcare Syst, West Haven, CT USA.; Watkins, LE (reprint author), Yale Univ, Sch Med, Dept Psychiat, 950 Campbell Ave 151D, New Haven, CT USA. EM laura.watkins@yale.edu FU U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder FX The National Health and Resilience in Veterans Study was supported by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. NR 27 TC 3 Z9 3 U1 5 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD JUL PY 2016 VL 69 BP 98 EP 105 DI 10.1016/j.psyneuen.2016.04.001 PG 8 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA DO4CH UT WOS:000377728900012 PM 27078785 ER PT J AU Fan, VS Gylys-Colwell, I Locke, E Sumino, K Nguyen, HQ Thomas, RM Magzamen, S AF Fan, Vincent S. Gylys-Colwell, Ina Locke, Emily Sumino, Kaharu Nguyen, Huong Q. Thomas, Rachel M. Magzamen, Sheryl TI Overuse of short-acting beta-agonist bronchodilators in COPD during periods of clinical stability SO RESPIRATORY MEDICINE LA English DT Article DE Pulmonary disease, chronic obstructive; Metered dose inhaler; Telemedicine; Adrenergic beta-2 receptor agonists; Adherence; Medication ID CALCULATING CORRELATION-COEFFICIENTS; OBSTRUCTIVE PULMONARY-DISEASE; LUNG-DISEASE; AUDIT-C; ASTHMA; EXACERBATIONS; QUESTIONNAIRE; VALIDATION; KNOWLEDGE; DEVICES AB Background: Overuse of short-acting beta-agonists (SABA) is described in asthma, but little is known about overuse of SABA in chronic obstructive pulmonary disease (COPD). Methods: Prospective 3-month cohort study of patients with moderate-to-severe COPD who were provided a portable electronic inhaler sensor to monitor daily SABA use. Subjects wore a pedometer for 3 seven-day periods and were asked to complete a daily diary of symptoms and inhaler use. Overuse was defined as >8 actuations of their SABA per day while clinically stable. Results: Among 32 participants, 15 overused their SABA inhaler at least once (mean 8.6 +/- 5.0 puffs/day), and 6 overused their inhaler more than 50% of monitored days. Compared to those with no overuse, overusers had greater dyspnea (modified Medical Research Council Dyspnea Scale: 2.7 vs. 1.9, p = 0.02), were more likely to use home oxygen (67% vs. 29%, p = 0.04), and were more likely to be on maximal inhaled therapy (long-acting beta-agonist, long-acting antimuscarinic agent, and an inhaled steroid: 40% vs. 6%, p = 0.03), and most had completed pulmonary rehabilitation (67% vs. 0%, p < 0.001). However, 27% of overusers of SABA were not on guideline-concordant COPD therapy. Conclusions: Overuse of SABA was common and associated with increased disease severity and symptoms, even though overusers were on more COPD-related inhalers and more had completed pulmonary rehabilitation. More research is needed to understand factors associated with inhaler overuse and how to improve correct inhaler use. Published by Elsevier Ltd. C1 [Fan, Vincent S.; Gylys-Colwell, Ina; Locke, Emily; Thomas, Rachel M.] VA Puget Sound Hlth Care Syst, S-152,1660 S Columbian Way, Seattle, WA 98108 USA. [Fan, Vincent S.] Univ Washington, Seattle, WA 98195 USA. [Sumino, Kaharu] St Louis VA Med Ctr, St Louis, MO USA. [Sumino, Kaharu] Washington Univ, Sch Med, St Louis, MO USA. [Nguyen, Huong Q.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Magzamen, Sheryl] Colorado State Univ, Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. RP Fan, VS (reprint author), VA Puget Sound Hlth Care Syst, S-152,1660 S Columbian Way, Seattle, WA 98108 USA. EM vincent.fan@va.gov FU United States Department of Veterans Affairs Health Services Research and Development (VA HSRD) Program [PPO 10-299] FX Hong T.K. Nguyen and Carol Simons participated in recruitment, data collection and data management for the study. Leslie Taylor and Eric Gunnink assisted with data analysis and assistance with plots. This research was supported by grant from the United States Department of Veterans Affairs Health Services Research and Development (VA HSR&D PPO 10-299) Program. NR 27 TC 0 Z9 0 U1 2 U2 4 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD JUL PY 2016 VL 116 BP 100 EP 106 DI 10.1016/j.rmed.2016.05.011 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA DO6LI UT WOS:000377894500015 PM 27296828 ER PT J AU Millard, SP Shofer, J Braff, D Calkins, M Cadenhead, K Freedman, R Green, MF Greenwood, TA Gur, R Gur, R Lazzeroni, LC Light, GA Olincy, A Nuechterlein, K Seidman, L Siever, L Silverman, J Stone, WS Sprock, J Sugar, CA Swerdlow, NR Tsuang, M Turetsky, B Radant, A Tsuang, D AF Millard, Steven P. Shofer, Jane Braff, David Calkins, Monica Cadenhead, Kristin Freedman, Robert Green, Michael F. Greenwood, Tiffany A. Gur, Raquel Gur, Ruben Lazzeroni, Laura C. Light, Gregory A. Olincy, Ann Nuechterlein, Keith Seidman, Larry Siever, Larry Silverman, Jeremy Stone, William S. Sprock, Joyce Sugar, Catherine A. Swerdlow, Neal R. Tsuang, Ming Turetsky, Bruce Radant, Allen Tsuang, DebbyW. TI Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Endophenotype; Logistic regression; Random forest; Sensitivity; Specificity; Accuracy; ROC curve; Multiple imputation ID ANTISACCADE PERFORMANCE; NEUROPHYSIOLOGICAL ENDOPHENOTYPES; NEUROCOGNITIVE ENDOPHENOTYPES; 1ST-DEGREE RELATIVES; PREPULSE INHIBITION; CONSORTIUM; HERITABILITY; MULTISITE; DISORDER; RISK AB Past studies describe numerous endophenotypes associated with schizophrenia (SZ), but many endophenotypes may overlap in information they provide, and few studies have investigated the utility of a multivariate index to improve discrimination between SZ and healthy community comparison subjects (CCS). We investigated 16 endophenotypes from the first phase of the Consortium on the Genetics of Schizophrenia, a large, multi-site family study, to determine whether a subset could distinguish SZ probands and CCS just as well as using all 16. Participants included 345 SZ probands and 517 CCS with a valid measure for at least one endophenotype. We used both logistic regression and random forest models to choose a subset of endophenotypes, adjusting for age, gender, smoking status, site, parent education, and the reading subtest of the Wide Range Achievement Test. As a sensitivity analysis, we re-fit models using multiple imputations to determine the effect of missing values. We identified four important endophenotypes: antisaccade, Continuous Performance Test-Identical Pairs 3-digit version, California Verbal Learning Test, and emotion identification. The logistic regression model that used just these four endophenotypes produced essentially the same results as the model that used all 16 (84% vs. 85% accuracy). While a subset of endophenotypes cannot replace clinical diagnosis nor encompass the complexity of the disease, it can aid in the design of future endophenotypic and genetic studies by reducing study cost and subject burden, simplifying sample enrichment, and improving the statistical power of locating those genetic regions associated with schizophrenia that may be the easiest to identify initially. Published by Elsevier B.V. C1 [Millard, Steven P.; Shofer, Jane] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Millard, Steven P.; Shofer, Jane; Radant, Allen; Tsuang, DebbyW.] VA Puget Sound Hlth Care Syst, VISN Geriatr Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Braff, David; Light, Gregory A.; Sprock, Joyce] VA San Diego Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 22, San Diego, CA USA. [Braff, David; Cadenhead, Kristin; Greenwood, Tiffany A.; Light, Gregory A.; Sprock, Joyce; Swerdlow, Neal R.; Tsuang, Ming] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Calkins, Monica; Gur, Raquel; Gur, Ruben; Turetsky, Bruce] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Freedman, Robert; Olincy, Ann] Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. [Green, Michael F.; Nuechterlein, Keith; Sugar, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.; Sugar, Catherine A.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Seidman, Larry; Stone, William S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div,Med Sch,Dept Psychiat, Boston, MA 02215 USA. [Siever, Larry; Silverman, Jeremy] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Siever, Larry; Silverman, Jeremy] James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr 3, New York, NY USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA. [Radant, Allen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Tsuang, D (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,GRECC S182, Seattle, WA 98108 USA. EM dwt1@uw.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Greenwood, Tiffany/0000-0002-6080-6503 FU NIMH grants [R01 MH65571, R01 MH042228, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01 MH65578, R01 MH086135, R01 MH65558] FX This material is the result of work supported in part with resources and the use of facilities at the VA Puget Sound Health Care System, Seattle, WA; VA San Diego Healthcare System, San Diego, CA; VA Greater Los Angeles Health Care System, Los Angeles, CA; and James J. Peters VA Medical Center, New York, NY. The study was supported by NIMH grants R01 MH65571, R01 MH042228, R01 MH65588, R01 MH65562, R01 MH65707, R01 MH65554, R01 MH65578, R01 MH086135, and R01 MH65558. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, and the contents do not represent the views of the funders, the U.S. Department of Veterans Affairs, or the United States Government. NR 56 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD JUL PY 2016 VL 174 IS 1-3 BP 1 EP 9 DI 10.1016/j.schres.2016.04.011 PG 9 WC Psychiatry SC Psychiatry GA DO7AO UT WOS:000377934800001 PM 27132484 ER PT J AU El Ayadi, A Zigmond, MJ Smith, AD AF El Ayadi, Amina Zigmond, Michael J. Smith, Amanda D. TI IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases SO EXPERIMENTAL BRAIN RESEARCH LA English DT Article DE 6-OHDA; Akt; CREB; Parkinson's disease; Striatum; ERK1/2; GSK-3Beta ID GROWTH-FACTOR-I; SUBSTANTIA-NIGRA NEURONS; N-TERMINAL TRIPEPTIDE; NEUROTROPHIC FACTOR; CELL-LINE; PARKINSONS-DISEASE; NIGROSTRIATAL DOPAMINE; TYROSINE-HYDROXYLASE; DIFFERENTIAL EXPRESSION; HUMAN BRAIN AB Insulin-like growth factor-1 (IGF-1) is an endogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including an acute animal model of Parkinson's disease (PD). Motor deficits in PD are due largely to the progressive loss of nigrostriatal dopaminergic neurons. Thus, we examined the neuroprotective potential of IGF-1 in a progressive model of dopamine deficiency in which 6-hydroxydopamine (6-OHDA) is infused into the striatum. Rats received intrastriatal IGF-1 (5 or 50 A mu g) 6 h prior to infusion of 4 A mu g 6-OHDA into the same site and were euthanized 1 or 4 weeks later. Both concentrations of IGF-1 protected tyrosine hydroxylase (TH) immunoreactive terminals in striatum at 4 weeks but not at 1 week, indicating that IGF-induced restoration of the dopaminergic phenotype occurred over several weeks. TH-immunoreactive cell loss was only attenuated with 50 A mu g IGF-1. We then examined the effect of striatal IGF-1 on the Ras/ERK1/2 and PI3K/Akt pathways to ascertain whether their activation correlated with IGF-1-induced protection. Striatal and nigral levels of phospho-ERK1/2 were maximal 6 h after IGF-1 infusion and, with the exception of an increase in nigral pERK2 at 48 h, returned to basal levels by 7 days. Phospho-Akt (Ser473) was elevated 6-24 h post-IGF-1 infusion in both striatum and substantia nigra concomitant with inhibition of pro-death GSK-3 beta, a downstream target of Akt. These results suggest that IGF-1 can protect the nigrostriatal pathway in a progressive PD model and that this protection is preceded by activation of key pro-survival signaling cascades. C1 [El Ayadi, Amina; Zigmond, Michael J.; Smith, Amanda D.] Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, 3501 Fifth Ave,7026 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA. [Smith, Amanda D.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [El Ayadi, Amina] Univ Texas Med Branch, Dept Surg, Galveston, TX 77550 USA. RP Smith, AD (reprint author), Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, 3501 Fifth Ave,7026 Biomed Sci Tower 3, Pittsburgh, PA 15261 USA.; Smith, AD (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM smithad@pitt.edu FU Rita Levi-Montalcini Fellowship; Udall Center of Excellence in Parkinson's Disease Research [NS19608]; [NS45698]; [NS070825] FX The study was funded by Career Development Award (NS45698) to ADS, Rita Levi-Montalcini Fellowship to AE and both a Udall Center of Excellence in Parkinson's Disease Research (NS19608) and a Research Project Grant Award (NS070825) to MJZ. NR 57 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0014-4819 EI 1432-1106 J9 EXP BRAIN RES JI Exp. Brain Res. PD JUL PY 2016 VL 234 IS 7 BP 1863 EP 1873 DI 10.1007/s00221-016-4572-1 PG 11 WC Neurosciences SC Neurosciences & Neurology GA DN9ZW UT WOS:000377440200008 ER PT J AU Kang, JJ Liu, IY Wang, MB Srivatsan, ES AF Kang, James J. Liu, Isabelle Y. Wang, Marilene B. Srivatsan, Eri S. TI A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer SO HUMAN GENETICS LA English DT Review ID NF-KAPPA-B; CELL-LINES; GENE; PROTEIN; PATHWAY; DEGRADATION; UBIQUITINATION; CYTOSKELETON; POLYMORPHISM; RESTORATION AB Gigaxonin, the product of GAN gene localized to chromosome 16, is associated with the early onset neuronal degeneration disease giant axonal neuropathy (GAN). Gigaxonin is an E3 ubiquitin ligase adaptor protein involved in intermediate filament processing in neural cells, and vimentin filaments in fibroblasts. Mutations of the gene cause pre-neural filaments to accumulate and form giant axons resulting in the inhibition of neural cell signaling. Analysis of the catalog of somatic mutations in cancer, driver DB and IDGC data portal databases containing 21,000 tumor genomic sequences has identified GAN patient mutations in cancer cell lines and primary tumors. The database search has also shown the presence of identical missense and nonsense gigaxonin mutations in GAN and colon cancer. These mutations frequently occur in the domains associated with protein homodimerization and substrate interaction such as Broad-Complex, Tramtrack and Bric a brac (BTB), BTB associated C-terminal KELCH (BACK), and KELCH repeats. Analysis of the International HapMap Project database containing 1200 normal genomic sequences has identified a single nucleotide polymorphism (SNP), rs2608555, in exon 8 of the gigaxonin sequence. While this SNP is present in > 40 % of Caucasian population, it is present in less than 10 % of Japanese and Chinese populations. Although the role of gigaxonin polymorphism is not yet known, CFTR and MDR1 gene studies have shown that silent mutations play a role in the instability and aberrant splicing and folding of mRNAs. We believe that molecular and functional investigation of gigaxonin mutations including the exon 8 polymorphism could lead to an improved understanding of the relationship between GAN and cancer. C1 [Kang, James J.; Wang, Marilene B.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Liu, Isabelle Y.; Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90073 USA. [Wang, Marilene B.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. RP Srivatsan, ES (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Srivatsan, ES (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. EM esrivats@g.ucla.edu FU VAGLAHS; West Los Angeles Surgical Education Research Center; UCLA Academic Senate Grants; Veterans Administration, Washington, D.C. FX The study was supported by funds from VAGLAHS, West Los Angeles Surgical Education Research Center, UCLA Academic Senate Grants (M. B. Wang), and Merit grant from the Veterans Administration, Washington, D.C. (E. S. Srivatsan). NR 41 TC 2 Z9 2 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 EI 1432-1203 J9 HUM GENET JI Hum. Genet. PD JUL PY 2016 VL 135 IS 7 BP 675 EP 684 DI 10.1007/s00439-016-1659-5 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA DN8XX UT WOS:000377364300001 PM 27023907 ER PT J AU Merluzzi, AP Dean, DC Adluru, N Suryawanshi, GS Okonkwo, OC Oh, JM Hermann, BP Sager, MA Asthana, S Zhang, H Johnson, SC Alexander, AL Bendlin, BB AF Merluzzi, Andrew P. Dean, Douglas C., III Adluru, Nagesh Suryawanshi, Gaurav S. Okonkwo, Ozioma C. Oh, Jennifer M. Hermann, Bruce P. Sager, Mark A. Asthana, Sanjay Zhang, Hui Johnson, Sterling C. Alexander, Andrew L. Bendlin, Barbara B. TI Age-dependent differences in brain tissue microstructure assessed with neurite orientation dispersion and density imaging SO NEUROBIOLOGY OF AGING LA English DT Article DE Aging; Diffusion-weighted imaging; MRI; Neurites; Cognition; Microstructure ID WHITE-MATTER MICROSTRUCTURE; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; DIFFUSION MRI; IN-VIVO; EXECUTIVE FUNCTIONS; CEREBRAL-CORTEX; OLDER-ADULTS; NERVE-FIBERS; DEMENTIA AB Human aging is accompanied by progressive changes in executive function and memory, but the biological mechanisms underlying these phenomena are not fully understood. Using neurite orientation dispersion and density imaging, we sought to examine the relationship between age, cellular microstructure, and neuropsychological scores in 116 late middle-aged, cognitively asymptomatic participants. Results revealed widespread increases in the volume fraction of isotropic diffusion and localized decreases in neurite density in frontal white matter regions with increasing age. In addition, several of these microstructural alterations were associated with poorer performance on tests of memory and executive function. These results suggest that neurite orientation dispersion and density imaging is capable of measuring age-related brain changes and the neural correlates of poorer performance on tests of cognitive functioning, largely in accordance with published histological findings and brain-imaging studies of people of this age range. Ultimately, this study sheds light on the processes underlying normal brain development in adulthood, knowledge that is critical for differentiating healthy aging from changes associated with dementia. (C) 2016 Elsevier Inc. All rights reserved. C1 [Merluzzi, Andrew P.; Okonkwo, Ozioma C.; Oh, Jennifer M.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53705 USA. [Merluzzi, Andrew P.] Univ Wisconsin, Neurosci & Publ Policy Program, Madison, WI USA. [Dean, Douglas C., III; Adluru, Nagesh; Suryawanshi, Gaurav S.; Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. [Okonkwo, Ozioma C.; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. [Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Zhang, Hui] UCL, Dept Comp Sci, London WC1E 6BT, England. [Zhang, Hui] UCL, Ctr Med Image Comp, London, England. [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, 1530 Med Sci Ctr, Madison, WI 53706 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53705 USA. EM bbb@medicine.wisc.edu FU NIH [R01AG037639, AG027161, P50 AG033514]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [T32 HD007489]; UW Institute for Clinical and Translation Research grant [1UL1RR025011]; Waisman Core Grant [P30 HD003352-45]; National Science Foundation Graduate Research Fellowship [DGE-1256259] FX This project was supported by NIH grants R01AG037639 (BBB), AG027161 (SCJ), P50 AG033514 (SA), the Eunice Kennedy Shriver National Institute of Child Health and Human Development T32 HD007489 (DCD), the UW Institute for Clinical and Translation Research grant 1UL1RR025011, the Waisman Core Grant P30 HD003352-45, resources from the Geriatric Research, Education, and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, and the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1256259 (APM). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors(s) and do not necessarily reflect the views of the National Science Foundation. The authors acknowledge the support of researchers and staff at the Waisman Center and the Wisconsin Institute for Medical Research at the University of Wisconsin-Madison, where imaging data were collected. Finally, the authors thank their dedicated participants for their valuable time. NR 77 TC 3 Z9 3 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUL PY 2016 VL 43 BP 79 EP 88 DI 10.1016/j.neurobiolaging.2016.03.026 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA DN7XI UT WOS:000377293100008 PM 27255817 ER PT J AU Marcum, ZA Perera, S Thorpe, JM Switzer, GE Castle, NG Strotmeyer, ES Simonsick, EM Ayonayon, HN Phillips, CL Rubin, S Zucker-Levin, AR Bauer, DC Shorr, RI Kang, YH Gray, SL Hanlon, JT AF Marcum, Zachary A. Perera, Subashan Thorpe, Joshua M. Switzer, Galen E. Castle, Nicholas G. Strotmeyer, Elsa S. Simonsick, Eleanor M. Ayonayon, Hilsa N. Phillips, Caroline L. Rubin, Susan Zucker-Levin, Audrey R. Bauer, Douglas C. Shorr, Ronald I. Kang, Yihuang Gray, Shelly L. Hanlon, Joseph T. CA Hlth ABC Study TI Antidepressant Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE antidepressants; aging; drug-related problems; epidemiology; geriatrics; outcomes research/analysis; pharmacoepidemiology ID BODY-COMPOSITION; RISK-FACTOR; PEOPLE; MEDICATION; ASSOCIATIONS; PERFORMANCE; DEPRESSION; ELDERS; WOMEN AB Background: Few studies have compared the risk of recurrent falls across various antidepressant agents-using detailed dosage and duration data-among community-dwelling older adults, including those who have a history of a fall/fracture. Objective: To examine the association of antidepressant use with recurrent falls, including among those with a history of falls/fractures, in community-dwelling elders. Methods: This was a longitudinal analysis of 2948 participants with data collected via interview at year 1 from the Health, Aging and Body Composition study and followed through year 7 (19972004). Any antidepressant medication use was self-reported at years 1, 2, 3, 5, and 6 and further categorized as (1) selective serotonin reuptake inhibitors (SSRIs), (2) tricyclic antidepressants, and (3) others. Dosage and duration were examined. The outcome was recurrent falls (>= 2) in the ensuing 12-month period following each medication data collection. Results: Using multivariable generalized estimating equations models, we observed a 48% greater likelihood of recurrent falls in antidepressant users compared with nonusers (adjusted odds ratio [AOR] = 1.48; 95% CI = 1.12-1.96). Increased likelihood was also found among those taking SSRIs (AOR = 1.62; 95% CI = 1.15-2.28), with short duration of use (AOR = 1.47; 95% CI = 1.04-2.00), and taking moderate dosages (AOR = 1.59; 95% CI = 1.15-2.18), all compared with no antidepressant use. Stratified analysis revealed an increased likelihood among users with a baseline history of falls/fractures compared with nonusers (AOR = 1.83; 95% CI = 1.28-2.63). Conclusion: Antidepressant use overall, SSRI use, short duration of use, and moderate dosage were associated with recurrent falls. Those with a history of falls/fractures also had an increased likelihood of recurrent falls. C1 [Marcum, Zachary A.; Gray, Shelly L.] Univ Washington, Seattle, WA 98102 USA. [Perera, Subashan; Thorpe, Joshua M.; Switzer, Galen E.; Castle, Nicholas G.; Strotmeyer, Elsa S.; Kang, Yihuang; Hanlon, Joseph T.] Univ Pittsburgh, Pittsburgh, PA USA. [Thorpe, Joshua M.; Switzer, Galen E.; Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Simonsick, Eleanor M.; Phillips, Caroline L.] NIA, Baltimore, MD 21224 USA. [Ayonayon, Hilsa N.; Rubin, Susan; Bauer, Douglas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Zucker-Levin, Audrey R.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Shorr, Ronald I.] Vet Affairs Med Ctr, Gainesville, FL 32608 USA. RP Marcum, ZA (reprint author), Univ Washington, Sch Pharm, Dept Pharm, 1959 NE Pacific St,H375G,Box 357630, Seattle, WA 98102 USA. EM zmarcum@uw.edu FU National Institute on Aging (NIA) [P30AG024827, T32 AG021885, K07AG033174, R01AG028050]; National Institutes of Health; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; National Institute of Nursing Research [R01NR012459] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was primarily supported by National Institute on Aging (NIA) grants and contracts (P30AG024827, T32 AG021885, K07AG033174, R01AG028050). This research was also supported in part by the Intramural Research program of the National Institutes of Health and NIA (N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106) and a National Institute of Nursing Research grant (R01NR012459). NR 27 TC 2 Z9 2 U1 5 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1060-0280 EI 1542-6270 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD JUL PY 2016 VL 50 IS 7 BP 525 EP 533 DI 10.1177/1060028016644466 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DN5JO UT WOS:000377102900001 PM 27066988 ER PT J AU Jeganathan, AN Shanmugan, S Bleier, JIS Hall, GM Paulson, EC AF Jeganathan, Arjun N. Shanmugan, Skandan Bleier, Joshua I. S. Hall, Glenn M. Paulson, Emily C. TI Colorectal Specialization Increases Lymph Node Yield: Evidence from a National Database SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID TOTAL MESORECTAL EXCISION; COLON-CANCER; RECTAL-CANCER; SURVIVAL; SURGERY; ASSOCIATION; POPULATION; FELLOWSHIP; RECURRENCE; RETRIEVAL AB Current guidelines recommend the evaluation of at least 12 lymph nodes (LNs) in the pathologic specimen following surgery for colorectal cancer (CRC). We sought to examine the role of colorectal specialization on nodal identification. We conducted a retrospective cohort study using SEER-Medicare data to examine the association between colorectal specialization and LN identification following surgery for colon and rectal adenocarcinoma between 2001 and 2009. Our dataset included patients > 65 years who underwent surgical resection for CRC. We excluded patients with rectal cancer who had received neoadjuvant therapy. The primary outcome measure was the number of LNs identified in the pathologic specimen following surgery for CRC. Multivariate analysis was used to identify the association between surgical specialization and LN identification in the pathologic specimen. In multivariate analysis, odds of an adequate lymphadenectomy following surgery with a colorectal specialist were 1.32 and 1.41 times greater for colon and rectal cancer, respectively, than following surgery by a general surgeon (p < 0.001). These odds increased to 1.36 and 1.58, respectively, when analysis was limited to board-certified colorectal surgeons. Hospital factors associated with a parts per thousand yen12 LNs identified included high-volume CRC surgery (colon OR 1.84, p < 0.001; rectal OR 1.78, p < 0.001) and NCI-designated Cancer Centers (colon OR 1.75, p < 0.001; rectal OR 1.64; p = 0.007). Colorectal specialization and, in particular, board-certification in colorectal surgery, is significantly associated with increased LN identification following surgery for colon and rectal adenocarcinoma since the adoption of the 12-LN guideline in 2001. C1 [Jeganathan, Arjun N.] Univ Penn, Dept Gen Surg, Philadelphia, PA 19104 USA. [Shanmugan, Skandan; Bleier, Joshua I. S.; Hall, Glenn M.; Paulson, Emily C.] Univ Penn, Dept Gen Surg, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA. [Paulson, Emily C.] Philadelphia VA Med Ctr, Dept Gen Surg, Philadelphia, PA USA. RP Jeganathan, AN (reprint author), Univ Penn, Dept Gen Surg, Philadelphia, PA 19104 USA. EM arjun.jeganathan@uphs.upenn.edu OI Jeganathan, Arjun/0000-0003-1520-1473 NR 21 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD JUL PY 2016 VL 23 IS 7 BP 2258 EP 2265 DI 10.1245/s10434-016-5122-6 PG 8 WC Oncology; Surgery SC Oncology; Surgery GA DN6LL UT WOS:000377186000021 PM 26856723 ER PT J AU John-Baptiste, A Schapira, MM Cravens, C Chambers, JD Neumann, PJ Siegel, J Lawrence, W AF John-Baptiste, Ava Schapira, Marilyn M. Cravens, Catherine Chambers, James D. Neumann, Peter J. Siegel, Joanna Lawrence, William TI The Role of Decision Models in Health Care Policy: A Case Study SO MEDICAL DECISION MAKING LA English DT Article DE health care policy; decision models; policy discussion; colorectal cancer ID COST-EFFECTIVENESS ANALYSIS; MAKERS; IMPACT; TRANSPARENCY; NEED AB Background. In 2009, the Centers for Medicare and Medicaid Services (CMS) underwent a National Coverage Determination on computed tomography colonography (CTC) to screen for colorectal cancer. The Cancer Intervention & Surveillance Network developed decision models to inform this decision. The purpose of our study was to investigate the role of models in this decision. Methods. We performed a descriptive case study. We conducted semistructured telephone interviews with members of the CMS coverage and analysis group (CAG) and Medicare Coverage and Analysis Advisory Committee (MEDCAC) panelists. Informed by previously published literature, we developed a coding scheme to analyze interview transcripts, MEDCAC meeting transcripts, and the final CMS decision memo. Results. Four members of the CAG and 8 MEDCAC panelists were interviewed. The total number of codes across all study documents was 772. We found evidence that decision makers believed in the adequacy of models to inform decision making. In interview transcripts, the code Models Are Adequate to Inform was more frequent than the code Models Are Inadequate to Inform (47 times v. 5). Discussion of model conceptualization dominated the MEDCAC meeting (Model Conceptualization assigned 113 times) and was frequently discussed during interviews (Model Conceptualization assigned 84 times). We also found evidence that the models helped to focus the policy discussion. Across study documents, the codes Focus on Cost, Focus on ClinicalHealth Impact, and Focus on Inadequacy of Evidence Base were assigned 99, 98, and 97 times, respectively. Conclusions. Decision makers involved in the CTC decision believed in the adequacy of models to inform coverage decisions. The model played a role in focusing the CTC coverage policy discussion. C1 [John-Baptiste, Ava; Cravens, Catherine; Siegel, Joanna; Lawrence, William] Agcy Healthcare Res & Qual, Ctr Outcomes & Evidence, Dept Hlth & Human Serv, Rockville, MD USA. [John-Baptiste, Ava] Univ Western Ontario, Dept Anesthesia & Perioperat Med, Schulich Sch Med & Dent, Interfac Program Publ Hlth, London, ON, Canada. [John-Baptiste, Ava] Univ Western Ontario, Dept Epidemiol & Biostat, Schulich Sch Med & Dent, Interfac Program Publ Hlth, London, ON, Canada. [John-Baptiste, Ava] Ctr Med Evidence Decis Integr Clin MEDICI, London, ON, Canada. [John-Baptiste, Ava] Lawson Hlth Res Inst, London, ON, Canada. [John-Baptiste, Ava; Chambers, James D.; Neumann, Peter J.] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Schapira, Marilyn M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Ctr Hlth Equ & Res Program, Philadelphia, PA USA. RP John-Baptiste, A (reprint author), Western Ctr Publ Hlth & Family Med, Rm 4111,1465 Richmond St, London, ON N6G 2M1, Canada. EM ajohnbap@uwo.ca FU Society for Medical Decision Making (SMDM); Agency for Healthcare Research and Policy Health Policy Fellowship in Comparative Effectiveness; Canadian Institutes of Health Research (CIHR) Institute of Nutrition, Metabolism and Diabetes [OTG-88591]; Cancer Care Ontario; Ontario Institute for Cancer Research through Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research through Ministry of Economic Development and Innovation of the Government of Ontario; Canadian Institutes of Health Research through Ministry of Health and Long-Term Care FX This article was presented at the 32nd Annual Meeting of the Society for Medical Decision Making (Toronto, Ontario, Canada, 2010) and the annual symposium of the Canadian Agency for Drugs and Technologies in Health (Vancouver, British Columbia, Canada, 2011). During the conduct of the study, Ava John-Baptiste was funded by the Society for Medical Decision Making (SMDM), Agency for Healthcare Research and Policy Health Policy Fellowship in Comparative Effectiveness, and hosted in the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. The funding agreement ensured the author's independence in designing the study, interpreting the data, writing, and publishing the report. The following authors were employed by the Agency for Healthcare Research and Policy: Catherine Cravens, Joanna Siegel, and William Lawrence. Ava John-Baptiste was subsequently supported by a Team Grant (grant OTG-88591) from the Canadian Institutes of Health Research (CIHR) Institute of Nutrition, Metabolism and Diabetes, Cancer Care Ontario and the Ontario Institute for Cancer Research (through funding provided by the Ministry of Health and Long-Term Care and the Ministry of Economic Development and Innovation of the Government of Ontario). Ava John-Baptiste was also supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (through funding provided by the Ministry of Health and Long-Term Care). Revision accepted for publication 26 March 2016. NR 30 TC 0 Z9 0 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0272-989X EI 1552-681X J9 MED DECIS MAKING JI Med. Decis. Mak. PD JUL PY 2016 VL 36 IS 5 BP 666 EP 679 DI 10.1177/0272989X16646732 PG 14 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA DN5XL UT WOS:000377144900010 PM 27225487 ER PT J AU Kennelty, KA Witry, MJ Gehring, M Dattalo, M Rogus-Pulia, N AF Kennelty, Korey A. Witry, Matthew J. Gehring, Michael Dattalo, Melissa Rogus-Pulia, Nicole TI A four-phase approach for systematically collecting data and measuring medication discrepancies when patients transition between health care settings SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Community pharmacy; Medication discrepancies; Transitions of care; Adverse drug events ID HOSPITAL ADMISSION; INTERRATER RELIABILITY; RISK-FACTORS; RECONCILIATION; ERRORS; DISCHARGE; RECORDS; MATCH AB Background: No methodological standards are available for researchers and clinicians to examine medication discrepancies between health care settings. Systematic methods of examining medication discrepancies will allow researchers and clinicians to better understand factors driving medication discrepancies, to better measure effects of medication reconciliation interventions, and to compare findings across studies. Objective: This article proposes a four-phase approach for systematically collecting medication data and measuring medication discrepancies between a hospital and community pharmacies. Methodologic considerations related to studying medication discrepancies in health services research are also discussed. Methods: A multi-disciplinary study team developed a four-phase systematic approach to improve quality of data and study rigor: 1) operationalization of a medication discrepancy, 2) acquiring medication data, 3) abstraction of medication data and creation of dataset, and 4) measuring and reporting medication discrepancies. Results: Using this phase-based approach, the study team successfully identified and reported medication discrepancies between a hospital and community pharmacies at the patient, medication, and community pharmacy units of analyses. Conclusions: Systematically measuring medication discrepancies that occur in the care transitions process is a critical step as researchers, clinicians, and other stakeholders work to improve health care quality and patient outcomes. This article detailed how a phase-based approach can be used in research to examine medication discrepancies as well as address the complexity of collecting medication data and analyzing medication discrepancies. Such methods should be considered when developing, conducting, and reporting research on medication discrepancies. Published by Elsevier Inc. C1 [Kennelty, Korey A.; Gehring, Michael; Dattalo, Melissa; Rogus-Pulia, Nicole] William S Middleton Mem Vet Adm Med Ctr, GRECC, 2500 Overlook Terrace,11G, Madison, WI 53705 USA. [Kennelty, Korey A.] Univ Wisconsin, Sch Pharm, Social & Adm Sci Div, Madison, WI 53705 USA. [Kennelty, Korey A.; Gehring, Michael; Dattalo, Melissa; Rogus-Pulia, Nicole] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA. [Witry, Matthew J.] Univ Iowa, Coll Pharm, Dept Pharm Practice & Sci, Iowa City, IA 52242 USA. RP Kennelty, KA (reprint author), 2500 Overlook Terrace,11-G, Madison, WI 53705 USA. EM kennelty@wisc.edu OI Witry, Matthew/0000-0001-8381-7224 FU Agency for Healthcare Research and Quality (AHRQ) Health Services Research Dissertation Grant of the National Institutes of Health [R36HS021984]; UW-Madison School of Pharmacy Sonderegger Research Center Dissertation Grant; Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427] FX Research reported in this manuscript was supported by the Agency for Healthcare Research and Quality (AHRQ) Health Services Research Dissertation Grant of the National Institutes of Health under award number R36HS021984 [PI: Kennelty]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Research reported in this dissertation also was supported by the UW-Madison School of Pharmacy Sonderegger Research Center Dissertation Grant.; The project described also was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. NR 35 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD JUL-AUG PY 2016 VL 12 IS 4 BP 548 EP 558 DI 10.1016/j.sapharm.2015.09.001 PG 11 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DM6CN UT WOS:000376437600040 PM 26781670 ER PT J AU Murray, SS Murray, EJB Wang, JC Duarte, MEL AF Murray, Samuel S. Murray, Elsa J. Brochmann Wang, Jeffrey C. Leite Duarte, Maria Eugenia TI The history and histology of bone morphogenetic protein SO HISTOLOGY AND HISTOPATHOLOGY LA English DT Review DE Bone morphogenetic protein; Bone; Endochondral bone formation ID BOVINE OSTEOGENIC PROTEIN; PROCOLLAGEN C-PROTEINASE; TGF-BETA; DIFFUSION-CHAMBERS; DIFFERENTIATION; PURIFICATION; ANTAGONISTS; INDUCTION; CARTILAGE; REPAIR AB Bone morphogenetic proteins are a group of structurally related proteins within the TGF-beta superfamily of proteins with a diverse repertoire of functions in embryonic and adult organisms. As is apparent from the name, the members first characterized participate in bone growth, development, and remodeling. The "morphogenic" activity per se is defined as the induction of a recapitulation of endochondral bone formation by appropriate stem cells. The regenerative capacity of bone has been recognized since ancient times. The mechanism, applications, and conceptual basis of bone transplantation, bone implantation, ectopic bone formation, and exogenously induced bone formation have been studied by many investigators for more than a century. This review examines the efforts to characterize this activity in the European and American literature over approximately the last century. Because of the inherently complex nature of the process induced by these molecules (inflammation, stem cell proliferation, cartilage differentiation, replacement of cartilage with bone) it is important to evaluate previous investigations through a histological perspective. The cellular basis of the contemporary bioassay for BMP activity is illustrated and discussed from the histological point of view. C1 [Murray, Samuel S.; Murray, Elsa J. Brochmann] Univ Calif Los Angeles, Geriatr Res Educ & Clin Ctr, Sepulveda Ambulatory Care Ctr, VA Greater Los Angeles, Los Angeles, CA USA. [Murray, Samuel S.; Murray, Elsa J. Brochmann] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Wang, Jeffrey C.] Univ So Calif, Dept Orthopaed Surg, Los Angeles, CA USA. [Leite Duarte, Maria Eugenia] Natl Inst Traumatol & Orthopaed INTO, Rio De Janeiro, Brazil. RP Murray, SS (reprint author), VA Med Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. EM samuel.murray@va.gov FU Department of Veterans Affairs, USA; National Institute of Orthopaedics and Traumatology, Rio de Janeiro, Brazil FX This work was supported by the Department of Veterans Affairs, USA and the National Institute of Orthopaedics and Traumatology, Rio de Janeiro, Brazil. The authors would like to thank Nadia Vatamanu for her expert medical library assistance. NR 63 TC 1 Z9 1 U1 6 U2 14 PU F HERNANDEZ PI MURCIA PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN SN 0213-3911 EI 1699-5848 J9 HISTOL HISTOPATHOL JI Histol. Histopath. PD JUL PY 2016 VL 31 IS 7 BP 721 EP 732 DI 10.14670/HH-11-774 PG 12 WC Cell Biology; Pathology SC Cell Biology; Pathology GA DM3YZ UT WOS:000376284000002 PM 26907674 ER PT J AU Zhang, WT Zhang, H Mu, HF Zhu, W Jiang, XY Hu, XM Shi, YJ Leak, RK Dong, Q Chen, J Gao, YQ AF Zhang, Wenting Zhang, Hui Mu, Hongfeng Zhu, Wen Jiang, Xiaoyan Hu, Xiaoming Shi, Yejie Leak, Rehana K. Dong, Qiang Chen, Jun Gao, Yanqin TI Omega-3 polyunsaturated fatty acids mitigate blood-brain barrier disruption after hypoxic-ischemic brain injury SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Hypoxia/ischemia; Blood brain barrier; MMP-9; MMP-2; Tight junction ID FOCAL CEREBRAL-ISCHEMIA; RECEPTOR-RELATED PROTEIN-1; INFLAMMATORY RESPONSE; EXPERIMENTAL STROKE; MATRIX-METALLOPROTEINASE-9; CELLS; NEUROPROTECTION; SUPPLEMENTATION; INHIBITION; EXPRESSION AB Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been shown to protect the neonatal brain against hypoxic/ischemic (H/I) injury. However, the mechanism of n-3 PUFA-afforded neuroprotection is not well understood. One major determinant of H/I vulnerability is the permeability of the blood brain barrier (BBB). Therefore, we examined the effects of n-3 PUFAs on BBB integrity after neonatal H/I. Female rats were fed a diet with or without n-3 PUFA enrichment from day 2 of pregnancy to 14 days after parturition. H/I was introduced in 7 day-old offspring. We observed relatively rapid BBB penetration of the small molecule cadaverine (640 Da) at 4 h post-H/I and a delayed penetration of larger dextrans (3 kD-40 kD) 24-48 h after injury. Surprisingly, the neonatal BBB was impermeable to Evans Blue or 70 kD dextran leakage for up to 48 h post-H/I, despite evidence of IgG extravasation at this time. As expected, n-3 PUFAs ameliorated H/I-induced BBB damage, as shown by reductions in tracer efflux and IgG extravasation, preservation of BBB ultrastructure, and enhanced tight junction protein expression. Furthermore, n-3 PUFAs prevented the elevation in matrix metalloproteinase (MMP) activity in the brain and blood after H/I. Thus, n-3 PUFAs may protect neonates against BBB damage by blunting MMPs activation after H/I. Published by Elsevier Inc. C1 [Zhang, Wenting; Zhang, Hui; Mu, Hongfeng; Jiang, Xiaoyan; Hu, Xiaoming; Dong, Qiang; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Collaborat Innovat Ctr Brain Sci, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Zhang, Hui; Dong, Qiang] Fudan Univ, Dept Neurol, Huashan Hosp, Shanghai 200032, Peoples R China. [Zhang, Wenting; Zhu, Wen; Jiang, Xiaoyan; Hu, Xiaoming; Shi, Yejie; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis, Pittsburgh, PA 15213 USA. [Zhang, Wenting; Zhu, Wen; Jiang, Xiaoyan; Hu, Xiaoming; Shi, Yejie; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Mylan Sch Pharm, Pittsburgh, PA 15282 USA. [Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, S507 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.; Gao, YQ (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. EM chenj2@upmc.edu; yqgao@shmu.edu.cn RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Shi, Yejie/0000-0001-7502-9201 FU Chinese Natural Science Foundation [81020108021, 81171149, 81371306, 81571285, 81529002, 81100978, 81471332]; Shanghai Committee of Science and Technology Support Program [14431907002]; Young Teacher Program of Fudan University [20520131150]; U.S. NIH [NS095671, NS36736, NS089534, NS45048]; U.S. Department of Veterans Affairs [I01RX000420]; American Heart Association [13SDG14570025, 15POST22260011] FX This project was supported by the Chinese Natural Science Foundation grants 81020108021, 81171149, 81371306, 81571285 (to Dr Gao), 81529002 (to Dr Chen), 81100978 and 81471332 (to Dr Zhang); the Shanghai Committee of Science and Technology Support Program 14431907002 (to Dr Gao); Young Teacher Program of Fudan University 20520131150 (to Dr Zhang); the U.S. NIH grants NS095671, NS36736, NS089534 and NS45048 (to Dr Chen); the U.S. Department of Veterans Affairs Research Career Scientist Award and RR & D Merit Review I01RX000420 (to Dr Chen); and the American Heart Association Scientist Development grant 13SDG14570025 (to Dr Hu) and 15POST22260011 (to Dr. Shi). NR 42 TC 6 Z9 7 U1 2 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 EI 1095-953X J9 NEUROBIOL DIS JI Neurobiol. Dis. PD JUL PY 2016 VL 91 BP 37 EP 46 DI 10.1016/j.nbd.2016.02.020 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DL8IL UT WOS:000375885600004 PM 26921472 ER PT J AU Cao, B Bauer, IE Sharma, AN Mwangi, B Frazier, T Lavagnino, L Zunta-Soares, GB Walss-Bass, C Glahn, DC Kapczinski, F Nielsen, DA Soares, JC AF Cao, Bo Bauer, Isabelle E. Sharma, Ajaykumar N. Mwangi, Benson Frazier, Thomas Lavagnino, Luca Zunta-Soares, Giovana B. Walss-Bass, Consuelo Glahn, David C. Kapczinski, Flavio Nielsen, David A. Soares, Jair C. TI Reduced hippocampus volume and memory performance in bipolar disorder patients carrying the BDNF val66met met allele SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar disorder type I; BDNF val66met; Polymorphism; Hippocampus; Volume; Memory; MRI; Bipolar; Major depressive disorder ID NEUROTROPHIC FACTOR GENE; MAGNETIC-RESONANCE IMAGES; FAMILY-BASED ASSOCIATION; TEMPORAL-LOBE STRUCTURES; TERM LITHIUM TREATMENT; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; I DISORDER; COGNITIVE IMPAIRMENT; CORTICAL THICKNESS AB Background: Previous studies investigated the impact of brain-derived neurotrophic factor (BDNF) val66met (rs6265) on hippocampus volumes and neurocognition in bipolar disorders (BD), but the results were not consistent. This study aimed to investigate the effect of BDNF polymorphism on hippo campus volumes and memory performance in well-characterized adult populations diagnosed with type I BD (BD-I) and major depressive disorder (MDD) compared with healthy controls (HC). Methods: 48 BD-I patients, 33 MDD patients and 60 HC were genotyped for BDNF rs6265 using DNA isolated from white blood cells. Individuals with val/met and met/met genotypes were grouped as met carriers and compared to those with the val/val. Brain segmentations were obtained from structural magnetic resonance imaging (MRI) using the Freesurfer. Memory performance was assessed with the California Verbal Learning Task (CVLT). Results: We found a significant diagnosis effect and marginal interaction between diagnosis and BDNF genotype group for both hippocampus volumes and memory performance. BDNF met allele carrier BD patients had smaller hippocampus volumes and reduced performance on multiple CVLT scores compared to MDD patients and HC. Conclusions: We provide strong evidence for the BDNF val66met polymorphism as a putative biological signature for the neuroanatomical and cognitive abnormalities commonly observed in BD patients. (C) 2016 Elsevier B.V. All rights reserved. C1 [Cao, Bo; Bauer, Isabelle E.; Sharma, Ajaykumar N.; Mwangi, Benson; Lavagnino, Luca; Zunta-Soares, Giovana B.; Walss-Bass, Consuelo; Soares, Jair C.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Frazier, Thomas] Cleveland Clin, Ctr Pediat Behav Hlth, Cleveland, OH 44106 USA. [Frazier, Thomas] Cleveland Clin, Ctr Autism, Cleveland, OH 44106 USA. [Glahn, David C.] Yale Univ, Sch Med, Inst Living, Olin Neuropsychiat Res Ctr, New Haven, CT 06520 USA. [Glahn, David C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Kapczinski, Flavio] Univ Fed Rio Grande do Sul, Dept Psychiat, Rua Ramiro Barcelos 2350, BR-90035903 Rio Grande do Sul, RS, Brazil. [Nielsen, David A.] Baylor Coll Med, Dept Psychiat & Behav Sci, DeBakey VA Med Ctr, Houston, TX 77030 USA. RP Cao, B (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. EM CloudBoCao@gmail.com RI Cao, Bo/D-1983-2017 OI Cao, Bo/0000-0003-3401-6900 FU NIH/NIDA through MD Anderson's Cancer Center Support Grant [5 P50 DA018197-05, NIH/NIDA DA026120]; Toomim Family Fund; NIMH Grant [R01 085667]; Dunn Research Foundation; Pat Rutherford, Jr. Endowed Chair in Psychiatry FX The current work was supported by: NIH/NIDA 5 P50 DA018197-05 (DN), through MD Anderson's Cancer Center Support Grant NIH/NIDA DA026120 (DN), and the Toomim Family Fund (David A. Nielsen), NIMH Grant R01 085667, the Dunn Research Foundation and the Pat Rutherford, Jr. Endowed Chair in Psychiatry (Jair C. Soares). The genetic findings are the result of work supported with resources and the use of facilities at the Michael E. DeBakey VA Medical Center, Houston, TX (David Nielsen). NR 95 TC 2 Z9 2 U1 7 U2 14 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUL 1 PY 2016 VL 198 BP 198 EP 205 DI 10.1016/j.jad.2016.03.044 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DK6TK UT WOS:000375058100028 PM 27018938 ER PT J AU Yassine, HN Rawat, V Mack, WJ Quinn, JF Yurko-Mauro, K Bailey-Hall, E Aisen, PS Chui, HC Schneider, LS AF Yassine, Hussein N. Rawat, Varun Mack, Wendy J. Quinn, Joseph F. Yurko-Mauro, Karin Bailey-Hall, Eileen Aisen, Paul S. Chui, Helena C. Schneider, Lon S. TI The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease SO ALZHEIMERS RESEARCH & THERAPY LA English DT Article DE APOE; Alzheimer's disease; Cerebrospinal fluid; Amyloid ID POLYUNSATURATED FATTY-ACIDS; MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; DOCOSAHEXAENOIC ACID; PHOSPHOLIPASE A(2); FISH-OIL; BRAIN; TRIAL; CONSUMPTION; METABOLISM AB Background: Apolipoprotein E (APOE) epsilon 4 and low cerebrospinal fluid (CSF) amyloid-beta 42 (A beta 42) levels are predictors for developing Alzheimer's disease (AD). The results of several studies indicate an interaction between docosahexaenoic acid (DHA) consumption and cognitive outcomes by APOE genotype. Our objective in the present study was to examine whether APOE epsilon 4 genotype and low CSF A beta 42 levels were associated with reduced delivery of DHA to CSF in the Alzheimer's Disease Cooperative Study-sponsored DHA clinical trial. Methods: Phospholipid DHA was assayed in the plasma of 384 participants and CSF of 70 participants at baseline. Forty-four of the 70 participants completed the 18-month follow-up visit after allocation to placebo (n = 15) or DHA (n = 29). Plasma and CSF DHA levels, CSF A beta 42, Tau, and phosphorylated Tau were measured at baseline and after the 18-month intervention. Participants were divided into tertiles based on baseline A beta 42 CSF levels. To assess DHA delivery across the blood-brain barrier, the ratio of CSF to plasma DHA levels was calculated. Results: At baseline, there were no significant differences between CSF or plasma phospholipid DHA levels by CSF A beta 42 tertiles or epsilon 4 status. After 18 months of DHA supplementation, participants at the lowest A beta 42 tertile had significantly lower CSF DHA levels (p = 0.01) and lower CSF-to-plasma DHA ratios (p = 0.05) compared to the other tertiles. Baseline CSF A beta 42 levels were significantly lower in epsilon 4 carriers than in epsilon 4 noncarriers (p = 0.01). Participants carrying the epsilon 4 allele (n=25) demonstrated a less pronounced increase in CSF DHA level compared with noncarriers (n = 4), with a possible interaction effect between treatment and APOE genotype (p=0.07). Conclusions: APOE epsilon 4 allele and lower CSF A beta 42 levels were associated with less transport of DHA to CSF. Brain amyloid pathology may limit the delivery of DHA to the brain in AD. C1 [Yassine, Hussein N.; Rawat, Varun] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. [Mack, Wendy J.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. [Yurko-Mauro, Karin; Bailey-Hall, Eileen] DSM Nutr Prod, Dept Clin Res, Columbia, MD USA. [Aisen, Paul S.] Univ So Calif, Keck Sch Med, Alzheimers Therapeut Res Inst, Los Angeles, CA 90033 USA. [Chui, Helena C.; Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. RP Yassine, HN (reprint author), Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA. EM hyassine@usc.edu FU National Heart, Lung, and Blood Institute [K23HL107389]; Alzheimer's Association [NIRG-15-361854]; National Institute of Aging [P50-AG05142-31]; National Institute on Aging [U01 AG10483] FX HNY was supported by grant K23HL107389 from National Heart, Lung, and Blood Institute and grant NIRG-15-361854 from the Alzheimer's Association. ADRC project P50-AG05142-31 (to HCC) from the National Institute of Aging supported this project. This study was supported by grant U01 AG10483 from the National Institute on Aging. The placebo and DHA study drugs were provided by DSM. DSM also provided plasma and cerebrospinal fluid measurements of fatty acids. NR 45 TC 4 Z9 4 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-9193 J9 ALZHEIMERS RES THER JI Alzheimers Res. Ther. PD JUN 30 PY 2016 VL 8 AR 25 DI 10.1186/s13195-016-0194-x PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DQ1YP UT WOS:000378997400001 PM 27358067 ER PT J AU Tsai, J Pietrzak, RH Hoff, RA Harpaz-Rotem, I AF Tsai, Jack Pietrzak, Robert H. Hoff, Rani A. Harpaz-Rotem, Ilan TI Accuracy of screening for posttraumatic stress disorder in specialty mental health clinics in the U.S. Veterans Affairs Healthcare System SO PSYCHIATRY RESEARCH LA English DT Article DE Trauma; Posttraumatic stress disorder; Epidemiology; Assessment/diagnosis; Health services ID QUALITY-OF-LIFE; PTSD CHECKLIST; AFGHANISTAN VETERANS; PSYCHOMETRIC PROPERTIES; FEMALE VETERANS; RISK-FACTORS; IRAQ; BARRIERS; COMBAT; PREVALENCE AB This study 1) describes the prevalence of positive PTSD screens among male, female, and OEF/OIF/OND veterans using various PTSD Checklist -Military version (PCL-M) criteria; 2) evaluates the sensitivity and specificity of various PCL-M criteria; and 3) identifies optimal screening criteria in predicting clinician documented PTSD diagnoses. VA electronic medical records data from 327,093 veterans during 20082012 were analyzed. Receiver operating characteristic curve analyses compared PCL-M scores against clinician-documented PTSD diagnoses. Results showed that different PCL-M scoring criteria resulted in 62.0-84.5% of veterans screening positive for PTSD compared to 40.1% with a clinician-documented PTSD diagnosis. Sensitivity of the PCL-M ranged from 73.7 to 93.5% and specificity ranged from 21.6 to 45.8% for all veterans. The optimal PCL-M cut score according to Youden's index was >= 45 for male veterans, >= 35 for female veterans, and >= 38 for OEF/OIF/OND veterans. Self-report measures like the PCL-M may be a useful screening tool for identifying probable PTSD in VA specialty clinics, but they should be calibrated for different veteran subgroups and followed by structured clinical interviews. Published by Elsevier Ireland Ltd. C1 [Tsai, Jack] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Tsai, Jack; Pietrzak, Robert H.; Hoff, Rani A.; Harpaz-Rotem, Ilan] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Pietrzak, Robert H.; Hoff, Rani A.; Harpaz-Rotem, Ilan] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Hoff, Rani A.; Harpaz-Rotem, Ilan] Vet Affairs Northeast Program Evaluat Ctr, West Haven, CT USA. RP Tsai, J (reprint author), 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM Jack.Tsai@yale.edu NR 38 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD JUN 30 PY 2016 VL 240 BP 157 EP 162 DI 10.1016/j.psychres.2016.04.036 PG 6 WC Psychiatry SC Psychiatry GA DP2YM UT WOS:000378359500024 PM 27107669 ER PT J AU Kim, T Mehta, SL Kaimal, B Lyons, K Dempsey, RJ Vemuganti, R AF Kim, TaeHee Mehta, Suresh L. Kaimal, Balarama Lyons, Kirsten Dempsey, Robert J. Vemuganti, Raghu TI Poststroke Induction of alpha-Synuclein Mediates Ischemic Brain Damage SO JOURNAL OF NEUROSCIENCE LA English DT Article DE alpha-synuclein; brain; neuroprotection; stroke ID FOCAL CEREBRAL-ISCHEMIA; PARKINSONS-DISEASE; IN-VIVO; POSTTRANSLATIONAL MODIFICATIONS; CSP-ALPHA; RAT MODEL; NEURODEGENERATION; PHOSPHORYLATION; STROKE; OLIGOMERS AB alpha-Synuclein (alpha-Syn), one of the most abundant proteins in the CNS, is known to be a major player in the neurodegeneration observed in Parkinson's disease. We currently report that transient focal ischemia upregulates alpha-Syn protein expression and nuclear translocation in neurons of the adult rodent brain. We further show that knockdown or knock-out of alpha-Syn significantly decreases the infarction and promotes better neurological recovery in rodents subjected to focal ischemia. Furthermore, alpha-Syn knockdown significantly reduced postischemic induction of phospho-Drp1, 3-nitrotyrosine, cleaved caspase-3, and LC-3 II/I, indicating its role in modulating mitochondrial fragmentation, oxidative stress, apoptosis, and autophagy, which are known to mediate poststroke neuronal death. Transient focal ischemia also significantly upregulated serine-129 (S129) phosphorylation (p alpha-Syn) of alpha-Syn and nuclear translocation of p alpha-Syn. Furthermore, knock-out mice that lack PLK2 (the predominant kinase that mediates S129 phosphorylation) showed better functional recovery and smaller infarcts when subjected to transient focal ischemia, indicating a detrimental role of S129 phosphorylation of p alpha-Syn. In conclusion, our studies indicate that alpha-Syn is a potential therapeutic target to minimize poststroke brain damage. C1 [Kim, TaeHee; Mehta, Suresh L.; Kaimal, Balarama; Lyons, Kirsten; Dempsey, Robert J.; Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA. [Kim, TaeHee; Dempsey, Robert J.; Vemuganti, Raghu] Univ Wisconsin, Neurosci Training Program, Madison, WI 53792 USA. [Vemuganti, Raghu] Univ Wisconsin, Cellular & Mol Pathol Grad Program, Madison, WI 53792 USA. [Dempsey, Robert J.; Vemuganti, Raghu] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Vemuganti, R (reprint author), Univ Wisconsin, Dept Neurol Surg, 600 Highland Ave, Madison, WI 53792 USA. EM vemuganti@neurosurgery.wisc.edu FU U.S. Department of Veterans Affairs Merit Review Grant [I01 BX002985]; American Heart Association [15IRG23050015] FX This work was supported, in part, by the U.S. Department of Veterans Affairs Merit Review Grant (I01 BX002985). TaeHee Kim was supported by a predoctoral fellowship from the American Heart Association (15IRG23050015). We thank Dr. Kunlin Jin for providing the human brain sections. NR 63 TC 5 Z9 5 U1 1 U2 1 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JUN 29 PY 2016 VL 36 IS 26 BP 7055 EP 7065 DI 10.1523/JNEUROSCI.1241-16.2016 PG 11 WC Neurosciences SC Neurosciences & Neurology GA DQ2GJ UT WOS:000379020200019 PM 27358461 ER PT J AU McLoed, AG Sherrill, TP Cheng, DS Han, W Saxon, JA Gleaves, LA Wu, PS Polosukhin, VV Karin, M Yull, FE Stathopoulos, GT Georgoulias, V Zaynagetdinov, R Blackwell, TS AF McLoed, Allyson G. Sherrill, Taylor P. Cheng, Dong-Sheng Han, Wei Saxon, Jamie A. Gleaves, Linda A. Wu, Pingsheng Polosukhin, Vasiliy V. Karin, Michael Yull, Fiona E. Stathopoulos, Georgios T. Georgoulias, Vassilis Zaynagetdinov, Rinat Blackwell, Timothy S. TI Neutrophil-Derived IL-1 beta Impairs the Efficacy of NF-kappa B Inhibitors against Lung Cancer SO CELL REPORTS LA English DT Article ID MALIGNANT PLEURAL EFFUSION; IKK-BETA; MOUSE MODEL; ACTIVATION; CARCINOGENESIS; TUMORIGENESIS; INFLAMMATION; CELLS; ADENOCARCINOMA; PROLIFERATION AB Although epithelial NF-kappa B signaling is important for lung carcinogenesis, NF-kappa B inhibitors are ineffective for cancer treatment. To explain this paradox, we studied mice with genetic deletion of IK kappa beta in myeloid cells and found enhanced tumorigenesis in Kras(G12D) and urethane models of lung cancer. Myeloid-specific inhibition of NF-kappa B augmented pro-IL-1 beta processing by cathepsin G in neutrophils, leading to increased IL-1 beta and enhanced epithelial cell proliferation. Combined treatment with bortezomib, a proteasome inhibitor that blocks NF-kappa B activation, and IL-1 receptor antagonist reduced tumor formation and growth in vivo. In lung cancer patients, plasma IL-1 beta levels correlated with poor prognosis, and IL-1 beta increased following bortezomib treatment. Together, our studies elucidate an important role for neutrophils and IL-1 beta in lung carcinogenesis and resistance to NF-kappa B inhibitors. C1 [McLoed, Allyson G.; Saxon, Jamie A.; Yull, Fiona E.; Blackwell, Timothy S.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA. [Sherrill, Taylor P.; Cheng, Dong-Sheng; Han, Wei; Gleaves, Linda A.; Polosukhin, Vasiliy V.; Stathopoulos, Georgios T.; Zaynagetdinov, Rinat; Blackwell, Timothy S.] Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. [Wu, Pingsheng] Vanderbilt Univ, Dept Biostat, Nashville, TN 37232 USA. [Karin, Michael] Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, Sch Med, La Jolla, CA 92093 USA. [Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pathol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA. [Yull, Fiona E.; Blackwell, Timothy S.] Vanderbilt Ingram Canc Ctr, 691 Preston Bldg,2220 Pierce Ave, Nashville, TN 37232 USA. [Stathopoulos, Georgios T.] Univ Patras, Dept Physiol, Lab Mol Resp Carcinogenesis, Patras 26504, Greece. [Stathopoulos, Georgios T.] Univ Munich, Univ Hosp, CPC, Marchioninistr 15, D-81377 Munich, Germany. [Stathopoulos, Georgios T.] Helmholtz Zentrum Munchen, D-81377 Munich, Germany. [Stathopoulos, Georgios T.] German Ctr Lung Res DZL, D-81377 Munich, Germany. [Georgoulias, Vassilis] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Crete, Greece. [Blackwell, Timothy S.] US Dept Vet Affairs, Washington, DC 20420 USA. [Blackwell, Timothy S.] Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA. RP Zaynagetdinov, R (reprint author), Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. EM rinat.z.zaynagetdinov@vanderbilt.edu FU Cancer Initiative of North Carolina and Free to Breathe; NIH [T32HL094296]; European Research Council [FP7-IDEAS-ERC-StG-2010-260524-KRASHIMPE]; U.S. Department of Veterans Affairs; Vanderbilt-Ingram Cancer Center Spore FX This work was supported by a grant from the Lung Cancer Initiative of North Carolina and Free to Breathe (R.Z.), by NIH grant T32HL094296 (R.Z.), by European Research Council Starting Independent Investigator grant FP7-IDEAS-ERC-StG-2010-260524-KRASHIMPE (G.T.S.), by the U.S. Department of Veterans Affairs (T.S.B.), and by a Vanderbilt-Ingram Cancer Center Spore grant 2010 (T.S.B.). NR 47 TC 2 Z9 2 U1 2 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD JUN 28 PY 2016 VL 16 IS 1 BP 120 EP 132 DI 10.1016/j.celrep.2016.05.085 PG 13 WC Cell Biology SC Cell Biology GA DQ1GY UT WOS:000378950700012 PM 27320908 ER PT J AU MacKintosh, FR Sprenkle, PC Walter, LC Rawson, L Karnes, RJ Morrell, CH Kattan, MW Nawaf, CB Neville, TB AF MacKintosh, F. Roy Sprenkle, Preston C. Walter, Louise C. Rawson, Lori Karnes, R. Jeffrey Morrell, Christopher H. Kattan, Michael W. Nawaf, Cayce B. Neville, Thomas B. TI Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer SO FRONTIERS IN ONCOLOGY LA English DT Article DE prostate cancer; prostate-specific antigen; life expectancy; older men; death risk ID PREVENTION TRIAL; MORTALITY; CALCULATORS; VALIDATION; ERSPC; MEN; PSA AB A single early prostate-specific antigen (PSA) level has been correlated with a higher likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older men has been considered of limited utility. We evaluated prostate cancer death in relation to age and PSA level immediately prior to prostate cancer diagnosis. Using the Veterans Affairs database, we identified 230,081 men aged 50-89 years diagnosed with prostate cancer and at least one prior PSA test between 1999 and 2009. Prostate cancer-specific death over time was calculated for patients stratified by age group (e.g., 50-59 years, through 80-89 years) and PSA range at diagnosis (10 ranges) using Kaplan-Meier methods. Risk of 10-year prostate cancer mortality across age and PSA was compared using log-rank tests with a Bonferroni adjustment for multiple testing. 10.5% of men diagnosed with prostate cancer died of cancer during the 10-year study period (mean follow-up = 3.7 years). Higher PSA values prior to diagnosis predict a higher risk of death in all age groups (p < 0.0001). Within the same PSA range, older age groups are at increased risk for death from prostate cancer (p < 0.0001). For PSA of 7-10 ng/mL, cancer-specific death, 10 years after diagnosis, increased from 7% for age 50-59 years to 51% for age 80-89 years. Men older than 70 years are more likely to die of prostate cancer at any PSA level than younger men, suggesting prostate cancer remains a significant problem among older men (even those aged 80+) and deserves additional study. C1 [MacKintosh, F. Roy; Rawson, Lori] VA Sierra Nevada Hlth Care Syst, Reno, NV USA. [Sprenkle, Preston C.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94143 USA. [Karnes, R. Jeffrey] Mayo Clin, Rochester, MN USA. [Morrell, Christopher H.] Loyola Univ Maryland, Baltimore, MD USA. [Kattan, Michael W.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. [Nawaf, Cayce B.] Yale Univ, Sch Med, Dept Urol, New Haven, CT USA. [Neville, Thomas B.] Soar BioDynam Inc, Incline Village, NV USA. RP Sprenkle, PC (reprint author), Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA. EM preston.sprenkle@yale.edu NR 28 TC 0 Z9 0 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 2234-943X J9 FRONT ONCOL JI Front. Oncol. PD JUN 28 PY 2016 VL 6 AR 157 DI 10.3389/fonc.2016.00157 PG 7 WC Oncology SC Oncology GA DP7CM UT WOS:000378656600001 PM 27446803 ER PT J AU Mitra, S Federico, L Zhao, W Dennison, J Sarkar, TR Zhang, F Takiar, V Cheng, KW Mani, S Lee, JS Mills, GB AF Mitra, Shreya Federico, Lorenzo Zhao, Wei Dennison, Jennifer Sarkar, Tapasree Roy Zhang, Fan Takiar, Vinita Cheng, Kwai W. Mani, Sendurai Lee, Ju Seog Mills, Gordon B. TI Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT SO ONCOTARGET LA English DT Article DE Rab25; Rab coupling protein; breast cancer; luminal B; claudin low ID EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMA; CANINE KIDNEY-CELLS; ALPHA-5-BETA-1 INTEGRIN; 3D MICROENVIRONMENTS; MOLECULAR PORTRAITS; THERAPEUTIC TARGET; EXPRESSION; TRAFFICKING; METASTASIS AB The Rab GTPases regulate vesicular trafficking machinery that transports and delivers a diverse pool of cargo, including growth factor receptors, integrins, nutrient receptors and junction proteins to specific intracellular sites. The trafficking machinery is indeed a major posttranslational modifier and is critical for cellular homeostasis. Deregulation of this stringently controlled system leads to a wide spectrum of disorders including cancer. Herein we demonstrate that Rab25, a key GTPase, mostly decorating the apical recycling endosome, is a dichotomous variable in breast cancer cell lines with higher mRNA and protein expression in Estrogen Receptor positive (ER+ve) lines. Rab25 and its effector, Rab Coupling Protein (RCP) are frequently coamplified and coordinately elevated in ER+ve breast cancers. In contrast, Rab25 levels are decreased in basal-like and almost completely lost in claudin-low tumors. This dichotomy exists despite the presence of the 1q amplicon that hosts Rab25 across breast cancer subtypes and is likely due to differential methylation of the Rab25 promoter. Functionally, elevated levels of Rab25 drive major hallmarks of cancer including indefinite growth and metastasis but in case of luminal B breast cancer only. Importantly, in such ER+ve tumors, coexpression of Rab25 and its effector, RCP is significantly associated with a markedly worsened clinical outcome. Importantly, in claudin-low cell lines, exogenous Rab25 markedly inhibits cell migration. Similarly, during Snail-induced epithelial to mesenchymal transition (EMT) exogenous Rab25 potently reverses Snail-driven invasion. Overall, this study substantiates a striking context dependent role of Rab25 in breast cancer where Rab25 is amplified and enhances aggressiveness in luminal B cancers while in claudin-low tumors, Rab25 is lost indicating possible anti-tumor functions. C1 [Mitra, Shreya; Federico, Lorenzo; Zhao, Wei; Dennison, Jennifer; Zhang, Fan; Lee, Ju Seog; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. [Sarkar, Tapasree Roy] Texas A&M Univ, Ctr Stat Bioinformat, College Stn, TX USA. [Takiar, Vinita] Univ Cincinnati, Dept Radiat Oncol, Cincinnati, OH USA. [Cheng, Kwai W.] Michael & DeBakey Med Ctr, Cardiac Catheterizat Lab, Houston, TX USA. [Mani, Sendurai] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA. RP Mitra, S (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA. EM smitra@mdanderson.org RI Mani, Sendurai/A-7244-2009 OI Mani, Sendurai/0000-0002-5918-4276 FU Susan G Komen Postdoctoral Fellowship Grant [KG101340]; American Cancer Grant [CA0099031 08, CA16672]; Komen Foundation [KG08169404]; GlaxoSmithKline TRIUMPH post-doctoral fellowship FX This project was supported by4 funds from Susan G Komen Postdoctoral Fellowship Grant (KG101340) awarded to S.M and the American Cancer Grant (CA0099031 08 and CA16672) and Komen Foundation. (KG08169404) granted to G.B.M. J.B.D. was supported by a GlaxoSmithKline TRIUMPH post-doctoral fellowship. NR 67 TC 1 Z9 1 U1 4 U2 9 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD JUN 28 PY 2016 VL 7 IS 26 BP 40252 EP 40265 DI 10.18632/oncotarget.9730 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DP6NV UT WOS:000378614700100 PM 27259233 ER PT J AU Wynn, ML Yates, JA Evans, CR Van Wassenhove, LD Wu, ZF Bridges, S Bao, LW Fournier, C Ashrafzadeh, S Merrins, MJ Satin, LS Schnell, S Burant, CF Merajver, SD AF Wynn, Michelle L. Yates, Joel A. Evans, Charles R. Van Wassenhove, Lauren D. Wu, Zhi Fen Bridges, Sydney Bao, Liwei Fournier, Chelsea Ashrafzadeh, Sepideh Merrins, Matthew J. Satin, Leslie S. Schnell, Santiago Burant, Charles F. Merajver, Sofia D. TI RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE breast cancer; glutamine; hypoxia-inducible factor (HIF); Rho (Rho GTPase); tumor metabolism; N-acetylaspartate ID KINASE TYPE M2; PYRUVATE-KINASE; TUMOR-GROWTH; REDUCTIVE CARBOXYLATION; LUNG-CANCER; E-CADHERIN; IN-VIVO; HYPOXIA; OVEREXPRESSION; PROTEIN AB Inflammatory breast cancer (IBC) is an extremely lethal cancer that rapidly metastasizes. Although the molecular attributes of IBC have been described, little is known about the underlying metabolic features of the disease. Using a variety of metabolic assays, including C-13 tracer experiments, we found that SUM149 cells, the primary in vitro model of IBC, exhibit metabolic abnormalities that distinguish them from other breast cancer cells, including elevated levels of N-acetylaspartate, a metabolite primarily associated with neuronal disorders and gliomas. Here we provide the first evidence of N-acetylaspartate in breast cancer. We also report that the oncogene RhoC, a driver of metastatic potential, modulates glutamine and N-acetylaspartate metabolism in IBC cells in vitro, revealing a novel role for RhoC as a regulator of tumor cell metabolism that extends beyond its well known role in cytoskeletal rearrangement. C1 [Wynn, Michelle L.; Yates, Joel A.; Evans, Charles R.; Wu, Zhi Fen; Bridges, Sydney; Bao, Liwei; Fournier, Chelsea; Ashrafzadeh, Sepideh; Burant, Charles F.; Merajver, Sofia D.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Wynn, Michelle L.; Schnell, Santiago] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA. [Satin, Leslie S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA. [Van Wassenhove, Lauren D.] Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA. [Merrins, Matthew J.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Merrins, Matthew J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Merajver, SD (reprint author), Univ Michigan, Dept Internal Med, Ctr Canc 7217, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM smerajve@umich.edu OI Burant, Charles/0000-0001-9189-5003 FU National Institutes of Health [U24 DK097153] FX This work utilized core services of the Michigan Regional Comprehensive Metabolomics Resource Core, supported by National Institutes of Health Grant U24 DK097153. We thank Firas Midani for help with natural abundance correction algorithms and Mariana Rodriguez Ortiz for help with figure preparation. NR 51 TC 2 Z9 2 U1 4 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JUN 24 PY 2016 VL 291 IS 26 BP 13715 EP 13729 DI 10.1074/jbc.M115.703959 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DR2YZ UT WOS:000379771100026 PM 27129239 ER PT J AU Prabhu, SD Frangogiannis, NG AF Prabhu, Sumanth D. Frangogiannis, Nikolaos G. TI The Biological Basis for Cardiac Repair After Myocardial Infarction From Inflammation to Fibrosis SO CIRCULATION RESEARCH LA English DT Review DE chemokines; cytokines; fibrosis; immune cells; inflammation; myocytes, cardiac; myocardial infarction ID NF-KAPPA-B; ISCHEMIA-REPERFUSION INJURY; ACUTE CORONARY SYNDROME; TOLL-LIKE RECEPTOR-2; MOBILITY GROUP BOX-1; REGULATES FIBROBLAST PHENOTYPE; MARROW-DERIVED CELLS; KILLER T-CELLS; IN-VIVO; HEART-FAILURE AB In adult mammals, massive sudden loss of cardiomyocytes after infarction overwhelms the limited regenerative capacity of the myocardium, resulting in the formation of a collagen-based scar. Necrotic cells release danger signals, activating innate immune pathways and triggering an intense inflammatory response. Stimulation of toll-like receptor signaling and complement activation induces expression of proinflammatory cytokines (such as interleukin-1 and tumor necrosis factor-a) and chemokines (such as monocyte chemoattractant protein-1/ chemokine (C-C motif) ligand 2 [CCL2]). Inflammatory signals promote adhesive interactions between leukocytes and endothelial cells, leading to extravasation of neutrophils and monocytes. As infiltrating leukocytes clear the infarct from dead cells, mediators repressing inflammation are released, and anti-inflammatory mononuclear cell subsets predominate. Suppression of the inflammatory response is associated with activation of reparative cells. Fibroblasts proliferate, undergo myofibroblast transdifferentiation, and deposit large amounts of extracellular matrix proteins maintaining the structural integrity of the infarcted ventricle. The renin-angiotensin-aldosterone system and members of the transforming growth factor-beta family play an important role in activation of infarct myofibroblasts. Maturation of the scar follows, as a network of cross-linked collagenous matrix is formed and granulation tissue cells become apoptotic. This review discusses the cellular effectors and molecular signals regulating the inflammatory and reparative response after myocardial infarction. Dysregulation of immune pathways, impaired suppression of postinfarction inflammation, perturbed spatial containment of the inflammatory response, and overactive fibrosis may cause adverse remodeling in patients with infarction contributing to the pathogenesis of heart failure. Therapeutic modulation of the inflammatory and reparative response may hold promise for the prevention of postinfarction heart failure. C1 [Prabhu, Sumanth D.] Univ Alabama Birmingham, Div Cardiovasc Dis, 311 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA. [Prabhu, Sumanth D.] Birmingham VAMC, Med Serv, Birmingham, AL USA. [Frangogiannis, Nikolaos G.] Albert Einstein Coll Med, Wilf Family Cardiovasc Res Inst, Dept Med, 1300 Morris Pk Ave,Forchheimer G46B, Bronx, NY 10461 USA. RP Prabhu, SD (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, 311 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.; Frangogiannis, NG (reprint author), Albert Einstein Coll Med, Wilf Family Cardiovasc Res Inst, Dept Med, 1300 Morris Pk Ave,Forchheimer G46B, Bronx, NY 10461 USA. EM sprabhu@uab.edu; nikolaos.frangogiannis@einstein.yu.edu FU BLRD VA [I01 BX002706]; NHLBI NIH HHS [R01 HL076246, R01 HL085440, R01 HL125735]; NIDDK NIH HHS [P30 DK020541, P30 DK079626] NR 271 TC 22 Z9 24 U1 11 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7330 EI 1524-4571 J9 CIRC RES JI Circ.Res. PD JUN 24 PY 2016 VL 119 IS 1 BP 91 EP 112 DI 10.1161/CIRCRESAHA.116.303577 PG 22 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA DP4WA UT WOS:000378496500014 PM 27340270 ER PT J AU Lelegren, M Liu, YH Ross, C Tardif, S Salmon, AB AF Lelegren, Matthew Liu, Yuhong Ross, Corinna Tardif, Suzette Salmon, Adam B. TI Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate SO PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES LA English DT Article DE healthspan; protein chaperone; proteasome; immunoproteasome; autophagy ID GENETICALLY HETEROGENEOUS MICE; EXTENDS LIFE-SPAN; PROTEIN HOMEOSTASIS; MAMMALIAN TARGET; OXIDATIVE-STRESS; AUTOPHAGY; LONGEVITY; IMMUNOPROTEASOME; PROTEASOME; RESISTANCE AB Background: Inhibition of mechanistic target of rapamycin (mTOR) has emerged as a viable means to lengthen lifespan and healthspan in mice, although it is still unclear whether these benefits will extend to other mammalian species. We previously reported results from a pilot experiment wherein common marmosets (Callithrix jacchus) were treated orally with rapamycin to reduce mTOR signaling in vivo in line with previous reports in mice and humans. Further, long-term treatment did not significantly alter body weight, daily activity, blood lipid concentrations, or glucose metabolism in this cohort. Methods: In this study, we report on the molecular consequences of rapamycin treatment in marmosets on mechanisms that regulate protein homeostasis (proteostasis) in vivo. There is growing appreciation for the role of proteostasis in longevity and for the role that mTOR plays in regulating this process. Tissue samples of liver and skeletal muscle from marmosets in our pilot cohort were assessed for expression and activity of components of the ubiquitin-proteasome system, macroautophagy, and protein chaperones. Results: Rapamycin treatment was associated with increased expression of PSMB5, a core subunit of the 20S proteasome, but not PSMB8 which is involved in the formation of the immunoproteasome, in the skeletal muscle and liver. Surprisingly, proteasome activity measured in these tissues was not affected by rapamycin. Rapamycin treatment was associated with an increased expression of mitochondria-targeted protein chaperones in skeletal muscle, but not liver. Finally, autophagy was increased in skeletal muscle and adipose, but not liver, from rapamycin-treated marmosets. Conclusions: Overall, these data show tissue-specific upregulation of some, but not all, components of the proteostasis network in common marmosets treated with a pharmaceutical inhibitor of mTOR. C1 [Lelegren, Matthew; Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Lelegren, Matthew; Liu, Yuhong; Ross, Corinna; Tardif, Suzette; Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA. [Ross, Corinna; Tardif, Suzette] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX USA. [Ross, Corinna] Texas A&M Univ, Dept Biol, San Antonio, TX USA. [Ross, Corinna; Tardif, Suzette] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, San Antonio, TX USA. [Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX USA. RP Salmon, AB (reprint author), 15355 Lambda Dr, San Antonio, TX USA. EM salmona@uthscsa.edu FU NIA NIH HHS [R01 AG050797, T35 AG038048]; NIH HHS [P51 OD011133] NR 52 TC 1 Z9 2 U1 1 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN EI 2001-0001 J9 PATHOBIOL AGING AGE JI Pathobiol. Aging Age-relat. Dis. PD JUN 23 PY 2016 VL 6 AR 31793 DI 10.3402/pba.v6.31793 PG 9 WC Pathology SC Pathology GA DT4EX UT WOS:000381434000001 PM 27341957 ER PT J AU Waljee, AK Wiitala, WL Govani, S Stidham, R Saini, S Hou, J Feagins, LA Khan, N Good, CB Vijan, S Higgins, PDR AF Waljee, Akbar K. Wiitala, Wyndy L. Govani, Shail Stidham, Ryan Saini, Sameer Hou, Jason Feagins, Linda A. Khan, Nabeel Good, Chester B. Vijan, Sandeep Higgins, Peter D. R. TI Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort SO PLOS ONE LA English DT Article ID HEALTH-CARE-SYSTEM; ULCERATIVE-COLITIS; CROHNS-DISEASE; NETWORK METAANALYSIS; OSTEOPOROSIS; QUALITY; AZATHIOPRINE; GUIDELINES; FRACTURES; EFFICACY AB Background and Aims Corticosteroids are effective for the short-term treatment of inflammatory bowel disease (IBD). Long-term use, however, is associated with significant adverse effects. To define the: (1) frequency and duration of corticosteroid use, (2) frequency of escalation to corticosteroid-sparing therapy, (3) rate of complications related to corticosteroid use, (4) rate of appropriate bone density measurements (dual energy X-ray absorptiometry [ DEXA] scans), and (5) factors associated with escalation and DEXA scans. Methods Retrospective review of Veterans Health Administration (VHA) data from 2002-2010. Results Of the 30,456 Veterans with IBD, 32% required at least one course of corticosteroids during the study time period, and 17% of the steroid users had a prolonged course. Among these patients, only 26.2% underwent escalation of therapy. Patients visiting a gastroenterology (GI) physician were significantly more likely to receive corticosteroid-sparing medications. Factors associated with corticosteroid-sparing medications included younger age (OR = 0.96 per year, 95% CI: 0.95, 0.97), male gender (OR = 2.00,95% CI: 1.16,3.46), GI visit during the corticosteroid evaluation period (OR = 8.01,95% CI: 5.85,10.95) and the use of continuous corticosteroids vs. intermittent corticosteroids (OR = 2.28,95% CI: 1.33,3.90). Rates of complications per 1000 person-years after IBD diagnosis were higher among corticosteroid users (venous thromboembolism [VTE] 9.0%; fragility fracture 2.6%; Infections 54.3) than non-corticosteroid users (VTE 4.9%; fragility fracture 1.9%; Infections 26.9). DEXA scan utilization rates among corticosteroid users were only 7.8%. Conclusions Prolonged corticosteroid therapy for the treatment of IBD is common and is associated with significant harm to patients. Patients with prolonged use of corticosteroids for IBD should be referred to gastroenterology early and universal efforts to improve the delivery of high quality care should be undertaken. C1 [Waljee, Akbar K.; Wiitala, Wyndy L.; Saini, Sameer; Vijan, Sandeep] VA Ann Arbor Hlth Care Syst, VA Ctr Clin Management Res, Ann Arbor, MI USA. [Waljee, Akbar K.; Govani, Shail; Stidham, Ryan; Saini, Sameer; Vijan, Sandeep; Higgins, Peter D. R.] Univ Michigan Hlth Syst, Div Gastroenterol & Hepatol, Dept Internal Med, Ann Arbor, MI USA. [Hou, Jason] Michael E DeBakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Dept Internal Med, Div Gastroenterol & Hepatol, Houston, TX USA. [Hou, Jason] Baylor Coll Med, Med Ctr, Dept Med, Houston, TX 77030 USA. [Feagins, Linda A.] VA North Texas Hlth Care Syst, Div Gastroenterol & Hepatol, Dept Internal Med, Dallas, TX USA. [Feagins, Linda A.] Univ Texas SW Med Ctr Dallas, Div Gastroenterol, Dallas, TX 75390 USA. [Feagins, Linda A.] Univ Texas SW Med Ctr Dallas, Div Hepatol, Dallas, TX 75390 USA. [Khan, Nabeel] Philadelphia VA Med Ctr, Div Gastroenterol, Dept Internal Med, Philadelphia, PA USA. [Khan, Nabeel] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Good, Chester B.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. RP Waljee, AK (reprint author), VA Ann Arbor Hlth Care Syst, VA Ctr Clin Management Res, Ann Arbor, MI USA.; Waljee, AK (reprint author), Univ Michigan Hlth Syst, Div Gastroenterol & Hepatol, Dept Internal Med, Ann Arbor, MI USA. EM awaljee@med.umich.edu FU Veteran's Health Administration Health Services Research and Development Career Development Award (CDA-2) [1IK2HX000775]; National Institutes of Health Research Project Grant Program (R01) [GM097117] FX A.K.W.'s research is funded by a Veteran's Health Administration Health Services Research and Development Career Development Award (CDA-2) 1IK2HX000775. P.D.R.H.'s research is supported by National Institutes of Health Research Project Grant Program (R01) GM097117. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 23 PY 2016 VL 11 IS 6 AR e0158017 DI 10.1371/journal.pone.0158017 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DP3JL UT WOS:000378389200091 PM 27336296 ER PT J AU Brown, KA Jones, M Daneman, N Adler, FR Stevens, V Nechodom, KE Goetz, MB Samore, MH Mayer, J AF Brown, Kevin A. Jones, Makoto Daneman, Nick Adler, Frederick R. Stevens, Vanessa Nechodom, Kevin E. Goetz, Matthew B. Samore, Matthew H. Mayer, Jeanmarie TI Importation, Antibiotics, and Clostridium difficile Infection in Veteran Long-Term Care SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID MEDICAL-CENTERS; RISK-FACTORS; FACILITIES; DIARRHEA; TRANSMISSION; METAANALYSIS AB Background: Although clinical factors affecting a person's susceptibility to Clostridium difficile infection are well-understood, little is known about what drives differences in incidence across long-term care settings. Objective: To obtain a comprehensive picture of individual and regional factors that affect C difficile incidence. Design: Multilevel longitudinal nested case-control study. Setting: Veterans Health Administration health care regions, from 2006 through 2012. Participants: Long-term care residents. Measurements: Individual-level risk factors included age, number of comorbid conditions, and antibiotic exposure. Regional risk factors included importation of cases of acute care C difficile infection per 10 000 resident-days and antibiotic use per 1000 resident-days. The outcome was defined as a positive result on a long-term care C difficile test without a positive result in the prior 8 weeks. Results: 6012 cases (incidence, 3.7 cases per 10 000 resident-days) were identified in 86 regions. Long-term care C difficile incidence (minimum, 0.6 case per 10 000 resident-days; maximum, 31.0 cases per 10 000 resident-days), antibiotic use (minimum, 61.0 days with therapy per 1000 resident-days; maximum, 370.2 days with therapy per 1000 resident-days), and importation (minimum, 2.9 cases per 10 000 resident-days; maximum, 341.3 cases per 10 000 resident-days) varied substantially across regions. Together, antibiotic use and importation accounted for 75% of the regional variation in C difficile incidence (R-2 = 0.75). Multilevel analyses showed that regional factors affected risk together with individual-level exposures (relative risk of regional antibiotic use, 1.36 per doubling [95% CI, 1.15 to 1.60]; relative risk of importation, 1.23 per doubling [CI, 1.14 to 1.33]). Limitations: Case identification was based on laboratory criteria. Admission of residents with recent C difficile infection from non-Veterans Health Administration acute care sources was not considered. Conclusion: Only 25% of the variation in regional C difficile incidence in long-term care remained unexplained after importation from acute care facilities and antibiotic use were accounted for, which suggests that improved infection control and antimicrobial stewardship may help reduce the incidence of C difficile in long-term care settings. C1 Univ Utah, Salt Lake City, UT USA. [Jones, Makoto] Vet Affairs Salt Lake City Hlth Care Syst, 500 Foothill Dr,Mailstop 182, Salt Lake City, UT 84148 USA. [Daneman, Nick] Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave,G Wing Room 106, Toronto, ON M4N 3M5, Canada. [Goetz, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Brown, Kevin A.] Publ Hlth Ontario, 480 Univ Ave, Toronto, ON M5G1V2, Canada. [Adler, Frederick R.] Univ Utah, Dept Math, 155 South 1400 East, Salt Lake City, UT 84112 USA. [Stevens, Vanessa] Univ Utah, Coll Pharm, Dept Pharmacotherapy, 30 South 2000 East,Room 4410, Salt Lake City, UT 84112 USA. [Nechodom, Kevin E.; Samore, Matthew H.; Mayer, Jeanmarie] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, 295 Chipeta Way, Salt Lake City, UT 84132 USA. RP Brown, KA (reprint author), Publ Hlth Ontario, 480 Univ Ave, Toronto, ON M5G1V2, Canada. EM kevin.brown@oahpp.ca OI Brown, Kevin Antoine/0000-0002-1483-2188 FU Centers for Disease Control and Prevention [11FED1106563]; Veterans Health Administration (Centers of Innovation) [13-414] FX By the Centers for Disease Control and Prevention (Intra-agency agreement 11FED1106563) and the Veterans Health Administration (Centers of Innovation grant 13-414; Advanced Fellowship in Informatics [Dr. Brown]). NR 31 TC 2 Z9 2 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUN 21 PY 2016 VL 164 IS 12 BP 787 EP U39 DI 10.7326/M15-1754 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DQ6VG UT WOS:000379343000012 PM 27088642 ER PT J AU Ginsberg, JP AF Ginsberg, J. P. TI Editorial: Dysregulation of Autonomic Cardiac Control by Traumatic Stress and Anxiety SO FRONTIERS IN PSYCHOLOGY LA English DT Editorial Material DE autonomic nervous system; traumatic stress; heart rate variability; Hrv biofeedback; cardiac psychology C1 [Ginsberg, J. P.] US Dept Vet Affairs, Dorn VA Med Ctr, Dorn Res Inst, Columbia, SC USA. RP Ginsberg, JP (reprint author), US Dept Vet Affairs, Dorn VA Med Ctr, Dorn Res Inst, Columbia, SC USA. EM jay.ginsberg@va.gov NR 6 TC 0 Z9 0 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-1078 J9 FRONT PSYCHOL JI Front. Psychol. PD JUN 21 PY 2016 VL 7 AR 945 DI 10.3389/fpsyg.2016.00945 PG 2 WC Psychology, Multidisciplinary SC Psychology GA DP2CX UT WOS:000378296800001 PM 27445913 ER PT J AU Dasgupta, P Dorsey, NJ Li, JQ Qi, XL Smith, EP Yamaji-Kegan, K Keegan, AD AF Dasgupta, Preeta Dorsey, Nicolas J. Li, Jiaqi Qi, Xiulan Smith, Elizabeth P. Yamaji-Kegan, Kazuyo Keegan, Achsah D. TI The adaptor protein insulin receptor substrate 2 inhibits alternative macrophage activation and allergic lung inflammation SO SCIENCE SIGNALING LA English DT Article ID IL-4 RECEPTOR; SIGNAL TRANSDUCER; AIRWAY HYPERRESPONSIVENESS; MUCUS PRODUCTION; GENE-EXPRESSION; CELL-GROWTH; ALPHA-CHAIN; C/EBP-BETA; TH2 CELLS; IN-VIVO AB Insulin receptor substrate 2 (IRS2) is an adaptor protein that becomes tyrosine-phosphorylated in response to the cytokines interleukin-4 (IL-4) and IL-13, which results in activation of the phosphoinositide 3-kinase (PI3K)-Akt pathway. IL-4 and IL-13 contribute to allergic lung inflammation. To examine the role of IRS2 in allergic disease, we evaluated the responses of IRS2-deficient (IRS2(-/-)) mice. Unexpectedly, loss of IRS2 resulted in a substantial increase in the expression of a subset of genes associated with the generation of alternatively activated macrophages (AAMs) in response to IL-4 or IL-13 in vitro. AAMs secrete factors that enhance allergic responses and promote airway remodeling. Moreover, compared to IRS2(+/+) mice, IRS2+/- and IRS2(-/-) mice developed enhanced pulmonary inflammation, accumulated eosinophils and AAMs, and exhibited airway and vascular remodeling upon allergen stimulation, responses that partially depended onmacrophage-intrinsic IRS2 signaling. Both in unstimulated and IL-4-stimulated macrophages, lack of IRS2 enhanced phosphorylation of Akt and ribosomal S6 protein. Thus, we identified a critical inhibitory loop downstream of IRS2, demonstrating an unanticipated and previously unrecognized role for IRS2 in suppressing allergic lung inflammation and remodeling. C1 [Dasgupta, Preeta; Li, Jiaqi; Qi, Xiulan; Smith, Elizabeth P.; Keegan, Achsah D.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, 800 West Baltimore St, Baltimore, MD 21201 USA. [Dasgupta, Preeta; Keegan, Achsah D.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA. [Dorsey, Nicolas J.] Univ Maryland, Sch Med, Med Scientist Training Program, Baltimore, MD 21201 USA. [Yamaji-Kegan, Kazuyo] Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave, Baltimore, MD 21205 USA. [Keegan, Achsah D.] Vet Affairs Maryland Hlth Care Syst, US Dept Vet Affairs, Res & Dev Serv, Baltimore, MD 21201 USA. RP Keegan, AD (reprint author), Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, 800 West Baltimore St, Baltimore, MD 21201 USA.; Keegan, AD (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.; Keegan, AD (reprint author), Vet Affairs Maryland Hlth Care Syst, US Dept Vet Affairs, Res & Dev Serv, Baltimore, MD 21201 USA. EM akeegan@som.umaryland.edu FU U.S. Public Health Service (PHS) [AI038985, HL110111, T32HL06798, T32AI007540]; United Negro College Fund/Merck Science Initiative; VA-MERIT [I01 BX001850] FX This work was supported by U.S. Public Health Service (PHS) grants AI038985 and HL110111 and VA-MERIT I01 BX001850 to A.D.K., a Pulmonary Hypertension Association/American Thoracic Society/Pfizer Research Fellowship in Pulmonary Arterial Hypertension to K.Y.-K., and PHS grants T32HL06798 and T32AI007540 and a United Negro College Fund/Merck Science Initiative to N.J.D. NR 60 TC 2 Z9 2 U1 0 U2 0 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1945-0877 EI 1937-9145 J9 SCI SIGNAL JI Sci. Signal. PD JUN 21 PY 2016 VL 9 IS 433 AR ra63 DI 10.1126/scisignal.aad6724 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DP2RU UT WOS:000378339500003 PM 27330190 ER PT J AU Bibbins-Domingo, K Grossman, DC Curry, SJ Davidson, KW Epling, JW Garcia, FAR Gillman, MW Harper, DM Kemper, AR Krist, AH Kurth, AE Landefeld, CS Mangione, CM Owens, DK Phillips, WR Phipps, MG Pignone, MP Siu, AL AF Bibbins-Domingo, Kirsten Grossman, David C. Curry, Susan J. Davidson, Karina W. Epling, John W., Jr. Garcia, Francisco A. R. Gillman, Matthew W. Harper, Diane M. Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Landefeld, C. Seth Mangione, Carol M. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. Siu, Albert L. CA US Preventive Serv Task Force TI Screening for Colorectal Cancer US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID RANDOMIZED-CLINICAL-TRIAL; AMERICAN-COLLEGE; COLONOSCOPY; GUIDELINES; MORTALITY; PATTERNS; OUTCOMES AB IMPORTANCE Colorectal cancer is the second leading cause of cancer death in the United States. In 2016, an estimated 134 000 persons will be diagnosed with the disease, and about 49 000 will die from it. Colorectal cancer is most frequently diagnosed among adults aged 65 to 74 years; the median age at death from colorectal cancer is 68 years. OBJECTIVE To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for colorectal cancer. EVIDENCE REVIEW The USPSTF reviewed the evidence on the effectiveness of screening with colonoscopy, flexible sigmoidoscopy, computed tomography colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 DNA test in reducing the incidence of and mortality from colorectal cancer or all-cause mortality; the harms of these screening tests; and the test performance characteristics of these tests for detecting adenomatous polyps, advanced adenomas based on size, or both, as well as colorectal cancer. The USPSTF also commissioned a comparative modeling study to provide information on optimal starting and stopping ages and screening intervals across the different available screeningmethods. FINDINGS The USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asymptomatic adults aged 50 to 75 years is of substantial net benefit. Multiple screening strategies are available to choose from, with different levels of evidence to support their effectiveness, as well as unique advantages and limitations, although there are no empirical data to demonstrate that any of the reviewed strategies provide a greater net benefit. Screening for colorectal cancer is a substantially underused preventive health strategy in the United States. CONCLUSIONS AND RECOMMENDATIONS The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years (A recommendation). The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history (C recommendation). C1 [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Curry, Susan J.] Univ Iowa, Iowa City, IA USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Epling, John W., Jr.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew W.] Harvard Univ, Sch Med, Boston, MA USA. [Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Harper, Diane M.] Univ Louisville, Louisville, KY 40292 USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice Residency, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] Yale Univ, New Haven, CT USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA. [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. Univ Washington, Seattle, WA 98195 USA. Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM chair@uspstf.net OI Epling, John W/0000-0001-9445-8669; Phillips, William/0000-0003-2802-4349 FU Agency for Healthcare Research and Quality (AHRQ) FX The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF. NR 30 TC 48 Z9 48 U1 4 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 21 PY 2016 VL 315 IS 23 BP 2564 EP 2575 DI 10.1001/jama.2016.5989 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA DP2GQ UT WOS:000378306700020 ER PT J AU Stetler, RA Gao, YQ Leak, RK Weng, ZF Shi, YJ Zhang, LL Pu, HJ Zhang, F Hu, XM Hassan, S Ferguson, C Homanics, GE Cao, GD Bennett, MVL Chen, J AF Stetler, R. Anne Gao, Yanqin Leak, Rehana K. Weng, Zhongfang Shi, Yejie Zhang, Lili Pu, Hongjian Zhang, Feng Hu, Xiaoming Hassan, Sulaiman Ferguson, Carolyn Homanics, Gregg E. Cao, Guodong Bennett, Michael V. L. Chen, Jun TI APE1/Ref-1 facilitates recovery of gray and white matter and neurological function after mild stroke injury SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE ischemia; neurodegeneration; base excision repair; oxidative DNA; damage; white matter injury ID STRANDED DEOXYRIBONUCLEIC-ACID; TRANSIENT FOCAL ISCHEMIA; GLOBAL CEREBRAL-ISCHEMIA; BASE-EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; NEURONAL CELL-DEATH; APURINIC/APYRIMIDINIC ENDONUCLEASE; SIGNALING PATHWAY; HSP27 PROTECTS; APURINIC SITES AB A major hallmark of oxidative DNA damage after stroke is the induction of apurinic/apyrimidinic (AP) sites and strand breaks. To mitigate cell loss after oxidative DNA damage, ischemic cells rapidly engage the base excision-repair proteins, such as the AP site-repairing enzyme AP endonuclease-1 (APE1), also named redox effector factor-1 (Ref-1). Although forced overexpression of APE1 is known to protect against oxidative stress-induced neurodegeneration, there is no concrete evidence demonstrating a role for endogenous APE1 in the long-term recovery of gray and white matter following ischemic injury. To address this gap, we generated, to our knowledge, the first APE1 conditional knockout (cKO) mouse line under control of tatamoxifen-dependent Cre recombinase. Using a well-established model of transient focal cerebral ischemia (tFCI), we show that induced deletion of APE1 dramatically enlarged infarct volume and impaired the recovery of sensorimotor and cognitive deficits. APE1 cKO markedly increased postischemic neuronal and oligodendrocyte degeneration, demonstrating that endogenous APE1 preserves both gray and white matter after tFCI. Because white matter repair is instrumental in behavioral recovery after stroke, we also examined the impact of APE1 cKO on demyelination and axonal conduction and discovered that APE1 cKO aggravated myelin loss and impaired neuronal communication following tFCI. Furthermore, APE1 cKO increased AP sites and activated the prodeath signaling proteins, PUMA and PARP1, after tFCI in topographically distinct manners. Our findings provide evidence that endogenous APE1 protects against ischemic infarction in both gray and white matter and facilitates the functional recovery of the central nervous system after mild stroke injury. C1 [Stetler, R. Anne; Gao, Yanqin; Zhang, Feng; Hu, Xiaoming; Cao, Guodong; Bennett, Michael V. L.; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Stetler, R. Anne; Gao, Yanqin; Zhang, Feng; Hu, Xiaoming; Cao, Guodong; Bennett, Michael V. L.; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Stetler, R. Anne; Gao, Yanqin; Weng, Zhongfang; Shi, Yejie; Zhang, Lili; Pu, Hongjian; Zhang, Feng; Hu, Xiaoming; Hassan, Sulaiman; Cao, Guodong; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA. [Stetler, R. Anne; Weng, Zhongfang; Shi, Yejie; Zhang, Lili; Zhang, Feng; Hu, Xiaoming; Hassan, Sulaiman; Cao, Guodong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA. [Ferguson, Carolyn; Homanics, Gregg E.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Ferguson, Carolyn; Homanics, Gregg E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Bennett, Michael V. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA. RP Bennett, MVL; Chen, J (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.; Bennett, MVL; Chen, J (reprint author), Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China.; Chen, J (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA.; Chen, J (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.; Bennett, MVL (reprint author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA. EM michael.bennett@einstein.yu.edu; chenj2@upmc.edu OI Shi, Yejie/0000-0001-7502-9201 FU National Institutes of Health [NS036736, NS045048, NS089534, NS45287, AA10422]; US Department of Veterans Affairs Senior Research Career Scientist Award; Chinese Natural Science Foundation [81020108021, 81171149, 81371306, 81228008]; State Administration of Foreign Experts Affairs of China [GDW20133100069] FX We thank Ed Mallick for technical assistance in generating the apurinic/apyrimidinic endonuclease-1 conditional knockout mouse line. This research was supported by National Institutes of Health Grants NS036736, NS045048, and NS089534 (to J.C.), NS45287 (to M.V.L.B.), and AA10422 (to G.E.H); a US Department of Veterans Affairs Senior Research Career Scientist Award (to J.C.); Chinese Natural Science Foundation Grants 81020108021, 81171149, and 81371306 (to Y.G.), and 81228008 (to J.C.); and the High-end Distinguished Professorship GDW20133100069 from the State Administration of Foreign Experts Affairs of China (to M.V.L.B.). NR 47 TC 1 Z9 1 U1 2 U2 4 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD JUN 21 PY 2016 VL 113 IS 25 BP E3558 EP E3567 DI 10.1073/pnas.1606226113 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DP1TN UT WOS:000378272400015 PM 27274063 ER PT J AU Ramos, AD Attenello, FJ Lim, DA AF Ramos, Alexander D. Attenello, Frank J. Lim, Daniel A. TI Uncovering the roles of long noncoding RNAs in neural development and glioma progression SO NEUROSCIENCE LETTERS LA English DT Review DE Long noncoding RNA; IncRNA; Chromatin; Epigenetics; Neural stem; Cell; Neurogenesis; Brain development; Brain tumor; Glioma ID ADULT MAMMALIAN BRAIN; STEM-CELLS; SUBVENTRICULAR ZONE; BINDING-PROTEINS; MOUSE-BRAIN; IN-VIVO; NEURONAL DIFFERENTIATION; EPIGENETIC REGULATION; EXPRESSION PROFILES; RETINAL DEVELOPMENT AB In the past decade, thousands of long noncoding RNA5 (lncRNAs) have been identified, and emerging data indicate that IncRNAs can have important biological functions and roles in human diseases including cancer. Many IncRNAs appear to be expressed specifically in the brain, and the roles of IncRNAs in neural stem cells (NSCs) and brain development are now beginning to be discovered. Here we review recent advances in understanding the diversity of IncRNA structure and functions in NSCs and brain development. NSCs in the adult mouse ventricular-subventricular zone (V-SVZ) generate new neurons throughout life, and we discuss how key elements of this adult neurogenic system have facilitated the discovery and functional characterization of known and novel IncRNAs. A review of lncRNAs described in other NSC systems reveals a variety of molecular mechanisms, including binding and recruitment of transcription factors, epigenetic modifiers, and RNA-splicing factors. Finally, we review emerging evidence indicating that specific IncRNAs can be key drivers of glial tumors, and discuss next steps towards an in vivo understanding of IncRNA function in development and disease. Published by Elsevier Ireland Ltd. C1 [Ramos, Alexander D.; Attenello, Frank J.; Lim, Daniel A.] Dept Neurol Surg, San Francisco, CA 94121 USA. [Ramos, Alexander D.; Attenello, Frank J.; Lim, Daniel A.] Ctr Regenerat Med & Stem Cell Res, Eli & Edythe Broad, San Francisco, CA 94121 USA. [Lim, Daniel A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Attenello, Frank J.] Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90033 USA. RP Lim, DA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 35 Med Ctr Way,RMB 1037, San Francisco, CA 94143 USA. EM daniel.lim@ucsf.edu FU American Brain Tumor Association; Sontag Foundation; Shurl and Kay Curci Foundation; NCI-SPORE DRP; Hana Jabsheh Initiative; [VA 5I01 BX000252-06] FX This work was supported by VA 5I01 BX000252-06, American Brain Tumor Association, Sontag Foundation, Shurl and Kay Curci Foundation, NCI-SPORE DRP, and the Hana Jabsheh Initiative. NR 100 TC 4 Z9 6 U1 6 U2 8 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUN 20 PY 2016 VL 625 BP 70 EP 79 DI 10.1016/j.neulet.2015.12.025 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DQ7GC UT WOS:000379373900012 PM 26733304 ER PT J AU Mathew, ST Pakala, AV Thadani, U AF Mathew, Sunil T. Pakala, Aneesh V. Thadani, Udho TI Invasive strategy in acute coronary syndrome SO LANCET LA English DT Letter C1 [Mathew, Sunil T.] Univ Oklahoma, Hlth Sci Ctr, Cardiovasc Sect, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK 73104 USA. RP Mathew, ST (reprint author), Univ Oklahoma, Hlth Sci Ctr, Cardiovasc Sect, Oklahoma City, OK 73104 USA. EM stmathew@gmail.com NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD JUN 18 PY 2016 VL 387 IS 10037 BP 2503 EP 2504 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DO7FG UT WOS:000377947200021 PM 27353678 ER PT J AU Winter, L Moriarty, H Robinson, KM Newhart, B AF Winter, Laraine Moriarty, Helene Robinson, Keith M. Newhart, Brian TI Rating competency in everyday activities in patients with TBI: clinical insights from a close look at patient-family differences SO DISABILITY AND REHABILITATION LA English DT Article DE traumatic brain injury; family; Caregivers; competence in activities; veterans ID TRAUMATIC BRAIN-INJURY; COMMUNITY REINTEGRATION; SELF; CAREGIVER; SYMPTOMS; REHABILITATION; PERSPECTIVE; MECHANISMS; DEPRESSION; VETERANS AB Purpose: Families of patients with traumatic brain injury (TBI) often perceive patients' functional capabilities differently from patients themselves. Research documents inconsistent findings regarding direction of differences. Differences have implications for family support and are germane to clinicians' treatment planning during rehabilitation. We compared two analytic approaches to patient-family differences in ratings of 30 functional tasks: (a) comparing patients' and families' mean scores in domains derived from factor analysis versus (b) examining differences on a task-by-task basis. Method: In-home interviews were conducted with 83 outpatients with TBI at a Veteran Affairs polytrauma clinic and for each a family member, using the Patient Competency Rating Scale with both. Results: Principal components analysis identified three functional domains - cognitive, interpersonal/emotional and physical - with significant patient-family differences in the cognitive domain only (family competency ratings were higher). By contrast, task-by-task examination showed significant veteran-family differences in 12 items, mostly in interpersonal/emotional functioning, with mixed directions of differences. The task-by-task approach thus revealed a different picture of patient-family differences than examination by functional domains. Conclusions: Grouping tasks by domains may obscure important differences in functional ratings. Examination of patient-family differences by task has clinical applications for helping patients and families to manage TBI symptoms and for treatment planning. Implications for Rehabilitation Differences in functional capacity ratings by patients with TBI and their family members are not well understood, with past research demonstrating inconsistencies in direction of difference. Differences in ratings may affect family relationships and may inform clinicians' treatment plans. The study showed that different approaches to analyzing the same data yield two distinct pictures of patient-family differences. Examining patient-family differences by specific tasks is clinically meaningful. The Competency Rating Scale could be used as a clinical tool with patients and families. Its use may improve family understanding of the patient's strengths and struggles and also guide treatment planning. C1 [Winter, Laraine; Moriarty, Helene] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA. [Winter, Laraine] Philadelphia Res & Educ Fdn, Dept Vet Affairs Med Ctr, Philadelphia, PA USA. [Moriarty, Helene] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA. [Robinson, Keith M.; Newhart, Brian] Polytrauma Network Site Vet Integrated Serv Netwo, Rehabil Med Serv, Philadelphia, PA USA. [Robinson, Keith M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Winter, L (reprint author), Philadelphia Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM laraine.winter@gmail.com NR 49 TC 0 Z9 0 U1 3 U2 9 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0963-8288 EI 1464-5165 J9 DISABIL REHABIL JI Disabil. Rehabil. PD JUN 18 PY 2016 VL 38 IS 13 BP 1280 EP 1290 DI 10.3109/09638288.2015.1077531 PG 11 WC Rehabilitation SC Rehabilitation GA DH5OL UT WOS:000372839500006 PM 26314877 ER PT J AU Keene, CD Darvas, M Kraemer, B Liggitt, D Sigurdson, C Ladiges, W AF Keene, C. Dirk Darvas, Martin Kraemer, Brian Liggitt, Denny Sigurdson, Christina Ladiges, Warren TI Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines SO PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES LA English DT Editorial Material DE Alzheimer's disease; mouse models of Alzheimer's disease; neuropathological validation; NIA-AA guidelines ID AD AB Dozens of transgenic mouse models, generally based on mutations associated with familial Alzheimer's disease (AD), have been developed, in part, for preclinical testing of candidate AD therapies. However, none of these models has successfully predicted the clinical efficacy of drugs for treating AD patients. Therefore, development of more translationally relevant AD mouse models remains a critical unmet need in the field. A concept not previously implemented in AD preclinical drug testing is the use of mouse lines that have been validated for neuropathological features of human AD. Current thinking suggests that amyloid plaque and neurofibrillary tangle deposition is an essential component for accurate modeling of AD. Therefore, the AD translational paradigm would require pathologic Ab and tau deposition, a disease-relevant distribution of plaques and tangles, and a pattern of disease progression of Ab and tau isoforms similar to the neuropathological features found in the brains of AD patients. Additional parameters useful to evaluate parallels between AD and animal models would include 1) cerebrospinal fluid (CSF) AD biomarker changes with reduced Ab and increased phospho-tau/tau; 2) structural and functional neuroimaging patterns including MRI hippocampal atrophy, fluorodeoxyglucose (FDG), and amyloid/tau PET alterations in activity and/or patterns of pathologic peptide deposition and distribution; and 3) cognitive impairment with emphasis on spatial learning and memory to distinguish presymptomatic and symptomatic mice at specific ages. A validated AD mouse model for drug testing would likely show tau-related neurofibrillary degeneration following Ab deposition and demonstrate changes in pathology, CSF analysis, and neuroimaging that mirror human AD. Development of the ideal model would revolutionize the ability to establish the translational value of AD mouse models and serve as a platform for discussions about national phenotyping guidelines and standards for models of AD and other neurodegenerative disorders. C1 [Keene, C. Dirk; Darvas, Martin; Ladiges, Warren] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Kraemer, Brian] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Kraemer, Brian] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Liggitt, Denny; Ladiges, Warren] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA. [Sigurdson, Christina] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA. [Sigurdson, Christina] Scripps Res Inst, La Jolla, CA 92037 USA. RP Ladiges, W (reprint author), Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA. EM wladiges@u.washington.edu FU BLRD VA [I01 BX002619] NR 8 TC 0 Z9 0 U1 2 U2 2 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN EI 2001-0001 J9 PATHOBIOL AGING AGE JI Pathobiol. Aging Age-relat. Dis. PD JUN 16 PY 2016 VL 6 AR 32397 DI 10.3402/pba.v6.32397 PG 4 WC Pathology SC Pathology GA DT4EY UT WOS:000381434100001 PM 27317189 ER PT J AU Oscari, F Finetto, C Kautz, SA Rosati, G AF Oscari, Fabio Finetto, Christian Kautz, Steve A. Rosati, Giulio TI Changes in muscle coordination patterns induced by exposure to a viscous force field SO JOURNAL OF NEUROENGINEERING AND REHABILITATION LA English DT Article DE Motor adaptation; Learning; Motor modules; Viscous field; Dynamic perturbation; Robotics; Haptics ID STROKE REHABILITATION; ACTIVATION PATTERNS; REACHING MOVEMENTS; MOTOR ADAPTATION; MODULAR CONTROL; HUMAN WALKING; UPPER-LIMB; SYNERGIES; ERROR; MODEL AB Background: Robotic neurorehabilitation aims at promoting the recovery of lost function after neurological injury by leveraging strategies of motor learning. One important aspect of the rehabilitation process is the improvement of muscle coordination patterns, which can be drastically altered after stroke. However, it is not fully understood if and how robotic therapy can address these deficits. The aim of our study was to find how muscle coordination, analyzed from the perspective of motor modules, could change during motor adaptation to a dynamic environment generated by a haptic interface. Methods: In our experiment we employed the traditional paradigm of exposure to a viscous force field to subjects that grasped the handle of an actuated joystick during a reaching movement (participants moved directly forward and back by 30 cm). EMG signals of ten muscles of the tested arm were recorded. We extracted motor modules from the pooled EMG data of all subjects and analyzed the muscle coordination patterns. Results: We found that the participants reacted by using a coordination strategy that could be explained by a change in the activation of motor modules used during free motion and by two complementary modules. These complementary modules aggregated changes in muscle coordination, and evolved throughout the experiment eventually maintaining a comparable structure until the late phase of re-adaptation. Conclusions: This result suggests that motor adaptation induced by the interaction with a robotic device can lead to changes in the muscle coordination patterns of the subject. C1 [Oscari, Fabio; Rosati, Giulio] Univ Padua, Dept Management & Engn, Via Venezia 1, I-35135 Padua, Italy. [Finetto, Christian; Kautz, Steve A.] Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. [Kautz, Steve A.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Oscari, F (reprint author), Univ Padua, Dept Management & Engn, Via Venezia 1, I-35135 Padua, Italy. EM fabio.oscari@unipd.it FU Institutional Development Award (IDeA) from National Institute of General Medical Sciences of the National Institutes of Health [P20GM109040]; Rehabilitation Research and Development Service of the Department of Veterans Affairs FX The authors would like to thank Dr. Stefano Masiero for providing the EMG system used for the experiment. Furthermore, we would like to acknowledge the contribution of Alice Marcato to the organization and execution of all data collections. Dr. Kautz is supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM109040 and by the Rehabilitation Research and Development Service of the Department of Veterans Affairs. NR 49 TC 0 Z9 0 U1 11 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-0003 J9 J NEUROENG REHABIL JI J. NeuroEng. Rehabil. PD JUN 16 PY 2016 VL 13 AR 58 DI 10.1186/s12984-016-0164-3 PG 16 WC Engineering, Biomedical; Neurosciences; Rehabilitation SC Engineering; Neurosciences & Neurology; Rehabilitation GA DQ1XM UT WOS:000378994100002 PM 27305944 ER PT J AU Tokhtaeva, E Sun, HY Deiss-Yehiely, N Wen, Y Soni, PN Gabrielli, NM Marcus, EA Ridge, KM Sachs, G Vazquez-Levin, M Sznajder, JI Vagin, O Dada, LA AF Tokhtaeva, Elmira Sun, Haying Deiss-Yehiely, Nimrod Wen, Yi Soni, Pritin N. Gabrielli, Nieves M. Marcus, Elizabeth A. Ridge, Karen M. Sachs, George Vazquez-Levin, Monica Sznajder, Jacob I. Vagin, Olga Dada, Laura A. TI The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na, K-ATPase beta(1) subunits SO JOURNAL OF CELL SCIENCE LA English DT Article DE Na; K-ATPase; Epithelium; Epithelial cell adhesion molecule; Cell-cell interaction; Cell adhesion; O-glycosylation; FXYD5 ID ALVEOLAR EPITHELIAL-CELLS; PULMONARY-EDEMA CLEARANCE; LUNG LIQUID CLEARANCE; E-CADHERIN EXPRESSION; BREAST-CANCER CELLS; DYSADHERIN EXPRESSION; PLASMA-MEMBRANE; TIGHT JUNCTIONS; DOWN-REGULATION; NA+/K+-ATPASE AB FXYD5 (also known as dysadherin), a regulatory subunit of the Na, K-ATPase, impairs intercellular adhesion by a poorly understood mechanism. Here, we determined whether FXYD5 disrupts the trans-dimerization of Na, K-ATPase molecules located in neighboring cells. Mutagenesis of the Na, K-ATPase beta(1) subunit identified four conserved residues, including Y199, that are crucial for the intercellular Na, K-ATPase trans-dimerization and adhesion. Modulation of expression of FXYD5 or of the beta(1) subunit with intact or mutated beta(1)-beta(1) binding sites demonstrated that the anti-adhesive effect of FXYD5 depends on the presence of Y199 in the beta(1) subunit. Immunodetection of the plasma membrane FXYD5 was prevented by the presence of O-glycans. Partial FXYD5 deglycosylation enabled antibody binding and showed that the protein level and the degree of O-glycosylation were greater in cancer than in normal cells. FXYD5- induced impairment of adhesion was abolished by both genetic and pharmacological inhibition of FXYD5 O-glycosylation. Therefore, the extracellular O-glycosylated domain of FXYD5 impairs adhesion by interfering with intercellular beta(1)-beta(1) interactions, suggesting that the ratio between FXYD5 and alpha(1)-beta(1) heterodimer determines whether the Na, K-ATPase acts as a positive or negative regulator of intercellular adhesion. C1 [Tokhtaeva, Elmira; Wen, Yi; Sachs, George; Vagin, Olga] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Tokhtaeva, Elmira; Wen, Yi; Marcus, Elizabeth A.; Sachs, George; Vagin, Olga] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Sun, Haying; Deiss-Yehiely, Nimrod; Soni, Pritin N.; Gabrielli, Nieves M.; Ridge, Karen M.; Sznajder, Jacob I.; Dada, Laura A.] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA. [Gabrielli, Nieves M.; Vazquez-Levin, Monica] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, FIBYME, C1418ADN, Buenos Aires, DF, Argentina. [Marcus, Elizabeth A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. RP Dada, LA (reprint author), Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA. EM lauradada@northwestern.edu FU National Institutes of Health [R37-HL48129, HL071643, HL113350, USVA 2I01BX001006, DK105156-01, PICT_SU1072, K08DK100661]; UCLA Children's Discovery and Innovation Institute FX This work was supported, in part, by the National Institutes of Health [grant numbers R37-HL48129 to J.I.S., HL071643 to J.I.S., K.M.R. and L.A.D., HL113350 to L.A.D. and O.V., USVA 2I01BX001006 to G.S., DK105156-01 to G.S., PICT_SU1072 to M.V.-L., K08DK100661 to E.A.M.]; and the UCLA Children's Discovery and Innovation Institute (to E.A.M.). Deposited in PMC for release after 12 months. NR 65 TC 1 Z9 1 U1 0 U2 4 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 EI 1477-9137 J9 J CELL SCI JI J. Cell Sci. PD JUN 15 PY 2016 VL 129 IS 12 BP 2394 EP 2406 DI 10.1242/jcs.186148 PG 13 WC Cell Biology SC Cell Biology GA DQ8YV UT WOS:000379498500011 PM 27142834 ER PT J AU Kaji, I Akiba, Y Konno, K Watanabe, M Kimura, S Iwanaga, T Kuri, A Iwamoto, K Kuwahara, A Kaunitz, JD AF Kaji, Izumi Akiba, Yasutada Konno, Kohtarou Watanabe, Masahiko Kimura, Shunsuke Iwanaga, Toshihiko Kuri, Ayaka Iwamoto, Ken-ichi Kuwahara, Atsukazu Kaunitz, Jonathan D. TI Neural FFA3 activation inversely regulates anion secretion evoked by nicotinic ACh receptor activation in rat proximal colon SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID CHAIN FATTY-ACIDS; PROTEIN-COUPLED RECEPTOR; CHOLINE-ACETYLTRANSFERASE; ENTERIC NEURONS; GASTROINTESTINAL-TRACT; DISTAL COLON; IN-VITRO; EXPRESSION; ILEUM; TRANSPORT AB The proximal colonic mucosa is constantly exposed to high concentrations of microbially-produced short-chain fatty acids (SCFAs). Although luminal SCFAs evoke electrogenic anion secretion and smooth muscle contractility via neural and non-neural cholinergic pathways in the colon, the involvement of the SCFA receptor free fatty acid receptor (FFA)3, one of the free fatty acid receptor family members, has not been clarified. We investigated the contribution of FFA3 to cholinergic-mediated secretory responses in rat proximal colon. FFA3 was immunolocalized to enteroendocrine cells and to the enteric neural plexuses. Most FFA3-immunoreactive nerve fibres and nerve endings were cholinergic, colocalized with protein gene product (PGP)9.5, the vesicular ACh transporter, and the high-affinity choline transporter CHT1. In Ussing chambered mucosa-submucosa preparations (including the submucosal plexus) of rat proximal colon, carbachol (CCh)-induced Cl- secretion was decreased by TTX, hexamethonium, and the serosal FFA3 agonists acetate or propionate, although not by an inactive analogue 3-chloropropionate. Serosal application of a selective FFA3 agonist (N-[2-methylphenyl]-[4-furan-3-yl]-2-methyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxamide; MQC) dose-dependently suppressed the response to CCh but not to forskolin, with an IC50 of 13m. Pretreatment with MQC inhibited nicotine-evoked but not bethanechol-evoked secretion. The inhibitory effect of MQC was reversed by pretreatment with pertussis toxin, indicating that FFA3 acts via the G(i/o) pathway. Luminal propionate induced Cl- secretion via the cholinergic pathway, which was reduced by MQC, as well as by TTX, hexamethonium or removal of the submucosal plexus. These results suggest that the SCFA-FFA3 pathway has a novel anti-secretory function in that it inhibits cholinergic neural reflexes in the enteric nervous system. C1 [Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaji, Izumi; Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Kaji, Izumi; Akiba, Yasutada; Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. [Konno, Kohtarou; Watanabe, Masahiko; Kimura, Shunsuke; Iwanaga, Toshihiko] Hokkaido Univ, Grad Sch Med, Dept Anat, Sapporo, Hokkaido, Japan. [Kuri, Ayaka; Iwamoto, Ken-ichi; Kuwahara, Atsukazu] Univ Shizuoka, Grad Sch Integrated Pharmaceut & Nutr Sci, Shizuoka, Japan. RP Kaunitz, JD (reprint author), West Los Angeles VA Med Ctr, Bldg 114,Suite 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu RI Kimura, Shunsuke/D-7093-2012; WATANABE, Masahiko/A-4055-2012 OI Kimura, Shunsuke/0000-0001-9408-2884; FU Department of Veterans Affairs Merit Review Award; NIH [R01 DK54221]; Comprehensive Brain Science Network (CBSN) in Japan FX This work was supported by a Department of Veterans Affairs Merit Review Award and NIH R01 DK54221. Antibody production was supported by a project of Comprehensive Brain Science Network (CBSN) in Japan. NR 53 TC 1 Z9 1 U1 4 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 EI 1469-7793 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD JUN 15 PY 2016 VL 594 IS 12 BP 3339 EP 3352 DI 10.1113/JP271441 PG 14 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA DQ4PC UT WOS:000379184800017 PM 26854275 ER PT J AU Evans, TM Bhattacharya, A Shi, Y Qi, WB Block, TJ Chaudhuri, A Chaudhuri, AR Hawker, K Van Remmen, H AF Evans, Teresa M. Bhattacharya, Arunabh Shi, Yun Qi, Wenbo Block, Travis J. Chaudhuri, Asish Chaudhuri, Alakananda Ray Hawker, Kara Van Remmen, Holly TI Moderate modulation of disease in the G93A model of ALS by the compound 2-(2-hydroxypheny1)-benzoxazole (HBX) SO NEUROSCIENCE LETTERS LA English DT Article DE Amyotrophic lateral sclerosis; Mouse model; Protein aggregation; Denervation; Treatment; Chelation ID AMYOTROPHIC-LATERAL-SCLEROSIS; MUTANT SUPEROXIDE-DISMUTASE; MOTOR-NEURON DISEASE; CONGO-RED; LIPID-PEROXIDATION; OXIDATIVE STRESS; PROTEIN; MICE; AGGREGATION; SOD1 AB Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurological disease characterized by degeneration and death of motor neurons. Aberrant protein aggregation and oxidative stress are implicated in the etiology of ALS; thus preventing propagation of early aggregation events and oxidative damage could be an effective therapy. We tested the effect of dietary supplementation (initiated 40 days of age) with 2-(2-hydroxyphenyl)-benzoxazole (HBX), a compound with metal chelator and anti-aggregation properties, on disease onset, progression and lifespan in the G93A mouse model of ALS. Tests were not sufficiently powerful to detect any change to survival distribution of mice treated with HBX. However, the disease onset was delayed and max lifespan was increased in the treatment group. Additionally, disease progression was moderated as shown by reduced neuromuscular denervation measured by repetitive nerve stimulation. F-2-isoprostanes, a marker of oxidative damage, are elevated in skeletal muscle from G93A mice at onset and this increase is prevented in HBX fed G93A mice. Furthermore, HBX treatment reduced mutant SOD1 protein aggregation in whole spinal cord of G93A mice at disease onset. Overall, our data suggests that HBX may be able to improve the degenerative symptoms of ALS through the prevention of oxidative damage and protein aggregation. Further studies are needed to uncover the mechanistic effects of HBX in ameliorating ALS pathology. (C) 2016 Published by Elsevier Ireland Ltd. C1 [Evans, Teresa M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular Biol, San Antonio, TX 78229 USA. [Bhattacharya, Arunabh] Univ Texas Hlth Sci Ctr San Antonio, Dept Biol Struct, San Antonio, TX 78229 USA. [Shi, Yun; Qi, Wenbo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Block, Travis J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Chaudhuri, Asish] UT Southwestern, Dept Biochem, Dallas, TX USA. [Chaudhuri, Alakananda Ray; Hawker, Kara] Univ Incarnate Word, Dept Chem, San Antonio, TX USA. [Van Remmen, Holly] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Van Remmen, Holly] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. RP Van Remmen, H (reprint author), Oklahoma Med Res Fdn, Aging & Metab Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Holly-VanRemmen@omrf.org FU Veterans Administration Merit Review FX This work was supported by a Veterans Administration Merit Review grant to HVR. We acknowledge the support of Drs. Randy Strong and Elizabeth Fernandez with the Interventions Testing Program at UT Health Science Center San Antonio for their help in the HBX formulation and diet preparation. Additionally, we wish to acknowledge Vivian Diaz and the San Antonio Nathan Shock Center for the housing and survival studies. NR 41 TC 1 Z9 1 U1 1 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 EI 1872-7972 J9 NEUROSCI LETT JI Neurosci. Lett. PD JUN 15 PY 2016 VL 624 BP 1 EP 7 DI 10.1016/j.neulet.2016.04.035 PG 7 WC Neurosciences SC Neurosciences & Neurology GA DP3YV UT WOS:000378433200001 PM 27138280 ER PT J AU Patel, MB Jackson, JC Morandi, A Girard, TD Hughes, CG Thompson, JL Kiehl, AL Elstad, MR Wasserstein, ML Goodman, RB Beckham, JC Chandrasekhar, R Dittus, RS Ely, EW Pandharipande, PP AF Patel, Mayur B. Jackson, James C. Morandi, Alessandro Girard, Timothy D. Hughes, Christopher G. Thompson, Jennifer L. Kiehl, Amy L. Elstad, Mark R. Wasserstein, Mitzi L. Goodman, Richard B. Beckham, Jean C. Chandrasekhar, Rameela Dittus, Robert S. Ely, E. Wesley Pandharipande, Pratik P. TI Incidence and Risk Factors for Intensive Care Unit-related Post-traumatic Stress Disorder in Veterans and Civilians SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE post-traumatic stress disorder; intensive care unit; veterans ID LIFE EVENTS QUESTIONNAIRE; ACUTE LUNG INJURY; QUALITY-OF-LIFE; CRITICAL ILLNESS; PROSPECTIVE COHORT; CARDIAC-SURGERY; CRITICALLY-ILL; ICU TREATMENT; SEPTIC SHOCK; DSM-IV AB Rationale: The incidence and risk factors of post-traumatic stress disorder (PTSD) related to the intensive care unit (ICU) experience have not been reported in a mixed veteran and civilian cohort. Objectives: To describe the incidence and risk factors for ICU related PTSD in veterans and civilians. Methods: This is a prospective, observational, multicenter cohort enrolling adult survivors of critical illness after respiratory failure and/or shock from three Veterans Affairs and one civilian hospital. After classifying those with/without preexisting PTSD (i.e., PTSD before hospitalisation), we then assessed all subjects for ICU-related PTSD at 3 and 12 months post hospitalization. Measurements and Main Results: Of 255 survivors, 181 and 160 subjects were assessed for ICU-related PTSD at 3- and 12-month follow-up, respectively. A high probability of ICU-related PTSD was found in up to 10% of patients at either follow-up time point, whether assessed by PTSD Checklist Event-Specific Version (score 50) or item mapping using the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV). In the multivariable regression, preexisting PTSD was independently associated with ICU-related PTSD at both 3 and 12 months (P < 0.001), as was preexisting depression (P < 0.03), but veteran status was not a consistent independent risk factor for ICU-related PTSD (3-month P = 0.01, 12-month P = 0.48). Conclusions: This study found around 1 in 10 ICU survivors experienced ICU-related PTSD (i.e., PTSD anchored to their critical illness) in the year after hospitalization. Preexisting PTSD and depression were strongly associated with ICU-related PTSD. C1 [Patel, Mayur B.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville VA Med Ctr, Surg Serv, Nashville, TN USA. [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res,Dept Surg, Div Trauma & Surg Crit Care,Vanderbilt Brain Inst, Nashville, TN USA. [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Sect Surg Sci,Vanderbilt Brain Inst,Dept Neurosur, Nashville, TN USA. [Jackson, James C.; Girard, Timothy D.; Dittus, Robert S.; Ely, E. Wesley] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville VA Med Ctr, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Jackson, James C.; Girard, Timothy D.; Kiehl, Amy L.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Div Allergy Pulm & Crit Care Med,Dept Med, Nashville, TN USA. [Jackson, James C.] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN USA. [Morandi, Alessandro] Hosp Ancelle, Dept Rehabil & Aged Care Unit, Cremona, Italy. [Morandi, Alessandro] Geriatr Res Grp, Brescia, Italy. [Hughes, Christopher G.; Pandharipande, Pratik P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville VA Med Ctr, Anesthesia Serv, Nashville, TN USA. [Hughes, Christopher G.; Pandharipande, Pratik P.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Div Crit Care,Dept Anesthesiol, Nashville, TN USA. [Thompson, Jennifer L.; Chandrasekhar, Rameela] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA. [Elstad, Mark R.; Wasserstein, Mitzi L.] US Dept Vet Affairs, VA Salt Lake City Hlth Care Syst, George E Wahlen Dept Vet Affairs Med Ctr, Salt Lake City, UT USA. [Elstad, Mark R.] Univ Utah, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Salt Lake City, UT USA. [Goodman, Richard B.] US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Goodman, Richard B.] Univ Washington, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Beckham, Jean C.] US Dept Vet Affairs, Med Ctr, Durham Vet Affairs Med Ctr, Vet Affairs Mid Atlantic Mental Illness Res Educ, Durham, NC USA. [Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat, Div Behav Med, Durham, NC 27710 USA. [Dittus, Robert S.] Vanderbilt Univ, Med Ctr, Ctr Hlth Serv Res, Div Gen Internal Med & Publ Hlth, Nashville, TN USA. [Dittus, Robert S.] Vanderbilt Univ, Med Ctr, Dept Med, Ctr Hlth Serv Res, Nashville, TN USA. RP Patel, MB (reprint author), 1211 21st Ave South,404 Med Arts Bldg, Nashville, TN 37212 USA. EM mayur.b.patel@vanderbilt.edu OI Patel, Mayur/0000-0001-5230-0871; Girard, Timothy/0000-0002-9833-4871 FU NCATS NIH HHS [UL1 TR000445]; NHLBI NIH HHS [R01 HL111111]; NIA NIH HHS [R01 AG035117, K23 AG031322, K23 AG034257, R01 AG027472] NR 58 TC 5 Z9 5 U1 2 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JUN 15 PY 2016 VL 193 IS 12 BP 1373 EP 1381 DI 10.1164/rccm.201506-1158OC PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DO8FF UT WOS:000378017300013 PM 26735627 ER PT J AU Marcus, EA Tokhtaeva, E Turdikulova, S Capri, J Whitelegge, JP Scott, DR Sachs, G Berditchevski, F Vagin, O AF Marcus, Elizabeth A. Tokhtaeva, Elmira Turdikulova, Shahlo Capri, Joseph Whitelegge, Julian P. Scott, David R. Sachs, George Berditchevski, Fedor Vagin, Olga TI Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells SO BIOCHEMICAL JOURNAL LA English DT Article DE endocytosis; ErbB2; gastric cancer; lysosomal degradation; septin; ubiquitylation ID E3 UBIQUITIN LIGASE; ENDOCYTIC DOWN-REGULATION; MAMMALIAN SEPTIN; STIMULATES INTERNALIZATION; PROTEASOMAL ACTIVITY; HELICOBACTER-PYLORI; TYROSINE KINASES; BARRIER FUNCTION; PLASMA-MEMBRANE; ERBB RECEPTORS AB Septins are a family of cytoskeletal GTP-binding proteins that assemble into membrane-associated hetero-oligomers and organize scaffolds for recruitment of cytosolic proteins or stabilization of membrane proteins. Septins have been implicated in a diverse range of cancers, including gastric cancer, but the underlying mechanisms remain unclear. The hypothesis tested here is that septins contribute to cancer by stabilizing the receptor tyrosine kinase ErbB2, an important target for cancer treatment. Septins and ErbB2 were highly over-expressed in gastric cancer cells. Immunoprecipitation followed by MS analysis identified ErbB2 as a septin-interacting protein. Knockdown of septin-2 or cell exposure to forchlorfenuron (FCF), a well-established inhibitor of septin oligomerization, decreased surface and total levels of ErbB2. These treatments had no effect on epidermal growth factor receptor (EGFR), emphasizing the specificity and functionality of the septin-ErbB2 interaction. The level of ubiquitylated ErbB2 at the plasma membrane was elevated in cells treated with FCF, which was accompanied by a decrease in co-localization of ErbB2 with septins at the membrane. Cathepsin B inhibitor, but not bafilomycin or lactacystin, prevented FCF-induced decrease in total ErbB2 by increasing accumulation of ubiquitylated ErbB2 in lysosomes. Therefore, septins protect ErbB2 from ubiquitylation, endocytosis and lysosomal degradation. The FCF-induced degradation pathway is distinct from and additive with the degradation induced by inhibiting ErbB2 chaperone Hsp90. These results identify septins as novel regulators of ErbB2 expression that contribute to the remarkable stabilization of the receptor at the plasma membrane of cancer cells and may provide a basis for the development of new ErbB2-targeting anti-cancer therapies. C1 [Marcus, Elizabeth A.] Univ Calif Los Angeles, DGSOM, Dept Pediat, Los Angeles, CA 90095 USA. [Marcus, Elizabeth A.; Tokhtaeva, Elmira; Scott, David R.; Sachs, George; Vagin, Olga] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. [Tokhtaeva, Elmira; Scott, David R.; Sachs, George; Vagin, Olga] Univ Calif Los Angeles, Dept Physiol, DGSOM, Los Angeles, CA 90095 USA. [Turdikulova, Shahlo] Uzbek Acad Sci, Ctr High Technol, Tashkent 700174, Uzbekistan. [Capri, Joseph; Whitelegge, Julian P.] Univ Calif Los Angeles, NPI Semel Inst, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90024 USA. [Sachs, George] Univ Calif Los Angeles, DGSOM, Dept Med, Los Angeles, CA 90024 USA. [Berditchevski, Fedor] Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England. RP Vagin, O (reprint author), VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA.; Vagin, O (reprint author), Univ Calif Los Angeles, Dept Physiol, DGSOM, Los Angeles, CA 90095 USA. EM olgav@ucla.edu OI Turdikulova, Shahlo/0000-0003-0764-2332 FU NIH [K08DK100661, 1R01DK105156-01, R01HL113350]; UCLA Children's Discovery and Innovation Institute (CDI); United States Veteran Administration (USVA) [2I01BX001006] FX This work was supported by the NIH [grant number K08DK100661 (to E.A.M.)]; the UCLA Children's Discovery and Innovation Institute (CDI) (to E.A.M.); the United States Veteran Administration (USVA) [grant number 2I01BX001006 (to G.S.)]; the NIH [grant number 1R01DK105156-01 (to G.S.)]; and the NIH [grant number R01HL113350 (to O.V.)]. NR 86 TC 1 Z9 1 U1 1 U2 2 PU PORTLAND PRESS LTD PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND SN 0264-6021 EI 1470-8728 J9 BIOCHEM J JI Biochem. J. PD JUN 15 PY 2016 VL 473 BP 1703 EP 1718 DI 10.1042/BCJ20160203 PN 12 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DO7WC UT WOS:000377992700005 PM 27048593 ER PT J AU Huik, K Avi, R Pauskar, M Kallas, E Jogeda, EL Karki, T Ruutel, K Talu, A Abel-Ollo, K Uuskula, A Carrillo, A Ahuja, SK He, WJ Lutsar, I AF Huik, Kristi Avi, Radko Pauskar, Merit Kallas, Eveli Jogeda, Ene-Ly Karki, Tonis Ruutel, Kristi Talu, Ave Abel-Ollo, Katri Uuskula, Anneli Carrillo, Andrew Ahuja, Sunil K. He, Weijing Lutsar, Irja TI A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs SO PLOS ONE LA English DT Article ID HEPATITIS-C VIRUS; RANTES GENE VARIANTS; CD4(+) T-CELLS; CHEMOKINES; EXPRESSION; IL28B; LIVER; TRANSMISSION; POLYMORPHISM; LYMPHOCYTES AB Objective The role of CC chemokine receptor 5 (CCR5) and its ligand CCL5 on the pathogenesis of HIV infection has been well studied but not for HCV infection. Here, we investigated whether CCL5 haplotypes influence HIV and HCV seropositivity among 373 Caucasian people who inject drugs (PWID) from Estonia. Methods Study included 373 PWID; 56% were HIV seropositive, 44% HCV seropositive and 47% coinfected. Four CCL5 haplotypes (A-D) were derived from three CCL5 polymorphisms (rs2107538/rs2280788/rs2280789) typed by Taqman allelic discrimination assays. The data of CCR5 haplotypes were used from our previous study. The association between CCL5 haplotypes with HIV and/or HCV seropositivity was determined using logistic regression analysis. Results Possessing CCL5 haplotype D (defined by rs2107538A/rs2280788G/rs2280789C) decreased the odds of HCV seropositivity compared to those not possessing it (OR = 0.19; 95% CI 0.09-0.40), which remained significant after adjustment to co-variates (OR = 0.08; 95% CI 0.02-0.29). An association of this haplotype with HIV seropositivity was not found. In step-wise logistic regression with backward elimination CCL5 haplotype D and CCR5 HHG*1 had reduced odds for HCV seropositivity (OR = 0.28 95% CI 0.09-0.92; OR = 0.23 95% CI 0.08-0.68, respectively) compared to those who did not possess these haplotypes, respectively. Conclusions Our results suggest that among PWID CCL5 haplotype D and CCR5 HHG*1 independently protects against HCV. Our findings highlight the importance of CCL5 genetic variability and CCL5-CCR5 axis on the susceptibility to HCV. C1 [Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jogeda, Ene-Ly; Karki, Tonis; Lutsar, Irja] Univ Tartu, Inst Biomed & Translat Med, Dept Microbiol, EE-50411 Tartu, Estonia. [Ruutel, Kristi; Abel-Ollo, Katri] Natl Inst Hlth Dev, EE-11619 Tallinn, Estonia. [Talu, Ave; Uuskula, Anneli] Univ Tartu, Inst Family Med & Publ Hlth, EE-50411 Tartu, Estonia. [Carrillo, Andrew; Ahuja, Sunil K.; He, Weijing] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Carrillo, Andrew; Ahuja, Sunil K.; He, Weijing] South Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX 78229 USA. RP Huik, K (reprint author), Univ Tartu, Inst Biomed & Translat Med, Dept Microbiol, EE-50411 Tartu, Estonia. EM kristi.huik@ut.ee FU European Union through the European Regional Development Fund; Basic Financing; Target Financing [SF0180004s12]; Institutional research funding of Estonian Ministry of Education and Research [IUT34-24, IUT34-17]; European Commission - project Expanding Network for Comprehensive and Coordinated Action on HIV/AIDS prevention among IDUs and Bridging Population [2005305]; Global Fund; Tuberculosis and Malaria Program "Scaling up the response to HIV in Estonia"; National HIV/AIDS Strategy; US Civilian Research Development Foundation [ESX0-2722-TA-06]; US National Institutes of Health; National Institute on Drug Abuse [R01DA03574]; Archimedes Foundation and Norwegian Financial Mechanism/EEA [EE0016]; Veterans Affairs (VA) Center for AIDS and HIV Infection and VA Center for Personalized Medicine of the South Texas Veterans Health Care System; National Institutes of Health MERIT grant [R37AI046326]; Doris Duke Distinguished Clinical Scientist Award; VA MERIT award; Elizabeth Glaser Pediatric AIDS Foundation; Burroughs Welcome Clinical Scientist Award in Translational Research; Senior Scholar Award from the Max and Minnie Tomerlin Voelcker Fund FX Study was supported by: European Union through the European Regional Development Fund; Basic Financing and the Target Financing (SF0180004s12) and Institutional research funding (IUT34-24, IUT34-17) of Estonian Ministry of Education and Research; European Commission funded project Expanding Network for Comprehensive and Coordinated Action on HIV/AIDS prevention among IDUs and Bridging Population Nr. 2005305 (ENCAP); Global Fund to Fight HIV, Tuberculosis and Malaria Program "Scaling up the response to HIV in Estonia" for 2003-2007; National HIV/AIDS Strategy for 2006-2015; US Civilian Research Development Foundation (grant ESX0-2722-TA-06); US National Institutes of Health, National Institute on Drug Abuse (grant R01DA03574); the Archimedes Foundation and Norwegian Financial Mechanism/EEA (grant EE0016); the Veterans Affairs (VA) Center for AIDS and HIV Infection and VA Center for Personalized Medicine of the South Texas Veterans Health Care System, a National Institutes of Health MERIT grant (R37AI046326), and the Doris Duke Distinguished Clinical Scientist Award to S.K.A. S.K.A. is also supported by a VA MERIT award, the Elizabeth Glaser Pediatric AIDS Foundation, the Burroughs Welcome Clinical Scientist Award in Translational Research and the Senior Scholar Award from the Max and Minnie Tomerlin Voelcker Fund. NR 35 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 15 PY 2016 VL 11 IS 6 AR e0156850 DI 10.1371/journal.pone.0156850 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DO5LO UT WOS:000377824800026 PM 27304910 ER PT J AU Graham, ZA Collier, L Peng, YZ Saez, JC Bauman, WA Qin, WP Cardozo, CP AF Graham, Zachary A. Collier, Lauren Peng, Yuanzhen Saez, Juan C. Bauman, William A. Qin, Weiping Cardozo, Christopher P. TI A Soluble Activin Receptor IIB Fails to Prevent Muscle Atrophy in a Mouse Model of Spinal Cord Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE inflammation; metabolism; neural injury; spinal cord injury ID BONE-MINERAL DENSITY; MYOSTATIN INHIBITION; BODY-COMPOSITION; GENE-EXPRESSION; GROWING RATS; FIBER-TYPE; MICE; MASS; TRANSECTION; STIMULATION AB Myostatin (MST) is a potent regulator of muscle growth and size. Spinal cord injury (SCI) results in marked atrophy of muscle below the level of injury. Currently, there is no effective pharmaceutical treatment available to prevent sublesional muscle atrophy post-SCI. To determine whether inhibition of MST with a soluble activin IIB receptor (RAP-031) prevents sublesional SCI-induced muscle atrophy, mice were randomly assigned to the following groups: Sham-SCI; SCI+Vehicle group (SCI-VEH); and SCI+RAP-031 (SCI-RAP-031). SCI was induced by complete transection at thoracic level 10. Animals were euthanized at 56 days post-surgery. RAP-031 reduced, but did not prevent, body weight loss post-SCI. RAP-031 increased total lean tissue mass compared to SCI-VEH (14.8%). RAP-031 increased forelimb muscle mass post-SCI by 38% and 19% for biceps and triceps, respectively (p < 0.001). There were no differences in hindlimb muscle weights between the RAP-031 and SCI-VEH groups. In the gastrocnemius, messenger RNA (mRNA) expression was elevated for interleukin (IL)-6 (8-fold), IL-1 beta (3-fold), and tumor necrosis factor alpha (8-fold) in the SCI-VEH, compared to the Sham group. Muscle RING finger protein 1 mRNA was 2-fold greater in the RAP-031 group, compared to Sham-SCI. RAP-031 did not influence cytokine expression. Bone mineral density of the distal femur and proximal tibia were decreased post-SCI (-26% and -28%, respectively) and were not altered by RAP-031. In conclusion, MST inhibition increased supralesional muscle mass, but did not prevent sublesional muscle or bone loss, or the inflammation in paralyzed muscle. C1 [Graham, Zachary A.; Collier, Lauren; Peng, Yuanzhen; Bauman, William A.; Qin, Weiping; Cardozo, Christopher P.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher P.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Saez, Juan C.] Pontificia Univ Catolica Chile, Dept Physiol, Alameda 340, Santiago, Chile. [Saez, Juan C.] Ctr Interdisciplinario Neurociencias Valparais, Valparaiso, Chile. [Graham, Zachary A.; Bauman, William A.; Qin, Weiping; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Bauman, William A.; Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Cardozo, Christopher P.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Cardozo, CP (reprint author), James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM christopher.cardozo@mssm.edu FU Department of Veterans Affairs Rehabilitation Research and Development Service [B9212C]; James J. Peters VA Medical Center; Fondecyt [1111033]; Chilean Science Millennium Institute [P09-022-F] FX This work was supported by the Department of Veterans Affairs Rehabilitation Research and Development Service (B9212C), the James J. Peters VA Medical Center, and a Fondecyt project 1111033 (to J.C.S.), Chilean Science Millennium Institute (P09-022-F; to J.C.S.). The authors are grateful to Scott Pearsall and Ravi Kumar for their comments regarding study design and critical reading of the manuscript. RAP-031 was a generous gift from Acceleron Pharma (Cambridge MA). NR 47 TC 1 Z9 1 U1 2 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JUN 15 PY 2016 VL 33 IS 12 BP 1128 EP 1135 DI 10.1089/neu.2015.4058 PG 8 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DN9WT UT WOS:000377432100003 PM 26529111 ER PT J AU Roussos, P Giakoumaki, SG Zouraraki, C Fullard, JF Karagiorga, VE Tsapakis, EM Petraki, Z Siever, LJ Lencz, T Malhotra, A Spanaki, C Bitsios, P AF Roussos, Panos Giakoumaki, Stella G. Zouraraki, Chrysoula Fullard, John F. Karagiorga, Vasiliki-Eirini Tsapakis, Eva-Maria Petraki, Zoe Siever, Larry J. Lencz, Todd Malhotra, Anil Spanaki, Cleanthe Bitsios, Panos TI The Relationship of Common Risk Variants and Polygenic Risk for Schizophrenia to Sensorimotor Gating SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Baseline startle; Endophenotypes; eQTL; GWAS; Heritability; Prepulse inhibition ID ACOUSTIC STARTLE RESPONSE; GENOME-WIDE ASSOCIATION; PREPULSE INHIBITION; VAL(158)MET POLYMORPHISM; HEALTHY-VOLUNTEERS; REFLEX; HERITABILITY; MODULATION; CONSORTIUM; DEFICITS AB BACKGROUND: Prepulse inhibition (PPI) of the startle reflex has been suggested as a candidate endophenotype for schizophrenia research, as it shows high heritability and has been found deficient in schizophrenia spectrum disorders. The objectives of the study were to 1) identify common genetic variants associated with baseline startle and PPI; 2) estimate the single nucleotide polymorphism heritability; and 3) examine the relationship of polygenic score for schizophrenia with baseline startle and PPI. METHODS: A cohort of healthy young male subjects (n = 1493) originating from the Learning on Genetics of Schizophrenia Spectrum project was assessed for baseline startle and PPI. The most recent genome-wide association study in schizophrenia from the Psychiatric Genomics Consortium 2 was used to calculate polygenic scores. RESULTS: Eleven loci showed suggestive association (p < 10(-6)) with baseline startle and PPI in the discovery cohort. Additional genotyping in a replication cohort identified genome-wide significant association at two loci (rs61810702 and rs4718984). These loci were co-localized with expression quantitative trait loci associated with gene expression of nerve growth factor (NGF) and calneuron 1 (CALN1) genes. Estimation of the genetic and environmental contributions to baseline startle and PPI showed a substantial single nucleotide polymorphism heritability for 120-ms PPI stimuli. Increased polygenic risk score for schizophrenia was associated with reduced PPI. CONCLUSIONS: Common genetic variation has an important role in the etiology of schizophrenia and PPI impairments. Overall, these data support the idea that PPI is a valid endophenotype that can be used to explore the genetic architecture of schizophrenia. C1 [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos; Fullard, John F.; Karagiorga, Vasiliki-Eirini; Siever, Larry J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Roussos, Panos; Fullard, John F.; Karagiorga, Vasiliki-Eirini] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Roussos, Panos; Siever, Larry J.] Mental Illness Res Educ & Clin Ctr, James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Giakoumaki, Stella G.; Zouraraki, Chrysoula] Univ Crete, Dept Psychol, Rethimnon, Greece. [Tsapakis, Eva-Maria] Aghios Charalambos Mental Hlth Ctr, Iraklion, Greece. [Petraki, Zoe; Spanaki, Cleanthe] Univ Crete, Fac Med, Dept Neurol, Iraklion, Crete, Greece. [Lencz, Todd; Malhotra, Anil] Zucker Hillside Hosp, Div Psychiat Res, Glen Oaks, NY USA. [Lencz, Todd; Malhotra, Anil] Fenstein Inst Med Res, Ctr Psychiat Neurosci, Manhasset, NY USA. [Lencz, Todd; Malhotra, Anil] Hofstra Univ, Sch Med, Dept Psychiat, Hempstead, NY 11550 USA. [Lencz, Todd; Malhotra, Anil] Hofstra Univ, Sch Med, Dept Mol Med, Hempstead, NY 11550 USA. [Bitsios, Panos] Univ Crete, Fac Med, Dept Psychiat, Iraklion, Crete, Greece. RP Roussos, P (reprint author), Icahn Sch Med, Friedman Brain Inst, Inst Multiscale Biol, Dept Psychiat,Dept Genet & Genom Sci, 1470 Madison Ave, New York, NY USA. EM panagiotis.roussos@mssm.edu RI Roussos, Panos/J-7090-2013; Lencz, Todd/J-3418-2014 OI Roussos, Panos/0000-0002-4640-6239; Lencz, Todd/0000-0001-8586-338X FU Veterans Affairs Merit Grant [BX002395]; Brain Behavior Research Foundation; American Psychiatric Association-Merck & Co. Early Academic Career Research Award; Friedman Brain Institute at Icahn School of Medicine at Mount Sinai; Icahn Institute for Genomics and Multiscale Biology at Icahn School of Medicine at Mount Sinai FX We acknowledge funding support from Veterans Affairs Merit Grant Nos. BX002395 (to PR), the Brain Behavior Research Foundation (to PR), the American Psychiatric Association-Merck & Co. Early Academic Career Research Award (to PR), the Friedman Brain Institute at Icahn School of Medicine at Mount Sinai, and the Icahn Institute for Genomics and Multiscale Biology at Icahn School of Medicine at Mount Sinai. This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai. NR 59 TC 5 Z9 5 U1 3 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JUN 15 PY 2016 VL 79 IS 12 BP 988 EP 996 DI 10.1016/j.biopsych.2015.06.019 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DN0ZV UT WOS:000376796500009 PM 26212897 ER PT J AU Kennedy, BK Lamming, DW AF Kennedy, Brian K. Lamming, Dudley W. TI The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging SO CELL METABOLISM LA English DT Review ID MTOR COMPLEX 2; TUBEROUS SCLEROSIS COMPLEX; GLYCOGEN-SYNTHASE ACTIVITY; MESSENGER-RNA TRANSLATION; WHOLE-BODY METABOLISM; MAMMALIAN LIFE-SPAN; SKELETAL-MUSCLE; ADIPOSE-TISSUE; RAG GTPASES; GLUCOSE-HOMEOSTASIS AB Since the discovery that rapamycin, a small molecule inhibitor of the protein kinase mTOR (mechanistic target of rapamycin), can extend the lifespan of model organisms including mice, interest in understanding the physiological role and molecular targets of this pathway has surged. While mTOR was already well known as a regulator of growth and protein translation, it is now clear that mTOR functions as a central coordinator of organismal metabolism in response to both environmental and hormonal signals. This review discusses recent developments in our understanding of how mTOR signaling is regulated by nutrients and the role of the mTOR signaling pathway in key metabolic tissues. Finally, we discuss the molecular basis for the negative metabolic side effects associated with rapamycin treatment, which may serve as barriers to the adoption of rapamycin or similar compounds for the treatment of diseases of aging and metabolism. C1 [Kennedy, Brian K.] Buck Inst Res Aging, Novato, CA 94945 USA. [Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI 53705 USA. [Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Lamming, DW (reprint author), Univ Wisconsin, Dept Med, Madison, WI 53705 USA.; Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu FU NIH [R56 AG050441]; K99/R00 Pathway to Independence Award [R00 AG041765]; Wisconsin Partnership Program; Glenn Foundation Award for Research in the Biological Mechanisms of Aging; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; American Federation for Aging Research; Delos Pharmaceuticals FX We thank the reviewers for their thoughtful commentary and critiques. This work was supported in part by NIH grant R56 AG050441 to B.K.K. and a K99/R00 Pathway to Independence Award to D.W.L. (R00 AG041765). D.W.L. is supported in part by a New Investigator Program Award from the Wisconsin Partnership Program, a Glenn Foundation Award for Research in the Biological Mechanisms of Aging, and startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. This review was prepared while D.W.L. was an AFAR Research Grant recipient from the American Federation for Aging Research. This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. B.K.K. is the Board Chair of Mount Tam Pharmaceuticals, which seeks to develop novel therapeutics to treat autoimmune diseases by modifying the mTOR pathway. D.W.L has received funding from, and is a scientific advisory board member of, Delos Pharmaceuticals, which seeks to develop novel, selective mTOR inhibitors for the treatment of various diseases. NR 171 TC 21 Z9 23 U1 4 U2 18 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 EI 1932-7420 J9 CELL METAB JI Cell Metab. PD JUN 14 PY 2016 VL 23 IS 6 BP 990 EP 1003 DI 10.1016/j.cmet.2016.05.009 PG 14 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA DO7ZA UT WOS:000378000600012 PM 27304501 ER PT J AU Nelson, CM Dewald, JPA Murray, WM AF Nelson, Christa M. Dewald, Julius P. A. Murray, Wendy M. TI In vivo measurements of biceps brachii and triceps brachii fascicle lengths using extended field-of-view ultrasound SO JOURNAL OF BIOMECHANICS LA English DT Article DE Muscle architecture; Fascicle length; Ultrasonography; Upper extremity ID MUSCLE ARCHITECTURE; SKELETAL-MUSCLE; ULTRASONOGRAPHY; RELIABILITY; VALIDITY; US AB Muscle fascicle lengths are commonly measured in vivo using static 2D ultrasound. However, static ultrasound is best suited for muscles with shorter, pennate fascicles, in which entire fascicles can be viewed in one static image. An informal review of data from cadaver dissections suggests that over 60% of muscles in the upper and lower limbs have optimal lengths longer than the field-of-view of standard ultrasound transducers. Extended field-of-view ultrasound (EFOV) has been validated for measurement of fascicle lengths, but has yet to be implemented in the upper extremity in humans. In this study, EFOV ultrasound was used to measure the lengths of fascicles sampled from the anterior portion of the biceps brachii (long head) and the distal half of the triceps brachii (lateral head). Data were collected from both limbs of eleven healthy subjects in three elbow postures under passive conditions. Image analysis was completed via Image J. Fascicle length measurements were highly reliable, with intra-class correlations ranging from .92 to .95 for biceps and .81-.92 for triceps (p < .001). Systematic, significant differences in measured lengths, consistent with muscle function, were observed between elbow positions. In vivo measurements for both muscles in this study were within the range of cadaver data. This work establishes the feasibility and reliability of EFOV ultrasound for measurement of the long fascicles of muscles in the upper limb. Published by Elsevier Ltd. C1 [Nelson, Christa M.; Dewald, Julius P. A.; Murray, Wendy M.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA. [Dewald, Julius P. A.; Murray, Wendy M.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA. [Nelson, Christa M.; Dewald, Julius P. A.; Murray, Wendy M.] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Feinberg Sch Med, Chicago, IL 60611 USA. [Murray, Wendy M.] Rehabil Inst Chicago, Sensory Motor Performance Program, 345 E Super St, Chicago, IL 60611 USA. [Murray, Wendy M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. RP Murray, WM (reprint author), Rehabil Inst Chicago, Sensory Motor Performance Program, 345 E Super St, Chicago, IL 60611 USA. EM w-murray@northwestern.edu RI Murray, Wendy/D-1520-2009; Murray, Wendy/B-7629-2009 OI Murray, Wendy/0000-0002-7547-621X; FU American Heart Association [14PRE20240022]; Northwestern University; NIH-NIBIB [T32EB009406]; NIH R01 [1R01HD084009-01A1]; Northwestern University Department of Physical Therapy and Human Movement Sciences; Searle Funds of the Chicago Community Trust FX We would like to acknowledge funding from the American Heart Association (#14PRE20240022), Northwestern University terminal year fellowship, NIH-NIBIB (#T32EB009406), NIH R01 to Drs. Dewald and Murray (#1R01HD084009-01A1), Northwestern University Department of Physical Therapy and Human Movement Sciences, and the Searle Funds of the Chicago Community Trust. We would also like to acknowledge Ana Maria Acosta for her help with development of the experimental GUI, and Paul Krueger and Vikram Darbhe for their assistance during experiments. NR 26 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD JUN 14 PY 2016 VL 49 IS 9 BP 1948 EP 1952 DI 10.1016/j.jbiomech.2016.03.040 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA DO4DE UT WOS:000377731200073 PM 27083062 ER PT J AU Li, K Laird, AR Price, LR Mckay, DR Blangero, J Glahn, DC Fox, PT AF Li, Karl Laird, Angela R. Price, Larry R. McKay, D. Reese Blangero, John Glahn, David C. Fox, Peter T. TI Progressive Bidirectional Age-Related Changes in Default Mode Network Effective Connectivity across Six Decades SO FRONTIERS IN AGING NEUROSCIENCE LA English DT Article DE default mode network (DMN); structural equation modeling (SEM); meta-analytic connectivity modeling; functional connectivity (FC); normal aging ID STATE FUNCTIONAL CONNECTIVITY; EARLY ALZHEIMERS-DISEASE; CONSCIOUS RESTING STATE; HUMAN BRAIN; STRUCTURAL CONNECTIVITY; MOTION CORRECTION; HEMISPHERIC-ASYMMETRY; AMYLOID DEPOSITION; GRANGER CAUSALITY; OLDER-ADULTS AB The default mode network (DMN) is a set of regions that is tonically engaged during the resting state and exhibits task-related deactivation that is readily reproducible across a wide range of paradigms and modalities. The DMN has been implicated in numerous disorders of cognition and, in particular, in disorders exhibiting age-related cognitive decline. Despite these observations, investigations of the DMN in normal aging are scant. Here, we used blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) acquired during rest to investigate age-related changes in functional connectivity of the DMN in 120 healthy normal volunteers comprising six, 20-subject, decade cohorts (from 20-29 to 70-79). Structural equation modeling (SEM) was used to assess age related changes in inter-regional connectivity within the DMN. SEM was applied both using a previously published, meta-analytically derived, node-and-edge model, and using exploratory modeling searching for connections that optimized model fit improvement. Although the two models were highly similar (only 3 of 13 paths differed), the sample demonstrated significantly better fit with the exploratory model. For this reason, the exploratory model was used to assess age-related changes across the decade cohorts. Progressive, highly significant changes in path weights were found in 8 (of 13) paths: four rising, and four falling (most changes were significant by the third or fourth decade). In all cases, rising paths and falling paths projected in pairs onto the same nodes, suggesting compensatory increases associated with age-related decreases. This study demonstrates that age-related changes in DMN physiology (inter-regional connectivity) are bidirectional, progressive, of early onset and part of normal aging. C1 [Li, Karl; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Price, Larry R.] Texas State Univ, Dept Math, San Marcos, TX USA. [Price, Larry R.] Texas State Univ, Coll Educ, San Marcos, TX USA. [McKay, D. Reese; Glahn, David C.] Yale Univ, Dept Psychiat, Sch Med, New Haven, CT 06520 USA. [McKay, D. Reese; Glahn, David C.] Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06115 USA. [Blangero, John] Univ Texas Rio Grande Valley, Sch Med, South Texas Diabet & Obes Inst, Genom Comp Ctr, Edinburg, TX USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA. [Fox, Peter T.] Shenzhen Univ, Sch Med, Neuroimaging Lab, Shenzhen, Guangdong, Peoples R China. RP Fox, PT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.; Fox, PT (reprint author), South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX USA.; Fox, PT (reprint author), Shenzhen Univ, Sch Med, Neuroimaging Lab, Shenzhen, Guangdong, Peoples R China. EM fox@uthscsa.edu FU National Institutes of Health [5R01MH074457-09]; NIH [1R01MH078111-01]; Genetics of Brain Structure, and Function study FX This was supported by the National Institutes of Health grant 5R01MH074457-09, Meta-Analysis in Human Brain Mapping. The data was provided for by NIH grant 1R01MH078111-01, the Genetics of Brain Structure, and Function study. Special thanks to Crystal Franklin for help in data pre-processing and Mary Woosley for help in providing demographic information for the data used. NR 112 TC 0 Z9 0 U1 0 U2 6 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1663-4365 J9 FRONT AGING NEUROSCI JI Front. Aging Neurosci. PD JUN 14 PY 2016 VL 8 AR 137 DI 10.3389/fnagi.2016.00137 PG 16 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA DO2AQ UT WOS:000377582100001 PM 27378909 ER PT J AU Singh, JA Schleck, C Harmsen, S Lewallen, D AF Singh, Jasvinder A. Schleck, Cathy Harmsen, Scott Lewallen, David TI Clinically important improvement thresholds for Harris Hip Score and its ability to predict revision risk after primary total hip arthroplasty SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE Harris Hip Score; Total Hip Arthroplasty; Responsiveness; Discriminant ability; Predictability; Clinically important improvement; Minimal clinically important improvement; MCII; Minimal clinically important difference; MCID ID RESPONSIVENESS; REPLACEMENT; TRIALS; KNEE; PAIN; OSTEOARTHRITIS; FRACTURES; MORTALITY; ARTHRITIS; TRENDS AB Background: Some aspects of validity are missing for the Harris Hip Score (HHS). Our objective was to examine the clinically meaningful change thresholds, responsiveness and the predictive ability of the HHS questionnaire. Methods: We included a cohort of patients who underwent primary total hip arthroplasty (THA) and responded to the HHS preoperatively and at 2- or 5-year post-THA (change score) to examine the clinically meaningful change thresholds (Minimal clinically important improvement, MCII; and moderate improvement), responsiveness (effect size (ES) and standardized response mean (SRM)) based on pre- to post-operative change and the predictive ability of change score or absolute postoperative score at 2- and 5-years post-THA for future revision. Results: Two thousand six hundred sixty-seven patients with a mean age of 64 years completed baseline HHS; 1036 completed both baseline and 2-year HHS and 669 both baseline and 5-year HHS. MCII and moderate improvement thresholds ranged 15.9-18 points and 39.6-40.1 points, respectively. ES was 3.12 and 3.02 at 2- and 5-years; respective SRM was 2.73 and 2.52. There were 3195 hips with HHS scores at 2-years and 2699 hips with HHS scores at 5-years (regardless of the completion of baseline HHS; absolute postoperative scores). Compared to patients with absolute HHS scores of 81-100 (score range, 0-100), patients with scores <55 at 2- and 5-years had higher hazards (95 % confidence interval) of subsequent revision, 4.34 (2.14, 7.95; p < 0.001) and 3.08 (1.45, 5.84; p = 0.002), respectively. Compared to HHS score improvement of >50 points from preoperative to 2-years post-THA, lack of improvement/worsening or 1-20 point improvement were associated with increased hazards of revision, 18.10 (1.41, 234.83; p = 0.02); and 6.21 (0.81, 60.73; p = 0.10), respectively. Conclusions: HHS is a valid measure of THA outcomes and is responsive to change. Both absolute HHS postoperative scores and HHS score change postoperatively are predictive of revision risk post-primary THA. We defined MCID and moderate improvement thresholds for HHS in this study. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Schleck, Cathy; Harmsen, Scott] Mayo Clin, Sch Med, Dept Biostat, Rochester, MN USA. [Singh, Jasvinder A.; Lewallen, David] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.; Singh, JA (reprint author), Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Department of Orthopedic Surgery at Mayo Clinic FX The funding source, Department of Orthopedic Surgery at Mayo Clinic, played no role in protocol development, study conduct, interpretation of results, or the decision to submit the manuscript for publication. NR 27 TC 3 Z9 3 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD JUN 10 PY 2016 VL 17 AR 256 DI 10.1186/s12891-016-1106-8 PG 8 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA DP0TN UT WOS:000378202600001 PM 27286675 ER PT J AU Szaflarski, JP Lee, S Allendorfer, JB Gaston, TE Knowlton, RC Pati, S Ver Hoef, LW Deutsch, G AF Szaflarski, Jerzy P. Lee, Seongtaek Allendorfer, Jane B. Gaston, Tyler E. Knowlton, Robert C. Pati, Sandipan Ver Hoef, Lawrence W. Deutsch, Georg TI White Matter Abnormalities in Patients with Treatment-Resistant Genetic Generalized Epilepsies SO MEDICAL SCIENCE MONITOR LA English DT Article DE Diffusion Magnetic Resonance Imaging; Diffusion Tensor Imaging; Epilepsy, Absence; Myoclonic Epilepsy, Juvenile ID JUVENILE MYOCLONIC EPILEPSY; TEMPORAL-LOBE EPILEPSY; LANGUAGE LATERALIZATION; FUNCTIONAL CONNECTIVITY; EPILEPTIFORM DISCHARGES; STRUCTURAL-CHANGES; WAVE DISCHARGE; SEIZURES; NETWORK; EEG AB Background: Genetic generalized epilepsies (GGEs) are associated with microstructural brain abnormalities that can be evaluated with diffusion tensor imaging (DTI). Available studies on GGEs have conflicting results. Our primary goal was to compare the white matter structure in a cohort of patients with video/EEG-confirmed GGEs to healthy controls (HCs). Our secondary goal was to assess the potential effect of age at GGE onset on the white matter structure. Material/Methods: A convenience sample of 23 patients with well-characterized treatment-resistant GGEs (13 female) was compared to 23 HCs. All participants received MRI at 3T. DTI indices, including fractional anisotropy (FA) and mean diffusivity (MD), were compared between groups using Tract-Based Spatial Statistics (TBSS). Results: After controlling for differences between groups, abnormalities in DTI parameters were observed in patients with GGEs, including decreases in functional anisotropy (FA) in the hemispheric (left>right) and brain stem white matter. The examination of the effect of age at GGE onset on the white matter integrity revealed a significant negative correlation in the left parietal white matter region FA (R=-0.504; p=0.017); similar trends were observed in the white matter underlying left motor cortex (R=-0.357; p=0.103) and left posterior limb of the internal capsule (R=-0.319; p=0.148). Conclusions: Our study confirms the presence of widespread white matter abnormalities in patients with GGEs and provides evidence that the age at GGE onset may have an important effect on white matter integrity. C1 [Szaflarski, Jerzy P.; Allendorfer, Jane B.; Gaston, Tyler E.; Knowlton, Robert C.; Pati, Sandipan; Ver Hoef, Lawrence W.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA. [Szaflarski, Jerzy P.; Lee, Seongtaek] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA. [Gaston, Tyler E.; Ver Hoef, Lawrence W.] Birmingham VAMC, Dept Neurol, Birmingham, AL USA. [Knowlton, Robert C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Deutsch, Georg] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA. RP Szaflarski, JP (reprint author), Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA.; Szaflarski, JP (reprint author), Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA.; Szaflarski, JP (reprint author), Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA. EM szaflaj@uab.edu OI Lee, Seongtaek/0000-0001-8954-6103 NR 53 TC 1 Z9 1 U1 1 U2 4 PU INT SCIENTIFIC LITERATURE, INC PI SMITHTOWN PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA SN 1643-3750 J9 MED SCI MONITOR JI Med. Sci. Monitor PD JUN 10 PY 2016 VL 22 BP 1966 EP 1975 DI 10.12659/MSM.897002 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DO2RY UT WOS:000377628900001 PM 27283395 ER PT J AU Malarkey, CS Gustafson, CE Saifee, JF Torres, RM Churchill, MEA Janoff, EN AF Malarkey, Christopher S. Gustafson, Claire E. Saifee, Jessica F. Torres, Raul M. Churchill, Mair E. A. Janoff, Edward N. TI Mechanism of Mitochondrial Transcription Factor A Attenuation of CpG-Induced Antibody Production SO PLOS ONE LA English DT Article ID PLASMACYTOID DENDRITIC CELLS; HIGH BINDING-AFFINITY; NF-KAPPA-B; INFLAMMATORY RESPONSES; BACTERIAL-DNA; CIRCULAR-DICHROISM; NUCLEIC-ACIDS; FACTOR-I; ACTIVATION; PROTEIN AB Mitochondrial transcription factor A (TFAM) had previously been shown to act as a damage associated molecular pattern with the ability to enhance CpG-A phosphorothioate oligodeoxynucleotide (ODN)-mediated stimulation of IFN alpha production from human plasmacytoid dendritic cells. Examination of the mechanism by which TFAM might influence CpG ODN mediated innate immune responses revealed that TFAM binds directly, tightly and selectively to the structurally related CpG-A, -B, and -C ODN. TFAM also modulated the ability of the CpG-B or -C to stimulate the production of antibodies from human B cells. TFAM showed a dose-dependent modulation of CpG-B, and -C -induced antibody production from human B cells in vitro, with enhancement of high dose and inhibition of low doses of CpG stimulation. This effect was linked to the ability of TFAM to directly inhibit the binding of CpG ODNs to B cells, in a manner consistent with the relative binding affinities of TFAM for the ODNs. These data suggest that TFAM alters the free concentration of the CpG available to stimulate B cells by sequestering this ODN in a TFAM-CpG complex. Thus, TFAM has the potential to decrease the pathogenic consequences of exposure to natural CpG-like hypomethylated DNA in vivo, as well as such as that found in traumatic injury, infection, autoimmune disease and during pregnancy. C1 [Malarkey, Christopher S.; Saifee, Jessica F.; Churchill, Mair E. A.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA. [Malarkey, Christopher S.; Saifee, Jessica F.; Churchill, Mair E. A.] Univ Colorado, Sch Med, Program Struct Biol & Biochem, Aurora, CO 80045 USA. [Gustafson, Claire E.; Janoff, Edward N.] Univ Colorado, Sch Med, Mucosal & Vaccine Res Program Colorado MAVRC, Dept Med, Aurora, CO 80045 USA. [Gustafson, Claire E.; Janoff, Edward N.] Univ Colorado, Sch Med, Program Immunol, Aurora, CO 80045 USA. [Gustafson, Claire E.; Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. [Torres, Raul M.] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA. [Malarkey, Christopher S.] Regis Univ, Sch Pharm, Dept Pharmaceut Sci, 3333 Regis Blvd,H-28, Denver, CO 80221 USA. [Gustafson, Claire E.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA. [Saifee, Jessica F.] 33 Dover Rd, Wellesley, MA 02482 USA. RP Churchill, MEA (reprint author), Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA. EM Mair.Churchill@ucdenver.edu FU University of Colorado Cancer Center Support Grant [P30CA046934]; Veterans Affairs Research Service; Mucosal and Vaccine Research Program Colorado (MAVRC); University of Colorado Cancer Center [P30CA046934]; National Institutes of Health [T32AI052066, R01AI108479, R01GM111902]; American Heart Association [13POST16330009, 11GRNT7380064]; Gerber Foundation FX The University of Colorado Cancer Center Support Grant (P30CA046934) partially supported the usage of core facilities. National Institutes of Health [T32AI052066 to C.E.G., R01AI108479 to E.N.J., R01GM111902 to M.E.A.C.]; American Heart Association [13POST16330009 to C.S.M., 11GRNT7380064 to M.E.A.C.]; Gerber Foundation [to C.E.G.].; We appreciate the ongoing support of the Veterans Affairs Research Service and the Mucosal and Vaccine Research Program Colorado (MAVRC). The University of Colorado Cancer Center Support Grant (P30CA046934) partially supported the usage of core facilities. This work was supported by the National Institutes of Health [T32AI052066 to C.E.G., R01AI108479 to E.N.J., R01GM111902 to M.E.A.C.]; American Heart Association [13POST16330009 to C.S.M., 11GRNT7380064 to M.E.A.C.]; Gerber Foundation [to C.E.G.]. NR 58 TC 0 Z9 0 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 9 PY 2016 VL 11 IS 6 AR e0157157 DI 10.1371/journal.pone.0157157 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DO1TW UT WOS:000377563000098 PM 27280778 ER PT J AU Grubbs, V Vittighoff, E Grimes, B Johansen, KL AF Grubbs, Vanessa Vittighoff, Eric Grimes, Barbara Johansen, Kirsten L. TI Mortality and illicit drug dependence among hemodialysis patients in the United States: a retrospective cohort analysis SO BMC NEPHROLOGY LA English DT Article DE Illicit drug use; Hemodialysis; Mortality ID STAGE RENAL-DISEASE; SUBSTANCE-ABUSE; TRANSPLANTATION; DIALYSIS; KIDNEY AB Background: Illicit drug use is common and known to cause and exacerbate a wide spectrum of kidney disease, often leading to end-stage renal disease (ESRD), but little is known about its prevalence or associated mortality among incident hemodialysis patients. Methods: This study is a retrospective cohort analysis using data obtained from the United States Renal Data System. We assembled a cohort of 511,821 incident hemodialysis patients age 20 years and older who initiated hemodialysis between January 1, 2006 and December 31, 2010. Illicit drug dependence was defined by comorbidity on the ESRD Medical Evidence Report (Form CMS-2728). We performed survival analysis to examine the association of drug dependence with overall mortality and mortality due to diagnoses that can be associated with intravenous drug use (drug-sensitive diagnoses) in the first year after initiating hemodialysis. Results: Drug dependence was recorded for 1.5 % (n = 7,461). Drug dependence was independently associated with a 1.3-fold and 2.5-fold higher hazard of overall mortality and mortality due to a potentially drug-sensitive diagnosis [adjusted hazard ratio (AHR) 1.34 (1.27-1.41) and 2.54 (2.05-3.14), p < 0.001, respectively]. This association varied significantly by age (p(interaction) < 0.001), with a 9-fold higher hazard of mortality due to a potentially drug-sensitive diagnosis among the youngest patients with drug dependence [AHR 9.21 (5.15-16.44), p < 0.001]. Conclusion: Illicit drug dependence is a burden within the ESRD program and is strongly associated with premature mortality, particularly among younger patients. Targeted intervention is needed to help reduce this burden. C1 [Grubbs, Vanessa; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA. [Grubbs, Vanessa] San Francisco Gen Hosp, Div Nephrol, 1001 Potrero Ave,Bldg 100,Room 342, San Francisco, CA 94110 USA. [Vittighoff, Eric; Grimes, Barbara] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] San Francisco Vet Adm Med Ctr, Div Nephrol, San Francisco, CA USA. RP Grubbs, V (reprint author), Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.; Grubbs, V (reprint author), San Francisco Gen Hosp, Div Nephrol, 1001 Potrero Ave,Bldg 100,Room 342, San Francisco, CA 94110 USA. EM vanessa.grubbs@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) [1K23DK093710-01A1, N01-DK-7-0005, 1K24DK085153]; Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation FX VG was supported by grant 1K23DK093710-01A1 from the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) and by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. KLJ was supported by contract N01-DK-7-0005 and grant 1K24DK085153 from NIDDK. NR 17 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD JUN 8 PY 2016 VL 17 AR 56 DI 10.1186/s12882-016-0271-1 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA DO2DH UT WOS:000377589400001 PM 27278934 ER PT J AU Di Maio, R Barrett, PJ Hoffman, EK Barrett, CW Zharikov, A Borah, A Hu, XP Mccoy, J Chu, CT Burton, EA Hastings, TG Greenamyre, JT AF Di Maio, Roberto Barrett, Paul J. Hoffman, Eric K. Barrett, Caitlyn W. Zharikov, Alevtina Borah, Anupom Hu, Xiaoping Mccoy, Jennifer Chu, Charleen T. Burton, Edward A. Hastings, Teresa G. Greenamyre, J. Timothy TI alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID MAMMALIAN-CELLS; RECEPTOR TOM20; COMPLEX-I; NEURONS; OVEREXPRESSION; NEURODEGENERATION; STABILIZATION; TRANSLOCATION; INCREASES; MEMBRANES AB alpha-Synuclein accumulation and mitochondrial dysfunction have both been strongly implicated in the pathogenesis of Parkinson's disease (PD), and the two appear to be related. Mitochondrial dysfunction leads to accumulation and oligomerization of alpha-synuclein, and increased levels of alpha-synuclein cause mitochondrial impairment, but the basis for this bidirectional interaction remains obscure. We now report that certain posttranslationally modified species of alpha-synuclein bind with high affinity to the TOM20 (translocase of the outer membrane 20) presequence receptor of the mitochondrial protein import machinery. This binding prevented the interaction of TOM20 with its co-receptor, TOM22, and impaired mitochondrial protein import. Consequently, there were deficient mitochondrial respiration, enhanced production of reactive oxygen species, and loss of mitochondrial membrane potential. Examination of postmortem brain tissue from PD patients revealed an aberrant alpha-synuclein-TOM20 interaction in nigrostriatal dopaminergic neurons that was associated with loss of imported mitochondrial proteins, thereby confirming this pathogenic process in the human disease. Modest knockdown of endogenous alpha-synuclein was sufficient to maintain mitochondrial protein import in an in vivo model of PD. Furthermore, in in vitro systems, overexpression of TOM20 or a mitochondrial targeting signal peptide had beneficial effects and preserved mitochondrial protein import. This study characterizes a pathogenic mechanism in PD, identifies toxic species of wildtype alpha-synuclein, and reveals potential new therapeutic strategies for neuroprotection. C1 [Di Maio, Roberto; Barrett, Paul J.; Hoffman, Eric K.; Barrett, Caitlyn W.; Zharikov, Alevtina; Borah, Anupom; Hu, Xiaoping; Mccoy, Jennifer; Chu, Charleen T.; Burton, Edward A.; Hastings, Teresa G.; Greenamyre, J. Timothy] Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15213 USA. [Di Maio, Roberto; Barrett, Paul J.; Hoffman, Eric K.; Barrett, Caitlyn W.; Zharikov, Alevtina; Hu, Xiaoping; Mccoy, Jennifer; Burton, Edward A.; Hastings, Teresa G.; Greenamyre, J. Timothy] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Di Maio, Roberto] Ri MED Fdn, Palermo, Italy. [Zharikov, Alevtina; Burton, Edward A.; Greenamyre, J. Timothy] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Borah, Anupom] Assam Univ, Dept Life Sci & Bioinformat, Silchar 788011, India. [Chu, Charleen T.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA. RP Greenamyre, JT (reprint author), Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15213 USA.; Greenamyre, JT (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.; Greenamyre, JT (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. EM jgreena@pitt.edu OI Burton, Edward/0000-0002-8072-4636 FU DSF Charitable Foundation; Ri.MED Foundation; Consolidated Anti-Aging Foundation; NIH [NS095387, NS059806, ES022644, ES020718, ES020327, NS065789, AG026389, P50AG005133]; U.S. Department of Veterans Affairs [1I01BX000548]; Blechman Foundation; American Parkinson Disease Association; Department of Biotechnology, Government of India FX This work was supported by research grants from the DSF Charitable Foundation, the Ri.MED Foundation, the Consolidated Anti-Aging Foundation, NIH (NS095387, NS059806, ES022644, ES020718, ES020327, NS065789, AG026389, and P50AG005133), the U.S. Department of Veterans Affairs (1I01BX000548), the Blechman Foundation, the American Parkinson Disease Association, and the Department of Biotechnology, Government of India. NR 41 TC 16 Z9 16 U1 3 U2 11 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD JUN 8 PY 2016 VL 8 IS 342 AR 342ra78 DI 10.1126/scitranslmed.aaf3634 PG 14 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA DO0BG UT WOS:000377443800002 PM 27280685 ER PT J AU Diaz-Ochoa, VE Lam, D Lee, CS Klaus, S Behnsen, J Liu, JZ Chim, N Nuccio, SP Rathi, SG Mastroianni, JR Edwards, RA Jacobo, CM Cerasi, M Battistoni, A Ouellette, AJ Goulding, CW Chazin, WJ Skaar, EP Raffatellu, M AF Diaz-Ochoa, Vladimir E. Lam, Diana Lee, Carlin S. Klaus, Suzi Behnsen, Judith Liu, Janet Z. Chim, Nicholas Nuccio, Sean-Paul Rathi, Subodh G. Mastroianni, Jennifer R. Edwards, Robert A. Jacobo, Christina M. Cerasi, Mauro Battistoni, Andrea Ouellette, Andre J. Goulding, Celia W. Chazin, Walter J. Skaar, Eric P. Raffatellu, Manuela TI Salmonella Mitigates Oxidative Stress and Thrives in the Inflamed Gut by Evading Calprotectin-Mediated Manganese Sequestration SO CELL HOST & MICROBE LA English DT Article ID ENTERICA SEROVAR TYPHIMURIUM; INNATE IMMUNE-RESPONSE; IRON TRANSPORT-SYSTEM; HOST-DEFENSE PROTEIN; SUPEROXIDE-DISMUTASE; INTESTINAL MICROBIOTA; ESCHERICHIA-COLI; FULL VIRULENCE; BACTERIAL; INFLAMMATION AB Neutrophils hinder bacterial growth by a variety of antimicrobial mechanisms, including the production of reactive oxygen species and the secretion of proteins that sequester nutrients essential to microbes. A major player in this process is calprotectin, a host protein that exerts antimicrobial activity by chelating zinc and manganese. Here we show that the intestinal pathogen Salmonella enterica serovar Typhimurium uses specialized metal transporters to evade calprotectin sequestration of manganese, allowing the bacteria to outcompete commensals and thrive in the inflamed gut. The pathogen's ability to acquire manganese in turn promotes function of SodA and KatN, enzymes that use the metal as a cofactor to detoxify reactive oxygen species. This manganese-dependent SodA activity allows the bacteria to evade neutrophil killing mediated by calprotectin and reactive oxygen species. Thus, manganese acquisition enables S. Typhimurium to overcome host antimicrobial defenses and support its competitive growth in the intestine. C1 [Diaz-Ochoa, Vladimir E.; Lam, Diana; Lee, Carlin S.; Klaus, Suzi; Behnsen, Judith; Liu, Janet Z.; Nuccio, Sean-Paul; Jacobo, Christina M.; Raffatellu, Manuela] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA. [Diaz-Ochoa, Vladimir E.; Lam, Diana; Lee, Carlin S.; Klaus, Suzi; Behnsen, Judith; Liu, Janet Z.; Nuccio, Sean-Paul; Jacobo, Christina M.; Raffatellu, Manuela] Univ Calif Irvine, Inst Immunol, Irvine, CA 92697 USA. [Chim, Nicholas; Goulding, Celia W.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA. [Goulding, Celia W.] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92697 USA. [Rathi, Subodh G.; Chazin, Walter J.] Vanderbilt Univ, Dept Biochem & Chem, Nashville, TN 37232 USA. [Mastroianni, Jennifer R.; Ouellette, Andre J.] Univ So Calif, Dept Pathol & Lab Med, Los Angeles, CA 90089 USA. [Edwards, Robert A.] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA. [Cerasi, Mauro; Battistoni, Andrea] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy. [Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. RP Raffatellu, M (reprint author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.; Raffatellu, M (reprint author), Univ Calif Irvine, Inst Immunol, Irvine, CA 92697 USA. EM manuelar@uci.edu OI Battistoni, Andrea/0000-0003-4085-7917; Raffatellu, Manuela/0000-0001-6487-4215; Nuccio, Sean-Paul/0000-0002-9683-9278 FU Public Health Service Grants (PHSGs) [AI83663, AI101784, AI105374, AI114625, DK058057]; Burroughs Wellcome Fund; National Institutes of Health (NIH) Minority Biomedical Research Support Initiative for Maximizing Student Development grant [GM055246]; NIH [T32 AI60573]; PHSG [AI101171]; Office of Medical Research, Department of Veterans Affairs [BX002482]; PHSGs [AI099687, AI095208] FX We thank Russell Gerards for help with ICP-MS. M.R.'s lab is supported by Public Health Service Grants (PHSGs) AI83663, AI101784, AI105374, AI114625, and DK058057. M.R. holds an Investigator in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. Other M.R. lab support: V.E.D.-O. by National Institutes of Health (NIH) Minority Biomedical Research Support Initiative for Maximizing Student Development grant GM055246 and a University of California, Irvine, President's Dissertation Year Award; S.K. by an American Heart Association (AHA) predoctoral fellowship; J.Z.L. by NIH grant T32 AI60573 and an AHA predoctoral fellowship; J.B. by an AHA postdoctoral fellowship. E.P.S.'s and W.J.C.'s labs are supported by PHSG AI101171. E.P.S. holds a Merit Review Grant (BX002482) from the Office of Medical Research, Department of Veterans Affairs. C.W.G.'s lab is supported by PHSGs AI099687 and AI095208. NR 66 TC 4 Z9 4 U1 4 U2 10 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA SN 1931-3128 EI 1934-6069 J9 CELL HOST MICROBE JI Cell Host Microbe PD JUN 8 PY 2016 VL 19 IS 6 BP 814 EP 825 DI 10.1016/j.chom.2016.05.005 PG 12 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA DO0CM UT WOS:000377447000012 PM 27281571 ER PT J AU Nairn, BL Lonergan, ZR Wang, JF Braymer, JJ Zhang, YF Calcutt, MW Lisher, JP Gilston, BA Chazin, WJ de Crecy-Lagard, V Giedroc, DP Skaar, EP AF Nairn, Brittany L. Lonergan, Zachery R. Wang, Jiefei Braymer, Joseph J. Zhang, Yaofang Calcutt, M. Wade Lisher, John P. Gilston, Benjamin A. Chazin, Walter J. de Crecy-Lagard, Valerie Giedroc, David P. Skaar, Eric P. TI The Response of Acinetobacter baumannii to Zinc Starvation SO CELL HOST & MICROBE LA English DT Article ID METAL HOMEOSTASIS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; COG0523 FAMILY; HISTIDINE; PROTEIN; INHIBITION; ACTIVATION; INSIGHTS; GTPASE AB Zinc (Zn) is an essential metal that vertebrates sequester from pathogens to protect against infection. Investigating the opportunistic pathogen Acinetobacter baumannii's response to Zn starvation, we identified a putative Zn metallochaperone, ZigA, which binds Zn and is required for bacterial growth under Zn-limiting conditions and for disseminated infection in mice. ZigA is encoded adjacent to the histidine (His) utilization (Hut) system. The His ammonialyase HutH binds Zn very tightly only in the presence of high His and makes Zn bioavailable through His catabolism. The released Zn enables A. baumannii to combat host-imposed Zn starvation. These results demonstrate that A. baumannii employs several mechanisms to ensure bioavailability of Zn during infection, with ZigA functioning predominately during Zn starvation, but HutH operating in both Zn-deplete and -replete conditions to mobilize a labile His-Zn pool. C1 [Nairn, Brittany L.; Lonergan, Zachery R.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Wang, Jiefei; Braymer, Joseph J.; Lisher, John P.; Giedroc, David P.] Indiana Univ, Dept Chem, Bloomington, IN 47405 USA. [Zhang, Yaofang; Calcutt, M. Wade] Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA. [Gilston, Benjamin A.; Chazin, Walter J.] Vanderbilt Univ, Sch Med, Struct Biol Ctr, Nashville, TN 37232 USA. [Zhang, Yaofang; Calcutt, M. Wade; Chazin, Walter J.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA. [Chazin, Walter J.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [de Crecy-Lagard, Valerie] Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Giedroc, DP (reprint author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.; Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA. EM giedroc@indiana.edu; eric.skaar@vanderbilt.edu FU NIH [R01 AI1091771, R01 AI101171, R01 GM042569, R01 GM70641]; NIAID [F32 AI108192]; Childhood Infection Research Program [T32 AI095202]; Training Program in Environmental Toxicology [T32 ES007028] FX Work presented in this manuscript was supported by grants R01 AI1091771, R01 AI101171, and R01 GM042569 from the NIH. B.L.N. was supported by grant F32 AI108192 from the NIAID and the Childhood Infection Research Program T32 AI095202. Z.R.L. is supported by the Training Program in Environmental Toxicology T32 ES007028. V.d.C.-L. is supported by the grant R01 GM70641 from the NIH. The content of this article does not necessarily represent the views of the NIH or NIAID and is solely the responsibility of the authors. NR 39 TC 6 Z9 6 U1 2 U2 3 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA SN 1931-3128 EI 1934-6069 J9 CELL HOST MICROBE JI Cell Host Microbe PD JUN 8 PY 2016 VL 19 IS 6 BP 826 EP 836 DI 10.1016/j.chom.2016.05.007 PG 11 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA DO0CM UT WOS:000377447000013 PM 27281572 ER PT J AU Wang, ZW Young, MRI AF Wang, Zhewu Young, M. Rita I. TI PTSD, a Disorder with an Immunological Component SO FRONTIERS IN IMMUNOLOGY LA English DT Review DE cytokines; immune regulation; inflammation; plasma; post-traumatic stress disorder ID POSTTRAUMATIC-STRESS-DISORDER; T-LYMPHOCYTE FUNCTION; QUALITY-OF-LIFE; EXOGENOUS SEROTONIN; GENE-EXPRESSION; CYTOKINE LEVELS; VETERANS; IMMUNE; BRAIN; INTERLEUKIN-6 AB Post-traumatic stress disorder (PTSD) has been associated with an inflammatory state. However, few studies have addressed the mechanisms underlying this immune imbalance that favors inflammation or how this imbalance contributes to PTSD. Whether the immune imbalance influences responsiveness or unresponsiveness of patients to PTSD treatments is currently not known. This review brings forward an immune emphasis to a mental health disorder that is unprecedented in its prevalence among combat Veterans of the ongoing conflicts in Iraq and Afghanistan and which also afflicts civilians who have undergone extreme traumatic experiences, such as following natural disasters, serious accidents, or assaults. Included is an overview of the correlative associations in human subjects between PTSD and inflammation and studies in animal models of PTSD, demonstrating causal contributions of inflammation and immune dysregulation to PTSD-like behavior following stress exposure. C1 [Wang, Zhewu] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Wang, Zhewu] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.; Young, MRI (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. EM rita.young@va.gov FU Clinical Sciences Research and Development Program of the Department of Veterans Affairs [I01 CX000851, 1 I01 CX000487] FX This work was supported by the Clinical Sciences Research and Development Program of the Department of Veterans Affairs (Merit Review grants I01 CX000851 to MY and 1 I01 CX000487 to ZW). NR 66 TC 2 Z9 2 U1 5 U2 11 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD JUN 6 PY 2016 VL 7 AR 219 DI 10.3389/fimmu.2016.00219 PG 6 WC Immunology SC Immunology GA DN4TX UT WOS:000377061200002 PM 27375619 ER PT J AU Radonovich, LJ Bessesen, MT Cummings, DA Eagan, A Gaydos, C Gibert, C Gorse, GJ Nyquist, AC Reich, NG Rodrigues-Barradas, M Savor-Price, C Shaffer, RE Simberkoff, MS Perl, TM AF Radonovich, Lewis J., Jr. Bessesen, Mary T. Cummings, Derek A. Eagan, Aaron Gaydos, Charlotte Gibert, Cynthia Gorse, Geoffrey J. Nyquist, Ann-Christine Reich, Nicholas G. Rodrigues-Barradas, Maria Savor-Price, Connie Shaffer, Ronald E. Simberkoff, Michael S. Perl, Trish M. TI The Respiratory Protection Effectiveness Clinical Trial (ResPECT): a cluster-randomized comparison of respirator and medical mask effectiveness against respiratory infections in healthcare personnel SO BMC INFECTIOUS DISEASES LA English DT Article DE Respirators; Masks; Healthcare personnel; Influenza; Respiratory infections ID NOSE-THROAT SWABS; N95 RESPIRATORS; SURGICAL MASK; NASOPHARYNGEAL ASPIRATE; FACE MASKS; NASAL SWAB; WORKERS; INFLUENZA; TRANSMISSION; PERFORMANCE AB Background: Although N95 filtering facepiece respirators and medical masks are commonly used for protection against respiratory infections in healthcare settings, more clinical evidence is needed to understand the optimal settings and exposure circumstances for healthcare personnel to use these devices. A lack of clinically germane research has led to equivocal, and occasionally conflicting, healthcare respiratory protection recommendations from public health organizations, professional societies, and experts. Methods: The Respiratory Protection Effectiveness Clinical Trial (ResPECT) is a prospective comparison of respiratory protective equipment to be conducted at multiple U.S. study sites. Healthcare personnel who work in outpatient settings will be cluster-randomized to wear N95 respirators or medical masks for protection against infections during respiratory virus season. Outcome measures will include laboratory-confirmed viral respiratory infections, acute respiratory illness, and influenza-like illness. Participant exposures to patients, coworkers, and others with symptoms and signs of respiratory infection, both within and beyond the workplace, will be recorded in daily diaries. Adherence to study protocols will be monitored by the study team. Discussion: ResPECT is designed to better understand the extent to which N95s and MMs reduce clinical illness among healthcare personnel. A fully successful study would produce clinically relevant results that help clinician-leaders make reasoned decisions about protection of healthcare personnel against occupationally acquired respiratory infections and prevention of spread within healthcare systems. C1 [Radonovich, Lewis J., Jr.; Eagan, Aaron] US Dept Vet Affairs, Natl Ctr Occupat Hlth & Infect Control, 1601 SW Archer Rd,Mailstop 151E, Gainesville, FL 32608 USA. [Bessesen, Mary T.] Vet Affairs Eastern Colorado Healthcare Syst, Denver, CO USA. [Gaydos, Charlotte; Perl, Trish M.] Johns Hopkins Sch Med, Baltimore, MD USA. [Gibert, Cynthia] Vet Affairs Med Ctr, 50 Irving St NW, Washington, DC 20422 USA. [Gibert, Cynthia] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Gorse, Geoffrey J.] Vet Affairs St Louis Healthcare Syst, St Louis, MO USA. [Gorse, Geoffrey J.] St Louis Univ, Sch Med, St Louis, MO 63103 USA. [Nyquist, Ann-Christine] Childrens Hosp Colorado, Aurora, CO USA. [Reich, Nicholas G.] Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA. [Rodrigues-Barradas, Maria] Michael E DeBakey VAMC, Houston, TX USA. [Rodrigues-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA. [Savor-Price, Connie] Denver Hlth, Denver, CO USA. [Shaffer, Ronald E.] NIOSH, Natl Personal Protect Technol Lab, Pittsburgh, PA USA. [Simberkoff, Michael S.] Vet Affairs New York Harbor Healthcare Syst, New York, NY USA. [Bessesen, Mary T.; Nyquist, Ann-Christine; Savor-Price, Connie] Univ Colorado, Sch Med, Denver, CO 80202 USA. [Cummings, Derek A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Cummings, Derek A.] Univ Florida, Gainesville, FL USA. RP Radonovich, LJ (reprint author), US Dept Vet Affairs, Natl Ctr Occupat Hlth & Infect Control, 1601 SW Archer Rd,Mailstop 151E, Gainesville, FL 32608 USA. EM lewis.radonovich@va.gov FU U.S. Department of Veterans Affairs (Veterans Health Administration); U.S. Department of Health and Human Services (Centers for Disease Control and Prevention); U.S. Department of Health and Human Services (National Institute for Occupational Safety and Health); U.S. Department of Health and Human Services (Biomedical Advanced Research and Development Authority) FX We wish to thank the members of the ResPECT Team (complete list to be provided prior to publication). ResPECT is jointly funded by the U.S. Department of Veterans Affairs (Veterans Health Administration) and the U.S. Department of Health and Human Services (Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, and the Biomedical Advanced Research and Development Authority). NR 49 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JUN 2 PY 2016 VL 16 AR 243 DI 10.1186/s12879-016-1494-2 PG 10 WC Infectious Diseases SC Infectious Diseases GA DO7EA UT WOS:000377944000001 PM 27255755 ER PT J AU Sutherland, MT Riedel, MC Flannery, JS Yanes, JA Fox, PT Stein, EA Laird, AR AF Sutherland, Matthew T. Riedel, Michael C. Flannery, Jessica S. Yanes, Julio A. Fox, Peter T. Stein, Elliot A. Laird, Angela R. TI Chronic cigarette smoking is linked with structural alterations in brain regions showing acute nicotinic drug-induced functional modulations SO BEHAVIORAL AND BRAIN FUNCTIONS LA English DT Article DE Cigarettes; Nicotine; Addiction; Gray matter; Morphometry; Insula; Mediodorsal thalamus; Ventromedial prefrontal cortex; Cerebellum ID GRAY-MATTER VOLUME; INTRINSIC CONNECTIVITY NETWORKS; VOXEL-BASED MORPHOMETRY; YOUNG-ADULT SMOKERS; NEUROIMAGING DATA; DECISION-MAKING; METAANALYTIC CONNECTIVITY; ACETYLCHOLINE-RECEPTORS; COGNITIVE-PROCESSES; CORTICAL THICKNESS AB Background: Whereas acute nicotine administration alters brain function which may, in turn, contribute to enhanced attention and performance, chronic cigarette smoking is linked with regional brain atrophy and poorer cognition. However, results from structural magnetic resonance imaging (MRI) studies comparing smokers versus nonsmokers have been inconsistent and measures of gray matter possess limited ability to inform functional relations or behavioral implications. The purpose of this study was to address these interpretational challenges through metaanalytic techniques in the service of clarifying the impact of chronic smoking on gray matter integrity and more fully contextualizing such structural alterations. Methods: We first conducted a coordinate-based meta-analysis of structural MRI studies to identify consistent structural alterations associated with chronic smoking. Subsequently, we conducted two additional meta-analytic assessments to enhance insight into potential functional and behavioral relations. Specifically, we performed a multimodal meta-analytic assessment to test the structural-functional hypothesis that smoking-related structural alterations overlapped those same regions showing acute nicotinic drug-induced functional modulations. Finally, we employed database driven tools to identify pairs of structurally impacted regions that were also functionally related via meta-analytic connectivity modeling, and then delineated behavioral phenomena associated with such functional interactions via behavioral decoding. Results: Across studies, smoking was associated with convergent structural decreases in the left insula, right cerebellum, parahippocampus, multiple prefrontal cortex (PFC) regions, and the thalamus. Indicating a structural-functional relation, we observed that smoking-related gray matter decreases overlapped with the acute functional effects of nicotinic agonist administration in the left insula, ventromedial PFC, and mediodorsal thalamus. Suggesting structural-behavioral implications, we observed that the left insula's task-based, functional interactions with multiple other structurally impacted regions were linked with pain perception, the right cerebellum's interactions with other regions were associated with overt body movements, interactions between the parahippocampus and thalamus were linked with memory processes, and interactions between medial PFC regions were associated with face processing. Conclusions: Collectively, these findings emphasize brain regions (e.g., ventromedial PFC, insula, thalamus) critically linked with cigarette smoking, suggest neuroimaging paradigms warranting additional consideration among smokers (e.g., pain processing), and highlight regions in need of further elucidation in addiction (e.g., cerebellum). C1 [Sutherland, Matthew T.; Riedel, Michael C.; Flannery, Jessica S.] Florida Int Univ, Dept Psychol, AHC 4,RM 312,11200 SW 8th St, Miami, FL 33199 USA. [Riedel, Michael C.; Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Yanes, Julio A.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China. [Stein, Elliot A.] NIDA, Neuroimaging Res Branch, Intramural Res Program, NIH DHHS, Baltimore, MD USA. RP Sutherland, MT (reprint author), Florida Int Univ, Dept Psychol, AHC 4,RM 312,11200 SW 8th St, Miami, FL 33199 USA. EM masuther@fiu.edu OI Sutherland, Matthew/0000-0002-6091-4037 FU National Institute on Drug Abuse of the NIH [K01-DA037819]; National Institute of Mental Health of the NIH [R01-MH074457, R56-MH097870]; Intramural Research Program of the National Institute on Drug Abuse FX This work was supported by the National Institute on Drug Abuse (K01-DA037819, MTS) and the National Institute of Mental Health (R01-MH074457 and R56-MH097870, ARL and PTF) of the NIH. EAS is supported by the Intramural Research Program of the National Institute on Drug Abuse. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 112 TC 1 Z9 1 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1744-9081 J9 BEHAV BRAIN FUNCT JI Behav. Brain Funct. PD JUN 2 PY 2016 VL 12 AR 16 DI 10.1186/s12993-016-0100-5 PG 15 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA DN4TV UT WOS:000377061000001 PM 27251183 ER PT J AU Tickell, KD Lokken, EM Schaafsma, TT Goldberg, J Lannon, SMR AF Tickell, Kirkby D. Lokken, Erica M. Schaafsma, Torin T. Goldberg, Jack Lannon, Sophia M. R. TI Lower respiratory tract disorder hospitalizations among children born via elective early-term delivery SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE LA English DT Article DE Asthma; bronchiolitis; bronchitis; gestational age; pneumonia ID FETAL LUNG MATURITY; LATE-PRETERM; NEONATAL OUTCOMES; CHILDHOOD ASTHMA; BIRTH; PREGNANCY; ADMISSION; RISK AB Objective: We evaluated the hypothesis that elective early-term delivery increases the risk of childhood lower respiratory tract disorder hospitalization.Methods: Children born via early-term elective inductions were compared to full- or late-term elective inductions in a retrospective cohort study using Washington State birth certificate and hospital discharge data. Outcomes were the odds of lower respiratory disorder hospitalization before age five and cause specific odds ratios for asthma, bronchiolitis, bronchitis, and pneumonia. In addition, a subgroup analysis excluding infants with perinatal complications was conducted.Results: Electively induced early-term children were at significantly increased risk of hospitalization before age five for lower respiratory disorders compared to similar full- or late-term children (adjusted OR: 1.31, 95% CI: 1.11-1.55). Bronchiolitis was the only cause-specific outcome with a statistically significant increase in odds of hospitalization, though comparable increases were found for the less common diagnoses of asthma (adjusted OR: 1.39, 95% CI: 0.93-2.08) and pneumonia (adjusted OR: 1.27, 95% CI: 0.99-1.64). Excluding infants with perinatal complications did not alter the results.Conclusions: There was an association between electively induced early-term delivery and hospitalization for lower respiratory tract disorders before age five. This reinforces policies discouraging elective early-term delivery. C1 [Tickell, Kirkby D.; Lokken, Erica M.; Schaafsma, Torin T.; Goldberg, Jack] Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. [Goldberg, Jack] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Lannon, Sophia M. R.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. RP Tickell, KD (reprint author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. EM kirkbt@uw.edu NR 19 TC 1 Z9 1 U1 0 U2 14 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1476-7058 EI 1476-4954 J9 J MATERN-FETAL NEO M JI J. Matern.-Fetal Neonatal Med. PD JUN 2 PY 2016 VL 29 IS 11 BP 1871 EP 1876 DI 10.3109/14767058.2015.1066774 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DI5CN UT WOS:000373515800033 PM 26302650 ER PT J AU Li, L Shelton, RC Chassan, RA Hammond, JC Gower, BA Garvey, TW AF Li, Li Shelton, Richard Charles Chassan, Rachel Ann Hammond, John Charles Gower, Barbara Ann Garvey, Timothy W. TI Impact of Major Depressive Disorder on Prediabetes by Impairing Insulin Sensitivity SO JOURNAL OF DIABETES & METABOLISM LA English DT Article DE Insulin sensitivity; Prediabetes; Atherosclerosis; Phosphorylation; Cardiovascular diseases; Glucose tolerance test ID TYPE-2 DIABETES-MELLITUS; ORAL GLUCOSE-TOLERANCE; RISK-FACTOR; PLASMA-GLUCOSE; DSM-IV; RESISTANCE; METABOLISM; ADIPOSITY; DISEASE; HEALTH AB Reports regarding the associations between major depressive disorder (MDD) and diabetes remain heterogeneous. Our aim was to investigate whether glucose homeostasis and insulin sensitivity were impaired in the MDD patients and its mechanisms. A total of 30 patients with MDD and 30 matched controls were recruited. The oral glucose tolerance test and dual-energy X-ray absorptiometry scan were performed in each participant. Insulin signaling in postmortem brain tissues from other depressive patients and controls (obtained from Alabama brain bank) was examined. Insulin sensitivity was reduced substantially in the MDD patients, however, the fasting and 2-h glucose concentrations remained within the normal range through compensatory insulin secretion. Despite increased insulin secretion, 1-h glucose concentrations in the MDD patients were significantly elevated compared with the controls. MDD patients had greater visceral fat mass but lower adiponectin levels compared with the controls. Furthermore, phosphorylated-AKT levels in insulin signaling were decreased in postmortem brain tissues in patients with MDD. These results suggest that MDD patients are at a greater risk for diabetes due to decreased insulin sensitivity, reduced disposition index, and impaired glucose tolerance as manifested by elevated 1-h glucose concentrations following an oral glucose challenge. Mechanistic studies reveal that decreased insulin sensitivity is associated with increased visceral fat mass, lower adiponectin levels and impaired insulin action in postmortem brain tissues in the MDD patients. Our findings emphasize the importance of screening depressive patients to identify susceptible individuals for developing future diabetes with the hope of improving their health outcomes. C1 [Li, Li; Shelton, Richard Charles; Chassan, Rachel Ann] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 Univ Blvd, Birmingham, AL 35294 USA. [Gower, Barbara Ann; Garvey, Timothy W.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, Timothy W.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Li, L (reprint author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 Univ Blvd, Birmingham, AL 35294 USA. EM lili978@uab.edu FU Brain and Behavior Research Foundation [P30DK056336]; National Institute of Diabetes [P30DK079626]; Digestive And Kidney Diseases to Nutrition Obesity Research Center and Diabetes Research Center, at the University of Alabama at Birmingham FX We would like to thank Dr. Rosalinda C. Roberts for her technical assistance in the preparation of postmortem human brain samples. This work was supported by a Young Investigator Award from the Brain and Behavior Research Foundation to L.L. and awards, P30DK056336 and P30DK079626, from the National Institute of Diabetes And Digestive And Kidney Diseases to Nutrition Obesity Research Center and Diabetes Research Center, respectively, at the University of Alabama at Birmingham. NR 30 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2155-6156 J9 J DIABETES METAB JI J. Diabetes Metab. PD JUN PY 2016 VL 7 SI SI AR UNSP 4 DI 10.4172/2155-6156.1000664 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EO0FY UT WOS:000396374900004 ER PT J AU Mansh, M Arron, ST AF Mansh, Matthew Arron, Sarah T. TI Indoor tanning and melanoma: are gay and bisexual men more at risk? SO MELANOMA MANAGEMENT LA English DT Editorial Material DE epidemiology; gay and bisexual; indoor tanning; melanoma; public health; sexual minority; skin cancer ID METAANALYSIS C1 [Mansh, Matthew] Calif Pacific Med Ctr, Dept Internal Med, San Francisco, CA 94115 USA. [Arron, Sarah T.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA. [Arron, Sarah T.] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA. RP Arron, ST (reprint author), Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.; Arron, ST (reprint author), San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA. EM sarah.arron@ucsf.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 2045-0885 EI 2045-0893 J9 MELANOMA MANAG JI Melanoma Manag. PD JUN PY 2016 VL 3 IS 2 BP 89 EP 92 DI 10.2217/mmt-2015-0002 PG 4 WC Oncology SC Oncology GA EK0SG UT WOS:000393636800002 ER PT J AU Wilkinson, JR Spindler, M Wood, SM Marcus, SC Weintraub, D Morley, JF Stineman, MG Duda, JE AF Wilkinson, Jayne R. Spindler, Meredith Wood, Stephanie M. Marcus, Steven C. Weintraub, Daniel Morley, James F. Stineman, Margaret G. Duda, John E. TI High patient satisfaction with telehealth in Parkinson disease A randomized controlled study SO NEUROLOGY-CLINICAL PRACTICE LA English DT Article ID RATING-SCALE; HEALTH-CARE; TELEMEDICINE; COMMUNICATION; TRIAL AB Background: Parkinson disease (PD) is a complex neurodegenerative disorder that benefits from specialty care. Telehealth is an innovative resource that can enhance access to this care within a patient-centered framework. Research suggests that telehealth can lead to increased patient satisfaction, equal or better clinical outcomes, and cost savings, but these outcomes have not been well-studied in PD. Methods: We conducted a dual active-arm 12-month randomized controlled trial to assess patient satisfaction, clinical outcomes, travel burden, and health care utilization in PD using video telehealth for follow-up care with specialty providers. Telehealth visits took place either at a facility nearer to the patient (satellite clinic arm) or in the patient's home (home arm). Each control group received usual in-person care. Patient satisfaction, assessed by quantitative questionnaires, was the primary outcome. Results: Eighty-six men were enrolled (home arm: 18 active, 18 control; satellite clinic arm: 26 active, 24 control) with a mean age of 73 years (range 42-87). There were no differences in baseline characteristics between the active group and the controls in each arm (p. 0.05). A significant difference in overall patient satisfaction was not found; however, high levels of patient satisfaction were found in all groups. Greater satisfaction for the telehealth modality was found in assessments of convenience and accessibility/distance. Clinical outcomes were similar between groups, travel burden was reduced using telehealth, and health care utilization was largely similar in both groups. Conclusions: As the need for PD subspecialty care increases, innovative patient-centered solutions to overcoming barriers to access, such as video telehealth, will be invaluable to patients and may provide high patient satisfaction. C1 [Wilkinson, Jayne R.; Spindler, Meredith; Wood, Stephanie M.; Weintraub, Daniel; Morley, James F.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19104 USA. [Wilkinson, Jayne R.; Spindler, Meredith; Weintraub, Daniel; Morley, James F.; Duda, John E.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Stineman, Margaret G.] Univ Penn, Dept Phys Med Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Wilkinson, JR (reprint author), Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA 19104 USA.; Wilkinson, JR (reprint author), Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. EM jayne.wilkinson@va.gov FU VA grant - Center for the Evaluation of the Patient-Aligned Care Team (CEPACT) based out of the Philadelphia VAMC FX Funding was provided by a VA grant issued by the Center for the Evaluation of the Patient-Aligned Care Team (CEPACT) based out of the Philadelphia VAMC. NR 22 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD JUN PY 2016 VL 6 IS 3 BP 241 EP 251 DI 10.1212/CPJ.0000000000000252 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA EJ3FY UT WOS:000393099200014 ER PT J AU Kopacz, MS Feldstein, BD Asekoff, CA Kaprow, MS Smith-Coggins, R Connery, AL AF Kopacz, Marek S. Feldstein, Bruce D. Asekoff, Cecille Allman Kaprow, Maurice S. Smith-Coggins, Rebecca Connery, April L. TI A preliminary study examining chaplains' support for veterans at the end of life SO INTERNATIONAL JOURNAL OF PALLIATIVE NURSING LA English DT Article DE Chaplains; Veterans; End of Life AB This descriptive study examines the involvement of professional chaplains in addressing loss of dignity, inconsequential life or not having a legacy, fear of burdensomeness, and fear of pain in veterans at the end of life. A convenience sample of Jewish chaplains responded to an online survey gauging their involvement in these areas. Results are presented descriptively. Most respondents stated either rarely (<= 1 x month) or sometimes (>= 1 x month) encountering veterans with end-of-life issues. Respondents reported varying degrees of involvement in supporting veterans at the end of life with respect to the aforementioned areas. As research into the end-of-life care needs of veterans continues to develop, recognising chaplains as a source of both spiritual and psychosocial support can serve as an opportunity for better meeting the needs of this population. C1 [Kopacz, Marek S.; Connery, April L.] US Dept Vet Affairs, Canandaigua, NY 14424 USA. [Feldstein, Bruce D.] Stanford Med, Stanford, CA USA. [Asekoff, Cecille Allman; Kaprow, Maurice S.] Neshama Assoc Jewish Chaplains, Paramus, NJ USA. [Smith-Coggins, Rebecca] Stanford Univ, Emergency Med, Stanford, CA 94305 USA. RP Kopacz, MS (reprint author), US Dept Vet Affairs, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 13 TC 1 Z9 1 U1 0 U2 0 PU MARK ALLEN GROUP PI LONDON PA ST JUDES CHURCH, DULWICH RD, LONDON, SE24 0PB, ENGLAND SN 1357-6321 J9 INT J PALLIAT NURS JI Int. J. Palliat. Nurs. PD JUN PY 2016 VL 22 IS 6 BP 300 EP 302 PG 3 WC Nursing SC Nursing GA EE1CQ UT WOS:000389318800007 PM 27349849 ER PT J AU Beristianos, MH Maguen, S Neylan, TC Byers, AL AF Beristianos, Matthew H. Maguen, Shira Neylan, Thomas C. Byers, Amy L. TI TRAUMA EXPOSURE AND RISK OF SUICIDAL IDEATION AMONG ETHNICALLY DIVERSE ADULTS SO DEPRESSION AND ANXIETY LA English DT Article DE trauma exposure; suicidal ideation; race/ethnicity; posttraumatic stress disorder; major depressive disorder; child maltreatment ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; SURVEY REPLICATION; PREVALENCE; EVENTS; SAMPLE; CHILD; EPIDEMIOLOGY; PREDICTORS; COMMUNITY AB Background: Little is known about the association between trauma exposure and suicidal ideation across racial/ethnic groups. Our study aim was to determine the association between trauma exposure and suicidal ideation in a nationally representative ethnically diverse sample of adults. Methods: This study included 14,866 White, Hispanic, Black, and Asian participants 18 years and older involved in the Collaborate Psychiatric Epidemiology Surveys (2001-2003), comprised of three nationally representative studies (NCS-R, NSAL, and NLAAS). Lifetime history of suicidal ideation as assessed in the World Health Organization'sWorld Mental Health Survey Initiative version of the Composite International Diagnostic Interview (WMH-CIDI). Results: Of the 81% respondents who reported being exposed to trauma as assessed in the WMH-CIDI, 12.1% endorsed lifetime suicidal ideation. Additionally, of the 19% who did not report trauma, 1.1% endorsed lifetime suicidal ideation. Fully adjusted, multivariable logistic regression models revealed two traumas consistently associated with significantly higher odds for suicidal ideation across all four racial groups examined: Assaultive/interpersonal violence and child maltreatment. Asians, in particular, had the highest likelihood for suicidal ideation in both trauma categories, with a near threefold increased odds for assaultive/interpersonal violence exposure (OR: 2.56; 95% CI: 1.71-3.83) and nearly ninefold increased odds for child maltreatment exposure (OR: 8.43; 95% CI: 4.91-14.49). Discussion: : Suicidal ideation in racially/ethnically diverse American adults is strongly associated with assaultive/interpersonal violence and child maltreatment, independent of PTSD, MDD, and substance use. These findings highlight the need for monitoring of suicidal behavior following assaultive/interpersonal trauma and child maltreatment, regardless of the presence of a psychiatric disorder. Depression and Anxiety 33:495-501, 2016. (C) 2016 Wiley Periodicals, Inc. C1 [Beristianos, Matthew H.; Maguen, Shira; Neylan, Thomas C.; Byers, Amy L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Beristianos, Matthew H.; Maguen, Shira; Neylan, Thomas C.; Byers, Amy L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Beristianos, Matthew H.] Alliant Int Univ, San Francisco, CA USA. RP Beristianos, MH (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, 4150 Clement St 116H, San Francisco, CA 94121 USA. EM matthew.beristianos@va.gov FU National Institutes of Health; National Institute on Minority Health and Health Disparities; Northern California Institute for Research and Education; San Francisco Veterans Affairs Medical Center; National Institute of Mental Health [U01-MH60220, U01-MH57716, U01-MH062209, U01-MH62207]; National Institute of Drug Abuse [R01-DA12058-05]; Office of Behavioral and Social Sciences Research at the National Institute of Health; University of Michigan; Office of Behavioral and Social Sciences Research at the National Institutes of Health; Substance Abuse and Mental Health Services Agency; Latino Research Program Project [P01-MH059876] FX Contract grant sponsor: National Institutes of Health, National Institute on Minority Health and Health Disparities (to A.L.B); contract grant sponsor: Northern California Institute for Research and Education and with resources from the San Francisco Veterans Affairs Medical Center (to M.H.B.); contract grant sponsor: National Institute of Mental Health; contract grant number: U01-MH60220; contract grant sponsor: National Institute of Drug Abuse; contract grant number: R01-DA12058-05; contract grant sponsor: National Institute of Mental Health; contract grant number: U01-MH57716; contract grant sponsor: Office of Behavioral and Social Sciences Research at the National Institute of Health, and the University of Michigan; contract grant sponsor: National Institute of Mental Health; contract grant number: U01-MH062209 and U01-MH62207; contract grant sponsor: Office of Behavioral and Social Sciences Research at the National Institutes of Health, the Substance Abuse and Mental Health Services Agency, and the Latino Research Program Project; contract grant number: P01-MH059876. NR 31 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUN PY 2016 VL 33 IS 6 BP 495 EP 501 DI 10.1002/da.22485 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DW5SW UT WOS:000383708200005 PM 26992150 ER PT J AU Bryan, CJ Clemans, TA Hernandez, AM Mintz, J Peterson, AL Yarvis, JS Resick, PA AF Bryan, Craig J. Clemans, Tracy A. Hernandez, Ann Marie Mintz, Jim Peterson, Alan L. Yarvis, Jeffrey S. Resick, Patricia A. CA The Strong Star Consortium TI EVALUATING POTENTIAL IATROGENIC SUICIDE RISK IN TRAUMA-FOCUSED GROUP COGNITIVE BEHAVIORAL THERAPY FOR THE TREATMENT OF PTSD IN ACTIVE DUTY MILITARY PERSONNEL SO DEPRESSION AND ANXIETY LA English DT Article DE suicidal ideation; PTSD; depression; adverse effects; psychotherapy ID POSTTRAUMATIC-STRESS-DISORDER; SERVICEMEMBERS ARMY STARRS; IV MENTAL-DISORDERS; PROCESSING THERAPY; IDEATION; PREVALENCE; RESILIENCE; VETERANS; EXPOSURE; SOLDIERS AB Objective: To determine whether group cognitive processing therapy-cognitive only version (CPT-C) is associated with iatrogenic suicide risk in a sample of active duty US Army personnel diagnosed with posttraumatic stress disorder (PTSD). Possible iatrogenic effects considered include the incidence and severity of suicide ideation, worsening of preexisting suicide ideation, incidence of new-onset suicide ideation, and incidence of suicide attempts among soldiers receiving group CPT-C. Comparison with group present-centered therapy (PCT) was made to contextualize findings. Method: One hundred eight soldiers (100 men, eight women) diagnosed with PTSD were randomized to receive either group CPT-C or group PCT. PTSD diagnosis was confirmed via structured clinician interview. Suicide ideation, depression severity, and PTSD severity were assessed at pretreatment, weekly during treatment, and 2 weeks, 6 months, and 12 months posttreatment. Results: Rates of suicide ideation significantly decreased across both treatments. Among soldiers with pretreatment suicide ideation, severity of suicide ideation significantly decreased across both treatments and was maintained for up to 12 months posttreatment. Exacerbation of preexisting suicide ideation was uncommon in both treatments. New-onset suicide ideation was rare and similar across both treatments (<16%). There were no suicide attempts during treatment or follow-up in either group. Change in depression symptoms predicted change in suicide risk. Conclusions: Suicide-related outcomes were similar across both treatments and primarily associated with comorbid depression. Suicide-related outcomes in group CPT-C were rare and comparable to patterns observed in an active, nontrauma-focused therapy, even among soldiers who entered treatment with suicide ideation. Clinical Trials.gov Identifier: NCT01286415, https://clinicaltrials.gov/ct2/show/NCT01286415. Depression and Anxiety 33:549-557, 2016. (C) 2015 Wiley Periodicals, Inc. C1 [Bryan, Craig J.] Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA. [Bryan, Craig J.] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA. [Clemans, Tracy A.] Natl Ctr Vet Studies, Salt Lake City, UT USA. [Hernandez, Ann Marie; Mintz, Jim; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Peterson, Alan L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Peterson, Alan L.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA. [Yarvis, Jeffrey S.] Carl R Darnall Army Med Ctr, Dept Behav Hlth, Ft Hood, TX USA. [Resick, Patricia A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. RP Bryan, CJ (reprint author), Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA. EM craig.bryan@utah.edu FU US Department of Defense; Military Suicide Research Consortium (MSRC) FX Contract grant sponsor: US Department of Defense; Contract grant sponsor: Military Suicide Research Consortium (MSRC). NR 39 TC 4 Z9 4 U1 6 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD JUN PY 2016 VL 33 IS 6 BP 549 EP 557 DI 10.1002/da.22456 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DW5SW UT WOS:000383708200011 PM 26636426 ER PT J AU Cho, J Copeland, LA Stock, EM Zeber, JE Restrepo, MI MacCarthy, AA Ory, MG Smith, PA Stevens, AB AF Cho, Jinmyoung Copeland, Laurel A. Stock, Eileen M. Zeber, John E. Restrepo, Marcos I. MacCarthy, Andrea A. Ory, Marcia G. Smith, Paul A. Stevens, Alan B. TI Protective and Risk Factors for 5-Year Survival in the Oldest Veterans: Data from the Veterans Health Administration SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE health services; oldest; survival; veterans ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY SERVICE; BLOOD-PRESSURE; MORTALITY; CARE; ADULTS; AFFAIRS; IMPACT; LIFE; SCHIZOPHRENIA AB OBJECTIVES: To characterize physical and mental diseases and use of healthcare services and identify factors associated with mortality in the oldest individuals using the Veterans Health Administration (VHA). DESIGN: Retrospective study with 5-year survival follow-up. SETTING: VHA, system-wide. PARTICIPANTS: Veterans using the VHA aged 80 and older as of October 2008 (N = 721,588: n = 665,249 aged 80-89, n = 56,118 aged 90-99, n = 221 aged 100-115). MEASUREMENTS: Demographic characteristics, physical and mental diseases, healthcare services, and 5-year survival were measured. RESULTS: Accelerated failure time models identified protective and risk factors associated with mortality according to age group. During 5 years of follow-up, 44% of participants died (survival rate: 59% aged 80-89, 32% aged 90-99, 15% aged >= 100). In the multivariable model, protective effects for veterans aged 80-99 were female sex, minority race or ethnicity, being married, having certain physical and mental diagnoses (hypertension, cataract, dyslipidemia, posttraumatic stress disorder, bipolar disorder), having urgent care visits, having invasive surgery, and having few (1-3) prescriptions. Risk factors were lower VHA priority status, physical and mental conditions (diabetes mellitus, anemia, congestive heart failure, dementia, anxiety, depression, smoking, substance abuse disorder), hospital admission, and nursing home care. For those aged 100 and older, being married, smoking, hospital admission, nursing home care, invasive surgery, and prescription use were significant risk factors; only emergency department (ED) use was protective. CONCLUSION: Although the data are limited to VHA care (thus missing Medicare services), this study shows that many veterans served by the VHA live to advanced old age despite multiple chronic conditions. Further study is needed to determine whether a comprehensive, coordinated care system like VHA is associated with greater longevity for very old persons. C1 [Cho, Jinmyoung; Copeland, Laurel A.; Stock, Eileen M.; Zeber, John E.; Smith, Paul A.; Stevens, Alan B.] Baylor Scott & White Hlth, MS 01-501,2401 S 31st St, Temple, TX 76508 USA. [Cho, Jinmyoung; Copeland, Laurel A.; Stock, Eileen M.; Zeber, John E.; Ory, Marcia G.; Stevens, Alan B.] Texas A&M Hlth Sci Ctr, College Stn, TX USA. [Copeland, Laurel A.; Stock, Eileen M.; Zeber, John E.] Cent Texas Vet Hlth Care Syst, Temple, TX USA. [Restrepo, Marcos I.] Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX USA. [Restrepo, Marcos I.; MacCarthy, Andrea A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Cho, J (reprint author), Baylor Scott & White Hlth, MS 01-501,2401 S 31st St, Temple, TX 76508 USA. EM jinmyoung.cho@bswhealth.org OI Copeland, Laurel/0000-0002-9478-0209 FU VHA [HX-09-335]; National Institute of Mental Health; Scott White Research; VA Office of Rural Health; Henry M. Jackson Foundation for the Advancement of Military Medicine; Wounded Warrior Project; Walmart Foundation; May & Stanley Smith Charitable Trust; Robert R. McCormick Foundation; Onward Veterans and Schultz Family Foundation; Bob Woodruff Foundation; Phil Marge Odeen; Rumsfeld Foundation; National Heart, Lung, and Blood Institute [K23HL096054] FX Laurel Copeland: unpaid Governing Board member representing Baylor Scott & White in the Health Care Systems Research Network (formerly HMO Research Network); grant funding from the VHA including HX-09-335, National Institute of Mental Health, Scott & White Research, VA Office of Rural Health, the Henry M. Jackson Foundation for the Advancement of Military Medicine (with Wounded Warrior Project, Walmart Foundation, May & Stanley Smith Charitable Trust, Robert R. McCormick Foundation, Onward Veterans and Schultz Family Foundation, Bob Woodruff Foundation, Phil & Marge Odeen, and the Rumsfeld Foundation). John Zeber: Health Services Research and Development Service merit grant on infectious disease (PI), Mental Health Research Network (coinvestigator), Astra-Zeneca drug safety study (PI, pending); board (unpaid): Academy health behavioral interest group advisory board, World Journal of Psychiatry editorial board. Marcos Restrepo's time is partially protected by Award K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute; National Institutes of Health; or Department of Veterans Affairs. NR 49 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2016 VL 64 IS 6 BP 1250 EP 1257 DI 10.1111/jgs.14161 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DW3MY UT WOS:000383546900012 PM 27321603 ER PT J AU Cagle, JG McClymont, KM Thai, JN Smith, AK AF Cagle, John G. McClymont, Keelan M. Thai, Julie N. Smith, Alexander K. TI "If You Don't Know, All of a Sudden, They're Gone": Caregiver Perspectives About Prognostic Communication for Disabled Elderly Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE informal caregivers; communication; prognosis; life expectancy; uncertainty; hope; older adults ID LATE-LIFE DISABILITY; OF-LIFE; DISCUSSING PROGNOSIS; OLDER-ADULTS; FAMILY CAREGIVERS; END; PREFERENCES; PERCEPTIONS; DEATH; CARE AB OBJECTIVES: To describe preferences and experiences of caregivers of disabled older adults regarding being included in patient-clinician discussions about life expectancy. DESIGN: Qualitative interview study. SETTING: Caregivers were recruited from a Program of All-Inclusive Care for the Elderly (PACE), caregiver support groups and an advertisement on a nationwide caregiver advocacy group website. PARTICIPANTS: Active and bereaved caregivers whose primary language was either English or Cantonese who had provided care within the last 5 years to a disabled adult aged 65 and older (N = 42, 79% female, 60% white, average age 54). MEASUREMENTS: Semistructured telephone interviews were conducted with caregivers who were asked about experiences and preferences related to clinician communication about life expectancy, including preferences for and attitudes toward being included in discussions about life expectancy, how such information should be delivered, and how clinicians should address concerns about uncertainty and hope. Responses were analyzed qualitatively using constant comparison until thematic saturation was reached. RESULTS: Twenty-six percent of caregivers had been involved in a conversation with a clinician about life expectancy, even though 79% expressed a preference to have such a discussion. According to caregivers, clinician concerns about taking away hope or the uncertainty of prognostic information should not deter them from bringing up the topic of life expectancy. Thematic analysis suggested several approaches that may facilitate prognosis communication: establishing a relationship with the care-giver and care recipient; delivering the prognosis in clear, plain language; and responding to emotion with empathy. CONCLUSION: Caregivers reported a preference for being included in conversations about a care recipient's life expectancy. C1 [Cagle, John G.] Univ Maryland, Baltimore, MD 21201 USA. [McClymont, Keelan M.; Thai, Julie N.; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [McClymont, Keelan M.; Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Cagle, JG (reprint author), 525 West Redwood St,3W13, Baltimore, MD 21201 USA. EM jcagle@ssw.umaryland.edu FU National Institute on Aging (NIA) [5T32AG000212]; National Palliative Care Research Center; NIA [K23 040772]; American Federation for Aging Research FX Dr. Cagle's efforts were supported by the National Institute on Aging (NIA) (5T32AG000212) and a Junior Faculty Career Development Award from the National Palliative Care Research Center. Dr. Smith was supported by the NIA (K23 040772) and the American Federation for Aging Research. NR 27 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JUN PY 2016 VL 64 IS 6 BP 1299 EP 1306 DI 10.1111/jgs.14137 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DW3MY UT WOS:000383546900019 PM 27321609 ER PT J AU Clancy, CJ Meslin, C Badrane, H Cheng, SJ Losada, LC Nierman, WC Vergidis, P Clark, NL Nguyen, MH AF Clancy, Cornelius J. Meslin, Camille Badrane, Hassan Cheng, Shaoji Losada, Liliana C. Nierman, William C. Vergidis, Pascalis Clark, Nathan L. Nguyen, M. Hong TI Candida albicans Transcriptional Profiling Within Biliary Fluid From a Patient With Cholangitis, Before and After Antifungal Treatment and Surgical Drainage SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE Candida albicans; cholangitis; fluconazole; RNA-Seq; transcriptional profiling ID DIFFERENTIAL EXPRESSION ANALYSIS; GENE-EXPRESSION; RNA-SEQ; HOST; INFECTION AB We used ribonucleic acid sequencing to profile Candida albicans transcription within biliary fluid from a patient with cholangitis; samples were collected before and after treatment with fluconazole and drainage. Candida albicans transcriptomes at the infection site distinguished treated from untreated cholangitis. After treatment, 1131 C. albicans genes were differentially expressed in biliary fluid. Up-regulated genes were enriched in hyphal growth, cell wall organization, adhesion, oxidation reduction, biofilm, and fatty acid and ergosterol biosynthesis. This is the first study to define Candida global gene expression during deep-seated human infection. Successful treatment of cholangitis induced C. albicans genes involved in fluconazole responses and pathogenesis. C1 [Clancy, Cornelius J.; Badrane, Hassan; Cheng, Shaoji; Vergidis, Pascalis; Nguyen, M. Hong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Clancy, Cornelius J.] Univ Pittsburgh, Sch Med, Div Infect Dis, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Meslin, Camille; Clark, Nathan L.] Univ Pittsburgh, Sch Med, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA. [Losada, Liliana C.; Nierman, William C.] J Craig Venter Inst, Rockville, MD USA. [Losada, Liliana C.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Scaife Hall,Suite 871,3550 Terrace St, Pittsburgh, PA 15261 USA. EM mhn5@pitt.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2016 VL 3 IS 3 DI 10.1093/ofid/ofw120 PG 5 WC Infectious Diseases SC Infectious Diseases GA ED0YZ UT WOS:000388571700016 ER PT J AU Anton, A Ratarasarn, K AF Anton, Andreea Ratarasarn, Kavita TI Pulmonary Function Testing and Role of Pulmonary Rehabilitation in the Elderly Population with Pulmonary Diseases SO CURRENT GERIATRICS REPORTS LA English DT Article DE Geriatric; Elderly; Pulmonary function; Respiratory function; Pulmonary rehabilitation; Physical activity; Quality of life ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; RESPIRATORY REHABILITATION; EXERCISE CAPACITY; LUNG-FUNCTION; COPD; ASTHMA; MORTALITY; DIAGNOSIS; WORKSHOP AB With an aging population worldwide, the incidence and prevalence of certain pulmonary conditions such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are increasing. Pulmonary function tests (PFTs) are helpful tools to confirm pulmonary disorders. However, in the elderly population, age-associated changes in PFTs increase the risk for over diagnosis of obstructive lung disease. Therefore, an individualized approach to diagnosis of pulmonary disorders is essential for optimal management. For patients with established pulmonary disorders, pulmonary rehabilitation is a valuable but underutilized therapeutic intervention which has been shown to improve patient's quality of life, exercise tolerance, and overall prognosis. Recent evidence confirms that benefits of pulmonary rehabilitation are similar between the elderly and younger populations. C1 [Anton, Andreea; Ratarasarn, Kavita] US Dept Vet Affairs, Zablocki VAMC, 5000 W Natl Ave, Milwaukee, WI 53295 USA. [Anton, Andreea; Ratarasarn, Kavita] Med Coll Wisconsin, Div Pulm Crit Care & Sleep Med, 9200 W Wisconsin Ave, Milwaukee, WI 53266 USA. RP Anton, A (reprint author), US Dept Vet Affairs, Zablocki VAMC, 5000 W Natl Ave, Milwaukee, WI 53295 USA.; Anton, A (reprint author), Med Coll Wisconsin, Div Pulm Crit Care & Sleep Med, 9200 W Wisconsin Ave, Milwaukee, WI 53266 USA. EM aturcu@mcw.edu NR 56 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 2196-7865 J9 CURR GERIATR REP JI Curr. Geriatr. Rep. PD JUN PY 2016 VL 5 IS 2 BP 117 EP 123 DI 10.1007/s13670-016-0164-y PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA EC1JR UT WOS:000387861200008 ER PT J AU Lofgreen, SJ Ashack, K Burton, KA Dellavalle, RP AF Lofgreen, Seth J. Ashack, Kurt Burton, Kyle A. Dellavalle, Robert P. TI Mobile Device Use in Dermatologic Patient Care SO CURRENT DERMATOLOGY REPORTS LA English DT Article DE Mobile phone patient care; Smartphones; Mobile apps; Applications teledermatology; Telemedicine; Teledermoscopy ID RANDOMIZED-CONTROLLED-TRIAL; FORWARD TELEDERMATOLOGY; HISTORICAL-PERSPECTIVE; EMERGING TECHNIQUES; TELEDERMOSCOPY; NEED; TECHNOLOGIES; SMARTPHONES; PHOTOGRAPHY; DERMOSCOPY AB Rapidly evolving technology, improved mobile device optics, and the uniquely visual nature of dermatology all promote mobile device use in the clinic. This paper examines how dermatologists use mobile device technology in direct patient care. We discuss mobile applications (apps) for both dermatologists and patients, as well as for integration with the electronic health record. Furthermore, we discuss aspects of teledermatology (including teledermoscopy), both from consults from a primary care provider and in using teledermatology to directly connect to the patient. Finally, we address patient perception of mobile devices in the clinic. C1 [Lofgreen, Seth J.] Univ Colorado, Denver Sch Med, Aurora, CO USA. [Ashack, Kurt] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Burton, Kyle A.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Med Ctr, Dermatol Serv, Eastern Colorado Hlth Care Syst, 1055 Clermont St,Box 165, Denver, CO 80220 USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO 80045 USA. RP Dellavalle, RP (reprint author), Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA.; Dellavalle, RP (reprint author), US Dept Vet Affairs, Med Ctr, Dermatol Serv, Eastern Colorado Hlth Care Syst, 1055 Clermont St,Box 165, Denver, CO 80220 USA.; Dellavalle, RP (reprint author), Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO 80045 USA. EM robert.dellavalle@ucdenver.edu NR 39 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA EI 2162-4933 J9 CURR DERMATOL REP JI Curr. Dermatol. Rep. PD JUN PY 2016 VL 5 IS 2 BP 77 EP 82 DI 10.1007/s13671-016-0132-y PG 6 WC Dermatology SC Dermatology GA EA1ND UT WOS:000386358100002 ER PT J AU Gutierrez, PM Davidson, CL Friese, AH Forster, JE AF Gutierrez, Peter M. Davidson, Collin L. Friese, Ariel H. Forster, Jeri E. TI Physical Activity, Suicide Risk Factors, and Suicidal Ideation in a Veteran Sample SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; HEART-RATE-VARIABILITY; COLLEGE-STUDENTS; SLEEP PROBLEMS; PUBLIC-HEALTH; EXERCISE; BEHAVIOR; DEPRESSION; ADULTS AB The association between current level of suicidal ideation and physical activity was tested in a broad sample of veterans seeking care from the Veterans Health Administration. It was hypothesized that the two variables would be significantly inversely related. It was further hypothesized that the relationship would be mediated by depressive symptoms, disturbed sleep, and a measure of heart rate variability based on existing research regarding physical activity and sleep. Due to the first hypothesis not being supported, the second could not be tested. Post hoc correlation analyses did find associations between physical activity and depressive symptoms, in expected directions, and are discussed. Possible explanations for the negative findings along with recommendations for future research to continue exploring links between suicide risk and physical activity are presented. We conclude by suggesting that physical activity may have promise as a risk reduction intervention and that prospective data are more likely to yield significant results than the cross-sectional methodology employed in the current study. C1 [Gutierrez, Peter M.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, 1055 Clermont St, Denver, CO 80220 USA. [Gutierrez, Peter M.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA. [Davidson, Collin L.; Friese, Ariel H.; Forster, Jeri E.] Denver VA Med Ctr, Rocky Mt MIRECC, Denver, CO USA. [Forster, Jeri E.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA. [Forster, Jeri E.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. RP Gutierrez, PM (reprint author), Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov OI Gutierrez, Peter/0000-0001-8981-8404 FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs FX This material is the result of work supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. The expressed views do not necessarily represent those of the Department of Veterans Affairs or the U.S. Government. NR 42 TC 0 Z9 0 U1 8 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD JUN PY 2016 VL 46 IS 3 BP 284 EP 292 DI 10.1111/sltb.12190 PG 9 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DZ2XK UT WOS:000385705800003 PM 26404757 ER PT J AU Ricklefs, CA Asdigian, NL Kalra, HL Mayer, JA Dellavalle, RP Holman, DM Crane, LA AF Ricklefs, Christine A. Asdigian, Nancy L. Kalra, Heidi L. Mayer, Joni A. Dellavalle, Robert P. Holman, Dawn M. Crane, Lori A. TI Indoor tanning promotions on social media in six US cities #UVTanning #tanning SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Indoor tanning; Skin cancer; Social media; Advertising ID SKIN-CANCER; UNITED-STATES; MELANOMA; PREVALENCE; FACILITIES; COSTS; ADVERTISEMENTS; MORTALITY; EXPOSURE; BURDEN AB There is no research investigating indoor tanning advertising on social media. We assessed the use of social media to promote indoor tanning. We subscribed to social media platforms in six US cities and content-analyzed promotional messages received. We captured 662 messages on Twitter and Facebook, through salon emails, and in daily deal coupons. Salon postings were most frequent on Twitter and Facebook, with an average of 2-3 postings per week. National chains posted more frequently than local businesses. Forty percent of messages were devoid of tanning content and included photos, jokes, or popular references. Thirty percent mentioned price reductions, and 28 % referenced an upcoming holiday. Sunless tanning (17 %) was promoted more often than ultraviolet tanning (9 %). Tanning salons actively use social media as a strategy for maintaining relationships with customers and offer pricing deals that promote loyalty and high-frequency tanning. C1 [Ricklefs, Christine A.] Univ Colorado, Ctr Canc, Res Informat Shared Resource, Anschutz Med Campus, Aurora, CO USA. [Asdigian, Nancy L.; Crane, Lori A.] Univ Colorado, Dept Community & Behav Hlth, Colorado Sch Publ Hlth, Anschutz Med Campus,13001 E 17th Pl,B119, Aurora, CO 80045 USA. [Kalra, Heidi L.] Chatham Univ, Studies Program, Pittsburgh, PA USA. [Mayer, Joni A.] San Diego State Univ, Grad Sch Publ Hlth, Div Hlth Promot, San Diego, CA 92182 USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Dermatol Serv, Aurora, CO USA. [Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Denver, CO USA. [Holman, Dawn M.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Crane, LA (reprint author), Univ Colorado, Dept Community & Behav Hlth, Colorado Sch Publ Hlth, Anschutz Med Campus,13001 E 17th Pl,B119, Aurora, CO 80045 USA. EM lori.crane@ucdenver.edu FU Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Prevention Research Center [U48DP001938-0451] FX This research was supported by the Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Prevention Research Center grant number U48DP001938-0451 to Lori A. Crane. NR 43 TC 2 Z9 2 U1 4 U2 4 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD JUN PY 2016 VL 6 IS 2 BP 260 EP 270 DI 10.1007/s13142-015-0378-0 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DY6TL UT WOS:000385261100012 PM 27356996 ER PT J AU Schapira, MM Shea, JA Duey, KA Kleiman, C Werner, RM AF Schapira, Marilyn M. Shea, Judy A. Duey, Katia A. Kleiman, Carly Werner, Rachel M. TI The Nursing Home Compare Report Card: Perceptions of Residents and Caregivers Regarding Quality Ratings and Nursing Home Choice SO HEALTH SERVICES RESEARCH LA English DT Article DE Nursing home; public reporting; quality indicators ID INFORMATION; CONSUMERS; DISPARITIES AB Objective. To evaluate the perceived usefulness of publicly reported nursing home quality indicators. Study Setting. Primary data were collected from October 2013 to August 2014 among a convenience sample of persons (or family member) recently admitted or anticipating admission to a nursing home within 75 miles of the city of Philadelphia. Study Design. Structured interviews were conducted to assess the salience of data on the Medicare Nursing Home Compare website, including star ratings, clinical quality measures, and benchmarking of individual nursing home quality with state and national data. Data Collection. Interviews were transcribed verbatim, independently coded by two reviewers, and agreement determined. A thematic analysis of transcripts was undertaken. Principal Findings. Thirty-five interviews were completed. Eighty-three percent (n = 29) were caregivers and 17 percent (n = 6) were residents. Star ratings, clinical quality measures, and benchmarking information were salient to decision making, with preferred formats varying across participants. Participants desired additional information on the source of quality data. Confusion was evident regarding the relationship between domain-specific and overall star quality ratings. Conclusions. The Nursing Home Compare website provides salient content and formats for consumers. Increased awareness of this resource and clarity regarding the definition of measures could further support informed decision making regarding nursing home choice. C1 [Schapira, Marilyn M.; Shea, Judy A.; Duey, Katia A.; Kleiman, Carly; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Div Gen Med, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Shea, Judy A.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Schapira, MM (reprint author), Univ Penn, Perelman Sch Med, Div Gen Med, 1110 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM mschap@upenn.edu FU Agency for Healthcare Research and Quality (AHRQ) [R21HS02861]; NIA [K24-AG047908] FX This study was supported by a grant from the Agency for Healthcare Research and Quality (AHRQ) R21HS02861. This study also acknowledges support for Dr. Werner from the NIA (K24-AG047908). There was no requirement from the funder to review work prior to submission. NR 26 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD JUN PY 2016 VL 51 SU 2 BP 1212 EP 1228 DI 10.1111/1475-6773.12458 PG 17 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DX9UY UT WOS:000384743500004 PM 26867949 ER PT J AU Werner, RM Konetzka, RT Polsky, D AF Werner, Rachel M. Konetzka, R. Tamara Polsky, Daniel TI Changes in Consumer Demand Following Public Reporting of Summary Quality Ratings: An Evaluation in Nursing Homes SO HEALTH SERVICES RESEARCH LA English DT Article DE Quality of care; public reporting; quality measures; nursing home ID REPORT CARDS; PERFORMANCE DATA; OF-CARE; INFORMATION; CHOICE; MARKET AB Objective. Limited consumer use of health care report cards may be due to the large amount of information presented in report cards, which can be difficult to understand. These limitations may be overcome with summary measures. Our objective was to evaluate consumer response to summary measures in the setting of nursing homes. Data Sources/Study Setting. 2005-2010 nursing home Minimum Data Set and Online Survey, Certification and Reporting (OSCAR) datasets. Study Design. In December 2008, Medicare converted its nursing home report card to summary or star ratings. We test whether there was a change in consumer demand for nursing homes related to the nursing home's star rating after the information was released. Principal Findings. The star rating system was associated with a significant change in consumer demand for low-and high-scoring facilities. After the star-based rating system was released, 1-star facilities typically lost 8 percent of their market share and 5-star facilities gained over 6 percent of their market share. Conclusions. The nursing home star rating system significantly affected consumer demand for high-and low-rated nursing homes. These results support the use of summary measures in report cards. C1 [Werner, Rachel M.; Polsky, Daniel] Univ Penn, Perelman Sch Med, Div Gen Internal Med, 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Werner, Rachel M.] Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Werner, Rachel M.; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. RP Werner, RM (reprint author), Univ Penn, Perelman Sch Med, Div Gen Internal Med, 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu FU Agency for Healthcare Research and Quality [R21-HS021861]; National Institute on Aging [K24-AG047908] FX This research was supported by grant number R21-HS021861 from the Agency for Healthcare Research and Quality. Rachel Werner was supported in part by grant number K24-AG047908 from the National Institute on Aging. We gratefully thank Chris Wirtalla for his help with data management and programming. NR 31 TC 2 Z9 2 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD JUN PY 2016 VL 51 SU 2 BP 1291 EP 1309 DI 10.1111/1475-6773.12459 PG 19 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DX9UY UT WOS:000384743500008 PM 26868034 ER PT J AU Makarov, DV Hu, EYC Walter, D Braithwaite, RS Sherman, S Gold, HT Zhou, XHA Gross, CP Zeliadt, SB AF Makarov, Danil V. Hu, Elaine Y. C. Walter, Dawn Braithwaite, R. Scott Sherman, Scott Gold, Heather T. Zhou, Xiao-Hua Andrew Gross, Cary P. Zeliadt, Steven B. TI Appropriateness of Prostate Cancer Imaging among Veterans in a Delivery System without Incentives for Overutilization SO HEALTH SERVICES RESEARCH LA English DT Article DE Health care organizations and systems; VA health care system; surgery ID HOSPITAL VOLUME; UNITED-STATES; OF-LIFE; CARE; SURGERY; QUALITY; TRENDS; SURVIVAL; STAGE; MEN AB Objective. To determine the frequency of appropriate and inappropriate prostate cancer imaging in an integrated health care system. Data Sources/Study Setting. Veterans Health Administration Central Cancer Registry linked to VA electronic medical records and Medicare claims (2004-2008). Study Design. We performed a retrospective cohort study of VA patients diagnosed with prostate cancer (N = 45,084). Imaging (CT, MRI, bone scan, PET) use was assessed among patients with low-risk disease, for whom guidelines recommend against advanced imaging, and among high-risk patients for whom guidelines recommend it. Principal Findings. We found high rates of inappropriate imaging among men with low-risk prostate cancer (41 percent) and suboptimal rates of appropriate imaging among men with high-risk disease (70 percent). Veterans utilizing Medicare-reimbursed care had higher rates of inappropriate imaging [OR: 1.09 (1.03-1.16)] but not higher rates of appropriate imaging. Veterans treated in middle [OR: 0.51 (0.47-0.56)] and higher [OR: 0.50 (0.46-0.55)] volume medical centers were less likely to undergo inappropriate imaging without compromising appropriate imaging. Conclusions. Our results highlight the overutilization of imaging, even in an integrated health care system without financial incentives encouraging provision of health care services. Paradoxically, imaging remains underutilized among high-risk patients who could potentially benefit from it most. C1 [Makarov, Danil V.] 550 First Ave,VZ30 Sixth Floor,Off 613, New York, NY 10016 USA. [Makarov, Danil V.; Walter, Dawn; Sherman, Scott] VA New York Harbor Healthcare Syst, New York, NY USA. [Makarov, Danil V.] NYU, Robert Wagner Grad Sch Publ Serv, Dept Urol, New York, NY USA. [Makarov, Danil V.] NYU, Robert Wagner Grad Sch Publ Serv, Dept Populat Hlth, New York, NY USA. [Makarov, Danil V.] NYU, Robert Wagner Grad Sch Publ Serv, Inst Canc, New York, NY USA. [Hu, Elaine Y. C.; Zhou, Xiao-Hua Andrew; Zeliadt, Steven B.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Hu, Elaine Y. C.; Zhou, Xiao-Hua Andrew; Zeliadt, Steven B.] Univ Washington, Seattle, WA 98195 USA. [Walter, Dawn] NYU, Dept Urol, New York, NY USA. [Walter, Dawn] NYU, Dept Populat Hlth, New York, NY USA. [Walter, Dawn] NYU, Inst Canc, New York, NY USA. [Braithwaite, R. Scott; Sherman, Scott; Gold, Heather T.] NYU, Inst Canc, Populat Hlth, New York, NY USA. [Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Makarov, DV (reprint author), 550 First Ave,VZ30 Sixth Floor,Off 613, New York, NY 10016 USA.; Makarov, DV (reprint author), NYU, Robert Wagner Grad Sch Publ Serv, Dept Urol, New York, NY USA.; Makarov, DV (reprint author), NYU, Robert Wagner Grad Sch Publ Serv, Dept Populat Hlth, New York, NY USA.; Makarov, DV (reprint author), NYU, Robert Wagner Grad Sch Publ Serv, Inst Canc, New York, NY USA. EM danil.makarov@nyumc.org OI Makarov, Danil/0000-0002-0565-9272; Sherman, Scott/0000-0003-1752-7303 FU United States Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [CDA 11-257/Makarov CDP 12/254/Makarov, IIR 07-235/Zhou]; Louis Feil Charitable Lead Trust; Medtronic; Johnson Johnson; 21st Century Oncology FX The authors acknowledge the following funding sources: United States Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (CDA 11-257/Makarov CDP 12/254/Makarov "Optimizing Imaging Use Among Veterans with Prostate Cancer" and IIR 07-235/Zhou "Modeling of Health Care Costs (MHCC) of Veterans with Chronic Diseases"), and the Louis Feil Charitable Lead Trust. Dr. Makarov is a consultant for Castlight Health, LLC and for the United States Food and Drug Administration; Dr. Gross receives research support from Medtronic, Johnson & Johnson, and 21st Century Oncology. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 61 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD JUN PY 2016 VL 51 IS 3 BP 1021 EP 1051 DI 10.1111/1475-6773.12395 PG 31 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DX9UN UT WOS:000384741900010 PM 26423687 ER PT J AU Speier, W Ong, MK Arnold, CW AF Speier, William Ong, Michael K. Arnold, Corey W. TI Using phrases and document metadata to improve topic modeling of clinical reports SO JOURNAL OF BIOMEDICAL INFORMATICS LA English DT Article DE Topic modeling; LDA; n-grams; Document metadata ID INFORMATION AB Probabilistic topic models provide an unsupervised method for analyzing unstructured text, which have the potential to be integrated into clinical automatic summarization systems. Clinical documents are accompanied by metadata in a patient's medical history and frequently contains multiword concepts that can be valuable for accurately interpreting the included text. While existing methods have attempted to address these problems individually, we present a unified model for free-text clinical documents that integrates contextual patient- and document-level data, and discovers multi-word concepts. In the proposed model, phrases are represented by chained n-grams and a Dirichlet hyper-parameter is weighted by both document-level and patient-level context. This method and three other Latent Dirichlet allocation models were fit to a large collection of clinical reports. Examples of resulting topics demonstrate the results of the new model and the quality of the representations are evaluated using empirical log likelihood. The proposed model was able to create informative prior probabilities based on patient and document information, and captured phrases that represented various clinical concepts. The representation using the proposed model had a significantly higher empirical log likelihood than the compared methods. Integrating document metadata and capturing phrases in clinical text greatly improves the topic representation of clinical documents. The resulting clinically informative topics may effectively serve as the basis for an automatic summarization system for clinical reports. (C) 2016 Elsevier Inc. All rights reserved. C1 [Speier, William; Arnold, Corey W.] Univ Calif Los Angeles, Med Imaging Informat, Los Angeles, CA 90095 USA. [Ong, Michael K.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Ong, Michael K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Arnold, Corey W.] Univ Calif Los Angeles, Dept Radiol Sci, Los Angeles, CA 90024 USA. [Speier, William] 924 Westwood Blvd Ste 420, Los Angeles, CA 90024 USA. RP Arnold, CW (reprint author), Univ Calif Los Angeles, Med Imaging Informat, Los Angeles, CA 90095 USA. EM speier@ucla.edu; cwarnold@ucla.edu FU National Library of Medicine of the National Institutes of Health [R21LM011937] FX This work was supported by a grant from the National Library of Medicine of the National Institutes of Health under award number R21LM011937 (PI Arnold). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 43 TC 1 Z9 1 U1 3 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-0464 EI 1532-0480 J9 J BIOMED INFORM JI J. Biomed. Inform. PD JUN PY 2016 VL 61 BP 260 EP 266 DI 10.1016/j.jbi.2016.04.005 PG 7 WC Computer Science, Interdisciplinary Applications; Medical Informatics SC Computer Science; Medical Informatics GA DX9HN UT WOS:000384704300026 PM 27109931 ER PT J AU Knight, EM Kim, SH Kottwitz, JC Hatami, A Albay, R Suzuki, A Lublin, A Alberini, CM Klein, WL Szabo, P Relkin, NR Ehrlich, M Glabe, CG Gandy, S Steele, JW AF Knight, Elysse M. Kim, Soong Ho Kottwitz, Jessica C. Hatami, Asa Albay, Ricardo Suzuki, Akinobu Lublin, Alex Alberini, Cristina M. Klein, William L. Szabo, Paul Relkin, Norman R. Ehrlich, Michelle Glabe, Charles G. Gandy, Sam Steele, John W. TI Effective anti-Alzheimer A beta therapy involves depletion of specific A beta oligomer subtypes SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION LA English DT Article ID HUMAN INTRAVENOUS IMMUNOGLOBULIN; AMYLOID-BETA; MOUSE MODEL; MONOCLONAL-ANTIBODIES; DISEASE BRAIN; IN-VITRO; PEPTIDE; PATHOLOGY; MICE; DYSFUNCTION AB Background: Recent studies have implicated specific assembly subtypes of \-amyloid (A beta) peptide, specifically soluble oligomers (soA beta) as disease-relevant structures that may underlie memory loss in Alzheimer disease. Removing existing soluble and insoluble A beta assemblies is thought to be essential for any attempt at stabilizing brain function and slowing cognitive decline in Alzheimer disease. IV immunoglobulin (IVIg) therapies have been shown to contain naturally occurring polyclonal antibodies that recognize conformational neoepitopes of soluble or insoluble A beta assemblies including soA beta. These naturally occurring polyclonal antibodies have been suggested to underlie the apparent clinical benefits of IVIg. However, direct evidence linking anti-A beta antibodies to the clinical bioactivity of IVIg has been lacking. Methods: Five-month-old female Dutch APP E693Q mice were treated for 3 months with neat IVIg or with IVIg that had been affinity-depleted over immobilized A beta conformers in 1 of 2 assembly states. Memory was assessed in a battery of tests followed by quantification of brain soA beta levels using standard anti-soA beta antibodies. Results: We provide evidence that NU4-type soA beta (NU4-soA beta) assemblies accumulate in the brains of Dutch APP E693Q mice and are associated with defects in memory, even in the absence of insoluble A beta plaques. Memory benefits were associated with depletion from APP E693Q mouse brain of NU4-soA beta and A11-soA beta but not OC-type fibrillar A beta oligomers. Conclusions: We propose that targeting of specific soA beta assembly subtypes may be an important consideration in the therapeutic and/or prophylactic benefit of anti-A beta antibody drugs. C1 [Knight, Elysse M.; Kim, Soong Ho; Kottwitz, Jessica C.; Lublin, Alex; Gandy, Sam; Steele, John W.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Knight, Elysse M.; Kim, Soong Ho; Kottwitz, Jessica C.; Lublin, Alex; Ehrlich, Michelle; Gandy, Sam; Steele, John W.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Ehrlich, Michelle] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Knight, Elysse M.; Kim, Soong Ho; Kottwitz, Jessica C.; Lublin, Alex; Ehrlich, Michelle; Gandy, Sam; Steele, John W.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Hatami, Asa; Albay, Ricardo; Glabe, Charles G.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA. [Hatami, Asa; Albay, Ricardo; Glabe, Charles G.] KAU, King Fahd Med Res Ctr, Jeddah, Saudi Arabia. [Suzuki, Akinobu] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Fac Med, Dept Biochem, Toyama, Toyama, Japan. [Alberini, Cristina M.] NYU, Ctr Neural Sci, New York, NY 10003 USA. [Klein, William L.] Northwestern Univ, Chicago, IL 60611 USA. [Szabo, Paul; Relkin, Norman R.] Weill Cornell Med Coll, Dept Neurol, New York, NY USA. [Szabo, Paul; Relkin, Norman R.] Weill Cornell Med Coll, Brain Mind Res Inst, New York, NY USA. [Glabe, Charles G.] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia. [Glabe, Charles G.] King Abdulaziz Univ, Expt Biochem Unit, King Fahd Med Res Ctr, Jeddah, Saudi Arabia. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA. [Steele, John W.] Univ Calif San Diego, Sanford Consortium Regenerat Med, La Jolla, CA 92093 USA. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.; Gandy, S (reprint author), James J Peters VA Med Ctr, Bronx, NY USA. EM Samuel.Gandy@mssm.edu RI Faculty of, Sciences, KAU/E-7305-2017 FU NIA NIH HHS [P01 AG000538]; NIGMS NIH HHS [K12 GM068524]; NIMH NIH HHS [R37 MH065635] NR 40 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2332-7812 J9 NEUROL-NEUROIMMUNOL JI Neurol.-Neuroimmunol. Neuroinflammation PD JUN PY 2016 VL 3 IS 3 AR e237 DI 10.1212/NXI.0000000000000237 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DX7OO UT WOS:000384577900019 PM 27218118 ER PT J AU Sher, L Grunebaum, MF Sullivan, GM Burke, AK Cooper, TB Mann, JJ Oquendo, MA AF Sher, Leo Grunebaum, Michael F. Sullivan, Gregory M. Burke, Ainsley K. Cooper, Thomas B. Mann, J. John Oquendo, Maria A. TI Association of testosterone levels and future suicide attempts in women with bipolar disorder: A prospective study SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract CT 30th Seoul World Congress of the International-College-of-Neuropsychopharmacology (CINP) CY JUL 03-07, 2016 CL Seoul, SOUTH KOREA SP Int Coll Neuropsychopharmacol C1 [Sher, Leo; Grunebaum, Michael F.; Sullivan, Gregory M.; Burke, Ainsley K.; Cooper, Thomas B.; Mann, J. John; Oquendo, Maria A.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Sher, Leo; Grunebaum, Michael F.; Sullivan, Gregory M.; Burke, Ainsley K.; Cooper, Thomas B.; Mann, J. John; Oquendo, Maria A.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1461-1457 EI 1469-5111 J9 INT J NEUROPSYCHOPH JI Int. J. Neuropsychopharmacol. PD JUN PY 2016 VL 19 SU 1 MA PS278 BP 147 EP 148 PG 2 WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA DW8PI UT WOS:000383917600394 ER PT J AU Ward, MM Deodhar, A Reveille, JD Caplan, L AF Ward, Michael M. Deodhar, Atul Reveille, John D. Caplan, Liron TI Treatment of patients with nonradiographic axial spondyloarthritis who have negative magnetic resonance imaging results and normal C-reactive protein levels at baseline: comment on the article by Ward et al Reply SO ARTHRITIS & RHEUMATOLOGY LA English DT Letter ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; EFFICACY; SACROILIITIS; ADALIMUMAB C1 [Ward, Michael M.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Deodhar, Atul] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Aurora, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. RP Ward, MM (reprint author), NIAMSD, NIH, Bethesda, MD 20892 USA. FU Intramural NIH HHS [Z01 AR041153-04] NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JUN PY 2016 VL 68 IS 6 BP 1563 EP 1564 DI 10.1002/art.39524 PG 3 WC Rheumatology SC Rheumatology GA DW2TB UT WOS:000383493600033 PM 26636978 ER PT J AU Toba, H Bras, LED Baicu, CF Zile, MR Lindsey, ML Bradshaw, AD AF Toba, Hiroe Bras, Lisandra E. de Castro Baicu, Catalin F. Zile, Michael R. Lindsey, Merry L. Bradshaw, Amy D. TI Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE secreted protein acidic and rich in cysteine; heart; a disintegrin and metalloproteinase with thrombospondin-like motifs 1; fibroblast; matrix metalloproteinase ID GROWTH-FACTOR-BETA; RAT LEFT-VENTRICLE; EXTRACELLULAR-MATRIX; SECRETED PROTEIN; HEART-FAILURE; DIASTOLIC DYSFUNCTION; MATRICELLULAR PROTEIN; THERAPEUTIC TARGETS; FIBRILLAR COLLAGEN; CYSTEINE SPARC AB Secreted protein acidic and rich in cysteine (SPARC) is a collagen-binding matricellular protein highly expressed during fibrosis. Fibrosis is a prominent component of cardiac aging that reduces myocardial elasticity. Previously, we reported that SPARC deletion attenuated myocardial stiffness and collagen deposition in aged mice. To investigate the mechanisms by which SPARC promotes age-related cardiac fibrosis, we evaluated six groups of mice (n = 5-6/group): young (3-5 mo old), middle-aged (10-12 mo old), and old (18-29 mo old) C57BL/6 wild type (WT) and SPARC-null (Null) mice. Collagen content, determined by picrosirius red staining, increased in an age-dependent manner in WT but not in Null mice. A disintegrin and metalloproteinase with thrombospondin-like motifs 1 (ADAMTS1) increased in middle-aged and old WT compared with young, whereas in Null mice only old animals showed increased ADAMTS1 expression. Versican, a substrate of ADAMTS1, decreased with age only in WT. To assess the mechanisms of SPARC-induced collagen deposition, we stimulated cardiac fibroblasts with SPARC. SPARC treatment increased secretion of collagen I and ADAMTS1 (both the 110-kDa latent and 87-kDa active forms) into the conditioned media as well as the cellular expression of transforming growth factor-beta 1-induced protein (Tgfbi) and phosphorylated Smad2. An ADAMTS1 blocking antibody suppressed the SPARC-induced collagen I secretion, indicating that SPARC promoted collagen production directly through ADAMTS1 interaction. In conclusion, ADAMTS1 is an important mediator of SPARC-regulated cardiac aging. C1 [Toba, Hiroe; Bras, Lisandra E. de Castro; Lindsey, Merry L.] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Mississippi Ctr Heart Res, Jackson, MS 39216 USA. [Toba, Hiroe] Kyoto Pharmaceut Univ, Div Pathol Sci, Dept Clin Pharmacol, Kyoto, Japan. [Bras, Lisandra E. de Castro] East Carolina Univ, Dept Physiol, Greenville, NC USA. [Baicu, Catalin F.; Zile, Michael R.; Bradshaw, Amy D.] Med Univ South Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Zile, Michael R.; Bradshaw, Amy D.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. [Lindsey, Merry L.] GV Sonny Montgomery Vet Affairs Med Ctr, Jackson, MS USA. RP Toba, H (reprint author), Kyoto Pharmaceut Univ, Dept Clin Pharmacol, Div Pathol Sci, Yamashina Ku, 1 Misasagi Shichono Cho, Kyoto 6078412, Japan. EM toba@mb.kyoto-phu.ac.jp OI Lindsey, Merry/0000-0002-4090-0391 FU American Heart Association [14SDG18860050]; Biomedical Laboratory Research, Development Service of the Veterans Affairs Office of Research and Development Awards [1I01BX001385, 5I01BX000505]; National Institutes of Health [HL-075360, HL-051971, GM-104357] FX We acknowledge support from American Heart Association for Grant no. 14SDG18860050, from the Biomedical Laboratory Research, Development Service of the Veterans Affairs Office of Research and Development Awards 1I01BX001385 and 5I01BX000505, and from the National Institutes of Health for Grants HL-075360, HL-051971, and GM-104357. NR 48 TC 2 Z9 2 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD JUN 1 PY 2016 VL 310 IS 11 BP E1027 EP E1035 DI 10.1152/ajpendo.00040.2016 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA DV9TV UT WOS:000383286000004 PM 27143554 ER PT J AU Krzysiak, TC Chen, BB Lear, T Mallampalli, RK Gronenborn, AM AF Krzysiak, Troy C. Chen, Bill B. Lear, Travis Mallampalli, Rama K. Gronenborn, Angela M. TI Crystal structure and interaction studies of the human FBxo3 ApaG domain SO FEBS JOURNAL LA English DT Article DE ApaG; F-box; FBxl2; FBxo3; inflammation ID CRYSTALLOGRAPHIC STRUCTURE DETERMINATION; ESCHERICHIA-COLI; PROTEINS; INFLAMMATION; SOFTWARE; RECEPTOR; RECRUITMENT; COMPLEX; APPPPA; SYSTEM AB Transcriptional activation of proinflammatory cytokines, mediated by tumor necrosis factor receptor-associated factors (TRAFs), is in part triggered by the degradation of the F-box protein, FBxl2, via an E3 ligase that contains another F-box protein, FBxo3. The ApaG domain of FBxo3 is required for the interaction with and degradation of FBxl2 [Mallampalli RK et al., (2013) J Immunol 191, 5247-5255]. Here, we report the X-ray structure of the human FBxo3 ApaG domain, residues 278-407, at 2.0 angstrom resolution. Like bacterial ApaG proteins, this domain is characterized by a classic Immunoglobin/Fibronectin III-type fold, comprising a seven-stranded beta-sheet core, surrounded by four extended loops. Although cation binding had been proposed for bacterial ApaG proteins, no interactions with Mg2+ or Co2+ were detected for the human ApaG domain. In addition, dinucleotide polyphosphates, which have been reported to be second messengers in the inflammation response and targets of the bacterial apaG-containing operon, are not bound by the human ApaG domain. In the context of the full-length protein, loop 1, comprising residues 294-303, is critical for the interaction with FBxl2. However, titration of the individual ApaG domain with a 15-mer FBxl2 peptide that was phosphorylated on the crucial T404, as well as the inability of the ApaG domain to interact with full-length FBxl2, assessed by coimmunoprecipitation, indicate that the ApaG domain alone is necessary, but not sufficient for binding and degradation of FBxl2. C1 [Krzysiak, Troy C.; Gronenborn, Angela M.] Univ Pittsburgh, Sch Med, Pittsburgh Ctr HIV Prot Interact, Dept Biol Struct, Pittsburgh, PA 15260 USA. [Chen, Bill B.; Lear, Travis; Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15260 USA. [Chen, Bill B.; Lear, Travis; Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15260 USA. [Lear, Travis] Univ Pittsburgh, Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. RP Gronenborn, AM (reprint author), Univ Pittsburgh, Dept Biol Struct, Sch Med, 3501 Fifth Ave, Pittsburgh, PA 15260 USA. EM amg100@pitt.edu OI Lear, Travis/0000-0001-9156-0844 FU US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174, HL081784, HL114453, HL116472] FX We thank Bill Furey for assistance in collecting and processing of synchrotron diffraction data, Elena Matei for assistance with the PYMOL software, and NMR and X-ray core facility managers Michael Delk and Doowon Lee for assistance with instrument use and maintenance. This work was funded by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376, HL098174, HL081784, and HL114453 to R.K.M and a National Institutes of Health R01 grant HL116472 to B.B.C. NR 34 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1742-464X EI 1742-4658 J9 FEBS J JI FEBS J. PD JUN PY 2016 VL 283 IS 11 BP 2091 EP 2101 DI 10.1111/febs.13721 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DT2NI UT WOS:000381316600007 PM 27010866 ER PT J AU Anderson, CA Filley, CM AF Anderson, C. Alan Filley, Christopher M. TI Delusional Misidentification Syndromes: Progress and New Challenges SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Editorial Material C1 [Anderson, C. Alan] Univ Colorado, Sch Med, Behav Neurol Sect, Dept Neurol, Aurora, CO 80045 USA. [Anderson, C. Alan] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Anderson, CA (reprint author), Univ Colorado, Sch Med, Behav Neurol Sect, Dept Neurol, Aurora, CO 80045 USA.; Anderson, CA (reprint author), Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA. EM Al.Anderson@ucdenver.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2016 VL 28 IS 3 BP 160 EP 161 DI 10.1176/appi.neuropsych.16030055 PG 2 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DV9MI UT WOS:000383264200003 PM 27444049 ER PT J AU Granadillo, ED Mendez, MF AF Granadillo, Elias D. Mendez, Mario F. TI Pathological Joking or Witzelsucht Revisited SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID FRONTOTEMPORAL DEMENTIA; ORBITOFRONTAL CORTEX; MIRTHFUL LAUGHTER; FRONTAL-LOBE; VERBAL HUMOR; COMPREHENSION; APPRECIATION; FMRI; DISINHIBITION; EVOLUTION AB Humor, or the perception or elicitation of mirth and funniness, is distinguishable from laughter and can be differentially disturbed by neuropsychiatric disease. The authors describe two patients with constant joking, or Witzelsucht, in the absence of pseudobulbar affect and review the literature on pathological humor. These patients had involvement of frontal structures, impaired appreciation of nonsimple humor, and a compulsion for disinhibited joking. Current neuroscience suggests that impaired humor integration from right lateral frontal injury and disinhibition from orbitofrontal damage results in disinhibited humor, preferentially activating limbic and subcortical reward centers. Additional frontal-subcortical circuit dysfunction may promote pathological joking as a compulsion. C1 [Granadillo, Elias D.; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA. [Granadillo, Elias D.] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Los Angeles, CA USA. RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.; Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA.; Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA USA. EM mmendez@UCLA.edu FU National Institute on Aging [R01AG034499] FX This work was supported by National Institute on Aging grant R01AG034499. NR 52 TC 0 Z9 0 U1 3 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SUM PY 2016 VL 28 IS 3 BP 162 EP 167 DI 10.1176/appi.neuropsych.15090238 PG 6 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DV9MI UT WOS:000383264200004 PM 26900737 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Why Referring Physicians Rarely Diagnose Gastrointestinal Diseases SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr GI P3, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.; Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr GI P3, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD JUN PY 2016 VL 111 IS 6 BP 905 EP 906 DI 10.1038/ajg.2016.116 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU1YH UT WOS:000382006300040 PM 27249995 ER PT J AU Mooney-Doyle, K Deatrick, JA AF Mooney-Doyle, Kim Deatrick, Janet A. TI Parenting in the face of childhood life-threatening conditions: The ordinary in the context of the extraordinary SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Palliative care; Pediatric; Parenting; Qualitative description; Life-threatening condition ID PALLIATIVE CARE; BEREAVED SIBLINGS; SERIOUS ILLNESS; CHILDREN; CANCER; FAMILIES; PERSPECTIVES; FRAMEWORK; DISTRESS; OUTCOMES AB Objective: Uncovering what it means to be a parent during the extraordinary time of a child's life-threatening condition (LTC) is important for understanding family goals, decision making, and the work of parenting within this context. Method: Qualitative descriptive methods were employed to describe the everyday experience of parenting both children who have an LTC and their healthy siblings. Results: Some 31 parents of 28 children with an LTC who have healthy siblings participated in our study. Four themes emerged from the data that describe a parental desire to maintain emotional connection with all of their children, how parents use cues from their children to know them better and develop parenting strategies, how parents change as a result of caring for a child with an LTC, and how they strive to decrease suffering for all of their children. Significance of results: The findings of our study have implications for clinical practice, family-focused research, and health policy pertaining to families of children with life threatening conditions. C1 [Mooney-Doyle, Kim] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Mooney-Doyle, Kim; Deatrick, Janet A.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. RP Mooney-Doyle, K (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA. EM kemooney@nursing.upenn.edu FU National Institutes of Health/National Institute for Nursing Research Ruth L. Kirschstein National Research Service Award [5F31-NR011533-03]; [T32NR007100] FX The authors acknowledge receipt of the following financial support for the research, authorship, and/or publication of this article. The National Institutes of Health/National Institute for Nursing Research Ruth L. Kirschstein National Research Service Award (5F31-NR011533-03 PI: Mooney-Doyle) supported our study. Dr. Mooney-Doyle is also currently supported by an institutional training grant (T32NR007100 PI: Sommers). NR 40 TC 1 Z9 1 U1 4 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD JUN PY 2016 VL 14 IS 3 BP 187 EP 198 DI 10.1017/S1478951515000905 PG 12 WC Health Policy & Services SC Health Care Sciences & Services GA DT2DF UT WOS:000381290300003 PM 26462446 ER PT J AU Aligeti, S Baig, MR Barrera, FF AF Aligeti, Sabitha Baig, Muhammad R. Barrera, Fernando F. TI Terminal delirium misdiagnosed as major psychiatric disorder: Palliative care in a psychiatric inpatient unit SO PALLIATIVE & SUPPORTIVE CARE LA English DT Article DE Delirium; Terminal delirium; Depression; Dementia; End-of-life care ID DEATH; LIFE AB Background: Delirium is a neuropsychiatric condition characterized by acute change in cognition and disturbance of consciousness. A similar state during the final days of life is termed "terminal delirium." Method: We present three cases with end-stage chronic medical problems without any significant psychiatric history who were admitted to an inpatient psychiatric unit or a locked dementia unit for management of "depression," "dementia," or "psychosis." Conclusions: Early diagnosis of terminal delirium helps prevent patients, family members, and staff from undergoing severe emotional distress and facilitates appropriate end-of-life care. C1 [Baig, Muhammad R.] Audie L Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Aligeti, Sabitha] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Barrera, Fernando F.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. RP Baig, MR (reprint author), Audie L Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.; Baig, MR (reprint author), 7400 Merton Minter, San Antonio, TX 78229 USA. EM raisbaig@hotmail.com NR 15 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1478-9515 EI 1478-9523 J9 PALLIAT SUPPORT CARE JI Palliat. Support Care PD JUN PY 2016 VL 14 IS 3 BP 307 EP 310 DI 10.1017/S147895151500098X PG 4 WC Health Policy & Services SC Health Care Sciences & Services GA DT2DF UT WOS:000381290300016 PM 26490485 ER PT J AU Walsh, CM Ruoff, L Varbel, J Walker, K Grinberg, LT Boxer, AL Kramer, JH Miller, BL Neylan, TC AF Walsh, Christine M. Ruoff, Leslie Varbel, Jonathan Walker, Kathleen Grinberg, Lea T. Boxer, Adam L. Kramer, Joel H. Miller, Bruce L. Neylan, Thomas C. TI Rest-activity rhythm disruption in progressive supranuclear palsy SO SLEEP MEDICINE LA English DT Article DE Progressive supranuclear palsy; Actigraphy; Sleep; Circadian rhythms ID SLEEP BEHAVIOR DISORDER; RICHARDSON-OLSZEWSKI SYNDROME; PARKINSONS-DISEASE; REM-SLEEP; CIRCADIAN-RHYTHMS; DEMENTIA; SCALE; DEGENERATION; ASSOCIATION; DIAGNOSIS AB Objective/Background: The brainstem is among the first regions affected in progressive supranuclear palsy (PSP) and is part of the sleep/circadian regulation network. In two small studies, blood pressure and core body temperature circadian patterns were disrupted in PSP; however, it is unclear if circadian activity rhythms are also affected. Our objective was to perform circadian analyses of the rest-activity rhythms in PSP and determine the association with increasing disease severity. Patients/Methods: Individuals with a clinical PSP diagnosis (n = 17; nine men) and healthy older adults (n = 17; nine men) were selected for this study. Participants wore actigraphy wristbands and completed sleep diaries for up to 14 consecutive days. Data were analyzed to assess circadian activity strength (amplitude, mesor, f-ratio), phase (acrophase), and circadian stability (intradaily variability, interdaily stability, relative amplitude). Analyses controlled for sleep fragmentation, cognition, and self-reported depression. The association between disease severity using the PSP rating scale and circadian activity rhythm disruption was assessed. Results: Individuals with PSP had significantly lower circadian activity mesor (p <= 0.001), amplitude (<= = 0.001), robustness (f-ratio, p < 0.01), relative amplitude (p <= 0.001), and interdaily stability (p = 0.01), with increased intradaily variability (p < 0.05). CAR remained weaker in PSP after controlling for sleep fragmentation, and again when also controlling for cognitive impairment and depression. Weaker circadian activity (mesor, amplitude, f-ratio, and relative amplitude) was associated with increased disease severity. Conclusions: Circadian activity rhythms are disrupted in individuals with PSP as compared to controls, and worsen with disease severity. This is the first study of its kind to describe circadian activity rhythms in PSP. (C) 2016 Elsevier B.V. All rights reserved. C1 [Walsh, Christine M.; Walker, Kathleen; Grinberg, Lea T.; Boxer, Adam L.; Kramer, Joel H.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, 675 Nelson Rising Lane,Suite 190, San Francisco, CA 94158 USA. [Ruoff, Leslie; Varbel, Jonathan; Neylan, Thomas C.] San Francisco VA Med Ctr, Dept Mental Hlth, Stress & Hlth Res Program, 4150 Clement St 116P Bldg 8, San Francisco, CA 94121 USA. [Kramer, Joel H.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave, San Francisco, CA 94143 USA. RP Walsh, CM (reprint author), Memory & Aging Ctr, UCSF MC 1207,675 Nelson Rising Lane,Suite 190, San Francisco, CA 94158 USA. EM christine.walsh@ucsf.edu FU Rainwater Foundation; Hillblom Foundation Network Grant; National Institute on Aging (NIA) [P01 AG019724, RO1 AG038791, U54NS092089, R01 AG032289] FX The authors would like to thank the research coordinators who referred and helped to schedule participants to this study. In particular, we thank Nihar Patel, Jessica Zakrzewski, Nik Block, Aly Caplan, Robert Chen, Ali Dallich, Erwin Kong, Danny Luong, Natanya Russek, Lisa Voltarelli, and Matthew Wynn. This study was financially supported by the Rainwater Foundation (Neylan), Hillblom Foundation Network Grant (Kramer & Miller), National Institute on Aging (NIA) under the following grant numbers: P01 AG019724 (Miller), RO1 AG038791 & U54NS092089 (Boxer), and R01 AG032289 (Kramer). NR 28 TC 1 Z9 1 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD JUN PY 2016 VL 22 BP 50 EP 56 DI 10.1016/j.sleep.2016.05.002 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DU6EI UT WOS:000382306400009 PM 27544836 ER PT J AU Padua, D Vu, JP Germano, PM Pisegna, JR AF Padua, David Vu, John P. Germano, Patrizia M. Pisegna, Joseph R. TI The Role of Neuropeptides in Mouse Models of Colitis SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Article DE Pituitary adenylate cyclase-activating polypeptide (PACAP); Vasoactive intestinal polypeptide (VIP); Gastrin; Gastric acid secretion; Gastrointestinal hormones ID VASOACTIVE-INTESTINAL-PEPTIDE; DEXTRAN SULFATE SODIUM; INFLAMMATORY-BOWEL-DISEASE; CYCLASE-ACTIVATING POLYPEPTIDE; ACID-INDUCED COLITIS; EXPERIMENTAL ULCERATIVE COLITIS; INHIBITS CYTOKINE PRODUCTION; EXPERIMENTAL MURINE COLITIS; CD4(+) T-CELLS; CROHNS-DISEASE AB Inflammatory bowel disease (IBD) constitutes an important clinically significant condition that results in morbidity and mortality. IBD can be generally classified into either ulcerative colitis (UC) or Crohn's disease (CD) that differs in the clinical and histopathology. The role of neuropeptides in the pathogenesis of these conditions is becoming increasingly recognized for their importance in modulating the inflammatory state. Animal models provide the greatest insight to better understand the pathophysiology of both disorders which will hopefully allow for improved treatment strategies. This review will provide a better understanding of the role of murine models for studying colitis. C1 [Padua, David; Vu, John P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Vu, John P.; Germano, Patrizia M.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Div Pulm, Los Angeles, CA 90073 USA. [Vu, John P.; Germano, Patrizia M.] VA Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Div Crit Care, Los Angeles, CA 90073 USA. [Pisegna, Joseph R.] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gastroenterol Hepatol & Parenteral Nutr, Los Angeles, CA USA. [Pisegna, Joseph R.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Pisegna, JR (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gastroenterol Hepatol & Parenteral Nutr, Los Angeles, CA USA.; Pisegna, JR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. EM jpisegna@ucla.edu FU Department of Veterans Affairs RRD [F0873-R]; NIH [DK-41301]; Human Studies CORE through CURE; Digestive Diseases Research Center by NIH [P30DK41301]; NIH NIDDK FX This work received grant support from the Department of Veterans Affairs RR&D Merit Review (JRP), Department of Veterans Affairs RR&D Merit Review F0873-R (PG), NIH DK-41301, Human Studies CORE through CURE, Digestive Diseases Research Center supported by NIH grant P30DK41301, and NIH NIDDK T32 (DP). NR 74 TC 4 Z9 5 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 EI 1559-1166 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD JUN PY 2016 VL 59 IS 2 BP 203 EP 210 DI 10.1007/s12031-015-0688-1 PG 8 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DS3ZG UT WOS:000380720600004 PM 26646243 ER PT J AU Singh, JA Ramachandran, R AF Singh, Jasvinder A. Ramachandran, Rekha TI Persisting Racial Disparities in Total Shoulder Arthroplasty Utilization and Outcomes SO JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES LA English DT Article DE Race; Total shoulder arthroplasty; TSA; Utilization; Outcomes; Mortality; Hospital stay; Discharge; Time-trends ID PATIENT-PHYSICIAN COMMUNICATION; ELECTIVE JOINT REPLACEMENT; QUALITY-OF-LIFE; KNEE REPLACEMENT; ETHNIC DISPARITIES; UNEQUAL TREATMENT; HIP-REPLACEMENT; UNITED-STATES; HEALTH-CARE; RACE AB Objective The purpose was to study whether racial disparities in total shoulder arthroplasty (TSA) utilization and outcomes have declined over time. Methods We used the US Nationwide Inpatient Sample from 1998 to 2011. We used chi-squared test to compare characteristics, Cochran-Armitage test to compare utilization rates, and Cochran-Armitage test and logistic regression to compare time-trends in outcomes by race. Results From 1998 to 2011, 176,141 Whites and 7694 Blacks underwent TSA. Compared to Whites, Blacks who underwent TSA were younger (69.1 vs. 64.2 years; p < 0.0001), more likely to be female (54.9 vs. 71.0 %; p < 0.0001), and have rheumatoid arthritis or avascular necrosis as the underlying diagnosis (1.7 vs. 3.0% and 1.7 vs. 6.1 %; p < 0.0001 for both) and a Deyo-Charlson index of 2 or higher (8.5 vs. 16.7 %; p < 0.0001). Compared to Whites, Blacks had much lower TSA utilization rate/100,000 in 1998 (2.97 vs. 0.83; p < 0.0001) and in 2011 (12.27 vs. 3.33; p < 0.0001); racial disparities increased from 1998 to 2011 (p < 0.0001). A higher proportion of Blacks than Whites had a hospital stay greater than median in 1998-2000, 62 vs. 51.4 % (p = 0.02), and in 2009-2011, 34.4 vs. 27.3 % (p < 0.0001); disparities did not change over time (p = 0.31). These disparities in utilization were borderline significant in adjusted analyses. There were no racial differences in proportion discharged to inpatient medical facility in 1998-2000, 15.2 vs. 15.0 % (p = 0.95), and in 2009-2011, 12.3 vs. 11.1%(p = 0.37), respectively. Conclusions We found increasing racial disparities in TSA utilization. Some disparities in outcomes exist as well. Patients, surgeons, and policy-makes should be aware of these findings and take action to reduce racial disparities. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandran, Rekha] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Birmingham, AL USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Dept Orthoped Surg, Coll Med, Rochester, MN USA. EM jasvinder.md@gmail.com NR 44 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2197-3792 EI 2196-8837 J9 J RACIAL ETHN HEALTH JI J. Racial Ethn. Health Disparities PD JUN PY 2016 VL 3 IS 2 BP 259 EP 266 DI 10.1007/s40615-015-0138-3 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DT5FY UT WOS:000381508200010 PM 27271067 ER PT J AU Graham, SH AF Graham, Steven H. TI Modification of ubiquitin C-terminal hydrolase L1 by reactive lipid species: role in neural regeneration and diseases of aging SO NEURAL REGENERATION RESEARCH LA English DT Article ID UCH-L1; AGGREGATION; NEURONS C1 [Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. EM Steven.Graham@va.gov FU NIA NIH HHS [P30 AG024827]; NINDS NIH HHS [R01 NS037459]; RRD VA [I01 RX000310] NR 10 TC 0 Z9 0 U1 3 U2 3 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 1673-5374 EI 1876-7958 J9 NEURAL REGEN RES JI Neural Regen. Res. PD JUN PY 2016 VL 11 IS 6 BP 908 EP 909 DI 10.4103/1673-5374.184482 PG 2 WC Cell Biology; Neurosciences SC Cell Biology; Neurosciences & Neurology GA DS9QU UT WOS:000381119200016 PM 27482212 ER PT J AU Holers, VM Tomlinson, S Kulik, L Atkinson, C Rohrer, B Banda, N Thurman, JM AF Holers, V. Michael Tomlinson, Stephen Kulik, Liudmila Atkinson, Carl Rohrer, Barbel Banda, Nirmal Thurman, Joshua M. TI New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities SO SEMINARS IN IMMUNOLOGY LA English DT Review DE Therapeutics; Targeting; Natural antibodies; Cell injury; Neoepitopes; Imaging ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ISCHEMIA-REPERFUSION INJURY; ISCHEMIA/REPERFUSION INJURY; INTESTINAL ISCHEMIA; BINDING-PROTEINS; IN-VIVO; PATHWAY; MEMBRANE; RECEPTOR; INNATE AB Despite substantial opportunity and commercial interest in developing drugs that modulate the complement system in a broad range of non-orphan indications, several obstacles remain to be overcome. Among these issues is the biophysical nature of complement proteins, whose circulating levels are typically very high and whose turnover rates are relatively rapid, especially in the setting of chronic inflammatory conditions. This situation necessitates the use of very high levels of therapeutic compounds in order to achieve both multi-pathway and multiple effector mechanism inhibition. In addition, one must avoid infectious complications or the systemic impairment of the other important physiological functions of complement. Herein we focus on the development of a novel therapeutic strategy based on injured tissue-specific targeting of complement inhibitors using the antigen-combining domains of a small subset of natural IgM antibodies, which as endogenous antibodies specifically recognize sites of local damage across a broad range of tissues and locally activate complement C3, resulting in C3 fragment covalent fixation. Because the use of such recombinant tissue-targeting inhibitors precludes the utility of measuring systemic levels of complement biomarkers or function, since a goal of this targeting strategy is to leave those processes intact and unimpeded, we also briefly describe a new method designed to quantitatively measure using imaging modalities the inhibition of generation of fixed C3 fragments at sites of inflammation/injury. In addition to the ability to determine whether complement activation is locally constrained with the use of inhibitors, there is also a broader application of this imaging approach to inflammatory and autoimmune diseases characterized by local complement activation. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Holers, V. Michael; Kulik, Liudmila; Banda, Nirmal] Univ Colorado, Sch Med, Dept Med & Immunol, Aurora, CO USA. [Tomlinson, Stephen; Rohrer, Barbel] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Tomlinson, Stephen; Atkinson, Carl] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Atkinson, Carl] Med Univ South Carolina, Dept Surg, Transplant Immunobiol Lab, Charleston, SC 29425 USA. [Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 171 Ashley Ave, Charleston, SC 29425 USA. [Thurman, Joshua M.] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. RP Holers, VM (reprint author), Univ Colorado, Sch Med, Div Rheumatol, B115,1775 Aurora Court, Aurora, CO 80045 USA. EM Michael.Holers@ucdenver.edu FU National Institutes of Health (NIH) grants [R01 AR051749, R01 DK076690, R01 EY019320, R01 HL091944, P20 GM109040]; KIDNEEDS Foundation; Lupus Research Institute; Department of Veterans Affairs Merit Awards [1I01RX001141, 1BX001218, I01 RX000444]; Research to Prevent Blindness FX This work discussed herein was supported by a National Institutes of Health (NIH) grants R01 AR051749 (VMH), R01 DK076690 (JMT), R01 EY019320 (BR), R01 HL091944 (CA), and P20 GM109040, in addition to a grant from the KIDNEEDS Foundation (JMT), a grant from the Lupus Research Institute (JMT), the Department of Veterans Affairs Merit Awards 1I01RX001141 (ST), 1BX001218 (ST) and I01 RX000444 (BR), and an unrestricted grant to MUSC from Research to Prevent Blindness (BR). NR 63 TC 1 Z9 1 U1 1 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1044-5323 J9 SEMIN IMMUNOL JI Semin. Immunol. PD JUN PY 2016 VL 28 IS 3 BP 260 EP 267 DI 10.1016/j.smim.2016.05.007 PG 8 WC Immunology SC Immunology GA DT9TQ UT WOS:000381845600006 PM 27282113 ER PT J AU Kulkarni, T O'Reilly, P Antony, VB Gaggar, A Thannickal, VJ AF Kulkarni, Tejaswini O'Reilly, Philip Antony, Veena B. Gaggar, Amit Thannickal, Victor J. TI Matrix Remodeling in Pulmonary Fibrosis and Emphysema SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE extracellular matrix; myofibroblasts; transforming growth factor-beta; pulmonary fibrosis; emphysema ID GROWTH-FACTOR-BETA; HUMAN LUNG FIBROBLASTS; ACTIVATES LATENT TGF-BETA-1; TROPOELASTIN MESSENGER-RNA; ALVEOLAR EPITHELIAL-CELLS; SMOKE-INDUCED EMPHYSEMA; POSITIVE FEEDBACK LOOP; EXTRACELLULAR-MATRIX; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 AB Pulmonary fibrosis and emphysema are chronic lung diseases characterized by a progressive decline in lung function, resulting in significant morbidity and mortality. A hallmark of these diseases is recurrent or persistent alveolar epithelial injury, typically caused by common environmental exposures such as cigarette smoke. We propose that critical determinants of the outcome of the injury-repair processes that result in fibrosis versus emphysema are mesenchymal cell fate and associated extracellular matrix dynamics. In this review, we explore the concept that regulation of mesenchymal cells under the influence of soluble factors, in particular transforming growth factor-beta 1, and the extracellular matrix determine the divergent tissue remodeling responses seen in pulmonary fibrosis and emphysema. C1 [Kulkarni, Tejaswini; O'Reilly, Philip; Antony, Veena B.; Gaggar, Amit; Thannickal, Victor J.] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Kulkarni, Tejaswini; O'Reilly, Philip; Antony, Veena B.; Gaggar, Amit; Thannickal, Victor J.] Program Protease & Matrix Biol Ctr, Birmingham, AL USA. [Gaggar, Amit; Thannickal, Victor J.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Thannickal, VJ (reprint author), 1900 Univ Blvd,422 THT, Birmingham, AL 35294 USA. EM vjthan@uab.edu FU National Institutes of Health (NIH) [P01 HL114470, R01 AG046210]; NIH [HL102371]; Veteren's Administration grant [I01BX001756] FX This work was supported by National Institutes of Health (NIH) grants P01 HL114470 and R01 AG046210 (V.J.T.), and NIH grant HL102371 and Veteren's Administration grant I01BX001756 (A.G.). NR 116 TC 5 Z9 5 U1 0 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1044-1549 EI 1535-4989 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD JUN 1 PY 2016 VL 54 IS 6 BP 751 EP 760 DI 10.1165/rcmb.2015-0166PS PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA DT7XQ UT WOS:000381702000001 PM 26741177 ER PT J AU Rocque, BG AF Rocque, Brandon G. TI Neuroendoscopy for Intraventricular Tumor Resection SO WORLD NEUROSURGERY LA English DT Editorial Material ID CHILDREN C1 [Rocque, Brandon G.] Univ Alabama Birmingham, Childrens Alabama, Dept Neurosurg, Birmingham, AL USA. [Rocque, Brandon G.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Rocque, BG (reprint author), Univ Alabama Birmingham, Childrens Alabama, Dept Neurosurg, Birmingham, AL USA.; Rocque, BG (reprint author), Birmingham VA Med Ctr, Birmingham, AL USA. EM brandon.rocque@childrensal.org FU NCATS NIH HHS [UL1 TR001417, KL2 TR001419] NR 7 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1878-8750 EI 1878-8769 J9 WORLD NEUROSURG JI World Neurosurg. PD JUN PY 2016 VL 90 BP 619 EP 620 DI 10.1016/j.wneu.2015.12.010 PG 2 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA DS1MS UT WOS:000380360500080 PM 26721614 ER PT J AU Asselin, PK Avedissian, M Knezevic, S Kornfeld, S Spungen, AM AF Asselin, Pierre K. Avedissian, Manuel Knezevic, Steven Kornfeld, Stephen Spungen, Ann M. TI Training Persons with Spinal Cord Injury to Ambulate Using a Powered Exoskeleton SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS LA English DT Article DE Bioengineering; Issue 112; 6MWT; ambulatory device; overground walking; paraplegia; powered exoskeleton; reciprocating gait orthosis; RGO; spinal cord injury ID RECIPROCATING GAIT ORTHOSIS; PARAPLEGIC LOCOMOTION; ELECTRICAL-STIMULATION; ENERGY-COST; WALKING; PERFORMANCE; REHABILITATION; PARAWALKER; MOBILITY; CLASSIFICATION AB Powered exoskeletons have become available for overground ambulation in persons with paralyses due to spinal cord injury (SCI) who have intact upper extremity function and are able to maintain upright balance using forearm crutches. To ambulate in an exoskeleton, the user must acquire the ability to maintain balance while standing, sitting and appropriate weight shifting with each step. This can be a challenging task for those with deficits in sensation and proprioception in their lower extremities. This manuscript describes screening criteria and a training program developed at the James J. Peters VA Medical Center, Bronx, NY to teach users the skills needed to utilize these devices in institutional, home or community environments. Before training can begin, potential users are screened for appropriate range of motion of the hip, knee and ankle joints. Persons with SCI are at an increased risk of sustaining lower extremity fractures, even with minimal strain or trauma, therefore a bone mineral density assessment is performed to reduce the risk of fracture. Also, as part of screening, a physical examination is performed in order to identify additional health-related contraindications. Once the person has successfully passed all screening requirements, they are cleared to begin the training program. The device is properly adjusted to fit the user. A series of static and dynamic balance tasks are taught and performed by the user before learning to walk. The person is taught to ambulate in various environments ranging from indoor level surfaces to outdoors over uneven or changing surfaces. Once skilled enough to be a candidate for home use with the exoskeleton, the user is then required to designate a companion-walker who will train alongside them. Together, the pair must demonstrate the ability to perform various advanced tasks in order to be permitted to use the exoskeleton in their home/community environment. C1 [Asselin, Pierre K.; Avedissian, Manuel; Knezevic, Steven; Spungen, Ann M.] James J Peters VA Med Ctr, Dept Vet Affairs VA, Rehabil Res & Dev Natl Ctr Excellence Med Consequ, Bronx, NY 10468 USA. [Kornfeld, Stephen] James J Peters VA Med Ctr, Dept Vet Affairs VA, Spinal Cord Injury Serv, Bronx, NY 10468 USA. RP Spungen, AM (reprint author), James J Peters VA Med Ctr, Dept Vet Affairs VA, Rehabil Res & Dev Natl Ctr Excellence Med Consequ, Bronx, NY 10468 USA. EM Ann.Spungen@va.gov FU VA Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (VA RRD) [B9212C] FX Support for this work was obtained by the VA Rehabilitation Research & Development National Center of Excellence for the Medical Consequences of Spinal Cord Injury (VA RR&D #B9212C). Two of the four powered exoskeleton devices were used on a loaner basis at no cost from ReWalk Robotics, Inc. (Marlborough, Massachusetts). Additionally a portion of participants obtained Orthopedic shoes which were donated by Aetrex Worldwide Inc. (Teaneck, New Jersey). NR 45 TC 0 Z9 0 U1 8 U2 14 PU JOURNAL OF VISUALIZED EXPERIMENTS PI CAMBRIDGE PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA SN 1940-087X J9 JOVE-J VIS EXP JI J. Vis. Exp. PD JUN PY 2016 IS 112 AR e54071 DI 10.3791/54071 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DS0CX UT WOS:000380264100057 ER PT J AU Rasmussen, DD Johanson, SS Kincaid, CL AF Rasmussen, D. D. Johanson, S. S. Kincaid, C. L. TI MELATONIN TREATMENT DURING ALCOHOL WITHDRAWAL AND PROTRACTED DEPRIVATION REVERSES RAT THYROID HORMONE DYSREGULATION: CORRELATION WITH STARTLE RESPONSE SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 [Rasmussen, D. D.; Johanson, S. S.; Kincaid, C. L.] VA Puget Sound HCS, Mental Hlth Serv, VISN MIRECC 20, Seattle, WA 98108 USA. [Rasmussen, D. D.; Johanson, S. S.; Kincaid, C. L.] Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 078 BP 35A EP 35A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601078 ER PT J AU McDonald, J Pennington, DL Lasher, B Yohannes, S Wong, T Bielenberg, J Dack, J Tomlinson, E Hoyman, L Kinzler, A Batki, SL AF McDonald, J. Pennington, D. L. Lasher, B. Yohannes, S. Wong, T. Bielenberg, J. Dack, J. Tomlinson, E. Hoyman, L. Kinzler, A. Batki, S. L. TI AN EXAMINATION OF MEDICAL COMORBIDITIES AND CIGARETTE USE AMONG VETERANS WITH ALCOHOL USE DISORDER AND COMORBID PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 581 BP 161A EP 161A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601579 ER PT J AU Batki, SL Pennington, DL Lasher, B Yohannes, S McDonald, J Kinzler, A Bielenberg, J Dack, J Tomlinson, E Hoyman, L Herbst, E Wong, T AF Batki, S. L. Pennington, D. L. Lasher, B. Yohannes, S. McDonald, J. Kinzler, A. Bielenberg, J. Dack, J. Tomlinson, E. Hoyman, L. Herbst, E. Wong, T. TI TOPIRAMATE TREATMENT FOR ALCOHOL USE DISORDER IN VETERANS WITH MILD TRAUMATIC BRAIN INJURY: PRELIMINARY RESULTS OF A PILOT CONTROLLED CLINICAL TRIAL SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 588 BP 162A EP 162A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601586 ER PT J AU Yohannes, S Pennington, DL Lasher, B Wong, T McDonald, J Dack, J Bielenberg, J Hoyman, LC Tomlinson, ES Kinzler, A Herbst, E Batki, SL AF Yohannes, S. Pennington, D. L. Lasher, B. Wong, T. McDonald, J. Dack, J. Bielenberg, J. Hoyman, L. C. Tomlinson, E. S. Kinzler, A. Herbst, E. Batki, S. L. TI EDUCATION PREDICTS ATTENDANCE AND RETENTION IN A RANDOMISED TRIAL OF TOPIRMATE TREATMENT FOR VETERANS WITH AUD AND PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 587 BP 162A EP 162A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601585 ER PT J AU Pennington, DL Tomlinson, ES Lasher, B Yohannes, S Wong, T McDonald, J Dack, J Bielenberg, J Hoyman, LC Kinzler, A AF Pennington, D. L. Tomlinson, E. S. Lasher, B. Yohannes, S. Wong, T. McDonald, J. Dack, J. Bielenberg, J. Hoyman, L. C. Kinzler, A. TI ASSOCIATIONS OF PTSD, AUD, AND TBI SEVERITY ON COGNITIVE FUNCTION IN VETERANS ENTERING CONTROLLED TRIALS OF TOPIRAMATE TREATMENT SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 589 BP 163A EP 163A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601587 ER PT J AU Kinzler, A Pennington, DL Lasher, B Yohannes, S McDonald, J Wong, T Bielenberg, J Dack, J Tomlinson, E Hoyman, L Herbst, E Batki, SL AF Kinzler, A. Pennington, D. L. Lasher, B. Yohannes, S. McDonald, J. Wong, T. Bielenberg, J. Dack, J. Tomlinson, E. Hoyman, L. Herbst, E. Batki, S. L. TI ABSORPTION SUBTYPE OF DISTRESS TOLERANCE PREDICTS DRINKING BEHAVIOR IN VETERANS WITH AUD AND PTSD SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 611 BP 168A EP 168A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601609 ER PT J AU Rasmussen, DD Johanson, SS Burns, JN Kincaid, CL AF Rasmussen, D. D. Johanson, S. S. Burns, J. N. Kincaid, C. L. TI REDUCTION OF alpha 1-AND beta-ADRENERGIC SIGNALING AT THE TIME OF TRAUMATIC STRESS REDUCES SUBSEQUENT DEVELOPMENT OF INCREASED ALCOHOL DRINKING IN RATS SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 VA Puget Sound HCS, Mental Hlth Serv, VISN MIRECC 20, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat, Seattle, WA 98108 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 729 BP 198A EP 198A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814601727 ER PT J AU Anderson, RI Lopez, MF Becker, HC AF Anderson, R. I. Lopez, M. F. Becker, H. C. TI MODELING STRESS-INDUCED ETHANOL CONSUMPTION IN MICE WITH A HISTORY OF CHRONIC INTERMITTENT ETHANOL EXPOSURE: INVOLVEMENT OF CRF AND DYNORPHIN SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 39th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) CY JUN 25-29, 2016 CL New Orleans, LA SP Res Soc Alcoholism C1 [Anderson, R. I.; Lopez, M. F.; Becker, H. C.] Med Univ South Carolina, Charleston, SC 29425 USA. [Anderson, R. I.; Lopez, M. F.; Becker, H. C.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2016 VL 40 SU 1 SI SI MA 010 BP 250A EP 250A PG 1 WC Substance Abuse SC Substance Abuse GA DR3PH UT WOS:000379814602010 ER PT J AU Doyle, BJ Nuckols, TK AF Doyle, Brian J. Nuckols, Teryl K. TI In Reference to "Patient Financial Responsibility for Observation Care" and "Observation Versus Inpatient Hospitalization: What do Medicare Beneficiaries Pay?" SO JOURNAL OF HOSPITAL MEDICINE LA English DT Letter C1 [Doyle, Brian J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Doyle, Brian J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Nuckols, Teryl K.] Cedars Sinai Med Ctr, Dept Med, Div Gen Internal Med, Los Angeles, CA 90048 USA. [Nuckols, Teryl K.] RAND Corp, Santa Monica, CA USA. RP Doyle, BJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.; Doyle, BJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. OI Doyle, Brian/0000-0003-2782-2306 NR 3 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JUN PY 2016 VL 11 IS 6 BP 457 EP 457 DI 10.1002/jhm.2562 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DR6VW UT WOS:000380040400012 PM 26914288 ER PT J AU Banducci, AN Bujarski, SJ Bonn-Miller, MO Patel, A Connolly, KM AF Banducci, Anne N. Bujarski, Sarah J. Bonn-Miller, Marcel O. Patel, Amee Connolly, Kevin M. TI The impact of intolerance of emotional distress and uncertainty on veterans with co-occurring PTSD and substance use disorders SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Distress tolerance; PTSD; Substance use disorders; Intolerance of uncertainty; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; ANXIETY SENSITIVITY; CANNABIS USE; SYMPTOM SEVERITY; SERVICE MEMBERS; TOLERANCE; SCALE; IRAQ; INDIVIDUALS; AFGHANISTAN AB The risk of developing a substance use disorder (SUD) is significantly higher among veterans with post traumatic stress disorder (PTSD). Veterans with this co-occurrence have poorer outcomes than singly diagnosed veterans, which may be related to two risk factors: intolerance uncertainty (IU) and low tolerance of emotional distress (TED). We hypothesized low TED and high IU would independently and interactively relate to heightened PTSD symptomatology and trauma-cue elicited SUD cravings. A sample of 70 veterans (M age = 50; 95% men; 65% Black) with co-occurring PTSD-SUD was recruited. The Posttraumatic Stress Disorder Checklist (PCL), Craving Questionnaire, Distress Tolerance Scale, and Intolerance of Uncertainty Scale were administered. In general, low TED and high IU were significantly correlated with the PCL total and subscale scores. When examined within regression models, low TED was associated with elevated PCL scores and trauma-cue elicited SUD cravings; IU was not. However, there was a significant interaction between IU and TED; veterans with elevated IU and low TED had higher PCL Total, Hyperarousal, and Intrusions scores. This highlights the importance of assessing TED and IU among veterans with co-occurring PTSD-SUD, as these risk factors may not only be prognostic indicators of outcomes, but also treatment targets. Published by Elsevier Ltd. C1 [Banducci, Anne N.; Bujarski, Sarah J.; Patel, Amee; Connolly, Kevin M.] GV Sonny Montgomery Vet Affairs Med Ctr, 1500 E Woodrow Wilson Ave, Jackson, MS 39216 USA. [Banducci, Anne N.; Bujarski, Sarah J.; Patel, Amee; Connolly, Kevin M.] Univ Mississippi, Med Ctr, 2500N State St, Jackson, MS 39216 USA. [Banducci, Anne N.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Substance Abuse Treatment & Educ, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. RP Banducci, AN (reprint author), VA Palo Alto Hlth Care Syst, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. EM anne.banducci@va.gov OI Banducci, Anne N/0000-0003-1213-7998 NR 59 TC 6 Z9 6 U1 5 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD JUN PY 2016 VL 41 BP 73 EP 81 DI 10.1016/j.janxdis.2016.03.003 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DR7JS UT WOS:000380076500009 PM 27004450 ER PT J AU Farmer, GW Blosnich, JR Jabson, JM Matthews, DD AF Farmer, Grant W. Blosnich, John R. Jabson, Jennifer M. Matthews, Derrick D. TI Gay Acres: Sexual Orientation Differences in Health Indicators Among Rural and Nonrural Individuals SO JOURNAL OF RURAL HEALTH LA English DT Article DE bisexuality; health disparities; homosexuality; rural health; sexual orientation ID BREAST-CANCER RISK; SUBSTANCE USE; MINORITY WOMEN; MENTAL-HEALTH; UNITED-STATES; BISEXUAL POPULATIONS; SOUTHERN LESBIANS; URBAN DIFFERENCES; CARE UTILIZATION; US STATES AB PurposeGeographic location is a significant factor that influences health status and health disparities. Yet, little is known about the relationship between geographic location and health and health disparities among lesbian, gay, and bisexual (LGB) persons. This study used a US population-based sample to evaluate the associations of sexual orientation with health indicators by rural/nonrural residence. MethodsData were pooled from the 10 states that collected sexual orientation in the 2010 Behavioral Risk Factor Surveillance System surveys. Rural status was defined using metropolitan statistical area, and group differences by sexual orientation were stratified by gender and rural/nonrural status. Chi-square tests for categorical variables were used to assess bivariate relationships. Multivariable logistic regression models stratified by gender and rural/nonrural status were used to assess the association of sexual orientation to health indicators, while adjusting for age, race/ethnicity, education, and partnership status. All analyses were weighted to adjust for the complex sampling design. FindingsSignificant differences between LGB and heterosexual participants emerged for several health indicators, with bisexuals having a greater number of differences than gay men/lesbians. There were fewer differences in health indicators for rural LGB participants compared to heterosexuals than nonrural participants. ConclusionsRural residence appears to influence the pattern of LGB health disparities. Future work is needed to confirm and identify the exact etiology or rural/nonrural differences in LGB health. C1 [Farmer, Grant W.] Washington Univ, Dept Surg, Div Publ Hlth Sci, St Louis, MO USA. [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Blosnich, John R.; Matthews, Derrick D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Jabson, Jennifer M.] Univ Tennessee, Coll Educ Hlth & Human Sci, Dept Publ Hlth, Knoxville, TN USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C,151C-U,Bldg 30, Pittsburgh, PA 15240 USA. EM John.blosnich@va.gov OI Matthews, Derrick/0000-0002-3579-3608 FU National Cancer Institute [5U54CA155496]; National Institute of Mental Health [T32MH094174]; National Institute on Minority Health and Health Disparities [L60 MD009167]; Department of Veterans Affairs Office of Academic Affiliations [TPP 72-013] FX This research was supported in part by the National Cancer Institute (grant 5U54CA155496), the National Institute of Mental Health (grant T32MH094174), National Institute on Minority Health and Health Disparities (grant L60 MD009167), and a postdoctoral fellowship through the Department of Veterans Affairs Office of Academic Affiliations (TPP 72-013). NR 55 TC 1 Z9 1 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD SUM PY 2016 VL 32 IS 3 BP 321 EP 331 DI 10.1111/jrh.12161 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DR3FX UT WOS:000379789100011 PM 26625172 ER PT J AU Axon, RN Gebregziabher, M Hunt, KJ Lynch, CP Payne, E Walker, RJ Egede, LE AF Axon, Robert Neal Gebregziabher, Mulugeta Hunt, Kelly J. Lynch, Cheryl P. Payne, Elizabeth Walker, Rebekah J. Egede, Leonard E. TI Comorbid depression is differentially associated with longitudinal medication nonadherence by race/ethnicity in patients with type 2 diabetes SO MEDICINE LA English DT Article DE depression; diabetes; medication adherence; race; ethnicity ID RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; GLYCEMIC CONTROL; ADHERENCE; MELLITUS; VETERANS; THERAPY; CARE; INTERVENTIONS AB The aim of the study was to examine whether depression impacts medication nonadherence (MNA) over time and determine if race has a differential impact on MNA in patients with type 2 diabetes and comorbid depression.Generalized estimating equations were used with a longitudinal national cohort of 740,197 veterans with type 2 diabetes. MNA was the main outcome defined by <80% medication possession ratio for diabetes medications. The primary independent variable was comorbid depression. Analyses were adjusted for the longitudinal nature of the data and covariates including age, sex, marital status, and rural/urban residence.In adjusted models, MNA was higher in non-Hispanic blacks (NHBs) (odds ratio [OR] 1.58 [95% confidence intervalCI: 1.57, 1.59]), Hispanics (OR 1.34 [95% CI: 1.32, 1.35]), and the other/missing racial/ethnic group (OR 1.37 [95% CI: 1.36, 1.38]) than in non-Hispanic whites (NHWs). In stratified analyses, the odds of MNA associated with depression were highest in NHWs (OR 1.14 [95% CI: 1.12, 1.15]) and were significantly associated in the other 3 minority racial/ethnic groups. MNA was lower in rural than urban NHWs (OR 0.91 [95% CI: 0.90, 0.92]), NHBs (OR 0.92 [95% CI: 0.91, 0.94]), and the other/unknown racial/ethnic group (OR 0.89 [95% CI: 0.88, 0.90]), but higher in rural Hispanic patients (OR 1.12 [95% CI: 1.09, 1.14]).Depression was associated with increased odds of MNA in NHWs, as well as in minority groups, although associations were weaker in minority groups, perhaps as a result of the high baseline levels of MNA in minority groups. There were also differences by race/ethnicity in MNA in rural versus urban subjects. C1 [Axon, Robert Neal; Gebregziabher, Mulugeta; Hunt, Kelly J.; Lynch, Cheryl P.; Payne, Elizabeth; Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.; Payne, Elizabeth] Med Univ South Carolina, Dept Publ Hlth, Charleston, SC USA. [Lynch, Cheryl P.; Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,MSC 593, Charleston, SC 29425 USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU VHA Health Services Research and Development (HSRD) program [IIR-06-219] FX This study was supported by grant #IIR-06-219 funded by the VHA Health Services Research and Development (HSR&D) program. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The manuscript represents the views of the authors and not those of the VA or HSR&D. Drs LEE and MG are the guarantor's of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. NR 40 TC 0 Z9 0 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD JUN PY 2016 VL 95 IS 25 AR e3983 DI 10.1097/MD.0000000000003983 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DR1JH UT WOS:000379661300043 PM 27336900 ER PT J AU Ward, MM Deodhar, A Reveille, JD Caplan, L AF Ward, Michael M. Deodhar, Atul Reveille, John D. Caplan, Liron TI Treatment of patients with nonradiographic axial spondyloarthritis who have negative magnetic resonance imaging results and normal C-reactive protein levels at baseline: comment on the article by Ward et al Reply SO ARTHRITIS CARE & RESEARCH LA English DT Letter ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; EFFICACY; SACROILIITIS; ADALIMUMAB C1 [Ward, Michael M.] NIAMSD, NIH, Bethesda, MD 20892 USA. [Deodhar, Atul] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Aurora, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. RP Ward, MM (reprint author), NIAMSD, NIH, Bethesda, MD 20892 USA. FU Intramural NIH HHS [Z01 AR041153-04] NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JUN PY 2016 VL 68 IS 6 BP 886 EP 887 DI 10.1002/acr.22878 PG 3 WC Rheumatology SC Rheumatology GA DR1ON UT WOS:000379674900023 PM 26990665 ER PT J AU Rudmik, L Soler, ZM Hopkins, C Schlosser, RJ Peters, A White, AA Orlandi, RR Fokkens, WJ Douglas, R Smith, TL AF Rudmik, Luke Soler, Zachary M. Hopkins, Claire Schlosser, Rodney J. Peters, Anju White, Andrew A. Orlandi, Richard R. Fokkens, Wytske J. Douglas, Richard Smith, Timothy L. TI Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; sinusitis; patient selection; maximal medical therapy; appropriateness criteria; RAND; quality of health care; sinus surgery; surgery indications ID REFRACTORY CHRONIC RHINOSINUSITIS; CONTINUED MEDICAL THERAPY; SMALL-AREA VARIATION; COMPUTED-TOMOGRAPHY; UNITED-STATES; GEOGRAPHIC-VARIATION; SYMPTOM OUTCOMES; IMPACT OUTCOMES; NASAL POLYPOSIS; HEALTH-CARE AB BackgroundAppropriate indications for endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS) are currently poorly defined. The lack of clear surgical indications for ESS likely contributes to the large geographic variation in surgical rates and contributes to reduced quality of care. The objective of this study was to define appropriateness criteria for ESS during management of adult patients with uncomplicated CRS. MethodsThe RAND/UCLA appropriateness methodology was performed. An international, multidisciplinary panel of 10 experts in CRS was formed and completed 2 rounds of a modified Delphi ranking process along with a face-to-face meeting. ResultsA total of 624 clinical scenarios were ranked, 312 scenarios each for CRS with and CRS without nasal polyps. For adult patients with uncomplicated CRS with nasal polyps, ESS can be appropriately offered when the CT Lund-Mackay score is 1 and there has been a minimum trial of a topical intranasal corticosteroid plus a short-course of systemic corticosteroid with a post-treatment total SNOT-22 score 20. For adult patients with uncomplicated CRS without nasal polyps, ESS can be appropriately offered when the CT Lund-Mackay score is 1 and there has been a minimum trial of a topical intranasal corticosteroid plus either a short-course of a broad spectrum/culture-directed systemic antibiotic or the use of a prolonged course of systemic low-dose anti-inflammatory antibiotic with a post-treatment total SNOT-22 score 20. ConclusionThis study has developed and reported of list of appropriateness criteria to offer ESS as a treatment option during management of uncomplicated adult CRS. The extent or technique of ESS was not addressed in this study and will depend on surgeon and patient factors. Furthermore, these criteria are the minimal threshold to make ESS a treatment option and do not imply that all patients meeting these criteria require surgery. The decision to perform ESS should be made after an informed patient makes a preference-sensitive decision to proceed with surgery. Applying these appropriateness criteria for ESS may optimize patient selection, reduce the incidence of unwarranted surgery, and assist clinicians in providing high-quality, patient-centered care to patients with CRS C1 [Rudmik, Luke] Univ Calgary, Div Otolaryngol Head & Neck Surg, Dept Surg, Calgary, AB, Canada. [Soler, Zachary M.] Med Univ South Carolina, Div Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Charleston, SC USA. [Hopkins, Claire] Guys & St Thomas NHS Trust, Dept ENT, London, England. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Peters, Anju] Northwestern Univ, Div Allergy, Dept Internal Med, Chicago, IL 60611 USA. [White, Andrew A.] Scripps Clin, Div Allergy & Immunol, La Jolla, CA 92037 USA. [Orlandi, Richard R.] Univ Utah, Div Otolaryngol Head & Neck Surg, Salt Lake City, UT USA. [Fokkens, Wytske J.] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands. [Douglas, Richard] Univ Auckland, Dept Surg, Auckland, New Zealand. [Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Oregon Sinus Ctr, Portland, OR 97201 USA. RP Rudmik, L (reprint author), Univ Calgary, Richmond Rd Diagnost & Treatment Ctr, Div Otolaryngol Head & Neck Surg, Dept Surg, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada. EM Lukerudmik@gmail.com NR 71 TC 6 Z9 6 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JUN PY 2016 VL 6 IS 6 BP 557 EP 567 DI 10.1002/alr.21769 PG 11 WC Otorhinolaryngology SC Otorhinolaryngology GA DR1YL UT WOS:000379700700002 PM 26970538 ER PT J AU Carroll, WW Schlosser, RJ O'Connell, BP Soler, ZM Mulligan, JK AF Carroll, William W. Schlosser, Rodney J. O'Connell, Brendan P. Soler, Zachary M. Mulligan, Jennifer K. TI Vitamin D deficiency is associated with increased human sinonasal fibroblast proliferation in chronic rhinosinusitis with nasal polyps SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; endoscopic sinus surgery; fibroblast; vitamin D; nasal polyps ID DENDRITIC CELLS; MESENCHYMAL TRANSITION; EXPRESSION; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; INDUCTION; SINUSITIS; EXPOSURE; RECEPTOR; ANALOGS AB BackgroundVitamin D3 (VD3) is a steroid hormone with known antiproliferative properties. Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have been shown to be VD3-deficient. Moreover, VD3 deficiency is associated with worse disease in patients with CRSwNP. One cell type thought to play a role in chronic rhinosinusitis (CRS) is the human sinonasal fibroblast (HSNF). The aim of this study was to investigate VD3 deficiency and HSNF proliferation in CRSwNP. MethodsBlood and sinus tissue explants were collected at the time of surgery from patients with CRSwNP (n = 15). Control subjects (n = 12) were undergoing surgery for cerebrospinal fluid leak repair or to remove non-hormone-secreting pituitary tumors. Ex vivo HSNF proliferation was analyzed with flow cytometry using expression of fibroblast-specific protein (FSP) and the proliferation marker Ki67. Plasma levels of 25-hydroxyvitamin D3 (25VD3) were measured by enzyme-linked immunosorbent assay. In vitro analysis of HSNF proliferation after treatment with calcitriol (1,25VD3) was performed using carboxyfluorescein succinimidyl ester (CFSE) and analyzed with flow cytometry. ResultsIn CRSwNP patients there was an inverse correlation between 25VD3 and proliferating HSNFs (p = 0.0135). This correlation was not seen for control patients (p = 0.3869). In vitro analysis showed that HSNFs from patients with CRSwNP had a higher proliferation index at baseline than HSNFs from control patients (p < 0.01). When treated with 1,25VD3, there was a significant decrease in HSNF proliferation index in patients with CRSwNP (p < 0.01), but not control patients. ConclusionVD3 deficiency is associated with increased HSNF proliferation in CRSwNP. Further investigation into how HSNFs and VD3 impact CRSwNP pathophysiology is warranted. C1 [Carroll, William W.; Schlosser, Rodney J.; O'Connell, Brendan P.; Soler, Zachary M.; Mulligan, Jennifer K.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ South Carolina, Dept Pediat, Charleston, SC USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU American Academy of Otolaryngology-Head and Neck Surgery; Flight Attendant Medical Research Institute [092401, 113039]; Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award [CSRD 1I01CX000377-01A2] FX American Academy of Otolaryngology-Head and Neck Surgery (to W.W.C.); Flight Attendant Medical Research Institute (092401 to J.K.M.; 113039 to R.J.S.); Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development Merit Award (CSRD 1I01CX000377-01A2 to R.J.S.). NR 35 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JUN PY 2016 VL 6 IS 6 BP 605 EP 610 DI 10.1002/alr.21704 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DR1YL UT WOS:000379700700008 PM 26750566 ER PT J AU Perlis, ML Grandner, MA Brown, GK Basner, M Chakravorty, S Morales, KH Gehrman, PR Chaudhary, NS Thase, ME Dinges, DF AF Perlis, Michael L. Grandner, Michael A. Brown, Gregory K. Basner, Mathias Chakravorty, Subhajit Morales, Knashawn H. Gehrman, Philip R. Chaudhary, Ninad S. Thase, Michael E. Dinges, David F. TI Nocturnal Wakefulness as a Previously Unrecognized Risk Factor for Suicide SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article DE Sleep Disorders; Suicide ID SLEEP PROBLEMS; TIME; MILITARY; INSOMNIA; BEHAVIOR; ADULTS; PHASE AB Objective: Suicide is a major public health problem and the 10th leading cause of death in the United States. The identification of modifiable risk factors is essential for reducing the prevalence of suicide. Recently, it has been shown that insomnia and nightmares significantly increase the risk for suicidal ideation, attempted suicide, and death by suicide. While both forms of sleep disturbance may independently confer risk, and potentially be modifiable risk factors, it is also possible that simply being awake at night represents a specific vulnerability for suicide. The present analysis evaluates the frequency of completed suicide per hour while taking into account the percentage of individuals awake at each hour. Methods: Archival analyses were conducted estimating the time of fatal injury using the National Violent Death Reporting System for 2003-2010 and the proportion of the American population awake per hour across the 24-hour day using the American Time Use Survey. Results: The mean +/- SD incident rate from 06:00-23:59 was 2.2% +/- 0.7%, while the mean +/- SD incident rate from 00:00-05:59 was 10.3% +/- 4.9%. The maximum incident rate was from 02:00-02:59 (16.3%). Hour-by-hour observed values differed from those that would be expected by chance (P < .001), and when 6-hour blocks were examined, the observed frequency at night was 3.6 times higher than would be expected by chance (P < .001). Conclusions: Being awake at night confers greater risk for suicide than being awake at other times of the day, suggesting that disturbances of sleep or circadian neurobiology may potentiate suicide risk. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Perlis, Michael L.; Grandner, Michael A.; Chakravorty, Subhajit; Gehrman, Philip R.; Chaudhary, Ninad S.] Univ Penn, Dept Psychiat, Perelman Sch Med, Behav Sleep Med Program, Philadelphia, PA 19104 USA. [Perlis, Michael L.; Grandner, Michael A.; Basner, Mathias; Chakravorty, Subhajit; Gehrman, Philip R.; Dinges, David F.] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Perlis, Michael L.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Brown, Gregory K.] Univ Penn, Dept Psychiat, Perelman Sch Med, Ctr Prevent Suicide, Philadelphia, PA 19104 USA. [Basner, Mathias; Dinges, David F.] Univ Penn, Dept Psychiat, Perelman Sch Med, Div Sleep & Chronobiol,Unit Expt Psychiat, Philadelphia, PA 19104 USA. [Chakravorty, Subhajit] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Morales, Knashawn H.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Chaudhary, Ninad S.] Washington Univ, Populat Hlth Sci Program, St Louis, MO USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Mood & Anxiety Disorders Treatment & Res Program, Philadelphia, PA 19104 USA. [Grandner, Michael A.] Univ Arizona, Dept Psychiat, Tucson, AZ USA. [Chaudhary, Ninad S.] Univ Alabama Birmingham, Sch Med, Dept Emergency Med, Birmingham, AL USA. [Chaudhary, Ninad S.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. RP Perlis, ML (reprint author), Univ Penn, Dept Psychiat, Behav Sleep Med Program, 3535 Market St,Ste 670, Philadelphia, PA 19104 USA. EM mperlis@upenn.edu FU National Institute on Aging [R01AG041783]; National Center for Complementary and Alternative Medicine [R01AT003332]; National Institute of Mental Health [R01MH077900, R01MH086572, R21MH103963, R01MH082794]; National Institute of Environmental Health Services [R21ES022931]; National Heart, Lung, and Blood Institute [K23HL110216]; National Institute of Nursing Research [R01NR004281]; National Space Biomedical Research Institute through the National Aeronautics and Space Administration [NCC 9-58]; US Department of Veterans Affairs [IK2CX000855] FX The study had no direct support by grant funding. Partial salary support was provided by the National Institute on Aging grant R01AG041783 (Drs Perlis and Morales); National Center for Complementary and Alternative Medicine grant R01AT003332 (Drs Perlis and Morales); National Institute of Mental Health grant R01MH077900 (Drs Perlis and Morales), R01MH086572 (Dr Brown), R21MH103963 (Dr Gehrman), and R01MH082794 (Dr Thase); National Institute of Environmental Health Services grant R21ES022931 (Dr Grandner); National Heart, Lung, and Blood Institute grant K23HL110216 (Dr Grandner); National Institute of Nursing Research grant R01NR004281 (Dr Dinges); National Space Biomedical Research Institute grant NCC 9-58 through the National Aeronautics and Space Administration (Dr Basner); and US Department of Veterans Affairs grant IK2CX000855 (Dr Chakravorty). NR 27 TC 0 Z9 0 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JUN PY 2016 VL 77 IS 6 BP E726 EP E733 DI 10.4088/JCP.15m10131 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ6GM UT WOS:000379302500006 PM 27337421 ER PT J AU Caska-Wallace, CM Katon, JG Lehavot, K McGinn, MM Simpson, TL AF Caska-Wallace, Catherine M. Katon, Jodie G. Lehavot, Keren McGinn, Meghan M. Simpson, Tracy L. TI Posttraumatic Stress Disorder Symptom Severity and Relationship Functioning Among Partnered Heterosexual and Lesbian Women Veterans SO LGBT HEALTH LA English DT Article DE military; partner support; PTSD; relationship satisfaction; sexual orientation; women Veterans ID SOCIAL SUPPORT; MENTAL-HEALTH; RELATIONSHIP QUALITY; FAMILY ADJUSTMENT; VIETNAM VETERANS; PTSD; GAY; COUPLES; IRAQ; AFGHANISTAN AB Purpose: Few studies have examined associations of posttraumatic stress disorder (PTSD) and relationship satisfaction among women Veterans, and no research has explored these factors in lesbian women Veterans, a large subgroup that may have unique concerns. This study examined the link between PTSD and relationship satisfaction in partnered heterosexual and lesbian women Veterans and evaluated potential moderation by sexual orientation, partner support, and conflict. Methods: Women Veterans (heterosexual n=260; lesbian n=128) were recruited nationally to complete a cross-sectional online survey. Multiple linear regression models were used to evaluate moderation, using two- and three-way interactions. Results: Partner support moderated the association between PTSD symptoms and relationship satisfaction to a different degree for heterosexual and lesbian women Veterans, playing a more prominent role in this association for lesbian women. Specifically, for lesbians with low partner support, as PTSD symptoms worsened, relationship satisfaction decreased at a steeper rate than for heterosexual women with low partner support. On the other hand, for lesbians with high partner support, as PTSD symptoms worsened, relationship satisfaction decreased less sharply than for heterosexual women with high partner support. Degree of conflict was highly correlated with relationship satisfaction and also appeared to moderate these relations differently by sexual orientation. Conclusion: These findings suggest that women Veterans with PTSD experience impairments in their romantic relationships, which vary by sexual orientation, partner support, and conflict. Partner support and conflict may be important targets in assessment and therapy for women Veterans with PTSD, and especially so for sexual minorities. C1 [Caska-Wallace, Catherine M.; McGinn, Meghan M.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, 1660 S Columbian Way 116MHC, Seattle, WA 98108 USA. [Caska-Wallace, Catherine M.; Lehavot, Keren; McGinn, Meghan M.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Katon, Jodie G.; Lehavot, Keren] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Katon, Jodie G.; Lehavot, Keren] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Katon, Jodie G.] Womens Hlth Serv, US Dept Vet Affairs VA, Off Patient Care Serv, Washington, DC USA. [Lehavot, Keren; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA. RP Caska-Wallace, CM (reprint author), VA Puget Sound Hlth Care Syst, Mental Hlth Serv, 1660 S Columbian Way 116MHC, Seattle, WA 98108 USA. EM catherine.wallace@va.gov FU VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC); VA CSR&D Career Development Award [IK2 CX000867] FX This research was supported by a research grant to K. Lehavot and T. Simpson from the VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC). Dr. Lehavot's effort was supported by a VA CSR&D Career Development Award (IK2 CX000867). This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. The views expressed in this article are those of the authors and do not represent the views of the Department of Veterans Affairs or the United States government. NR 34 TC 0 Z9 0 U1 4 U2 5 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD JUN PY 2016 VL 3 IS 3 BP 186 EP 192 DI 10.1089/lgbt.2015.0097 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DR1KM UT WOS:000379664400004 PM 26895547 ER PT J AU Closser, S Finley, EP AF Closser, Svea Finley, Erin P. TI A New Reflexivity: Why Anthropology Matters in Contemporary Health Research and Practice, and How to Make It Matter More SO AMERICAN ANTHROPOLOGIST LA English DT Editorial Material ID EVIDENCE-BASED PSYCHOTHERAPIES; ROUTINE IMMUNIZATION; POLIO ERADICATION; CARE; PROGRAMS; IMPACT C1 [Closser, Svea] Middlebury Coll, Dept Sociol & Anthropol, Middlebury, VT 05753 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA. [Finley, Erin P.] South Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. RP Closser, S (reprint author), Middlebury Coll, Dept Sociol & Anthropol, Middlebury, VT 05753 USA. OI Finley, Erin/0000-0003-4497-7721 NR 18 TC 1 Z9 1 U1 2 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-7294 EI 1548-1433 J9 AM ANTHROPOL JI Am. Anthropol. PD JUN PY 2016 VL 118 IS 2 BP 385 EP 390 DI 10.1111/aman.12532 PG 6 WC Anthropology SC Anthropology GA DQ2GB UT WOS:000379019400017 ER PT J AU Emmens, JE ter Maaten, JM Matsue, Y Metra, M O'Connor, CM Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JG Givertz, MM Bloomfield, DM Dittrich, HC Todd, J van Veldhuisen, DJ Hillege, HL Damman, K van der Meer, P Voors, AA AF Emmens, Johanna E. ter Maaten, Jozine M. Matsue, Yuya Metra, Marco O'Connor, Christopher M. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. Todd, John van Veldhuisen, Dirk J. Hillege, Hans L. Damman, Kevin van der Meer, Peter Voors, Adriaan A. TI Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Plasma KIM-1; Heart failure; Prognosis ID GLOMERULAR-FILTRATION-RATE; TUBULAR DAMAGE; DISEASE; METAANALYSIS; ROLOFYLLINE; ANTAGONIST; MORTALITY; BIOMARKER; RECEPTOR; KIM-1 AB AimsUrinary kidney injury molecule-1 (KIM-1) is a marker of tubular damage and associated with worse outcome in heart failure (HF). Plasma KIM-1 has not been described in HF. Methods and resultsIn a renal mechanistic cohort of 120 chronic HF patients, we established the association between plasma KIM-1, renal invasive haemodynamic parameters {renal blood flow ([I-131]hippuran clearance) and measured glomerular filtration rate (GFR; [I-125]iothalamate)} and urinary tubular damage markers. The association between plasma KIM-1, plasma creatinine, and clinical outcome was further explored in a cohort of 2033 acute HF patients. Median plasma KIM-1 was 171.5pg/mL (122.8-325.7) in chronic (n = 99) and 295.1pg/mL (182.2-484.2) in acute HF (n = 1588). In chronic HF, plasma KIM-1 was associated with GFR (P < 0.001), creatinine, and cystatin C. Plasma KIM-1 was associated with urinary N-acetyl--d-glucosaminidase (NAG), but not with other urinary tubular damage markers. Log plasma KIM-1 predicted adverse clinical outcome after adjustment for age, gender, and GFR [hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.07-3.53, P = 0.030]. Statistical significance was lost after correction for NT-proBNP (HR 1.61, 95% CI 0.81-3.20, P = 0.175). In acute HF, higher plasma KIM-1 levels were associated with higher creatinine, lower albumin, and presence of diabetes. Log plasma KIM-1 predicted 60-day HF rehospitalization (HR 1.27, 95% CI 1.03-1.55, P = 0.024), but not 180-day mortality or 60-day death or renal or cardiovascular rehospitalization. ConclusionsPlasma KIM-1 is associated with glomerular filtration and urinary NAG, but not with other urinary tubular damage markers. Plasma KIM-1 does not predict outcome in chronic HF after correction for NT-proBNP. In acute HF, plasma KIM-1 predicts HF rehospitalization in multivariable analysis. C1 [Emmens, Johanna E.; ter Maaten, Jozine M.; Matsue, Yuya; van Veldhuisen, Dirk J.; Hillege, Hans L.; Damman, Kevin; van der Meer, Peter; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Metra, Marco] Univ Brescia, Brescia, Italy. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Todd, John] Singulex Inc, Alameda, CA USA. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016 NR 22 TC 1 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD JUN PY 2016 VL 18 IS 6 BP 641 EP 649 DI 10.1002/ejhf.426 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DQ5PL UT WOS:000379257200009 PM 26511274 ER PT J AU Chevalier, FD Le Clech, W Eng, N Rugel, AR de Assis, RR Oliveira, G Holloway, SP Cao, XH Hart, PJ LoVerde, PT Anderson, TJC AF Chevalier, Frederic D. Le Clech, Winka Eng, Nina Rugel, Anastasia R. de Assis, Rafael Ramiro Oliveira, Guilherme Holloway, Stephen P. Cao, Xiaohang Hart, P. John LoVerde, Philip T. Anderson, Timothy J. C. TI Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Schistosoma mansoni; Oxamniquine resistance; Sulfotransferase; Loss-of-function; Biochemical assay; Soft selective event ID GENETIC COMPLEMENTATION ANALYSIS; NUCLEOTIDE SUBSTITUTIONS; HYCANTHONE RESISTANCE; CLINICAL-TRIALS; DISEASE-CONTROL; MANSONI; DNA; COMBINATION; ATOVAQUONE; STANDARD AB Molecular surveillance provides a powerful approach to monitoring the resistance status of parasite populations in the field and for understanding resistance evolution. Oxamniquine was used to treat Brazilian schistosomiasis patients (mid-1970s to mid-2000s) and several cases of parasite infections resistant to treatment were recorded. The gene underlying resistance (SmSULT-OR) encodes a sulfotransferase required for intracellular drug activation. Resistance has a recessive basis and occurs when both SmSULT-OR alleles encode for defective proteins. Here we examine SmSULT-OR sequence variation in a natural schistosome population in Brazil similar to 40 years after the first use of this drug. We sequenced SmSULT-OR from 189 individual miracidia (1-11 per patient) recovered from 49 patients, and tested proteins expressed from putative resistance alleles for their ability to activate oxamniquine. We found nine mutations (four non-synonymous single nucleotide polymorphisms, three non-coding single nucleotide polymorphisms and two indels). Both mutations (p.E142del and p.C35R) identified previously were recovered in this field population. We also found two additional mutations (a splice site variant and 1 bp coding insertion) predicted to encode non-functional truncated proteins. Two additional substitutions (p.G206V, p.N215Y) tested had no impact on oxamniquine activation. Three results are of particular interest: (i) we recovered the p.E142del mutation from the field: this same deletion is responsible for resistance in an oxamniquine selected laboratory parasite population; (ii) frequencies of resistance alleles are extremely low (0.27-0.8%), perhaps due to fitness costs associated with carriage of these alleles; (iii) that four independent resistant alleles were found is consistent with the idea that multiple mutations can generate loss-of-function alleles. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. C1 [Chevalier, Frederic D.; Le Clech, Winka; Eng, Nina; Anderson, Timothy J. C.] Texas Biomed Res Inst, Dept Genet, POB 760549, San Antonio, TX 78245 USA. [Rugel, Anastasia R.; Holloway, Stephen P.; Cao, Xiaohang; Hart, P. John; LoVerde, Philip T.] Univ Texas Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA. [Rugel, Anastasia R.; Holloway, Stephen P.; Cao, Xiaohang; Hart, P. John; LoVerde, Philip T.] Univ Texas Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. [de Assis, Rafael Ramiro; Oliveira, Guilherme] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Ave Augusta Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil. [Oliveira, Guilherme] Vale Inst Technol, Rua Boaventura da Silva 955, BR-66055090 Belem, Para, Brazil. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Chevalier, FD; Anderson, TJC (reprint author), Texas Biomed Res Inst, Dept Genet, POB 760549, San Antonio, TX 78245 USA. EM fcheval@txbiomed.org; tanderso@txbiomed.org OI CHEVALIER, Frederic/0000-0003-2611-8106; Oliveira, Guilherme/0000-0003-0054-3438 FU NIH [R01-A1097576, 1R01A1115691, P50 AI 098507]; World Health Organization [HQNTD1206356]; UTHSCSA Presidents Collaborative Research Fund; Robert A. Welch Foundation [AQ-1399]; National Center for Research Resources (NIH) [C06 RR013556]; ATT Foundation; National Center for Research Resources Grant [S10 RR029392]; University of Texas Health Science Center, San Antonio; Office of the Vice President for Research; San Antonio Cancer Institute [P30 CA054174]; Texas Biomedical Research Institute; City of San Antonio Summer Ambassador Program; CNPq [168260/2014-0, 309312/20124]; CAPES [070/13, REDE 21/2015]; FAPEMIG [RED-00014-14, PPM-00439-10] FX This study was supported by NIH grants [R01-A1097576 (T.J.C. A.), 1R01A1115691 and P50 AI 098507 (P.T.L./P.J.H.)], World Health Organization [HQNTD1206356 (P.T.L.)], the UTHSCSA Presidents Collaborative Research Fund (P.T.L./P.J.H.) and the Robert A. Welch Foundation [AQ-1399 (P.J.H.)]. The molecular work at TBRI was conducted in facilities constructed with support from Research Facilities Improvement Program Grant (C06 RR013556) from the National Center for Research Resources (NIH). The AT&T Genomics Computing Center supercomputing facilities were supported by the AT&T Foundation and the National Center for Research Resources Grant (S10 RR029392). The X-ray Crystallography Core Laboratory is supported by the University of Texas Health Science Center, San Antonio, Office of the Vice President for Research and by the San Antonio Cancer Institute Grant (P30 CA054174). W.L was supported by a Cowles fellowship from Texas Biomedical Research Institute. N.E. was supported by the City of San Antonio Summer Ambassador Program. R.R.A. received support from CNPq (168260/2014-0). G.O. received support from CNPq (309312/20124), CAPES (070/13, REDE 21/2015) and FAPEMIG (RED-00014-14, PPM-00439-10). We thank Guilherme Oliveira, Dr. Fernanda Ludolf Ribeiro, Maycon Bruno and Nilvande Ferreira for technical assistance during stool processing and miracidia sampling, Dr. Andrea Gazzinelli and Dr. Leonardo Matoso for stool sampling at Ponto dos Volantes, Dr. Ricardo Toshio Fujiwara at Universidade Federal de Minas Gerais and Dr. Rodrigo Correa -Oliveira at Centro de Pesquisas Rene Rachou for providing laboratory space for stool processing and miracidia sampling, and Joanne Curran for use of a capillary sequencer. NR 44 TC 2 Z9 2 U1 2 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 EI 1879-0135 J9 INT J PARASITOL JI Int. J. Parasit. PD JUN PY 2016 VL 46 IS 7 BP 417 EP 424 DI 10.1016/j.ijpara.2016.03.006 PG 8 WC Parasitology SC Parasitology GA DQ1NV UT WOS:000378968600007 PM 27073078 ER PT J AU Scott, A Rouch, JD Jabaji, Z Khalil, HA Solorzano, S Lewis, M Martin, MG Stelzner, MG Dunn, JCY AF Scott, Andrew Rouch, Joshua D. Jabaji, Ziyad Khalil, Hassan A. Solorzano, Sergio Lewis, Michael Martin, Martin G. Stelzner, Matthias G. Dunn, James C. Y. TI Long-term renewable human intestinal epithelial stem cells as monolayers: A potential for clinical use SO JOURNAL OF PEDIATRIC SURGERY LA English DT Article; Proceedings Paper CT 67th Annual Meeting of the Section-on-Surgery of the American-Academy-of-Pediatrics CY OCT 23-25, 2015 CL Washington, DC SP Amer Acad Pediat, Sect Surg DE Human intestinal epithelial stem cells; Monolayers; Differentiation; Type I collagen; Human laminin; Spheroids; Enteroids; In vitro culture ID IN-VITRO; CULTURE-SYSTEM; GROWTH-FACTORS; SELF-RENEWAL; ORGANOIDS; TISSUE; COLON; DIFFERENTIATION; EXPANSION; NICHE AB Purpose: Current culture schema for human intestinal stem cells (hISCs) frequently rely on a 3D culture system using Matrigel (TM), a laminin-rich matrix derived from murine sarcoma that is not suitable for clinical use. We have developed a novel 2D culture system for the in vitro expansion of hISCs as an intestinal epithelial monolayer without the use of Matrigel. Methods: Cadaveric duodenal samples were processed to isolate intestinal crypts from the mucosa. Crypts were cultured on a thin coat of type I collagen or laminin. Intestinal epithelial monolayers were supported with growth factors to promote self-renewal or differentiation of the hISCs. Proliferating monolayers were sub-cultured every 4-5 days. Results: Intestinal epithelial monolayers were capable of long-term cell renewal. Less differentiated monolayers expressed high levels of gene marker LGR5, while more differentiated monolayers had higher expressions of CDX2, MUC2, LYZ, DEF5, and CHGA. Furthermore, monolayers were capable of passaging into a 3D culture system to generate spheroids and enteroids. Conclusion: This 2D system is an important step to expand hISCs for further experimental studies and for clinical cell transplantation. (C) 2016 Elsevier Inc. All rights reserved. C1 [Scott, Andrew; Rouch, Joshua D.; Jabaji, Ziyad; Khalil, Hassan A.; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Pediat Surg, Los Angeles, CA 90095 USA. [Solorzano, Sergio; Martin, Martin G.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Gastroenterol & Nutr, Dept Pediat, Los Angeles, CA USA. [Solorzano, Sergio; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Martin G.; Dunn, James C. Y.] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA. [Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Stelzner, Matthias G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Dunn, James C. Y.] Univ Calif Los Angeles, Sch Engn, Dept Bioengn, Los Angeles, CA USA. RP Dunn, JCY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Surg, Box 709818, Los Angeles, CA 90095 USA. EM jdunn@mednet.ucla.edu OI Khalil, Hassan/0000-0002-3835-1290 FU NIDDK NIH HHS [P30 DK041301, R01 DK083319, R01 DK083762, U01 DK085535] NR 31 TC 1 Z9 1 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0022-3468 EI 1531-5037 J9 J PEDIATR SURG JI J. Pediatr. Surg. PD JUN PY 2016 VL 51 IS 6 BP 995 EP 1000 DI 10.1016/j.jpedsurg.2016.02.074 PG 6 WC Pediatrics; Surgery SC Pediatrics; Surgery GA DQ0RW UT WOS:000378908600025 PM 26995514 ER PT J AU Cortes, JA Gomez, G Ehnerd, C Gurnsey, K Nicolazzo, J Bradberry, CW Jedema, HP AF Cortes, Jennifer A. Gomez, Gustavo Ehnerd, Carol Gurnsey, Kate Nicolazzo, Jessica Bradberry, Charles W. Jedema, Hank P. TI Altered activity-based sleep measures in rhesus monkeys following cocaine self-administration and abstinence SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Cocaine; Rhesus macaque; Sleep efficiency; Stimulant; Cognition; Actigraphy ID MACACA-MULATTA; ADMINISTERED COCAINE; ACTIGRAPHY; DEPENDENCE; USERS; ARCHITECTURE; DISORDERS; DOPAMINE; INSOMNIA; RHYTHMS AB Background: Impairments in sleep and cognitive function have been observed in patients with substance abuse disorders and may be potential factors contributing to drug relapse. In addition, sleep disruption may itself contribute to cognitive deficits. In the present study we examined the impact of prolonged cocaine self-administration and abstinence on actigraphy-based measures of night-time activity in rhesus macaques as an inferential measure of sleep, and determined whether sleep-efficiency correlated with cognitive impairments in the same subjects on drug free days. Methods: Actigraphy data was obtained from a group of rhesus macaques intravenously self-administering cocaine (n=6) and a control group (n=5). Periods were evaluated during which the mean cumulative doses of cocaine were 3.0 + 0.0 and 4.5 + 0.2 mg/kg/day for 4 days (Tuesday Thursday) each week. Results: Actigraphy-based sleep efficiency decreased during days of cocaine self-administration in a dose dependent manner. Consistent with this observation, sleep became more fragmented. Activity-based sleep efficiency normalized during the weekend without cocaine prior to cognitive assessment on Monday. The magnitude of activity-based sleep disruption during self-administration did not correlate with the level of cognitive impairment on drug free days. With continued self-administration, the impact of cocaine on activity-based sleep efficiency declined indicating the development of tolerance. Conclusions: Cocaine self-administration disrupted sleep efficiency in rhesus macaques as measured by actigraphy, but normalized quickly in the absence of cocaine. The cognitive impairment observed on drug free days was unlikely to be related to disruption of the nightly activity patterns on days of cocaine self-administration. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Cortes, Jennifer A.] Univ Pittsburgh, Dept Bioengn, 3501 Fifth Ave, Pittsburgh, PA 15261 USA. [Gomez, Gustavo; Bradberry, Charles W.] Univ Pittsburgh, Dept Neurosci, 3501 Fifth Ave, Pittsburgh, PA 15261 USA. [Ehnerd, Carol; Gurnsey, Kate; Nicolazzo, Jessica; Bradberry, Charles W.; Jedema, Hank P.] Univ Pittsburgh, Dept Psychiat, 3501 Fifth Ave, Pittsburgh, PA 15261 USA. [Bradberry, Charles W.] VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. RP Jedema, HP (reprint author), Univ Pittsburgh, Dept Psychiat, 3501 Fifth Ave, Pittsburgh, PA 15261 USA. EM Jedema@pitt.edu FU VA Medical Research Award [VA BLRD1IO1BX000782]; [NIH/NIDADA025636] FX This research was supported by NIH/NIDADA025636 and VA Medical Research Award VA BLR&D1IO1BX000782. NR 39 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD JUN 1 PY 2016 VL 163 BP 202 EP 208 DI 10.1016/j.drugalcdep.2016.04.014 PG 7 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DP4HM UT WOS:000378457000026 PM 27114202 ER PT J AU Mota, N Pietrzak, RH Sareen, J AF Mota, Natalie Pietrzak, Robert H. Sareen, Jitender TI Preventing Veteran Homelessness by Reducing Military Sexual Trauma Ensuring a Welcome Home SO JAMA PSYCHIATRY LA English DT Editorial Material ID US VETERANS C1 [Mota, Natalie] Univ Manitoba, Dept Clin Hlth Psychol, Winnipeg, MB, Canada. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Sareen, Jitender] Univ Manitoba, Psychiat Psychol & Community Hlth Sci, Winnipeg, MB, Canada. RP Sareen, J (reprint author), PZ 430 PsycHlth Ctr, 771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada. EM jitender.sareen@umanitoba.ca NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD JUN PY 2016 VL 73 IS 6 BP 551 EP 552 DI 10.1001/jamapsychiatry.2016.0136 PG 2 WC Psychiatry SC Psychiatry GA DQ0DH UT WOS:000378868100004 PM 27096528 ER PT J AU Barr, ML Chiu, HK Li, N Yeh, MW Rhee, CM Casillas, J Iskander, PJ Leung, AM AF Barr, Meaghan L. Chiu, Harvey K. Li, Ning Yeh, Michael W. Rhee, Connie M. Casillas, Jacqueline Iskander, Paul J. Leung, Angela M. TI Thyroid Dysfunction in Children Exposed to Iodinated Contrast Media SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CONGENITAL HEART-DISEASE; HYPOTHYROIDISM; INFANTS AB Context: Iodinated contrast media (ICM) is routinely used in imaging studies and contains several 100-fold the recommended daily allowance of iodine. Objective: To determine whether children exposed to ICM have a higher risk of iodine-induced thyroid dysfunction. Design: This was a single-institution case-control study, examining patients with incident thyroid dysfunction aged less than 18 years from 2001 to 2015. Cases were matched 1:1 to euthyroid controls by age, sex, and race. Setting: This was a single-institution case-control study occurring at tertiary care center. Participants: Cases were defined as those with thyroid dysfunction (by International Classification of Diseases, Ninth Revision diagnosis codes and/or 2 consecutive abnormal serum TSH values <6 mo apart). We analyzed 870 cases matched to 870 controls (64% female, 51% White). Main Outcomes Measures: Using conditional logistic regression, the association between ICM exposure and the primary outcome, thyroid dysfunction, occurring within 2 years of exposure was assessed. Results: Sixty-nine patients received ICM, including 53 (6%) among cases and 16 (2%) among controls. The risk of incident hypothyroidism was significantly higher after ICM exposure (odds ratio 2.60; 95% confidence interval, 1.43-4.72; P < .01). The median interval between exposureand onset of hypothyroidism was 10.8 months (interquartile range, 6.6-17.9). In hypothyroid cases, the median serum TSH concentration was 6.5 mIU/L (interquartile range, 5.8-9.6). Conclusions: ICM exposure increases the risk of incident hypothyroidism in pediatric patients. Children receiving ICM should be monitored for iodine-induced thyroid dysfunction, particularly during the first year after exposure. C1 [Barr, Meaghan L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Chiu, Harvey K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Pediat Endocrinol, Los Angeles, CA 90073 USA. [Li, Ning] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biomath, Los Angeles, CA 90073 USA. [Yeh, Michael W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Sect Endocrine Surg, Los Angeles, CA 90073 USA. [Rhee, Connie M.] Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens, Irvine, CA 92697 USA. [Casillas, Jacqueline] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Pediat Hematol & Oncol, Los Angeles, CA 90073 USA. [Iskander, Paul J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90073 USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol, Los Angeles, CA 90073 USA. [Leung, Angela M.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. RP Leung, AM (reprint author), 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. EM amleung@mednet.ucla.edu FU National Institutes of Health [K23HD068552]; University of California Los Angeles David Geffen School of Medicine FX This work was supported by the National Institutes of Health Grant K23HD068552 (to A.M.L.) and the University of California Los Angeles David Geffen School of Medicine Short-Term Training Project (M.L.B.). NR 27 TC 1 Z9 1 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2016 VL 101 IS 6 BP 2366 EP 2370 DI 10.1210/jc.2016-1330 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MU UT WOS:000378821100011 PM 27018967 ER PT J AU Wakeman, CA Moore, JL Noto, MJ Zhang, YF Singleton, MD Prentice, BM Gilston, BA Doster, RS Gaddy, JA Chazin, WJ Caprioli, RM Skaar, EP AF Wakeman, Catherine A. Moore, Jessica L. Noto, Michael J. Zhang, Yaofang Singleton, Marc D. Prentice, Boone M. Gilston, Benjamin A. Doster, Ryan S. Gaddy, Jennifer A. Chazin, Walter J. Caprioli, Richard M. Skaar, Eric P. TI The innate immune protein calprotectin promotes Pseudomonas aeruginosa and Staphylococcus aureus interaction SO NATURE COMMUNICATIONS LA English DT Article ID IMAGING MASS-SPECTROMETRY; CYSTIC-FIBROSIS; BIOFILM FORMATION; MICROBIAL BIOFILMS; IRON HOMEOSTASIS; HUMAN-DISEASE; PATHOGENESIS; INFECTION; PYOVERDINE; ADAPTATION AB Microorganisms form biofilms containing differentiated cell populations. To determine factors driving differentiation, we herein visualize protein and metal distributions within Pseudomonas aeruginosa biofilms using imaging mass spectrometry. These in vitro experiments reveal correlations between differential protein distribution and metal abundance. Notably, zinc- and manganese-depleted portions of the biofilm repress the production of anti-staphylococcal molecules. Exposure to calprotectin (a host protein known to sequester metal ions at infectious foci) recapitulates responses occurring within metal-deplete portions of the biofilm and promotes interaction between P. aeruginosa and Staphylococcus aureus. Consistent with these results, the presence of calprotectin promotes co-colonization of the murine lung, and polymicrobial communities are found to co-exist in calprotectin-enriched airspaces of a cystic fibrosis lung explant. These findings, which demonstrate that metal fluctuations are a driving force of microbial community structure, have clinical implications because of the frequent occurrence of P. aeruginosa and S. aureus co-infections. C1 [Wakeman, Catherine A.; Gaddy, Jennifer A.; Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA. [Wakeman, Catherine A.; Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Moore, Jessica L.; Singleton, Marc D.; Chazin, Walter J.; Caprioli, Richard M.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Noto, Michael J.; Doster, Ryan S.; Gaddy, Jennifer A.] Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA. [Zhang, Yaofang; Prentice, Boone M.; Gilston, Benjamin A.; Chazin, Walter J.; Caprioli, Richard M.] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA. RP Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.; Skaar, EP (reprint author), Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Caprioli, RM (reprint author), Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.; Caprioli, RM (reprint author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA. EM r.caprioli@vanderbilt.edu; eric.skaar@vanderbilt.edu FU NIH/NIGMS [8P41 GM103391-05, S10 RR026742, P30 ES000267, R01 Al101171]; United States Department of Veterans Affairs Merit Award [INFB-024-13F]; Cystic Fibrosis Foundation; Department of Veterans Affairs [CDA-2 1IK2BX001701]; [T32 GM065086]; [T32AI007474-20]; [2T32HD060554-06A2] FX We thank Dr Hayes McDonald and Anna Felix of the Vanderbilt University Proteomics Core Laboratory for bottom-up proteomics analyses, Dr Nripesh Prasad from HudsonAlpha for analysis of RNA sequencing data, Dr Shannon Cornett of Bruker Daltonics for assistance with the rapifleX MALDI Tissuetyper, and members of the Caprioli and Skaar laboratories for critical reading of this manuscript. This work was supported by NIH/NIGMS grants 8P41 GM103391-05 to R.M.C., and by S10 RR026742, P30 ES000267 and R01 Al101171 to E.P.S., as well as the United States Department of Veterans Affairs Merit Award INFB-024-13F. J.L.M. is supported by grant number T32 GM065086. M.J.N. is supported by the Cystic Fibrosis Foundation. J.A.G. is supported by the Department of Veterans Affairs CDA-2 1IK2BX001701. R.S.D. has been supported by grants T32AI007474-20 and 2T32HD060554-06A2. Scanning electron imaging was performed in part through the use of the VUMC Cell Imaging Shared Resource. NR 67 TC 4 Z9 4 U1 7 U2 11 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUN PY 2016 VL 7 AR 11951 DI 10.1038/ncomms11951 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DP7NL UT WOS:000378686000001 PM 27301800 ER PT J AU Gleysteen, J Clayburgh, D Cohen, J AF Gleysteen, John Clayburgh, Daniel Cohen, James TI Management of Carotid Blowout from Radiation Necrosis SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Carotid blowout; Endovascular; Radiation complication ID ARTERY RUPTURE; NECK CANCERS; HEAD; EXPERIENCE; OUTCOMES AB Although the incidence of carotid blowout has decreased with the advent of better reconstructive techniques, it remains a real risk after major head and neck surgery, especially in an irradiated field. A systematic, multidisciplinary approach incorporating appropriate history and physical examination, adequate resuscitation, diagnostic computed tomography, and diagnostic and therapeutic angiography can manage most of these patients in a safe and effective manner. Surgery has a limited role in acute management, although surgical techniques are useful both for prevention of this problem and for wound management after carotid blowout. C1 [Gleysteen, John; Clayburgh, Daniel] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Otolaryngol Head & Neck Surg, Portland, OR USA. [Cohen, James] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Otolaryngol Head & Neck Surg, ENT, P3-OC,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA. RP Cohen, J (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Otolaryngol Head & Neck Surg, ENT, P3-OC,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA. EM James.Cohen2@va.gov NR 15 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0030-6665 EI 1557-8259 J9 OTOLARYNG CLIN N AM JI Otolaryngol. Clin. N. Am. PD JUN PY 2016 VL 49 IS 3 BP 829 EP + DI 10.1016/j.otc.2016.02.001 PG 13 WC Otorhinolaryngology SC Otorhinolaryngology GA DP6BL UT WOS:000378581800024 PM 27267029 ER PT J AU Fung, CH Martin, JL Josephson, K Fiorentino, L Dzierzewski, JM Jouldjian, S Tapia, JCR Mitchell, MN Alessi, C AF Fung, Constance H. Martin, Jennifer L. Josephson, Karen Fiorentino, Lavinia Dzierzewski, Joseph M. Jouldjian, Stella Rodriguez Tapia, Juan Carlos Mitchell, Michael N. Alessi, Cathy TI Efficacy of Cognitive Behavioral Therapy for Insomnia in Older Adults With Occult Sleep-Disordered Breathing SO PSYCHOSOMATIC MEDICINE LA English DT Article DE aged; cognitive behavioral therapy; continuous positive airway pressure; sleep apnea syndromes ID RANDOMIZED CONTROLLED-TRIAL; LATE-LIFE INSOMNIA; PLACEBO-CONTROLLED TRIAL; SYMPTOMS; VALIDITY; ISSUES; INDEX; APNEA AB Objectives The aims of the study were to determine whether mild, occult sleep-disordered breathing (SDB) moderates the efficacy of cognitive behavioral therapy for insomnia (CBTI) in older adults and to explore whether CBTI reduces the number of patients eligible for positive airway pressure (PAP) therapy. Methods Data were analyzed for 134 adults 60 years or older with insomnia and apnea-hypopnea index (AHI) of less than 15 who were randomized to a larger study of CBTI versus a sleep education control. Sleep outcomes (sleep onset latency, total wake time, wake after sleep onset, sleep efficiency, Pittsburgh Sleep Quality Index) were compared between CBTI and control at 6 months using repeated-measures analysis of variance adjusted for baseline values. AHI of 5 or greater versus less than 5 was included as an interaction term to evaluate changes in sleep outcomes. The number of participants at baseline and 6 months with mild SDB for whom insomnia was their only other indication for PAP was also compared between CBTI and control. Results AHI status (AHI 5 [75.5% of participants] versus AHI < 5) did not moderate improvements in sleep associated with CBTI (all p values .12). Nine (45.0%) of 20 participants with mild SDB for whom insomnia was their only other indication for PAP therapy at baseline no longer had another indication for PAP at 6 months, with no significant difference between CBTI and control. Conclusions CBTI improves sleep in older veterans with insomnia and untreated mild SDB. Larger trials are needed to assess whether CBTI reduces the number of patients with mild SDB eligible for PAP. C1 [Fung, Constance H.; Martin, Jennifer L.; Josephson, Karen; Dzierzewski, Joseph M.; Jouldjian, Stella; Rodriguez Tapia, Juan Carlos; Mitchell, Michael N.; Alessi, Cathy] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Fung, Constance H.; Martin, Jennifer L.; Dzierzewski, Joseph M.; Rodriguez Tapia, Juan Carlos; Alessi, Cathy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Fiorentino, Lavinia] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Rodriguez Tapia, Juan Carlos] Pontificia Univ Catolica Chile, Dept Med, Alameda 340, Santiago, Region Metropol, Chile. RP Fung, CH (reprint author), 16111 Plummer St,11E, North Hills, CA 91343 USA. EM constance.fung@va.gov FU Veterans Administration Health Services Research and Development [08-295]; Veterans Administration Greater Los Angeles Geriatric Research, Education and Clinical Center; American Federation for Aging Research; American SleepMedicine Foundation Physician Scientist Training Award; National Institute on Aging of the National Institutes of Health [K23AG045937]; National Institute on Aging, American Federation for Aging Research; John A. Hartford Foundation; Atlantic Philanthropies; UCLA Claude Pepper Older Americans Independence Center [5P30AG028748]; National Center for Advancing Translational Sciences UCLA Clinical and Translational Institute [UL1TR000124] FX This study was funded by Veterans Administration Health Services Research and Development (Alessi IIR 08-295), Veterans Administration Greater Los Angeles Geriatric Research, Education and Clinical Center, American Federation for Aging Research (to Fung), American SleepMedicine Foundation Physician Scientist Training Award (to Fung), and National Institute on Aging of the National Institutes of Health under Award Number K23AG045937 (to Fung)/The Beeson Career Development in Aging Research Award Program (supported by National Institute on Aging, American Federation for Aging Research, The John A. Hartford Foundation, and The Atlantic Philanthropies; to Fung). Dzierzewski was supported by UCLA Claude Pepper Older Americans Independence Center (5P30AG028748) and National Center for Advancing Translational Sciences UCLA Clinical and Translational Institute (UL1TR000124). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, US Department of Veterans Affairs, or the United States Government. The authors report no conflicts of interest. This study did not involve any off-label or investigational use. NR 28 TC 1 Z9 1 U1 5 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD JUN PY 2016 VL 78 IS 5 BP 629 EP 639 DI 10.1097/PSY.0000000000000314 PG 11 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DP8AD UT WOS:000378719400013 PM 27136498 ER PT J AU Fisher, CE Alexander, J Bhattacharya, R Rakita, RM Kirby, KA Boeckh, M Limaye, AP AF Fisher, C. E. Alexander, J. Bhattacharya, R. Rakita, R. M. Kirby, K. A. Boeckh, M. Limaye, A. P. TI Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE solid organ transplant; cytomegalovirus disease; gastrointestinal; diagnosis; sensitivity ID CELL TRANSPLANTATION; ANTIGENEMIA ASSAY; CMV ANTIGENEMIA; INFECTION; PLASMA; DNA AB BackgroundGastrointestinal (GI) cytomegalovirus (CMV) disease is the most common manifestation of tissue-invasive CMV infection in solid organ transplant (SOT) recipients, but the diagnostic yields of blood and tissue testing have not been systematically assessed in a large patient cohort. MethodsWe retrospectively identified consecutive SOT recipients with biopsy-confirmed GI CMV disease who had both tissue and blood (CMV polymerase chain reaction or antigenemia) diagnostic testing performed within 14 days of diagnosis. Descriptive statistics and logistic regression were used to assess the association between patient factors and viremia and the diagnostic yield of tests performed on biopsy specimens. ResultsA total of 101 patients (73% donor seropositive/recipient seronegative [D+/R-], 22% recipient seropositive [R+]) had GI CMV disease (58% upper, 22% lower, and 20% both) at a median of 185 days (range, 21-6345 days) post transplant. In multivariate analysis, R+ CMV serostatus (odds ratio [OR] 0.1 [0.0-0.4], P < 0.001) and diagnosis >6 months post transplant (OR 0.3 [0.1-0.9], P = 0.03) were each independently associated with absence of CMV viremia at time of diagnosis. In the subset of patients (n = 29) in whom both histopathology and viral culture were performed on biopsy specimens, 11 (39%) had CMV detected only by culture and had similar clinical characteristics and outcomes to those with positive histopathology (P > 0.05 for all comparisons). ConclusionsThe sensitivity of viremia in SOT recipients with GI CMV disease is significantly lower in CMV-seropositive patients and in those >6 months post transplant. Addition of viral culture to endoscopic biopsy specimens significantly increases the diagnostic yield for GI CMV disease. C1 [Fisher, C. E.; Rakita, R. M.; Boeckh, M.; Limaye, A. P.] Univ Washington, Dept Med, Div Allergy, Seattle, WA USA. [Fisher, C. E.; Rakita, R. M.; Boeckh, M.; Limaye, A. P.] Univ Washington, Dept Med, Div Infect Dis, Seattle, WA USA. [Fisher, C. E.; Boeckh, M.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA. [Alexander, J.; Bhattacharya, R.] Univ Washington, Dept Med, Gastroenterol, Seattle, WA USA. [Kirby, K. A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Kirby, K. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Limaye, AP (reprint author), Univ Washington, Box 356174,1959 NE Pacific St, Seattle, WA 98195 USA. EM limaye@u.washington.edu FU National Institutes of Health [5 UO1 HL102547, AI NO1 272201100041C-0-0-1, K24 HL093294] FX This work was supported in part by National Institutes of Health grants 5 UO1 HL102547 and AI NO1 272201100041C-0-0-1 to A.P.L., and K24 HL093294 to M.B. NR 15 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2016 VL 18 IS 3 BP 372 EP 380 DI 10.1111/tid.12531 PG 9 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA DP8AX UT WOS:000378721400007 PM 27004439 ER PT J AU Baksh, SN Gellad, WF Alexander, GC AF Baksh, Sheriza N. Gellad, Walid F. Alexander, G. Caleb TI Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients. SO ZEITSCHRIFT FUR SEXUALFORSCHUNG LA German DT Editorial Material DE Flibanserin; sexual dysfunction in women; sexual health ID SEXUAL DESIRE DISORDER; PREMENOPAUSAL WOMEN EFFICACY AB In August 2015, the US Food and Drug Administration (FDA) made the controversial decision to approve flibanserin (Addyi (R)) for women experiencing hypoactive sexual desire disorder. A number of factors contributed to disagreements regarding the FDA's decision, including the product's two prior failed FDA reviews, the unmet need of women with this disorder, extensive advocacy and politicization surrounding the product's relevance to women and sexual health, the potential for widespread off-label use, and the product's tenuous risk/benefit profile. Despite that, attention now shifts to maximizing the safe use of the product, including the optimal means to avoid numerous drug-drug interactions as well as the concomitant use of alcohol, both of which potentiate the risks of dizziness, hypotension, and syncope. Although the FDA has implemented a comprehensive Risk Evaluation and Mitigation Strategies program to maximize the product's safe use, patients, clinicians, and regulators must exhibit heightened vigilance early in the product's post-market life. C1 [Baksh, Sheriza N.; Alexander, G. Caleb] Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA. [Baksh, Sheriza N.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Baltimore, MD USA. RP Baksh, SN (reprint author), Johns Hopkins Univ, Ctr Drug Safety & Effectiveness, Baltimore, MD 21205 USA. NR 22 TC 0 Z9 0 U1 4 U2 4 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0932-8114 EI 1438-9460 J9 Z SEXUALFORSCH JI Z. Sex.forsch. PD JUN PY 2016 VL 29 IS 2 BP 176 EP + DI 10.1055/s-0042-108602 PG 13 WC Psychology, Clinical; Social Sciences, Interdisciplinary SC Psychology; Social Sciences - Other Topics GA DP5HV UT WOS:000378527800008 ER PT J AU Osier, ND Dixon, CE AF Osier, Nicole D. Dixon, C. Edward TI Catecholaminergic based therapies for functional recovery after TBI SO BRAIN RESEARCH LA English DT Review DE Traumatic brain injury; Catecholamine; Dopamine; Epinephrine; Norepinephrine; Therapy ID TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; RANDOMIZED CONTROLLED-TRIAL; NUCLEUS-ACCUMBENS DOPAMINE; CONDITIONED FEAR RESPONSE; WATER MAZE PERFORMANCE; N-METHYL TRANSFERASE; CLOSED-HEAD-INJURY; METHYLPHENIDATE TREATMENT AB Among the many pathophysiologic consequences of traumatic brain injury are changes in catecholamines, including dopamine, epinephrine, and norepinephrine. In the context of TBI, dopamine is the one most extensively studied, though some research exploring epinephrine and norepinephrine have also been published. The purpose of this review is to summarize the evidence surrounding use of drugs that target the catecholaminergic system on pathophysiological and functional outcomes of TBI using published evidence from pre-clinical and clinical brain injury studies. Evidence of the effects of specific drugs that target catecholamines as agonists or antagonists will be discussed. Taken together, available evidence suggests that therapies targeting the catecholaminergic system may attenuate functional deficits after TBI. Notably, it is fairly common for TBI patients to be treated with catecholamine agonists for either physiological symptoms of TBI (e.g. altered cerebral perfusion pressures) or a co-occuring condition (e.g. shock), or cognitive symptoms (e.g. attentional and arousal deficits). Previous clinical trials are limited by methodological limitations, failure to replicate findings, challenges translating therapies to clinical practice, the complexity or lack of specificity of catecholamine receptors, as well as potentially counfounding effects of personal and genetic factors. Overall, there is a need for additional research evidence, along with a need for systematic dissemination of important study details and results as outlined in the common data elements published by the National Institute of Neurological Diseases and Stroke. Ultimately, a better understanding of catecholamines in the context of TBI may lead to therapeutic advancements. This article is part of a Special Issue entitled SI:Brain injury and recovery. Published by Elsevier B.V. C1 [Osier, Nicole D.; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA. [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] VA Pittsburgh Healthcare, Pittsburgh, PA 15240 USA. [Osier, Nicole D.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA. RP Dixon, CE (reprint author), Univ Pittsburgh, Dept Neurol Surg, 201 Hill Bldg,3434 Fifth Ave, Pittsburgh, PA 15260 USA. EM dixonec@upmc.edu FU VA RRD [B1127-1, F31NR014957, T32NR009759]; Pittsburgh Foundation; Sigma Theta Tau International Eta Chapter; International Society for Nurses in Genetics; American Association of Neuroscience Nursing/Neuroscience Nursing Foundation; [R01NS079061]; [R01NS091062] FX This work was generously supported by several Grants, including: R01NS079061, R01NS091062, VA RR&D #B1127-1, F31NR014957 and T32NR009759. Additional support for this work was provided by Grants from the following foundations and professional societies: The Pittsburgh Foundation, Sigma Theta Tau International Eta Chapter, The International Society for Nurses in Genetics, and The American Association of Neuroscience Nursing/Neuroscience Nursing Foundation. The authors would like to thank Marilyn K. Farmer and Amanda Savarese for their continued editorial support and Michael D. Farmer for generously volunteering his time and talents to make the figures. NR 206 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD JUN 1 PY 2016 VL 1640 SI SI BP 15 EP 35 DI 10.1016/j.brainres.2015.12.026 PN A PG 21 WC Neurosciences SC Neurosciences & Neurology GA DP4DY UT WOS:000378447600003 PM 26711850 ER PT J AU ter Maaten, JM Valente, MAE Damman, K Cleland, JG Givertz, MM Metra, M O'Connor, CM Teerlink, JR Ponikowski, P Bloomfield, DM Cotter, G Davison, B Subacius, H van Veldhuisen, DJ van der Meer, P Hillege, HL Gheorghiade, M Voors, AA AF ter Maaten, Jozine M. Valente, Mattia A. E. Damman, Kevin Cleland, John G. Givertz, Michael M. Metra, Marco O'Connor, Christopher M. Teerlink, John R. Ponikowski, Piotr Bloomfield, Daniel M. Cotter, Gadi Davison, Beth Subacius, Haris van Veldhuisen, Dirk J. van der Meer, Peter Hillege, Hans L. Gheorghiade, Mihai Voors, Adriaan A. TI Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE diuretics; heart failure; hemoglobin; hospitalization ID ACUTE MYOCARDIAL-INFARCTION; RENAL-FUNCTION; POSTDISCHARGE OUTCOMES; AN ANALYSIS; DIAGNOSIS; DECONGESTION; ROLOFYLLINE; GUIDELINES; ANTAGONIST; PNEUMONIA AB Background-Both diuretic response and hemoconcentration are indicators of decongestion and have individually been found to predict rehospitalization after admission for acute heart failure (HF). This study examines the value of combining diuretic response and hemoconcentration to better predict patients at low risk for rehospitalization after admission for acute HF. Methods and Results-Diuretic response (defined as weight change per 40 mg of furosemide on day 4 after admission) and hemoconcentration (change in hemoglobin at discharge or day 7) were tested both individually and combined to predict the risk of HF and cardiovascular rehospitalization 60 days after hospitalization for acute HF. Analyses were performed in 1180 patients enrolled in the Placebo-Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial and validated in 1776 patients enrolled in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial. Poor diuretic response was associated with low systolic blood pressure, high blood urea nitrogen, and history of coronary revascularization in both data sets (all P<0.05). Hemoconcentration was mainly associated with better renal function (P<0.05). Patients who displayed both favorable diuretic response and hemoconcentration had a markedly lower risk of rehospitalization for HF in PROTECT (multivariable HR, 0.41; 95% CI, 0.24 to 0.70; P<0.001) compared with all other patients. This finding was confirmed in EVEREST (multivariable HR, 0.52; 95% CI, 0.33 to 0.82; P=0.004) for patients with favorable diuretic response and hemoconcentration compared with all other patients. Conclusions-Combining 2 indicators of decongestion, hemoconcentration and diuretic response improves risk prediction for early rehospitalization after an admission for acute HF and may provide clinicians with an easily accessible tool to identify low-risk patients. C1 [ter Maaten, Jozine M.; Valente, Mattia A. E.; Damman, Kevin; van Veldhuisen, Dirk J.; van der Meer, Peter; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 AB Groningen, Netherlands. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Metra, Marco] Univ Brescia, I-25121 Brescia, Italy. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Cotter, Gadi; Davison, Beth] Momentum Res, Durham, NC USA. [Subacius, Haris; Gheorghiade, Mihai] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Subacius, Haris; Gheorghiade, Mihai] Northwestern Univ, Ctr Cardiovasc Innovat, Feinberg Sch Med, Chicago, IL 60611 USA. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064 FU Otsuka, Inc, Rockville, MD FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Financial and material support for the EVEREST trial was provided by Otsuka, Inc, Rockville, MD. NR 17 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JUN PY 2016 VL 9 IS 6 AR e002845 DI 10.1161/CIRCHEARTFAILURE.115.002845 PG 19 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DO9WP UT WOS:000378139000006 ER PT J AU Meah, FA DiMeglio, LA Greenbaum, CJ Blum, JS Sosenko, JM Pugliese, A Geyer, S Xu, P Evans-Molina, C AF Meah, Farah A. DiMeglio, Linda A. Greenbaum, Carla J. Blum, Janice S. Sosenko, Jay M. Pugliese, Alberto Geyer, Susan Xu, Ping Evans-Molina, Carmella CA Type 1 Diabet TrialNet Study Grp TI The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants SO DIABETOLOGIA LA English DT Article DE Accelerator hypothesis; BMI; Diabetes in childhood; HOMA1-IR; Insulin sensitivity and resistance; Pancreatic autoantibodies; Pathway to Prevention; Prediction and prevention of type 1 diabetes; TrialNet; Type 1 diabetes ID 1 RISK SCORE; BETA-CELL FUNCTION; ACCELERATOR HYPOTHESIS; NATURAL-HISTORY; UNITED-STATES; INCIDENCE TRENDS; TOLERANCE-TEST; WEIGHT-GAIN; BODY-MASS; AUTOIMMUNITY AB Aims/hypothesis The incidence of type 1 diabetes is increasing at a rate of 3-5% per year. Genetics cannot fully account for this trend, suggesting an influence of environmental factors. The accelerator hypothesis proposes an effect of metabolic factors on type 1 diabetes risk. To test this in the TrialNet Pathway to Prevention (PTP) cohort, we analysed the influence of BMI, weight status and insulin resistance on progression from single to multiple islet autoantibodies (Aab) and progression from normoglycaemia to diabetes. Methods HOMA1-IR was used to estimate insulin resistance in Aab-positive PTP participants. Cox proportional hazards models were used to evaluate the effects of BMI, BMI percentile (BMI%), weight status and HOMA1-IR on the progression of autoimmunity or the development of diabetes. Results Data from 1,310 single and 1,897 multiple Aab-positive PTP participants were included. We found no significant relationships between BMI, BMI%, weight status or HOMA1-IR and the progression from one to multiple Aabs. Similarly, among all Aab-positive participants, no significant relationships were found between BMI, weight status or HOMA1-IR and progression to diabetes. Diabetes risk was modestly increased with increasing BMI% among the entire cohort, in obese participants 13-20 years of age and with increasing HOMA1-IR in adult Aab-positive participants. Conclusions/interpretation Analysis of the accelerator hypothesis in the TrialNet PTP cohort does not suggest a broad influence of metabolic variables on diabetes risk. Efforts to identify other potentially modifiable environmental factors should continue. C1 [Meah, Farah A.; Evans-Molina, Carmella] Indiana Univ Sch Med, Dept Med, 635 Barnhill Dr,MS 2031A, Indianapolis, IN 46202 USA. [Meah, Farah A.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Endocrinol, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. [DiMeglio, Linda A.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA. [DiMeglio, Linda A.; Evans-Molina, Carmella] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA. [Greenbaum, Carla J.] Benaroya Res Inst, Diabet Program, Seattle, WA USA. [Blum, Janice S.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA. [Sosenko, Jay M.] Univ Miami, Leonard Miller Sch Med, Diabet Res Inst, Miami, FL USA. [Sosenko, Jay M.; Pugliese, Alberto] Univ Miami, Dept Med, Div Diabet Endocrinol & Metab, Leonard Miller Sch Med, Miami, FL USA. [Pugliese, Alberto] Univ Miami, Leonard Miller Sch Med, Dept Microbiol & Immunol, Miami, FL USA. [Geyer, Susan; Xu, Ping] Univ S Florida, Hlth Informat Inst, Tampa, FL USA. RP Evans-Molina, C (reprint author), Indiana Univ Sch Med, Dept Med, 635 Barnhill Dr,MS 2031A, Indianapolis, IN 46202 USA.; Evans-Molina, C (reprint author), Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA. EM cevansmo@iu.edu FU National Institutes of Health (NIH) through National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266]; Juvenile Diabetes Research Foundation International (JDRF); NIH grants [R01 DK093954, UC4 DK 104166]; VA Merit Award [I01BX001733]; JDRF grant [SRA-2014-41] FX The sponsor of the trial was the Type 1 Diabetes TrialNet Pathway to Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266 and the Juvenile Diabetes Research Foundation International (JDRF). This work was also partially supported by NIH grants R01 DK093954 and UC4 DK 104166 (to CEM), VA Merit Award I01BX001733 (to CEM) and JDRF grant SRA-2014-41 (to CEM, LAD and JSB). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, the US Department of Veterans Affairs or the United States Government, the JDRF or American Diabetes Association. NR 50 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JUN PY 2016 VL 59 IS 6 BP 1186 EP 1195 DI 10.1007/s00125-016-3924-5 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO8QN UT WOS:000378048500016 PM 26995649 ER PT J AU Jenkinson, CP Goring, HHH Arya, R Blangero, J Duggirala, R DeFronzo, RA AF Jenkinson, Christopher P. Goring, Harald H. H. Arya, Rector Blangero, John Duggirala, Ravindranath DeFronzo, Ralph A. TI Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype SO GENOMICS DATA LA English DT Article DE Type 2 diabetes; Insulin resistance; Obesity; Gene expression; Mexican Americans; VAGES; ADH1B; Transcriptomics; GWAS; eQTL ID GENOME-WIDE ASSOCIATION; HUMAN SKELETAL-MUSCLE; LONG NONCODING RNAS; BETA-CELL FUNCTION; IN-VIVO; MITOCHONDRIAL-FUNCTION; INSULIN-RESISTANCE; FASTING GLUCOSE; RARE VARIANTS; GENETIC ARCHITECTURE AB Type 2 diabetes (T2D) is a common, multifactorial disease that is influenced by genetic and environmental factors and their interactions. However, common variants identified by genome wide association studies (GWAS) explain only about 10% of the total trait variance for T2D and less than 5% of the variance for obesity, indicating that a large proportion of heritability is still unexplained. The transcriptomic approach described here uses quantitative gene expression and disease-related physiological data (deep phenotyping) to measure the direct correlation between the expression of specific genes and physiological traits. Transcriptomic analysis bridges the gulf between GWAS and physiological studies. Recent GWAS studies have utilized very large population samples, numbering in the tens of thousands (or even hundreds of thousands) of individuals, yet establishing causal functional relationships between strongly associated genetic variants and disease remains elusive. In light of the findings described below, it is appropriate to consider how and why transcriptomic approaches in small samples might be capable of identifying complex disease-related genes which are not apparent using GWAS in large samples. (C) 2015 Published by Elsevier Inc. C1 [Jenkinson, Christopher P.; Goring, Harald H. H.; Arya, Rector; Blangero, John; Duggirala, Ravindranath] UTRGV, STDOI, Edinburg, TX USA. [DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Diabet, San Antonio, TX USA. [DeFronzo, Ralph A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Jenkinson, CP (reprint author), UTRGV, STDOI, ERAHC, 1214 W Schunior, Edinburg, TX 78541 USA. EM christopher.jenkinson@utrgv.edu NR 76 TC 0 Z9 0 U1 3 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-5960 J9 GENOM DATA JI Genom. Data PD JUN PY 2016 VL 8 BP 25 EP 36 DI 10.1016/j.gdata.2015.12.001 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA DO4OF UT WOS:000377761900006 PM 27114903 ER PT J AU Generoso, JR Latoures, RE Acar, Y Miller, DS Ciano, M Sandrei, R Vieira, M Luong, S Hirsch, J Fidler, RL AF Generoso, Jose Roberto, Jr. Latoures, Renee Elizabeth Acar, Yahya Miller, Dean Scott Ciano, Mark Sandrei, Renan Vieira, Marlon Luong, Sean Hirsch, Jan Fidler, Richard Lee TI Simulation Training in Early Emergency Response (STEER) SO JOURNAL OF CONTINUING EDUCATION IN NURSING LA English DT Article ID HOSPITAL CARDIAC-ARREST; INDUCED RESPIRATORY DEPRESSION; UNITED-STATES; OLDER-ADULTS; CARDIOPULMONARY-RESUSCITATION; DELIBERATE PRACTICE; 1ST 5; FALLS; TEAM; PERFORMANCE AB Little has been published about nurses' responses in the first 5 minutes of in-hospital emergencies. This study aimed to test a simulation curriculum based on institutional priorities using high-intensity, short-duration, frequent in situ content delivery based on deliberate practice. The study design was a prospective, single-center, mixed-methods quasi-experimental study. Scenarios used in this study were ventricular fibrillation, opiate-related respiratory depression, syncopal fall, and hemorrhagic stroke. The convenience sample included 41 teams (147 participants). Improvements were noted in initiating chest compressions (p = .018), time to check blood glucose (p = .046), and identification of heparin as a contributor to stroke (p = .043). Establishing in situ simulation-based teaching program is feasible and well received. This approach appears effective in increasing confidence, initiating life-saving measures, and empowering nurses to manage emergencies. Future studies should evaluate and improve on the curriculum, on data collection tools quantitatively, and on overcoming barriers to high-quality emergency care. C1 [Generoso, Jose Roberto, Jr.; Latoures, Renee Elizabeth; Acar, Yahya; Sandrei, Renan; Vieira, Marlon] Univ Calif San Francisco, 94150 Clement St, San Francisco, CA 94121 USA. [Hirsch, Jan] Univ Calif San Francisco, Anesthesia, San Francisco, CA 94121 USA. [Hirsch, Jan; Fidler, Richard Lee] San Francisco VA Med Ctr, Simulat Fellowship, San Francisco, CA USA. [Fidler, Richard Lee] Univ Calif San Francisco, Nursing, San Francisco, CA 94121 USA. [Miller, Dean Scott; Ciano, Mark; Luong, Sean] San Francisco VA Med Ctr, San Francisco, CA USA. [Luong, Sean] San Francisco VA Med Ctr, Adv Clin Simulat & Nurse Educ Informat, San Francisco, CA USA. RP Generoso, JR (reprint author), Univ Calif San Francisco, 94150 Clement St, San Francisco, CA 94121 USA. EM josegeneroso@va.gov NR 28 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0022-0124 EI 1938-2472 J9 J CONTIN EDUC NURS JI J. Contin. Educ. Nursing PD JUN PY 2016 VL 47 IS 6 BP 255 EP 265 DI 10.3928/00220124-20160518-06 PG 11 WC Nursing SC Nursing GA DP1FR UT WOS:000378236400006 PM 27232223 ER PT J AU Katiyar, SK AF Katiyar, Santosh K. TI Dietary proanthocyanidins inhibit UV radiation-induced skin tumor development through functional activation of the immune system SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Review DE Cyclobutane pyrimidine dimers; Dendritic cells; Skin cancer; T cells; Ultraviolet radiation ID ULTRAVIOLET-INDUCED CARCINOGENESIS; PRESENTING CELL-FUNCTION; DNA EXCISION-REPAIR; GRAPE SEED EXTRACT; CD8(+) T-CELLS; CONTACT HYPERSENSITIVITY; DENDRITIC CELLS; XERODERMA-PIGMENTOSUM; TRANSPLANT RECIPIENTS; MOLECULAR-MECHANISMS AB The incidence of skin cancer is equivalent to the incidence of malignancies in all other organs combined. The main risk factor for this disease is overexposure of the skin to solar ultraviolet (UV) radiation. UV irradiation induces inflammation, oxidative stress, DNA damage, and suppression of the immune system in the skin, which together contribute to carcinogenesis. The use of dietary phytochemicals shows great promise as a complementary and alternative strategy for skin cancer prevention. Grape seed proanthocyanidins (GSPs) have been tested extensively for their anti-skin cancer effect using in vivo animal models. Supplementation of an AIN76A control diet with GSPs (0.2 and 0.5%, w/w) significantly inhibits UV radiation-induced skin tumor development as well as malignant transformation of papillomas to carcinoma in mice. The inhibition of UVB-induced skin tumor development by GSPs is mediated through interrelated mechanisms of action including: (i) inhibition of inflammation, (ii) rapid repair of damaged DNA, and (iii) stimulation of immune system. Additionally, the chemopreventive effects of GSPs involve DNA repair-dependent functional activation of antigen-presenting cells and stimulation of CD8(+) effector T cells. These effects of GSPs could be useful in attenuation of the adverse effects of UV radiation and may have health benefits in humans. C1 [Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. EM skatiyar@uab.edu FU National Cancer Institute/NIH [CA104428]; Veterans Administration Merit Review Award [1I01BX001410] FX The work reported from Dr. Katiyar's research laboratory was financially supported from the funds from National Cancer Institute/NIH (CA104428) and Veterans Administration Merit Review Award (1I01BX001410). Grateful thanks are due to our former and current research staff members for their outstanding contribution in the related studies. The content of this publication does not necessarily reflect the views or policies of the funding sources. NR 70 TC 1 Z9 1 U1 6 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1613-4125 EI 1613-4133 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD JUN PY 2016 VL 60 IS 6 SI SI BP 1374 EP 1382 DI 10.1002/mnfr.201501026 PG 9 WC Food Science & Technology SC Food Science & Technology GA DP5GE UT WOS:000378523500013 PM 26991736 ER PT J AU Seeganna, C Antai-Otong, D AF Seeganna, Carolyn Antai-Otong, Deborah TI Managing the Care of the Older Patient with Delirium and Dementia SO NURSING CLINICS OF NORTH AMERICA LA English DT Article DE Geriatric psychiatric emergencies; Delirium; Dementia; Cognitive disorders ID PREVALENCE; MANAGEMENT; PROGNOSIS; SUBTYPES; PROPHYLAXIS; PEOPLE; RISK AB As the population ages, nurses in various clinical settings must identify high-risk groups that are vulnerable to delirium and dementia. They also must be able to provide psychosocial and pharmacologic interventions that promote comfort and safety for patients and their families experiencing these distressful medical conditions. Efforts to facilitate health resolution and restore the patient and caregivers to an optimal level of functioning must be priorities. C1 [Seeganna, Carolyn] US Dept Vet Affairs, Mat Su Community Based Outpatient Clin, 865 North Seward Meridian Pkwy, Wasilla, AK 99654 USA. [Antai-Otong, Deborah] Vet Integrated Serv Networks VISN 17, Dept Vet Affairs, 2301 E Lamar Blvd, Arlington, TX 76006 USA. RP Seeganna, C (reprint author), US Dept Vet Affairs, Mat Su Community Based Outpatient Clin, 865 North Seward Meridian Pkwy, Wasilla, AK 99654 USA. EM Carolyn.Seeganna@va.gov NR 51 TC 0 Z9 0 U1 6 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0029-6465 EI 1558-1357 J9 NURS CLIN N AM JI Nurs. Clin. North Am. PD JUN PY 2016 VL 51 IS 2 BP 261 EP + DI 10.1016/j.cnur.2016.01.009 PG 14 WC Nursing SC Nursing GA DP3BM UT WOS:000378367400011 PM 27229280 ER PT J AU Clark, TJT Pokharel, S Meier, J Wang, C Maximin, S AF Clark, Toshimasa J. T. Pokharel, Sajal Meier, Jeffrey Wang, Carolyn Maximin, Suresh TI Thyroid Nodule Doubling Time is Not a Reliable Indicator of Benign or Malignant Nature SO ULTRASOUND QUARTERLY LA English DT Article DE thyroid nodules; doubling time; papillary thyroid carcinoma ID INTEROBSERVER VARIATION; TUMOR-GROWTH; ULTRASOUND; HISTORY; US AB Thyroid nodules are often followed up with serial ultrasound imaging. Doubling time is well established in the evaluation of lung nodules. We examined whether benign and malignant thyroid nodules exhibit differences in doubling time. This retrospective, IRB-approved study included patients with nodules aspirated between January and June 2012 (benign), and January 2012 to December 2014 (suspicious or malignant), no interval thyroidectomy, and two ultrasound examinations longer than 180 days apart. Diameters and morphology were assessed by a single observer, demographics recorded, and doubling time calculated. Area under the receiver operating characteristic curve was derived. Society of Radiologists in Ultrasound criteria were used to determine aspiration appropriateness initially and after follow-up. 59 patients with 61 nodules were included. Statistically significant between-group differences exist for sex, solidity, echogenicity, and microcalcifications, with no significant differences in doubling time, age, days between studies, vascularity, or mean diameter. Benign nodules' doubling time was 340 to 7134 days (mean, 2196; median, 1593), with 9 nodules that decreased in size. Malignant nodules' doubling time was 451 to 17182 days (mean, 3940; median, 2137), with 7 nodules that decreased in size. Using a threshold of 1100 days, sensitivity and specificity of doubling time to predict malignancy are 19.0% and 86.7%, respectively. Area under the receiver operating characteristic curve is 0.39. Follow-up imaging resulted in 6 additional benign and 0 additional malignant nodules meeting criteria. There is no significant difference in benign or malignant nodules' doubling times, and a decrease in nodule size is nonspecific. These findings challenge the underlying rationale for routine imaging follow-up of thyroid nodules. C1 [Clark, Toshimasa J. T.; Pokharel, Sajal; Meier, Jeffrey] Univ Colorado Denver, Dept Radiol, Abdominal Imaging Sect, 12401 E 17th Ave,Mail Stop L-954, Aurora, CO 80045 USA. [Wang, Carolyn; Maximin, Suresh] Univ Washington, Dept Radiol, Body Imaging Sect, Seattle, WA 98195 USA. [Maximin, Suresh] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Clark, TJT (reprint author), Univ Colorado Denver, 12401 E 17th Ave,Mail Stop L-954, Aurora, CO 80045 USA. EM toshimasa.clark@ucdenver.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-8771 EI 1536-0253 J9 ULTRASOUND Q JI Ultrasound Q. PD JUN PY 2016 VL 32 IS 2 BP 132 EP 135 DI 10.1097/RUQ.0000000000000190 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DP3RR UT WOS:000378413100006 PM 26441381 ER PT J AU Chidi, AP Bryce, CL Donohue, JM Fine, MJ Landsittel, DP Myaskovsky, L Rogal, SS Switzer, GE Tsung, A Smith, KJ AF Chidi, Alexis P. Bryce, Cindy L. Donohue, Julie M. Fine, Michael J. Landsittel, Douglas P. Myaskovsky, Larissa Rogal, Shari S. Switzer, Galen E. Tsung, Allan Smith, Kenneth J. TI Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients SO VALUE IN HEALTH LA English DT Article DE cost-effectiveness; hepatitis C; interferon-free; Medicaid; Medicare ID INTERFERON-FREE REGIMENS; ADVANCED LIVER-DISEASE; GENOTYPE 1 INFECTION; ALL-CAUSE MORTALITY; UNITED-STATES; VIRUS-INFECTION; COST-EFFECTIVENESS; COMPENSATED CIRRHOSIS; ANTIVIRAL THERAPY; TREATMENT-NAIVE AB Background: Interferon-free hepatitis C treatment regimens are effective but very costly. The cost-effectiveness, budget, and public health impacts of current Medicaid treatment policies restricting treatment to patients with advanced disease remain unknown. Objectives: To evaluate the cost-effectiveness of current Medicaid policies restricting hepatitis C treatment to patients with advanced disease compared with a strategy providing unrestricted access to hepatitis C treatment, assess the budget and public health impact of each strategy, and estimate the feasibility and long-term effects of increased access to treatment for patients with hepatitis C. Methods: Using a Markov model, we compared two strategies for 45- to 55-year-old Medicaid beneficiaries: 1) Current Practice only advanced disease is treated before Medicare eligibility and 2) Full Access both early-stage and advanced disease are treated before Medicare eligibility. Patients could develop progressive fibrosis, cirrhosis, or hepatocellular carcinoma, undergo transplantation, or die each year. Morbidity was reduced after successful treatment. We calculated the incremental cost-effectiveness ratio and compared the costs and public health effects of each strategy from the perspective of Medicare alone as well as the Centers for Medicare & Medicaid Services perspective. We varied model inputs in one-way and probabilistic sensitivity analyses. Results: Full Access was less costly and more effective than Current Practice for all cohorts and perspectives, with differences in cost ranging from $5,369 to $11,960 and in effectiveness from 0.82 to 3.01 quality-adjusted life-years. In a probabilistic sensitivity analysis, Full Access was cost saving in 93% of model iterations. Compared with Current Practice, Full Access averted 5,994 hepatocellular carcinoma cases and 121 liver transplants per 100,000 patients. Conclusions: Current Medicaid policies restricting hepatitis C treatment to patients with advanced disease are more costly and less effective than unrestricted, full-access strategies. Collaboration between state and federal payers may be needed to realize the full public health impact of recent innovations in hepatitis C treatment. C1 [Chidi, Alexis P.; Fine, Michael J.; Landsittel, Douglas P.; Myaskovsky, Larissa; Rogal, Shari S.; Switzer, Galen E.; Tsung, Allan; Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Chidi, Alexis P.; Fine, Michael J.; Myaskovsky, Larissa; Rogal, Shari S.; Switzer, Galen E.; Tsung, Allan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bryce, Cindy L.; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Chidi, AP (reprint author), 3471 Fifth Ave,Suite 300, Pittsburgh, PA 15213 USA. EM apc10@pitt.edu FU Gilead Sciences FX S. Rogal receives research funding for unrelated projects from Gilead Sciences. The rest of the authors report no potential conflicts of interest. NR 79 TC 1 Z9 1 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD JUN PY 2016 VL 19 IS 4 BP 326 EP 334 DI 10.1016/j.jval.2016.01.010 PG 9 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DO9GU UT WOS:000378094200006 PM 27325324 ER PT J AU Weppner, WG Davis, K Sordahl, J Willis, J Fisher, A Brotman, A Tivis, R Gordon, T Smith, CS AF Weppner, William G. Davis, Kyle Sordahl, Jeffrey Willis, Janet Fisher, Amber Brotman, Adam Tivis, Rick Gordon, Tim Smith, C. Scott TI Interprofessional Care Conferences for High-Risk Primary Care Patients SO ACADEMIC MEDICINE LA English DT Article ID EDUCATION AB Problem As health care systems convert to team-based care, the need to improve interprofessional education is tremendous. In addition to formal instruction, trainees need authentic team-based workplace learning experiences. Approach The authors designed the PACTICU (Patient-Aligned Care Team Interprofessional Care Update) conference to provide team-based care to high-risk patients while teaching trainees principles of interprofessionalism and modeling relevant behaviors. Trainees, supervisors, and affiliated support staff from the fields of internal medicine, nurse practitioner, pharmacy, psychology, and nursing all participate in this conference. During the conference, each participant focuses on the narrative of the patient's illness from his/ her own professional perspective. A multifaceted care plan with specific action items is the product of the conference. To evaluate this workplace learning opportunity, the authors recorded patient characteristics, plus trainees' participation and satisfaction. Outcomes Over the first 16 months (2013-2014) of the PACT-ICU, 33 trainees presented 79 patients. Each trainee presented two or three times each academic year. Patients were 90% male; their mean age was 64.5 years (SD 9.3, range 28-92), and their mean calculated 90-day risk of death or hospitalization was 22% (SD 14%, range 1%-45%). Overall, all surveyed trainees (n = 32; 97% response rate) expressed satisfaction, reporting that the conference was "helpful" or "very helpful" in developing treatment plans. Next Steps Further assessment of change in trainee behavior related to interprofessional team care, patient-level outcomes (e.g., quality of care and utilization), and factors facilitating dissemination of the model to other academic clinic settings is necessary. C1 [Weppner, William G.; Willis, Janet; Fisher, Amber; Brotman, Adam; Tivis, Rick; Gordon, Tim] Boise VA Ctr Excellence Primary Care Educ, Boise, ID USA. [Weppner, William G.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Davis, Kyle] St Lukes Mt States Tumor Inst, Boise, ID USA. [Sordahl, Jeffrey] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Smith, C. Scott] VA Ctr Excellence Primary Care Educ, Seattle, WA USA. [Smith, C. Scott] Univ Washington, Div Gen Internal Med & Med Educ, Seattle, WA 98195 USA. RP Weppner, WG (reprint author), Boise VA Med Ctr, Med Serv Off 111, Boise, ID 83702 USA. EM William.weppner@va.gov FU VA Centers of Excellence in Primary Care Education, Office of Academic Affairs FX VA Centers of Excellence in Primary Care Education, Office of Academic Affairs. NR 10 TC 1 Z9 1 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD JUN PY 2016 VL 91 IS 6 BP 798 EP 802 DI 10.1097/ACM.0000000000001151 PG 5 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA DO8OB UT WOS:000378041800020 PM 27008359 ER PT J AU Karp, JF Dew, MA Wahed, AS Fitzgerald, K Bolon, CA Weiner, DK Morse, JQ Albert, S Butters, M Gildengers, A Reynolds, CF AF Karp, Jordan F. Dew, Mary Amanda Wahed, Abdus S. Fitzgerald, Kelley Bolon, Chloe A. Weiner, Debra K. Morse, Jennifer Q. Albert, Steve Butters, Meryl Gildengers, Ariel Reynolds, Charles F., III TI Challenges and Solutions for Depression Prevention Research: Methodology for a Depression Prevention Trial for Older Adults with Knee Arthritis and Emotional Distress SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depression; prevention; pain; anxiety; late life ID LATE-LIFE DEPRESSION; ADAPTIVE TREATMENT STRATEGIES; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; CHRONIC PAIN; MACULAR DEGENERATION; COLLABORATIVE CARE; PHYSICAL-THERAPY; MANUAL THERAPY AB Objective: To describe the methodology, challenges, and baseline characteristics of a prevention development trial entitled" Reducing Pain, Preventing Depression." Methods: A sequential multiple assignment randomized trial (SMART) compared sequences of cognitive behavioral therapy (CBT) and physical therapy for knee pain and prevention of depression and anxiety. Participants were randomized to CBT, physical therapy, or enhanced usual care and followed for 12 months for new-episode depression or anxiety. Participants were age >= 60 with knee osteoarthritis and subsyndromal depression, defined as 9-item Patient Health Questionnaire (PHQ-9) score >= 1 (which included the endorsement of one of the cardinal symptoms of depression How mood or anhedonia]) and no diagnosis of major depressive disorder per the Structured Clinical Interview for DSM-IV. Depression and anxiety severity and characterization of new episodes were assessed with the PHQ-9, Generalized Anxiety Disorder-7, and the PRIME-MD. Knee pain was characterized with the Western Ontario McMaster Arthritis Index. Response was defined as at least "Very Much Better" on a Patient Global Impression of Change. Results: At baseline there were 99 patients with an average age of 71; 61.62% were women and 81.8% white. The average PHQ-9 was 5.6 and average Generalized Anxiety Disorder-7, was 3.2. Most were satisfied with the interventions and study procedures. The challenges and solutions described here will also be used in a confirmatory clinical trial of efficacy. Conclusion: A SMART design for depression and anxiety prevention, using both CBT and physical therapy, appears to be feasible and acceptable to participants. The methodologic innovations of this project may advance the field of late-life depression and anxiety prevention. C1 [Karp, Jordan F.; Dew, Mary Amanda; Bolon, Chloe A.; Weiner, Debra K.; Butters, Meryl; Gildengers, Ariel; Reynolds, Charles F., III] Univ Pittsburgh, Dept Psychiat, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. [Karp, Jordan F.; Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. [Fitzgerald, Kelley] Univ Pittsburgh, Dept Phys Therapy, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. [Dew, Mary Amanda; Albert, Steve] Univ Pittsburgh, Sch Publ Hlth, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. [Wahed, Abdus S.] Univ Pittsburgh, Dept Biostat, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. [Karp, Jordan F.; Weiner, Debra K.] Geriatr Res Educ & Clin Ctr, Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Morse, Jennifer Q.] Chatham Univ, Dept Psychol, Pittsburgh, PA USA. RP Reynolds, CF (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Sch Med, 758 Bellefield Towers,3811 OHara St, Pittsburgh, PA 15213 USA. EM reynoldscf@upmc.edu OI Wahed, Abdus/0000-0001-6911-7221; Albert, Steven/0000-0001-6786-9956 FU National Institutes of Health [P30 MH090333, AG033575, UL1RR024153, UL1TR000005] FX This study was funded by National Institutes of Health grants P30 MH090333, AG033575, UL1RR024153, and UL1TR000005. NR 33 TC 1 Z9 1 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD JUN PY 2016 VL 24 IS 6 BP 433 EP 443 DI 10.1016/j.jagp.2015.10.012 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DO6AZ UT WOS:000377865900003 PM 26809601 ER PT J AU Shankar, J Nguyen, MH Crespo, MM Kwak, EJ Lucas, SK McHugh, KJ Mounaud, S Alcorn, JF Pilewski, JM Shigemura, N Kolls, JK Nierman, WC Clancy, CJ AF Shankar, J. Nguyen, M. H. Crespo, M. M. Kwak, E. J. Lucas, S. K. McHugh, K. J. Mounaud, S. Alcorn, J. F. Pilewski, J. M. Shigemura, N. Kolls, J. K. Nierman, W. C. Clancy, C. J. TI Looking Beyond Respiratory Cultures: Microbiome-Cytokine Signatures of Bacterial Pneumonia and Tracheobronchitis in Lung Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID VENTILATOR-ASSOCIATED TRACHEOBRONCHITIS; CARE-ASSOCIATED PNEUMONIA; REGULATORY T-CELLS; ANTIMICROBIAL TREATMENT; BRONCHOALVEOLAR LAVAGE; GENETIC ASSOCIATION; ANTIBIOTIC-THERAPY; TRIAL DESIGN; INFECTIONS; DIVERSITY AB Bacterial pneumonia and tracheobronchitis are diagnosed frequently following lung transplantation. The diseases share clinical signs of inflammation and are often difficult to differentiate based on culture results. Microbiome and host immune-response signatures that distinguish between pneumonia and tracheobronchitis are undefined. Using a retrospective study design, we selected 49 bronchoalveolar lavage fluid samples from 16 lung transplant recipients associated with pneumonia (n = 8), tracheobronchitis (n = 12) or colonization without respiratory infection (n = 29). We ensured an even distribution of Pseudomonas aeruginosa or Staphylococcus aureus culture-positive samples across the groups. Bayesian regression analysis identified non-culture-based signatures comprising 16S ribosomal RNA microbiome profiles, cytokine levels and clinical variables that characterized the three diagnoses. Relative to samples associated with colonization, those from pneumonia had significantly lower microbial diversity, decreased levels of several bacterial genera and prominent multifunctional cytokine responses. In contrast, tracheobronchitis was characterized by high microbial diversity and multifunctional cytokine responses that differed from those of pneumonia colonization comparisons. The dissimilar micro biomes and cytokine responses underlying bacterial pneumonia and tracheobronchitis following lung transplantation suggest that the diseases result from different pathogenic processes. Microbiomes and cytokine responses had complementary features, suggesting that they are closely interconnected in the pathogenesis of both diseases. C1 [Shankar, J.; Lucas, S. K.; Mounaud, S.; Nierman, W. C.] J Craig Venter Inst, Rockville, MD 20850 USA. [Nguyen, M. H.; Kwak, E. J.; Clancy, C. J.] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA. [Crespo, M. M.; Pilewski, J. M.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. [McHugh, K. J.; Alcorn, J. F.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Pediat, Pittsburgh, PA 15213 USA. [Shigemura, N.] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA USA. [Kolls, J. K.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Richard King Mellon Fdn,Inst Pediat Res, Pittsburgh, PA 15213 USA. [Clancy, C. J.] VA Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA USA. RP Shankar, J (reprint author), J Craig Venter Inst, Rockville, MD 20850 USA.; Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA. EM jyoti.shankar@gmail.com; mhn5@pitt.edu FU National Institutes of Health [R21AI107290, R21AI111037, R01HL107380]; Bill and Melinda Gates Foundation [OPP1017579] FX We express our gratitude to the patients and families in the University of Pittsburgh Medical Center (UPMC) Lung Transplantation Program who consented to participate in this project and to the health care providers and coordinators for their excellent patient care and ongoing support of translational research, We thank Ellen Press and Lloyd Clarke of the UPMC Infectious Diseases Division for maintaining our biorepository and providing detailed data on the usage of antimicrobials and other therapeutic agents. We thank Sebastian Szpakowski and Andrey Tovchigrechko for contributing the open source bioinformatics workflow for taxonomic classification of microbiome sequences and the authors of BoomSpikeSlab, ggplot2, scales, tidyr, reshape2, data.table, Hmisc and R Studio and the R Core Development Team for their statistical packages, We thank Karla Stucker for constructive comments that greatly improved our manuscript, We gratefully acknowledge the collaborative platforms from Google Docs, Paperpile, and GitHub. This work was supported in part by awards from the National Institutes of Health (R21AI107290, R21AI111037, R01HL107380) and the Bill and Melinda Gates Foundation (OPP1017579). NR 81 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUN PY 2016 VL 16 IS 6 BP 1766 EP 1778 DI 10.1111/ajt.13676 PG 13 WC Surgery; Transplantation SC Surgery; Transplantation GA DO2EO UT WOS:000377592900016 PM 26693965 ER PT J AU Tran, NT Su, HR Khodadadi-Jamayran, A Lin, S Zhang, L Zhou, DW Pawlik, KM Townes, TM Chen, YB Mulloy, JC Zhao, XY AF Ngoc-Tung Tran Su, Hairui Khodadadi-Jamayran, Alireza Lin, Shan Zhang, Li Zhou, Dewang Pawlik, Kevin M. Townes, Tim M. Chen, Yabing Mulloy, James C. Zhao, Xinyang TI The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation SO EMBO REPORTS LA English DT Article DE antisense RNA; hematopoiesis; RBM15 ID LONG NONCODING RNAS; HEMATOPOIETIC STEM-CELLS; NATURAL ANTISENSE TRANSCRIPT; GENOME-WIDE ANALYSIS; MEGAKARYOBLASTIC LEUKEMIA; ADULT HEMATOPOIESIS; MESSENGER-RNA; C-MYC; GENE; RUNX1 AB Antisense RNAs regulate the transcription and translation of the corresponding sense genes. Here, we report that an antisense RNA, AS-RBM15, is transcribed in the opposite direction within exon 1 of RBM15. RBM15 is a regulator of megakaryocyte (MK) differentiation and is also involved in a chromosome translocation t(1; 22) in acute megakaryocytic leukemia. MK terminal differentiation is enhanced by up-regulation of AS-RBM15 expression and attenuated by AS-RBM15 knockdown. At the molecular level, AS-RBM15 enhances RBM15 protein translation in a CAP-dependent manner. The region of the antisense AS-RBM15 RNA, which overlaps with the 5'UTR of RBM15, is sufficient for the up-regulation of RBM15 protein translation. In addition, we find that transcription of both RBM15 and AS-RBM15 is activated by the transcription factor RUNX1 and repressed by RUNX1-ETO, a leukemic fusion protein. Therefore, AS-RBM15 is a regulator of megakaryocyte differentiation and may play a regulatory role in leukemogenesis. C1 [Ngoc-Tung Tran; Su, Hairui; Khodadadi-Jamayran, Alireza; Zhang, Li; Zhou, Dewang; Pawlik, Kevin M.; Townes, Tim M.; Zhao, Xinyang] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA. [Lin, Shan; Mulloy, James C.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Chen, Yabing] Birmingham Vet Affairs Med Ctr, Res Dept, Birmingham, AL USA. RP Zhao, XY (reprint author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA. EM Zhaox88@uab.edu OI Zhao, Xinyang/0000-0001-6677-7072 FU UAB new investigator start-up fund; NIH [HL092215, DK100847]; VA [BX000369, BX001591] FX We would like to thank Drs. Yinfeng Zhang, Sunnie Thompson, and David Schneider for valuable advice and Dr. Qingbai She at the University of Kentucky for reagents. The project is funded by a UAB new investigator start-up fund (XZ). YC is supported by NIH grants HL092215 and DK100847 and VA grants BX000369 and BX001591. We would like to thank the UAB Comprehensive Flow Cytometry Core as part of RDCC (P30AR048311 and P30AI027767) for technical support. NR 59 TC 2 Z9 2 U1 6 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-221X EI 1469-3178 J9 EMBO REP JI EMBO Rep. PD JUN PY 2016 VL 17 IS 6 BP 887 EP 900 DI 10.15252/embr.201541970 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DO3UM UT WOS:000377707400013 PM 27118388 ER PT J AU Le, KT Sawicki, MP Wang, MB Hershman, JM Leung, AM AF Le, Karen T. Sawicki, Mark P. Wang, Marilene B. Hershman, Jerome M. Leung, Angela M. TI HIGH PREVALENCE OF AGENT ORANGE EXPOSURE AMONG THYROID CANCER PATIENTS IN THE NATIONAL VA HEALTHCARE SYSTEM SO ENDOCRINE PRACTICE LA English DT Article ID KOREAN VIETNAM VETERANS; ARYL-HYDROCARBON RECEPTOR; HORMONE LEVELS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; ASSOCIATION; FORCE; TCDD; RISK AB Objective: Thyroid cancer is the most common endocrine malignancy and the most rapidly increasing cancer in the U.S. Little is known regarding the epidemiology and characteristics of patients with thyroid cancer within the national Veterans Health Administration (VHA) integrated healthcare system. The aim of this study was to further understand the characteristics of thyroid cancer patients in the VHA population, particularly in relation to Agent Orange exposure. Methods: This is a descriptive analysis of the VA (Veterans Affairs) Corporate Data Warehouse database from all U.S. VHA healthcare sites from October1, 1999, to December 31, 2013. Information was extracted for all thyroid cancer patients based on International Classification of Diseases ninth revision diagnosis codes; histologic subtypes of thyroid cancer were not available. Results: There were 19,592 patients (86% men, 76% white, 58% married, 42% Vietnam-era Veteran) in the VHA system with a diagnosis of thyroid cancer within this 14-year study period. The gender-stratified prevalence rates of thyroid cancer among the Veteran population during the study period were 1:1,114 (women) and 1:1,023 (men), which were lower for women but similar for men, when compared to the U.S. general population in 2011 (1:350 for women and 1:1,219 for men). There was a significantly higher proportion of self-reported Agent Orange exposure among thyroid cancer patients (10.0%), compared to the general VHA population (6.2%) (P<.0001). Conclusion: Thyroid cancer patients, in this sample, have a higher prevalence of self-reported Agent Orange exposure compared to the overall national VA patient population. C1 [Le, Karen T.; Hershman, Jerome M.; Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Endocrinol, Los Angeles, CA USA. [Le, Karen T.] Cedars Sinai Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Los Angeles, CA 90048 USA. [Sawicki, Mark P.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Sawicki, Mark P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Wang, Marilene B.] VA Greater Los Angeles Healthcare Syst, Dept Otolaryngol, Los Angeles, CA USA. [Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Hershman, Jerome M.; Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol, Los Angeles, CA 90095 USA. RP Leung, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Div Endocrinol, 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. EM angela.leung@va.gov FU National Institutes of Health [K23HD068552] FX This work was supported in part by National Institutes of Health grant K23HD068552 (to A.M.L.). NR 24 TC 0 Z9 0 U1 4 U2 5 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JUN PY 2016 VL 22 IS 6 BP 699 EP 702 DI 10.4158/EP151108.OR PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7NQ UT WOS:000377969700006 PM 27176142 ER PT J AU So-Armah, KA Tate, JP Chang, CCH Butt, AA Gerschenson, M Gibert, CL Leaf, D Rimland, D Rodriguez-Barradas, MC Budoff, MJ Samet, JH Kuller, LH Deeks, SG Crothers, K Tracy, RP Crane, HM Sajadi, MM Tindle, HA Justice, AC Freiberg, MS AF So-Armah, Kaku A. Tate, Janet P. Chang, Chung-Chou H. Butt, Adeel A. Gerschenson, Mariana Gibert, Cynthia L. Leaf, David Rimland, David Rodriguez-Barradas, Maria C. Budoff, Matthew J. Samet, Jeffrey H. Kuller, Lewis H. Deeks, Steven G. Crothers, Kristina Tracy, Russell P. Crane, Heidi M. Sajadi, Mohammad M. Tindle, Hilary A. Justice, Amy C. Freiberg, Matthew S. CA VACS Project Team TI Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; mortality; inflammation; monocyte activation; coagulation ID VETERANS AGING COHORT; ALL-CAUSE MORTALITY; ANTIRETROVIRAL THERAPY; GENERAL-POPULATION; HEPATITIS-C; RISK; INDEX; ASSOCIATION; DISEASE; ADULTS AB Background: HIV infection and biomarkers of inflammation [measured by interleukin-6 (IL-6)], monocyte activation [soluble CD14 (sCD14)], and coagulation (D-dimer) are associated with morbidity and mortality. We hypothesized that these immunologic processes mediate (explain) some of the excess risk of mortality among HIV infected (HIV+) versus uninfected people independently of comorbid diseases. Methods: Among 2350 (1521 HIV+) participants from the Veterans Aging Cohort Study Biomarker Cohort (VACS BC), we investigated whether the association between HIV and mortality was altered by adjustment for IL-6, sCD14, and D-dimer, accounting for confounders. Participants were followed from date of blood draw for biomarker assays (baseline) until death or July 25, 2013. Analyses included ordered logistic regression and Cox Proportional Hazards regression. Results: During 6.9 years (median), 414 deaths occurred. The proportional odds of being in a higher quartile of IL-6, sCD14, or D-dimer were 2-3 fold higher for viremic HIV+ versus uninfected people. Mortality rates were higher among HIV+ compared with uninfected people [incidence rate ratio (95% CI): 1.31 (1.06 to 1.62)]. Mortality risk increased with increasing quartiles of IL-6, sCD14, and D-dimer regardless of HIV status. Adjustment for IL-6, sCD14, and D-dimer partially attenuated mortality risk among HIV+ people with unsuppressed viremia (HIV-1 RNA >= 10,000 copies per milliliter) compared with uninfected people-hazard ratio (95% CI) decreased from 2.18 (1.60 to 2.99) to 2.00 (1.45 to 2.76). Conclusions: HIV infection is associated with elevated IL-6, sCD14, and D-dimer, which are in turn associated with mortality. Baseline measures of these biomarkers partially mediate excess mortality risk among HIV+ versus uninfected people. milliliter) compared with uninfected people-hazard ratio (95% CI) decreased from 2.18 (1.60 to 2.99) to 2.00 (1.45 to 2.76). Conclusions: HIV infection is associated with elevated IL-6, sCD14, and D-dimer, which are in turn associated with mortality. Baseline measures of these biomarkers partially mediate excess mortality risk among HIV+ versus uninfected people. C1 [So-Armah, Kaku A.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Tate, Janet P.; Justice, Amy C.] VA Connecticut Healthcare Syst, Gen Internal Med Sect, West Haven, CT USA. [Tate, Janet P.; Justice, Amy C.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. [Chang, Chung-Chou H.; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Butt, Adeel A.] Hamad Med Corp, Hamad Healthcare Qual Inst, Doha, Qatar. [Butt, Adeel A.] Weill Cornell Med Coll, Dept Med, Doha, Qatar. [Butt, Adeel A.] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Gerschenson, Mariana] Univ Hawaii Manoa, Cell & Mol Biol Dept, John A Burns Sch Med, Honolulu, HI 96822 USA. [Gibert, Cynthia L.] VA Med Ctr, Med Serv Infect Dis, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Dept Med, Washington, DC 20037 USA. [Leaf, David] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Leaf, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Rimland, David] VA Med Ctr, Med Serv, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Med Serv, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. [Budoff, Matthew J.] Los Angeles Biomed Res Inst, Dept Med, Torrance, CA USA. [Samet, Jeffrey H.] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA. [Samet, Jeffrey H.] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Samet, Jeffrey H.] Boston Med Ctr, Dept Gen Internal Med, Boston, MA USA. [Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Deeks, Steven G.] San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94110 USA. [Crothers, Kristina] Univ Washington, Div Pulm & Crit Care, Dept Internal Med, Seattle, WA 98195 USA. [Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT USA. [Tracy, Russell P.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA. [Crane, Heidi M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Sajadi, Mohammad M.] Baltimore VA Med Ctr, Dept Med, Baltimore, MD USA. [Sajadi, Mohammad M.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. [Tindle, Hilary A.; Freiberg, Matthew S.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Freiberg, Matthew S.] VA Tennessee Valley Healthcare Syst, Geriatr Res Educ & Clin Ctr, Nashville, TN USA. RP So-Armah, KA (reprint author), Boston Univ, Sch Med, 801 Massachusetts Ave, Boston, MA 02118 USA. EM kaku@bu.edu OI Crothers, Kristina/0000-0001-9702-0371 FU National Institute on Alcohol Abuse and Alcoholism; National Heart Lung and Blood Institute at the National Institutes of Health [R01HC095136-04 5R01HC095126-04, R01AI110259-01A1, 1I01BX002358-01A1]; National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566]; Gilead; AbbVie FX Supported by National Institute on Alcohol Abuse and Alcoholism and National Heart Lung and Blood Institute at the National Institutes of Health (Grant Number R01HC095136-04 5R01HC095126-04 to M.F; R01AI110259-01A1 and 1I01BX002358-01A1 to MMS). Veterans Aging Cohort Study funded by: National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566). The authors would also like to acknowledge the substantial in-kind support we receive from the Veterans Affairs Healthcare System. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. And also supported by Gilead and AbbVie (Adeel Butt). NR 25 TC 4 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2016 VL 72 IS 2 BP 206 EP 213 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DO8UI UT WOS:000378059300022 PM 26885807 ER PT J AU Johanning, JM Hall, D Arya, S AF Johanning, Jason M. Hall, Daniel Arya, Shipra TI Frailty and Mortality After Noncardiac Surgery in Elderly Individuals Metrics, Systems, and the Elephant SO JAMA SURGERY LA English DT Editorial Material ID CARE C1 [Johanning, Jason M.] Nebraska Western Iowa VA Med Ctr, Dept Surg, 4101 Woolworth Ave, Omaha, NE 68105 USA. [Hall, Daniel] VA Pittsburgh Healthcare Syst, Dept Surg, Pittsburgh, PA USA. [Arya, Shipra] Emory Univ, Div Vasc Surg & Endovasc Therapy, Surg Res, Atlanta, GA 30322 USA. RP Johanning, JM (reprint author), Nebraska Western Iowa VA Med Ctr, Dept Surg, 4101 Woolworth Ave, Omaha, NE 68105 USA. EM jason.johanning@va.gov OI Hall, Daniel/0000-0001-6382-0522 NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD JUN PY 2016 VL 151 IS 6 BP 545 EP 546 DI 10.1001/jamasurg.2015.5235 PG 3 WC Surgery SC Surgery GA DO6ZT UT WOS:000377932700014 PM 26790639 ER PT J AU VanEpps, EM Downs, JS Loewenstein, G AF VanEpps, Eric M. Downs, Julie S. Loewenstein, George TI Advance Ordering for Healthier Eating? Field Experiments on the Relationship Between the Meal Order-Consumption Time Delay and Meal Content SO JOURNAL OF MARKETING RESEARCH LA English DT Article DE time delay; field experiment; eating ID DECISION-MAKING; CHOICES; FUTURE; FOOD; INCONSISTENCY; PATERNALISM; PREFERENCE; IMMEDIATE; REWARD; STATES AB Encouraging consumers to select meals in advance rather than at mealtime has been proposed as a strategy to promote healthier eating decisions, taking advantage of the improved self-control that is thought to accompany decisions about the future. In two field studies at an employee cafeteria and a third in a university setting, we examine how time delays between placing a lunch order and picking it up affect the healthfulness of that lunch. The first study, a secondary data analysis, finds that longer delays between placing an order and picking up the meal are associated with reductions in calorie content. The second study tests the causality of this relationship by exogenously restricting some lunch orders to be substantially delayed, leading to a marginally significant (approximately 5%) reduction in calories among delayed orders. The third study compares orders for truly immediate consumption versus orders placed in advance and demonstrates a significant (100 calorie, or approximately 10%) reduction in lunch calories. We discuss evidence regarding possible theoretical mechanisms underlying this effect, as well as practical implications of our findings. C1 [VanEpps, Eric M.] Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Downs, Julie S.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Loewenstein, George] Carnegie Mellon Univ, Econ & Psychol, Pittsburgh, PA 15213 USA. RP VanEpps, EM (reprint author), Univ Penn, VA Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. EM vanepps@mail.med.upenn.edu; downs@andrew.cmu.edu; gl20@andrew.cmu.edu NR 51 TC 2 Z9 2 U1 15 U2 25 PU AMER MARKETING ASSOC PI CHICAGO PA 311S WACKER DR, STE 5800, CHICAGO, IL 60606-6629 USA SN 0022-2437 EI 1547-7193 J9 J MARKETING RES JI J. Mark. Res. PD JUN PY 2016 VL 53 IS 3 BP 369 EP 380 DI 10.1509/jmr.14.0234 PG 12 WC Business SC Business & Economics GA DO7SM UT WOS:000377983300005 ER PT J AU Marshall, D Rose, S Rice, S Beller, A Peskind, E Keene, C AF Marshall, Desiree Rose, Shannon Rice, Samantha Beller, Allison Peskind, Elaine Keene, C. TI Results of NINDS/NIBIB CTE neuropathology screening in an ADRC cohort. SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Meeting Abstract CT 92nd Annual Meeting of the American-Association-of-Neuropathologist-Inc CY JUN 16-19, 2016 CL Baltimore, MD SP Amer Assoc Neuropathologist Inc C1 [Marshall, Desiree; Rose, Shannon; Rice, Samantha; Beller, Allison; Keene, C.] Univ Washington Pathol, Seattle, WA USA. [Peskind, Elaine] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD JUN PY 2016 VL 75 IS 6 MA 133 BP 604 EP 604 PG 1 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DO3FC UT WOS:000377665000142 ER PT J AU Rocque, GB Partridge, EE Pisu, M Martin, MY Demark-Wahnefried, W Acemgil, A Kenzik, K Kvale, EA Meneses, K Li, XL Li, YF Halilova, KI Jackson, BE Chambless, C Lisovicz, N Fouad, M Taylor, RA AF Rocque, Gabrielle B. Partridge, Edward E. Pisu, Maria Martin, Michelle Y. Demark-Wahnefried, Wendy Acemgil, Aras Kenzik, Kelly Kvale, Elizabeth A. Meneses, Karen Li, Xuelin Li, Yufeng Halilova, Karina I. Jackson, Bradford E. Chambless, Carol Lisovicz, Nedra Fouad, Mona Taylor, Richard A. TI The Patient Care Connect Program: Transforming Health Care Through Lay Navigation SO JOURNAL OF ONCOLOGY PRACTICE LA English DT Article ID DEEP SOUTH NETWORK; CANCER CONTROL; UNITED-STATES; COMMUNITY; DISTRESS; THERMOMETER; DISPARITIES; COST AB The Patient Care Connect Program (PCCP) is a lay patient navigation program, implemented by the University of Alabama at Birmingham Health System Cancer Community Network. The PCCP's goal is to provide better health and health care, as well as to lower overall expenditures. The program focuses on enhancing the health of patients, with emphasis on patient empowerment and promoting proactive participation in health care. Navigator training emphasizes palliative care principles and includes development of skills to facilitate advance care planning conversations. Lay navigators are integrated into the health care team, with the support of a nurse supervisor, physician medical director, and administrative champion. The intervention focuses on patients with high needs to reach those with the greatest potential for benefit from supportive services. Navigator activities are guided by frequent distress assessments, which help to identify patient concerns across multiple domains, triage patients to appropriate resources, and ultimately overcome barriers to health care. In this article, we describe the PCCP's development, infrastructure, selection and training of lay navigators, and program operations. C1 [Rocque, Gabrielle B.] Univ Alabama Birmingham, 1824 6th Ave S,WTI 240E, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Rocque, GB (reprint author), Univ Alabama Birmingham, 1824 6th Ave S,WTI 240E, Birmingham, AL 35294 USA. EM grocque@uabmc.edu NR 36 TC 2 Z9 2 U1 1 U2 6 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 1554-7477 EI 1935-469X J9 J ONCOL PRACT JI J. Oncol. Pract. PD JUN PY 2016 VL 12 IS 6 BP 551 EP E642 DI 10.1200/JOP.2015.008896 PG 12 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DO5KD UT WOS:000377821100003 ER PT J AU Hsu, MC Weber, CN Mohammed, MA Gade, TP Hunt, S Nadolski, GJ Clark, TWI AF Hsu, Michael C. Weber, Charles N. Mohammed, Mustafa A. Gade, Terence P. Hunt, Stephen Nadolski, Gregory J. Clark, Timothy W. I. TI Thermal Changes during Rheolytic Mechanical Thrombectomy SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID HEAT-SHOCK PROTEINS; PERCUTANEOUS THROMBOLYTIC DEVICE; VASCULAR INJURY; HSP90; THERMOTOLERANCE; EXPRESSION; MODEL; CD31 AB Purpose: To characterize thermal changes induced by rheolytic thrombectomy (RT) within an ex vivo venous model and evaluate resultant changes of endothelial and vessel wall injury. Materials and Methods: Patent human saphenous vein segments without thrombus were mounted in an ex vivo perfusion system with a temperature probe apposed to the adventitial surface. RT was performed over a guide wire to, facilitate device centering. Continuous RT was performed for 4 minutes with temperature recorded every 10 seconds. Pulsed RT was performed for eight cycles of 30 seconds followed by 10 seconds of deactivation. Mean temperature increase, maximum temperature (T-max), intimal/medial thickness, endothelial cell staining (CD31), and heat shock protein 90 (HSP90) expression were compared between untreated and RT-treated venous segments. Results: Continuous RT produced a mean 7.6 degrees C increase in temperature above baseline with mean T-max of 44.1 degrees C. Pulsed RT produced a mean 7.3 degrees C increase in temperature and mean T-max of 43.8 degrees C. Differences in mean temperature increase (P = .66) and T-max (P =.71) between the two groups were not statistically significant. RT-treated segments showed intima/media thinning (0.32 mm before RT and 0.18 mm after RT; P = .004) and reduction in intact endothelium (38.8% before RT and 13.8% after RT; P = .002). Staining for HSP90 showed a 3.1% increase in expression after RT (P = .31). Conclusions: RT in this venous model showed reproducible increases in vessel temperature and evidence of endothelial and vessel wall injury. Avoiding prolonged RT application to a focal vascular segment during clinical use may be beneficial. C1 [Hsu, Michael C.; Weber, Charles N.; Gade, Terence P.; Hunt, Stephen; Nadolski, Gregory J.; Clark, Timothy W. I.] Univ Penn, Perelman Sch Med, Sect Intervent Radiol, Philadelphia, PA 19104 USA. [Hsu, Michael C.; Weber, Charles N.; Gade, Terence P.; Hunt, Stephen; Nadolski, Gregory J.; Clark, Timothy W. I.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hsu, Michael C.; Weber, Charles N.; Mohammed, Mustafa A.; Gade, Terence P.; Hunt, Stephen; Nadolski, Gregory J.] Philadelphia Vet Affairs Med Ctr, Penn Image Guided Intervent Lab, Philadelphia, PA USA. RP Clark, TWI (reprint author), Penn Presbyterian Med Ctr, Sect Intervent Radiol, 51 North 39 St, Philadelphia, PA 19104 USA. EM timothy.clark@uphs.upenn.edu FU Guerbet LLC (Bloomington, Indiana); Velano Vascular (San Francisco, California); Teleflex (Morrisville, North Carolina); C.R. Bard, Inc (Murray Hill, New Jersey); Guerbet LLC; Teleflex; Merit Medical Systems, Inc (South Jordan, Utah) FX T.P.G. received grants from Guerbet LLC (Bloomington, Indiana) and Velano Vascular (San Francisco, California). G J N. received grants from Teleflex (Morrisville, North Carolina), C.R. Bard, Inc (Murray Hill, New Jersey), and Guerbet LLC and is a consultant for Teleflex. T W.I C. is a consultant for and receives personal fees from Teleflex and Merit Medical Systems, Inc (South Jordan, Utah). None of the other authors have identified a conflict of interest. NR 32 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JUN PY 2016 VL 27 IS 6 BP 905 EP 912 DI 10.1016/j.jvir.2016.02.008 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA DO2QY UT WOS:000377626200019 PM 27103145 ER PT J AU Blosnich, JR Hanmer, J Yu, L Matthews, DD Kavalieratos, D AF Blosnich, John R. Hanmer, Janel Yu, Lan Matthews, Derrick D. Kavalieratos, Dio TI Health Care Use, Health Behaviors, and Medical Conditions Among Individuals in Same-Sex and Opposite-Sex Partnerships A Cross-Sectional Observational Analysis of the Medical Expenditures Panel Survey (MEPS), 2003-2011 SO MEDICAL CARE LA English DT Article DE sexual orientation; health disparities; health care utilization; minority health ID YOUNG-ADULTS; LIFE SURVEY; HETEROSEXUAL INDIVIDUALS; CARDIOVASCULAR-DISEASE; MENTAL-DISORDERS; UNITED-STATES; HELP-SEEKING; ORIENTATION; GAY; DISPARITIES AB Background: Prior research documents disparities between sexual minority and nonsexual minority individuals regarding health behaviors and health services utilization. However, little is known regarding differences in the prevalence of medical conditions. Objectives: To examine associations between sexual minority status and medical conditions. Research Design: We conducted multiple logistic regression analyses of the Medical Expenditure Panel Survey (2003-2011). We identified individuals who reported being partnered with an individual of the same sex, and constructed a matched cohort of individuals in opposite-sex partnerships. Subjects: A total of 494 individuals in same-sex partnerships and 494 individuals in opposite-sex partnerships. Measures: Measures of health risk (eg, smoking status), health services utilization (eg, physician office visits), and presence of 15 medical conditions (eg, cancer, diabetes, arthritis, HIV, alcohol disorders). Results: Same-sex partnered men had nearly 4 times the odds of reporting a mood disorder than did opposite-sex partnered men [ adjusted odds ratio (aOR) = 3.96; 95% confidence interval (CI), 1.85-8.48]. Compared with opposite-sex partnered women, samesex partnered women had greater odds of heart disease (aOR = 2.59; 95% CI, 1.19-5.62), diabetes (aOR = 2.75; 95% CI, 1.10-6.90), obesity (aOR = 1.92; 95% CI, 1.26-2.94), high cholesterol (aOR = 1.89; 95% CI, 1.03-3.50), and asthma (aOR = 1.90; 95% CI, 1.02-1.19). Even after adjusting for sociodemographics, health risk behaviors, and health conditions, individuals in same-sex partnerships had 67% increased odds of past-year emergency department utilization and 51% greater odds of Z3 physician visits in the last year compared with opposite-sex partnered individuals. Conclusions: A combination of individual-level, provider-level, and system-level approaches are needed to reduce disparities in medical conditions and health care utilization among sexual minority individuals. C1 [Blosnich, John R.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Blosnich, John R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA. [Hanmer, Janel; Yu, Lan; Kavalieratos, Dio] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Matthews, Derrick D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA. RP Blosnich, JR (reprint author), VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Univ Dr C 151C-U,Bldg 30, Pittsburgh, PA 15240 USA. EM john.blosnich@va.gov FU Department of Veterans Affairs (VA) Office of Academic Affiliations; Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System; National Institute of Mental Health [T32MH094174]; National Institutes of Health [KL2 TR000146]; Agency for Healthcare Research and Quality [K12HS022989]; Junior Faculty Career Development Award from the National Palliative Care Research Center FX Supported by a postdoctoral fellowship to J.R.B. through the Department of Veterans Affairs (VA) Office of Academic Affiliations and the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System. D.D.M. was supported by the National Institute of Mental Health Training Program to Address HIV-Related Health Disparities in MSM (T32MH094174). J.H. was supported by the National Institutes of Health through Grant Number KL2 TR000146. D.K. was supported by supported by K12HS022989 from the Agency for Healthcare Research and Quality, and a Junior Faculty Career Development Award from the National Palliative Care Research Center. NR 50 TC 0 Z9 0 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUN PY 2016 VL 54 IS 6 BP 547 EP 554 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DO8UR UT WOS:000378060400002 PM 26974678 ER PT J AU Moriarty, H Winter, L Robinson, K Piersol, CV Vause-Earland, T Iacovone, DB Newhart, B True, G Fishman, D Hodgson, N Gitlin, LN AF Moriarty, Helene Winter, Laraine Robinson, Keith Piersol, Catherine Verrier Vause-Earland, Tracey Iacovone, Delores Blazer Newhart, Brian True, Gala Fishman, Deborah Hodgson, Nancy Gitlin, Laura N. TI A Randomized Controlled Trial to Evaluate the Veterans' In-home Program for Military Veterans With Traumatic Brain Injury and Their Families: Report on Impact for Family Members SO PM&R LA English DT Article ID CAREGIVER BURDEN; NEUROPSYCHIATRIC SEQUELAE; SOCIAL SUPPORT; OLDER-ADULTS; HEALTH-CARE; INTERVENTION; REHABILITATION; DEPRESSION; INDIVIDUALS; DEMENTIA AB Background: Traumatic brain injury (TBI) creates many challenges for families as well as for patients. Few intervention studies have considered both the needs of the person with TBI and his or her family and included both in the intervention process. To address this gap, we designed an innovative intervention for veterans with TBI and families-the Veterans' In-home Program (VIP)-targeting veterans' environment, delivered in veterans' homes, and involving their families. Objectives: To determine whether the VIP is more effective than standard outpatient clinic care in improving family members' well-being in 3 domains (depressive symptoms, burden, and satisfaction) and to assess its acceptability to family members. Design: In this randomized controlled trial, 81 dyads (veteran/family member) were randomly assigned to VIP or an enhanced usual care control condition. Randomization occurred after the baseline interview. Follow-up interviews occurred 3-4 months after baseline, and the interviewer was blinded to group assignment. Setting: Interviews and intervention sessions were conducted in veterans' homes or by telephone. Participants: A total of 81 veterans with TBI recruited from a Veterans Affairs (VA) polytrauma program and a key family member for each participated. Of the 81 family members, 63 completed the follow-up interview. Intervention: The VIP, guided by the person-environment fit model, consisted of 6 home visits and 2 telephone calls delivered by occupational therapists over a 3- to 4-month period. Family members were invited to participate in the 6 home sessions. Main Outcome Measures: Family member well-being was operationally defined as depressive symptomatology, caregiver burden, and caregiver satisfaction 3- 4 months after baseline. Acceptability was operationally defined through 3 indicators. Results: Family members in the VIP showed significantly lower depressive symptom scores and lower burden scores when compared to controls at follow-up. Satisfaction with caregiving did not differ between groups. Family members' acceptance of the intervention was high. Conclusions: VIP represents the first evidence-based intervention that considers both the veteran with TBI and the family. VIP had a significant impact on family member well-being and thus addresses a large gap in previous research and services for families of veterans with TBI. C1 [Moriarty, Helene] Villanova Univ, Coll Nursing, 800 Lancaster Ave,Driscoll Hall, Villanova, PA 19085 USA. [Moriarty, Helene; Winter, Laraine; Fishman, Deborah] Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA. [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA USA. [Robinson, Keith; Iacovone, Delores Blazer; Newhart, Brian] Corporal Michael J Crescenz Vet Affairs Med Ctr, Rehabil Med Serv, Polytrauma Network Site Vet Integrated Serv Netwo, Philadelphia, PA USA. [Robinson, Keith; True, Gala] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Piersol, Catherine Verrier; Vause-Earland, Tracey] Thomas Jefferson Univ, Jefferson Coll Hlth Profess, Philadelphia, PA 19107 USA. [True, Gala] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Ctr Innovat Care Aging, Sch Nursing, Baltimore, MD USA. RP Moriarty, H (reprint author), Villanova Univ, Coll Nursing, 800 Lancaster Ave,Driscoll Hall, Villanova, PA 19085 USA.; Moriarty, H (reprint author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA. EM helene.moriarty@villanova.edu FU Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health [R21 HD068857-01] FX The project described was supported by Award Number R21 HD068857-01 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health. NR 90 TC 0 Z9 0 U1 9 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD JUN PY 2016 VL 8 IS 6 BP 495 EP 509 DI 10.1016/j.pmrj.2015.10.008 PG 15 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DO6OX UT WOS:000377904100001 PM 26514790 ER PT J AU Gao, N Dolce, J Rio, J Heitzmann, C Loving, S AF Gao, Ni Dolce, Joni Rio, John Heitzmann, Carma Loving, Samantha TI In-Vivo Job Development Training Among Peer Providers of Homeless Veterans Supported Employment Programs SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE Department of Veterans Affairs; homeless veterans; supported employment; in vivo training; job development AB Topic: This column describes a goal-oriented, time-limited in vivo coaching/training approach for skills building among peer veterans vocational rehabilitation specialists of the Homeless Veteran Supported Employment Program (HVSEP). Purpose: Planning, implementing, and evaluating the training approach for peer providers was intended, ultimately, to support veterans in their goal of returning to community competitive employment. Sources Used: The description draws from the training experience that aimed to improve the ability of peer providers to increase both rates of employment and wages of the homeless veterans using their services. Conclusions and Implications for Practice: Training peers using an in vivo training approach provided a unique opportunity for the veterans to improve their job development skills with a focus to support employment outcomes for the service users. Peers who received training also expressed that learning skills through an in vivo training approach was more engaging than typical classroom trainings. C1 [Gao, Ni; Dolce, Joni] Rutgers State Univ, Dept Psychiat Rehabil & Counseling Profess, Stratford, NJ USA. [Rio, John] Advocates Human Potential, Albany, NY USA. [Heitzmann, Carma] US Dept Vet Affairs, Menlo Pk, CA USA. [Loving, Samantha] US Dept Vet Affairs, Richmond, VA USA. RP Gao, N (reprint author), Rutgers State Univ, Dept Psychiat Rehabil & Counseling Profess, Stratford, NJ USA. EM gaoni@rutgers.edu NR 9 TC 0 Z9 0 U1 3 U2 4 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD JUN PY 2016 VL 39 IS 2 BP 191 EP 192 DI 10.1037/prj0000196 PG 2 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA DO2TS UT WOS:000377633600017 PM 27281042 ER PT J AU Stanley, B Chaudhury, SR Chesin, M Pontoski, K Bush, AM Knox, KL Brown, GK AF Stanley, Barbara Chaudhury, Sadia R. Chesin, Megan Pontoski, Kristin Bush, Ashley Mahler Knox, Kerry L. Brown, Gregory K. TI An Emergency Department Intervention and Follow-Up to Reduce Suicide Risk in the VA: Acceptability and Effectiveness SO PSYCHIATRIC SERVICES LA English DT Article ID VETERANS; PREVENTION AB Objective: Emergency departments (EDs) are often the primary contact point for suicidal individuals. The post-ED visit period is a high suicide risk time. To address the need for support during this time, a novel intervention was implemented in five Department of Veterans Affairs medical center EDs. The intervention combined the Safety Planning Intervention (SPI) with structured follow-up and monitoring (SFU) by telephone for suicidal individuals who did not require hospitalization. This study assessed the intervention's acceptability and perceived usefulness. Methods: A selected sample of 100 intervention participants completed a semistructured interview consisting of open-ended questions about the intervention's acceptability, usefulness, and helpfulness. Satisfaction with the SPI and SFU was separately evaluated. Results: Nearly all participants found the SAFE VET intervention to be acceptable, reporting that it was helpful in preventing further suicidal behavior and fostering treatment engagement. Conclusions: The SAFE VET intervention showed promise as an ED intervention for suicidal patients. C1 [Stanley, Barbara; Chaudhury, Sadia R.] Columbia Univ, Dept Psychiat, New York, NY USA. [Stanley, Barbara; Chaudhury, Sadia R.; Chesin, Megan] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Chesin, Megan] William Paterson Univ, Dept Psychol, Wayne, NJ USA. [Pontoski, Kristin; Bush, Ashley Mahler; Brown, Gregory K.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Brown, Gregory K.] US Dept Vet Affairs, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Knox, Kerry L.] Univ Rochester, Dept Psychiat, Rochester, NY USA. RP Stanley, B (reprint author), Columbia Univ, Dept Psychiat, New York, NY USA. EM bhs2@cumc.columbia.edu FU Mental Health Services and Quality Enhancement Research Initiative, U.S. Department of Veterans Affairs; VISN 2 Center of Excellence for Suicide Prevention FX The SAFE VET project was supported by the Mental Health Services and Quality Enhancement Research Initiative, U.S. Department of Veterans Affairs, and the VISN 2 Center of Excellence for Suicide Prevention. Ira Katz, M.D., Ph.D., and Jan Kemp, Ph.D., provided valuable insight into the project design. Coordination of the SAFE VET project was provided by site leaders Lisa Brenner, Ph.D., Joan Chips, L.C.S.W., Joshua Hooberman, Ph.D., Christine Jackson, Ph.D., Mitchel Kling, M.D., and Keith Rogers, M.D., and by acute services coordinators Patricia Alexander, Ph.D., Laura Blandy, Psy. D., Aimee Coughlin, M.S.W., John Dennis, Ph.D., Michael Miello, Ph.D., Katherine Mostkoff, L.C.S.W., and Jarrod Reisweber, Psy. D. The authors also acknowledge project interviewers Emily Biggs, M.A., Jason Cha, M. Phil. Ed., Maryanne McGinn, M. A., and Laura Mowery, Psy. D. Essential guidance and support were provided by Lauren Denneson, Ph.D., Steven Dobscha, M.D., Walter Matweychuk, Ph.D., Gerd Naydock, M.S.W., Keith Rogers, M.D., Donald Tavakoli, M.D., and Adam Wolkin, M.D. NR 12 TC 0 Z9 0 U1 2 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUN PY 2016 VL 67 IS 6 BP 679 EP 682 DI 10.1176/appi.ps.201500082 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4UK UT WOS:000377779900019 ER PT J AU Rudmikl, L Soler, ZM Hopkins, C Schlosser, RJ Peters, A White, AA Orlandi, RR Fokkens, WJ Douglas, R Smith, TL AF Rudmikl, Luke Soler, Zachary M. Hopkins, Claire Schlosser, Rodney J. Peters, Anju White, Andrew A. Orlandi, Richard R. Fokkens, Wytske J. Douglas, Richard Smith, Timothy L. TI Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study SO RHINOLOGY LA English DT Article DE sinusitis; patient selection; criteria selection; sinus surgery; quality of health care ID REFRACTORY CHRONIC RHINOSINUSITIS; CONTINUED MEDICAL THERAPY; SMALL-AREA VARIATION; COMPUTED-TOMOGRAPHY; UNITED-STATES; GEOGRAPHIC-VARIATION; SYMPTOM OUTCOMES; IMPACT OUTCOMES; NASAL POLYPOSIS; HEALTH-CARE AB Introduction: Appropriate indications for endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS) are currently poorly defined. The lack of clear surgical indications for ESS likely contributes to the large geographic variation in surgical rates and contributes to reduced quality of care. The objective of this study was to define appropriateness criteria for ESS during management of adult patients with uncomplicated CRS. Methods:The RAND/UCLA appropriateness methodology was performed. An international, multi-disciplinary panel of 10 experts in CRS was formed and completed two rounds of a modified Delphi ranking process along with a face-to-face meeting. Results: A total of 624 clinical scenarios were ranked, 312 scenarios each for CRS with and CRS without nasal polyps. For adult patients with uncomplicated CRS with nasal polyps, ESS can be appropriately offered when the CT Lund-Mackay score is 1 and there has been a minimum trial of a topical intranasal corticosteroid plus a short-course of systemic corticosteroid with a post-treatment total SNOT-22 score >= 20. For adult patients with uncomplicated CRS without nasal polyps, ESS can be appropriately offered when the CT Lund-Mackay score is >= 1 and there has been a minimum trial of a topical intranasal corticosteroid plus either a short-course of a broad spectrum/culture-directed systemic antibiotic or the use of a prolonged course of systemic low-dose anti-inflammatory antibiotic with a post-treatment total SNOT-22 score >= 20. Conclusion:This study has developed and reported of list of appropriateness criteria to offer ESS as a treatment'option'during management of uncomplicated adult CRS. The extent or technique of ESS was not addressed in this study and will depend on surgeon and patient factors. Furthermore, these criteria are the minimal threshold to make ESS a treatment'option'and do not imply that all patients meeting these criteria require surgery. The decision to perform ESS should be made after an informed patient makes a preference-sensitive decision to proceed with surgery. Applying these appropriateness criteria for ESS may optimize patient selection, reduce the incidence of unwarranted surgery, and assist clinicians in providing high quality, patient-centered care to patients with CRS. C1 [Rudmikl, Luke] Univ Calgary, Dept Surg, Div Otolaryngol Head & Neck Surg, Calgary, AB, Canada. [Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Charleston, SC 29425 USA. [Hopkins, Claire] Guys & St Thomas NHS Trust, Dept ENT, London, England. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Peters, Anju] Northwestern Univ, Div Allergy, Dept Internal Med, Chicago, IL 60611 USA. [White, Andrew A.] Scripps Clin, Div Allergy & Immunol, La Jolla, CA 92037 USA. [Orlandi, Richard R.] Univ Utah, Div Otolaryngol Head & Neck Surg, Salt Lake City, UT USA. [Fokkens, Wytske J.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. [Douglas, Richard] Univ Auckland, Dept Surg, Auckland 1, New Zealand. [Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Oregon Sinus Ctr, Div Rhinol & Sinus Surg, Portland, OR 97201 USA. RP Rudmikl, L (reprint author), Univ Calgary, Dept Surg, Div Otolaryngol Head & Neck Surg, Richmond Rd Diagnost & Treatment Ctr, 1820 Richmond Rd SW, Calgary, AB T2T 5C7, Canada. EM Lukerudmik@gmail.com FU MSI Foundation FX The authors would like to thank the MSI Foundation for their grant to support this project. NR 70 TC 4 Z9 4 U1 1 U2 1 PU INT RHINOLOGIC SOC PI UTRECHT PA UNIV MEDICAL CENTER UTRECHT, RM G05 127, DEPT OTORHINOL, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS SN 0300-0729 J9 RHINOLOGY JI Rhinology PD JUN PY 2016 VL 54 IS 2 BP 117 EP 128 DI 10.4193/Rhino16.023 PG 12 WC Otorhinolaryngology SC Otorhinolaryngology GA DO8EM UT WOS:000378015400005 PM 26934470 ER PT J AU Akiba, Y Kaunitz, JD Montrose, MH AF Akiba, Yasutada Kaunitz, Jonathan D. Montrose, Marshall H. TI CFTR and pH(i) regulation SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Letter ID CYSTIC-FIBROSIS; PH C1 [Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Montrose, Marshall H.] Univ Cincinnati, Dept Mol & Cellular Physiol, Cincinnati, OH USA. RP Kaunitz, JD (reprint author), VAGLAHS, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu NR 8 TC 1 Z9 1 U1 1 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD JUN 1 PY 2016 VL 310 IS 11 BP G1183 EP G1183 DI 10.1152/ajpgi.00133.2016 PG 1 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA DN9XE UT WOS:000377433200031 PM 27281734 ER PT J AU de Vries, YA de Jonge, P van den Heuvel, E Turner, EH Roest, AM AF de Vries, Ymkje Anna de Jonge, Peter van den Heuvel, Edwin Turner, Erick H. Roest, Annelieke M. TI Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Review ID OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; VENLAFAXINE EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; COMORBIDITY SURVEY REPLICATION; RANDOMIZED CONTROLLED-TRIAL; DSM-IV DISORDERS; DOUBLE-BLIND; PANIC DISORDER; SOCIAL PHOBIA AB Background Antidepressants are established first-line treatments for anxiety disorders, but it is not clear whether they are equally effective across the severity range. Aims To examine the influence of baseline severity of anxiety on antidepressant efficacy for generalised anxiety disorder (GAD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD) and panic disorder. Method Fifty-six trials of second-generation antidepressants for the short-term treatment of an anxiety disorder were included. Baseline and change scores were extracted for placebo and treatment groups in each trial. Mixed effects meta-regression was used to investigate the effects of treatment group, baseline severity and their interaction. Results Increased baseline severity did not predict greater improvement in drug groups compared with placebo groups. Standardised regression coefficients of the interaction term between baseline severity and treatment group were 0.04 (95% CI -0.13 to 0.20, P = 0.65) for GAD, 70.06 (95% CI -0.20 to 0.09, P = 0.43) for SAD, 0.04 (95% CI -0.07 to 0.16, P = 0.46) for OCD, 0.16 (95% CI -0.22 to 0.53, P = 0.37) for PTSD and 0.002 (95% CI -0.10 to 0.10, P = 0.96) for panic disorder. For OCD, baseline severity did predict improvement in both placebo and drug groups equally (b = 0.11, 95% CI 0.05 to 0.17, P = 0.001). Conclusions No relationship between baseline severity and drug-placebo difference was found for anxiety disorders. These results suggest that if the efficacy of antidepressants is considered clinically relevant, they may be prescribed to patients with anxiety regardless of symptom severity. C1 [de Vries, Ymkje Anna; de Jonge, Peter; Roest, Annelieke M.] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat, Interdisciplinary Ctr Psychopathol & Emot Regulat, NL-9700 AB Groningen, Netherlands. [van den Heuvel, Edwin] Tech Univ Eindhoven, Dept Math & Comp Sci, POB 513, NL-5600 MB Eindhoven, Netherlands. [Turner, Erick H.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Behav Hlth & Neurosci Div, Portland, OR 97201 USA. [Turner, Erick H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP de Vries, YA (reprint author), Univ Med Ctr Groningen, Dept Psychiat, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM y.a.de.vries@umcg.nl FU Dutch Brain Foundation [KS2011(1)-120] FX The study was supported by grant KS2011(1)-120 from the Dutch Brain Foundation to P.J. The funder had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 74 TC 3 Z9 3 U1 4 U2 8 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 EI 1472-1465 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD JUN PY 2016 VL 208 IS 6 BP 515 EP + DI 10.1192/bjp.bp.115.173450 PG 19 WC Psychiatry SC Psychiatry GA DO1HV UT WOS:000377530000004 PM 26989093 ER PT J AU Foster, CL Badlam, J De Groote, MA Chan, ED AF Foster, Clayton L. Badlam, Jessica De Groote, Mary Ann Chan, Edward D. TI A 65-Year-Old Groundskeeper With High Fever, Pulmonary Nodules, and Thoracic Lymphadenopathy Typhoidal tularemia with secondary pulmonary involvement SO CHEST LA English DT Editorial Material ID FRANCISELLA-TULARENSIS; UNITED-STATES AB A 65-year-old man with treated latent tuberculous infection presented with 1 week of fevers (up to 39.6 degrees C), chills, headache, lightheadedness, and malaise. He reported a chronic, nonproductive cough without hemoptysis but denied other localizing symptoms, sick contacts, or recent travel. He lived in an urban area in eastern Colorado and owned one healthy dog but otherwise denied known animal exposures. He was a retired oil driller who had worked in southern Arizona, New Mexico, and northern Mexico (Sonora region). Other travel included 3 years in the early 1970s working as a military aircraft mechanic in Vietnam, Laos, and Thailand. Six weeks prior to admission, he began work as a groundskeeper on a golf course that had experienced recent flooding, using a riding mower and exposing himself to airborne dust and organic debris. He smoked a pipe daily for 30 years but quit 2 months prior to presentation, although he continued to smoke marijuana weekly. He denied intravenous drug use. C1 [Foster, Clayton L.] Univ Colorado Anschutz Med Campus, Div Infect Dis, Aurora, CO USA. [Badlam, Jessica; Chan, Edward D.] Univ Colorado Anschutz Med Campus, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [De Groote, Mary Ann] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Chan, Edward D.] Natl Jewish Hlth, Dept Med & Acad Affairs, Denver, CO 80206 USA. [Chan, Edward D.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. RP Chan, ED (reprint author), Natl Jewish Hlth, D509 Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 8 TC 0 Z9 0 U1 2 U2 4 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD JUN PY 2016 VL 149 IS 6 BP E191 EP E194 DI 10.1016/j.chest.2015.12.035 PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DN7YL UT WOS:000377296000007 PM 27287596 ER PT J AU Danielson, CK McCauley, JL Gros, KS Jones, AM Barr, SC Borkman, AL Bryant, BG Ruggiero, KJ AF Danielson, Carla Kmett McCauley, Jenna L. Gros, Kirstin Stauffacher Jones, Andrea M. Barr, Simone C. Borkman, April L. Bryant, Brittany G. Ruggiero, Kenneth J. TI SiHLEWeb.com: Development and usability testing of an evidence-based HIV prevention website for female African-American adolescents SO HEALTH INFORMATICS JOURNAL LA English DT Article DE adolescents; African-American; e-Health; prevention; mixed-methods ID COMMUNITY-BASED ORGANIZATIONS; RANDOMIZED CONTROLLED-TRIAL; HEALTH INTERVENTIONS; PRELIMINARY EFFICACY; COMPUTER-TECHNOLOGY; STRATEGIES; INTERNET; PROGRAMS; DELIVERY; WOMEN AB African-American adolescent girls are at disproportionate risk for HIV infection. Although numerous evidence-based risk-reduction interventions exist, dissemination and implementation resources remain limited, and prevention services remain notably inaccessible to the very populations at highest risk for HIV infection. Internet delivery of HIV risk-reduction programming has promise as a mechanism for extending the reach of existing prevention efforts and overcoming barriers associated with traditional service delivery. This article (1) details the development process for the creation of SiHLEWeb, a web-adapted version of an evidence-based, culturally informed HIV prevention program traditionally delivered to female African-American adolescents via an in-person group format, and (2) presents findings from quantitative and qualitative usability testing conducted among 18 African-American girls (13-18 years). Results suggest that users found the website improved knowledge and learning, was helpful, efficient to use, and generally attractive. Users reported some concerns about website navigation. Implications for Internet delivery of health prevention programming are discussed. C1 [Danielson, Carla Kmett; McCauley, Jenna L.; Jones, Andrea M.; Ruggiero, Kenneth J.] Med Univ S Carolina, Charleston, SC 29425 USA. [Gros, Kirstin Stauffacher; Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Jones, Andrea M.] Univ Georgia, Athens, GA 30602 USA. [Barr, Simone C.] Univ Texas Houston, Sch Med, Houston, TX USA. [Bryant, Brittany G.] Communities Sch, Arlington, VA USA. RP Danielson, CK (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC 861, Charleston, SC 29425 USA. EM danielso@musc.edu FU South Carolina Clinical & Translational Research (SCTR) Institute; National Center for Research Resources (NCRR) at the National Institutes of Health (NIH) [UL1 RR029882, UL1 TR000062]; Substance Abuse and Mental Health Services Administration [1U79SP015156]; [R01DA031285]; [K12DA031794] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by a Pilot Health Disparities Research Grant (PI: Danielson) from the South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, funded through the National Center for Research Resources (NCRR) at the National Institutes of Health (NIH) Grant Numbers UL1 RR029882 and UL1 TR000062 (PI: Brady) and by a grant from the Substance Abuse and Mental Health Services Administration (1U79SP015156; PI: Danielson). The preparation of this manuscript was supported by R01DA031285 (PI: Danielson) and K12DA031794 (PI: Brady; McCauley). NR 45 TC 0 Z9 0 U1 3 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1460-4582 EI 1741-2811 J9 HEALTH INFORM J JI Health Inform. J. PD JUN PY 2016 VL 22 IS 2 BP 194 EP 208 DI 10.1177/1460458214544048 PG 15 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA DN6RM UT WOS:000377203500010 PM 25167865 ER PT J AU Long, MD Onyiah, JC Miller, M Herfarth, HH AF Long, Millie D. Onyiah, Joseph C. Miller, Melissa Herfarth, Hans H. TI Cytomegalovirus Viral Load in the Colon and Risk of Colectomy in Hospitalized Patients With Inflammatory Bowel Diseases SO INFLAMMATORY BOWEL DISEASES LA English DT Letter ID ULCERATIVE-COLITIS C1 [Long, Millie D.; Onyiah, Joseph C.; Herfarth, Hans H.] Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Onyiah, Joseph C.] Univ Colorado, Dept Med, Div Gastroenterol & Hepatol, Aurora, CO USA. [Onyiah, Joseph C.] Denver VA Med Ctr, Denver, CO USA. [Miller, Melissa] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA. RP Long, MD (reprint author), Univ N Carolina, Dept Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. NR 5 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JUN PY 2016 VL 22 IS 6 BP E21 EP E22 DI 10.1097/MIB.0000000000000799 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DN9DM UT WOS:000377379500007 PM 27120572 ER PT J AU Wang, CH Charlton, B Kohlwes, J AF Wang, Christina Hao Charlton, Blake Kohlwes, Jeffrey TI The Horrible Taste of Nectar and Honey-Inappropriate Use of Thickened Liquids in Dementia A Teachable Moment SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID ASPIRATION; INTERVENTIONS; PNEUMONIA C1 [Wang, Christina Hao; Charlton, Blake; Kohlwes, Jeffrey] Univ Calif San Francisco, PRIME Residency Program, Dept Internal Med, 4150 Clement St, San Francisco, CA 94121 USA. [Wang, Christina Hao; Charlton, Blake; Kohlwes, Jeffrey] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. RP Wang, CH (reprint author), Univ Calif San Francisco, PRIME Residency Program, Dept Internal Med, 4150 Clement St, San Francisco, CA 94121 USA.; Wang, CH (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM hao.wang@ucsf.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2016 VL 176 IS 6 BP 735 EP 736 DI 10.1001/jamainternmed.2016.1384 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DN6KU UT WOS:000377184000004 PM 27135181 ER PT J AU Kepes, JA Wilhite, JB Markland, AD AF Kepes, Jeffrey A. Wilhite, James B., Jr. Markland, Alayne D. TI Complications of Indwelling Urinary Catheter Care and Care Transitions A Teachable Moment SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Kepes, Jeffrey A.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, BDB 327,1720 Second Ave S, Birmingham, AL 35294 USA. [Wilhite, James B., Jr.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Markland, Alayne D.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr, Clin Programs, Birmingham, AL USA. [Markland, Alayne D.] Birmingham VA Med Ctr, Birmingham, AL USA. [Markland, Alayne D.] Univ Alabama Birmingham, Dept Gerontol Geriatr & Palliat Care, Birmingham, AL USA. RP Kepes, JA (reprint author), Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, BDB 327,1720 Second Ave S, Birmingham, AL 35294 USA. EM jkepes@uabmc.edu OI Markland, Alayne/0000-0002-6567-6744 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2016 VL 176 IS 6 BP 737 EP 738 DI 10.1001/jamainternmed.2016.0606 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DN6KU UT WOS:000377184000005 PM 27088441 ER PT J AU Moin, T AF Moin, Tannaz TI Obesity Management and Prevention More Questions Than Answers SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Moin, Tannaz] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Moin, T (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 911 Broxton Ave,Off 302, Los Angeles, CA 90024 USA. EM tmoin@mednet.ucla.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD JUN PY 2016 VL 176 IS 6 BP 753 EP 754 DI 10.1001/jamainternmed.2016.1211 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DN6KU UT WOS:000377184000009 PM 27135966 ER PT J AU Beijers, RJHCG van den Borst, B Newman, AB Yende, S Kritchevsky, SB Cassano, PA Bauer, DC Harris, TB Schols, AMWJ AF Beijers, Rosanne J. H. C. G. van den Borst, Bram Newman, Anne B. Yende, Sachin Kritchevsky, Stephen B. Cassano, Patricia A. Bauer, Douglas C. Harris, Tamara B. Schols, Annemie M. W. J. CA Hlth ABC Study TI A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE COPD; pulmonary disease; older age persons; Cox proportional hazards modeling ID PULMONARY-DISEASE; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; ELDERLY SUBJECTS; COPD; MORTALITY; PERFORMANCE; COMORBIDITIES; POPULATION; TIOTROPIUM AB Background: Both respiratory and nonrespiratory hospitalizations are common and costly events in older individuals with obstructive lung disease. Prevention of any hospitalization in these individuals is essential. We aimed to construct a prediction model for all-cause hospitalization risk in community-dwelling older individuals with obstructive lung disease. Methods: We studied 268 community-dwelling individuals with obstructive lung disease (defined as FEV1/FVC 0.37 considered large. The effect size for responsiveness to change was interpreted as follows: 0.20-0.49 small, 0.50-0.79 medium and > 0.79 large. Results. In 147 subjects, reliability was acceptable for total GIS (0.93) and all GIS scales (0.82-0.94) except Medication Side Effects and Unmet Treatment Need. Total GIS and all scales except Medication Side Effects discriminated between subjects with and without recent gout attacks (P < 0.05). Total GIS showed moderate-to-large correlations with HAQ-DI, SF-36 PCS and MCS (0.33-0.46). Improvement in total GIS tracked with improved physician and patient severity scores. Worsening physician severity score and recent gout attack predicted worsening total GIS. Conclusion. Total GIS score is reliable, valid and responsive to change in patients with gout, and differentiates between subjects with and without recent gout attacks. C1 [Wallace, Beth; Khanna, Dinesh; Khanna, Puja P.] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Aquino-Beaton, Cleopatra] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Rheumatol, Los Angeles, CA USA. [Singh, Jasvinder A.] Univ Alabama & Birmingham VA, Div Rheumatol, Dept Med, Birmingham, AL USA. [Duffy, Erin; Elashoff, David] Univ Calif Los Angeles, Dept Med Stat Core, Los Angeles, CA USA. [Khanna, Puja P.] Ann Arbor VA Med Ctr, Div Rheumatol, Dept Med, Ann Arbor, MI USA. RP Khanna, PP (reprint author), Dept Internal Med, Div Rheumatol, 300 North Ingalls,Ste 7C27, Ann Arbor, MI 48109 USA. EM pkhanna@med.umich.edu NR 24 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 EI 1462-0332 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD JUN PY 2016 VL 55 IS 6 BP 982 EP 990 DI 10.1093/rheumatology/kew007 PG 9 WC Rheumatology SC Rheumatology GA DN9WU UT WOS:000377432200004 PM 26888852 ER PT J AU Metra, M Mentz, RJ Hernandez, AF Heizer, GM Armstrong, PW Clausell, N Corbalan, R Costanzo, MR Dickstein, K Dunlap, ME Ezekowitz, JA Howlett, JG Komajda, M Krum, H Lombardi, C Fonarow, GC McMurray, JJV Nieminen, MS Swedberg, K Voors, AA Starling, RC Teerlink, JR O'Connor, CM AF Metra, Marco Mentz, Robert J. Hernandez, Adrian F. Heizer, Gretchen M. Armstrong, Paul W. Clausell, Nadine Corbalan, Ramon Costanzo, Maria Rosa Dickstein, Kenneth Dunlap, Mark E. Ezekowitz, Justin A. Howlett, Jonathan G. Komajda, Michel Krum, Henry Lombardi, Carlo Fonarow, Gregg C. McMurray, John J. V. Nieminen, Markku S. Swedberg, Karl Voors, Adriaan A. Starling, Randall C. Teerlink, John R. O'Connor, Christopher M. TI Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; INTERNATIONAL DIFFERENCES; READMISSION RATES; OUTCOMES; MANAGEMENT; NESIRITIDE; GLOBALIZATION; CLOPIDOGREL; TICAGRELOR; COUNTRIES AB A growing number of countries and geographical regions are involved in major clinical trials. Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure is the largest trial in acutely decompensated heart failure (HF) with patients from 5 geographical regions: North America (NA), Latin America (LA), Western Europe (WE), Central Europe (CE), and Asia-Pacific (AP). Data from the 5 geographical, areas were compared including baseline characteristics, medications, 30-day outcomes (mortality and mortality or HF hospitalization), and 180-day mortality. Of the 7,141 study patients, 3,243 (45.4%) were from NA (average of 15.2 patients/site), 1,762 (24.7%) from AP (28.4 patients/site), 967 (13.5%) from CE (20.2 patients/site), 665 (9.3%) from LA (17.1 patients/site), and 504 (7.1%) from WE (14.4 patients/site). There were marked differences in co-morbidities, clinical profile, medication use, length of stay, 30-day event rates, and 180-day mortality by region. Compared with NA, the adjusted risk for death or HF hospitalization at 30 days was significantly lower in CE (odds ratio [OR] 0.46, 95% CI 0.33 to 0.64), WE (OR 0.52 95% CI 0.35 to 0.75), and AP (OR 0.62 95% CI 0.48 to 0:79) and numerically lower in LA (OR 0.77, 95% CI 0.57 to 1.04) with similar results for 180-day mortality. In conclusion, in patients with acutely decompensated HF, major differences in baseline characteristics, treatments, length of the hospital stay, and 30-day HF rehospitalization rates, and 180-day mortality were found in patients enrolled from different, geographical areas. (C) 2016 Elsevier Inc. All rights reserved. C1 [Metra, Marco; Lombardi, Carlo] Univ Brescia, Dept Med & Surg Specialties, Div Cardiol, Brescia, Italy. [Mentz, Robert J.; Hernandez, Adrian F.; Heizer, Gretchen M.; O'Connor, Christopher M.] Duke Univ, Med Ctr, Dept Med, Duke Clin Res Inst,Div Cardiol, Durham, NC 27710 USA. [Armstrong, Paul W.; Ezekowitz, Justin A.] Univ Alberta, Div Cardiol, Edmonton, AB, Canada. [Clausell, Nadine] Hosp Clin Porto Alegre, Serv Cardiol, Porto Alegre, RS, Brazil. [Corbalan, Ramon] Pontificia Univ Catolica Chile, Cardiovasc Div, Alameda 340, Santiago, Chile. [Costanzo, Maria Rosa] Advocate Heart Inst, Naperville, IL USA. [Dickstein, Kenneth] Univ Bergen, Stavenger Univ Hosp, Div Cardiol, Bergen, Norway. [Dunlap, Mark E.] Metrohlth Med Ctr, Heart & Vasc Ctr, Cleveland, OH USA. [Howlett, Jonathan G.] Univ Calgary, Libin Cardiovasc Inst, Calgary, AB, Canada. [Komajda, Michel] Univ Paris 06, Pitie Salpetriere Hosp, Paris, France. [Krum, Henry] Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3004, Australia. [Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA. [McMurray, John J. V.] Univ Glasgow, BHF Cardiovasc Res Ctr, Glasgow, Lanark, Scotland. [Nieminen, Markku S.] Meilahti Hosp, Heart & Lung Ctr, Helsinki, Finland. [Swedberg, Karl] Univ Gothenburg, Sahlgrenska Acad, Dept Emergency & Cardiovasc Med, Gothenburg, Sweden. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Starling, Randall C.] Cleveland Clin, Inst Heart & Vasc, Dept Cardiovasc Med, Cleveland, OH 44106 USA. [Teerlink, John R.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Metra, M (reprint author), Univ Brescia, Dept Med & Surg Specialties, Div Cardiol, Brescia, Italy. EM metramarco@libero.it OI mcmurray, john/0000-0002-6317-3975 FU National Institutes of Health [U10HL110312]; Amgen; Gilead; Novartis; Otsuka; ResMed; Respicardia; Cardikinetix; Impulse Dynamics; St. Jude; Lung LLC; ARCA FX Dr. Metra has received consulting honoraria from Bayer, Novartis, Servier. Dr. Mentz receives research support with the grant U10HL110312 from National Institutes of Health, Amgen, Gilead, Novartis, Otsuka, and ResMed; and honoraria from HeartWare, Luitpold, Novartis, ResMed, and Thoratec. Dr. Costanzo has received consulting honoraria from Metronic, St. Jude, Respicardia, and ZS Pharma; and grants to Advocate Heart Institute from Respicardia, Cardikinetix, Impulse Dynamics, St. Jude, Novartis, Lung LLC, and ARCA. Dr. Fonarow reports consulting for Abbot, Amgen, Bayer, Baxter, Janssen, Novartis, Medtronic. The other authors have no conflicts of interest to disclose. NR 30 TC 2 Z9 2 U1 2 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD JUN 1 PY 2016 VL 117 IS 11 BP 1771 EP 1778 DI 10.1016/j.amjcard.2016.03.002 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DN4RH UT WOS:000377054400011 PM 27108685 ER PT J AU Decker, BK Clancy, CJ AF Decker, Brooke K. Clancy, Cornelius J. TI Culture positivity and bacterial burden thresholds for Legionella in hospital water: Proceed with caution SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Letter ID LEGIONNAIRES-DISEASE C1 [Decker, Brooke K.; Clancy, Cornelius J.] Vet Affairs Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C,Med IIIE U, Pittsburgh, PA 15240 USA. [Decker, Brooke K.; Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. RP Decker, BK (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C,Med IIIE U, Pittsburgh, PA 15240 USA. EM brooke.decker@va.gov NR 7 TC 1 Z9 1 U1 3 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD JUN 1 PY 2016 VL 44 IS 6 BP 730 EP 730 DI 10.1016/j.ajic.2015.11.038 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DN0IK UT WOS:000376747400029 PM 26851195 ER PT J AU Flanagan, JC Hakes, JK McClure, EA Snead, AL Back, SE AF Flanagan, Julianne C. Hakes, Jahn K. McClure, Erin A. Snead, Alexandra L. Back, Sudie E. TI Effects of Intimate Partner Violence, PTSD, and Alcohol Use on Cigarette Smoking in a Nationally Representative Sample SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENERAL-POPULATION SAMPLE; SUBSTANCE USE DISORDERS; GENDER-DIFFERENCES; UNITED-STATES; TOBACCO USE; EPIDEMIOLOGIC SURVEY; NICOTINE DEPENDENCE; ANXIETY DISORDERS; RANDOMIZED-TRIAL AB Background and Objectives: Separate literatures indicate that intimate partner violence (IPV), posttraumatic stress disorder (PTSD), and alcohol use are independently associated with increased risk for cigarette smoking. No previous studies have examined the cooccurrence of these problems on smoking quantity and potential gender-specific relationships. This study will address this gap in the literature. Methods: Data from Wave 2 of the National Epidemiologic Study on Alcohol and Related Conditions (NESARC) were examined. Variables were assessed during the past year. Individuals (N = 25,604) who reported being married, dating, or involved in a romantic relationship were included. Results: Among men, PTSD and alcohol use were associated with more cigarettes smoked per day. Among women, PTSD, alcohol use, and IPV victimization were associated with more cigarettes smoked per day. Women who experienced IPV victimization smoked approximately three additional cigarettes per day. Discussion and Conclusions: IPV victimization, PTSD, and alcohol use were associated with cigarettes smoked among women, while IPV experiences were not associated with smoking risk among men. Scientific Significance: These findings represent an important contribution to the existing literature in that it elucidates the compounding relationship between a common and complex comorbidity and cigarette smoking. Findings indicate a critical need to implement routine smoking screening and intervention in venueswhere intimate partner violence is commonly encountered, such as advocacy and substance use treatment settings. C1 [Flanagan, Julianne C.; McClure, Erin A.; Back, Sudie E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29455 USA. [Hakes, Jahn K.] US Bur Census, Suitland, MD USA. [Snead, Alexandra L.] Univ Houston, Dept Psychol, Houston, TX USA. [Back, Sudie E.] Ralph H Johnson VAMC, Charleston, SC USA. RP Flanagan, JC (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 5 Charleston Ctr Dr,Suite 151, Charleston, SC 29455 USA. EM hellmuth@musc.edu FU National Institute on Child Health and Human Development; Office of Research on Women's Health [K12HD055885]; National Institute on Drug Abuse in Bethesda, Maryland [K01DA036739] FX This manuscript is the result of work supported, in part, by the National Institute on Child Health and Human Development and the Office of Research on Women's Health (K12HD055885; PI: Kathleen T. Brady, Medical University of South Carolina) and National Institute on Drug Abuse (K01DA036739; PI: Erin McClure) in Bethesda, Maryland. NR 42 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JUN PY 2016 VL 25 IS 4 BP 283 EP 290 DI 10.1111/ajad.12381 PG 8 WC Substance Abuse SC Substance Abuse GA DN6YC UT WOS:000377221500007 PM 27196699 ER PT J AU Fuehrlein, B Mota, N Kachadourian, L Arias, A Trevisan, L Krystal, J Southwick, S Pietrzak, R AF Fuehrlein, Brian Mota, Natalie Kachadourian, Lorig Arias, Albert Trevisan, Louis Krystal, John Southwick, Steven Pietrzak, Robert TI High Burden of Alcohol Use Disorders in the US Veteran Population: Results from the National Health and Resilience in Veterans Study SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 [Fuehrlein, Brian; Kachadourian, Lorig; Arias, Albert; Trevisan, Louis; Krystal, John; Southwick, Steven; Pietrzak, Robert] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Mota, Natalie] US Dept Vet Affairs, Washington, DC USA. FU Department of Veterans Affairs (VA National Center for PTSD); National Institute on Alcohol Abuse and Alcoholism [P50AA12870, M01RR00125]; Yale Center for Clinical Investigation [UL1 RR024139] FX Department of Veterans Affairs (VA National Center for PTSD), the National Institute on Alcohol Abuse and Alcoholism (P50AA12870, M01RR00125), and the Yale Center for Clinical Investigation (UL1 RR024139). NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JUN PY 2016 VL 25 IS 4 BP 314 EP 314 PG 1 WC Substance Abuse SC Substance Abuse GA DN6YC UT WOS:000377221500024 ER PT J AU Seth, A Ajagbe, T Wang, DL Middleton, F Batki, SL Meszaros, ZS AF Seth, Amit Ajagbe, Tolani Wang, Dongliang Middleton, Frank Batki, Steven L. Meszaros, Zsuzsa Szombathyne TI A Retrospective Study of Prenatal, Childhood, and Adolescent Nicotine, Alcohol, and Drug Exposure in Schizophrenia SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 [Seth, Amit; Ajagbe, Tolani; Batki, Steven L.; Meszaros, Zsuzsa Szombathyne] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Wang, Dongliang] Dept Publ Hlth & Prevent Med, Syracuse, NY USA. [Middleton, Frank] SUNY Upstate Med Univ, Dept Neurosci Physiol, Syracuse, NY 13210 USA. [Batki, Steven L.] UCSF, Dept Psychiat, San Francisco, CA USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. FU Brain and Behavior Research Foundation FX This research was supported by the Brain and Behavior Research Foundation ( PI: Dr. Meszaros). NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JUN PY 2016 VL 25 IS 4 BP 337 EP 337 PG 1 WC Substance Abuse SC Substance Abuse GA DN6YC UT WOS:000377221500075 ER PT J AU Wong, T Pennington, D Schmeling, B Lasher, B Schrodek, E Yohannes, S McDonald, J Batki, SL AF Wong, Tiffany Pennington, David Schmeling, Brandi Lasher, Brooke Schrodek, Emily Yohannes, Seghel McDonald, Jordan Batki, Steven L. TI Relationships between Alcohol Use and Cognitive Reserve, Complaints, and Function in Veterans with Traumatic Injury SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Meeting Abstract C1 [Wong, Tiffany; Pennington, David; Schmeling, Brandi; Lasher, Brooke; Schrodek, Emily; Yohannes, Seghel; McDonald, Jordan] San Francisco VA Med Ctr, San Francisco, CA USA. [Wong, Tiffany; Schmeling, Brandi] Palo Alto Univ, Palo Alto, CA USA. [Pennington, David; Lasher, Brooke; Schrodek, Emily; Yohannes, Seghel; McDonald, Jordan; Batki, Steven L.] NCIRE, Palo Alto, CA USA. [Batki, Steven L.] UCSF, San Francisco VA Med Ctr, San Francisco, CA USA. FU Department of Defense [W81XWH-12-2-0137, W81XWH-11-2-0245] FX Department of Defense W81XWH-12-2-0137 and W81XWH-11-2-0245 (SLB), administered by the Northern California Institute for Research and Education. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JUN PY 2016 VL 25 IS 4 BP 341 EP 341 PG 1 WC Substance Abuse SC Substance Abuse GA DN6YC UT WOS:000377221500085 ER PT J AU Badrane, H Nguyen, MH Clancy, CJ AF Badrane, Hassan Nguyen, M. Hong Clancy, Cornelius J. TI Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against Candida albicans SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID TRANSCRIPTIONAL REGULATOR CAS5; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; HYPHAL FORMATION; DAMAGE RESPONSE; CYTOKINESIS; VIRULENCE; CANDIDA-ALBICANS-IRS4; PHOSPHOINOSITIDES AB Phosphatidylinositol 4,5-bisphosphate [PI(4,5) P-2] activates the yeast cell wall integrity pathway. Candida albicans exposure to caspofungin results in the rapid redistribution of PI(4,5) P-2 and septins to plasma membrane foci and subsequent fungicidal effects. We studied C. albicans PI(4,5) P-2 and septin dynamics and protein kinase C (PKC)-Mkc1 cell wall integrity pathway activation following exposure to caspofungin and other drugs. PI(4,5) P-2 and septins were visualized by live imaging of C. albicans cells coexpressing green fluorescent protein (GFP)-pleckstrin homology (PH) domain and red fluorescent protein-Cdc10p, respectively. PI(4,5) P-2 was also visualized in GFP-PH domain-expressing C. albicans mkc1 mutants. Mkc1p phosphorylation was measured as a marker of PKC-Mkc1 pathway activation. Fungicidal activity was assessed using 20-h time-kill assays. Caspofungin immediately induced PI(4,5) P-2 and Cdc10p colocalization to aberrant foci, a process that was highly dynamic over 3 h. PI(4,5) P-2 levels increased in a dose-response manner at caspofungin concentrations of <= 4x MIC and progressively decreased at concentrations of >= 8x MIC. Caspofungin exposure resulted in broad-based mother-daughter bud necks and arrested septum-like structures, in which PI(4,5) P-2 and Cdc10 colocalized. PKC-Mkc1 pathway activation was maximal within 10 min, peaked in response to caspofungin at 4x MIC, and declined at higher concentrations. The caspofungin-induced PI(4,5) P-2 redistribution remained apparent in mkc1 mutants. Caspofungin exerted dose-dependent killing and paradoxical effects at <= 4x and >= 8x MIC, respectively. Fluconazole, amphotericin B, calcofluor white, and H2O2 did not impact the PI(4,5) P-2 or Cdc10p distribution like caspofungin did. Caspofungin exerts rapid PI(4,5) P-2-septin and PKC-Mkc1 responses that correlate with the extent of C. albicans killing, and the responses are not induced by other antifungal agents. PI(4,5) P-2-septin regulation is crucial in early caspofungin responses and PKC-Mkc1 activation. C1 [Badrane, Hassan; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Div Infect Dis, Dept Med, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Badrane, H (reprint author), Univ Pittsburgh, Div Infect Dis, Dept Med, Pittsburgh, PA USA. EM hab42@pitt.edu FU U.S. Department of Veterans Affairs (VA) [1IO1BX001955] FX This work, including the efforts of Cornelius J. Clancy, was funded by U.S. Department of Veterans Affairs (VA) (1IO1BX001955). NR 48 TC 1 Z9 1 U1 2 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUN PY 2016 VL 60 IS 6 BP 3591 EP 3600 DI 10.1128/AAC.02711-15 PG 10 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA DN4PE UT WOS:000377048900040 PM 27021331 ER PT J AU Padrez, KA Ungar, L Schwartz, HA Smith, RJ Hill, S Antanavicius, T Brown, DM Crutchley, P Asch, DA Merchant, RM AF Padrez, Kevin A. Ungar, Lyle Schwartz, Hansen Andrew Smith, Robert J. Hill, Shawndra Antanavicius, Tadas Brown, Dana M. Crutchley, Patrick Asch, David A. Merchant, Raina M. TI Linking social media and medical record data: a study of adults presenting to an academic, urban emergency department SO BMJ QUALITY & SAFETY LA English DT Article ID BEHAVIOR-CHANGE INTERVENTIONS; ALZHEIMERS-DISEASE; HEALTH INFORMATION; FACEBOOK; TWITTER; CARE; COMMUNICATION; NETWORKS; INTERNET; QUALITY AB Background Social media may offer insight into the relationship between an individual's health and their everyday life, as well as attitudes towards health and the perceived quality of healthcare services. Objective To determine the acceptability to patients and potential utility to researchers of a database linking patients' social media content with their electronic medical record (EMR) data. Methods Adult Facebook/Twitter users who presented to an emergency department were queried about their willingness to share their social media data and EMR data with health researchers for the purpose of building a databank for research purposes. Shared posts were searched for select terms about health and healthcare. Results Of the 5256 patients approached, 2717 (52%) were Facebook and/or Twitter users. 1432 (53%) of those patients agreed to participate in the study. Of these participants, 1008 (71%) consented to share their social media data for the purposes of comparing it with their EMR. Social media data consisted of 1 395 720 posts/tweets to Facebook and Twitter. Participants sharing social media data were slightly younger (29.1 +/- 9.8 vs 31.9 +/- 10.4 years old; p<0.001), more likely to post at least once a day (42% vs 29%; p=0.003) and more likely to present to the emergency room via self-arrival mode and have private insurance. Of Facebook posts, 7.5% (95% CI 4.8% to 10.2%) were related to health. Individuals with a given diagnosis in their EMR were significantly more likely to use terms related to that diagnosis on Facebook than patients without that diagnosis in their EMR (p<0.0008). Conclusions Many patients are willing to share and link their social media data with EMR data. Sharing patients have several demographic and clinical differences compared with non-sharers. A database that merges social media with EMR data has the potential to provide insights about individuals' health and health outcomes. C1 [Padrez, Kevin A.] Univ Calif San Francisco, Emergency Med, San Francisco, CA 94143 USA. [Padrez, Kevin A.; Ungar, Lyle; Schwartz, Hansen Andrew; Smith, Robert J.; Hill, Shawndra; Antanavicius, Tadas; Brown, Dana M.; Crutchley, Patrick; Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA. [Ungar, Lyle; Schwartz, Hansen Andrew] Univ Penn, Comp & Informat Sci, Philadelphia, PA 19104 USA. [Ungar, Lyle; Schwartz, Hansen Andrew; Smith, Robert J.; Antanavicius, Tadas; Crutchley, Patrick] Univ Penn, Posit Psychol Ctr, Philadelphia, PA 19104 USA. [Smith, Robert J.; Brown, Dana M.; Merchant, Raina M.] Univ Penn, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Hill, Shawndra] Univ Penn, Operat & Informat Management Dept, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, Dept Emergency Med, Penn Med Social Media & Hlth Innovat Lab, Philadelphia, PA 19104 USA. EM Raina.merchant@uphs.upenn.edu OI Crutchley, Patrick/0000-0003-4400-9309; Smith, Robert James/0000-0001-9746-1230 FU Leonard Davis Institute of Health Economics; NIH [HL122457-01A1, 109083-01] FX Leonard Davis Institute of Health Economics. RMM received funding support from NIH, R01, and (HL122457-01A1) and NIH, K23 (109083-01). NR 45 TC 5 Z9 5 U1 4 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD JUN PY 2016 VL 25 IS 6 BP 414 EP 423 DI 10.1136/bmjqs-2015-004489 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DN2WT UT WOS:000376924400006 PM 26464519 ER PT J AU Reid, AT Bzdok, D Langner, R Fox, PT Laird, AR Amunts, K Eickhoff, SB Eickhoff, CR AF Reid, Andrew T. Bzdok, Danilo Langner, Robert Fox, Peter T. Laird, Angela R. Amunts, Katrin Eickhoff, Simon B. Eickhoff, Claudia R. TI Multimodal connectivity mapping of the human left anterior and posterior lateral prefrontal cortex SO BRAIN STRUCTURE & FUNCTION LA English DT Article DE Meta-analytic connectivity modeling; Functional connectivity; Structural covariance; Working memory; Anterior lateral prefrontal cortex; Posterior lateral prefrontal cortex ID SPATIAL WORKING-MEMORY; TRANSCRANIAL MAGNETIC STIMULATION; CENTRAL EXECUTIVE FUNCTIONS; GLOBAL SIGNAL REGRESSION; HUMAN CEREBRAL-CORTEX; FUNCTIONAL CONNECTIVITY; DEFAULT-MODE; HUMAN BRAIN; COGNITIVE CONTROL; FRONTAL LOBES AB Working memory is essential for many of our distinctly human abilities, including reasoning, problem solving, and planning. Research spanning many decades has helped to refine our understanding of this high-level function as comprising several hierarchically organized components, some which maintain information in the conscious mind, and others which manipulate and reorganize this information in useful ways. In the neocortex, these processes are likely implemented by a distributed frontoparietal network, with more posterior regions serving to maintain volatile information, and more anterior regions subserving the manipulation of this information. Recent meta-analytic findings have identified the anterior lateral prefrontal cortex, in particular, as being generally engaged by working memory tasks, while the posterior lateral prefrontal cortex was more strongly associated with the cognitive load required by these tasks. These findings suggest specific roles for these regions in the cognitive control processes underlying working memory. To further characterize these regions, we applied three distinct seed-based methods for determining cortical connectivity. Specifically, we employed meta-analytic connectivity mapping across task-based fMRI experiments, resting-state BOLD correlations, and VBM-based structural covariance. We found a frontoparietal pattern of convergence which strongly resembled the working memory networks identified in previous research. A contrast between anterior and posterior parts of the lateral prefrontal cortex revealed distinct connectivity patterns consistent with the idea of a hierarchical organization of frontoparietal networks. Moreover, we found a distributed network that was anticorrelated with the anterior seed region, which included most of the default mode network and a subcomponent related to social and emotional processing. These findings fit well with the internal attention model of working memory, in which representation of information is processed according to an anteroposterior gradient of abstract-to-concrete representations. C1 [Reid, Andrew T.; Bzdok, Danilo; Langner, Robert; Amunts, Katrin; Eickhoff, Simon B.; Eickhoff, Claudia R.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Bzdok, Danilo; Langner, Robert; Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Claudia R.] Univ Hosp Aachen, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Laird, Angela R.] Florida Int Univ, Miami, FL 33199 USA. [Amunts, Katrin] Univ Dusseldorf, C&O Vogt Inst Brain Res, Dusseldorf, Germany. [Bzdok, Danilo] CEA Saclay, Parietal Team, INRIA, Neurospin,Bat 145, F-91191 Gif Sur Yvette, France. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Reid, AT (reprint author), Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. EM a.reid@fz-juelich.de RI Reid, Andrew/O-4359-2015 OI Reid, Andrew/0000-0002-0523-926X; Langner, Robert/0000-0002-3237-001X; Amunts, Katrin/0000-0001-5828-0867 FU Deutsche Forschungsgemeinschaft (DFG) [EI 816/4-1, LA 3071/3-1, EI 816/6-1]; National Institute of Mental Health [R01-MH074457]; Helmholtz-Portfolio Project on "Supercomputing and Modeling for the Human Brain"; European Union [604102] FX This study was supported by the Deutsche Forschungsgemeinschaft (DFG, EI 816/4-1, LA 3071/3-1; EI 816/6-1.), the National Institute of Mental Health (R01-MH074457), the Helmholtz-Portfolio Project on "Supercomputing and Modeling for the Human Brain" and the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 604102 (Human Brain Project). NR 104 TC 4 Z9 4 U1 5 U2 11 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2653 EI 1863-2661 J9 BRAIN STRUCT FUNCT JI Brain Struct. Funct. PD JUN PY 2016 VL 221 IS 5 BP 2589 EP 2605 DI 10.1007/s00429-015-1060-5 PG 17 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA DN4DB UT WOS:000377012100013 PM 25982222 ER PT J AU Auerbach, JS Schott, CK AF Auerbach, Jonathan S. Schott, Christopher K. TI Solid-Organ Graft-Versus-Host Disease After Liver Transplant: A Case Report SO CRITICAL CARE NURSE LA English DT Article ID LUNG; MACROCHIMERISM AB Solid-organ transplant graft-versus-host disease (SOT-GVHD) is a rare complication of organ transplant that is associated with high mortality. The initial signs and symptoms are vague, so this disease is easily confused with other posttransplant complications. A case of SOT-GVHD occurred after ortho-topic liver transplant for liver failure due to hepatitis C in a patient in a Veterans Affairs intensive care unit. The patient had dehydration, acute kidney injuries, rashes, diarrhea, and pancytopenia. Results of skin biopsy, bone marrow biopsy, and cytogenetic studies were consistent with SOT-GVHD. Despite supportive care including antibiotics, antiviral and antifungal therapy, high-dose steroids, antithymoglobulin and neupogen, the patient died of overwhelming sepsis. Owing to the rarity of SOT-GVHD, no evidence-based guidelines or recommendations for treatment exist. Treatment includes high-dose corticosteroids and antibiotic, antifungal, and antiviral prophylaxis. Treatment of liver transplant-related GVHD with anti-tumor necrosis factor a agents has been successful. C1 [Auerbach, Jonathan S.] Boca Raton Reg Hosp, Boca Raton, FL USA. [Auerbach, Jonathan S.] Bethesda Hosp, Boca Raton, FL USA. [Auerbach, Jonathan S.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA. [Schott, Christopher K.] VA Pittsburgh Hlth Care Syst, Mail Route 124-U,Univ Dr C, Pittsburgh, PA 15240 USA. [Schott, Christopher K.] Univ Pittsburgh, Med Ctr, Crit Care & Emergency Med, Pittsburgh, PA USA. [Schott, Christopher K.] Univ Pittsburgh, Med Ctr, Crit Care Ultrasonog, Pittsburgh, PA USA. [Schott, Christopher K.] Univ Pittsburgh, Med Ctr, Med Student Crit Care Elect, Pittsburgh, PA USA. RP Schott, CK (reprint author), VA Pittsburgh Hlth Care Syst, Mail Route 124-U,Univ Dr C, Pittsburgh, PA 15240 USA. EM schottck@upmc.edu NR 17 TC 0 Z9 0 U1 2 U2 2 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 EI 1940-8250 J9 CRIT CARE NURSE JI Crit. Care Nurse PD JUN PY 2016 VL 36 IS 3 BP E7 EP E11 DI 10.4037/ccn2016988 PG 5 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA DN5BZ UT WOS:000377082500002 PM 27252108 ER PT J AU Cefalu, WT Rubino, F Cummings, DE AF Cefalu, William T. Rubino, Francesco Cummings, David E. TI Metabolic Surgery for Type 2 Diabetes: Changing the Landscape of Diabetes Care SO DIABETES CARE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; Y GASTRIC BYPASS; INTENSIVE MEDICAL-MANAGEMENT; LIFE-STYLE INTERVENTION; SWEDISH OBESE SUBJECTS; BARIATRIC SURGERY; CLINICAL-TRIAL; GASTROINTESTINAL SURGERY; SYSTEMATIC ANALYSIS; GLUCOSE-METABOLISM C1 [Cefalu, William T.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. [Rubino, Francesco] Kings Coll London, Div Diabet & Nutr Sci, London WC2R 2LS, England. [Cummings, David E.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Cummings, David E.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. RP Cefalu, WT (reprint author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA. EM cefaluwt@pbrc.edu FU NCCIH NIH HHS [P50 AT002776]; NIDDK NIH HHS [R01 DK084324, R01 DK089528, R01 DK103842, U34 DK107917]; NIGMS NIH HHS [U54 GM104940] NR 52 TC 4 Z9 4 U1 2 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2016 VL 39 IS 6 BP 857 EP 860 DI 10.2337/dc16-0686 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN3RJ UT WOS:000376980500010 PM 27222543 ER PT J AU Batterham, RL Cummings, DE AF Batterham, Rachel L. Cummings, David E. TI Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery SO DIABETES CARE LA English DT Article ID Y GASTRIC BYPASS; VERTICAL SLEEVE GASTRECTOMY; BETA-CELL FUNCTION; OUTCOMES LONGITUDINAL DATABASE; DUODENAL-JEJUNAL BYPASS; BARIATRIC SURGERY; WEIGHT-LOSS; BILE-ACIDS; INSULIN SENSITIVITY; HYPERINSULINEMIC HYPOGLYCEMIA AB More than 20 years ago, Pories et al. published a seminal article, Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus. This was based on their observation that bariatric surgery rapidly normalized blood glucose levels in obese people with type 2 diabetes mellitus (T2DM), and 10 years later, almost 90% remained diabetes free. Pories et al. suggested that caloric restriction played a key role and that the relative contributions of proximal intestinal nutrient exclusion, rapid distal gut nutrient delivery, and the role of gut hormones required further investigation. These findings of T2DM improvement/remission after bariatric surgery have been widely replicated, together with the observation that bariatric surgery prevents or delays incident T2DM. Over the ensuing two decades, important glucoregulatory roles of the gastrointestinal (GI) tract have been firmly established. However, the physiological and molecular mechanisms underlying the beneficial glycemic effects of bariatric surgery remain incompletely understood. In addition to the mechanisms proposed by Pories et al., changes in bile acid metabolism, GI tract nutrient sensing and glucose utilization, incretins, possible anti-incretin(s), and the intestinal microbiome are implicated. These changes, acting through peripheral and/or central pathways, lead to reduced hepatic glucose production, increased tissue glucose uptake, improved insulin sensitivity, and enhanced -cell function. A constellation of factors, rather than a single overarching mechanism, likely mediate postoperative glycemic improvement, with the contributing factors varying according to the surgical procedure. Thus, different bariatric/metabolic procedures provide us with experimental tools to probe GI tract physiology. Embracing this approach through the application of detailed phenotyping, genomics, metabolomics, and gut microbiome studies will enhance our understanding of metabolic regulation and help identify novel therapeutic targets. C1 [Batterham, Rachel L.] UCL, Dept Med, Obes Res Ctr, London, England. [Batterham, Rachel L.] Univ Coll London Hosp, Bariatr Ctr Weight Management & Metab Surg, London, England. [Batterham, Rachel L.] Univ Coll London Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England. [Cummings, David E.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Cummings, David E.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. RP Batterham, RL (reprint author), UCL, Dept Med, Obes Res Ctr, London, England.; Batterham, RL (reprint author), Univ Coll London Hosp, Bariatr Ctr Weight Management & Metab Surg, London, England.; Batterham, RL (reprint author), Univ Coll London Hosp, Natl Inst Hlth Res, Biomed Res Ctr, London, England. EM r.batterham@ucl.ac.uk FU Rosetrees Trust; Stoneygate Trust; National Institute of Diabetes and Digestive and Kidney Diseases [RO1-DK-103842, RO1-DK-084324, RO1-DK-089528, U34-DK-107917] FX R.L.B. is supported by grants from the Rosetrees Trust and Stoneygate Trust. D.E.C. is supported by National Institute of Diabetes and Digestive and Kidney Diseases grants RO1-DK-103842, RO1-DK-084324, RO1-DK-089528, and U34-DK-107917. NR 67 TC 11 Z9 12 U1 5 U2 13 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2016 VL 39 IS 6 BP 893 EP 901 DI 10.2337/dc16-0145 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN3RJ UT WOS:000376980500014 PM 27222547 ER PT J AU Cummings, DE Cohen, RV AF Cummings, David E. Cohen, Ricardo V. TI Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI < 35 kg/m(2) SO DIABETES CARE LA English DT Article ID SWEDISH OBESE SUBJECTS; GASTRIC BYPASS-SURGERY; BODY-MASS INDEX; RANDOMIZED CONTROLLED-TRIAL; INTENSIVE MEDICAL THERAPY; LONG-TERM REMISSION; BARIATRIC SURGERY; METABOLIC SURGERY; GASTROINTESTINAL SURGERY; CONTROLLED INTERVENTION AB OBJECTIVEGlobal usage of bariatric surgery has been dictated for the past quarter century by National Institutes of Health recommendations restricting these operations to individuals with a BMI 35 kg/m(2). Strong evidence now demonstrates that bariatric procedures markedly improve or cause remission of type 2 diabetes mellitus (T2DM), in part through weight-independent mechanisms, and that baseline BMI does not predict surgical benefits on glycemic or cardiovascular outcomes. This impels consideration of such operations as metabolic surgery, which is used expressly to treat T2DM, including among patients with a BMI <35 kg/m(2) who constitute the majority of people with diabetes worldwide. Here, we review available evidence to inform that consideration.RESULTSA meta-analysis of the 11 published randomized clinical trials (RCTs) directly comparing bariatric/metabolic surgery versus a variety of medical/lifestyle interventions for T2DM provides level 1A evidence that surgery is superior for T2DM remission, glycemic control, and HbA(1c) lowering. Importantly, this is equally true for patients whose baseline BMI is below or above 35 kg/m(2). Similar conclusions derive from meta-analyses of high-quality nonrandomized prospective comparisons. Meta-analysis of all pertinent published studies indicates that T2DM remission rates following bariatric/metabolic surgery are comparable above and below the 35 kg/m(2) BMI threshold. The safety, antidiabetes durability, and benefits on other cardiovascular risk factors from bariatric/metabolic surgery appear roughly comparable among patients with a BMI below or above 35 kg/m(2). Further studies are needed to extend long-term findings and measure hard macrovascular/microvascular outcomes and mortality in RCTs.CONCLUSIONSExtant data, including level 1A evidence from numerous RCTs, support new guidelines from the 2nd Diabetes Surgery Summit that advocate for the consideration of bariatric/metabolic surgery as one option, along with lifestyle and medical therapy, to treat T2DM among patients with a BMI <35 kg/m(2). C1 [Cummings, David E.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Cummings, David E.] Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. [Cohen, Ricardo V.] Oswaldo Cruz Hosp, Ctr Diabet & Obes, Sao Paulo, Brazil. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.; Cummings, DE (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, Seattle, WA 98195 USA. EM davidec@u.washington.edu FU NIH [RO1 DK103842, RO1 DK084324, RO1 DK089528, U34 DK107917] FX D.E.C. is supported by NIH grants RO1 DK103842, RO1 DK084324, RO1 DK089528, and U34 DK107917. NR 45 TC 3 Z9 3 U1 2 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2016 VL 39 IS 6 BP 924 EP 933 DI 10.2337/dc16-0350 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN3RJ UT WOS:000376980500017 PM 27222550 ER PT J AU Livny, A Ravona-Springer, R Heymann, A Priess, R Kushnir, T Tsarfaty, G Rabinov, L Moran, R Hoffman, H Cooper, I Greenbaum, L Silverman, J Sano, M Johnson, SC Bendlin, BB Beeri, MS AF Livny, Abigail Ravona-Springer, Ramit Heymann, Anthony Priess, Rachel Kushnir, Tammar Tsarfaty, Galia Rabinov, Leeron Moran, Reut Hoffman, Hadass Cooper, Itzik Greenbaum, Lior Silverman, Jeremy Sano, Mary Johnson, Sterling C. Bendlin, Barbara B. Beeri, Michal Schnaider TI Long-term Variability in Glycemic Control Is Associated With White Matter Hyperintensities in APOE4 Genotype Carriers With Type 2 Diabetes SO DIABETES CARE LA English DT Article ID VASCULAR RISK-FACTORS; COGNITIVE DECLINE; APOLIPOPROTEIN-E; DISEASE; BRAIN; METAANALYSIS; EPSILON-4; DEMENTIA; MELLITUS; PEOPLE AB OBJECTIVEWe assessed whether the apolipoprotein epsilon 4 (APOE4) genotype affects the relationship of variability in long-term glycemic control (measured by HbA(1c) SD of multiple measurements) with white matter hyperintensities (WMHs) in elderly patients with type 2 diabetes (T2D).RESEARCH DESIGN AND METHODSWMH volume was generated from structural T1 and fluid-attenuated inversion recovery MRI in each subject. The analysis included 124 subjects; 27 (21.8%) had one or more APOE4 alleles.RESULTSHbA(1c) variability was associated with significantly higher WMH in APOE4 carriers (r = 0.47, P = 0.03), controlling for age, sex, mean HbA(1c), number of follow-up years, and a composite of cardiovascular risk factors, but not in noncarriers (r = -0.04, P = 0.71; P for interaction = 0.050).CONCLUSIONSThe results suggest that the APOE4 genotype affects the relationship of long-term glycemic control with WMH load so that APOE4 carriers may be more vulnerable to the insults of poor control. C1 [Livny, Abigail; Kushnir, Tammar; Tsarfaty, Galia; Rabinov, Leeron; Moran, Reut] Chaim Sheba Med Ctr, Dept Diagnost Imaging, IL-52621 Tel Hashomer, Israel. [Livny, Abigail; Ravona-Springer, Ramit; Hoffman, Hadass; Cooper, Itzik; Greenbaum, Lior; Beeri, Michal Schnaider] Chaim Sheba Med Ctr, Josef Sagol Neurosci Ctr, IL-52621 Tel Hashomer, Israel. [Ravona-Springer, Ramit] Chaim Sheba Med Ctr, Memory Clin, IL-52621 Tel Hashomer, Israel. [Heymann, Anthony; Priess, Rachel] Maccabi Healthcare Serv, Tel Aviv, Israel. [Heymann, Anthony; Kushnir, Tammar; Tsarfaty, Galia] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Cooper, Itzik; Sano, Mary; Beeri, Michal Schnaider] Interdisciplinary Ctr Herzliya, Sch Psychol, Herzliyya, Israel. [Silverman, Jeremy] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Silverman, Jeremy] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Johnson, Sterling C.; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Johnson, Sterling C.; Bendlin, Barbara B.] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. RP Livny, A (reprint author), Chaim Sheba Med Ctr, Dept Diagnost Imaging, IL-52621 Tel Hashomer, Israel.; Livny, A (reprint author), Chaim Sheba Med Ctr, Josef Sagol Neurosci Ctr, IL-52621 Tel Hashomer, Israel. EM abigail.livnyezer@gmail.com FU American Federation for Aging Research; National Institute on Aging [P50-AG-05138, R01-AG-034087, R21-AG-043878]; Helen Bader Foundation; Leroy Schecter Foundation; Irma T. Hirschl Scholar Award FX This research was conducted while I.C. was a New Investigator Award in Alzheimer Disease recipient from the American Federation for Aging Research and was supported by National Institute on Aging grants P50-AG-05138 (to M.S.) and R01-AG-034087 and R21-AG-043878 (to M.S.B.) as well as the Helen Bader Foundation, the Leroy Schecter Foundation, and the Irma T. Hirschl Scholar Award (to M.S.B.). NR 17 TC 1 Z9 1 U1 1 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2016 VL 39 IS 6 BP 1056 EP 1059 DI 10.2337/dc15-2331 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DN3RJ UT WOS:000376980500034 PM 27208321 ER PT J AU Rinke, ML Singh, H Ruberman, S Adelman, J Choi, SJ O'Donnell, H Stein, REK Brady, TM Heo, M Lehmann, CU Kairys, S Rice-Conboy, E Theissen, K Bundy, DG AF Rinke, Michael L. Singh, Hardeep Ruberman, Sarah Adelman, Jason Choi, Steven J. O'Donnell, Heather Stein, Ruth E. K. Brady, Tammy M. Heo, Moonseong Lehmann, Christoph U. Kairys, Steven Rice-Conboy, Elizabeth Theissen, Keri Bundy, David G. TI Primary care pediatricians' interest in diagnostic error reduction SO DIAGNOSIS LA English DT Article DE diagnostic error; pediatrics; primary care AB Background: Diagnostic errors causing harm in children are understudied, resulting in a knowledge gap regarding pediatricians' interest in reducing their incidence. Methods: Electronic survey of general pediatricians focusing on diagnostic error incidence, errors they were interested in trying to improve, and errors reduced by their electronic health record (EHR). Results: Of 300 contacted pediatricians, 77 (26%) responded, 58 (19%) served ambulatory patients, and 48 (16%) completed the entire questionnaire. Of these 48, 17 (35%) reported making a diagnostic error at least monthly, and 16 (33%) reported making a diagnostic error resulting in an adverse event at least annually. Pediatricians were "most" interested in "trying to improve" missed diagnosis of hypertension (17%), delayed diagnosis due to missed subspecialty referral (15%), and errors associated with delayed follow-up of abnormal laboratory values (13%). Among the 44 pediatricians with an EHR, 16 (36%) said it reduced the likelihood of missing obesity and 14 (32%) said it reduced the likelihood of missing hypertension. Also, 15 (34%) said it helped avoid delays in follow-up of abnormal laboratory values. A third (36%) reported no help in diagnostic error reduction from their EHR. Conclusions: Pediatricians self-report an appreciable number of diagnostic errors and were most interested in preventing high frequency, non-life-threatening errors. There exists a need to leverage EHRs to support error reduction efforts. C1 [Rinke, Michael L.; Choi, Steven J.; O'Donnell, Heather; Stein, Ruth E. K.] Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA. [Rinke, Michael L.; Ruberman, Sarah; Choi, Steven J.; O'Donnell, Heather; Stein, Ruth E. K.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Michael E Debakey Vet Affairs Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX 77030 USA. [Adelman, Jason] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Brady, Tammy M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Heo, Moonseong] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Lehmann, Christoph U.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Kairys, Steven] Jersey Shore Univ, Med Ctr, Neptune, NJ USA. [Kairys, Steven; Rice-Conboy, Elizabeth; Theissen, Keri] Amer Acad Pediat, Div Qual, Qual Improvement Innovat Networks, Elk Grove Village, IL USA. [Bundy, David G.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Rinke, ML (reprint author), Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA.; Rinke, ML (reprint author), Albert Einstein Coll Med, Bronx, NY 10467 USA. EM mrinke@montefiore.org FU AHRQ HHS [R01 HS023608]; NCATS NIH HHS [UL1 TR001073] NR 13 TC 0 Z9 0 U1 0 U2 0 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 2194-8011 EI 2194-802X J9 DIAGNOSIS JI Diagnosis PD JUN PY 2016 VL 3 IS 2 BP 65 EP 69 DI 10.1515/dx-2015-0033 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DN7FU UT WOS:000377241500005 PM 28111611 ER PT J AU Heck, JE Park, AS Contreras, ZA Davidson, TB Hoggatt, KJ Cockburn, M Ritz, B AF Heck, Julia E. Park, Andrew S. Contreras, Zuelma A. Davidson, Tom B. Hoggatt, Katherine J. Cockburn, Myles Ritz, Beate TI Risk of Childhood Cancer by Maternal Birthplace A Test of the Hispanic Paradox SO JAMA PEDIATRICS LA English DT Article ID UNITED-STATES; PREGNANCY OUTCOMES; PRETERM BIRTH; EPIDEMIOLOGY; CALIFORNIA; CHILDREN; MEXICO; US; POPULATIONS; IMMIGRANTS AB IMPORTANCE The Hispanic epidemiologic paradox is the phenomenon that non-US-born Hispanic mothers who immigrate to the United States have better pregnancy outcomes than their US-born counterparts. It is unknown whether this advantage extends to childhood cancer risk. OBJECTIVE To determine whether the risk for childhood cancers among Hispanic children varies by maternal birthplace. DESIGN, SETTING, AND PARTICIPANTS In this population-based case-control study conducted in June 2015, cohort members were identified through California birth records of children born in California from January 1, 1983, to December 31, 2011. Information on cancer diagnoses was obtained from California Cancer Registry records from 1988 to 2012. Cases (n = 13 666) were identified from among children younger than 6 years in the California Cancer Registry and matched to California birth certificates. Control children (n = 15 513 718) included all other children born in California during the same period. Maternal birthplace and ethnic ancestry were identified from the birth certificate. MAIN EXPOSURES Maternal race/ethnicity and birthplace. MAIN OUTCOMES AND MEASURES We used Cox proportional hazards modeling to estimate hazard ratios (HRs) of childhood cancer. RESULTS Included in the study were 4 246 295 children of non-Hispanic white mothers (51.3% male), 2 548 822 children of US-born Hispanic mothers (51.0% male), and 4 397 703 children of non-US-born Hispanic mothers (51.0% male). Compared with children of non-Hispanic white mothers, the children of non-US-born Hispanic mothers had a reduced risk for glioma (HR, 0.50; 95% CI, 0.44-0.58), astrocytoma (HR, 0.43; 95% CI, 0.36-0.51), neuroblastoma (HR, 0.47; 95% CI, 0.40-0.54), and Wilms tumor (HR, 0.70; 95% CI, 0.59-0.82). For these cancer types, the risk estimates for children of US-born Hispanic mothers fell between those of the children of US-born white and non-US-born Hispanic mothers. Children of Mexican-born mothers had a higher risk of yolk sac tumors (HR, 1.46; 95% CI, 0.99-2.17), while children of US-born Hispanic mothers with ancestry from countries other than Mexico had a higher risk for unilateral retinoblastoma (HR, 2.03; 95% CI, 1.33-3.11). CONCLUSIONS AND RELEVANCE For several cancers, we observed differential risk by maternal place of birth. Examining the differences in health behaviors and environment between Hispanic groups may shed light on childhood cancer etiology. C1 [Heck, Julia E.; Park, Andrew S.; Contreras, Zuelma A.; Hoggatt, Katherine J.; Ritz, Beate] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, 650 Charles Young Dr,Box 951772, Los Angeles, CA 90095 USA. [Davidson, Tom B.] Univ Calif Los Angeles, Div Pediat Hematol Oncol, David Geffen Sch Med, 650 Charles Young Dr,Box 951772, Los Angeles, CA 90095 USA. [Hoggatt, Katherine J.] Vet Affairs Greater Los Angeles, Los Angeles, CA USA. [Cockburn, Myles] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. RP Heck, JE (reprint author), Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, 650 Charles Young Dr,Box 951772, Los Angeles, CA 90095 USA. EM jeheck@ucla.edu RI Heck, Julia/B-5230-2009 OI Heck, Julia/0000-0001-8713-8413 FU US National Institutes of Health [R21ES018960, R21ES019986, T32CA009142]; Department of Veterans Affairs Health Services Research and Development/Quality Enhancement Research Initiative Career Development Award [CDA 11-261]; National Cancer Institute's Surveillance, Epidemiology and End Results Program [HHSN261201000140C, HHSN261201000035C, HHSN261201000034C]; Centers for Disease Control and Prevention's National Program of Cancer Registries [U58DP003862-01] FX This work was supported by grants R21ES018960 and R21ES019986 from the US National Institutes of Health. Ms Contreras was supported by predoctoral fellowship T32CA009142 from the US National Institutes of Health. Dr Hoggatt was funded through Department of Veterans Affairs Health Services Research and Development/Quality Enhancement Research Initiative Career Development Award CDA 11-261. Dr Cockburn was supported in part by the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute, as well as the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. NR 39 TC 4 Z9 4 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD JUN PY 2016 VL 170 IS 6 BP 585 EP 592 DI 10.1001/jamapediatrics.2016.0097 PG 8 WC Pediatrics SC Pediatrics GA DN6LC UT WOS:000377185000018 PM 27110958 ER PT J AU Smith, NB Mota, N Tsai, J Monteith, L Harpaz-Rotem, I Southwick, SM Pietrzak, RH AF Smith, Noelle B. Mota, Natalie Tsai, Jack Monteith, Lindsey Harpaz-Rotem, Ilan Southwick, Steven M. Pietrzak, Robert H. TI Nature and determinants of suicidal ideation among US veterans: Results from the national health and resilience in veterans study SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Suicidal ideation; Longitudinal time points; Nationally representative veteran sample; Protective and risk factors ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; SOCIAL SUPPORT; PROTECTIVE FACTORS; DANISH SOLDIERS; FOLLOW-UP; RISK; DEPRESSION; ANXIETY; ADULTS AB Background: Suicidal thoughts and behaviors among U.S. military veterans are a major public health concern. To date, however, scarce data are available regarding the nature and correlates of suicidal ideation (SI) among U.S. veterans. This study evaluated the prevalence and correlates of suicidal ideation in a contemporary, nationally representative, 2-year prospective cohort study. Method: Data were analysed from a total of 2157 U.S. veterans who participated in the National Health and Resilience Veterans Study (NHRVS; Wave 1 conducted in 2011; Wave 2 in 2013). Veterans completed measures assessing SI, sociodemographic characteristics, and potential risk and protective correlates. Results: The majority of veterans (86.3%) denied SI at either time point, 5.0% had SI onset (no SI at Wave 1, SI at Wave 2), 4.9% chronic SI (SI at Waves 1 and 2), and 3.8% had remitted SI (SI at Wave 1, no SI Wave 2). Greater Wave 1 psychiatric distress was associated with increased likelihood of chronic SI (relative risk ratio [RRR]=3.72), remitted SI (RRR=3.38), SI onset (RRR=1.48); greater Wave 1 physical health difficulties were additionally associated with chronic SI (RRR=1.64) and SI onset (RRR=1.47); and Wave 1 substance abuse history was associated with chronic SI (RRR 1.57). Greater protective psychosocial characteristics (e.g., resilience, gratitude) at Wave 1 were negatively related to SI onset (RRR=0.57); and greater social connectedness at Wave 1, specifically perceived social support and secure attachment style, was negatively associated with SI onset (RRR=0.75) and remitted SI (RRR=0.44), respectively. Limitations: Suicidal ideation was assessed using a past two-week timeframe, and the limited duration of follow-up precludes conclusions regarding more dynamic changes in SI over time. Conclusions: These results indicate that a significant minority (13.7%) of U.S. veterans has chronic, onset, or remitted SI. Prevention and treatment efforts designed to mitigate psychiatric and physical health difficulties, and bolster social connectedness and protective psychosocial characteristics may help mitigate risk for SI. Published by Elsevier B.V. C1 [Smith, Noelle B.; Mota, Natalie; Harpaz-Rotem, Ilan; Southwick, Steven M.; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr PTSD, West Haven, CT USA. [Smith, Noelle B.; Mota, Natalie; Tsai, Jack; Harpaz-Rotem, Ilan; Southwick, Steven M.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Tsai, Jack] VA Connecticut Healthcare Syst, Res Educ & Clin Ctr, New England Mental Illness, West Haven, CT USA. [Monteith, Lindsey] Rocky Mt MIRECC, Denver VA Med Ctr, Denver, CO USA. [Monteith, Lindsey] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Harpaz-Rotem, Ilan] VA Northeast Program Evaluat Ctr, West Haven, CT USA. RP Smith, NB (reprint author), Yale Univ, Natl Ctr Posttraumat Stress Disorder, Dept Psychiat, VA Connecticut Healthcare Syst,Sch Med, 950 Campbell Ave 116B, West Haven, CT 06516 USA. EM Noelle.smith2@va.gov FU U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment Department of Veterans Affairs FX The National Health and Resilience in Veterans Study was supported by the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder. Preparation of this manuscript was supported in part by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment Department of Veterans Affairs. Dr. Pietrzak is a scientific consultant to Cogstate and Mitsubishi Tanabe Pharma America, Inc. for work that is unrelated to this manuscript. The other authors have no disclosures. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. NR 59 TC 0 Z9 0 U1 6 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JUN PY 2016 VL 197 BP 66 EP 73 DI 10.1016/j.jad.2016.02.069 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DJ7EN UT WOS:000374374800010 PM 26970267 ER PT J AU Hopkins, LB Medina, JL Baird, SO Rosenfield, D Powers, MB Smits, JAJ AF Hopkins, Lindsey B. Medina, Johnna L. Baird, Scarlett O. Rosenfield, David Powers, Mark B. Smits, Jasper A. J. TI Heated Hatha Yoga to Target Cortisol Reactivity to Stress and Affective Eating in Women at Risk for Obesity-Related Illnesses: A Randomized Controlled Trial SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE yoga; eating; stress; cortisol; obesity ID SALIVARY CORTISOL; PERCEIVED STRESS; BEHAVIOR; FOOD; QUESTIONNAIRE; DISORDERS; RESPONSES; WEIGHT; BODY; TOOL AB Objective: Cortisol reactivity to stress is associated with affective eating, an important behavioral risk factor for obesity and related metabolic diseases. Yoga practice is related to decreases in stress and cortisol levels, thus emerging as a potential targeted complementary intervention for affective eating. This randomized controlled trial examined the efficacy of a heated, hatha yoga intervention for reducing cortisol reactivity to stress and affective eating. Method: Females (N = 52; ages 25-46 years; 75% White) at risk for obesity and related illnesses were randomly assigned to 8 weeks of Bikram Yoga practice or to waitlist control. Cortisol reactivity to a laboratory stress induction were measured at Weeks 0 (pretreatment) and 9 (posttreatment). Self-reported binge eating frequency and coping motives for eating were assessed at Weeks 0, 3, 6, and 9. Results: Among participants with elevated cortisol reactivity at pretreatment ("high reactors"), those randomized to the yoga condition evidenced greater pre- to posttreatment reductions in cortisol reactivity (p = .042, d = .85), but there were not significant condition differences for the "low reactors" (p = .178, d = .53). Yoga participants reported greater decreases in binge eating frequency (p = .040, d = .62) and eating to cope with negative affect (p = .038, d = .54). Conclusions: This study provides preliminary support for the efficacy of heated hatha yoga for treating physiological stress reactivity and affective eating among women at risk for obesity-related illnesses. C1 [Hopkins, Lindsey B.; Medina, Johnna L.; Baird, Scarlett O.; Rosenfield, David; Powers, Mark B.; Smits, Jasper A. J.] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA. [Hopkins, Lindsey B.] San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA 94121 USA. [Medina, Johnna L.; Baird, Scarlett O.; Powers, Mark B.; Smits, Jasper A. J.] Univ Texas Austin, Dept Psychol, Mental Hlth Res Inst, Austin, TX 78712 USA. RP Hopkins, LB (reprint author), San Francisco VA Med Ctr, Stress & Hlth Res Program, San Francisco, CA 94121 USA. EM lbhopkins@gmail.com OI Hopkins, Lindsey/0000-0002-0577-2961; Powers, Mark/0000-0001-7898-073X FU National Institute on Drug Addiction [R01 DA027533, K01 DA035930, F31 DA036919]; Pure Action, Inc., Austin, Texas, a 501c3 nonprofit organization FX Research reported in this article was supported in part by Grants R01 DA027533, K01 DA035930, and F31 DA036919 awarded by the National Institute on Drug Addiction. Cortisol assays for this study were funded by a grant from Pure Action, Inc., Austin, Texas, a 501c3 nonprofit organization. Jasper A. J. Smits receives royalties from Oxford University Press for books on exercise as a treatment for mood and anxiety disorders. This article is based on the first author's doctoral dissertation. Trial Registration: ClinicalTrials.gov, NCT01652807, https:/clinicaltrials.govct2showNCT01652807. NR 31 TC 0 Z9 0 U1 3 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD JUN PY 2016 VL 84 IS 6 BP 558 EP 564 DI 10.1037/ccp0000091 PG 7 WC Psychology, Clinical SC Psychology GA DN2WN UT WOS:000376923800009 PM 26963599 ER PT J AU Wyatt, A Shriki, JE Bhargava, P AF Wyatt, Alvin, II Shriki, Jabi E. Bhargava, Puneet TI Dealing With No Shows: A Quality Improvement Initiative at a Tertiary Care Veterans Affairs Medical Center SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; RATES C1 [Wyatt, Alvin, II; Bhargava, Puneet] Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,Room BB308,Box 357115, Seattle, WA 98195 USA. [Shriki, Jabi E.] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. [Shriki, Jabi E.] Univ Washington, Sch Med, Seattle, WA USA. RP Bhargava, P (reprint author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,Room BB308,Box 357115, Seattle, WA 98195 USA. EM bhargp@uw.edu NR 13 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD JUN PY 2016 VL 13 IS 6 BP 702 EP 704 DI 10.1016/j.jacr.2015.08.013 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DN4QY UT WOS:000377053500020 PM 26475374 ER PT J AU Han, MLK Martinez, CH Au, DH Bourbeau, J Boyd, CM Branson, R Criner, GJ Kalhan, R Kallstrom, TJ King, A Krishnan, JA Lareau, SC Lee, TA Lindell, K Mannino, DM Martinez, FJ Meldrum, C Press, VG Thomashow, B Tycon, L Sullivan, JL Walsh, J Wilson, KC Wright, J Yawn, B Zueger, PM Bhatt, SP Dransfield, MT AF Han, MeiLan K. Martinez, Carlos H. Au, David H. Bourbeau, Jean Boyd, Cynthia M. Branson, Richard Criner, Gerard J. Kalhan, Ravi Kallstrom, Thomas J. King, Angela Krishnan, Jerry A. Lareau, Suzanne C. Lee, Todd A. Lindell, Kathleen Mannino, David M. Martinez, Fernando J. Meldrum, Catherine Press, Valerie G. Thomashow, Byron Tycon, Laura Sullivan, Jamie Lamson Walsh, John Wilson, Kevin C. Wright, Jean Yawn, Barbara Zueger, Patrick M. Bhatt, Surya P. Dransfield, Mark T. TI Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective SO LANCET RESPIRATORY MEDICINE LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS ANALYSIS; VOLUME-REDUCTION SURGERY; QUALITY-OF-CARE; LONG-ACTING BRONCHODILATORS; ACUTE MYOCARDIAL-INFARCTION; AMERICAN THORACIC SOCIETY; POSITIVE-PRESSURE VENTILATION; SELF-MANAGEMENT INTERVENTION AB The burden of chronic obstructive pulmonary disease (COPD) in the USA continues to grow. Although progress has been made in the the development of diagnostics, therapeutics, and care guidelines, whether patients' quality of life is improved will ultimately depend on the actual implementation of care and an individual patient's access to that care. In this Commission, we summarise expert opinion from key stakeholders-patients, caregivers, and medical professionals, as well as representatives from health systems, insurance companies, and industry-to understand barriers to care delivery and propose potential solutions. Health care in the USA is delivered through a patchwork of provider networks, with a wide variation in access to care depending on a patient's insurance, geographical location, and socioeconomic status. Furthermore, Medicare's complicated coverage and reimbursement structure pose unique challenges for patients with chronic respiratory disease who might need access to several types of services. Throughout this Commission, recurring themes indude poor guideline implementation among health-care providers and poor patient access to key treatments such as affordable maintenance drugs and pulmonary rehabilitation. Although much attention has recently been focused on the reduction of hospital readmissions for COPD exacerbations, health systems in the USA struggle to meet these goals, and methods to reduce readmissions have not been proven. There are no easy solutions, but engaging patients and innovative thinkers in the development of solutions is crucial. Financial incentives might be important in raising engagement of providers and health systems. Lowering co-pays for maintenance drugs could result in improved adherence and, ultimately, decreased overall health-care spending. Given the substantial geographical diversity, health systems will need to find their own solutions to improve care coordination and integration, until better data for interventions that are universally effective become available. C1 [Han, MeiLan K.; Martinez, Carlos H.; Meldrum, Catherine] Univ Michigan Hlth Syst, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA. [Au, David H.] US Dept Vet Affairs, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Au, David H.] US Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Bourbeau, Jean] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Boyd, Cynthia M.] Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA. [Branson, Richard] Univ Cincinnati, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA. [Criner, Gerard J.] Temple Univ, Dept Thorac Med & Surg, Lewis Katz Sch Med, Philadelphia, PA 19122 USA. [Kalhan, Ravi] Northwestern Univ, Feinberg Sch Med, Asthma & COPD Program, Chicago, IL 60611 USA. [Kallstrom, Thomas J.] Amer Assoc Resp Care, Dallas, TX USA. [King, Angela] Mobile Med Homecare, Leo, IN USA. [Krishnan, Jerry A.] Univ Illinois, Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA. [Lee, Todd A.] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA. [Zueger, Patrick M.] Univ Illinois, Coll Pharm, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA. [Lareau, Suzanne C.] Univ Colorado Denver, Anschutz Med Campus, Aurora, CO USA. [Tycon, Laura] Univ Pittsburgh, Med Ctr, Palliat & Support Inst, Pittsburgh, PA USA. [Lindell, Kathleen] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Mannino, David M.] Univ Kentucky, Dept Prevent Med & Environm Hlth, Lexington, KY USA. [Martinez, Fernando J.] Weill Cornell Sch Med, Dept Internal Med, New York, NY USA. [Press, Valerie G.] Univ Chicago Med, Sect Hosp Med, Chicago, IL USA. [Thomashow, Byron] Columbia Univ, Med Ctr, Div Pulm Crit Care & Sleep Med, New York, NY USA. [Sullivan, Jamie Lamson] COPD Fdn, Washington, DC USA. [Walsh, John] COPD Fdn, Miami, FL USA. [Wilson, Kevin C.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Wilson, Kevin C.] Amer Thorac Soc, New York, NY USA. [Wright, Jean] Carolinas HealthCare Syst, Charlotte, NC USA. [Yawn, Barbara] Univ Minnesota, Sch Med, Family & Community Hlth, Minneapolis, MN 55455 USA. [Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA. [Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Han, MLK (reprint author), Univ Michigan Hlth Syst, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA. EM mrking@umich.edu OI Mannino, David/0000-0003-3646-7828; Zueger, Patrick/0000-0002-3412-9895 FU Society of Hospital Medicine; 6 American Board of Internal Medicine; Novartis Pharmaceuticals; Patient-Centered Outcomes Research Institute; US National Institutes of Health; Maryland Cigarette Restitution Fund; UpToDate; Boehringer Ingelheim; GlaxoSmithKline; Astra Zeneca; Society of Hospital Medicine COPD Expert Panel; US National Heart, Lung, and Blood Institute; American Lung Association; American Thoracic Society; Seattle VA; Regeneron; Novartis; Forest Laboratories; Smith Medical; PneumRx; Spiration; McGill University; Research Institute of the McGill University Health Centre; Canadian Respiratory Research Network; Canadian Institute of Health Research; Aerocrine; Almirall; AstraZeneca; Boston Scientific; Ikaria; Aeris; Pearl; Pulmonx; Otsuka; American Heart Association; US Department of Defense; Celerion; Pfizer; Merck; Amgen FX DHA reports personal fees from the Society of Hospital Medicine, the 6 American Board of Internal Medicine, and Novartis Pharmaceuticals outside of the submitted work. CMB reports grants from the Patient-Centered Outcomes Research Institute, the US National Institutes of Health, and the Maryland Cigarette Restitution Fund; and personal fees from UpToDate. BT reports personal fees from Boehringer Ingelheim, GlaxoSmithKline, and Astra Zeneca outside of the submitted work; he is the Chairman of Board of COPD Foundation, a non-profit organisation. KCW is employed by the American Thoracic Society. SCL reports being on the advisory board of Boehringer Ingelheim outside of the submitted work VGP reports personal fees from the Society of Hospital Medicine COPD Expert Panel during the conduct of the study; and grants from the US National Heart, Lung, and Blood Institute, the American Lung Association, the American Thoracic Society, and the Patient-Centered Outcomes Research Institute, and personal fees from Seattle VA Consulting outside of the submitted work MKH reports personal fees from GlaxoSmithKline, Regeneron, Boehringer Ingelheim, and Novartis outside of the submitted work SPB reports grants from the US National Institutes of Health during the conduct of the study. RK reports personal fees from Forest Laboratories; grants and personal fees from Boehringer Ingelheim; personal fees from Merck and Smith Medical; and grants from GlaxoSmithKline, PneumRx (BTG), and Spiration outside of the submitted work JB has received funding for a COPD Research Chair from McGill University and GlaxoSmithKline; grants from the Research Institute of the McGill University Health Centre, the Canadian Respiratory Research Network, and the Canadian Institute of Health Research; and a consortium of the pharmaceutical industry (Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis). MTD reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, Boston Scientific; personal fees from Ikaria; and grants from AstraZeneca, Aeris, Pearl, PneumRx, Pulmonx, Otsuka, Forest Laboratories, the American Heart Association, the US National Institutes of Health, the US Department of Defense, Novartis, and Celerion outside of the submitted work DMM has received honoraria and consulting fees from and served on speaker bureaus for GlaxoSmithKline, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, Forest Laboratories, Merck, and Amgen; he has received royalties from UpToDate, is on the Board of Directors of the COPD Foundation, and has served as an expert witness in litigation involving tobacco use. BY is an advisory board member of Boehringer Ingelheim, Novartis, and GlaxoSmithKline; and has received grants from Boehringer Ingelheim and the US National Heart, Lung, and Blood Institute outside of the submitted work TJK is on the Board of Directors for the Allergy and Asthma Network All other authors declare no competing interests. NR 438 TC 4 Z9 4 U1 9 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD JUN PY 2016 VL 4 IS 6 BP 473 EP 526 DI 10.1016/S2213-2600(16)00094-1 PG 54 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DN4TC UT WOS:000377059100023 PM 27185520 ER PT J AU Muir, ER Cardenas, DP Duong, TQ AF Muir, Eric R. Cardenas, Damon P. Duong, Timothy Q. TI MRI of brain tissue oxygen tension under hyperbaric conditions SO NEUROIMAGE LA English DT Article DE Hyperbaric oxygen; MRI; T-1; Tissue oxygenation ID CEREBRAL-BLOOD-FLOW; LONGITUDINAL RELAXATION-TIME; MAGNETIC-FIELD STRENGTHS; PARTIAL-PRESSURE; BOLD FMRI; MITOCHONDRIAL-FUNCTION; RAT-BRAIN; ARTERIAL; HYPOXIA; HYPEROXIA AB The brain depends on a continuous supply of oxygen to maintain its structural and functional integrity. This study measured T-1 from MRI under normobaric air, normobaric oxygen, hyperbaric air, and hyperbaric oxygen (HBO) conditions as a marker of tissue pO2 since dissolved molecular oxygen acts as an endogenous contrast agent. Brain tissue T-1 decreased corresponding to increased pO2 with increasing inhaled oxygen concentrations, and tissue oxygenation was estimated from the T-1 changes between different inhaled oxygen levels. Tissue pO2 difference maps between different oxygen conditions showed heterogeneous pO2 changes in the brain. MRI-derived tissue pO2 was markedly lower than the arterial pO2 but was slightly higher than venous pO2. Additionally, for comparison with published extracellular tissue pO2 data obtained using oxygen electrodes and other invasive techniques, a model was used to estimate extracellular and intracellular pO2 from the MRI-derived mean tissue pO2. This required multiple assumptions, and so the effects of the assumptions and parameters used in modeling brain pO2 were evaluated. MRI-derived pO2 values were strongly dependent on assumptions about the extra- and intracellular compartments but were relatively less sensitive to variations in the relaxivity constant of oxygen and contribution from oxygen in the cerebral blood compartment. This approach may prove useful in evaluating tissue oxygenation in disease states such as stroke. (C) 2016 Elsevier Inc. All rights reserved. C1 [Muir, Eric R.; Cardenas, Damon P.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Muir, Eric R.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Cardenas, Damon P.] Univ Texas Hlth Sci Ctr San Antonio, Grad Sch Biomed Sci, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Muir, ER; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM muire@uthscsa.edu; duongt@uthscsa.edu FU NIGMS NIH HHS [R25 GM060655] NR 45 TC 1 Z9 1 U1 1 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 EI 1095-9572 J9 NEUROIMAGE JI Neuroimage PD JUN PY 2016 VL 133 BP 498 EP 503 DI 10.1016/j.neuroimage.2016.03.040 PG 6 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA DN4PB UT WOS:000377048600045 PM 27033683 ER PT J AU Tahmasian, M Rosenzweig, I Eickhoff, SB Sepehry, AA Laird, AR Fox, PT Morrell, MJ Khazaie, H Eickhoff, CR AF Tahmasian, Masoud Rosenzweig, Ivana Eickhoff, Simon B. Sepehry, Amir A. Laird, Angela R. Fox, Peter T. Morrell, Mary J. Khazaie, Habibolah Eickhoff, Claudia R. TI Structural and functional neural adaptations in obstructive sleep apnea: An activation likelihood estimation meta-analysis SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Voxel-based morphometry (VBM); Functional magnetic resonance imaging (fMRI); Insula; Amygdala; Hippocampus; Obstructive sleep apnea ID POSITIVE AIRWAY PRESSURE; HUMAN PARIETAL OPERCULUM; HUMAN BRAIN NETWORKS; WORKING-MEMORY TASK; CEREBRAL-BLOOD-FLOW; INTERMITTENT HYPOXIA; RESTING-STATE; BASOLATERAL AMYGDALA; INSULAR CORTEX; NEUROCOGNITIVE FUNCTION AB Obstructive sleep apnea (OSA) is a common multisystem chronic disorder. Functional and structural neuroimaging has been widely applied in patients with OSA, but these studies have often yielded diverse results. The present quantitative meta-analysis aims to identify consistent patterns of abnormal activation and grey matter loss in OSA across studies. We used PubMed to retrieve task/resting-state functional magnetic resonance imaging and voxel-based morphometry studies. Stereotactic data were extracted from fifteen studies, and subsequently tested for convergence using activation likelihood estimation. We found convergent evidence for structural atrophy and functional disturbances in the right basolateral amygdala/hippocampus and the right central insula. Functional characterization of these regions using the BrainMap database suggested associated dysfunction of emotional, sensory, and limbic processes. Assessment of task-based co-activation patterns furthermore indicated that the two regions obtained from the meta-analysis are part of a joint network comprising the anterior insula, posterior-medial frontal cortex and thalamus. Taken together, our findings highlight the role of right amygdala, hippocampus and insula in the abnormal emotional and sensory processing in OSA. (C) 2016 The Authors. Published by Elsevier Ltd. C1 [Tahmasian, Masoud; Khazaie, Habibolah] Kermanshah Univ Med Sci KUMS, Sleep Disorders Res Ctr, POB 6719851151, Kermanshah, Iran. [Tahmasian, Masoud] Shahid Beheshti Univ, Natl Brain Mapping Ctr, Gen & Med Campus, Tehran, Iran. [Rosenzweig, Ivana; Morrell, Mary J.] Kings Coll London, Dept Neuroimaging, Sleep & Brain Plast Ctr, IOPPN, London WC2R 2LS, England. [Rosenzweig, Ivana; Morrell, Mary J.] Univ London Imperial Coll Sci Technol & Med, London, England. [Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Simon B.; Eickhoff, Claudia R.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Sepehry, Amir A.] Univ British Columbia, Fac Med, Div Neurol, Vancouver, BC, Canada. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Morrell, Mary J.] Univ London Imperial Coll Sci Technol & Med, Acad Unit Sleep & Breathing, Natl Heart & Lung Inst, London, England. [Morrell, Mary J.] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Dis Biomed Res Unit, London, England. [Eickhoff, Claudia R.] Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany. RP Khazaie, H (reprint author), Kermanshah Univ Med Sci KUMS, Sleep Disorders Res Ctr, POB 6719851151, Kermanshah, Iran. EM Sepehryaa@alumni.ubc.ca; hakhazaie@gmail.com OI Sepehry, Amir/0000-0002-6055-4457 FU Kermanshah University of Medical Sciences; Wellcome Trust [103952/Z/14/Z] FX Author M.T is supported by the Kermanshah University of Medical Sciences; Author I. R. is supported by the Wellcome Trust [103952/Z/14/Z]. NR 144 TC 3 Z9 3 U1 2 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 EI 1873-7528 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD JUN PY 2016 VL 65 BP 142 EP 156 DI 10.1016/j.neubiorev.2016.03.026 PG 15 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA DN0WJ UT WOS:000376787400007 PM 27039344 ER PT J AU Jarlenski, M Borrero, S La Charite, T Zite, NB AF Jarlenski, Marian Borrero, Sonya La Charite, Trey Zite, Nikki B. TI Episode-Based Payment for Perinatal Care in Medicaid Implications for Practice and Policy SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID REFORM; START AB Medicaid is an important source of health insurance coverage for low-income pregnant women and covers nearly half of all deliveries in the United States. In the face of budgetary pressures, several state Medicaid programs have implemented or are considering implementing episode-based payments for perinatal care. Under the episode-based payment model, Medicaid programs make a single payment for all pregnancy-related medical services provided to women with low- and medium-risk pregnancies from 40 weeks before delivery through 60 days postpartum. The health care provider who delivers a live birth is assigned responsibility for all care and must meet certain quality metrics and stay within delineated cost-per-episode parameters. Implementation of cost- and quality-dependent episode-based payments for perinatal care is notable because there is no published evidence about the effects of such initiatives on pregnancy or birth outcomes. In this article, we highlight challenges and potential adverse consequences related to defining the perinatal episode and assigning a responsible health care provider. We also describe concerns that perinatal care quality metrics may not address the most pressing health care issues that are likely to improve health outcomes and reduce costs. In their current incarnations, Medicaid programs' episode-based payments for perinatal care may not improve perinatal care delivery and subsequent health outcomes. Rigorous evaluation of the new episode-based payment initiatives is critically needed to inform policymakers about the intended and unintended consequences of implementing episode-based payments for perinatal care. C1 [Jarlenski, Marian] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Ctr Womens Hlth Res & Innovat, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Tennessee, Grad Sch Med, Dept Internal Med, Div Hosp Med, Knoxville, TN USA. Univ Tennessee, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN USA. RP Jarlenski, M (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,A647, Pittsburgh, PA 15261 USA. EM marian.jarlenski@pitt.edu OI Jarlenski, Marian/0000-0001-6907-5447 NR 13 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUN PY 2016 VL 127 IS 6 BP 1080 EP 1084 DI 10.1097/AOG.0000000000001423 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DN3CH UT WOS:000376939500016 PM 27159762 ER PT J AU Wang, Y Liu, G Hong, DD Chen, FH Ji, XM Cao, GD AF Wang, Yuan Liu, Gang Hong, Dandan Chen, Fenghua Ji, Xunming Cao, Guodong TI White matter injury in ischemic stroke SO PROGRESS IN NEUROBIOLOGY LA English DT Review ID SMALL-VESSEL DISEASE; CHRONIC CEREBRAL HYPOPERFUSION; INDUCED MOVEMENT THERAPY; DAMAGE FOLLOWING STROKE; TENSOR IMAGING DETECTS; DIFFUSION TENSOR; MAGNETIC-RESONANCE; COGNITIVE IMPAIRMENT; NEUROTROPHIC FACTOR; NMDA RECEPTORS AB Stroke is one of the major causes of disability and mortality worldwide. It is well known that ischemic stroke can cause gray matter injury. However, stroke also elicits profound white matter injury, a risk factor for higher stroke incidence and poor neurological outcomes. The majority of damage caused by stroke is located in subcortical regions and, remarkably, white matter occupies nearly half of the average infarct volume. Indeed, white matter is exquisitely vulnerable to ischemia and is often injured more severely than gray matter. Clinical symptoms related to white matter injury include cognitive dysfunction, emotional disorders, sensorimotor impairments, as well as urinary incontinence and pain, all of which are closely associated with destruction and remodeling of white matter connectivity. White matter injury can be noninvasively detected by MRI, which provides a three-dimensional assessment of its morphology, metabolism, and function. There is an urgent need for novel white matter therapies, as currently available strategies are limited to preclinical animal studies. Optimal protection against ischemic stroke will need to encompass the fortification of both gray and white matter. In this review, we discuss white matter injury after ischemic stroke, focusing on clinical features and tools, such as imaging, manifestation, and potential treatments. We also briefly discuss the pathophysiology of WMI and future research directions. Published by Elsevier Ltd. C1 [Wang, Yuan; Liu, Gang] Capital Univ Med, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China. [Hong, Dandan] Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15260 USA. [Chen, Fenghua; Cao, Guodong] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA. [Ji, Xunming] Capital Univ Med, Xuanwu Hosp, Dept Neurosurg, Beijing 100053, Peoples R China. [Cao, Guodong] VA Pittsburgh Healthcare Syst, Geriatr Res Educ Ctr, Pittsburgh, PA 15240 USA. [Cao, Guodong] VA Pittsburgh Healthcare Syst, Ctr Clin, Pittsburgh, PA 15240 USA. RP Ji, XM (reprint author), Capital Univ Med, Xuanwu Hosp, Dept Neurosurg, Beijing 100053, Peoples R China.; Cao, GD (reprint author), Univ Pittsburgh, Dept Neurol, BST S505,3500 Terrace St, Pittsburgh, PA 15260 USA. EM robertjixm@hotmail.com; caog@upmc.edu FU National Institutes of Health/NINDS [NS079345]; VA Merit Review grant [BX002346]; Chinese 12th Five science and technology support program [2013BAI07B01] FX This project was supported by National Institutes of Health/NINDS grant NS079345 (to G. C.) and VA Merit Review grant BX002346 (to G. C.), and Chinese 12th Five science and technology support program 2013BAI07B01 (to X. J). NR 191 TC 1 Z9 1 U1 5 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 EI 1873-5118 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD JUN PY 2016 VL 141 BP 45 EP 60 DI 10.1016/j.pneurobio.2016.04.00 PG 16 WC Neurosciences SC Neurosciences & Neurology GA DN1FM UT WOS:000376811700003 PM 27090751 ER PT J AU Tsai, J Link, B Rosenheck, RA Pietrzak, RH AF Tsai, Jack Link, Bruce Rosenheck, Robert A. Pietrzak, Robert H. TI Homelessness among a nationally representative sample of US veterans: prevalence, service utilization, and correlates SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Homelessness; Veterans; Epidemiology; Health services ID RISK-FACTORS; UNITED-STATES; UNINSURED VETERANS; 5-YEAR PREVALENCE; MENTAL-ILLNESS; HEALTH; MANAGEMENT; LIFETIME; NEEDS; CARE AB To examine the prevalence of lifetime homelessness among veterans and use of Veterans Affairs (VA) homeless services, as well as their association with sociodemographic and clinical characteristics. A nationally representative sample of 1533 US veterans was surveyed July-August 2015. Among all veterans, 8.5 % reported any lifetime homelessness in their adult life, but only 17.2 % of those reported using VA homeless services. Prevalence of homelessness and VA homeless service use did not significantly differ by gender. Being low income, aged 35-44, and having poor mental and physical health were each independently associated with lifetime homelessness. Veterans who were White or lived in rural areas were significantly less likely to have used VA homeless services. Homelessness remains a substantial problem across different generations of veterans. The low reported uptake of VA homeless services suggests there are barriers to care in this population, especially for veterans who live in rural areas. Governmental resources dedicated to veteran homelessness should be supported, and obtaining accurate prevalence estimates are important to tracking progress over time. C1 [Tsai, Jack; Rosenheck, Robert A.] New England Mental Illness Res Educ & Clin Ctr, US Dept Vet Affairs, 950 Campbell Ave,151D, West Haven, CT 06516 USA. [Tsai, Jack; Rosenheck, Robert A.; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. [Link, Bruce] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Link, Bruce] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Pietrzak, Robert H.] Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT 06516 USA. RP Tsai, J (reprint author), New England Mental Illness Res Educ & Clin Ctr, US Dept Vet Affairs, 950 Campbell Ave,151D, West Haven, CT 06516 USA. EM Jack.Tsai@yale.edu NR 47 TC 0 Z9 0 U1 5 U2 7 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 EI 1433-9285 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD JUN PY 2016 VL 51 IS 6 BP 907 EP 916 DI 10.1007/s00127-016-1210-y PG 10 WC Psychiatry SC Psychiatry GA DN7IQ UT WOS:000377249200014 PM 27075492 ER PT J AU Panchal, H Paholpak, P Lee, G Carr, A Barsuglia, JP Mather, M Jimenez, E Mendez, MF AF Panchal, Hemali Paholpak, Pongsatorn Lee, Grace Carr, Andrew Barsuglia, Joseph P. Mather, Michelle Jimenez, Elvira Mendez, Mario F. TI Neuropsychological and Neuroanatomical Correlates of the Social Norms Questionnaire in Frontotemporal Dementia Versus Alzheimer's Disease SO AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS LA English DT Article DE social norms; behavioral variant frontotemporal dementia; anterior temporal lobe Alzheimer's disease; tensor-based morphometry ID ANTERIOR TEMPORAL-LOBES; BEHAVIORAL VARIANT; BRAIN; COGNITION; LESIONS AB Traditional neuropsychological batteries may not distinguish early behavioral variant frontotemporal dementia (bvFTD) from Alzheimer's disease (AD) without the inclusion of a social behavioral measure. We compared 33 participants, 15 bvFTD, and 18 matched patients with early-onset AD (eAD), on the Social Norms Questionnaire (SNQ), neuropsychological tests and 3-dimensional T1-weighted magnetic resonance imaging (MRI). The analyses included correlations of SNQ results (total score, overendorsement or overadhere errors, and violations or break errors) with neuropsychological results and tensor-based morphometry regions of interest. Patients with BvFTD had significantly lower SNQ total scores and higher overadhere errors than patients with eAD. On neuropsychological measures, the SNQ total scores correlated significantly with semantic knowledge and the overadhere subscores with executive dysfunction. On MRI analysis, the break subscores significantly correlated with lower volume of lateral anterior temporal lobes (aTL). The results also suggest that endorsement of social norm violations corresponds to the role of the right aTL in social semantic knowledge. C1 [Panchal, Hemali; Paholpak, Pongsatorn; Carr, Andrew; Barsuglia, Joseph P.; Mather, Michelle; Jimenez, Elvira; Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Panchal, Hemali; Paholpak, Pongsatorn; Mather, Michelle; Jimenez, Elvira; Mendez, Mario F.] Dept Neurol, Los Angeles, CA USA. [Paholpak, Pongsatorn] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Dept Psychiat, Khon Khaen, Thailand. [Lee, Grace] Sch Behav Hlth, Dept Psychol, Loma Linda, CA USA. [Jimenez, Elvira; Mendez, Mario F.] Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. RP Panchal, H (reprint author), West Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Neurol, 11301 Wilshire Blvd,Mail Code 116AF, Los Angeles, CA 90073 USA. EM hpanchal@g.ucla.edu FU National Institute on Aging (NIA) [5R01AG034499]; VA GRECC Advanced Fellowship in Geriatrics FX This work was supported by grant 5R01AG034499 (Mendez) from the National Institute on Aging (NIA). J.P. Barsuglia was funded by the VA GRECC Advanced Fellowship in Geriatrics. NR 42 TC 1 Z9 1 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1533-3175 EI 1938-2731 J9 AM J ALZHEIMERS DIS JI Am. J. Alzheimers Dis. Other Dement. PD JUN PY 2016 VL 31 IS 4 BP 326 EP 332 DI 10.1177/1533317515617722 PG 7 WC Geriatrics & Gerontology; Clinical Neurology SC Geriatrics & Gerontology; Neurosciences & Neurology GA DM4GO UT WOS:000376305200004 PM 26646114 ER PT J AU Hutchinson, N Baird, GL Garg, M AF Hutchinson, Nora Baird, Grayson L. Garg, Megha TI Examining the Reading Level of Internet Medical Information for Common Internal Medicine Diagnoses SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Health literacy; Internal medicine; Online education; Patient health information; Readability AB BACKGROUND: The National Institutes of Health (NIH) recommend that health materials be written at a grade 6-7 reading level, which has generally not been achieved in online reading materials. Up to the present time, there have not been any assessments focused on the reading level of online educational materials across the most popular consumer Web sites for common internal medicine diagnoses. In this study, we examined the readability of open-access online health information for 9 common internal medicine diagnoses. METHODS: Nine of the most frequently encountered inpatient and ambulatory internal medicine diagnoses were selected for analysis. In November and December 2014, these diagnoses were used as search terms in Google, and the top 5 Web sites across all diagnoses and a diagnosis-specific site were analyzed across 5 validated reading indices. RESULTS: On average, the lowest reading grade-level content was provided by the NIH (10.7), followed by WebMD (10.9), Mayo Clinic (11.3), and diagnosis-specific Web sites (11.5). Conversely, Wikipedia provided content that required the highest grade-level readability (14.6). The diagnoses with the lowest reading grade levels were chronic obstructive pulmonary disease (10.8), followed by diabetes (10.9), congestive heart failure (11.7), osteoporosis (11.7) and hypertension (11.7). Depression had the highest grade-level readability (13.8). DISCUSSION: Despite recommendations for patient health information to be written at a grade 6-7 reading level, our examination of online educational materials pertaining to 9 common internal medicine diagnoses revealed reading levels significantly above the NIH recommendation. This was seen across both diagnosis-specific and general Web sites. There is a need to improve the readability of online educational materials made available to patients. These improvements have the potential to greatly enhance patient awareness, engagement, and physician-patient communication. Published by Elsevier Inc. C1 [Hutchinson, Nora] Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI 02912 USA. [Baird, Grayson L.] Rhode Isl Hosp, Lifespan Biostat Core, Providence, RI USA. [Garg, Megha] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Garg, M (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Rm 1A-71, San Francisco, CA 94121 USA. EM megha.garg@ucsf.edu NR 4 TC 1 Z9 1 U1 4 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD JUN PY 2016 VL 129 IS 6 BP 637 EP 639 DI 10.1016/j.amjmed.2016.01.008 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DM6YO UT WOS:000376499100041 PM 26829438 ER PT J AU Zhang, YJ Chee, A Shi, P Adams, SL Markova, DZ Anderson, DG Smith, HE Deng, YP Plastaras, CT An, HS AF Zhang, Yejia Chee, Ana Shi, Peng Adams, Sherrill L. Markova, Dessislava Z. Anderson, David Greg Smith, Harvey E. Deng, Youping Plastaras, Christopher T. An, Howard S. TI Intervertebral Disc Cells Produce Interleukins Found in Patients with Back Pain SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Intervertebral Disc; Discogenic Back Pain; Chemokine; Cytokine; Interleukin ID MATRIX METALLOPROTEINASES; ASYMPTOMATIC SUBJECTS; PROSTAGLANDIN E(2); NITRIC-OXIDE; EXPRESSION; IL-8; DEGENERATION; DISCOGRAPHY; IL-1-BETA; CYTOKINES AB Objective: To examine the link between cytokines in intervertebral disc (IVD) tissues and axial back pain. Design: In vitro study with human IVD cells cultured from cadaveric donors and annulus fibrosus (AF) tissues from patients. Results: Cultured nucleus pulposus (NP) and AF cells were stimulated with interleukin (IL)-1 beta. IL-8 and IL-7 gene expression was analyzed using real-time polymerase chain reaction. IL-8 protein was quantified by enzyme-linked immunosorbent assay. After IL-1 beta stimulation, IL-8 gene expression increased 26,541 fold in NP cells and 22,429 fold in AF cells, whereas protein released by the NP and AF cells increased 2,389- and 1,784-fold, respectively. IL-7 gene expression increased 3.3-fold in NP cells (P < 0.05). Cytokine profiles in AF tissues collected from patients undergoing surgery for back pain (painful group) or scoliosis (controls) were compared by cytokine array. IL-8 protein in the AF tissues from patients with back pain was 1.81-fold of that in controls. IL-7 and IL-10 in AF tissues from the painful group were 6.87 and 4.63 times greater than the corresponding values in controls, respectively (P < 0.05). Conclusion: Inflammatory mediators found in AF tissues from patients with discogenic back pain are likely produced by IVD cells and may play a key role in back pain. C1 [Zhang, Yejia; Plastaras, Christopher T.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Zhang, Yejia; Smith, Harvey E.] Univ Penn, Perelman Sch Med, Dept Orthoped Surg, Philadelphia, PA 19104 USA. [Zhang, Yejia; Smith, Harvey E.] Philadelphia Vet Affairs Med Ctr, TMRC, Philadelphia, PA USA. [Chee, Ana; Shi, Peng; An, Howard S.] Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA. [Adams, Sherrill L.] Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA. [Deng, Youping] Rush Univ, Med Ctr, Dept Internal Med, Chicago, IL 60612 USA. [Markova, Dessislava Z.; Anderson, David Greg] Thomas Jefferson Univ, Dept Orthoped Surg, Philadelphia, PA 19107 USA. RP Zhang, YJ (reprint author), Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA.; Zhang, YJ (reprint author), Philadelphia Vet Affairs Med Ctr, TMRC, Philadelphia, PA USA. FU NICHD [K08 HD049598]; North American Spine Society (NASS); Scott F. Nadler, DO Research Grant Award by the Physiatric Association of Spine, Sports and Occupational Rehabilitation (PASSOR) FX Yejia Zhang was supported by NICHD (K08 HD049598). This work was supported in part by a grant from the North American Spine Society (NASS) and Scott F. Nadler, DO Research Grant Award by the Physiatric Association of Spine, Sports and Occupational Rehabilitation (PASSOR). This work has been presented as a poster presentation at the 2014 Philadelphia Spine Research Society Meeting. NR 29 TC 2 Z9 2 U1 11 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD JUN PY 2016 VL 95 IS 6 BP 407 EP 415 DI 10.1097/PHM.0000000000000399 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DM7ST UT WOS:000376561000010 PM 26495812 ER PT J AU Baker, JF Conaghan, PG Emery, P Baker, DG Ostergaard, M AF Baker, Joshua F. Conaghan, Philip G. Emery, Paul Baker, Daniel G. Ostergaard, Mikkel TI Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID DISEASE-ACTIVITY; RADIOGRAPHIC PROGRESSION; PHASE-III; DOUBLE-BLIND; FOLLOW-UP; METHOTREXATE; THERAPY; GOLIMUMAB; REMISSION; ANTIBODY AB Objective To evaluate the construct validity of the rheumatoid arthritis MRI score (RAMRIS) erosion evaluation as structural damage end point and to assess the potential impact of incorporation in clinical trials. Methods In a randomised trial of early methotrexatenaive RA (GO-BEFORE), RAMRIS scores were determined from MRIs and van der Heijde-Sharp (vdHS) scores from radiographs, at baseline, week 12, week 24 and week 52. Progression in damage scores was defined as change > 0.5. Associations of X-ray and MRI outcomes with clinical features were evaluated for convergent validity. Iterative Wilcoxon rank sum tests and tests of proportion estimated the sample size required to detect differences between combination therapy (methotrexate + golimumab) and methotrexate-monotherapy arms in (A) change in damage score and (B) proportion of patients progressing. Results Patients with early MRI progression had higher DAS28, C reactive protein (CRP) and vdHS at baseline, and higher 2-year HAQ. Associations were similar to those with 1-year vdHS progression. Differences in change in structural damage between treatment arms achieved significance with fewer subjects when 12-week or 24-week MRI erosion score was the outcome (150 patients; 100 among an enriched sample with baseline-synovitis > 5) compared with the 52-week vdHS (275 patients). Differences in the proportion progressing could be detected in 234 total subjects with 12-week MRI in an enriched sample whereas 1-year X-ray required between 468 and 1160 subjects. Conclusions Early MRI erosion progression is a valid measure of structural damage that could substantially decrease sample size and study duration if used as structural damage end point in RA clinical trials. C1 [Baker, Joshua F.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Baker, Joshua F.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Conaghan, Philip G.; Emery, Paul] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England. [Conaghan, Philip G.; Emery, Paul] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England. [Baker, Daniel G.] Janssen Res & Dev LLC, Horsham, PA USA. [Ostergaard, Mikkel] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci,Glostrup Hosp, Copenhagen Ctr Arthrit Res,Ctr Rheumatol & Spine, Copenhagen, Denmark. RP Baker, JF (reprint author), Hosp Univ Penn, Dept Med, Div Rheumatol, 8 Penn Tower Bldg,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM bakerjo@uphs.upenn.edu FU Veterans Affairs Clinical Science Research and Development Career Development Award [IK2 CX000955] FX JFB is supported by a Veterans Affairs Clinical Science Research and Development Career Development Award (IK2 CX000955). NR 20 TC 5 Z9 5 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JUN PY 2016 VL 75 IS 6 BP 1114 EP 1119 DI 10.1136/annrheumdis-2014-206934 PG 6 WC Rheumatology SC Rheumatology GA DM6DP UT WOS:000376440900028 PM 26091907 ER PT J AU Cozen, ML Ryan, JC Shen, H Cheung, R Kaplan, DE Pocha, C Brau, N Aytaman, A Schmidt, WN Pedrosa, M Anand, BS Chang, KM Morgan, T Monto, A AF Cozen, Myrna L. Ryan, James C. Shen, Hui Cheung, Ramsey Kaplan, David E. Pocha, Christine Brau, Norbert Aytaman, Ayse Schmidt, Warren N. Pedrosa, Marcos Anand, Bhupinderjit S. Chang, Kyong-Mi Morgan, Timothy Monto, Alexander TI Improved Survival Among all Interferon-alpha-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Hepatitis C; Hepatitis C therapy; Cirrhosis; Hepatocellular carcinoma; Survival ID VIRUS-INFECTION; US VETERANS; CLINICAL-OUTCOMES; ELDERLY-PATIENTS; PLUS RIBAVIRIN; LIVER FIBROSIS; FOLLOW-UP; THERAPY; HCV; METAANALYSIS AB As the era of interferon-alpha (IFN)-based therapy for hepatitis C ends, long-term treatment outcomes are now being evaluated. To more fully understand the natural history of hepatitis C infection by following a multisite cohort of patients. Patients with chronic HCV were prospectively enrolled in 1999-2000 from 11 VA medical centers and followed through retrospective medical record review. A total of 2211 patients were followed for an average of 8.5 years after enrollment. Thirty-one percent of patients received HCV antiviral therapy, 15 % with standard IFN/ribavirin only, 16 % with pegylated IFN/ribavirin, and 26.7 % of treated patients achieved sustained virologic response (SVR). Cirrhosis developed in 25.8 % of patients. Treatment nonresponders had a greater than twofold increase in the hazard of cirrhosis and hepatocellular carcinoma, compared to untreated patients, whereas SVR patients were only marginally protected from cirrhosis. Nearly 6 % developed hepatocellular carcinoma, and 27.1 % died during the follow-up period. Treated patients, regardless of response, had a significant survival benefit compared to untreated patients (HR 0.58, CI 0.46-0.72). Improved survival was also associated with college education, younger age, lower levels of alcohol consumption, and longer duration of medical service follow-up-factors typically associated with treatment eligibility. As more hepatitis C patients are now being assessed for all-oral combination therapy, these results highlight that patient compliance and limiting harmful behaviors contribute a significant proportion of the survival benefit in treated patients and that the long-term clinical benefits of SVR may be less profound than previously reported. C1 [Cozen, Myrna L.; Ryan, James C.; Shen, Hui; Monto, Alexander] San Francisco VA Med Ctr, 4150 Clement St 111B, San Francisco, CA 94121 USA. [Cozen, Myrna L.; Ryan, James C.; Shen, Hui; Monto, Alexander] Univ Calif San Francisco, 4150 Clement St 111B, San Francisco, CA 94121 USA. [Cheung, Ramsey] Palo Alto VA Med Ctr, 3801 Miranda Ave,GI Hepatol 154C, Palo Alto, CA 94304 USA. [Cheung, Ramsey] Stanford Univ, 3801 Miranda Ave,GI Hepatol 154C, Palo Alto, CA 94304 USA. [Kaplan, David E.; Chang, Kyong-Mi] Philadelphia VA Med Ctr, A212 Med Res,Univ & Woodland Ave, Philadelphia, PA 19104 USA. [Kaplan, David E.; Chang, Kyong-Mi] Univ Penn, A212 Med Res,Univ & Woodland Ave, Philadelphia, PA 19104 USA. [Pocha, Christine] Minneapolis VA Med Ctr, 1 Vet Dr,GI, Minneapolis, MN 55417 USA. [Brau, Norbert] Bronx VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. [Aytaman, Ayse] New York Harbor Brooklyn & Manhattan VA Med Ctr, 800 Poly Pl, Brooklyn, NY 11209 USA. [Schmidt, Warren N.] Iowa City VA Med Ctr, 200 Hawkins Dr, Iowa City, IA 52242 USA. [Schmidt, Warren N.] Univ Iowa, 200 Hawkins Dr, Iowa City, IA 52242 USA. [Pedrosa, Marcos] Boston VA Hlth Care Syst & AbbVie Pharmaceut, 85 E Concord St 7700, Boston, MA 02118 USA. [Anand, Bhupinderjit S.] Houston VA Med Ctr, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. [Anand, Bhupinderjit S.] Baylor Univ, Digest Dis Sect, 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. [Morgan, Timothy] Long Beach VA Med Ctr, 111G,5901 E 7th St, Long Beach, CA 90822 USA. [Morgan, Timothy] Univ Calif Irvine, 111G,5901 E 7th St, Long Beach, CA 90822 USA. RP Monto, A (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111B, San Francisco, CA 94121 USA.; Monto, A (reprint author), Univ Calif San Francisco, 4150 Clement St 111B, San Francisco, CA 94121 USA. EM Alexander.Monto@va.gov FU VA Merit [1I01 CX000295-01A1]; UCSF Liver Center NIH [P30 DK026743] FX Grant Support: VA Merit 1I01 CX000295-01A1 (PI: Monto) and the UCSF Liver Center NIH P30 DK026743 (Monto, Ryan). NR 43 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUN PY 2016 VL 61 IS 6 BP 1744 EP 1756 DI 10.1007/s10620-016-4122-5 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DM8CG UT WOS:000376587600045 PM 27059981 ER PT J AU Sonnenberg, A Bakis, G AF Sonnenberg, Amnon Bakis, Gennadiy TI Probability of Iatrogenesis in Gastroenterology SO DIGESTIVE DISEASES AND SCIENCES LA English DT Letter C1 [Sonnenberg, Amnon; Bakis, Gennadiy] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol Hepatol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Div Gastroenterol Hepatol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JUN PY 2016 VL 61 IS 6 BP 1775 EP 1777 DI 10.1007/s10620-015-4030-0 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DM8CG UT WOS:000376587600051 PM 26781257 ER PT J AU Naples, JG Marcum, ZA Perera, S Newman, AB Greenspan, SL Gray, SL Bauer, DC Simonsick, EM Shorr, RI Hanlon, JT AF Naples, Jennifer G. Marcum, Zachary A. Perera, Subashan Newman, Anne B. Greenspan, Susan L. Gray, Shelly L. Bauer, Douglas C. Simonsick, Eleanor M. Shorr, Ronald I. Hanlon, Joseph T. TI Impact of Drug-Drug and Drug-Disease Interactions on Gait Speed in Community-Dwelling Older Adults SO DRUGS & AGING LA English DT Article ID PHYSICAL PERFORMANCE-MEASURES; BODY-COMPOSITION; FUNCTIONAL STATUS; MEDICATION USE; HEALTH ABC; DECLINE; ASSOCIATION; PEOPLE; ELDERS; FALLS AB Background Gait speed decline, an early marker of functional impairment, is a sensitive predictor of adverse health outcomes in older adults. The effect of potentially inappropriate medications, including drug-disease and drug-drug interactions, on gait speed decline is not well known. Objective The aim of this study was to determine if drug interactions impair functional status as measured by gait speed. Methods The sample included 2402 older adults with medication and gait speed data from the Health, Aging and Body Composition study. The independent variable was the frequency of drug-disease and/or drug-drug interactions at baseline and 3 additional years. The main outcome was a clinically meaningful gait speed decline of >= 0.1 m/s the year following drug interaction assessment. Adjusted odds ratios and 95 % confidence intervals (CIs) were calculated using multivariate generalized estimating equations for both the overall sample and a sample stratified by gait speed at time of drug interaction assessment. Results The prevalence of drug-disease and drug-drug interactions ranged from 7.6 to 9.3 and 10.5 to 12.3 %, respectively, with few participants (3.8-5.7 %) having multiple drug interactions. At least 22 % of participants had a gait speed decline of >= 0.1 m/s annually. Drug interactions were not significantly associated with gait speed decline overall or in the stratified sample of fast walkers. There was some evidence, however, that drug interactions increased the risk of gait speed decline among those participants with slower gait speeds, though p values did not reach statistical significance (adjusted odds ratio 1.22; 95 % CIs 0.96-1.56; p = 0.11). Moreover, a marginally significant dose-response relationship was seen with multiple drug interactions and gait speed decline (adjusted odds ratio 1.40; 95 % CIs 0.95-2.04; p = 0.08). Conclusions Drug interactions may increase the likelihood of gait speed decline among older adults with evidence of preexisting debility. Future studies should focus on frail elders with less physiological reserve who may be more susceptible to the harms associated with potentially inappropriate medications. C1 [Naples, Jennifer G.; Perera, Subashan; Newman, Anne B.; Greenspan, Susan L.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Div Geriatr, Dept Med, Kaufmann Med Bldg,Suite 500,3471 Fifth Ave, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Marcum, Zachary A.; Gray, Shelly L.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Perera, Subashan] Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA. [Newman, Anne B.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Bauer, Douglas C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bauer, Douglas C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Shorr, Ronald I.] Malcolm Randall Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA. RP Naples, JG (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr, Dept Med, Kaufmann Med Bldg,Suite 500,3471 Fifth Ave, Pittsburgh, PA 15213 USA.; Naples, JG (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15213 USA.; Naples, JG (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. EM jgn13@pitt.edu OI Newman, Anne B./0000-0002-0106-1150 FU NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, P30-AG024827, T32-AG021885, K07-AG033174, R01-AG028050, R01-AG037451]; NINR Grant [R01-NR012459]; Intramural Research Program of the NIH, National Institute on Aging FX This research was supported by NIA contracts (N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106), Grants (P30-AG024827, T32-AG021885, K07-AG033174, R01-AG028050, R01-AG037451), NINR Grant (R01-NR012459), and in part by the Intramural Research Program of the NIH, National Institute on Aging. NR 28 TC 0 Z9 0 U1 5 U2 5 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1170-229X EI 1179-1969 J9 DRUG AGING JI Drugs Aging PD JUN PY 2016 VL 33 IS 6 BP 411 EP 418 DI 10.1007/s40266-016-0373-2 PG 8 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA DM5UT UT WOS:000376416400004 PM 27138955 ER PT J AU Bralet, MC Buchsbaum, MS DeCastro, A Hazlett, EA Haznedar, MM Shihabuddin, L Mitelman, SA AF Bralet, Marie-Cecile Buchsbaum, Monte S. DeCastro, Alex Hazlett, Erin A. Haznedar, M. Mehmet Shihabuddin, Lina Mitelman, Serge A. TI FDG-PET scans in patients with Kraepelinian and non-Kraepelinian schizophrenia (vol 266, pg 379, 2016) SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE LA English DT Correction C1 [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Psychiat, 11388 Sorrento Valley Rd, San Diego, CA 92103 USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Radiol, 11388 Sorrento Valley Rd, San Diego, CA 92103 USA. [Bralet, Marie-Cecile] CHI Clermont Oise, Crisalid Unit FJ5, 2 Rue Finets, F-60607 Clermont, France. [Bralet, Marie-Cecile] Univ Paris 05, Inserm Unit U669, Maison Solenn, F-75014 Paris, France. [Bralet, Marie-Cecile] Univ Paris 11, F-75014 Paris, France. [Bralet, Marie-Cecile] GDR 3557 Rech Psychiat, Paris, France. [DeCastro, Alex] Univ Calif San Diego, Dept Psychiat, 11388 Sorrento Valley Rd, San Diego, CA 92103 USA. [Hazlett, Erin A.; Haznedar, M. Mehmet; Shihabuddin, Lina; Mitelman, Serge A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Hazlett, Erin A.; Haznedar, M. Mehmet] James J Peters Vet Adm Med Ctr, Bronx, NY USA. [Mitelman, Serge A.] Elmhurst Hosp Ctr, Dept Psychiat, 79 01 Broadway, Elmhurst, NY 11373 USA. RP Buchsbaum, MS (reprint author), Univ Calif San Diego, Dept Psychiat, 11388 Sorrento Valley Rd, San Diego, CA 92103 USA.; Buchsbaum, MS (reprint author), Univ Calif San Diego, Dept Radiol, 11388 Sorrento Valley Rd, San Diego, CA 92103 USA. EM mcbralet@gmail.com; monte.buchsbaum@gmail.com; alexdecastro2@gmail.com; linashihabuddin@comcast.net; serge.mitelman@mssm.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0940-1334 EI 1433-8491 J9 EUR ARCH PSY CLIN N JI Eur. Arch. Psych. Clin. Neurosci. PD JUN PY 2016 VL 266 IS 4 BP 379 EP 379 DI 10.1007/s00406-015-0661-6 PG 1 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DM9GO UT WOS:000376673400012 ER PT J AU Serper, M Choi, G Forde, KA Kaplan, DE AF Serper, Marina Choi, Gina Forde, Kimberly A. Kaplan, David E. TI Care Delivery and Outcomes Among US Veterans With Hepatitis B: A National Cohort Study SO HEPATOLOGY LA English DT Article ID C VIRUS-INFECTION; UNITED-STATES; HEPATOCELLULAR-CARCINOMA; ADMINISTRATIVE DATABASE; IDENTIFY PATIENTS; PREVALENCE; SURVEILLANCE; VALIDATION; MANAGEMENT; ADHERENCE AB Previous studies have identified gaps in hepatitis B care. The objectives of this study were to evaluate the delivery of care among a national cohort of US veterans with chronic hepatitis B infection and examine risk factors for adverse clinical outcomes. We conducted a retrospective cohort study using the Veterans Health Administration Corporate Data Warehouse from 1999 to 2013 to evaluate (1) care delivery and (2) clinical outcomes such as hepatocellular carcinoma, hepatic decompensation, and mortality among US veterans with hepatitis B. Incidence rates with 95% confidence intervals were calculated and Cox regression models were used to evaluate clinical outcomes. We identified 21,419 veterans with a positive hepatitis B surface antigen, and 97% of patients had alanine aminotransferase and 44% had hepatitis B virus DNA testing; hepatitis B e antigen and hepatitis B e antibody were tested <50% of the time. Patients receiving specialty care had a higher prevalence of recommended laboratory testing. Patients with elevated alanine aminotransferase in specialty care were more likely to receive antiviral therapy (50% versus 24% for specialty care versus no specialty care, P < 0.001). Among patients with cirrhosis, 69% received one-time liver imaging. The proportion of follow-up time adherent to annual imaging was 0.39 (standard deviation = 0.42), and the proportion was 0.28 (standard deviation = 0.33) for biannual imaging; both proportions were higher in the specialty care group (all P < 0.05). Antiviral therapy (hazard ratio = 0.85, 95% confidence interval 0.76-0.95, P = 0.005) and liver imaging (hazard ratio = 0.84, 95% confidence interval 0.76-0.91, P < 0.001) were independently associated with decreased mortality in adjusted analyses. Conclusion: We observed a low prevalence of recommended laboratory testing, antiviral therapy initiation, and liver imaging among a national cohort of veterans with hepatitis B infection; antiviral therapy and liver imaging were independently associated with decreased mortality. C1 [Serper, Marina; Kaplan, David E.] Philadelphia VA Med Ctr, Gastroenterol Sect, 3900 Woodland Ave,4th Floor,South Bldg, Philadelphia, PA 19104 USA. [Serper, Marina] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, 3900 Woodland Ave,4th Floor,South Bldg, Philadelphia, PA 19104 USA. [Serper, Marina; Choi, Gina; Forde, Kimberly A.; Kaplan, David E.] Hosp Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA. [Forde, Kimberly A.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. RP Serper, M (reprint author), Philadelphia VA Med Ctr, Gastroenterol Sect, 3900 Woodland Ave,4th Floor,South Bldg, Philadelphia, PA 19104 USA.; Serper, M (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, 3900 Woodland Ave,4th Floor,South Bldg, Philadelphia, PA 19104 USA.; Serper, M (reprint author), Hosp Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.; Serper, M (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave,4th Floor,South Bldg, Philadelphia, PA 19104 USA. EM marina.serper@uphs.upenn.edu OI Kaplan, David E./0000-0002-3839-336X NR 32 TC 3 Z9 3 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD JUN PY 2016 VL 63 IS 6 BP 1774 EP 1782 DI 10.1002/hep.28340 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DM5BN UT WOS:000376361800008 PM 26561023 ER PT J AU Morgan, DJ Safdar, N Milstone, AM Anderson, DJ AF Morgan, Daniel J. Safdar, Nasia Milstone, Aaron M. Anderson, Deverick J. TI Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article AB Research in Healthcare Epidemiology and Antimicrobial Stewardship (HE&AS) is rapidly expanding with the involvement of researchers from varied countries and backgrounds. Researchers must use scientific methods that will provide the strongest evidence to advance healthcare epidemiology, but there are limited resources for information on specific aspects of HE&AS research or easy ways to access examples of studies using specific methods with HE&AS. In response to this need, the SHEA Research Committee has developed a series of white papers on research methods in HE&AS. The objective of this series is to promote rigorous healthcare epidemiology research by summarizing critical components, practical considerations, and pitfalls of commonly used research methods. C1 [Morgan, Daniel J.] VA Maryland Healthcare Syst, Baltimore, MD USA. [Morgan, Daniel J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Morgan, Daniel J.] Ctr Dis Dynam Econ & Policy, Washington, DC USA. [Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Dept Infect Dis, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Milstone, Aaron M.] Johns Hopkins Univ, Dept Pediat, Div Infect Dis, Baltimore, MD 21218 USA. [Anderson, Deverick J.] Duke Univ, Med Ctr, Div Infect Dis, Durham, NC USA. RP Anderson, DJ (reprint author), Duke Univ, Med Ctr, Med, DUMC Box 102359, Durham, NC 27710 USA. EM deverick.anderson@duke.edu FU National Insitutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [K23AI095357] FX D.J.A. was supported by a grant from the National Insitutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (grant no. K23AI095357). NR 3 TC 0 Z9 0 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2016 VL 37 IS 6 BP 627 EP 628 DI 10.1017/ice.2016.91 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DM7LO UT WOS:000376541900001 PM 27074955 ER PT J AU Chou, AF Graber, CJ Jones, M Zhang, Y Goetz, MB Madaras-Kelly, K Samore, M Kelly, A Glassman, PA AF Chou, Ann F. Graber, Christopher J. Jones, Makoto Zhang, Yue Goetz, Matthew Bidwell Madaras-Kelly, Karl Samore, Matthew Kelly, Allison Glassman, Peter A. TI Characteristics of Antimicrobial Stewardship Programs at Veterans Affairs Hospitals: Results of a Nationwide Survey SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES; ANTIBIOTIC-THERAPY; FRENCH HOSPITALS; CARE; IMPACT; INTERVENTION; ASSOCIATION; MANAGEMENT; GUIDELINE AB BACKGROUND. Antimicrobial stewardship programs (ASPs) are variably implemented. OBJECTIVE. To characterize variations of antimicrobial stewardship structure and practices across all inpatient Veterans Affairs facilities in 2012 and correlate key characteristics with antimicrobial usage. DESIGN. A web-based survey regarding stewardship activities was administered to each facility's designated contact. Bivariate associations between facility characteristics and inpatient antimicrobial use during 2012 were determined. SETTING. Total of 130 Veterans Affairs facilities with inpatient services. RESULTS. Of 130 responding facilities, 29 (22%) had a formal policy establishing an ASP, and 12 (9%) had an approved ASP business plan. Antimicrobial stewardship teams were present in 49 facilities (38%); 34 teams included a clinical pharmacist with formal infectious diseases (ID) training. Stewardship activities varied across facilities, including development of yearly antibiograms (122 [94%]), formulary restrictions (120 [92%]), stop orders for antimicrobial duration (98 [75%]), and written clinical pathways for specific conditions (96 [74%]). Decreased antimicrobial usage was associated with having at least 1 full-time ID physician (P =.03), an ID fellowship program (P =.003), and a clinical pharmacist with formal ID training (P =. 006) as well as frequency of systematic patient-level reviews of antimicrobial use (P =.01) and having a policy to address antimicrobial use in the context of Clostridium difficile infection (P =.01). Stop orders for antimicrobial duration were associated with increased use (P =. 03). CONCLUSIONS. ASP-related activities varied considerably. Decreased antibiotic use appeared related to ID presence and certain select practices. Further statistical assessments may help optimize antimicrobial practices. C1 [Chou, Ann F.] Univ Oklahoma, Coll Publ Hlth, Dept Hlth Adm & Policy, Oklahoma City, OK USA. [Chou, Ann F.] Univ Oklahoma, Coll Med, Dept Family & Prevent Med, 900 NE 10th St, Oklahoma City, OK 73104 USA. [Chou, Ann F.] Vet Affairs VA Greater Los Angeles Healthcare Sys, Los Angeles, CA USA. [Graber, Christopher J.; Goetz, Matthew Bidwell; Glassman, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Graber, Christopher J.; Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Jones, Makoto; Samore, Matthew] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA. [Jones, Makoto; Samore, Matthew] Univ Utah, Div Epidemiol, Salt Lake City, UT USA. [Jones, Makoto; Samore, Matthew] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [Zhang, Yue] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA. [Zhang, Yue] Univ Utah, Dept Family & Prevent Med, Salt Lake City, UT USA. [Madaras-Kelly, Karl] Vet Affairs Med Ctr, Boise, ID USA. [Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Meridian, ID USA. [Kelly, Allison] VA Cent Off, Natl Infect Dis Serv, Washington, DC USA. [Glassman, Peter A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RP Chou, AF (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Family & Prevent Med, 900 NE 10th St, Oklahoma City, OK 73104 USA. EM ann-chou@ouhsc.edu FU VA Office of Health Services Research and Development [HX-12-018, CRE 12-313] FX VA Office of Health Services Research and Development (HX-12-018, Collaborative Research to Enhance and Advance Transformation and Excellence Initiative, and CRE 12-313, "Cognitive Support Informatics for Antimicrobial Stewardship [PI: P. Glassman]"). NR 37 TC 2 Z9 2 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2016 VL 37 IS 6 BP 647 EP 654 DI 10.1017/ice.2016.26 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DM7LO UT WOS:000376541900004 PM 26905338 ER PT J AU Egede, LE Walker, RJ Bishu, K Dismuke, CE AF Egede, Leonard E. Walker, Rebekah J. Bishu, Kinfe Dismuke, Clara E. TI Trends in Costs of Depression in Adults with Diabetes in the United States: Medical Expenditure Panel Survey, 2004-2011 SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article ID QUALITY-OF-LIFE; COMORBID DEPRESSION; CARE; PEOPLE; INDIVIDUALS; PREVALENCE; AGREEMENT; MODELS AB To investigate differences in healthcare cost trends over 8 years in adults with diabetes and one of four categories of comorbid depression: no depression, unrecognized depression, asymptomatic depression, or symptomatic depression. Data from the 2004-2011 Medical Expenditure Panel Survey (MEPS) was used to create nationally representative estimates. The dependent variable was total healthcare expenditures for the calendar year, including office-based, hospital outpatient, emergency room, inpatient hospital, prescription, dental, and home health care expenditures. The 2004-2011 direct medical costs were adjusted to a common 2014 dollar value. The primary independent variable was four mutually exclusive depression categories created from ICD-9-CM codes and the PHQ-2 depression screening tool. Healthcare expenditures were estimated using a two-part model and were adjusted for age, sex, race, marital status, education, health insurance, metropolitan statistical area status, region, income level, and comorbidities. Based on a national sample of adults with diabetes (unweighted sample of 15,548, weighted sample of 17,465,579), 10.2 % had unrecognized depression, 13.6 % had asymptomatic depression, and 8.9 % had symptomatic depression. In the pooled sample, after adjusting for covariates, the incremental cost of unrecognized depression was $2872 (95 % CI 1660-4084), asymptomatic depression increased by $3347 (95 % CI 2568-4386), and symptomatic depression increased by $5170 (CI 95 % 3610-6731) compared to patients with no depression. Adjusted analyses showed that expenditures were $2000-3000 higher for unrecognized and asymptomatic depression than no depression, and $5000 higher for symptomatic depression. Higher medical expenditures persisted over time, with only symptomatic depression showing a sustained decrease over time. C1 [Egede, Leonard E.; Walker, Rebekah J.; Bishu, Kinfe; Dismuke, Clara E.] Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280,POB 250593, Charleston, SC 29425 USA. [Egede, Leonard E.; Bishu, Kinfe] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.; Walker, Rebekah J.; Dismuke, Clara E.] Ralph H Johnson Vet Affairs Med Ctr, Hlth Equity & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Dept Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K24DK093699] FX This study was supported by grant no. K24DK093699 from The National Institute of Diabetes and Digestive and Kidney Diseases (PI: Leonard Egede). NR 38 TC 4 Z9 4 U1 4 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2016 VL 31 IS 6 BP 615 EP 622 DI 10.1007/s11606-016-3650-1 PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DM5PY UT WOS:000376403700008 PM 26969312 ER PT J AU Melzer, AC Feemster, LC Collins, MP Au, DH AF Melzer, Anne C. Feemster, Laura C. Collins, Margaret P. Au, David H. TI Predictors of Pharmacotherapy for Tobacco Use Among Veterans Admitted for COPD: The Role of Disparities and Tobacco Control Processes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE COPD; tobacco; smoking; pharmacotherapy; nicotine replacement; disparities; processes of care ID NICOTINE REPLACEMENT THERAPY; OBSTRUCTIVE PULMONARY-DISEASE; SMOKING-CESSATION ADVICE; SERIOUS MENTAL-ILLNESS; RACIAL/ETHNIC DISPARITIES; ETHNIC DISPARITIES; NATIONAL-HEALTH; UNITED-STATES; PREVALENCE; SMOKERS AB Many smokers admitted for chronic obstructive pulmonary disease (COPD) are not given smoking cessation medications at discharge. The reasons behind this are unclear, and may reflect an interplay of patient characteristics, health disparities, and the receipt of inpatient tobacco control processes. We aimed to assess potential disparities in treatment for tobacco use following discharge for COPD, examined in the context of inpatient tobacco control processes. Smokers aged a parts per thousand yen 40 years, admitted for treatment of a COPD exacerbation within the VA Veterans Integrated Service Network 20, identified using ICD-9 discharge codes and admission diagnoses from 2005-2012. The outcome was any tobacco cessation medication dispensed within 48 hours of discharge. We assessed potential predictors administratively up to 1 year prior to admission. We created the final logistic regression model using manual model building, clustered by site. Variables with p < 0.2 in biviariate models were considered for inclusion in the final model. We identified 1511 subjects. 16.9 % were dispensed a medication at discharge. In the adjusted model, several predictors were associated with decreased odds of receiving medications: older age (OR per year older 0.96, 95 % CI 0.95-0.98), black race (OR 0.34, 95 % CI 0.12-0.97), higher comorbidity score (OR 0.89, 95 % CI 0.82-0.96), history of psychosis (OR 0.40, 95 % CI 0.31-0.52), hypertension (OR 0.75, 95 % CI 0.62-0.90), and treatment with steroids in the past year (OR 0.80, 95 % CI 0.70-0.90). Inpatient tobacco control processes were associated with increased odds of receiving medications: documented brief counseling at discharge (OR 3.08, 95 % CI 2.02-4.68) and receipt of smoking cessation medications while inpatient (OR 5.95, 95 % CI 3.19-11.10). Few patients were treated with tobacco cessation medications at discharge. We found evidence for disparities in treatment, but also potentially beneficial effects of inpatient tobacco control measures. Further focus should be on using novel processes of care to improve provision of medications and decrease the observed disparities. C1 [Melzer, Anne C.; Feemster, Laura C.; Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA. [Melzer, Anne C.; Feemster, Laura C.; Collins, Margaret P.; Au, David H.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA. RP Melzer, AC (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA. EM acmelzer@uw.edu FU Department of Veterans Affairs, Health Services Research and Development (HSRD); University of Washington Department of Pulmonary and Critical Care [HL007287-36]; NIH NHLBI K23 Mentored Career Development Award [HL111116]; Gilead Sciences; VA Health Services Research and Development (HSRD) FX This material is based upon work supported by the Department of Veterans Affairs, Health Services Research and Development (HSR&D), who provided access to data, office space, and programming and data management. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. We would like to acknowledge Mr. Robert Plumley, who performed the data extraction and natural language processing necessary to complete this project. Dr. Au is an unpaid research consultant for Analysis Group. Dr. Melzer is supported by an institutional F-32 (HL007287-36) through the University of Washington Department of Pulmonary and Critical Care. Dr. Feemster is supported by an NIH NHLBI K23 Mentored Career Development Award (HL111116). Partial support of this project was provided by Gilead Sciences with research funding to the Seattle Institute for Biomedical and Clinical Research. Additional support was received through the VA Health Services Research and Development (HSR&D). NR 53 TC 1 Z9 1 U1 4 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2016 VL 31 IS 6 BP 623 EP 629 DI 10.1007/s11606-016-3623-4 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DM5PY UT WOS:000376403700009 PM 26902236 ER PT J AU Gros, DF Korte, KJ Horner, MD Brady, KT Back, SE AF Gros, Daniel F. Korte, Kristina J. Horner, Michael David Brady, Kathleen T. Back, Sudie E. TI Co-Occurring Traumatic Brain Injury, PTSD Symptoms, and Alcohol Use in Veterans SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE TBI; Traumatic brain injury; Loss of consciousness; PTSD; Alcohol; Substance use; Comorbidity ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; ADDICTION SEVERITY INDEX; PROLONGED EXPOSURE; HEAD-INJURIES; IRAQ; CONCUSSION; DIAGNOSIS; VALIDITY; THERAPY AB Traumatic brain injury (TBI) has been identified as a significant health problem among veterans. Recent research demonstrates the potential interaction and magnification of symptoms of posttraumatic stress disorder (PTSD) and substance use disorders (SUD) in veterans with a history of TBI; however, there is very limited research on the co-occurrence of the three conditions. Veterans (N = 115) with comorbid PTSD and SUD completed a baseline assessment for enrollment into a larger treatment study. As part of that assessment, participants completed a TBI screener as well as self-report measures for pain and physical health, affective symptoms, and substance use. Almost half of the sample (48 %) endorsed a history of a previous head trauma with loss of consciousness (LOC). Participants with and without head trauma with LOC were compared across various measures of functioning. Increased severity of physical health complaints and affective symptoms were reported by the TBI group compared to controls. However, the increases in affective symptoms were relatively small. No group differences were observed for alcohol use. Together, the findings suggest that treatment-seeking veterans with a history of head trauma with LOC may present with roughly equivalent symptoms of PTSD and SUD to those without said history. C1 [Gros, Daniel F.; Korte, Kristina J.; Horner, Michael David; Brady, Kathleen T.; Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. [Gros, Daniel F.; Korte, Kristina J.; Horner, Michael David; Brady, Kathleen T.; Back, Sudie E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. RP Gros, DF (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.; Gros, DF (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. EM grosd@musc.edu FU NIDA [DA021228]; Department of Veteran Affairs CSR & D Career Development Award [CX000845] FX This research was supported by NIDA grant DA021228 (PI: Back) and Department of Veteran Affairs CSR & D Career Development Award CX000845 (PI: Gros). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of NIDA, Department of Veterans Affairs, or the United States government. NR 38 TC 0 Z9 0 U1 5 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 EI 1573-3505 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD JUN PY 2016 VL 38 IS 2 BP 266 EP 273 DI 10.1007/s10862-015-9513-y PG 8 WC Psychology, Clinical SC Psychology GA DM8NY UT WOS:000376622400012 ER PT J AU Brothers, TE Mixson, J AF Brothers, Thomas E. Mixson, Joshua TI Revascularization of Smokers With Claudication Is Associated With Better Patient Quality of Life Despite Higher Failure Risk SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Vascular Annual Meeting of the Society-for-Vascular-Surgery CY JUN 08-11, 2016 CL National Harbor, MD SP Soc Vasc Surg C1 [Brothers, Thomas E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29403 USA. [Mixson, Joshua] Med Univ S Carolina, Charleston, SC 29425 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2016 VL 63 IS 6 SU S MA IP169 BP 107S EP 108S PG 2 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DM3EW UT WOS:000376230600171 ER PT J AU Kulkarni, T Willoughby, J Lara, MDA Kim, YI Ramachandran, R Alexander, CB Luckhardt, T Thannickal, VJ de Andrade, JA AF Kulkarni, Tejaswini Willoughby, John Lara, Maria del Pilar Acosta Kim, Young-il Ramachandran, Rekha Alexander, C. Bruce Luckhardt, Tracy Thannickal, Victor J. de Andrade, Joao A. TI A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival SO RESPIRATORY MEDICINE LA English DT Article DE Idiopathic pulmonary fibrosis; Transplant-free survival; Bundled care ID INTERSTITIAL LUNG-DISEASE; HEART-FAILURE; MANAGEMENT; EFFICACY; TRIALS AB Background: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with poor prognosis and limited therapeutic options. The 2011 ATS/ERS/JRS/ALAT consensus statement provided a number of recommendations for the management of IPF patients. The primary objective of this study was to determine if "bundling" these recommendations in the management of patients with IPF impacts clinical outcomes. Methods: We conducted a single center, retrospective cohort study of 284 patients diagnosed with IPF. The proposed bundle of care (BOC) components were: (1) visits to a specialized interstitial lung diseases clinic with evaluation of pulmonary function tests at least twice yearly; (2) referral to pulmonary rehabilitation yearly; (3) timed walk test yearly; (4) echocardiogram yearly; and (5) gastroesophageal reflux therapy. Each component of the BOC was given a score of "1" per year of follow up, and the average sum of the scores (ranging from 0 to 5) was determined for the entire period of follow-up (BOCS), as well as during the first year of follow-up (BOCY1). The primary outcome measure was transplant-free survival. Results: Age, gender, smoking status, BMI, %FVC, %DLCO did not differ between levels of BOCS and BOCY1. Lowest BOCS (<= 1) was associated with a lower transplant-free survival independent of age and %FVC compared to patients with the highest BOCS (>4) (HR 2.274, CI 1.12-4.64, p = 0.024). Lower BOCY1 was associated with a higher risk for transplant or death independent of age and %FVC in comparison to patients with highest BOCY1 (<= 1 vs. >4, HR 2.23, p = 0.014; >1 to 2 vs. >4, HR 1.87, p = 0.011; >2 to 3 vs. >4, HR 1.72, p = 0.019). Conclusion: IPF patients with higher BOC scores had improved transplant-free survival. Prospective studies are needed to confirm these findings and determine the best strategies for the management of patients with IPF. Published by Elsevier Ltd. C1 [Kulkarni, Tejaswini; Willoughby, John; Lara, Maria del Pilar Acosta; Kim, Young-il; Ramachandran, Rekha; Luckhardt, Tracy; Thannickal, Victor J.; de Andrade, Joao A.] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Dept Med, 1900 Univ Blvd,Tinsley Harrison Tower,Suite 422, Birmingham, AL 35294 USA. [Kim, Young-il; Ramachandran, Rekha] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Med Towers,Suite 621,1720 2nd Ave South, Birmingham, AL 35294 USA. [Alexander, C. Bruce] Univ Alabama Birmingham, Dept Pathol, P210 West Pavil,619 South 19th St, Birmingham, AL 35233 USA. [Kulkarni, Tejaswini; Lara, Maria del Pilar Acosta; Kim, Young-il; Thannickal, Victor J.; de Andrade, Joao A.] Birmingham VA Med Ctr, 700 South 19th St,6th Floor,Rm 6318, Birmingham, AL 35233 USA. RP de Andrade, JA (reprint author), 1900 Univ Blvd,513 THT, Birmingham, AL 35294 USA. EM joao@uab.edu FU UAB Interstitial Lung Disease Program; NIH [PO1HL114470] FX This study was funded by the UAB Interstitial Lung Disease Program and the NIH grant PO1HL114470. NR 21 TC 0 Z9 0 U1 1 U2 2 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD JUN PY 2016 VL 115 BP 33 EP 38 DI 10.1016/j.rmed.2016.04.010 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA DM7EE UT WOS:000376518200006 PM 27215501 ER PT J AU Piotrowska, A Wierzbicka, J Slebioda, T Wozniak, M Tuckey, RC Slominski, AT Zmijewski, MA AF Piotrowska, Anna Wierzbicka, Justyna Slebioda, Tomasz Wozniak, Michal Tuckey, Robert C. Slominski, Andrzej T. Zmijewski, Michal A. TI Vitamin D derivatives enhance cytotoxic effects of H2O2 or cisplatin on human keratinocytes SO STEROIDS LA English DT Article DE Vitamin D; Vitamin D analogues; Keratinocytes; Reactive oxygen species; Oxidative stress; Cisplatin ID BREAST-CANCER CELLS; CYTOCHROME P450SCC CYP11A1; INDUCED DNA-DAMAGE; OXIDATIVE STRESS; 1,25-DIHYDROXYVITAMIN D-3; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PROSTATE-CANCER; D-RECEPTOR; IN-VIVO; ANTIPROLIFERATIVE ACTIVITY AB Although the skin production of vitamin D is initiated by ultraviolet radiation type B (UVB), the role vitamin D plays in antioxidative or pro-oxidative responses remains to be elucidated. We have used immortalized human HaCaT keratinocytes as a model of proliferating epidermal cells to test the influence of vitamin Don cellular response to H2O2 or the anti-cancer drug, cisplatin. Incubation of keratinocytes with 1,25(OH)(2)D-3 or its low calcemic analogues, 20(OH)D-3, 21(OH)pD or calcipotriol, sensitized cells to ROS resulting in more potent inhibition of keratinocyte proliferation by H2O2 in the presence of vitamin D compounds. These results were supported by cell cycle and apoptosis analyses, and measurement of the mitochondrial transmembrane potentials (MMP), however some unique properties of individual sec asteroids were observed. Furthermore, in HaCaT keratinocytes treated with H2O2, 1,25(OH)(2)D-3, 21(OH) pD and calcipotriol stimulated the expression of SOD1 and CAT genes, but not SOD2, indicating a possible role of mitochondria in ROS-modulated cell death. 1,25(OH)(2)D-3 also showed a short-term, protective effect on HaCaT keratinocytes, as exemplified by the inhibition of apoptosis and the maintenance of MMP. However, with prolonged incubation with H2O2 or cisplatin, 1,25(OH)(2)D-3 caused an acceleration in the death of the keratinocytes. Therefore, we propose that lead vitamin D derivatives can protect the epidermis against neoplastic transformation secondary to oxidative or UV-induced stress through activation of vitamin D-signaling. Furthermore, our data suggest that treatment with low calcemic vitamin D analogues or the maintenance of optimal level of vitamin D by proper supplementation, can enhance the anticancer efficacy of cisplatin (C) 2016 Elsevier Inc. All rights reserved. C1 [Piotrowska, Anna; Wierzbicka, Justyna; Slebioda, Tomasz; Zmijewski, Michal A.] Med Univ Gdansk, Dept Histol, Ul Debinki 1a,Room 230, PL-80211 Gdansk, Pomorskie, Poland. [Wozniak, Michal] Med Univ Gdansk, Dept Med Chem, PL-80211 Gdansk, Pomorskie, Poland. [Tuckey, Robert C.] Univ Western Australia, Sch Chem & Biochem, Crawley, WA, Australia. [Slominski, Andrzej T.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL USA. [Slominski, Andrzej T.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA. [Slominski, Andrzej T.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Zmijewski, MA (reprint author), Med Univ Gdansk, Dept Histol, Ul Debinki 1a,Room 230, PL-80211 Gdansk, Pomorskie, Poland. EM mzmijewski@gumed.edu.pl OI Zmijewski, Michal/0000-0003-2206-3531 FU grant of Polish Ministry of Science and Higher Education [N405 623238, R21 AR066505-01A1, 1R01AR056666-01A2] FX The study was supported by a grant of the Polish Ministry of Science and Higher Education, Project No. N405 623238 to Michal A. Zmijewski, and in part and R21 AR066505-01A1 and 1R01AR056666-01A2 (A.S.). NR 120 TC 0 Z9 0 U1 4 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-128X EI 1878-5867 J9 STEROIDS JI Steroids PD JUN PY 2016 VL 110 BP 49 EP 61 DI 10.1016/j.steroids.2016.04.002 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA DM9QO UT WOS:000376701000005 PM 27083311 ER PT J AU Das, A McDonald, DG Dixon-Mah, YN Jacqmin, DJ Samant, VN Vandergrift, WA Lindhorst, SM Cachia, D Varma, AK Vanek, KN Banik, NL Jenrette, JM Raizer, JJ Giglio, P Patel, SJ AF Das, Arabinda McDonald, Daniel G. Dixon-Mah, Yaenette N. Jacqmin, Dustin J. Samant, Vikram N. Vandergrift, William A., III Lindhorst, Scott M. Cachia, David Varma, Abhay K. Vanek, Kenneth N. Banik, Naren L. Jenrette, Joseph M., III Raizer, Jeffery J. Giglio, Pierre Patel, Sunil J. TI RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma SO TUMOR BIOLOGY LA English DT Article DE Apoptosis; Glioblastoma; Radiation necrosis; RIP ID CELL-DEATH; BRAIN; INFLAMMATION; APOPTOSIS; THERAPY; PATHOPHYSIOLOGY; NECROPTOSIS; DIAGNOSIS AB Radiation-induced necrosis (RN) is a relatively common side effect of radiation therapy for glioblastoma. However, the molecular mechanisms involved and the ways RN mechanisms differ from regulated cell death (apoptosis) are not well understood. Here, we compare the molecular mechanism of cell death (apoptosis or necrosis) of C6 glioma cells in both in vitro and in vivo (C6 othotopically allograft) models in response to low and high doses of X-ray radiation. Lower radiation doses were used to induce apoptosis, while high-dose levels were chosen to induce radiation necrosis. Our results demonstrate that active caspase-8 in this complex I induces apoptosis in response to low-dose radiation and inhibits necrosis by cleaving RIP1 and RI. When activation of caspase-8 was reduced at high doses of X-ray radiation, the RIP1/RIP3 necrosome complex II is formed. These complexes induce necrosis through the caspase-3-independent pathway mediated by calpain, cathepsin B/D, and apoptosis-inducing factor (AIF). AIF has a dual role in apoptosis and necrosis. At high doses, AIF promotes chromatinolysis and necrosis by interacting with histone H2AX. In addition, NF-kappa B, STAT-3, and HIF-1 play a crucial role in radiation-induced inflammatory responses embedded in a complex inflammatory network. Analysis of inflammatory markers in matched plasma and cerebrospinal fluid (CSF) isolated from in vivo specimens demonstrated the upregulation of chemokines and cytokines during the necrosis phase. Using RIP1/RIP3 kinase specific inhibitors (Nec-1, GSK'872), we also establish that the RIP1-RIP3 complex regulates programmed necrosis after either high-dose radiation or TNF-alpha-induced necrosis requires RIP1 and RIP3 kinases. Overall, our data shed new light on the relationship between RIP1/RIP3-mediated programmed necrosis and AIF-mediated caspase-independent programmed necrosis in glioblastoma. C1 [Das, Arabinda; Dixon-Mah, Yaenette N.; Samant, Vikram N.; Vandergrift, William A., III; Lindhorst, Scott M.; Cachia, David; Varma, Abhay K.; Banik, Naren L.; Giglio, Pierre; Patel, Sunil J.] Med Univ S Carolina, Dept Neurosurg, Div Neurooncol, Charleston, SC 29425 USA. [Das, Arabinda; Dixon-Mah, Yaenette N.; Samant, Vikram N.; Vandergrift, William A., III; Lindhorst, Scott M.; Cachia, David; Varma, Abhay K.; Banik, Naren L.; Giglio, Pierre; Patel, Sunil J.] Med Univ S Carolina, MUSC Brain & Spine Tumor Program CSB 310, Charleston, SC 29425 USA. [McDonald, Daniel G.; Jacqmin, Dustin J.; Vanek, Kenneth N.; Jenrette, Joseph M., III] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Giglio, Pierre] Ohio State Univ, Dept Neurol Surg, Wexner Med Coll, Columbus, OH 43210 USA. [Raizer, Jeffery J.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Raizer, Jeffery J.] Northwestern Univ, Feinberg Sch Med, Northwestern Brain Tumor Inst, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. RP Das, A (reprint author), Med Univ S Carolina, Dept Neurosurg, Div Neurooncol, Charleston, SC 29425 USA.; Das, A (reprint author), Med Univ S Carolina, MUSC Brain & Spine Tumor Program CSB 310, Charleston, SC 29425 USA. EM dasa@musc.edu FU MUSC Brain Tumor Research Fund; Department of Neurosurgery (MUSC) FX This investigation was supported by the MUSC Brain Tumor Research Fund and Department of Neurosurgery (MUSC). Alyssa Pierce assisted with revision of the final manuscript. We also appreciate the essential help of Philip Lee. NR 28 TC 4 Z9 5 U1 5 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1010-4283 EI 1423-0380 J9 TUMOR BIOL JI Tumor Biol. PD JUN PY 2016 VL 37 IS 6 BP 7525 EP 7534 DI 10.1007/s13277-015-4621-6 PG 10 WC Oncology SC Oncology GA DM6LT UT WOS:000376464700051 PM 26684801 ER PT J AU Menschikowski, M Hagelgans, A Nacke, B Jandeck, C Mareninova, OA Asatryan, L Siegert, G AF Menschikowski, Mario Hagelgans, Albert Nacke, Brit Jandeck, Carsten Mareninova, Olga A. Asatryan, Liana Siegert, Gabriele TI Epigenetic control of group V phospholipase A(2) expression in human malignant cells SO TUMOR BIOLOGY LA English DT Article DE Group V sPLA2; Leukaemia; Solid cancer cells; DNA methylation ID HUMAN NEUTROPHILS; DNA METHYLATION; GENE-EXPRESSION; EMERGING ROLES; CANCER; MECHANISMS; ENZYMES; DISEASE; PROMOTER; HYDROLYSIS AB Secreted phospholipases A(2) (sPLA(2)) are suggested to play an important role in inflammation and tumorigenesis. Different mechanisms of epigenetic regulation are involved in the control of group IIA, III and X sPLA(2)s expression in cancer cells, but group V sPLA(2) (GV-PLA(2)) in this respect has not been studied. Here, we demonstrate the role of epigenetic mechanisms in regulation of GV-PLA(2) expression in different cell lines originating from leukaemia and solid cancers. In blood leukocytes from leukaemic patients, levels of GV-PLA(2) transcripts were significantly lower in comparison to those from healthy individuals. Similarly, in DU-145 and PC-3 prostate and CAL-51 and MCF-7 mammary cancer cell lines, levels of GV-PLA(2) transcripts were significantly lower in relation to those found in normal epithelial cells of prostate or mammary. By sequencing and methylation-specific high-resolution melting (MS-HRM) analyses of bisulphite-modified DNA, distinct CpG sites in the GV-PLA(2) promoter region were identified that were differentially methylated in cancer cells in comparison to normal epithelial and endothelial cells. Spearman rank order analysis revealed a significant negative correlation between the methylation degree and the cellular expression of GV-PLA(2) (r = -0.697; p = 0.01). The effects of demethylating agent (5-aza-2'-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) on GV-PLA(2) transcription in the analysed cells confirmed the importance of DNA methylation and histone modification in the regulation of the GV-PLA(2) gene expression in leukaemic, prostate and mammary cancer cell lines. The exposure of tumour cells to human recombinant GV-PLA(2) resulted in a reduced colony forming activity of MCF-7, HepG2 and PC-3 cells, but not of DU-145 cells suggesting a cell-type-dependent effect of GV-PLA(2) on cell growth. In conclusion, our results suggest that epigenetic mechanisms such as DNA methylation and histone modification play an important role in downregulation of GV-PLA(2) expression in cancer cells. C1 [Menschikowski, Mario; Hagelgans, Albert; Nacke, Brit; Jandeck, Carsten; Siegert, Gabriele] Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany. [Mareninova, Olga A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mareninova, Olga A.] Univ Calif Los Angeles, Los Angeles, CA USA. [Asatryan, Liana] USC Sch Pharm, Titus Family Dept Clin Pharm, Los Angeles, CA USA. RP Menschikowski, M (reprint author), Tech Univ Dresden, Carl Gustav Carus Univ Hosp, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany. EM Mario.Menschikowski@uniklinikum-dresden.de NR 47 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1010-4283 EI 1423-0380 J9 TUMOR BIOL JI Tumor Biol. PD JUN PY 2016 VL 37 IS 6 BP 8097 EP 8105 DI 10.1007/s13277-015-4670-x PG 9 WC Oncology SC Oncology GA DM6LT UT WOS:000376464700109 PM 26715269 ER PT J AU Kang, JH Mollenhauer, B Coffey, CS Toledo, JB Weintraub, D Galasko, DR Irwin, DJ Van Deerlin, V Chen-Plotkin, AS Caspell-Garcia, C Waligorska, T Taylor, P Shah, N Pan, S Zero, P Frasier, M Marek, K Kieburtz, K Jennings, D Tanner, CM Simuni, T Singleton, A Toga, AW Chowdhury, S Trojanowski, JQ Shaw, LM AF Kang, Ju-Hee Mollenhauer, Brit Coffey, Christopher S. Toledo, Jon B. Weintraub, Daniel Galasko, Douglas R. Irwin, David J. Van Deerlin, Vivianna Chen-Plotkin, Alice S. Caspell-Garcia, Chelsea Waligorska, Teresa Taylor, Peggy Shah, Nirali Pan, Sarah Zero, Pawel Frasier, Mark Marek, Kenneth Kieburtz, Karl Jennings, Danna Tanner, Caroline M. Simuni, Tanya Singleton, Andrew Toga, Arthur W. Chowdhury, Sohini Trojanowski, John Q. Shaw, Leslie M. TI CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study SO ACTA NEUROPATHOLOGICA LA English DT Article DE Parkinson's disease; Cerebrospinal fluid biomarker; Parkinson's Progression Markers Initiative; A beta(1-42); Tau; Alpha-synuclein ID HEALTH-EXPLORATORY-TRIALS; NET-PD EXPERIENCE; ALPHA-SYNUCLEIN; AMYLOID-BETA; COGNITIVE PERFORMANCE; INCIDENT DEMENTIA; TAU; RISK; SUBTYPES; COHORT AB The development of biomarkers to predict the progression of Parkinson's disease (PD) from its earliest stage through its heterogeneous course is critical for research and therapeutic development. The Parkinson's Progression Markers Initiative (PPMI) study is an ongoing international multicenter, prospective study to validate biomarkers in drug-na < ve PD patients and matched healthy controls (HC). We quantified cerebrospinal fluid (CSF) alpha-synuclein (alpha-syn), amyloid-beta1-42 (A beta(1-42)), total tau (t-tau), and tau phosphorylated at Thr181 (p-tau) in 660 PPMI subjects at baseline, and correlated these data with measures of the clinical features of these subjects. We found that CSF alpha-syn, t-tau and p-tau levels, but not A beta(1-42), were significantly lower in PD compared with HC, while the diagnostic value of the individual CSF biomarkers for PD diagnosis was limited due to large overlap. The level of alpha-syn, but not other biomarkers, was significantly lower in PD patients with non-tremor-dominant phenotype compared with tremor-dominant phenotype. In addition, in PD patients the lowest A beta(1-42), or highest t-tau/A beta(1-42) and t-tau/alpha-syn quintile in PD patients were associated with more severe non-motor dysfunction compared with the highest or lowest quintiles, respectively. In a multivariate regression model, lower alpha-syn was significantly associated with worse cognitive test performance. APOE epsilon 4 genotype was associated with lower levels of A beta(1-42), but neither with PD diagnosis nor cognition. Our data suggest that the measurement of CSF biomarkers in early-stage PD patients may relate to disease heterogeneity seen in PD. Longitudinal observations in PPMI subjects are needed to define their prognostic performance. C1 [Kang, Ju-Hee; Toledo, Jon B.; Irwin, David J.; Van Deerlin, Vivianna; Waligorska, Teresa; Shah, Nirali; Pan, Sarah; Zero, Pawel; Trojanowski, John Q.; Shaw, Leslie M.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, 7-103 Founders Pavil 3400 Spruce St, Philadelphia, PA 19104 USA. [Kang, Ju-Hee] Inha Univ, Hypoxiarelated Dis Res Ctr, Sch Med, Dept Pharmacol, Inchon, South Korea. [Mollenhauer, Brit] Paracelsus Elena Klin, Kassel, Germany. [Mollenhauer, Brit] Univ Med Ctr Goettingen, Dept Neuropathol & Neurosurg, Gottingen, Germany. [Coffey, Christopher S.; Caspell-Garcia, Chelsea] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA. [Toledo, Jon B.; Irwin, David J.; Van Deerlin, Vivianna; Chen-Plotkin, Alice S.; Trojanowski, John Q.; Shaw, Leslie M.] Univ Penn, Ctr Neurodegenerat Dis Res, Perelman Sch Med, Inst Aging, Philadelphia, PA 19104 USA. [Weintraub, Daniel; Irwin, David J.; Chen-Plotkin, Alice S.; Trojanowski, John Q.] Univ Penn, Morris K Udall Ctr Excellence Parkinsons Dis Res, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Dept Vet Affairs, Philadelphia, PA USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. [Taylor, Peggy] BioLegend Inc, Dedham, MA USA. [Frasier, Mark; Chowdhury, Sohini] Michael J Fox Fdn Parkinsons Res, New York, NY USA. [Marek, Kenneth; Jennings, Danna] Inst Neurodegenerat Disorders, New Haven, CT USA. [Kieburtz, Karl] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY USA. [Tanner, Caroline M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tanner, Caroline M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Simuni, Tanya] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA. [Singleton, Andrew] NIA, Mol Genet Sect, Neurogenet Lab, NIH, Bethesda, MD 20892 USA. [Toga, Arthur W.] Univ So Calif, Keck Sch Med, Inst Neuroimaging & Informat, Lab Neuro Imaging, Los Angeles, CA 90033 USA. RP Shaw, LM (reprint author), Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, 7-103 Founders Pavil 3400 Spruce St, Philadelphia, PA 19104 USA.; Shaw, LM (reprint author), Univ Penn, Ctr Neurodegenerat Dis Res, Perelman Sch Med, Inst Aging, Philadelphia, PA 19104 USA. EM Les.Shaw@uphs.upenn.edu RI Singleton, Andrew/C-3010-2009 OI Toledo, Jon/0000-0003-4366-9268 FU Michael J. Fox Foundation for Parkinson's Research; Abbott; Avid Radiopharmaceuticals; BiogenIdec; Covance; Elan; Eli Lilly and Co; F. Hoffman-LaRoche Ltd; GE Healthcare; Genentech; Glaxo Smith Kline; Merck and Co; Pfizer Inc; UCB Pharma SA; Morris K. Udall Center of Excellence for Parkinson's Disease Research [P50NS053488-05]; Training in Age-Related Neurodegenerative Diseases from the National Institute on Aging, National Institutes of Health [T32-AG000255]; Intramural Research Program, National Institute on Aging, National Institutes of Health [Z01AG000949-06]; MRC FX This work was supported by The Michael J. Fox Foundation for Parkinson's Research, Abbott, Avid Radiopharmaceuticals, BiogenIdec, Covance, Elan, Eli Lilly and Co, F. Hoffman-LaRoche Ltd, GE Healthcare, Genentech, Glaxo Smith Kline, Merck and Co, Pfizer Inc, and UCB Pharma SA. Trojanowski and Chen-Plotkin were supported by core grant P50NS053488-05 from the Morris K. Udall Center of Excellence for Parkinson's Disease Research. Irwin was supported by Training in Age-Related Neurodegenerative Diseases grant T32-AG000255 from the National Institute on Aging, National Institutes of Health. Singleton was supported by Grant Z01AG000949-06 from the Intramural Research Program, National Institute on Aging, National Institutes of Health. Ju-Hee was supported by Grant MRC NR 43 TC 15 Z9 15 U1 4 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD JUN PY 2016 VL 131 IS 6 BP 935 EP 949 DI 10.1007/s00401-016-1552-2 PG 15 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DM3WM UT WOS:000376277400011 PM 27021906 ER PT J AU Cadoni, S Falt, P Sanna, S Argiolas, M Fanari, V Gallittu, P Liggi, M Mura, D Porcedda, ML Smajstrla, V Erriu, M Leung, FW AF Cadoni, Sergio Falt, Premysl Sanna, Stefano Argiolas, Mariangela Fanari, Viviana Gallittu, Paolo Liggi, Mauro Mura, Donatella Porcedda, Maria L. Smajstrla, Vit Erriu, Matteo Leung, Felix W. TI Insertion water exchange increases right colon adenoma and hyperplastic polyp detection rates during withdrawal SO DIGESTIVE AND LIVER DISEASE LA English DT Article DE Adenoma detection rate; Colon cleanliness; Interval colon cancer; Right colon hyperplastic polyps ID INTERVAL COLORECTAL-CANCER; QUALITY INDICATORS; NEGATIVE COLONOSCOPY; MISS RATE; IMMERSION; IMPACT; RISK; RECOMMENDATIONS; LESIONS; CLASSIFICATION AB Background: Single site studies in male Veterans in the U.S. reported increased detection of presumptive cancer precursors (adenomas, hyperplastic polyps) in the proximal colon (cecum-splenic flexure) by water exchange. Aims: Assess the reproducibility of the observation. Methods: Analysis of secondary outcomes collected prospectively in 3 similarly designed randomized controlled trials using water exchange, water immersion and insufflation (air or carbon dioxide). Main outcome: detection rates of adenomas and hyperplastic polyps in proximal, transverse and right colon (cecum-ascending). Results: 704 males (173 screening) were evaluated. In the proximal colon, WE showed increased detection of small adenomas (p = 0.009) and adenomas plus hyperplastic polyps (p = 0.015) (vs insufflation); increased detection of adenomas plus hyperplastic polyps of any size (p = 0.045) and of small size (p = 0.04) (vs water immersion). In the right colon water exchange increased detection of small adenomas (19% vs 12.1%, p = 0.04) (vs insufflation); small adenomas (19% vs 12%, p = 0.038), adenomas plus hyperplastic polyps of any size (25% vs 16.7%, p = 0.028) and of small size (23.7% vs 14.6%, p = 0.012) (vs water immersion). Water exchange significantly improved bowel cleanliness. Sedation had no impact on lesion detection. Conclusions: Water exchange is a superior insertion technique for detection of adenomas and hyperplastic polyps primarily in the right colon, especially those of small size. (C) 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. C1 [Cadoni, Sergio; Gallittu, Paolo; Liggi, Mauro; Mura, Donatella] St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. [Falt, Premysl; Smajstrla, Vit] Vtkovice Hosp, Ctr Digest Dis, Ostrava, Czech Republic. [Sanna, Stefano; Argiolas, Mariangela; Fanari, Viviana; Porcedda, Maria L.] NS di Bonaria Hosp, Digest Endoscopy Unit, San Gavino Monreale, VS, Italy. [Erriu, Matteo] Univ Cagliari, Dept Surg Sci, Cagliari, CA, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Via S Leonardo 1, I-09016 Iglesias, CI, Italy. EM cadonisergio@gmail.com NR 51 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1590-8658 EI 1878-3562 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD JUN PY 2016 VL 48 IS 6 BP 638 EP 643 DI 10.1016/j.dld.2016.03.004 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DL9HA UT WOS:000375951200012 PM 27017108 ER PT J AU Pellegrini, CN Scheinman, MM AF Pellegrini, Cara N. Scheinman, Melvin M. TI Epidemiology and definition of inappropriate sinus tachycardia SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY LA English DT Review DE Inappropriate sinus tachycardia; Epidemiology; Clinical syndrome; Postural orthostatic tachycardia syndrome ID RADIOFREQUENCY ABLATION AB Inappropriate sinus tachycardia (IST) is a clinical syndrome lacking formal diagnostic criteria. It is generally defined as an elevated resting heart rate (HR; > 90-100 bpm) with an exaggerated response to physical or emotional stress and a clearly sinus mechanism. Clinical manifestations are broad from a complete lack of symptoms to incapacitating incessant tachycardia. Now understood to be relatively prevalent, it is observed to have a generally benign prognosis, though symptoms may persist for years. Whether IST is a single discrete entity or a heterogeneous condition with overlap to other syndromes such as postural orthostatic tachycardia syndrome remains a matter of debate. C1 [Pellegrini, Cara N.] San Francisco VA Med Ctr, 4150 Clement St,111C, San Francisco, CA 94121 USA. [Scheinman, Melvin M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Pellegrini, CN (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111C, San Francisco, CA 94121 USA. EM cara.pellegrini@va.gov NR 15 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1383-875X EI 1572-8595 J9 J INTERV CARD ELECTR JI J. Interv. Card. Electrophysiol. PD JUN PY 2016 VL 46 IS 1 BP 29 EP 32 DI 10.1007/s10840-015-0039-8 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM3SX UT WOS:000376267900005 PM 26310298 ER PT J AU Saab, R Bajaj, NS Hage, FG AF Saab, Rayan Bajaj, Navkaranbir S. Hage, Fadi G. TI Caffeine does not significantly reduce the sensitivity of vasodilator stress myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID CORONARY VASODILATION; BLOOD-FLOW; ADENOSINE; DIPYRIDAMOLE; HEMODYNAMICS; TOMOGRAPHY; ISCHEMIA; RESERVE C1 [Saab, Rayan; Bajaj, Navkaranbir S.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 19 TC 4 Z9 4 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD JUN PY 2016 VL 23 IS 3 BP 442 EP 446 DI 10.1007/s12350-015-0364-4 PG 5 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DM3ZA UT WOS:000376284100014 PM 26667815 ER PT J AU Hage, FG AlJaroudi, WA AF Hage, Fadi G. AlJaroudi, Wael A. TI Review of Cardiovascular Imaging in the Journal of Nuclear Cardiology in 2015-Part 2 of 2: Myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review DE Myocardial perfusion imaging; SPECT; phase analysis; dyssynchrony; appropriateness; safety; regadenoson ID PROGNOSTIC VALUE; OBESE-PATIENTS; REGADENOSON; SPECT; STRESS; ERA AB In 2015, the Journal of Nuclear Cardiology (A (R)) published many high-quality articles. In this series, we will summarize key articles that have appeared in the Journal last year to provide for the interested reader a quick review of the advancements that have recently occurred in the field. In the first article of this 2-part series, we concentrated on publications dealing with plaque imaging, cardiac positron emission tomography, computed tomography, and magnetic resonance. This review will focus on myocardial perfusion imaging summarizing advances in the field including in diagnosis, prognosis, and appropriate use. C1 [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Cardiovasc Imaging, POB 11-2555, Beirut, Lebanon. RP AlJaroudi, WA (reprint author), Clemenceau Med Ctr, Div Cardiovasc Med, Cardiovasc Imaging, POB 11-2555, Beirut, Lebanon. EM wjaroudi@hotmail.com OI Hage, Fadi/0000-0002-1397-4942 NR 40 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD JUN PY 2016 VL 23 IS 3 BP 493 EP 498 DI 10.1007/s12350-016-0444-0 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DM3ZA UT WOS:000376284100022 PM 26892251 ER PT J AU Andrikopoulou, E Hage, FG AF Andrikopoulou, Efstathia Hage, Fadi G. TI Heart rate response to regadenoson: Making the case for its value in clinical practice SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID IMPAIRED CHRONOTROPIC RESPONSE; EMISSION COMPUTED-TOMOGRAPHY; STRESS MYOCARDIAL-PERFUSION; ALL-CAUSE MORTALITY; PROGNOSTIC VALUE; VASODILATOR STRESS; DIABETES-MELLITUS; CARDIAC DEATH; ADENOSINE; PREDICTOR C1 [Andrikopoulou, Efstathia; Hage, Fadi G.] Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Andrikopoulou, Efstathia; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 25 TC 3 Z9 3 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD JUN PY 2016 VL 23 IS 3 BP 575 EP 580 DI 10.1007/s12350-015-0269-2 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DM3ZA UT WOS:000376284100034 PM 26310538 ER PT J AU Saab, R Bajaj, NS Hage, FG AF Saab, Rayan Bajaj, Navkaranbir S. Hage, Fadi G. TI Caffeine intake and myocardial perfusion imaging SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Letter C1 [Saab, Rayan; Bajaj, Navkaranbir S.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Bajaj, Navkaranbir S.; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Saab, R (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM rsaab@uabmc.edu OI Hage, Fadi/0000-0002-1397-4942 NR 3 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD JUN PY 2016 VL 23 IS 3 BP 605 EP 605 DI 10.1007/s12350-016-0420-8 PG 1 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DM3ZA UT WOS:000376284100043 PM 26883777 ER PT J AU Mukherjee, R AF Mukherjee, Rupak TI Fire in the "hall''! Myocardial inflammation and recurrence of atrial fibrillation SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material ID SURGICAL-TREATMENT; CARDIOVERSION; MECHANISMS; HEART; LONE C1 [Mukherjee, Rupak] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Mukherjee, Rupak] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Mukherjee, R (reprint author), Div Cardiothorac Surg, MSC 777,114 Doughty St,Suite 338, Charleston, SC 29426 USA. EM mukherr@musc.edu NR 17 TC 0 Z9 0 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD JUN PY 2016 VL 151 IS 6 BP 1683 EP 1685 DI 10.1016/j.jtcvs.2016.02.043 PG 3 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DM2MM UT WOS:000376180900068 PM 26992604 ER PT J AU Liang, NL Guedes, BD Duvvuri, U Singh, MJ Chaer, RA Makaroun, MS Sachdev, U AF Liang, Nathan L. Guedes, Brian D. Duvvuri, Umamaheswar Singh, Michael J. Chaer, Rabih A. Makaroun, Michel S. Sachdev, Ulka TI Outcomes of interventions for carotid blowout syndrome in patients with head and neck cancer SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID NASOPHARYNGEAL CARCINOMA; ENDOVASCULAR MANAGEMENT AB Background: The purpose of this study was to examine outcomes of a patient cohort undergoing intervention for carotid blowout syndrome associated with head and neck cancer. Methods: Patients with head and neck cancer who presented with carotid distribution bleeding from 2000 to 2014 were identified in the medical record. Primary outcomes were short- and midterm mortality and recurrent bleeding. Standard statistical methods and survival analysis were used to analyze study population characteristics and outcomes. Results: Thirty-seven patients were included in the study. The mean age was 60.1 +/- 11.4 years (74% male). All malignancies were squamous cell type, stage IV, in a variety of primary locations: 32% oral cavity, 24% larynx, 16% superficial neck, with the remainder in the oropharynx, nasopharynx, and hypopharynx. Fifty-one percent of bleeds were of common carotid, 29% external carotid, and 19% internal carotid origin. Among the patients, 68% presented with acute hemorrhage, 24% with impending bleed, and 8% with threatened bleed. All patients underwent intervention: 38% received endovascular coil embolization, 30% stent grafts, 22% surgical ligation, and 10% primary vessel repair or bypass grafting. Although major complications were rare, 10.8% of patients had perioperative stroke. Sixteen recurrent bleeding episodes involving 12 arteries occurred in 11 patients (29.73%). Median rebleeding time was 7 days (interquartile range, 6-49). Estimated recurrent bleeding risk at 30 days and 6 months was 24% and 34%, respectively. Of the patients, 91.9% survived to hospital discharge. The 90-day and 1-year estimated survivals were 60.9% and 36.6%, respectively. Conclusions: Carotid blowout syndrome associated with head and neck cancer carries poor mid-and long-term prognoses; however, mortality may be related more to the advanced stage of disease rather than carotid involvement or associated intervention. Both surgical and endovascular approaches may be efficacious in cases of acute hemorrhage but carry a significant risk of periprocedural stroke and recurrent bleeding. C1 [Liang, Nathan L.; Singh, Michael J.; Chaer, Rabih A.; Makaroun, Michel S.; Sachdev, Ulka] Univ Pittsburgh, Med Ctr, Dept Surg, Div Vasc Surg, Pittsburgh, PA USA. [Liang, Nathan L.; Guedes, Brian D.; Duvvuri, Umamaheswar; Singh, Michael J.; Chaer, Rabih A.; Makaroun, Michel S.; Sachdev, Ulka] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, Med Ctr, Pittsburgh, PA 15260 USA. [Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Liang, NL (reprint author), 200 Lothrop St,Ste A-1017, Pittsburgh, PA 15213 USA. EM liangnl@upmc.edu OI Liang, Nathan/0000-0003-2863-4008 FU National Institutes of Health [2T32HL098036-06]; Department of Veterans Affairs BLSRD FX Supported by grant 2T32HL098036-06 from the National Institutes of Health and in part by funds from the Department of Veterans Affairs BLSR&D (UD). This work does not reflect the views of the U.S. Government or the Department of Veterans Affairs. NR 16 TC 2 Z9 2 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD JUN PY 2016 VL 63 IS 6 BP 1525 EP 1530 DI 10.1016/j.jvs.2015.12.047 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DM3FC UT WOS:000376231200015 PM 26926937 ER PT J AU Haque, A Ray, SK Cox, A Banik, NL AF Haque, Azizul Ray, Swapan K. Cox, April Banik, Naren L. TI Neuron specific enolase: a promising therapeutic target in acute spinal cord injury SO METABOLIC BRAIN DISEASE LA English DT Review DE Neuron specific enolase (NSE); Plasmin; Matrix metalloproteinase (MMP); Major histocompatibility complex (MHC); Inflammation; Neuronal death; Spinal cord injury (SCI) ID TRAUMATIC BRAIN-INJURY; ALPHA-ENOLASE; CARDIAC-ARREST; CEREBROSPINAL-FLUID; MATRIX METALLOPROTEINASES; CEREBRAL-ISCHEMIA; RHEUMATOID-ARTHRITIS; PLASMINOGEN BINDING; MONOCLONAL-ANTIBODY; EARLY PREDICTOR AB Enolase is a multifunctional protein, which is expressed abundantly in the cytosol. Upon stimulatory signals, enolase can traffic to cell surface and contribute to different pathologies including injury, autoimmunity, infection, inflammation, and cancer. Cell-surface expression of enolase is often detected on activated macrophages, microglia/macrophages, microglia, and astrocytes, promoting extracellular matrix degradation, production of pro-inflammatory cytokines/chemokines, and invasion of inflammatory cells in the sites of injury and inflammation. Inflammatory stimulation also induces translocation of enolase from the cytosolic pool to the cell surface where it can act as a plasminogen receptor and promote extracellular matrix degradation and tissue damage. Spinal cord injury (SCI) is a devastating debilitating condition characterized by progressive pathological changes including complex and evolving molecular cascades, and insights into the role of enolase in multiple inflammatory events have not yet been fully elucidated. Neuronal damage following SCI is associated with an elevation of neuron specific enolase (NSE), which is also known to play a role in the pathogenesis of hypoxic-ischemic brain injury. Thus, NSE is now considered as a biomarker in ischemic brain damage, and it has recently been suggested to be a biomarker in traumatic brain injury (TBI), stroke and anoxic encephalopathy after cardiac arrest and acute SCI as well. This review article gives an overview of the current basic research and clinical studies on the role of multifunctional enolase in neurotrauma, with a special emphasis on NSE in acute SCI. C1 [Haque, Azizul] Med Univ S Carolina, Dept Microbiol & Immunol, Hollings Canc Ctr, 173 Ashley Ave,BSB-201, Charleston, SC 29425 USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29209 USA. [Cox, April; Banik, Naren L.] Med Univ S Carolina, Dept Neurosurg, Charleston, SC 29425 USA. [Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, 109 Bee St, Charleston, SC 29401 USA. RP Haque, A (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Hollings Canc Ctr, 173 Ashley Ave,BSB-201, Charleston, SC 29425 USA. EM haque@musc.edu FU South Carolina Spinal Cord Injury Research Fund [SCIRF 2015 P-01]; National Institutes of Health [R01 CA129560, R01 CA129560-S1]; MUSC Center for Global Health Faculty Pilot Program FX This work was supported by grants from the South Carolina Spinal Cord Injury Research Fund (SCIRF 2015 P-01), National Institutes of Health (R01 CA129560 and R01 CA129560-S1), and MUSC Center for Global Health Faculty Pilot Program to A. Haque. NR 84 TC 2 Z9 2 U1 1 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 EI 1573-7365 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD JUN PY 2016 VL 31 IS 3 BP 487 EP 495 DI 10.1007/s11011-016-9801-6 PG 9 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA DM1GY UT WOS:000376094700002 PM 26847611 ER PT J AU McCullumsmith, RE O'Donovan, SM Drummond, JB Benesh, FS Simmons, M Roberts, R Lauriat, T Haroutunian, V Meador-Woodruff, JH AF McCullumsmith, R. E. O'Donovan, S. M. Drummond, J. B. Benesh, F. S. Simmons, M. Roberts, R. Lauriat, T. Haroutunian, V. Meador-Woodruff, J. H. TI Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons? SO MOLECULAR PSYCHIATRY LA English DT Article ID MEDIODORSAL THALAMIC NUCLEUS; ELDERLY-PATIENTS; GLIAL GLUTAMATE; PREFRONTAL CORTEX; RAT-BRAIN; DIFFERENTIAL EXPRESSION; SYNAPTIC-TRANSMISSION; PROTEIN; GLT-1; GAMMA AB Excitatory amino-acid transporters (EAATs) bind and transport glutamate, limiting spillover from synapses due to their dense perisynaptic expression primarily on astroglia. Converging evidence suggests that abnormalities in the astroglial glutamate transporter localization and function may underlie a disease mechanism with pathological glutamate spillover as well as alterations in the kinetics of perisynaptic glutamate buffering and uptake contributing to dysfunction of thalamo-cortical circuits in schizophrenia. We explored this hypothesis by performing cell-and region-level studies of EAAT1 and EAAT2 expression in the mediodorsal nucleus of the thalamus in an elderly cohort of subjects with schizophrenia. We found decreased protein expression for the typically astroglial-localized glutamate transporters in the mediodorsal and ventral tier nuclei. We next used laser-capture microdissection and quantitative polymerase chain reaction to assess cell-level expression of the transporters and their splice variants. In the mediodorsal nucleus, we found lower expression of transporter transcripts in a population of cells enriched for astrocytes, and higher expression of transporter transcripts in a population of cells enriched for relay neurons. We confirmed expression of transporter protein in neurons in schizophrenia using dual-label immunofluorescence. Finally, the pattern of transporter mRNA and protein expression in rodents treated for 9 months with antipsychotic medication suggests that our findings are not due to the effects of antipsychotic treatment. We found a compensatory increase in transporter expression in neurons that might be secondary to a loss of transporter expression in astrocytes. These changes suggest a profound abnormality in astrocyte functions that support, nourish and maintain neuronal fidelity and synaptic activity. C1 [McCullumsmith, R. E.; O'Donovan, S. M.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, 231 Albert Sabin Way ML0583,POB 670583, Cincinnati, OH 45267 USA. [Drummond, J. B.; Benesh, F. S.; Simmons, M.; Roberts, R.; Meador-Woodruff, J. H.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA. [Lauriat, T.] Steward St Elizabeths Med Ctr, Dept Psychiat, Brighton, MA USA. [Haroutunian, V.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Haroutunian, V.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Haroutunian, V.] MIRECC, James J Peters VA Med Ctr, Bronx, NY USA. RP McCullumsmith, RE (reprint author), Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, 231 Albert Sabin Way ML0583,POB 670583, Cincinnati, OH 45267 USA. EM robert.mccullumsmith@uc.edu OI Lauriat, Tara/0000-0003-0729-9386; O'Donovan, Sinead/0000-0003-3172-4952 FU Doris Duke Clinical Scientist Award; Lindsay Brinkmeyer Schizophrenia Research Fund; [MH53327]; [MH88752]; [MH094445]; [MH074016] FX This work was supported by MH53327 (JHM-W), MH88752 (JHM-W), MH094445 (REM), MH074016 (REM) and Doris Duke Clinical Scientist Award (REM). This work was also supported by the Lindsay Brinkmeyer Schizophrenia Research Fund. NR 76 TC 0 Z9 0 U1 5 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD JUN PY 2016 VL 21 IS 6 BP 823 EP 830 DI 10.1038/mp.2015.148 PG 8 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA DM2EN UT WOS:000376159600016 PM 26416546 ER PT J AU Warren, M McCarthy, MS Roberts, PR AF Warren, Malissa McCarthy, Mary S. Roberts, Pamela R. TI Practical Application of the Revised Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: A Case Study Approach SO NUTRITION IN CLINICAL PRACTICE LA English DT Article DE nutritional support; enteral nutrition; parenteral nutrition; critical care; critical illness; intensive care units; practice guidelines ID SEVERE ACUTE-PANCREATITIS; EARLY ENTERAL NUTRITION; RANDOMIZED CLINICAL-TRIAL; TOTAL PARENTERAL-NUTRITION; VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE INSULIN THERAPY; RESIDUAL GASTRIC VOLUME; ACUTE KIDNEY INJURY; OPEN ABDOMEN; SURGICAL-PATIENTS AB Background: Nutrition therapy is an essential component of the care plan for critically ill and injured patients. There is consensus that critically ill patients are at risk for malnutrition, and the associated consequences of increased infectious morbidity, multiorgan dysfunction, prolonged hospitalization, and disproportionate mortality can be minimized with specialized enteral and/or parenteral nutrition therapy. Methods: In this article, we describe 2 case studies that are intended to introduce the nutrition support clinician to key updates in the recently released Guidelines for Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). Results: The case studies demonstrate a pragmatic approach to nutrition therapy in the intensive care unit (ICU) and are intended to elicit dialogue for timely, appropriate nutrition care at policy meetings, professional conferences, and ICU daily rounds. Conclusions: While explicitly stated in the formal document, it is worth repeating that the guidelines are directed toward generalized patient populations, but as with any therapeutic intervention in the ICU, nutrition therapy should be tailored to the individual patient. In addition, protocols and procedures should reflect the local institutional culture and meet with approval of critical care clinicians. C1 [Warren, Malissa] Portland VA Med Ctr, Portland, OR USA. [McCarthy, Mary S.] Madigan Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, 9040 Jackson Ave, Tacoma, WA 98431 USA. [Roberts, Pamela R.] Univ Oklahoma, Coll Med, Dept Anesthesiol, Oklahoma City, OK 73190 USA. RP McCarthy, MS (reprint author), Madigan Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, 9040 Jackson Ave, Tacoma, WA 98431 USA. EM Mary.s.mccarthy1.civ@mail.mil NR 70 TC 2 Z9 2 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD JUN PY 2016 VL 31 IS 3 BP 334 EP 341 DI 10.1177/0884533616640451 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DM4CW UT WOS:000376294200007 PM 27072854 ER PT J AU Stark, AP Sacks, GD Rochefort, MM Donahue, TR Reber, HA Tomlinson, JS Dawson, DW Eibl, G Hines, OJ AF Stark, Alexander P. Sacks, Greg D. Rochefort, Matthew M. Donahue, Timothy R. Reber, Howard A. Tomlinson, James S. Dawson, David W. Eibl, Guido Hines, O. Joe TI Long-term survival in patients with pancreatic ductal adenocarcinoma SO SURGERY LA English DT Article ID PROGNOSTIC-FACTORS; 5-YEAR SURVIVORS; CURATIVE RESECTION; CLINICOPATHOLOGICAL ANALYSIS; PERINEURAL INVASION; SURGICAL RESECTION; TUMOR GRADE; CANCER; SURGERY; IMPACT AB Background. Long-term survival (LTS) is uncommon for patients with pancreatic ductal adenocarcinoma (PDAC). We sought to identify factors that predict 10-year, LTS after resection of PDAC. Methods. We identified all patients with PDAC who underwent resection at UCLA after 1990 and included all patients eligible for observed LTS (1/1/1990-12/31/2004). An independent pathologist reconfirmed the diagnosis of PDAC in patients with LTS. Logistic regression was used to predict LTS on the basis of patient and tumor characteristics. Results. Of 173 included patients, 53% were male, median age at diagnosis was 66 years, and median survival was 23 months. The rate of observed LTS was 12.1 % (n = 21). Age, sex, number of lymph nodes evaluated, margin status, lymphovascular invasion, and adjuvant chemotherapy and radiation were not associated with LTS. The following were associated with LTS on bivariate analysis: low AJCC stage (Ia, Ib, IIa) (P = .034), negative lymph node status (P = .034), low grade (well-, moderately-differentiated) (P = .001), and absence of perineural invasion (P = .019). Only low grade (odds ratio 7.17, P = .012) and absent perineural invasion (odds ratio 3.28, P = .036) were independently associated with increased odds of LTS. Our multivariate model demonstrated good discriminatory power for LTS, as indicated by a c-statistic of 0.7856. Conclusion. Absence of perineural invasion and low tumor grade were associated with greater likelihood of LTS. Understanding the tumor biology of LTS may provide critical insight into a disease that is typically marked by aggressive behavior and limited survival. C1 [Stark, Alexander P.; Sacks, Greg D.; Rochefort, Matthew M.; Donahue, Timothy R.; Reber, Howard A.; Tomlinson, James S.; Eibl, Guido; Hines, O. Joe] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Dawson, David W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Rochefort, Matthew M.; Tomlinson, James S.] Greater Los Angeles VA Healthcare Syst, Dept Surg, Los Angeles, CA USA. RP Hines, OJ (reprint author), 10833 Le Conte Ave,72-180 CHS, Los Angeles, CA 90095 USA. EM joehines@mednet.ucla.edu OI Stark, Alexander/0000-0001-8463-5414; Dawson, Warrick/0000-0003-0050-6717 FU NCI NIH HHS [P01 CA163200]; NIDDK NIH HHS [P30 DK041301] NR 38 TC 0 Z9 0 U1 4 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0039-6060 J9 SURGERY JI Surgery PD JUN PY 2016 VL 159 IS 6 BP 1520 EP 1527 DI 10.1016/j.surg.2015.12.024 PG 8 WC Surgery SC Surgery GA DL8KH UT WOS:000375890400004 PM 26847803 ER PT J AU Romo, RD Wallhagen, MI Smith, AK AF Romo, Rafael D. Wallhagen, Margaret I. Smith, Alexander K. TI Viewing Hospice Decision Making as a Process SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Review DE hospice; end-of-life care; prognosis; communication; decision making; older adults ID END-OF-LIFE; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; TREATMENT PREFERENCES; RACIAL-DIFFERENCES; SUSTAINING TREATMENT; PATIENT PREFERENCES; ADULTS PREFERENCES; SPIRITUAL SUPPORT; ADVANCED ILLNESS AB Research focused on understanding that the nature of hospice decision making has both described the characteristics of those who do and do not utilize hospice and identified many factors related to choosing hospice. However, this literature has not explored the underlying decision-making processes, limiting our understanding. We examine the extant literature and propose a framework that views hospice decisions as an evolving process, identify key factors that bear directly on this process, and discuss the contextual environment, including the idea of a decision maker triad. We end with a discussion of how this framework can be used to support clinical practice and future research. Our goal is to provide a framework from which to understand the end-of-life needs of all patients, no matter where they receive care. C1 [Romo, Rafael D.; Wallhagen, Margaret I.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Romo, Rafael D.; Smith, Alexander K.] San Francisco Vet Affair Med Ctr, Geriatr Palliat & Extended Care, San Francisco, CA USA. [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. RP Romo, RD (reprint author), San Francisco VA Med Ctr, 4150 Clement St 181G, San Francisco, CA 94121 USA. EM rafael.romo@ucsf.edu FU John A. Hartford Foundation/Building Academic Geriatric Nursing Capacity scholarship FX The authors disclose receipt of the following financial support for the research, authorship and/or publication of this article: John A. Hartford Foundation/Building Academic Geriatric Nursing Capacity scholarship. NR 74 TC 1 Z9 1 U1 1 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD JUN PY 2016 VL 33 IS 5 BP 503 EP 510 DI 10.1177/1049909115569592 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DL7RG UT WOS:000375837200014 PM 25635114 ER PT J AU Kamil, RJ Betz, J Powers, BB Pratt, S Kritchevsky, S Ayonayon, HN Harris, TB Helzner, E Deal, JA Martin, K Peterson, M Satterfield, S Simonsick, EM Lin, FR AF Kamil, Rebecca J. Betz, Joshua Powers, Becky Brott Pratt, Sheila Kritchevsky, Stephen Ayonayon, Hilsa N. Harris, Tammy B. Helzner, Elizabeth Deal, Jennifer A. Martin, Kathryn Peterson, Matthew Satterfield, Suzanne Simonsick, Eleanor M. Lin, Frank R. CA Hlth ABC study TI Association of Hearing Impairment With Incident Frailty and Falls in Older Adults SO JOURNAL OF AGING AND HEALTH LA English DT Article DE hearing impairment; frailty; falls; older adults; Health ABC ID RISK-FACTORS; COGNITIVE IMPAIRMENT; PHYSICAL-ACTIVITY; UNITED-STATES; OSTEOPOROTIC FRACTURES; CARDIOVASCULAR-DISEASE; FUNCTIONAL DECLINE; ELDERLY PERSONS; HEALTH; WOMEN AB Objective: We aimed to determine whether hearing impairment (HI) in older adults is associated with the development of frailty and falls. Method: Longitudinal analysis of observational data from the Health, Aging and Body Composition study of 2,000 participants aged 70 to 79 was conducted. Hearing was defined by the pure-tone-average of hearing thresholds at 0.5, 1, 2, and 4 kHz in the better hearing ear. Frailty was defined as a gait speed of <0.60 m/s and/or inability to rise from a chair without using arms. Falls were assessed annually by self-report. Results: Older adults with moderate-or-greater HI had a 63% increased risk of developing frailty (adjusted hazard ratio [HR] = 1.63, 95% confidence interval [CI] = [1.26, 2.12]) compared with normal-hearing individuals. Moderate-or-greater HI was significantly associated with a greater annual percent increase in odds of falling over time (9.7%, 95% CI = [7.0, 12.4] compared with normal hearing, 4.4%, 95% CI = [2.6, 6.2]). Discussion: HI is independently associated with the risk of frailty in older adults and with greater odds of falling over time. C1 [Kamil, Rebecca J.; Betz, Joshua; Deal, Jennifer A.; Simonsick, Eleanor M.; Lin, Frank R.] Johns Hopkins Univ, Baltimore, MD USA. [Powers, Becky Brott; Pratt, Sheila; Peterson, Matthew] US Dept Vet Affairs, Washington, DC USA. [Pratt, Sheila] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Kritchevsky, Stephen] Wake Forest Univ, Winston Salem, NC 27109 USA. [Ayonayon, Hilsa N.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Harris, Tammy B.; Simonsick, Eleanor M.] NIA, Bethesda, MD 20892 USA. [Helzner, Elizabeth] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Martin, Kathryn] Univ Aberdeen, Aberdeen AB9 1FX, Scotland. [Peterson, Matthew] Duke Univ, Durham, NC USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. RP Kamil, RJ (reprint author), Johns Hopkins Univ, Ctr Aging & Hlth, 2024 E Monument St,Suite 2-700, Baltimore, MD 21205 USA. EM rkamil1@jhmi.edu OI Betz, Joshua/0000-0003-4488-9799 FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01-NR012459]; Intramural Research Program of the NIH, National Institute on Aging; National Institute of Deafness and Communication Disorders [K23DC011279]; Triological Society; American College of Surgeons Clinician Scientist Award; Eleanor Schwartz Charitable Foundation; Oticon Foundation; Geriatric Research Education and Clinical Center in the Veterans Administration Pittsburgh Healthcare System FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by National Institute on Aging (NIA) Contracts N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106; NIA Grant R01-AG028050; and NINR Grant R01-NR012459. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging. Frank Lin is supported by the National Institute of Deafness and Communication Disorders K23DC011279 Grant, Triological Society and American College of Surgeons Clinician Scientist Award, and Eleanor Schwartz Charitable Foundation. Rebecca Kamil's coursework at Bloomberg School of Public Health is supported by the Oticon Foundation. Sheila Pratt and Becky Brott Powers were supported by the Geriatric Research Education and Clinical Center in the Veterans Administration Pittsburgh Healthcare System during the development of this article. NR 55 TC 1 Z9 1 U1 4 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 EI 1552-6887 J9 J AGING HEALTH JI J. Aging Health PD JUN PY 2016 VL 28 IS 4 BP 644 EP 660 DI 10.1177/0898264315608730 PG 17 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA DL5ZC UT WOS:000375714700005 PM 26438083 ER PT J AU Wild, KV Mattek, N Austin, D Kaye, JA AF Wild, Katherine V. Mattek, Nora Austin, Daniel Kaye, Jeffrey A. TI "Are You Sure?": Lapses in Self-Reported Activities Among Healthy Older Adults Reporting Online SO JOURNAL OF APPLIED GERONTOLOGY LA English DT Article DE in-home monitoring; technology; self-report assessments ID ECOLOGICAL MOMENTARY ASSESSMENT; MILD COGNITIVE IMPAIRMENT; PHYSICAL-ACTIVITY; ACCELEROMETER; TECHNOLOGIES; ACCURACY; DIARIES; PEOPLE AB Accurate retrospective reporting of activities and symptoms has been shown to be problematic for older adults, yet standard clinical care relies on self-reports to aid in assessment and management. Our aim was to examine the relationship between self-report and sensor-based measures of activity. We administered an online activity survey to participants in our ongoing longitudinal study of in-home ubiquitous monitoring. We found a wide range of accuracies when comparing self-report with time-stamped sensor-based data. Of the 95 participants who completed the 2-hr activity log, nearly one quarter did not complete the task in a way that could potentially be compared with sensor data. Where comparisons were possible, agreement between self-reported and sensor-based activity was achieved by a minority of participants. The findings suggest that capture of real-time events with unobtrusive activity monitoring may be a more reliable approach to describing behavioral patterns and meaningful changes in older adults. C1 [Wild, Katherine V.] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Neurol & Psychiat, Portland, OR 97201 USA. [Mattek, Nora] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol ORCATECH, Portland, OR 97201 USA. [Mattek, Nora; Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. [Austin, Daniel] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Neurol & Biomed Engn, ORCATECH, Portland, OR 97201 USA. [Kaye, Jeffrey A.] Portland VA Med Ctr, Portland, OR USA. RP Wild, KV (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, CR131,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM wildk@ohsu.edu FU National Institutes of Health [P30AG024978, R01AG024059, P30AG008017] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by grants from the National Institutes of Health [P30AG024978, R01AG024059, P30AG008017]. NR 35 TC 2 Z9 2 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0733-4648 EI 1552-4523 J9 J APPL GERONTOL JI J. Appl. Gerontol. PD JUN PY 2016 VL 35 IS 6 BP 627 EP 641 DI 10.1177/0733464815570667 PG 15 WC Gerontology SC Geriatrics & Gerontology GA DL5XF UT WOS:000375709700004 PM 25669877 ER PT J AU Bernard, JD Baddeley, JL Rodriguez, BF Burke, PA AF Bernard, Jared D. Baddeley, Jenna L. Rodriguez, Benjamin F. Burke, Philip A. TI Depression, Language, and Affect: An Examination of the Influence of Baseline Depression and Affect Induction on Language SO JOURNAL OF LANGUAGE AND SOCIAL PSYCHOLOGY LA English DT Article DE language; linguistic style; depression; affect; mood ID NEGATIVE AFFECT; RUMINATION; LIWC; TALK AB Literature suggests that depression influences how individuals communicate. However, no studies examine the impact of affective state on language. The current study examined the influence of depression and affective state on linguistic style. Findings suggest that depression and temporary negative moods both affect pronoun use, but depression influences use of first-person pronouns, whereas negative affect influences use of third-person pronouns. C1 [Bernard, Jared D.] So Illinois Univ, Clin Psychol, Carbondale, IL 62901 USA. [Rodriguez, Benjamin F.; Burke, Philip A.] So Illinois Univ, Dept Psychol, 1125 Lincoln Dr,LSII281 MC6502, Carbondale, IL 62901 USA. [Baddeley, Jenna L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Baddeley, Jenna L.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Bernard, JD (reprint author), So Illinois Univ, Dept Psychol, 1125 Lincoln Dr,LSII281 MC6502, Carbondale, IL 62901 USA. EM jared.d.bernard@gmail.com NR 25 TC 0 Z9 0 U1 2 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0261-927X EI 1552-6526 J9 J LANG SOC PSYCHOL JI J. Lang. Soc. Psychol. PD JUN PY 2016 VL 35 IS 3 BP 317 EP 326 DI 10.1177/0261927X15589186 PG 10 WC Communication; Linguistics; Psychology, Social SC Communication; Linguistics; Psychology GA DL6RC UT WOS:000375765300005 ER PT J AU Madson, MB Schumacher, JA Baer, JS Martino, S AF Madson, Michael B. Schumacher, Julie A. Baer, John S. Martino, Steve TI Motivational Interviewing for Substance Use: Mapping Out the Next Generation of Research SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Editorial Material DE Motivational interviewing; Substance use; Research ID RANDOMIZED CONTROLLED-TRIAL; MANDATED COLLEGE-STUDENTS; PRIMARY-CARE SETTINGS; BRIEF INTERVENTION; DRUG-USE; CLINICAL-TRIAL; USE OUTCOMES; CHANGE TALK; METAANALYSIS; ALCOHOL C1 [Madson, Michael B.] Univ So Mississippi, Hattiesburg, MS 39406 USA. [Schumacher, Julie A.] Univ Mississippi, Med Ctr, University, MS 38677 USA. [Baer, John S.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Martino, Steve] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT 06520 USA. RP Madson, MB (reprint author), Univ So Mississippi, Hattiesburg, MS 39406 USA. NR 80 TC 1 Z9 1 U1 2 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUN PY 2016 VL 65 SI SI BP 1 EP 5 DI 10.1016/j.jsat.2016.02.003 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DL3DM UT WOS:000375514400001 PM 26971078 ER PT J AU Moyers, TB Rowell, LN Manuel, JK Ernst, D Houck, JM AF Moyers, Theresa B. Rowell, Lauren N. Manuel, Jennifer K. Ernst, Denise Houck, Jon M. TI The Motivational Interviewing Treatment Integrity Code (MITI 4): Rationale, Preliminary Reliability and Validity SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE MITI 4; Motivational interviewing; Treatment fidelity; Treatment integrity; Reliability; Supervision ID THERAPIST ADHERENCE; USE OUTCOMES; CHANGE TALK; INTERVENTION; ENHANCEMENT; ADOLESCENTS; COMPETENCE; FIDELITY; LANGUAGE; TRIAL AB The Motivational Interviewing Treatment Integrity code has been revised to address new evidence-based elements of motivational interviewing (MI). This new version (MITI 4) includes new global ratings to assess clinician's attention to client language, increased rigor in assessing autonomy support and client choice, and items to evaluate the use of persuasion when giving information and advice. Method: Four undergraduate, non-professional raters were trained in the MITI and used it to review 50 audiotapes of clinicians conducting MI in actual treatments sessions. Both kappa and intraclass correlation indices were calculated for all coders, for the best rater pair and for a 20% randomly selected sample from the best rater pair. Results: Reliability across raters, with the exception of Emphasize Autonomy and % Complex Reflections, were in the good to excellent range. Reliability estimates decrease when smaller samples are used and when fewer raters contribute. Conclusion: The advantages and drawbacks of this revision are discussed including implications for research and clinical applications. The MITI 4.0 represents a reliable method for assessing the integrity of MI including both the technical and relational components of the method. (C) 2016 Elsevier Inc. All rights reserved. C1 [Moyers, Theresa B.; Rowell, Lauren N.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. [Manuel, Jennifer K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ernst, Denise] Denise Ernst Training & Consulting, Portland, OR USA. [Houck, Jon M.] Univ New Mexico, Ctr Alcoholism Subst Abuse & Addict, Albuquerque, NM 87131 USA. RP Moyers, TB (reprint author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA. EM tmoyers@unm.edu OI Houck, Jon/0000-0002-6565-4481 FU National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health [K01AA021431] FX JMH's effort in this publication was supported by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under award number K01AA021431. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 53 TC 5 Z9 5 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUN PY 2016 VL 65 SI SI BP 36 EP 42 DI 10.1016/j.jsat.2016.01.001 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DL3DM UT WOS:000375514400006 PM 26874558 ER PT J AU Drapkin, ML Wilbourne, P Manuel, JK Baer, J Karlin, B Raffa, S AF Drapkin, Michelle L. Wilbourne, Paula Manuel, Jennifer K. Baer, John Karlin, Bradley Raffa, Susan TI National Dissemination of Motivation Enhancement Therapy in the Veterans Health Administration: Training Program Design and Initial Outcomes SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Motivational interviewing; Dissemination; Implementation; Motivational enhancement therapy; Veterans; Competency-based; Addictions; Substance use disorders AB Motivational enhancement therapy (MET) can be defined most simply as the ".... combination of Motivational Interviewing (MI) with assessment feedback ...." (Miller & Rollnick, 2013, p. 250). MET has a clear evidence base promoting its use especially for treatment of substance use disorders (SUDS). Despite its efficacy and utility, MET is not widely used in clinical settings. In 2012, to facilitate the dissemination of MET, the Veterans Health Administration [VHA; the health care component of the U.S. Department of Veterans Affairs (VA)] launched a national training program that provided competency-based training in MET to VA staff working in SUD specialty care clinics. All VA facilities are required to implement EBP5 for SUDs, such as MET, and ensure that they are available to veterans. This paper describes the VA MET training program and examines the impact of the MET training program on participants' knowledge of MET and self-reported MET skills. We review the components of the training and consultation and discuss adaptations made from the Project MATCH MET model to a real world clinical setting. Of the 264 training participants we trained 2012-2013, 213 (81%) successfully completed all requirements of the training program, including requirements for demonstrating competency and attending at least 75% of scheduled consultation calls. After completion of the training program, approximately 85% of the clinicians reported implementing MET often (either 1-3 times per week or daily). Furthermore, we saw significant increases in MI knowledge from pretraining assessment to post-workshop and from pretraining to post-consultations. Additional training program details and revisions are discussed. Published by Elsevier Inc. C1 [Drapkin, Michelle L.; Wilbourne, Paula; Manuel, Jennifer K.; Baer, John; Karlin, Bradley; Raffa, Susan] US Dept Vet Affairs, Mental Hlth Serv, Washington, DC 20420 USA. RP Drapkin, ML (reprint author), Rutgers State Univ, 17 Senior St, New Brunswick, NJ 08901 USA. EM drapkin@rutgers.edu NR 13 TC 1 Z9 1 U1 4 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD JUN PY 2016 VL 65 SI SI BP 83 EP 87 DI 10.1016/j.jsat.2016.02.002 PG 5 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DL3DM UT WOS:000375514400012 PM 26951921 ER PT J AU Handforth, A AF Handforth, Adrian TI Linking Essential Tremor to the Cerebellum-Animal Model Evidence SO CEREBELLUM LA English DT Review DE Tremor; Harmaline; Inferior olive; Cerebellum; Animal model ID PURKINJE-CELL DEGENERATION; HARMALINE-INDUCED TREMOR; COMPLEX SPIKE SYNCHRONY; LEANER MUTANT MICE; INFERIOR OLIVARY NEURONS; KNOCKOUT MICE; OLIVOCEREBELLAR CIRCUIT; PARVALBUMIN EXPRESSION; MORPHOLOGICAL-CHANGES; MOTOR COORDINATION AB In this review, we hope to stimulate interest in animal models as opportunities to understand tremor mechanisms within the cerebellar system. We begin by considering the harmaline model of essential tremor (ET), which has ET-like anatomy and pharmacology. Harmaline induces the inferior olive (IO) to burst fire rhythmically, recruiting rhythmic activity in Purkinje cells (PCs) and deep cerebellar nuclei (DCN). This model has fostered the IO hypothesis of ET, which postulates that factors that promote excess IO, and hence PC complex spike synchrony, also promote tremor. In contrast, the PC hypothesis postulates that partial PC cell loss underlies tremor of ET. We describe models in which chronic partial PC loss is associated with tremor, such as the Weaver mouse, and others with PC loss that do not show tremor, such as the Purkinje cell degeneration mouse. We postulate that partial PC loss with tremor is associated with terminal axonal sprouting. We then discuss tremor that occurs with large lesions of the cerebellum in primates. This tremor has variable frequency and is an ataxic tremor not related to ET. Another tremor type that is not likely related to ET is tremor in mice with mutations that cause prolonged synaptic GABA action. This tremor is probably due to mistiming within cerebellar circuitry. In the final section, we catalog tremor models involving neurotransmitter and ion channel perturbations. Some appear to be related to the IO hypothesis of ET, while in others tremor may be ataxic or due to mistiming. In summary, we offer a tentative framework for classifying animal action tremor, such that various models may be considered potentially relevant to ET, subscribing to IO or PC hypotheses, or not likely relevant, as with mistiming or ataxic tremor. Considerable further research is needed to elucidate the mechanisms of tremor in animal models. C1 [Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Handforth, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM charles.handforth@va.gov FU Veterans Affairs; Cyberonics Inc.; Medtronic; UCB Pharma; Ortho-McNeil; Forest Laboratories; Sonexa; Eisai FX We are grateful to Nicholas Franich, Ph.D. for the assistance with figure. The author was supported by Veterans Affairs. The author has received clinical research funding from Cyberonics Inc., Medtronic, UCB Pharma, Ortho-McNeil, Forest Laboratories, Sonexa, and Eisai. NR 106 TC 1 Z9 1 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1473-4222 EI 1473-4230 J9 CEREBELLUM JI Cerebellum PD JUN PY 2016 VL 15 IS 3 SI SI BP 285 EP 298 DI 10.1007/s12311-015-0750-0 PG 14 WC Neurosciences SC Neurosciences & Neurology GA DK7EL UT WOS:000375087600007 PM 26660708 ER PT J AU Lerrigo, R Beste, LA Leipertz, SL Green, PK Lok, ASF Kogut, MJ Ioannou, GN AF Lerrigo, Robert Beste, Lauren A. Leipertz, Steven L. Green, Pamela K. Lok, Anna S. F. Kogut, Matthew J. Ioannou, George N. TI Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article ID STAGE LIVER-DISEASE; HEPATORENAL-SYNDROME; REFRACTORY ASCITES; HEPATOCELLULAR-CARCINOMA; ADMINISTRATIVE DATABASES; HEPATIC HYDROTHORAX; MELD SCORE; CHILD-PUGH; SURVIVAL; VETERANS AB complications of portal hypertension. We aimed to describe post-TIPS mortality and its predictors in the modern era of covered stents. Patients and methods We identified patients with cirrhosis who underwent TIPS insertion at Veterans Affairs Healthcare facilities nationally from 2004 to 2014 (n=703), most of which (95%) were performed as elective procedures. We followed patients until the date of death, transplantation, or the end of the observation period. Results TIPS recipients had a mean age of 59.3 years (SD 8) and 97% were men. The mean Model for End Stage Liver Disease (MELD) score was 13 (SD 4.8); 47% had hepatitis C virus (HCV) infection, 48% had variceal hemorrhage, and 40% had ascites. During a mean follow-up of 1.72 years (SD 1.9), 57.5% of TIPS recipients died (n=404) and only 5.3% underwent liver transplantation (n=37). The median survival after TIPS was 1.74 years (interquartile range 0.3-4.7). Thirty-day mortality after TIPS was 11.6% [95% confidence interval (CI) 9.4-14.2], 1-year mortality was 40.3% (95% CI 36.7-44.2), and 3-year mortality was 61.9% (95% CI 57.9-66.0). Independent predictors of post-TIPS mortality included medical comorbidity burden, low albumin, HCV infection, and high MELD score (or high international normalized ratio and bilirubin when the components of the MELD score were analyzed individually). TIPS revision was performed at least once in 27.3% of TIPS recipients. Conclusion TIPS should not be considered simply as a bridge to transplantation. Burden of extra-hepatic comorbidities, HCV infection, and low serum albumin strongly predict post-TIPS mortality in addition to the MELD score. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Lerrigo, Robert; Beste, Lauren A.] Vet Affairs Puget Sound Healthcare Syst, Primary Care Serv, Seattle, WA USA. [Beste, Lauren A.; Leipertz, Steven L.; Green, Pamela K.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Kogut, Matthew J.] Vet Affairs Puget Sound Healthcare Syst, Dept Radiol, Seattle, WA USA. [Ioannou, George N.] Vet Affairs Puget Sound Healthcare Syst, Hosp & Specialty Med Serv, Seattle, WA USA. [Lerrigo, Robert; Beste, Lauren A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Kogut, Matthew J.] Univ Washington, Div Intervent Radiol, Seattle, WA 98195 USA. [Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Lok, Anna S. F.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Healthcare Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU VA Puget Sound HealthCare System (Seattle, Washington); Clinical Science Research and Development, Office of Research and Development, Veterans Affairs [CX000320]; VA Office of Public Health and Human Health Pathogens FX This work was supported by resources from the VA Puget Sound HealthCare System (Seattle, Washington). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.; The study was funded by a Merit Review grant (CX000320), Clinical Science Research and Development, Office of Research and Development, Veterans Affairs (GNI), and by the VA Office of Public Health and Human Health Pathogens (LAB). NR 31 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD JUN PY 2016 VL 28 IS 6 BP 667 EP 675 DI 10.1097/MEG.0000000000000604 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DK7ZX UT WOS:000375147100010 PM 26886386 ER PT J AU Shi, Y Shu, ZJ Xue, XL Yeh, CK Katz, MS Kamat, A AF Shi, Yun Shu, Zhen-Ju Xue, Xiaoling Yeh, Chih-Ko Katz, Michael S. Kamat, Amrita TI beta(2)-Adrenergic receptor ablation modulates hepatic lipid accumulation and glucose tolerance in aging mice SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE Lipid; Hepatocytes; Cide; Triglycerides; Metabolism; Nonalcoholic fatty liver disease ID FATTY LIVER-DISEASE; SYMPATHETIC-NERVOUS-SYSTEM; BETA-ADRENERGIC-RECEPTORS; INSULIN-RESISTANCE; RAT-LIVER; ADENYLATE-CYCLASE; METABOLISM; EXPRESSION; GLYCOGENOLYSIS; EPINEPHRINE AB Catecholamines acting through beta-adrenergic receptors (beta(1)-, beta(2)-, beta(3)-AR subtypes) modulate important biological responses in various tissues. Our previous studies suggest a role for increased hepatic beta-AR-mediated signaling during aging as a mediator of hepatic steatosis, liver glucose output, and insulin resistance in rodents. In the current study, we have utilized beta(2)-AR knockout (KO) and wildtype (WT) control mice to define further the role of beta(2)-AR signaling during aging on lipid and glucose metabolism. Our results demonstrate for the first time that age-related increases in hepatic triglyceride accumulation and body weight are attenuated upon beta(2)-AR ablation. Although no differences in plasma triglyceride, non-esterified fatty acids or insulin levels were detected between old WT and KO animals, an age-associated increase in hepatic expression of lipid homeostasis regulator Cidea was significantly reduced in old KO mice. Interestingly, we also observed a shift from reduced glucose tolerance in young adult KO animals to significantly improved glucose tolerance in old KO when compared to age-matched WT mice. These results provide evidence for an important role played by beta(2)-ARs in the regulation of lipid and glucose metabolism during aging. The effect of beta(2)-AR ablation on caloric intake during aging is currently not known and requires investigation. Future studies are also warranted to delineate the beta(2)-AR-mediated mechanisms involved in the control of lipid and glucose homeostasis, especially in the context of a growing aging population. Published by Elsevier Inc. C1 [Shi, Yun; Shu, Zhen-Ju; Xue, Xiaoling; Yeh, Chih-Ko; Katz, Michael S.; Kamat, Amrita] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX 78229 USA. [Shi, Yun; Shu, Zhen-Ju; Xue, Xiaoling; Katz, Michael S.; Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Yeh, Chih-Ko; Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Yeh, Chih-Ko; Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. RP Kamat, A (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr 182, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM shiy@uthscsa.edu; shuz2@uthscsa.edu; xue@uthscsa.edu; yeh@uthscsa.edu; katz@uthscsa.edu; Amrita.Kamat@va.gov FU VA Merit Review Award [1I01BX001744-01]; Kronos Longevity Research Institute Award FX This work was supported by VA Merit Review Award (1I01BX001744-01 to AK) and Kronos Longevity Research Institute Award (to MSK). NR 50 TC 0 Z9 0 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 EI 1873-6815 J9 EXP GERONTOL JI Exp. Gerontol. PD JUN 1 PY 2016 VL 78 BP 32 EP 38 DI 10.1016/j.exger.2016.03.005 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DJ6OR UT WOS:000374333300004 PM 26952573 ER PT J AU Robinson, MT Vickrey, BG Holloway, RG Chong, K Williams, LS Brook, RH Leng, M Parikh, P Zingmond, DS AF Robinson, Maisha T. Vickrey, Barbara G. Holloway, Robert G. Chong, Kelly Williams, Linda S. Brook, Robert H. Leng, Mei Parikh, Punam Zingmond, David S. TI The lack of documentation of preferences in a cohort of adults who died after ischemic stroke SO NEUROLOGY LA English DT Article ID OF-LIFE CARE; 30-DAY MORTALITY; PALLIATIVE CARE; INPATIENT; QUALITY; SCALE; END; HOSPITALS; ACCURACY; ICD-9-CM AB Objective:To measure the extent and timing of physicians' documentation of communication with patients and families regarding limitations on life-sustaining interventions, in a population cohort of adults who died within 30 days after hospitalization for ischemic stroke.Methods:We used the California Office of Statewide Health Planning and Development Patient Discharge Database to identify a retrospective cohort of adults with ischemic strokes at all California acute care hospitals from December 2006 to November 2007. Of 326 eligible hospitals, a representative sample of 39 was selected, stratified by stroke volume and mortality. Medical records of 981 admissions were abstracted, oversampled on mortality and tissue plasminogen activator receipt. Among 198 patients who died by 30 days postadmission, overall proportions and timing of documented preferences were calculated; factors associated with documentation were explored.Results:Of the 198 decedents, mean age was 80 years, 78% were admitted from home, 19% had mild strokes, 11% received tissue plasminogen activator, and 42% died during the index hospitalization. Preferences about at least one life-sustaining intervention were recorded on 39% of patients: cardiopulmonary resuscitation 34%, mechanical ventilation 23%, nasogastric tube feeding 10%, and percutaneous enteral feeding 6%. Most discussions occurred within 5 days of death. Greater stroke severity was associated with increased in-hospital documentation of preferences (p < 0.05).Conclusions:Documented discussions about limitations on life-sustaining interventions during hospitalization were low, even though this cohort died within 30 days poststroke. Improving the documentation of preferences may be difficult given the 2015 Centers for Medicare and Medicaid 30-day stroke mortality hospital performance measure that is unadjusted for patient preferences regarding life-sustaining interventions. C1 [Robinson, Maisha T.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. [Vickrey, Barbara G.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Brook, Robert H.] Univ Calif Los Angeles, David Geffen UCLA Sch Med, Los Angeles, CA 90024 USA. [Leng, Mei; Parikh, Punam; Zingmond, David S.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. [Vickrey, Barbara G.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Holloway, Robert G.] Univ Rochester, Dept Neurol, New York, NY USA. [Chong, Kelly] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. [Williams, Linda S.] Vet Affairs HSR&D Ctr Hlth Informat & Commun, Seattle, WA USA. [Williams, Linda S.] Indiana Univ, Dept Neurol, Bloomington, IN 47405 USA. [Williams, Linda S.] Regenstrief Inst Inc, Seattle, WA USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA 90406 USA. [Brook, Robert H.] Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA USA. [Zingmond, David S.] Vet Affairs Greater Los Angeles Healthcare Syst, San Francisco, CA USA. RP Robinson, MT (reprint author), Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. EM robinson.maisha@mayo.edu FU Office of Statewide Health Planning and Development (OSHPD) [08-9079]; Robert Wood Johnson Clinical Scholars Program at the University of California, Los Angeles FX This study was funded by the Office of Statewide Health Planning and Development (OSHPD), contract 08-9079, awarded to the University of California, Los Angeles. OSHPD approved the original stroke outcomes validation study as contracted work. After completion of the original contracted work and creation of the deidentified research database, OSHPD and the state of California institutional review board gave us permission to pursue the research protocol as an investigator-initiated study. Dr. Robinson's effort was also supported by the Robert Wood Johnson Clinical Scholars Program at the University of California, Los Angeles. NR 24 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 31 PY 2016 VL 86 IS 22 BP 2056 EP 2062 DI 10.1212/WNL.0000000000002625 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DN9WM UT WOS:000377431400011 PM 27060165 ER PT J AU Quinn, J AF Quinn, Joseph TI Comment: Gene-environment interactions in dementia: Not just another fish story SO NEUROLOGY LA English DT Article AB Many observational studies have shown relationships between dietary omega-3 fatty acids and cognitive outcomes, but relatively few have examined gene-environment interactions due to APOE genotype. In this study, van de Rest et al.(1) highlight the modifying effect of APOE genotype on cognitive effects of dietary omega-3 fatty acids, finding protective effects of dietary seafood/omega-3s only in the epsilon 4 carrier group, which is at higher risk of Alzheimer disease. Prior observational studies that have incorporated APOE genotype have reported mixed results, sometimes concluding that the omega-3 benefit is stronger in the epsilon 4 carriers and sometimes in the epsilon 4 noncarriers. The finding in the present study is strengthened by a recent report from the same group showing an inverse relationship between dietary omega-3 and autopsy-confirmed Alzheimer disease brain pathology, also only in epsilon 4 carriers.(2) However, observational studies and clinicopathologic studies cannot determine with certainty whether dietary or supplemental omega-3s will attenuate cognitive decline in individuals at risk. Randomized, placebo-controlled trials are necessary to definitively answer this question. While most of these have been negative,(3) few have included APOE stratification in the analyses, so may have failed to appreciate genotype-specific effects of omega-3 supplementation. C1 [Quinn, Joseph] Oregon Hlth & Sci Univ, Dept Neurol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Quinn, J (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland VA Med Ctr, Portland, OR 97201 USA. FU National Institute on Aging [R01AG031553, R01AG17917]; Judith Zwartz Foundation FX Supported by grants (R01AG031553 and R01AG17917) from the National Institute on Aging. A Scientific Travel Grant provided by the Judith Zwartz Foundation financed travel expenses of Dr. O. van de Rest to Rush University Medical Center in Chicago. NR 3 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 31 PY 2016 VL 86 IS 22 BP 2069 EP 2070 DI 10.1212/WNL.0000000000002728 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA DN9WM UT WOS:000377431400013 PM 27164701 ER PT J AU Sano, M Aisen, PS Andrews, HF Tsai, WY Lai, F Dalton, AJ AF Sano, Mary Aisen, Paul S. Andrews, Howard F. Tsai, Wei-Yann Lai, Florence Dalton, Arthur J. CA Int Down Syndrome Alzheimer's Dis TI Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial SO NEUROLOGY LA English DT Article ID ALZHEIMERS-DISEASE; INTELLECTUAL DISABILITY; LIPID-PEROXIDATION; RADICAL SCAVENGER; COGNITIVE DECLINE; OXIDATIVE DAMAGE; DEMENTIA; ADULTS; PREVALENCE; SUPPLEMENTATION AB Objective:To determine whether vitamin E would slow the progression of cognitive deterioration and dementia in aging persons with Down syndrome (DS).Methods:A randomized, double-blind controlled clinical trial was conducted at 21 clinical sites, and researchers trained in research procedures recruited adults with DS older than 50 years to participate. Participants were randomly assigned to receive 1,000 IU of vitamin E orally twice daily for 3 years or identical placebo. The primary outcome was change on the Brief Praxis Test (BPT). Secondary outcomes included incident dementia and measures of clinical global change, cognition, function, and behavior.Results:A total of 337 individuals were randomized, 168 to vitamin E and 169 to placebo. Both groups demonstrated deterioration on the BPT with no difference between drug and placebo. At baseline, 26% were diagnosed with dementia and there was an overall rate of incident dementia of 11%/year with no difference between groups. There was no effect on the secondary outcome measures. Though numerically higher in the treatment group, there was no difference in the number of adverse events (p = 0.079) and deaths (p = 0.086) between groups.Conclusions:Vitamin E did not slow the progression of cognitive deterioration in older individuals with DS.Classification of evidence:This study provides Class II evidence that vitamin E does not significantly slow the progression of cognitive deterioration in aging persons with DS. C1 [Sano, Mary] Icahn Sch Med Mt Sinai, Alzheimer Dis Res Ctr, Dept Psychiat, New York, NY 10029 USA. [Sano, Mary] James J Peters VAMC, Bronx, NY USA. [Aisen, Paul S.] Univ So Calif, Alzheimers Therapeut Res Inst, San Diego, CA USA. [Andrews, Howard F.] New York State Psychiat Inst & Hosp, Data Coordinating Ctr, New York, NY 10032 USA. [Andrews, Howard F.] Columbia Univ Coll Phys & Surg, Dept Psychiat, 630 W 168th St, New York, NY 10032 USA. [Tsai, Wei-Yann] Columbia Univ Coll Phys & Surg, Div Biostat, 630 W 168th St, New York, NY 10032 USA. [Lai, Florence] McLean Hosp, Dept Neurol, Belmont, MA 02178 USA. [Lai, Florence] Harvard Univ, Sch Med, Boston, MA USA. [Dalton, Arthur J.] New York State Inst Basic Res Dev Disabil, George Jervis Clin, Ctr Aging Studies, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA. RP Sano, M (reprint author), Icahn Sch Med Mt Sinai, Alzheimer Dis Res Ctr, Dept Psychiat, New York, NY 10029 USA.; Sano, M (reprint author), James J Peters VAMC, Bronx, NY USA. EM mary.sano@mssm.edu FU [R010AG16381] FX Supported by grant R010AG16381, A multicenter trial of vitamin E in aging persons with Down syndrome, PI: Arthur Dalton, PhD. NR 35 TC 2 Z9 2 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD MAY 31 PY 2016 VL 86 IS 22 BP 2071 EP 2076 DI 10.1212/WNL.0000000000002714 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA DN9WM UT WOS:000377431400014 PM 27164691 ER PT J AU Kasckow, J Zickmund, S Gurklis, J Luther, J Fox, L Taylor, M Richmond, I Haas, GL AF Kasckow, John Zickmund, Susan Gurklis, John Luther, James Fox, Lauren Taylor, Melissa Richmond, Ira Haas, Gretchen L. TI Using telehealth to augment an intensive case monitoring program in veterans with schizophrenia and suicidal ideation: A pilot trial SO PSYCHIATRY RESEARCH LA English DT Article DE Schizophrenia; Telehealth; Suicide ID NEGATIVE SYMPTOMS; RATING-SCALE; DEPRESSION; RISK; RELIABILITY; VALIDITY AB Veterans with schizophrenia admitted for suicidal ideation were recruited into a post-discharge program consisting of Intensive Case Monitoring (ICM) with daily monitoring with the Health Buddy (HB; experimental group) or ICM alone (control group). This study tested the feasibility of the telehealth monitoring intervention in this population. Secondly, we determined whether augmentation of ICM with our intervention for 3 months would result in a reduction in suicidal ideation. Twenty of 25 telehealth participants could set up the device. Monthly adherence for telehealth participants was > 80%. A qualitative analysis of endpoint surveys revealed that the majority of participants had positive responses. In both groups, there were improvements in Beck Scale for Suicidal Ideation (BSS) scores at endpoint relative to baseline. No group differences were present with survival analysis when using remission (i.e., BSS score = 0) as the outcome; however, in a subgroup with a history of suicide attempt, there was a trend (p = .093) for a higher rate of remission for those in the FIB condition. In conclusion, telehealth monitoring for this population appears to be feasible for those who are able to start using the system. The pilot data obtained should help investigators design better telehealth interventions for this population. Published by Elsevier Ireland Ltd. C1 [Kasckow, John; Gurklis, John; Luther, James; Fox, Lauren; Haas, Gretchen L.] VA Pittsburgh Hlth Care Syst, MIRECC & Behav Hlth, Pittsburgh, PA 15240 USA. [Kasckow, John; Haas, Gretchen L.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA. [Kasckow, John; Zickmund, Susan] VA Pittsburgh Ctr Hlth & Equity Promot, Pittsburgh, PA 15240 USA. [Zickmund, Susan] Univ Pittsburgh, Dept Med, Med Ctr, 930 Scaife Hall, Pittsburgh, PA 15213 USA. [Taylor, Melissa; Richmond, Ira] VA Pittsburgh Hlth Care Syst, VA Pittsburgh Patient Care Serv, Pittsburgh, PA 15240 USA. RP Kasckow, J (reprint author), VA Pittsburgh Hlth Care Syst, Univ Dr C,Behav Hlth 116a, Pittsburgh, PA 15240 USA. EM kasckowjw@upmc.edu FU VISN 4 MIRECC; VISN 4 CPPF award FX Funded by the VISN 4 MIRECC and a VISN 4 CPPF award. The contents do not represent the views of the US Government or the Department of Veterans Affairs of the US Government. Dr. Kasckow has received assistance from Bosch Health Care for the software and transmission costs associated with this project. NR 21 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAY 30 PY 2016 VL 239 BP 111 EP 116 DI 10.1016/j.psychres.2016.02.049 PG 6 WC Psychiatry SC Psychiatry GA DM7LS UT WOS:000376542700017 PM 27137970 ER PT J AU Price, M Szafranski, DD van Stolk-Cooke, K Gros, DE AF Price, Matthew Szafranski, Derek D. van Stolk-Cooke, Katherine Gros, Daniel E. TI Investigation of abbreviated 4 and 8 item versions of the PTSD Checklist 5 SO PSYCHIATRY RESEARCH LA English DT Article DE PTSD; Screening instruments; Assessment ID POSTTRAUMATIC-STRESS-DISORDER; ECOLOGICAL MOMENTARY ASSESSMENT; DSM-IV; PRIMARY-CARE; CRITERIA; VETERANS; EXPOSURE; ANXIETY; PREVALENCE; DEPRESSION AB Posttraumatic stress disorder (PTSD) is a significant public health concern associated with marked impairment across the lifespan. Exposure to traumatic events alone, however, is insufficient to determine if an individual has PTSD. PTSD is a heterogeneous diagnosis such that assessment of all 20 symptoms is problematic in time-limited treatment settings. Brief assessment tools that identify those at risk for PTSD and measure symptom severity are needed to improve access to care and assess treatment response. The present study evaluated abbreviated measures of PTSD symptoms derived from the PTSD Checklist for DSM-5 (PCL-5) - a 20-item validated measure of PTSD symptoms - across two studies. In the first, using a community sample of adults exposed to a traumatic event, 4- and 8-item versions of the PCL-5 were identified that were highly correlated with the full PCL-5. In the second, using a sample of combat veterans, the 4-and 8-item measures had comparable diagnostic utility to the total-scale PCL-5. These results provide support for an abbreviated measure of the PCL-5 as an alternative to the 20-item total scale. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Price, Matthew; van Stolk-Cooke, Katherine] Univ Vermont, Dept Psychol Sci, 2 Colchester Ave, Burlington, VT 05405 USA. [Szafranski, Derek D.; Gros, Daniel E.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Szafranski, Derek D.; Gros, Daniel E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. RP Price, M (reprint author), Univ Vermont, Dept Psychol Sci, 2 Colchester Ave, Burlington, VT 05405 USA. EM Matthew.Price@uvm.edu FU [CX000845] FX The project was supported by Career Development Award CX000845 awarded to DF Gros. The authors would like to thank Ryan Payne for his help in the preparation of this manuscript. NR 33 TC 2 Z9 2 U1 4 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAY 30 PY 2016 VL 239 BP 124 EP 130 DI 10.1016/j.psychres.2016.03.014 PG 7 WC Psychiatry SC Psychiatry GA DM7LS UT WOS:000376542700020 PM 27137973 ER PT J AU Dodds, SG Livi, CB Parihar, M Hsu, HK Benavides, AD Morris, J Javors, M Strong, R Christy, B Hasty, P Sharp, ZD AF Dodds, Sherry G. Livi, Carolina B. Parihar, Manish Hsu, Hang-Kai Benavides, Adriana D. Morris, Jay Javors, Martin Strong, Randy Christy, Barbara Hasty, Paul Sharp, Zelton Dave TI Adaptations to chronic rapamycin in mice SO PATHOBIOLOGY OF AGING AND AGE-RELATED DISEASES LA English DT Article DE mTORC1; rapamycin; translation; ribosome biogenesis ID EXTENDS LIFE-SPAN; GENETICALLY HETEROGENEOUS MICE; INITIATION-FACTOR 4E; EIF4E/4E-BP RATIO; MAMMALIAN TARGET; MTOR; INHIBITION; CANCER; EIF4E; PHOSPHORYLATION AB Rapamycin inhibits mechanistic (or mammalian) target of rapamycin (mTOR) that promotes protein production in cells by facilitating ribosome biogenesis (RiBi) and eIF4E-mediated 5'cap mRNA translation. Chronic treatment with encapsulated rapamycin (eRapa) extended health and life span for wild-type and cancer-prone mice. Yet, the long-term consequences of chronic eRapa treatment are not known at the organ level. Here, we report our observations of chronic eRapa treatment on mTORC1 signaling and RiBi in mouse colon and visceral adipose. As expected, chronic eRapa treatment decreased detection of phosphorylated mTORC1/S6K substrate, ribosomal protein (rpS6) in colon and fat. However, in colon, contrary to expectations, there was an upregulation of 18S rRNA and some ribosomal protein genes (RPGs) suggesting increased RiBi. Among RPGs, eRapa increases rpl22l1 mRNA but not its paralog rpl22. Furthermore, there was an increase in the cap-binding protein, eIF4E relative to its repressor 4E-BP1 suggesting increased translation. By comparison, in fat, there was a decrease in the level of 18S rRNA (opposite to colon), while overall mRNAs encoding ribosomal protein genes appeared to increase, including rpl22, but not rpl22l1 (opposite to colon). In fat, there was a decrease in eIF4E relative to actin (opposite to colon) but also an increase in the eIF4E/4E-BP1 ratio likely due to reductions in 4E-BP1 at our lower eRapa dose (similar to colon). Thus, in contrast to predictions of decreased protein production seen in cell-based studies, we provide evidence that colon from chronically treated mice exhibited an adaptive 'pseudo-anabolic' state, which is only partially present in fat, which might relate to differing tissue levels of rapamycin, cell-type-specific responses, and/or strain differences. C1 [Dodds, Sherry G.; Livi, Carolina B.; Parihar, Manish; Hsu, Hang-Kai; Morris, Jay; Christy, Barbara; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA. [Livi, Carolina B.] Agilent Technol, Santa Clara, CA USA. [Hsu, Hang-Kai] City Hope Natl Med Ctr, KCRB 2018, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Benavides, Adriana D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Benavides, Adriana D.] Childrens Hosp Philadelphia, Infect Dis Res Div, Philadelphia, PA 19104 USA. [Javors, Martin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Javors, Martin; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Strong, Randy; Hasty, Paul; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Strong, Randy] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. [Christy, Barbara] US Army Inst Surg Res, Coagulat & Blood Res Grp, JBSA Ft Sam Houston, TX USA. [Hasty, Paul; Sharp, Zelton Dave] Canc Therapy & Res Ctr S Texas, 4450 Med Dr, San Antonio, TX 78229 USA. RP Hasty, P; Sharp, ZD (reprint author), Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM hastye@uthscsa.edu; sharp@uthscsa.edu FU NCI NIH HHS [R01 CA193835]; NIA NIH HHS [P30 AG013319, U01 AG022307] NR 59 TC 2 Z9 2 U1 1 U2 1 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN EI 2001-0001 J9 PATHOBIOL AGING AGE JI Pathobiol. Aging Age-relat. Dis. PD MAY 27 PY 2016 VL 6 AR 31688 DI 10.3402/pba.v6.31688 PG 11 WC Pathology SC Pathology GA DT4ET UT WOS:000381433600001 PM 27237224 ER PT J AU Akocak, S Alam, MR Shabana, AM Sanku, RKK Vullo, D Thompson, H Swenson, ER Supuran, CT Hies, MA AF Akocak, Suleyman Alam, M. Raqibul Shabana, Ahmed M. Sanku, Rajesh Kishore Kumar Vullo, Daniela Thompson, Harry Swenson, Erik R. Supuran, Claudiu T. Hies, Marc A. TI PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID IN-VIVO SELECTIVITY; BREAST-CANCER; CRYSTAL-STRUCTURE; INTRINSIC MARKER; TUMOR HYPOXIA; ISOZYME-IX; DERIVATIVES; BINDING; XII; PH AB A series of aromatic/heterocyclic bis-sulfonamides were synthesized from three established aminosulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor pharmacophores, coupled with either ethylene glycol oligomeric or polymeric diamines to yield bis-sulfonamides with short or long (polymeric) linkers. Testing of novel inhibitors and their precursors against a panel of membrane-bound CA isoforms, including tumor-overexpressed CA IX and XII and cytosolic isozymes, identified nanomolar-potent inhibitors against both classes and several compounds with medium isoform selectivity in a detailed structure-activity relationship study. The ability of CA inhibitors to kill tumor cells overexpressing CA IX and XII was tested under normoxic and hypoxic conditions, using 2D and 3D in vitro cellular models. The study identified a nanomolar potent PEGylated bis-sulfonamide CA inhibitor (25) able to significantly reduce the viability of colon HT-29, breast MDA-MB231, and ovarian SKOV-3 cancer cell lines, thus revealing the potential of polymer conjugates in CA inhibition and cancer treatment. C1 [Akocak, Suleyman; Alam, M. Raqibul; Shabana, Ahmed M.; Sanku, Rajesh Kishore Kumar; Thompson, Harry; Hies, Marc A.] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, 3307 N Broad St, Philadelphia, PA 19140 USA. [Akocak, Suleyman; Alam, M. Raqibul; Shabana, Ahmed M.; Sanku, Rajesh Kishore Kumar; Thompson, Harry; Hies, Marc A.] Temple Univ, Sch Pharm, Molder Ctr Drug Discovery Res, 3307 N Broad St, Philadelphia, PA 19140 USA. [Akocak, Suleyman] Adiyaman Univ, Fac Pharm, Dept Pharmaceut Chem, TR-02040 Adiyaman, Turkey. [Vullo, Daniela; Supuran, Claudiu T.] Univ Florence, Neurofarba Dept, Pharmaceut Sci Sect, Polo Sci, Via Ugo Schiff 6, I-50019 Florence, Italy. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98195 USA. RP Hies, MA (reprint author), Temple Univ, Sch Pharm, Dept Pharmaceut Sci, 3307 N Broad St, Philadelphia, PA 19140 USA.; Hies, MA (reprint author), Temple Univ, Sch Pharm, Molder Ctr Drug Discovery Res, 3307 N Broad St, Philadelphia, PA 19140 USA.; Supuran, CT (reprint author), Univ Florence, Neurofarba Dept, Pharmaceut Sci Sect, Polo Sci, Via Ugo Schiff 6, I-50019 Florence, Italy. EM claudiu.supuran@unifi.it; mailies@temple.edu FU Seattle Foundation [255345]; Temple Drug Discovery Initiative, TUSP Dean's Office, Temple Undergraduate Research Program; Turkish Minister of Education FX The financial support of Seattle Foundation (grant 255345), Temple Drug Discovery Initiative, TUSP Dean's Office, Temple Undergraduate Research Program is gratefully acknowledged. S.A. acknowledges the financial support of the Turkish Minister of Education for a Ph.D. scholarship. We would like to acknowledge Dr. Salim Merali and Mr. George Mateo for their help with MALDI-TOF spectra. NR 89 TC 1 Z9 1 U1 1 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD MAY 26 PY 2016 VL 59 IS 10 BP 5077 EP 5088 DI 10.1021/acs.jmedchem.6b00492 PG 12 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DN1QN UT WOS:000376840600050 PM 27144971 ER PT J AU Kim, CC Nakamura, MC Hsieh, CL AF Kim, Charles C. Nakamura, Mary C. Hsieh, Christine L. TI Brain trauma elicits non-canonical macrophage activation states SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Innate immunity; Macrophage; Monocyte; Traumatic brain injury; Single-cell RNA sequencing; Neuroinflammation; RNA flow cytometry; Polarization; Neurotrauma; Myeloid cells ID ALTERNATIVE ACTIVATION; INJURY; INFLAMMATION; CCR2; POLARIZATION; HETEROGENEITY; MICROGLIA; DIVERSITY; RESPONSES; PATHWAYS AB Background: Macrophage polarization programs, commonly referred to as "classical" and "alternative" activation, are widely considered as distinct states that are exclusive of one another and are associated with different functions such as inflammation and wound healing, respectively. In a number of disease contexts, such as traumatic brain injury (TBI), macrophage polarization influences the extent of pathogenesis, and efforts are underway to eliminate pathogenic subsets. However, previous studies have not distinguished whether the simultaneous presence of both classical and alternative activation signatures represents the admixture of differentially polarized macrophages or if they have adopted a unique state characterized by components of both classical and alternative activation. Methods: We analyzed the gene expression profiles of individual monocyte-derived brain macrophages responding to TBI using single-cell RNA sequencing. RNA flow cytometry was used as another single-cell analysis technique to validate the single-cell RNA sequencing results. Results: The analysis of signature polarization genes by single-cell RNA sequencing revealed the presence of diverse activation states, including M(IL4), M(IL10), and M(LPS, IFN gamma). However, the expression of a given polarization marker was no more likely than at random to predict simultaneous expression or repression of markers of another polarization program within the same cell, suggesting a lack of exclusivity in macrophage polarization states in vivo in TBI. Also unexpectedly, individual TBI macrophages simultaneously expressed high levels of signature polarization genes across two or three different polarization states and in several distinct and seemingly incompatible combinations. Conclusions: Single-cell gene expression profiling demonstrated that monocytic macrophages in TBI are not comprised of distinctly polarized subsets but are uniquely and broadly activated. TBI macrophage activation in vivo is deeply complex, with individual cells concurrently adopting both inflammatory and reparative features with a lack of exclusivity. These data provide physiologically relevant evidence that the early macrophage response to TBI is comprised of novel activation states that are discordant with the current paradigm of macrophage polarization-a key consideration for therapeutic modulation. C1 [Nakamura, Mary C.; Hsieh, Christine L.] Univ Calif San Francisco, Dept Med, Div Rheumatol, 4150 Clement St 111R, San Francisco, CA 94121 USA. [Nakamura, Mary C.; Hsieh, Christine L.] San Francisco VA Med Ctr, Res Dept, Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA. [Kim, Charles C.] Univ Calif San Francisco, Dept Med, Div Expt Med, 1001 Potrero Ave,Bldg 3,Room 603,Box 1234, San Francisco, CA 94143 USA. [Kim, Charles C.] Verily, Mountain View, CA 94043 USA. RP Hsieh, CL (reprint author), Univ Calif San Francisco, Dept Med, Div Rheumatol, 4150 Clement St 111R, San Francisco, CA 94121 USA.; Hsieh, CL (reprint author), San Francisco VA Med Ctr, Res Dept, Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA. EM Christine.hsieh@ucsf.edu OI Kim, Charles/0000-0001-6474-8227 FU NIAID [P30 AI027763]; NIDDK [P30 DK063720]; United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program [I01 BX002690]; NIH R01 grant [AG046282]; Rheumatology Research Foundation; Russell/Engleman Rheumatology Research Center FX CCK was supported by NIAID P30 AI027763 and NIDDK P30 DK063720. CLH and this work was supported by a Career Development Award-2 and a Merit Review Award #I01 BX002690 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program to CLH. MCN is supported by NIH R01 grant AG046282, the Rheumatology Research Foundation, and the Russell/Engleman Rheumatology Research Center. NR 31 TC 8 Z9 8 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD MAY 24 PY 2016 VL 13 AR 117 DI 10.1186/s12974-016-0581-z PG 12 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DN7UW UT WOS:000377286500002 PM 27220367 ER PT J AU Psotka, MA Teerlink, JR AF Psotka, Mitchell A. Teerlink, John R. TI Ivabradine: Role in the Chronic Heart Failure Armamentarium SO CIRCULATION LA English DT Review DE clinical studies as topic; drug therapy; heart failure ID CORONARY-ARTERY-DISEASE; VENTRICULAR SYSTOLIC DYSFUNCTION; PRESERVED EJECTION FRACTION; PLACEBO-CONTROLLED TRIAL; I-F INHIBITOR; RANDOMIZED INTERVENTION TRIAL; CHRONIC STABLE ANGINA; BETA-BLOCKER THERAPY; RATE REDUCTION; ATRIAL-FIBRILLATION AB Ivabradine is approved to reduce hospitalizations for patients with symptomatic heart failure, reduced ejection fraction, and persistently elevated heart rate despite otherwise maximal medical therapy. However, the eligible patient population is a small fraction of those with heart failure overall. This review summarizes the major clinical evidence supporting the use of ivabradine, identifies and discusses areas of uncertainty from the clinical trial data, helps describe the population most likely to benefit, and attempts to place ivabradine within the multifaceted treatment scheme currently used for patients with heart failure and reduced ejection fraction. C1 [Psotka, Mitchell A.; Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, Cardiol Sect, San Francisco, CA USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol, 111C,Bldg 203,Room 2A-49,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu FU Amgen; Bayer; Cytokinetics; Medtronic; Novartis; St. Jude; Trevena; ZS Pharma FX Dr Teerlink has received research funding and honoraria from Amgen, Bayer, Cytokinetics, Medtronic, Novartis, St. Jude, Trevena, and ZS Pharma. Dr Psotka reports no conflicts. NR 65 TC 3 Z9 4 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAY 24 PY 2016 VL 133 IS 21 BP 2066 EP 2075 DI 10.1161/CIRCULATIONAHA.115.018094 PG 10 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DN3DZ UT WOS:000376943900012 PM 27217432 ER PT J AU Ravi, A AF Ravi, Anita TI Pimping as a Practice in Medical Education SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Ravi, Anita] US Dept Vet Affairs, 423 Guardian Dr,1310 Blockley Hall, Philadelphia, PA 19104 USA. [Ravi, Anita] Corporal Michael Crensenz Vet Affairs Med Ctr, Clin Scholars Program, Robert Wood Johnson Fdn, 423 Guardian Dr,1310 Blockley Hall, Philadelphia, PA USA. RP Ravi, A (reprint author), US Dept Vet Affairs, 423 Guardian Dr,1310 Blockley Hall, Philadelphia, PA 19104 USA.; Ravi, A (reprint author), Corporal Michael Crensenz Vet Affairs Med Ctr, Clin Scholars Program, Robert Wood Johnson Fdn, 423 Guardian Dr,1310 Blockley Hall, Philadelphia, PA USA. EM ravia@upenn.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 24 PY 2016 VL 315 IS 20 BP 2236 EP 2236 DI 10.1001/jama.2016.1571 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DM4US UT WOS:000376343000028 PM 27218641 ER PT J AU Hunt, CM Beste, LA Lowy, E Suzuki, A Moylan, CA Tillmann, HL Ioannou, GN Lim, JK Kelley, MJ Provenzale, D AF Hunt, Christine M. Beste, Lauren A. Lowy, Elliott Suzuki, Ayako Moylan, Cynthia A. Tillmann, Hans L. Ioannou, George N. Lim, Joseph K. Kelley, Michael J. Provenzale, Dawn TI Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration SO WORLD JOURNAL OF GASTROENTEROLOGY LA English DT Article DE Hepatitis B; Hepatitis B reactivation; Anti-CD20 antibody; Rituximab; Lymphoma; Chemotherapy; Hepatitis B antivirals; Vaccination; Veteran ID TASK-FORCE RECOMMENDATION; VIRUS-INFECTION; IMMUNOSUPPRESSIVE THERAPY; COST-EFFECTIVENESS; LYMPHOMA PATIENTS; HBV REACTIVATION; CHEMOTHERAPY; RITUXIMAB; PROPHYLAXIS; ADOLESCENTS AB AIM: To evaluate pretreatment hepatitis B virus (HBV) testing, vaccination, and antiviral treatment rates in Veterans Affairs patients receiving anti-CD20 Ab for quality improvement. METHODS: We performed a retrospective cohort study using a national repository of Veterans Health Administration (VHA) electronic health record data. We identified all patients receiving anti-CD20 Ab treatment (2002-2014). We ascertained patient demographics, laboratory results, HBV vaccination status (from vaccination records), pharmacy data, and vital status. The high risk period for HBV reactivation is during anti-CD20 Ab treatment and 12 mo follow up. Therefore, we analyzed those who were followed to death or for at least 12 mo after completing anti-CD20 Ab. Pretreatment serologic tests were used to categorize chronic HBV (hepatitis B surface antigen positive or HBsAg+), past HBV (HBsAg-, hepatitis B core antibody positive or HBcAb+), resolved HBV (HBsAg-, HBcAb+, hepatitis B surface antibody positive or HBsAb+), likely prior vaccination (isolated HBsAb+), HBV negative (HBsAg-, HBcAb-), or unknown. Acute hepatitis B was defined by the appearance of HBsAg+ in the high risk period in patients who were pretreatment HBV negative. We assessed HBV antiviral treatment and the incidence of hepatitis, liver failure, and death during the high risk period. Cumulative hepatitis, liver failure, and death after anti-CD20 Ab initiation were compared by HBV disease categories and differences compared using the. 2 test. Mean time to hepatitis peak alanine aminotransferase, liver failure, and death relative to anti-CD20 Ab administration and follow-up were also compared by HBV disease group. RESULTS: Among 19304 VHA patients who received anti-CD20 Ab, 10224 (53%) had pretreatment HBsAg testing during the study period, with 49% and 43% tested for HBsAg and HBcAb, respectively within 6 mo pretreatment in 2014. Of those tested, 2% (167/10224) had chronic HBV, 4% (326/7903) past HBV, 5% (427/8110) resolved HBV, 8% (628/8110) likely prior HBV vaccination, and 76% (6022/7903) were HBV negative. In those with chronic HBV infection, <= 37% received HBV antiviral treatment during the high risk period while 21% to 23% of those with past or resolved HBV, respectively, received HBV antiviral treatment. During and 12 mo after anti-CD20 Ab, the rate of hepatitis was significantly greater in those HBV positive vs negative (p = 0.001). The mortality rate was 35%-40% in chronic or past hepatitis B and 26%-31% in hepatitis B negative. In those pretreatment HBV negative, 16 (0.3%) developed acute hepatitis B of 4947 tested during anti-CD20Ab treatment and follow-up. CONCLUSION: While HBV testing of Veterans has increased prior to anti-CD20 Ab, few HBV+ patients received HBV antivirals, suggesting electronic health record algorithms may enhance health outcomes. C1 [Hunt, Christine M.; Moylan, Cynthia A.; Kelley, Michael J.; Provenzale, Dawn] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA. [Hunt, Christine M.; Moylan, Cynthia A.; Kelley, Michael J.; Provenzale, Dawn] Durham VA Med Ctr, Dept Med, Durham, NC 27705 USA. [Beste, Lauren A.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. [Beste, Lauren A.; Lowy, Elliott; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Beste, Lauren A.; Ioannou, George N.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Lowy, Elliott] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Suzuki, Ayako] Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA. [Suzuki, Ayako] Cent Arkansas Vet Heathcare Syst, Div Hepatol, Little Rock, AR 72205 USA. [Tillmann, Hans L.] Eastern Carolina Univ, Dept Med, Greenville, NC 27858 USA. [Lim, Joseph K.] Yale Univ, Sch Med, Yale Liver Ctr, Sect Digest Dis, 333 Cedar St, New Haven, CT 06520 USA. [Kelley, Michael J.] Dept Vet Affairs, Off Patient Care Serv, Washington, DC 20420 USA. [Kelley, Michael J.] Durham Vet Affairs Med Ctr, Hematol Oncol Serv, Durham, NC 27705 USA. [Provenzale, Dawn] Durham Vet Affairs Med Ctr, Cooperat Studies Program Epidemiol Ctr Durham, Durham, NC 27705 USA. [Provenzale, Dawn] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27710 USA. RP Hunt, CM (reprint author), Duke Univ, Dept Med, Sch Med, Med, 00550 Hosp South, Durham, NC 27710 USA. EM christine.hunt@va.gov FU Veterans Affairs (VA) Cooperative Studies Program Epidemiology Center-Durham; Puget Sound VA Health Care System; VA Office of Public Health and Human Health Pathogens FX Supported by (in part) by resources from the Veterans Affairs (VA) Cooperative Studies Program Epidemiology Center-Durham, the Puget Sound VA Health Care System, and the VA Office of Public Health and Human Health Pathogens. NR 29 TC 0 Z9 0 U1 0 U2 0 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1007-9327 EI 2219-2840 J9 WORLD J GASTROENTERO JI World J. Gastroenterol. PD MAY 21 PY 2016 VL 22 IS 19 BP 4732 EP 4740 DI 10.3748/wjg.v22.i19.4732 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DN4ZH UT WOS:000377075200012 PM 27217704 ER PT J AU Goalstone, ML Pugazhenthi, S AF Goalstone, Marc Lee Pugazhenthi, Subbiah TI Editorial: Molecular Mechanism of Neuronal Dysfunction in the Diabetic Brain SO FRONTIERS IN ENDOCRINOLOGY LA English DT Editorial Material DE Alzheimer's disease; diabetes; neuroinflammation; amyloid precursor protein; editorial ID GLYCATION END-PRODUCTS; DISEASE; SRAGE; RISK C1 [Goalstone, Marc Lee; Pugazhenthi, Subbiah] Denver VA Med Ctr, Denver, CO USA. [Goalstone, Marc Lee; Pugazhenthi, Subbiah] Univ Colorado, Sch Med, Aurora, CO USA. RP Pugazhenthi, S (reprint author), Denver VA Med Ctr, Denver, CO USA.; Pugazhenthi, S (reprint author), Univ Colorado, Sch Med, Aurora, CO USA. EM subbiah.pugazhenthi@ucdenver.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PD MAY 20 PY 2016 VL 7 AR 45 DI 10.3389/fendo.2016.00045 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP5BA UT WOS:000378509800001 PM 27242668 ER PT J AU Lushaj, EB Schreiner, A Jonuzi, B Badami, A DeOliveira, N Lozonschi, L AF Lushaj, Entela B. Schreiner, Athanasia Jonuzi, Besa Badami, Abbasali DeOliveira, Nilto Lozonschi, Lucian TI Short-term clinical outcomes after off-pump coronary artery bypass grafting at a single Veterans Affairs Medical Center SO JOURNAL OF CARDIOTHORACIC SURGERY LA English DT Article DE CABG; Off-Pump; Outcomes; Veterans Affairs ID ON-PUMP; SURGERY; METAANALYSIS; SURVIVAL; RISK AB Background: We retrospectively assessed the outcomes after coronary revascularization at a single Veterans Affairs Medical Center when a strategy of assigning higher risk patients to off-pump coronary artery bypass grafting (CABG) was employed. Methods: Over a 5 year period all consecutive patients that underwent CABG at our VA Medical Center were assigned to a surgeon who either performs the CABG exclusively off-pump or to one who performed the CABG on-pump. The higher risk patients were assigned preferentially for off-pump revascularization. VASQIP (VA Hospitals Surgical Quality Improvement Program) data between 10/2007 and 12/2012 were retrospectively reviewed at our VA Medical Center and the short term outcomes were assessed. Results: A total of 252 consecutive patients underwent off-pump CABG (n = 170) and on-pump CABG (n = 82). There were significantly more patients with low LVEF (<45 %; p = 0.008) and cerebrovascular disease in the off-pump group (p = 0.024). The number of patients smoking at the time of surgery was significantly higher in the off-pump group (p = 0.002) as well. The 30-day composite morbidity and mortality was 6 % for all CABG patients and significantly lower with off-pump vs. on-pump CABG (3.5 % vs. 11 %; p = 0.019). There were no conversions from off-pump to on-pump surgery. Conclusions: A selective strategy to direct higher risk patients towards an off-pump revascularization yielded favorable outcomes in an unselected veteran population treated at a single VA Medical Center over a 5 year period. C1 [Lushaj, Entela B.; Jonuzi, Besa; Badami, Abbasali; DeOliveira, Nilto; Lozonschi, Lucian] Univ Wisconsin, Div Cardiothorac Surg, Dept Surg, Sch Med & Publ Hlth, 600 Highland Ave, Madison, WI 53792 USA. [Schreiner, Athanasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Lozonschi, L (reprint author), Univ Wisconsin, Div Cardiothorac Surg, Dept Surg, Sch Med & Publ Hlth, 600 Highland Ave, Madison, WI 53792 USA. EM Lozon@surgery.wisc.edu FU University of Wisconsin, Department of Surgery FX This work was funded by the University of Wisconsin, Department of Surgery. None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflict of interest to disclose. NR 13 TC 1 Z9 1 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1749-8090 J9 J CARDIOTHORAC SURG JI J. Cardiothorac. Surg. PD MAY 17 PY 2016 VL 11 AR 83 DI 10.1186/s13019-016-0480-5 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DM6ZZ UT WOS:000376502900001 PM 27185173 ER PT J AU Davies, MR Liu, XH Lee, L Laron, D Ning, AY Kim, HT Feeley, BT AF Davies, Michael R. Liu, Xuhui Lee, Lawrence Laron, Dominique Ning, Anne Y. Kim, Hubert T. Feeley, Brian T. TI TGF-beta Small Molecule Inhibitor SB431542 Reduces Rotator Cuff Muscle Fibrosis and Fatty Infiltration By Promoting Fibro/Adipogenic Progenitor Apoptosis SO PLOS ONE LA English DT Article ID TRANSFORMING-GROWTH-FACTOR; SKELETAL-MUSCLE; MESENCHYMAL PROGENITORS; RAT MODEL; SUPRASCAPULAR NERVE; PROGNOSTIC-FACTORS; UP-REGULATION; REPAIR; TEAR; SB-431542 AB Rotator cuff tears represent a large burden of muscle-tendon injuries in our aging population. While small tears can be repaired surgically with good outcomes, critical size tears are marked by muscle atrophy, fibrosis, and fatty infiltration, which can lead to failed repair, frequent re-injury, and chronic disability. Previous animal studies have indicated that Transforming Growth Factor-beta (TGF-beta) signaling may play an important role in the development of these muscle pathologies after injury. Here, we demonstrated that inhibition of TGF-beta 1 signaling with the small molecule inhibitor SB431542 in a mouse model of massive rotator cuff tear results in decreased fibrosis, fatty infiltration, and muscle weight loss. These observed phenotypic changes were accompanied by decreased fibrotic, adipogenic, and atrophy-related gene expression in the injured muscle of mice treated with SB431542. We further demonstrated that treatment with SB431542 reduces the number of fibro/adipogenic progenitor (FAP) cells-an important cellular origin of rotator cuff muscle fibrosis and fatty infiltration, in injured muscle by promoting apoptosis of FAPs. Together, these data indicate that the TGF-beta pathway is a critical regulator of the degenerative muscle changes seen after massive rotator cuff tears. TGF-beta promotes rotator cuff muscle fibrosis and fatty infiltration by preventing FAP apoptosis. TGF-beta regulated FAP apoptosis may serve as an important target pathway in the future development of novel therapeutics to improve muscle outcomes following rotator cuff tear. C1 [Liu, Xuhui; Lee, Lawrence; Kim, Hubert T.; Feeley, Brian T.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Davies, Michael R.; Liu, Xuhui; Laron, Dominique; Ning, Anne Y.; Kim, Hubert T.; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. RP Feeley, BT (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.; Feeley, BT (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. EM feeleyb@orthosurg.ucsf.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Review Grant [1I01BX002680]; Orthopedic Research and Education Foundation Career Development and Stem Cell Research Grants FX This material is based upon work supported by U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Merit Review Grant (1I01BX002680) and Orthopedic Research and Education Foundation Career Development and Stem Cell Research Grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 2 Z9 2 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 17 PY 2016 VL 11 IS 5 AR e0155486 DI 10.1371/journal.pone.0155486 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DM3YJ UT WOS:000376282300038 PM 27186977 ER PT J AU Jagsi, R Griffith, KA Jones, R Perumalswami, CR Ubel, P Stewart, A AF Jagsi, Reshma Griffith, Kent A. Jones, Rochelle Perumalswami, Chithra R. Ubel, Peter Stewart, Abigail TI Sexual Harassment and Discrimination Experiences of Academic Medical Faculty SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Jagsi, Reshma; Jones, Rochelle] Univ Michigan, Dept Radiat Oncol, 1500 E Med Ctr Dr,UHB2C490-SPC 5010, Ann Arbor, MI 48109 USA. [Griffith, Kent A.] Univ Michigan, Ctr Canc Biostat, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Perumalswami, Chithra R.] Univ Michigan, US Dept Vet Affairs, Ann Arbor, MI 48109 USA. [Ubel, Peter] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA. [Stewart, Abigail] Univ Michigan, Dept Psychol, 580 Union Dr, Ann Arbor, MI 48109 USA. RP Jagsi, R (reprint author), Univ Michigan, Dept Radiat Oncol, 1500 E Med Ctr Dr,UHB2C490-SPC 5010, Ann Arbor, MI 48109 USA. EM rjagsi@med.umich.edu OI Jagsi, Reshma/0000-0001-6562-1228 FU NCATS NIH HHS [UL1TR000433]; NHLBI NIH HHS [5 R01 HL101997-04, R01 HL101997] NR 5 TC 5 Z9 5 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 17 PY 2016 VL 315 IS 19 BP 2120 EP 2121 DI 10.1001/jama.2016.2188 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DL9PN UT WOS:000375975300025 PM 27187307 ER PT J AU Mabray, MC Talbott, JF Whetstone, WD Dhall, SS Phillips, DB Pan, JZ Manley, GT Bresnahan, JC Beattie, MS Haefeli, J Ferguson, AR AF Mabray, Marc C. Talbott, Jason F. Whetstone, William D. Dhall, Sanjay S. Phillips, David B. Pan, Jonathan Z. Manley, Geoffrey T. Bresnahan, Jacqueline C. Beattie, Michael S. Haefeli, Jenny Ferguson, Adam R. TI Multidimensional Analysis of Magnetic Resonance Imaging Predicts Early Impairment in Thoracic and Thoracolumbar Spinal Cord Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE BASIC; MRI; spinal cord injury; thoracic; T2 hyperintensity; TLICS ID PRINCIPAL-COMPONENTS-ANALYSIS; OPTIMAL RADIOLOGIC METHOD; CANAL COMPROMISE; REPRODUCIBLE METHOD; MOTOR RECOVERY; MR; TRAUMA; CLASSIFICATION; COMPRESSION; SEVERITY AB Literature examining magnetic resonance imaging (MRI) in acute spinal cord injury (SCI) has focused on cervical SCI. Reproducible systems have been developed for MRI- based grading; however, it is unclear how they apply to thoracic SCI. Our hypothesis is that MRI measures will group as coherent multivariate principal component (PC) ensembles, and that distinct PCs and individual variables will show discriminant validity for predicting early impairment in thoracic SCI. We undertook a retrospective cohort study of 25 patients with acute thoracic SCI who underwent MRI on admission and had American Spinal Injury Association Impairment Scale (AIS) assessment at hospital discharge. Imaging variables of axial grade, sagittal grade, length of injury, thoracolumbar injury classification system (TLICS), maximum canal compromise (MCC), and maximum spinal cord compression (MSCC) were collected. We performed an analytical workflow to detect multivariate PC patterns followed by explicit hypothesis testing to predict AIS at discharge. All imaging variables loaded positively on PC1 (64.3% of variance), which was highly related to AIS at discharge. MCC, MSCC, and TLICS also loaded positively on PC2 (22.7% of variance), while variables concerning cord signal abnormality loaded negatively on PC2.PC2 was highly related to the patient undergoing surgical decompression. Variables of signal abnormality were all negatively correlated with AIS at discharge with the highest level of correlation for axial grade as assessed with the Brain and Spinal Injury Center (BASIC) score. A multiple variable model identified BASIC as the only statistically significant predictor of AIS at discharge, signifying that BASIC best captured the variance in AIS within our study population. Our study provides evidence of convergent validity, construct validity, and clinical predictive validity for the sampled MRI measures of SCI when applied in acute thoracic and thoracolumbar SCI. C1 [Mabray, Marc C.; Talbott, Jason F.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Whetstone, William D.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Dhall, Sanjay S.; Phillips, David B.; Manley, Geoffrey T.; Bresnahan, Jacqueline C.; Beattie, Michael S.; Haefeli, Jenny; Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Pan, Jonathan Z.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Talbott, Jason F.; Whetstone, William D.; Dhall, Sanjay S.; Phillips, David B.; Pan, Jonathan Z.; Manley, Geoffrey T.; Bresnahan, Jacqueline C.; Beattie, Michael S.; Haefeli, Jenny; Ferguson, Adam R.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA. [Ferguson, Adam R.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Talbott, JF (reprint author), San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave,Room 1X57C, San Francisco, CA 94110 USA.; Ferguson, AR (reprint author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Neurol Surg, Box 0899,1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA. EM Jason.talbott@ucsf.edu; adam.ferguson@ucsf.edu FU Craig H. Neilsen Foundation; Wings for Life Foundation; DOD grant CDMRP SCIRP [120559 (W81XWH-13-1-0297)]; NIH [5T32EB001631-10]; Craig H. Neilsen Foundation [313739]; [R01NS067092] FX This work was supported by R01NS067092 (ARF), the Craig H. Neilsen Foundation (ARF; JCB), Wings for Life Foundation (ARF), DOD grant CDMRP SCIRP 120559 (W81XWH-13-1-0297) (MSB and JCB). MCM was supported by an NIH T32 Fellowship, 5T32EB001631-10. JH was supported by a Craig H. Neilsen Foundation fellowship (313739). NR 59 TC 2 Z9 2 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAY 15 PY 2016 VL 33 IS 10 BP 954 EP 962 DI 10.1089/neu.2015.4093 PG 9 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DN3TC UT WOS:000376985400005 PM 26414451 ER PT J AU Skrypnyk, NI Siskind, LJ Faubel, S de Caestecker, MP AF Skrypnyk, Nataliya I. Siskind, Leah J. Faubel, Sarah de Caestecker, Mark P. TI Bridging translation for acute kidney injury with better preclinical modeling of human disease SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Review DE acute kidney injury; animal models; human disease; preclinical research; drug discovery ID ACUTE-RENAL-FAILURE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; CISPLATIN-INDUCED NEPHROTOXICITY; CONTRAST-INDUCED NEPHROPATHY; RANDOMIZED CONTROLLED-TRIAL; ISCHEMIA-REPERFUSION INJURY; CRITICALLY-ILL PATIENTS; TUMOR-NECROSIS-FACTOR; SODIUM-BICARBONATE INFUSION; ACUTE TUBULAR-NECROSIS AB The current lack of effective therapeutics for patients with acute kidney injury (AKI) represents an important and unmet medical need. Given the importance of the clinical problem, it is time for us to take a few steps back and reexamine current practices. The focus of this review is to explore the extent to which failure of therapeutic translation from animal studies to human studies stems from deficiencies in the preclinical models of AKI. We will evaluate whether the preclinical models of AKI that are commonly used recapitulate the known pathophysiologies of AKI that are being modeled in humans, focusing on four common scenarios that are studied in clinical therapeutic intervention trials: cardiac surgery-induced AKI; contrast-induced AKI; cisplatin-induced AKI; and sepsis associated AKI. Based on our observations, we have identified a number of common limitations in current preclinical modeling of AKI that could be addressed. In the long term, we suggest that progress in developing better preclinical models of AKI will depend on developing a better understanding of human AKI. To this this end, we suggest that there is a need to develop greater in-depth molecular analyses of kidney biopsy tissues coupled with improved clinical and molecular classification of patients with AKI. C1 [Skrypnyk, Nataliya I.; de Caestecker, Mark P.] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Nashville, TN USA. [Siskind, Leah J.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA. [Siskind, Leah J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Faubel, Sarah] Univ Colorado Denver, Div Renal, Aurora, CO USA. [Faubel, Sarah] Denver Vet Affairs Med Ctr, Aurora, CO USA. RP de Caestecker, MP (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, 1161 21st Ave South,S3223 Med Ctr North, Nashville, TN 37232 USA. EM mark.de.caestecker@vanderbilt.edu FU National Institutes of Health (NIH) [1RC4DK090770, VUMC44339-0R/P30DK079307-007, VUMC43321/U24 DK076169, 2R01 DK069403]; Vanderbilt Center for Kidney Disease (VCKD); NephroGenex, Inc.; NIH Grant [R01DK093462]; Veterans Afairs Merit Review Grants [I01 BX001498, R56 HL095363] FX This work was supported by National Institutes of Health (NIH) Grants 1RC4DK090770, VUMC44339-0R/P30DK079307-007, VUMC43321/U24 DK076169, and 2R01 DK069403, and the Vanderbilt Center for Kidney Disease (VCKD). A research grant from NephroGenex, Inc. supported M. P. de Caestecker; NIH Grant R01DK093462 supported L. J. Siskind; and S. Faubel was supported by Veterans Afairs Merit Review Grants I01 BX001498 and R56 HL095363. NR 178 TC 0 Z9 0 U1 1 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAY 15 PY 2016 VL 310 IS 10 BP P972 EP P984 DI 10.1152/ajprenal.00552.2015 PG 13 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA DL7TG UT WOS:000375842400005 ER PT J AU Amini, A Jones, BL McDermott, JD Serracino, HS Jimeno, A Raben, D Ghosh, D Bowles, DW Karam, SD AF Amini, Arya Jones, Bernard L. McDermott, Jessica D. Serracino, Hilary S. Jimeno, Antonio Raben, David Ghosh, Debashis Bowles, Daniel W. Karam, Sana D. TI Survival Outcomes With Concurrent Chemoradiation for Elderly Patients With Locally Advanced Head and Neck Cancer According to the National Cancer Data Base SO CANCER LA English DT Article DE chemoradiation; concurrent chemoradiotherapy; elderly; head and neck squamous cell carcinoma (HNSCC); National Cancer Data Base (NCDB); older ID SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY; RANDOMIZED-TRIAL; OLDER PATIENTS; INDUCTION CHEMOTHERAPY; HUMAN-PAPILLOMAVIRUS; CLINICAL-TRIALS; LATE TOXICITY; CHEMORADIOTHERAPY; RADIOTHERAPY AB BACKGROUND: The overall survival (OS) benefit of concurrent chemoradiotherapy (CRT) for head and neck squamous cell carcinoma patients older than 70 years is debated. This study examines the outcomes of elderly patients receiving CRT versus radiotherapy (RT) alone. METHODS: The National Cancer Data Base was queried for patients older than 70 years with nonmetastatic oropharyngeal, laryngeal, or hypopharyngeal cancer (T3-4 or N(+)). CRT was defined as chemotherapy started within 14 days of the initiation of RT. Univariate analysis, multivariate analysis (MVA), propensity score matching (PSM), and recursive partitioning analysis (RPA) were performed. RESULTS: The study included 4042 patients: 2538 (63%) received CRT. The median follow-up was 19 months. The unadjusted median OS was longer with the addition of CRT (P < .001). OS was superior with CRT in the MVA (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.58-0.68; P < .001) and PSM analyses (HR, 0.73; 95% CI, 0.66-0.80; P < .001) in comparison with RT alone. According to RPA, CRT was associated with longer OS for patients 81 years or younger with low comorbidity scores and either T1-2/N2-3 disease or T3-4/N0-3 disease. The survival benefit with CRT disappeared for 2 subgroups in the 71- to 81-year age range: those with T1-2, N1, and Charlson-Deyo 0-1 (CD0-1) disease and those with T3-4, N1+, and CD1+ disease. Patients who were older than 81 years did not have increased survival with CRT. The receipt of CRT was associated with a longer duration of RT (odds ratio, 1.74; 95% CI, 1.50-2.01; P < .001). CONCLUSIONS: Patients older than 70 years should not be denied concurrent chemotherapy solely on the basis of age; additional factors, including the performance status and the tumor stage, should be taken into account. (C) 2016 American Cancer Society. C1 [Amini, Arya; Jones, Bernard L.; Raben, David; Karam, Sana D.] Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Court,Room 1032, Aurora, CO 80045 USA. [McDermott, Jessica D.; Jimeno, Antonio; Bowles, Daniel W.] Univ Colorado, Div Med Oncol, Dept Med, Sch Med, Aurora, CO 80045 USA. [McDermott, Jessica D.; Bowles, Daniel W.] Eastern Colorado Hlth Care Syst, Denver Vet Affairs Med Ctr, Denver, CO USA. [Serracino, Hilary S.] Univ Colorado, Dept Pathol, Sch Med, Aurora, CO 80045 USA. [Ghosh, Debashis] Univ Colorado, Sch Publ Hlth, Dept Biostat, Aurora, CO 80045 USA. RP Karam, SD (reprint author), Univ Colorado, Sch Med, Dept Radiat Oncol, 1665 Aurora Court,Room 1032, Aurora, CO 80045 USA. EM sana.karam@ucdenver.edu OI Jones, Bernard/0000-0001-7169-559X NR 37 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAY 15 PY 2016 VL 122 IS 10 BP 1533 EP 1543 DI 10.1002/cncr.29956 PG 11 WC Oncology SC Oncology GA DL8MW UT WOS:000375897100010 PM 26969811 ER PT J AU Young, MRI Levingston, CA Johnson, SD AF Young, M. Rita I. Levingston, Corinne A. Johnson, Sara D. TI Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE head and neck cancer; HNSCC; IL-17; premalignant oral lesions; Th17; Treg ID SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; CYTOKINES; MICE; TH17; PLASTICITY; SUBSETS; DISEASE; RISK; HEAD AB While immune suppression is a hallmark of head and neck squamous cell carcinoma (HSNCC), the immunological impact of premalignant oral lesions, which often precedes development of HNSCC, is unknown. The present study assessed the changes in splenic and draining lymph node CD4(+) cell populations and their production of select cytokines that occur in mice with carcinogen-induced premalignant oral lesions and the changes that occur as lesions progress to oral cancer. These studies found skewing toward Th1 and Th17-type phenotypes in the spleen and lymph nodes of mice with premalignant oral lesions and a shift to Treg as lesions progress to cancer. Since the role of Th17 cells in the progression from premalignant lesions to cancer is not clear, studies determined the immunological and clinical effect of treating mice bearing premalignant oral lesions with a TGF- type 1 receptor inhibitor plus IL-23 as an approach to sustain the Th17 phenotype. These studies showed that the treatment approach not only sustained the Th17 phenotype, but also increased distal spleen cell and regional lymph node cell production of other stimulatory/inflammatory mediators and slowed premalignant lesion progression to cancer. What's new? While premalignant oral lesions generally are small and localized, their immunological impact on distant tissues is unknown. Here, the spleens and regional lymph nodes of mice with carcinogen-induced premalignant oral lesions were found to trend toward Th1- and Th17-type phenotypes. As lesions advanced to oral cancer, phenotypes transitioned to Treg and TGF- production. In mice with premalignant lesions, Th17 was sustained following treatment with a TGF- type 1 receptor inhibitor and IL-23. Treatment also elevated the production of other immunological mediators by the spleen and regional lymph nodes and decreased the rate of progression of premalignant oral lesions. C1 [Young, M. Rita I.; Levingston, Corinne A.; Johnson, Sara D.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Johnson, Sara D.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM rita.young@va.gov FU Clinical Sciences Research Program of the Department of Veterans Affairs [I01-CX000851]; National Institutes of Health [R01-CA128837] FX Grant sponsor: Clinical Sciences Research Program of the Department of Veterans Affairs; Grant number: I01-CX000851; Grant sponsor: National Institutes of Health; Grant number: R01-CA128837 (M.R.I. Young) NR 25 TC 2 Z9 2 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD MAY 15 PY 2016 VL 138 IS 10 BP 2487 EP 2498 DI 10.1002/ijc.29989 PG 12 WC Oncology SC Oncology GA DG7IF UT WOS:000372257300017 PM 26756968 ER PT J AU Bourguignon, LYW Wong, G Shiina, M AF Bourguignon, Lilly Y. W. Wong, Gabriel Shiina, Marisa TI Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NF-KAPPA-B; ALDEHYDE DEHYDROGENASE; GENE-EXPRESSION; CD44; METHYLATION; PROGRESSION; LEUKEMIA; RECEPTOR; MARKER; SENSITIVITY AB Human head and neck squamous cell carcinoma is a solid tumor malignancy associated with major morbidity and mortality. In this study, we determined that human head and neck squamous cell carcinoma-derived HSC-3 cells contain a sub-population of cancer stem cells (CSCs) characterized by a high level of CD44v3 and aldehyde dehydrogenase-1 (ALDH1) expression. Importantly, matrix hyaluronan (HA) induces the up-regulation of stem cell markers that display the hallmark CSC properties. Histone methyltransferase, DOT1L, is also up-regulated by HA in CSCs (isolated from HSC-3 cells). Further analyses indicate that the stimulation of microRNA-10b (miR-10b) expression is DOT1L-specific and HA/CD44-dependent in CSCs. This process subsequently results in the overexpression of RhoGTPases and survival proteins leading to tumor cell invasion and cisplatin resistance. Treatment of CSCs with DOT1L-specific small interfering RNAs (siRNAs) effectively blocks HA/CD44-mediated expression of DOT1L, miR-10b production, and RhoGTPase/survival protein up-regulation as well as reduces tumor cell invasion and enhances chemosensitivity. CSCs were also transfected with a specific anti-miR-10b inhibitor to silence miR-10b expression and block its target functions. Our results demonstrate that the anti-miR-10 inhibitor not only decreases RhoGTPase/survival protein expression and tumor cell invasion, but also increases chemosensitivity in HA-treated CSCs. Taken together, these findings strongly support the contention that histone methyltransferase, DOT1L-associated epigenetic changes induced by HA play pivotal roles in miR-10 production leading to up-regulation of RhoGTPase and survival proteins. All of these events are critically important for the acquisition of cancer stem cell properties, including self-renewal, tumor cell invasion, and chemotherapy resistance in HA/CD44-activated head and neck cancer. C1 Univ Calif San Francisco, Dept Med, Endocrine Unit, 4150 Clement St, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Bourguignon, LYW (reprint author), Univ Calif San Francisco, San Francisco Med Ctr, Dept Med, 4150 Clement St, San Francisco, CA 94121 USA. EM lilly.bourguignon@ucsf.edu FU Veterans Affairs Merit Review Award RR [D-1I01 RX000601]; Veterans Affairs Merit Review Award BLR [D-5I01 BX000628]; National Institutes of Health from USPHS [R01 CA66163]; Department of Defense FX This work was supported by Veterans Affairs Merit Review Awards RR and D-1I01 RX000601 and BLR and D-5I01 BX000628, National Institutes of Health Grant R01 CA66163 from USPHS, and a Department of Defense grant. The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 42 TC 2 Z9 2 U1 1 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAY 13 PY 2016 VL 291 IS 20 BP 10571 EP 10585 DI 10.1074/jbc.M115.700021 PG 15 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DN4MY UT WOS:000377042600012 PM 27002147 ER PT J AU Mao, SP Xiong, GX Zhang, L Dong, HM Liu, BH Cohen, NA Cohen, AS AF Mao, Shanping Xiong, Guoxiang Zhang, Lei Dong, Huimin Liu, Baohui Cohen, Noam A. Cohen, Akiva S. TI Verification of the Cross Immunoreactivity of A60, a Mouse Monoclonal Antibody against Neuronal Nuclear Protein SO FRONTIERS IN NEUROANATOMY LA English DT Article DE hybridoma; brain sections; neurocytoma; stem cell differentiation; immunohistology; epitopes ID NEURAL DIFFERENTIATION; MARKER NEUN; ADULT MICE; IN-VIVO; BRAIN; IMMUNOHISTOCHEMISTRY; EXPRESSION; ANTIGEN; IDENTIFICATION; LOCALIZATION AB A60, the mouse monoclonal antibody against the neuronal nuclear protein (NeuN), is the most widely used neuronal marker in neuroscience research and neuropathological assays. Previous studies identified fragments of A60immunoprecipitated protein as Synapsin I (Syn I), suggesting the antibody will demonstrate cross immunoreactivity. However, the likelihood of cross reactivity has never been verified by immunohistochemical techniques. Using our established tissue processing and immunofluorescent staining protocols, we found that A60 consistently labeled mossy fiber terminals in hippocampal area CA3. These A60-positive mossy fiber terminals could also be labeled by Syn I antibody. After treating brain slices with saponin in order to better preserve various membrane and/or vesicular proteins for immunostaining, we observed that A60 could also label additional synapses in various brain areas. Therefore, we used A60 together with a rabbit monoclonal NeuN antibody to confirm the existence of this cross reactivity. We showed that the putative band positive for A60 and Syn I could not be detected by the rabbit anti-NeuN in Western blotting. As efficient as Millipore A60 to recognize neuronal nuclei, the rabbit NeuN antibody demonstrated no labeling of synaptic structures in immunofluorescent staining. The present study successfully verified the cross reactivity present in immunohistochemistry, cautioning that A60 may not be the ideal biomarker to verify neuronal identity due to its cross immunoreactivity. In contrast, the rabbit monoclonal NeuN antibody used in this study may be a better candidate to substitute for A60. C1 [Mao, Shanping; Dong, Huimin; Liu, Baohui] Wuhan Univ, Renmin Hosp, Dept Neurol, Wuhan 430072, Peoples R China. [Xiong, Guoxiang; Zhang, Lei; Cohen, Akiva S.] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Univ Penn, Dept Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Akiva S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA. RP Xiong, GX (reprint author), Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA. EM xiong@email.chop.edu FU NIH [R37-HD059288, R01-NS069629] FX The present study was supported by NIH grants R37-HD059288 and R01-NS069629 (to ASC). NR 38 TC 0 Z9 0 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5129 J9 FRONT NEUROANAT JI Front. Neuroanat. PD MAY 13 PY 2016 VL 10 AR 54 DI 10.3389/fnana.2010.00054 PG 11 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA DL9UD UT WOS:000375987600001 PM 27242450 ER PT J AU Shah, AP Carreno, FR Wu, H Chung, YA Frazer, A AF Shah, A. P. Carreno, F. R. Wu, H. Chung, Y. A. Frazer, A. TI ROLE OF TrkB IN THE ANXIOLYTIC-LIKE AND ANTIDEPRESSANT-LIKE EFFECTS OF VAGAL NERVE STIMULATION: COMPARISON WITH DESIPRAMINE SO NEUROSCIENCE LA English DT Article DE antidepressants; vagal nerve stimulation; TrkB; BDNF; desipramine; depression ID TREATMENT-RESISTANT DEPRESSION; NEUROTROPHIC FACTOR-RECEPTOR; ELEMENT-BINDING PROTEIN; FORCED SWIMMING TEST; RAT-BRAIN; GROWTH-FACTOR; ELECTROCONVULSIVE SEIZURES; HIPPOCAMPAL NEUROGENESIS; SIGNALING PATHWAYS; BEHAVIORAL DESPAIR AB A current hypothesis regarding the mechanism of antidepressant (AD) action suggests the involvement of brain-derived neurotrophic factor (BDNF). Consistent with this hypothesis, the receptor for BDNF (and neurotrophin 4/5 (NT-4/5)), Tropomyosin-related kinase B (TrkB), is activated in rodents by treatment with classical AD drugs. Vagal nerve stimulation (VNS), a therapy for treatment resistant depression (TRD), also activates TrkB in rodents. However, the role of this receptor in the therapeutic effects of VNS is unclear. In the current study, the involvement of TrkB in the effects of VNS was investigated in rats using its inhibitor, K252a. Anxiolytic-like and AD-like effects were analyzed using the novelty suppressed feeding test (NSFT) and forced swim test (FST), respectively. K252a blocked the anxiolytic-like effect of chronic VNS treatment and the AD-like effect of acute VNS treatment. By contrast, blocking TrkB did not prevent either the anxiolytic-like or AD-like effect of chronic treatment with desipramine (DMI), a selective noradrenergic reuptake inhibitor; it did, however, block the acute effect of DMI in the FST. To examine whether the activation of TrkB caused by either VNS or DMI is ligand-dependent, use was made of TrkB-Fc, a molecular scavenger for ligands of TrkB. Intraventricular administration of TrkB-Fc blocked the acute activation of TrkB induced by either treatment, indicating that treatment-induced activation of this receptor is ligand-dependent. The behavioral results highlight differences in the involvement of TrkB in the chronic effects of an AD drug and a stimulation therapy as well as its role in acute versus chronic effects of DMI. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Shah, A. P.; Carreno, F. R.; Wu, H.; Chung, Y. A.; Frazer, A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Shah, A. P.; Carreno, F. R.; Wu, H.; Chung, Y. A.; Frazer, A.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX USA. [Frazer, A.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Shah, A. P.] Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 North Wolfe St, Baltimore, MD 21205 USA. RP Shah, AP (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.; Shah, AP (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 North Wolfe St, Baltimore, MD 21205 USA. EM ashah69@jhmi.edu FU National Institute of Mental Health [MH082933] FX This work was supported by the National Institute of Mental Health grant MH082933 (Alan Frazer). We would like to acknowledge the technical assistance of Marisa DeGuzman, Jonathan Chemello and Mohona Sadhu and thank Drs. David Morilak and Wouter Koek for their guidance with statistical analyses. We would also like to acknowledge that Cyberonics Inc., TX, generously provided the VNS stimulators, dummy stimulators and electrodes as gifts. NR 75 TC 0 Z9 0 U1 2 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD MAY 13 PY 2016 VL 322 BP 273 EP 286 DI 10.1016/j.neuroscience.2016.02.024 PG 14 WC Neurosciences SC Neurosciences & Neurology GA DG8QX UT WOS:000372349800024 PM 26899129 ER PT J AU Brown, RT Goodman, L Guzman, D Tieu, L Ponath, C Kushel, MB AF Brown, Rebecca T. Goodman, Leah Guzman, David Tieu, Lina Ponath, Claudia Kushel, Margot B. TI Pathways to Homelessness among Older Homeless Adults: Results from the HOPE HOME Study SO PLOS ONE LA English DT Article ID MENTAL-ILLNESS; RISK-FACTORS; LIFE-COURSE; SAN-FRANCISCO; POPULATION; HEALTH; CARE; AGE; PREDICTORS; COMMUNITY AB Little is known about pathways to homelessness among older adults. We identified life course experiences associated with earlier versus later onset of homelessness in older homeless adults and examined current health and functional status by age at first homelessness. We interviewed 350 homeless adults, aged 50 and older, recruited via population-based sampling. Participants reported age at first episode of adult homelessness and their life experiences during 3 time periods: childhood (<18 years), young adulthood (ages 18-25), and middle adulthood (ages 26-49). We used a structured modeling approach to identify experiences associated with first adult homelessness before age 50 versus at age 50 or older. Participants reported current health and functional status, including recent mental health and substance use problems. Older homeless adults who first became homeless before 50 had more adverse life experiences (i.e., mental health and substance use problems, imprisonment) and lower attainment of adult milestones (i.e., marriage, full-time employment) compared to individuals with later onset. After multivariable adjustment, adverse experiences were independently associated with experiencing a first episode of homelessness before age 50. Individuals who first became homeless before age 50 had higher prevalence of recent mental health and substance use problems and more difficulty performing instrumental activities of daily living. Life course experiences and current vulnerabilities of older homeless adults with first homelessness before age 50 differed from those with later onset of homelessness. Prevention and service interventions should be adapted to meet different needs. C1 [Brown, Rebecca T.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Brown, Rebecca T.] San Francisco VA Med Ctr, San Francisco, CA USA. [Goodman, Leah] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Guzman, David; Tieu, Lina; Ponath, Claudia; Kushel, Margot B.] Univ Calif San Francisco, Div Gen Internal Med, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA. [Guzman, David; Tieu, Lina; Ponath, Claudia; Kushel, Margot B.] Ctr Trauma, San Francisco, CA USA. [Guzman, David; Tieu, Lina; Ponath, Claudia; Kushel, Margot B.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. RP Kushel, MB (reprint author), Univ Calif San Francisco, Div Gen Internal Med, Zuckerberg San Francisco Gen Hosp, San Francisco, CA 94143 USA.; Kushel, MB (reprint author), Ctr Trauma, San Francisco, CA USA.; Kushel, MB (reprint author), Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. EM Margot.Kushel@ucsf.edu FU National Institute on Aging (NIA) at the National Institutes of Health (NIH) [K23AG045290, K24AG046372, R01AG041860, P30AG044281]; NIH National Center for Advancing Translational Sciences through the University of California, San Francisco, Clinical and Translational Science Institute [KL2TR000143]; NIH National Institute of Minority Health and Health Disparities through the University of California, San Francisco Promoting Research Opportunities Fully-Prospective Academics Transforming Health (PROFPATH) program award [R25MD006832]; UCSF Academic Senate Open Access Publishing Fund FX This work was supported by grants from the National Institute on Aging (NIA) at the National Institutes of Health (NIH) [grant numbers K23AG045290 to RB, K24AG046372 to MK, R01AG041860 to MK, P30AG044281 to RB and MK]; the NIH National Center for Advancing Translational Sciences through the University of California, San Francisco, Clinical and Translational Science Institute [grant number KL2TR000143 to RB]; the NIH National Institute of Minority Health and Health Disparities through the University of California, San Francisco Promoting Research Opportunities Fully-Prospective Academics Transforming Health (PROFPATH) program award [grant number R25MD006832 to L.G.]; and the UCSF Academic Senate Open Access Publishing Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 1 Z9 1 U1 5 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 10 PY 2016 VL 11 IS 5 AR e0155065 DI 10.1371/journal.pone.0155065 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DM8BN UT WOS:000376585700034 PM 27163478 ER PT J AU Hagedorn, HJ Brown, R Dawes, M Dieperink, E Myrick, DH Oliva, EM Wagner, TH Wisdom, JP Harris, AHS AF Hagedorn, Hildi J. Brown, Randall Dawes, Michael Dieperink, Eric Myrick, Donald Hugh Oliva, Elizabeth M. Wagner, Todd H. Wisdom, Jennifer P. Harris, Alex H. S. TI Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC SO IMPLEMENTATION SCIENCE LA English DT Article DE Alcohol use disorder treatment; Alcohol use disorder pharmacotherapy; Primary care mental health integration; Implementation ID NATIONAL EPIDEMIOLOGIC SURVEY; BUDGET IMPACT ANALYSIS; SUBSTANCE USE; UNITED-STATES; HEALTH-SERVICES; MENTAL-HEALTH; PREVALENCE; DEPENDENCE; IMPLEMENTATION; DRINKING AB Background: Only 7.8 % of individuals meeting diagnostic criteria for alcohol use disorder (AUD) receive treatment in a given year. Most individuals with AUDs are identified in primary care (PC) settings and referred to substance use disorders (SUD) clinics; however, only a minority of those referred attend treatment services. Safe and effective pharmacological treatments for AUD exist, but they are rarely prescribed by PC providers. The objective of this study is to refine, implement, and evaluate an intervention to integrate pharmacological AUD treatment options into PC settings. This paper provides a detailed description of the intervention design and the evaluation components. Methods/design: Three large Veterans Health Administration (VHA) facilities are participating in the intervention. The intervention targets stakeholder groups with tailored strategies based on implementation theory and prior research identifying barriers to implementation of AUD pharmacotherapy. Local SUD providers and primary care mental health integration (PCMHI) providers are trained to serve as local implementation/clinical champions and receive external facilitation. PC providers receive access to consultation from local and national clinical champions, educational materials, and a dashboard of patients with AUD on their caseloads for case identification. Veterans with AUD diagnoses receive educational information in the mail just prior to a scheduled PC visit. Effectiveness of the intervention will be evaluated through an interrupted time series with matched controls to monitor change in facility level AUD pharmacotherapy prescribing rates. Following Stetler's four-phase formative evaluation (FE) strategy, FE methods include (1) developmental FE (pre-implementation interviews with champions, PC providers, and Veterans), (2) implementation-focused FE (tracking attendance at facilitation meetings, academic detailing efforts by local champions, and patient dashboard utilization), (3) progress-focused FE (tracking rates of AUD pharmacotherapy prescribing and rates of referral to PCMHI and SUD specialty care), and (4) interpretive FE (post-implementation interviews with champions and PC providers). Analysis of FE data will be guided by the Consolidated Framework for Implementation Research (CFIR). Discussion: If demonstrated to be successful, this implementation strategy will provide a replicable, feasible, and relative low-cost method for integrating AUD treatment services into PC settings, thereby increasing access to AUD treatment. C1 [Hagedorn, Hildi J.; Dieperink, Eric] Minneapolis Vet Affairs Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Ctr Chron Dis Out, Minneapolis, MN 55417 USA. [Hagedorn, Hildi J.; Dieperink, Eric] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA. [Brown, Randall] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Brown, Randall] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI 53715 USA. [Dawes, Michael] South Texas Vet Affairs Hlth Care Syst, Subst Abuse Treatment Program, San Antonio, TX 78229 USA. [Dawes, Michael] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Myrick, Donald Hugh] Ralph H Johnson Vet Affairs Med Ctr, Ctr Drug & Alcohol Problems, Charleston, SC 29401 USA. [Myrick, Donald Hugh] Med Univ S Carolina, Dept Psychiat & Behav Serv, Charleston, SC 29425 USA. [Oliva, Elizabeth M.] Palo Alto Vet Affairs Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Ctr Innovat Imple, Menlo Pk, CA 94025 USA. [Wagner, Todd H.] Palo Alto Vet Affairs Hlth Care Syst, Hlth Econ Resource Ctr, Menlo Pk, CA 94025 USA. [Wisdom, Jennifer P.] George Washington Univ, Dept Hlth Policy, Washington, DC 20052 USA. RP Hagedorn, HJ (reprint author), Minneapolis Vet Affairs Hlth Care Syst, Vet Affairs Hlth Serv Res & Dev Ctr Chron Dis Out, Minneapolis, MN 55417 USA.; Hagedorn, HJ (reprint author), Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA. EM hildi.hagedorn@va.gov FU US Department of Veterans Affairs Health Services Research and Development Service's Quality Enhancement Research Initiative [11-411] FX This work was supported by Service Directed Project Award #11-411 from the US Department of Veterans Affairs Health Services Research and Development Service's Quality Enhancement Research Initiative. The contents do not represent the views of the US Department of Veterans Affairs or the US government. NR 37 TC 1 Z9 1 U1 2 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAY 10 PY 2016 VL 11 AR 64 DI 10.1186/s13012-016-0431-5 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DM1FT UT WOS:000376091500001 PM 27164835 ER PT J AU Chen, JC Bacanu, SA Yu, H Zhao, ZM Jia, PL Kendler, KS Kranzler, HR Gelernter, J Farrer, L Minica, C Pool, R Milaneschi, Y Boomsma, DI Penninx, BWJH Tyndale, RF Ware, JJ Vink, JM Kaprio, J Munafo, M Chen, XN AF Chen, Jingchun Bacanu, Silviu-Alin Yu, Hui Zhao, Zhongming Jia, Peilin Kendler, Kenneth S. Kranzler, Henry R. Gelernter, Joel Farrer, Lindsay Minica, Camelia Pool, Rene Milaneschi, Yuri Boomsma, Dorret I. Penninx, Brenda W. J. H. Tyndale, Rachel F. Ware, Jennifer J. Vink, Jacqueline M. Kaprio, Jaakko Munafo, Marcus Chen, Xiangning CA Cotinine Metaanal Grp FTND Metaanal Grp TI Genetic Relationship between Schizophrenia and Nicotine Dependence SO SCIENTIFIC REPORTS LA English DT Article ID GENOME-WIDE ASSOCIATION; LONG-TERM POTENTIATION; RECEPTOR SUBUNIT GENE; FALSE DISCOVERY RATE; COMMON VARIANTS; BIPOLAR DISORDER; SMOKING-BEHAVIOR; TOBACCO SMOKING; RISK; SMOKERS AB It is well known that most schizophrenia patients smoke cigarettes. There are different hypotheses postulating the underlying mechanisms of this comorbidity. We used summary statistics from large meta-analyses of plasma cotinine concentration (COT), Fagerstrom test for nicotine dependence (FTND) and schizophrenia to examine the genetic relationship between these traits. We found that schizophrenia risk scores calculated at P-value thresholds of 5 x 10(-3) and larger predicted FTND and cigarettes smoked per day (CPD), suggesting that genes most significantly associated with schizophrenia were not associated with FTND/CPD, consistent with the self-medication hypothesis. The COT risk scores predicted schizophrenia diagnosis at P-values of 5 x 10(-3) and smaller, implying that genes most significantly associated with COT were associated with schizophrenia. These results implicated that schizophrenia and FTND/CPD/COT shared some genetic liability. Based on this shared liability, we identified multiple long non-coding RNAs and RNA binding protein genes (DA376252, BX089737, LOC101927273, LINC01029, LOC101928622, HY157071, DA902558, RBFOX1 and TINCR), protein modification genes (MANBA, UBE2D3, and RANGAP1) and energy production genes (XYLB, MTRF1 and ENOX1) that were associated with both conditions. Further analyses revealed that these shared genes were enriched in calcium signaling, long-term potentiation and neuroactive ligand-receptor interaction pathways that played a critical role in cognitive functions and neuronal plasticity. C1 [Chen, Jingchun; Chen, Xiangning] Univ Nevada, Nevada Inst Personalized Med, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA. [Bacanu, Silviu-Alin; Kendler, Kenneth S.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, 800 E Leigh St, Richmond, VA 23298 USA. [Bacanu, Silviu-Alin; Kendler, Kenneth S.] Virginia Commonwealth Univ, Dept Psychiat, 800 E Leigh St, Richmond, VA 23298 USA. [Yu, Hui; Zhao, Zhongming; Jia, Peilin] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37203 USA. [Yu, Hui; Zhao, Zhongming; Jia, Peilin] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37203 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kranzler, Henry R.] Philadelphia VA Med Ctr, MIRECC VISN4, Philadelphia, PA USA. [Gelernter, Joel] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, New Haven, CT 06516 USA. [Gelernter, Joel] VA CT Healthcare Ctr, New Haven, CT 06516 USA. [Farrer, Lindsay] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Minica, Camelia; Pool, Rene; Boomsma, Dorret I.; Penninx, Brenda W. J. H.] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands. [Milaneschi, Yuri] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands. [Milaneschi, Yuri] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Tyndale, Rachel F.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada. [Ware, Jennifer J.; Munafo, Marcus] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England. [Vink, Jacqueline M.] Vrije Univ Amsterdam, Dept Biol Psychol, Amsterdam, Netherlands. [Vink, Jacqueline M.] Radboud Univ Nijmegen, Inst Behav Sci, NL-6525 ED Nijmegen, Netherlands. [Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, POB 41 Mannerheimintie 172, FIN-00014 Helsinki, Finland. [Kaprio, Jaakko] Natl Inst Hlth & Welf, Dept Mental Hlth & Substance Abuse Serv, POB 30 Mannerheimintie 166, Helsinki, Finland. [Kaprio, Jaakko] Univ Helsinki, Inst Mol Med, POB 20 Tukholmankatu 8, FIN-00014 Helsinki, Finland. [Munafo, Marcus] Univ Bristol, Sch Expt Psychol, UK Ctr Tobacco & Alcohol Studies, Bristol, Avon, England. [Chen, Xiangning] Univ Nevada, Dept Psychol, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA. RP Chen, XN (reprint author), Univ Nevada, Nevada Inst Personalized Med, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA.; Chen, XN (reprint author), Univ Nevada, Dept Psychol, 4505 S Maryland Pkwy, Las Vegas, NV 89154 USA. EM Xiangning.chen@unlv.edu RI Pool, Rene/B-3652-2009; Davey Smith, George/A-7407-2013 OI Pool, Rene/0000-0001-5579-0933; Davey Smith, George/0000-0002-1407-8314; Timpson, Nicholas/0000-0002-7141-9189; Kaprio, Jaakko/0000-0002-3716-2455 FU NIH [ML011177, MH101054, DA032246]; Academy of Finland [265240, 263278]; AbbVie; Alkermes; Ethypharm; Lilly; Lundbeck; Pfizer FX This work was supported in part by NIH grants ML011177, MH101054 and DA032246. JK has been supported by the Academy of Finland (grants # 265240 and 263278). We are grateful to the PGC schizophrenia analysis group for providing the summary statistics of its GWAS meta-analysis. Although unrelated to this research, H. Kranzler has been a consultant or advisory board member for Alkermes, Lilly, Lundbeck, Otsuka, Pfizer, and Roche. He is also a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which is supported by AbbVie, Alkermes, Ethypharm, Lilly, Lundbeck, and Pfizer. NR 76 TC 3 Z9 3 U1 2 U2 7 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAY 10 PY 2016 VL 6 AR 25671 DI 10.1038/srep25671 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DL2FF UT WOS:000375448100001 PM 27164557 ER PT J AU Morris, AM Ricci, KA Griffin, AR Heslin, KC Dobalian, A AF Morris, Andrea M. Ricci, Karen A. Griffin, Anne R. Heslin, Kevin C. Dobalian, Aram TI Personal and professional challenges confronted by hospital staff following hurricane sandy: a qualitative assessment of management perspectives SO BMC EMERGENCY MEDICINE LA English DT Article DE Disaster response; Recovery; Hospital; Professional duty; Veterans; US Department of Veterans Affairs ID CARE; WILLINGNESS; DISASTERS; VETERANS AB Background: Adequate hospital staffing during and after a disaster is critical to meet increased health care demands and to ensure continuity of care and patient safety. However, when a disaster occurs, staff may become both victim and responder, decreasing their ability and willingness to report for work. This qualitative study assessed the personal and professional challenges that affected staff decisions to report to work following a natural disaster and examined the role of management in addressing staff needs and concerns. Methods: Semi-structured interviews were conducted with individuals who filled key management roles in the United States Department of Veterans Affairs New York Harbor Healthcare System's response to Superstorm Sandy and during the facility's initial recovery phase. All interviews were audio recorded and transcribed. Three major themes were identified: 1) Barriers to reporting ("Barriers"), 2) Facilitators to reporting ("Facilitators"), and 3) Responses to staff needs and concerns ("Responses"). Atlas. ti 7.1.6 software program was used for the management and analysis of the transcripts. Results: Results indicated that staff encountered several barriers that impeded their ability to report to work at mobile vans at the temporarily nonoperational Manhattan campus or at two other VA facilities in Brooklyn and the Bronx in the initial post-Sandy period including transportation problems, personal property damage, and communication issues. In addition, we found evidence of facilitators to reporting as expressed through descriptions of professional duty. Our findings also revealed that management was aware of the challenges that staff was facing and made efforts to reduce barriers and accommodate staff affected by the storm. Conclusions: During and after a disaster event, hospital staff is often confronted with challenges that affect decisions to report for work and perform effectively under potentially harsh conditions. This study examined barriers and facilitators that hospital staff encountered following a major natural disaster from the management perspective. Insights gained from this study can be used to inform future disaster planning and preparedness efforts, and help ensure that there is adequate staffing to mount an effective response when a disaster occurs, and to recover from its aftermath. C1 [Morris, Andrea M.; Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Morris, Andrea M.; Griffin, Anne R.; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. [Ricci, Karen A.] Baystate Med Ctr, Dept OB GYN Res, Springfield, MA USA. [Heslin, Kevin C.] US Dept Hlth & Human Serv, Ctr Delivery Org & Markets, Agcy Healthcare Res & Qual, Rockville, MD USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. RP Dobalian, A (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.; Dobalian, A (reprint author), US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA.; Dobalian, A (reprint author), Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. EM aram.dobalian@va.gov FU AHRQ HHS [T32 HS000046] NR 30 TC 1 Z9 1 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-227X J9 BMC EMERG MED JI BMC Emerg. Med. PD MAY 5 PY 2016 VL 16 AR 18 DI 10.1186/s12873-016-0082-5 PG 7 WC Emergency Medicine SC Emergency Medicine GA DO9RQ UT WOS:000378124900001 PM 27151172 ER PT J AU Harris, LG Wang, SH Mani, SK Kasiganesan, H Chou, CJ Menick, DR AF Harris, Lillianne G. Wang, Sabina H. Mani, Santhosh K. Kasiganesan, Harinath Chou, C. James Menick, Donald R. TI Evidence for a non-canonical role of HDAC5 in regulation of the cardiac Ncx1 and Bnp genes SO NUCLEIC ACIDS RESEARCH LA English DT Article ID IIA HISTONE DEACETYLASES; TRANSCRIPTION FACTOR; CLASS IIHDACS; UP-REGULATION; HYPERTROPHY; EXPRESSION; ASSOCIATION; SUMOYLATION; REPRESSION; INHIBITION AB Class IIa histone deacetylases (HDACs) are very important for tissue specific gene regulation in development and pathology. Because class IIa HDAC catalytic activity is low, their exact molecular roles have not been fully elucidated. Studies have suggested that class IIa HDACs may serve as a scaffold to recruit the catalytically active class I HDAC complexes to their substrate. Here we directly address whether the class IIa HDAC, HDAC5 may function as a scaffold to recruit co-repressor complexes to promoters. We examined two well-characterized cardiac promoters, the sodium calcium exchanger (Ncx1) and the brain natriuretic peptide (Bnp) whose hypertrophic upregulation is mediated by both class I and IIa HDACs. Selective inhibition of class IIa HDACs did not prevent adrenergic stimulated Ncx1 upregulation, however HDAC5 knockout prevented pressure overload induced Ncx1 upregulation. Using the HDAC5((-/-)) mouse we show that HDAC5 is required for the interaction of the HDAC1/2/Sin3a co-repressor complexes with the Nkx2.5 and YY1 transcription factors and critical for recruitment of the HDAC1/Sin3a co-repressor complex to either the Ncx1 or Bnp promoter. Our novel findings support a non-canonical role of class IIa HDACs in the scaffolding of transcriptional regulatory complexes, which may be relevant for therapeutic intervention for pathologies. C1 [Harris, Lillianne G.; Wang, Sabina H.; Mani, Santhosh K.; Kasiganesan, Harinath; Menick, Donald R.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Chou, C. James] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Menick, Donald R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. RP Menick, DR (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.; Menick, DR (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. EM menickd@musc.edu FU National Institutes of Health [R01HL095696, R01HL094545]; Merit Award from the Veterans' Affairs Health Administration [BX002327]; South Carolina Clinical & Translational Research (SCTR) Institute; Medical University of South Carolina NIH/NCATS [UL1 TR000062]; NIH Postdoctoral Fellowship [T32HL07260] FX Funding for open access charge: National Institutes of Health [R01HL095696, R01HL094545, in part]; Merit Award from the Veterans' Affairs Health Administration [BX002327]; South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina NIH/NCATS UL1 TR000062 [to D.R.M.]; NIH Postdoctoral Fellowship [T32HL07260 to L.G.H., S.H.W.]. NR 41 TC 1 Z9 1 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD MAY 5 PY 2016 VL 44 IS 8 BP 3610 EP 3617 DI 10.1093/nar/gkv1496 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DM5KX UT WOS:000376389000020 PM 26704971 ER PT J AU Cubells, JF Schroeder, JP Barrie, ES Manvich, DF Sadee, W Berg, T Mercer, K Stowe, TA Liles, LC Squires, KE Mezher, A Curtin, P Perdomo, DL Szot, P Weinshenker, D AF Cubells, Joseph F. Schroeder, Jason P. Barrie, Elizabeth S. Manvich, Daniel F. Sadee, Wolfgang Berg, Tiina Mercer, Kristina Stowe, Taylor A. Liles, L. Cameron Squires, Katherine E. Mezher, Andrew Curtin, Patrick Perdomo, Dannie L. Szot, Patricia Weinshenker, David TI Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine beta-Hydroxylase Knockout Mice SO PLOS ONE LA English DT Article ID NOREPINEPHRINE-DEFICIENT MICE; MESSENGER-RNA; LACKING NOREPINEPHRINE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; BLOOD-PRESSURE; EXPRESSION; GENE; NORADRENALINE; PROMOTER AB Dopamine beta-hydroxylase (DBH) converts dopamine (DA) to norepinephrine (NE) in noradrenergic/adrenergic cells. DBH deficiency prevents NE production and causes sympathetic failure, hypotension and ptosis in humans and mice; DBH knockout (Dbh -/-) mice reveal other NE deficiency phenotypes including embryonic lethality, delayed growth, and behavioral defects. Furthermore, a single nucleotide polymorphism (SNP) in the human DBH gene promoter (-970C>T; rs1611115) is associated with variation in serum DBH activity and with several neurological-and neuropsychiatric-related disorders, although its impact on DBH expression is controversial. Phenotypes associated with DBH deficiency are typically treated with L-3,4-dihydroxyphenylserine (DOPS), which can be converted to NE by aromatic acid decarboxylase (AADC) in the absence of DBH. In this study, we generated transgenic mice carrying a human bacterial artificial chromosome (BAC) encompassing the DBH coding locus as well as similar to 45 kb of upstream and similar to 107 kb of downstream sequence to address two issues. First, we characterized the neuroanatomical, neurochemical, physiological, and behavioral transgenic rescue of DBH deficiency by crossing the BAC onto a Dbh -/- background. Second, we compared human DBH mRNA abundance between transgenic lines carrying either a "C" or a "T" at position -970. The BAC transgene drove human DBH mRNA expression in a pattern indistinguishable from the endogenous gene, restored normal catecholamine levels to the peripheral organs and brain of Dbh -/- mice, and fully rescued embryonic lethality, delayed growth, ptosis, reduced exploratory activity, and seizure susceptibility. In some cases, transgenic rescue was superior to DOPS. However, allelic variation at the rs1611115 SNP had no impact on mRNA levels in any tissue. These results indicate that the human BAC contains all of the genetic information required for tissue-specific, functional expression of DBH and can rescue all measured Dbh deficiency phenotypes, but did not reveal an impact of the rs11115 variant on DBH expression in mice. C1 [Cubells, Joseph F.; Schroeder, Jason P.; Manvich, Daniel F.; Berg, Tiina; Mercer, Kristina; Stowe, Taylor A.; Liles, L. Cameron; Squires, Katherine E.; Mezher, Andrew; Curtin, Patrick; Weinshenker, David] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA. [Cubells, Joseph F.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Emory Autism Ctr, Atlanta, GA USA. [Barrie, Elizabeth S.; Sadee, Wolfgang] Ohio State Univ, Coll Med, Ctr Pharmacogen, Columbus, OH 43210 USA. [Mercer, Kristina; Perdomo, Dannie L.] Emory Univ, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA. [Szot, Patricia] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA. [Szot, Patricia] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Weinshenker, D (reprint author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA. EM dweinshenker@genetics.emory.edu FU National Institute of Neurological Disorders and Stroke [NS072712]; National Institute on Drug Abuse [DA027535, DA038453, DA015040]; National Institute of General Medical Sciences [GM 092655]; Ohio State University; Department of Veterans Affairs VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC); [T32 DA015040] FX This work was supported by the National Institute of Neurological Disorders and Stroke (NS072712 to JFC; http://www.ninds.nih.gov/), the National Institute on Drug Abuse (DA027535 and DA038453 to DW and DA015040 to DLP; https://www.drugabuse.gov/), the National Institute of General Medical Sciences (GM 092655 to WS; https://www.nigms.nih.gov/), the Ohio State University (Distinguished University Fellowship to ESB; http://www.gradsch.osu.edu/fellowship-program.html), and the Department of Veterans Affairs VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC) to PS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Ellen Hess and Doug Bernhard for assistance with the HPLC experiments, and Dr. Michael J. Kuhar, Principal Investigator for T32 DA015040, which supported DLP for her role in the project. NR 50 TC 2 Z9 4 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 5 PY 2016 VL 11 IS 5 AR e0154864 DI 10.1371/journal.pone.0154864 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DL5KV UT WOS:000375676800074 PM 27148966 ER PT J AU Moussaoui, N Larauche, M Biraud, M Molet, J Million, M Mayer, E Tache, Y AF Moussaoui, Nabila Larauche, Muriel Biraud, Mandy Molet, Jenny Million, Mulugeta Mayer, Emeran Tache, Yvette TI Limited Nesting Stress Alters Maternal Behavior and In Vivo Intestinal Permeability in Male Wistar Pup Rats SO PLOS ONE LA English DT Article ID PITUITARY-ADRENAL AXIS; IRRITABLE-BOWEL-SYNDROME; EARLY-LIFE STRESS; ANIMAL-MODELS; NEONATAL STRESS; ADULT RATS; BARRIER FUNCTION; BREAST-MILK; DEPRIVATION; MATURATION AB A few studies indicate that limited nesting stress (LNS) alters maternal behavior and the hypothalamic pituitary adrenal (HPA) axis of dams and offspring in male Sprague Dawley rats. In the present study, we evaluated the impact of LNS on maternal behavior in Wistar rats, and on the HPA axis, glycemia and in vivo intestinal permeability of male and female offspring. Intestinal permeability is known to be elevated during the first week postnatally and influenced by glucocorticoids. Dams and neonatal litters were subjected to LNS or normal nesting conditions (control) from days 2 to 10 postnatally. At day 10, blood was collected from pups for determination of glucose and plasma corticosterone by enzyme immunoassay and in vivo intestinal permeability by oral gavage of fluorescein isothiocyanate-dextran 4kDa. Dams exposed to LNS compared to control showed an increase in the percentage of time spent building a nest (118%), self-grooming (69%), and putting the pups back to the nest (167%). LNS male and female pups exhibited a reduction of body weight by 5% and 4%, adrenal weights/100g body weight by 17% and 18%, corticosterone plasma levels by 64% and 62% and blood glucose by 11% and 12% respectively compared to same sex control pups. In male LNS pups, intestinal permeability was increased by 2.7-fold while no change was observed in females compared to same sex control. There was no sex difference in any of the parameters in control pups except the body weight. These data indicate that Wistar dams subjected to LNS during the first postnatal week have an altered repertoire of maternal behaviors which affects the development of the HPA axis in both sexes and intestinal barrier function in male offspring. C1 [Moussaoui, Nabila; Larauche, Muriel; Biraud, Mandy; Million, Mulugeta; Mayer, Emeran; Tache, Yvette] Univ Calif Los Angeles, Dept Med, Div Digest Dis, Ctr Neurobiol Stress,CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. [Moussaoui, Nabila; Larauche, Muriel; Biraud, Mandy; Million, Mulugeta; Mayer, Emeran; Tache, Yvette] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. [Moussaoui, Nabila; Larauche, Muriel; Biraud, Mandy; Million, Mulugeta; Mayer, Emeran; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Molet, Jenny] Univ Calif Irvine, Dept Anat Neurobiol, Irvine, CA 92697 USA. RP Moussaoui, N (reprint author), Univ Calif Los Angeles, Dept Med, Div Digest Dis, Ctr Neurobiol Stress,CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA.; Moussaoui, N (reprint author), Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA.; Moussaoui, N (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM NMoussaoui@mednet.ucla.edu FU National Institute of Health [P50 DK-64539, DK-41301, R01 DK-57238, K01 DK088937]; VA Career Scientist Award FX This work was supported by National Institute of Health grants P50 DK-64539 and Center Grant DK-41301 (Animal Model Core), R01 DK-57238, K01 DK088937, and VA Career Scientist Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 57 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 5 PY 2016 VL 11 IS 5 AR e0155037 DI 10.1371/journal.pone.0155037 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DL5KV UT WOS:000375676800111 PM 27149676 ER PT J AU Lui, HS Zhang, JS Makinson, SR Cahill, MK Kelley, KW Huang, HY Shang, YL Oldham, MC Martens, LH Gao, FY Coppola, G Sloan, SA Hsieh, CL Kim, CC Bigio, EH Weintraub, S Mesulam, MM Rademakers, R Mackenzie, IR Seeley, WW Karydas, A Miller, BL Borroni, B Ghidoni, R Farese, RV Paz, JT Barres, BA Huang, EJ AF Lui, Hansen Zhang, Jiasheng Makinson, Stefanie R. Cahill, Michelle K. Kelley, Kevin W. Huang, Hsin-Yi Shang, Yulei Oldham, Michael C. Martens, Lauren Herl Gao, Fuying Coppola, Giovanni Sloan, Steven A. Hsieh, Christine L. Kim, Charles C. Bigio, Eileen H. Weintraub, Sandra Mesulam, Marek-Marsel Rademakers, Rosa Mackenzie, Ian R. Seeley, William W. Karydas, Anna Miller, Bruce L. Borroni, Barbara Ghidoni, Roberta Farese, Robert V., Jr. Paz, Jeanne T. Barres, Ben A. Huang, Eric J. TI Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation SO CELL LA English DT Article ID FRONTOTEMPORAL LOBAR DEGENERATION; NEURONAL CEROID-LIPOFUSCINOSIS; OBSESSIVE-COMPULSIVE DISORDER; NETWORK ANALYSIS; DEMENTIA; MUTATION; CELLS; C1Q; TRANSCRIPTOME; ORGANIZATION AB Microglia maintain homeostasis in the brain, but whether aberrant microglial activation can cause neurodegeneration remains controversial. Here, we use transcriptome profiling to demonstrate that deficiency in frontotemporal dementia (FTD) gene progranulin (Grn) leads to an age-dependent, progressive upregulation of lysosomal and innate immunity genes, increased complement production, and enhanced synaptic pruning in microglia. During aging, Grn(-/-) mice show profound microglia infiltration and preferential elimination of inhibitory synapses in the ventral thalamus, which lead to hyperexcitability in the thalamocortical circuits and obsessive-compulsive disorder (OCD)-like grooming behaviors. Remarkably, deleting C1qa gene significantly reduces synaptic pruning by Grn(-/-) microglia and mitigates neurodegeneration, behavioral phenotypes, and premature mortality in Grn(-/-) mice. Together, our results uncover a previously unrecognized role of progranulin in suppressing aberrant microglia activation during aging. These results represent an important conceptual advance that complement activation and microglia-mediated synaptic pruning are major drivers, rather than consequences, of neurodegeneration caused by progranulin deficiency. C1 [Lui, Hansen; Zhang, Jiasheng; Cahill, Michelle K.; Huang, Hsin-Yi; Shang, Yulei; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA. [Makinson, Stefanie R.; Paz, Jeanne T.] Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA. [Makinson, Stefanie R.; Seeley, William W.; Karydas, Anna; Miller, Bruce L.; Paz, Jeanne T.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA. [Kelley, Kevin W.] Univ Calif San Francisco, Med Scientist Training Program, San Francisco, CA 94143 USA. [Oldham, Michael C.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94158 USA. [Martens, Lauren Herl] FORUM Pharmaceut, Waltham, MA 02451 USA. [Gao, Fuying; Coppola, Giovanni] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Sloan, Steven A.; Barres, Ben A.] Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA. [Hsieh, Christine L.] Univ Calif San Francisco, Immunol Sect, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Hsieh, Christine L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Kim, Charles C.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. [Bigio, Eileen H.; Weintraub, Sandra; Mesulam, Marek-Marsel] Northwestern Univ, Feinberg Sch Med, Northwestern Alzheimer Dis Ctr, Chicago, IL 60611 USA. [Rademakers, Rosa] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA. [Mackenzie, Ian R.] Univ British Columbia, Dept Pathol, Vancouver, BC V5Z 1M9, Canada. [Mackenzie, Ian R.] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada. [Seeley, William W.; Karydas, Anna; Miller, Bruce L.] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94158 USA. [Borroni, Barbara] Univ Brescia, Neurol Unit, Ctr Ageing Brain & Neurodegenerat Disorders, I-25100 Brescia, Italy. [Ghidoni, Roberta] IRCCS Ist Ctr San Giovanni Dio, Mol Markers Lab, I-25100 Brescia, Italy. [Farese, Robert V., Jr.] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA. [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA. [Lui, Hansen] UC Berkeley UCSF Joint Med Program JMP, Sch Publ Hlth, Berkeley, CA 94720 USA. [Huang, Hsin-Yi] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10002, Taiwan. [Kim, Charles C.] Verily, Mountain View, CA 94043 USA. RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.; Huang, EJ (reprint author), San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA. EM eric.huang2@ucsf.edu RI Ghidoni, Roberta/K-4507-2016 OI Ghidoni, Roberta/0000-0002-7691-1957; Huang, Eric/0000-0002-5381-3801; Kim, Charles/0000-0001-6474-8227 FU NIH [AG013854, P50 AG023501, P01 AG019724, P30 AI027763, P30 DK063720]; Italian Ministry of Health (Ricerca Corrente); JPB Foundation; Department of Veterans Affairs Career Development Award [BX002690, BX001108, RX002133]; Consortium for Frontotemporal Dementia Research (CFR); Bluefield Project FX We thank Ivy Hsieh for immunogold EM, Eric Bennett, Jordan Sorokin, and John Huguenard for their feedback on the Matlab code for analyzing the multi-unit recording in the thalamus, and Dr. Jennifer Cotter for critical comments on the manuscript. This work has been supported by NIH AG013854 (E.H.B.), P50 AG023501 and P01 AG019724 (B.L.M. and W.W.S.), P30 AI027763 and P30 DK063720 (C.C.K.), Italian Ministry of Health (Ricerca Corrente, R.G.), JPB Foundation (B.A.B.), Department of Veterans Affairs Career Development Award-2 (C.L.H.), Merit Awards BX002690 (C.L.H.) BX001108 (E.J.H.), and RX002133 (E.J.H.), and Consortium for Frontotemporal Dementia Research (CFR) and the Bluefield Project (B.L.M, W.W.S., and E.J.H.). Special thanks to Dr. Laura Mitic and Dr. Rodney Pearlman for their unwavering support. NR 41 TC 27 Z9 28 U1 8 U2 16 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAY 5 PY 2016 VL 165 IS 4 BP 921 EP 935 DI 10.1016/j.cell.2016.04.001 PG 15 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DL7DN UT WOS:000375800300019 PM 27114033 ER PT J AU Isvilanonda, V Iaquinto, JM Pai, S Mackenzie-Helnwein, P Ledoux, WR AF Isvilanonda, Vara Iaquinto, Joseph M. Pai, Shruti Mackenzie-Helnwein, Peter Ledoux, William R. TI Hyperelastic compressive mechanical properties of the subcalcaneal soft tissue: An inverse finite element analysis SO JOURNAL OF BIOMECHANICS LA English DT Article DE Foot; Finite element analysis; Plantar soft tissue; Material properties; Hyperelastic ID THERAPEUTIC FOOTWEAR; DESIGN; MODEL; PAD; VALIDATION; STIFFNESS; INSOLES; STRESS; ANKLE AB Finite element (FE) foot models can provide insight into soft tissue internal stresses and allow researchers to effectively conduct parametric analyses. Accurate plantar soft tissue material properties are essential for the development of FE foot models for clinical interventions. The aim of this study was to identify the first-order and second-order Ogden hyperelastic material properties of the subcalcaneal fat using an inverse FE analysis. The cylindrical soft tissue FE model was developed based on a priori in vitro dynamic compression experiment. The model simulated a 1 Hz triangle wave displacement to apply a compressive strain up to 48%. The hyperelastic properties were identified by systematically varying the material parameters to minimize the difference between the model predicted force and the target experimental data. Optimal material properties were obtained (mu(1)=0.0235 kPa and alpha(1)=12.07 for the first-order Ogden model and mu(1)=-4.629 x 10(-6) kPa, alpha(1)=-16.829; mu(2)=-1.613 kPa and alpha(2)=-1.043 for the second-order Ogden model). The second-order Ogden model was superior in capturing the highly nonlinear force-deformation response when compared to the first-order model (root mean square error (RMSE) 0.169 N vs. 0.570 N). The material sensitivity analysis indicated that the predicted force was strongly affected by the Poisson's ratio (12-fold increase in RMSE when reducing Poisson's ratio by 10% from the baseline) and the coefficient alpha(1) (3.2-fold and 32-fold increase in RMSE for both first-order and second-order Ogden models when increasing alpha(1) by 10% from the optimal value). Published by Elsevier Ltd. C1 [Isvilanonda, Vara; Iaquinto, Joseph M.; Pai, Shruti; Ledoux, William R.] Dept Vet Affairs, RR&D Ctr Limb Loss Prevent & Prosthet Engn, Seattle, WA USA. [Isvilanonda, Vara; Pai, Shruti; Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Mackenzie-Helnwein, Peter] Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, Ms 151 1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@uw.edu FU VA RRD Grant [A6973R] FX This work was supported in part by the VA RR&D Grant A6973R. The study sponsors had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. NR 32 TC 1 Z9 1 U1 6 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD MAY 3 PY 2016 VL 49 IS 7 BP 1186 EP 1191 DI 10.1016/j.jbiomech.2016.03.003 PG 6 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA DM0RB UT WOS:000376052400028 PM 27040391 ER PT J AU Volpp, KG AF Volpp, Kevin G. TI Price Transparency Not a Panacea for High Health Care Costs SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Wharton Sch Med & Hlth Care Management, Philadelphia VA Med Ctr, 423 Guardian Dr,1120 Blockley Hall, Philadelphia, PA 19104 USA. RP Volpp, KG (reprint author), Univ Penn, Perelman Sch Med, Wharton Sch Med & Hlth Care Management, Philadelphia VA Med Ctr, 423 Guardian Dr,1120 Blockley Hall, Philadelphia, PA 19104 USA. EM volpp70@exchange.upenn.edu NR 5 TC 1 Z9 1 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 3 PY 2016 VL 315 IS 17 BP 1842 EP 1843 DI 10.1001/jama.2016.4325 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DK9XF UT WOS:000375284400012 PM 27139056 ER PT J AU Crane, LA Dellavalle, RP AF Crane, Lori A. Dellavalle, Robert P. TI Recognizing Sun Safety as an Employee Health Issue SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID MELANOMA; US; COLORADO; EXPOSURE AB IMPORTANCE Skin cancer prevention remains a national priority. Reducing chronic UV radiation exposure for outdoor workers through sun-safety practices is an important step to help reduce the incidence of skin cancer. OBJECTIVE To determine the presence of occupational sun-safety policies at local government organizations in a single state. DESIGN, SETTING, AND PARTICIPANTS Of 571 potentially eligible local government organizations of Colorado cities, counties, and special tax districts, we enrolled 98 in a randomized pretest-posttest controlled experiment starting August 15, 2010, that evaluated an intervention to promote the adoption of sun-safety policies. We used a policy-coding protocol to evaluate personal sun-protection practices, environmental and administrative controls, and policy directives for sun safety starting February 10, 2011. We report the baseline assessment of the occupational sun-protection policies of these organizations. MAIN OUTCOMES AND MEASURES The presence of an occupational sun-safety policy. RESULTS Overall, 85 local government organizations (87%) had policies that required personal sun-protection practices, including the use of eyewear, hats, and protective clothing. However, of the 98 responding organizations, only 8 hat policies (8%), 10 eyewear policies (10%), and 7 clothing policies (7%) mentioned sun protection as the intent of the policy. Only cosmopoliteness, operationalized as proximity to an urban area, was associated with the presence of a sun-safety policy (odds ratio, 0.99 [95% CI, 0.98-1.00]; P = .02). CONCLUSIONS AND RELEVANCE Outdoorworkers are at increased risk for skin cancer because of long-term exposure to solar UV radiation. Although organizational policies have the potential to increase sun protection in occupational settings, occupational sun-safety policies were uncommon among local governments. Opportunities exist for dermatologists and other physicians to influence occupational sun-safety practices and policies, which are consistent with other safety procedures and could easily be integrated into existing workplace practices. C1 [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Anschutz Med Campus,13001 17th Pl,Box B119, Aurora, CO 80045 USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Aurora, CO USA. [Dellavalle, Robert P.] US Dept Vet Affairs, Dermatol Serv, Eastern Colorado Hlth Care Syst, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Crane, LA (reprint author), Univ Colorado, Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Anschutz Med Campus,13001 17th Pl,Box B119, Aurora, CO 80045 USA. EM lori.crane@ucdenver.edu NR 10 TC 0 Z9 0 U1 6 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAY 3 PY 2016 VL 315 IS 17 BP 1894 EP 1895 DI 10.1001/jama.2016.1008 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DK9XF UT WOS:000375284400018 PM 27139062 ER PT J AU Schwartz, JS Tajudeen, BA Cohen, NA AF Schwartz, Joseph S. Tajudeen, Bobby A. Cohen, Noam A. TI Medical management of chronic rhinosinusitis - an update SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY LA English DT Review DE aspirin desensitization; anti-IgE; topical irrigations; oral corticosteroids; antimicrobial therapy; intranasal corticosteroids; leukotriene antagonists; immunotherapy; Chronic rhinosinusitis; anti-IL 5 ID ENDOSCOPIC SINUS SURGERY; ADULT CHRONIC RHINOSINUSITIS; ALLERGIC FUNGAL RHINOSINUSITIS; RANDOMIZED CONTROLLED-TRIAL; NASAL POLYPS; LONG-TERM; SINONASAL IRRIGATIONS; POSTOPERATIVE CARE; MANUKA HONEY; DOUBLE-BLIND AB Chronic rhinosinusitis (CRS) is an epidemiologically important, chronic inflammatory disease process affecting the paranasal sinuses with significant and extensively reported economic implications. Despite an elusive pathophysiologic mechanism underlying this disease process, treatment outcomes are encouraging with the employment of an array of medical and surgical therapies. The goal of this paper is to provide a comprehensive, up to date analysis of the literature concerning the medical management of CRS by highlighting the most recent evidence based recommendations addressing this ongoing field of research. C1 [Schwartz, Joseph S.; Tajudeen, Bobby A.; Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,Ravdin 5, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Cohen, Noam A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Monell Chem Senses Ctr, 3500 Market St, Philadelphia, PA 19104 USA. RP Cohen, NA (reprint author), Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, 3400 Spruce St,Ravdin 5, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 NR 57 TC 3 Z9 3 U1 0 U2 10 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1751-2433 EI 1751-2441 J9 EXPERT REV CLIN PHAR JI Expert Rev. Clin. Pharmacol. PD MAY 3 PY 2016 VL 9 IS 5 BP 695 EP 704 DI 10.1586/17512433.2016.1150780 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DI8YO UT WOS:000373788600003 PM 26849215 ER PT J AU den Ouden, DB Dickey, MW Anderson, C Christianson, K AF den Ouden, Dirk-Bart Dickey, Michael Walsh Anderson, Catherine Christianson, Kiel TI Neural correlates of early-closure garden-path processing: Effects of prosody and plausibility SO QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY LA English DT Article DE Sentence processing; Prosody; Garden-path sentences; Plausibility; Functional magnetic resonance imaging ID SENTENCE COMPREHENSION; LANGUAGE COMPREHENSION; SYNTACTIC STRUCTURE; RIGHT-HEMISPHERE; WORKING-MEMORY; BROCAS AREA; AMBIGUOUS SENTENCES; CORTICAL REPRESENTATION; BRAIN ACTIVATION; CORPUS-CALLOSUM AB Functional magnetic resonance imaging (fMRI) was used to investigate neural correlates of early-closure garden-path sentence processing and use of extrasyntactic information to resolve temporary syntactic ambiguities. Sixteen participants performed an auditory picture verification task on sentences presented with natural versus flat intonation. Stimuli included sentences in which the garden-path interpretation was plausible, implausible because of a late pragmatic cue, or implausible because of a semantic mismatch between an optionally transitive verb and the following noun. Natural sentence intonation was correlated with left-hemisphere temporal activation, but also with activation that suggests the allocation of more resources to interpretation when natural prosody is provided. Garden-path processing was associated with upregulation in bilateral inferior parietal and right-hemisphere dorsolateral prefrontal and inferior frontal cortex, while differences between the strength and type of plausibility cues were also reflected in activation patterns. Region of interest (ROI) analyses in regions associated with complex syntactic processing are consistent with a role for posterior temporal cortex supporting access to verb argument structure. Furthermore, ROI analyses within left-hemisphere inferior frontal gyrus suggest a division of labour, with the anterior-ventral part primarily involved in syntactic-semantic mismatch detection, the central part supporting structural reanalysis, and the posterior-dorsal part showing a general structural complexity effect. C1 [den Ouden, Dirk-Bart] Univ S Carolina, Dept Commun Sci & Disorders, 915 Greene St, Columbia, SC 29208 USA. [Dickey, Michael Walsh] VA Pittsburgh Healthcare Syst, Commun Sci & Disorders, Pittsburgh, PA USA. [Dickey, Michael Walsh] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [Anderson, Catherine] McMaster Univ, Dept Linguist & Languages, Hamilton, ON, Canada. [Christianson, Kiel] Univ Illinois, Dept Educ Psychol, Champaign, IL USA. RP den Ouden, DB (reprint author), Univ S Carolina, Dept Commun Sci & Disorders, 915 Greene St, Columbia, SC 29208 USA. EM denouden@sc.edu OI Anderson, Catherine/0000-0002-7734-8422 FU McCausland Center for Brain Imaging, University of South Carolina FX This study was supported by the McCausland Center for Brain Imaging, University of South Carolina (M-funds, Den Ouden). It is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System. NR 90 TC 3 Z9 3 U1 6 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1747-0218 EI 1747-0226 J9 Q J EXP PSYCHOL JI Q. J. Exp. Psychol. PD MAY 3 PY 2016 VL 69 IS 5 SI SI BP 926 EP 949 DI 10.1080/17470218.2015.1028416 PG 24 WC Psychology, Biological; Physiology; Psychology; Psychology, Experimental SC Psychology; Physiology GA DG5FQ UT WOS:000372102000006 PM 25801097 ER PT J AU Hsieh, YH Tseng, CW Hu, CT Koo, M Leung, FW AF Hsieh, Yu-Hsi Tseng, Chih-Wei Hu, Chi-Tan Koo, Malcolm Leung, Felix W. TI Prospective Multicenter Randomized Controlled Trial Demonstrating Water Exchange (WE), But Not Water Immersion (WI), Significantly Increases Adenoma Detection Compared With Air Insufflation (AI) Even in Propofol Sedated Patients SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) / Meeting of the American-Society-for-Gastrointestinal-Endoscopy (ASGE) CY MAY 21-24, 2016 CL San Diego, CA SP Amer Soc Gastrointestinal Endoscopy C1 [Hsieh, Yu-Hsi; Tseng, Chih-Wei; Hu, Chi-Tan] Buddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan. [Hu, Chi-Tan] Hualien Tzu Chi Hosp, Gastroenterol, Hualien, Taiwan. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hill, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hsieh, Yu-Hsi; Tseng, Chih-Wei] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Div Gastroenterol, Chiayi, Taiwan. [Koo, Malcolm] Buddhist Tzu Chi Med Fdn, Dalin Tzu Chi Hosp, Dept Med Researc, Chiayi, Taiwan. [Koo, Malcolm] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA 1010 BP AB194 EP AB194 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU0PL UT WOS:000381906900190 ER PT J AU Overbey, D Robinson, TN Chapman, B Patel, SG Mengshol, JA Arcomano, TR Jones, EL AF Overbey, Douglas Robinson, Thomas N. Chapman, Brandon Patel, Swati G. Mengshol, John A. Arcomano, Todd R. Jones, Edward L. TI Patterns of Complications Associated With Endoscopic Energy-Based Devices SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) / Meeting of the American-Society-for-Gastrointestinal-Endoscopy (ASGE) CY MAY 21-24, 2016 CL San Diego, CA SP Amer Soc Gastrointestinal Endoscopy C1 [Overbey, Douglas; Chapman, Brandon; Jones, Edward L.] Univ Colorado, Surg, Aurora, CO USA. [Robinson, Thomas N.; Arcomano, Todd R.] Denver Vet Affairs Hosp, Surg, Denver, CO USA. [Patel, Swati G.; Mengshol, John A.] Univ Colorado, Gastroenterol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Sa1011 BP AB203 EP AB204 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU0PL UT WOS:000381906900215 ER PT J AU Shergill, A McQuaid, K Pereira, A Hsieh, CM Harris-Adamson, C Lee, DL Rempel, D AF Shergill, Amandeep McQuaid, Kenneth Pereira, Anna Hsieh, Chih Ming Harris-Adamson, Carisa Lee, David L. Rempel, David TI The Effect of an Anti-Gravity Support Device on Left Forearm Muscle Load During Simulated Colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) / Meeting of the American-Society-for-Gastrointestinal-Endoscopy (ASGE) CY MAY 21-24, 2016 CL San Diego, CA SP Amer Soc Gastrointestinal Endoscopy C1 [Shergill, Amandeep; McQuaid, Kenneth] Univ CA San Francisco, San Francisco Vet Affairs Med Ctr, Med, Gastroenterol, San Francisco, CA USA. [Harris-Adamson, Carisa; Rempel, David] Univ CA San Francisco, Occupat & Environm Med, San Francisco, CA USA. [Harris-Adamson, Carisa; Lee, David L.; Rempel, David] Univ CA Berkeley, Ergon, Richmond, CA USA. [Hsieh, Chih Ming] Univ CA Davis, Biomed Engn, Davis, CA USA. [Pereira, Anna] Microsoft, Redmond, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Sa1233 BP AB265 EP AB266 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU0PL UT WOS:000381906900373 ER PT J AU Shergill, A Harris-Adamson, C Lee, DL McQuaid, K Rempel, D AF Shergill, Amandeep Harris-Adamson, Carisa Lee, David L. McQuaid, Kenneth Rempel, David TI Ergonomic Evaluation of Colonoscopy: Assessment of Biomechanical Risk Factors Associated With Distal Upper Extremity Musculoskeletal Disorders in Endoscopists Performing Routine Colonoscopy SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) / Meeting of the American-Society-for-Gastrointestinal-Endoscopy (ASGE) CY MAY 21-24, 2016 CL San Diego, CA SP Amer Soc Gastrointestinal Endoscopy C1 [Shergill, Amandeep; McQuaid, Kenneth] Univ CA, San Francisco Vet Affairs Med Ctr, Med, Gastroenterol, San Francisco, CA USA. [Harris-Adamson, Carisa; Lee, David L.; Rempel, David] Univ CA, Ergon, Richmond, CA USA. [Harris-Adamson, Carisa; Rempel, David] Univ CA, Occupat & Environm Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA 886 BP AB180 EP AB180 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU0PL UT WOS:000381906900149 ER PT J AU Woodward, ZJ Rodriguez, Z Degnin, CR Chen, YY Thomas, CR Elta, GH D'Souza, SL AF Woodward, Zibing J. Rodriguez, Zaida Degnin, Catherine R. Chen, Yiyi Thomas, Charles R. Elta, Grace H. D'Souza, Sharlene L. TI Gender Disparities in Fourth Year Gastroenterology Fellowship Program Leadership in the United States SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) / Meeting of the American-Society-for-Gastrointestinal-Endoscopy (ASGE) CY MAY 21-24, 2016 CL San Diego, CA SP Amer Soc Gastrointestinal Endoscopy C1 [Woodward, Zibing J.; D'Souza, Sharlene L.] Oregon Hlth & Sci Univ, Gastroenterol, Portland, OR 97201 USA. [Woodward, Zibing J.; D'Souza, Sharlene L.] Portland VA Med Ctr, Gastroenterol, Portland, OR USA. [Rodriguez, Zaida] Oregon Hlth & Sci Univ, Internal Med, Portland, OR 97201 USA. [Rodriguez, Zaida] Portland VA Med Ctr, Internal Med, Portland, OR USA. [Degnin, Catherine R.; Chen, Yiyi] Oregon Hlth & Sci Univ, Biostat, Portland, OR 97201 USA. [Thomas, Charles R.] Oregon Hlth & Sci Univ, Radiat Oncol, Portland, OR 97201 USA. [Elta, Grace H.] Univ Michigan, Gastroenterol, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Sa1241 BP AB269 EP AB269 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU0PL UT WOS:000381906900381 ER PT J AU Woodward, ZJ Rodriguez, Z Chen, YY Thomas, CR Elta, GH D'Souza, SL AF Woodward, Zibing J. Rodriguez, Zaida Chen, Yiyi Thomas, Charles R. Elta, Grace H. D'Souza, Sharlene L. TI Gender Disparities in Academic Gastroenterology Fellowship Director Positions in the United States SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract CT Digestive Disease Week (DDW) / Meeting of the American-Society-for-Gastrointestinal-Endoscopy (ASGE) CY MAY 21-24, 2016 CL San Diego, CA SP Amer Soc Gastrointestinal Endoscopy C1 [Woodward, Zibing J.; D'Souza, Sharlene L.] Portland VA Med Ctr, Gastroenterol, Portland, OR USA. [Rodriguez, Zaida] Oregon Hlth & Sci Univ, Internal Med, Portland, OR 97201 USA. [Rodriguez, Zaida] Portland VA Med Ctr, Internal Med, Portland, OR USA. [Chen, Yiyi] Oregon Hlth & Sci Univ, Sch Publ Heath Biostat, Portland, OR 97201 USA. [Woodward, Zibing J.; D'Souza, Sharlene L.] Oregon Hlth & Sci Univ, Gastroenterol, Portland, OR 97201 USA. [Thomas, Charles R.] Oregon Hlth & Sci Univ, Radiat Oncol, Portland, OR 97201 USA. [Elta, Grace H.] Univ Michigan, Ann Arbor, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA 47 BP AB115 EP AB115 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU0PL UT WOS:000381906900005 ER PT J AU Augustine, MR Nelson, KM Fihn, SD Wong, E AF Augustine, Matthew R. Nelson, Karin M. Fihn, Stephan D. Wong, Edwin TI ACCESS TO THE VA: WHICH VETERANS ARE SEEKING PRIMARY CARE SERVICES? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Augustine, Matthew R.; Nelson, Karin M.; Fihn, Stephan D.; Wong, Edwin] Dept Vet Affairs, Seattle, WA USA. [Fihn, Stephan D.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2468914 BP S111 EP S111 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600048 ER PT J AU Beach, MC O'Conor, K Haywood, C Lanzkron, S Saha, S AF Beach, Mary Catherine O'Conor, Katie Haywood, Carlton Lanzkron, Sophie Saha, Somnath TI LANGUAGE USED IN MEDICAL RECORDS MAY REFLECT (UNCONSCIOUS) BIAS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Beach, Mary Catherine; O'Conor, Katie; Lanzkron, Sophie] Johns Hopkins Univ, Baltimore, MD USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Haywood, Carlton] Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2470492 BP S290 EP S290 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600363 ER PT J AU Borrero, S Callegari, LS Sileanu, F Zhao, XH Mor, M Switzer, GE Zickmund, SL Washington, DL Zephyrin, LC Schwarz, EB AF Borrero, Sonya Callegari, Lisa S. Sileanu, Florentina Zhao, Xinhua Mor, Maria Switzer, Galen E. Zickmund, Susan L. Washington, Donna L. Zephyrin, Laurie C. Schwarz, E. Bimla TI RATES OF UNINTENDED PREGNANCY, CONTRACEPTIVE USE, AND UNMET CONTRACEPTIVE NEED AMONG WOMEN VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Zephyrin, Laurie C.] Dept Vet Affairs, Washington, DC USA. [Schwarz, E. Bimla] Univ Calif Davis, Sacramento, CA 95817 USA. [Borrero, Sonya; Switzer, Galen E.] Univ Pittsburgh, Pittsburgh, PA USA. [Borrero, Sonya; Sileanu, Florentina; Zhao, Xinhua; Mor, Maria] VA Pittsburgh, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Washington, Donna L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Callegari, Lisa S.] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S382 EP S383 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601154 ER PT J AU Callon, W Beach, MC Saha, S Chander, G Wilson, I Laws, MB Sharp, VL Cohn, JA Moore, RD Korthuis, PT AF Callon, Wynne Beach, Mary Catherine Saha, Somnath Chander, Geetanjali Wilson, Ira Laws, Michael B. Sharp, Victoria L. Cohn, Jonathan A. Moore, Richard D. Korthuis, Philip T. TI ASSESSING PROBLEMATIC SUBSTANCE USE IN HIV CARE: WHICH QUESTIONS ELICIT ACCURATE PATIENT DISCLOSURES? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Wilson, Ira; Laws, Michael B.] Brown Univ, Providence, RI 02912 USA. [Moore, Richard D.] Johns Hopkins, Baltimore, MD USA. [Callon, Wynne] Johns Hopkins Sch Med, Baltimore, MD USA. [Beach, Mary Catherine; Chander, Geetanjali] Johns Hopkins Univ, Baltimore, MD USA. [Korthuis, Philip T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Sharp, Victoria L.] St Lukes Roosevelt Hosp, New York, NY 10025 USA. [Cohn, Jonathan A.] Wayne State Univ, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2437684 BP S125 EP S125 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600073 ER PT J AU Chang, W Walk, TJ Painter, T AF Chang, Woody Walk, Thomas J. Painter, Thomas TI WHEN CT IS NOT ENOUGH: USING EUS TO DETECT INSULINOMAS WHEN NONINVASIVE IMAGING IS NEGATIVE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Painter, Thomas] Univ Pittsburgh, Pittsburgh, PA USA. [Chang, Woody] Univ Pittsburgh, Med Ctr, Presbyterian Montefiore, Pittsburgh, PA USA. [Walk, Thomas J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S788 EP S789 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603145 ER PT J AU Cordasco, KM Zuchowski, JL Chrystal, JG Zephyrin, LC Hamilton, A AF Cordasco, Kristina M. Zuchowski, Jessica L. Chrystal, Joya G. Zephyrin, Laurie C. Hamilton, Alison TI THE ROLE OF VA PRIMARY CARE IN COORDINATING NON-VA GYNECOLOGIC ONCOLOGY CARE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Zephyrin, Laurie C.] Dept Vet Affairs, Washington, DC USA. [Cordasco, Kristina M.; Zuchowski, Jessica L.] US Dept Vet Affairs, North Hills, CA USA. [Hamilton, Alison] VA Greater Los Angeles, Los Angeles, CA USA. [Chrystal, Joya G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cordasco, Kristina M.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S432 EP S433 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601251 ER PT J AU Duan-Porter, W Goldstein, KM McDuffie, J Hughes, JM Clowse, M Klap, R Masilamani, V LaPointe, NA Nagi, A Gierisch, JM Williams, JW AF Duan-Porter, Wei Goldstein, Karen M. McDuffie, Jennifer Hughes, Jaime M. Clowse, Megan Klap, Ruth Masilamani, Varsha LaPointe, Nancy Allen Nagi, Avishek Gierisch, Jennifer M. Williams, John W. TI MAPPING THE EVIDENCE: INTERVENTION SEX EFFECTS FOR DEPRESSION, DIABETES, AND CHRONIC PAIN SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Clowse, Megan; LaPointe, Nancy Allen] Duke Univ, Durham, NC USA. [Duan-Porter, Wei; Goldstein, Karen M.; McDuffie, Jennifer; Masilamani, Varsha; Nagi, Avishek; Gierisch, Jennifer M.; Williams, John W.] Durham VA Hlth Serv Res & Dev, Durham, NC USA. [Duan-Porter, Wei; Goldstein, Karen M.; Gierisch, Jennifer M.; Williams, John W.] Duke Univ, Sch Med, Durham, NC USA. [Hughes, Jaime M.] Univ N Carolina, Chapel Hill, NC USA. [Klap, Ruth] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2464493 BP S296 EP S297 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600377 ER PT J AU Edwards, ST Helfrich, CD Hulen, E Williams, JL Clinton, WL Wood, GB Stewart, G AF Edwards, Samuel T. Helfrich, Christian D. Hulen, Elizabeth Williams, Jeffery L. Clinton, Walter L. Wood, Gordon B. Stewart, Greg TI DISCORDANCE IN PERCEIVED TASK RESPONSIBILITY BETWEEN NURSES AND PRIMARY CARE PROVIDERS AND BURNOUT IN VETERANS AFFAIRS PATIENT ALIGNED CARE TEAMS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Clinton, Walter L.] US Dept Vet Affairs, Seattle, WA USA. [Helfrich, Christian D.; Wood, Gordon B.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Edwards, Samuel T.; Hulen, Elizabeth; Williams, Jeffery L.] VA Portland Hlth Care Syst, Portland, OR USA. [Edwards, Samuel T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Stewart, Greg] VA Iowa Coty Hlth Care Syst, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S192 EP S193 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600190 ER PT J AU Evans, MW Rosenfeld, EA Borrero, S AF Evans, Mark W. Rosenfeld, Elian A. Borrero, Sonya TI SEXUAL BEHAVIORS AND SEXUALLY TRANSMITTED INFECTIONS AMONG MALE VETERANS AND NON-VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Evans, Mark W.; Borrero, Sonya] Univ Pittsburgh, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh, Pittsburgh, PA USA. [Rosenfeld, Elian A.; Borrero, Sonya] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S397 EP S397 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601184 ER PT J AU Frank, JW Lovejoy, T Becker, W Morasco, BJ Koenig, CJ Dischinger, HR Dobscha, S Krebs, EE AF Frank, Joseph W. Lovejoy, Travis Becker, William Morasco, Benjamin J. Koenig, Christopher J. Dischinger, Hannah R. Dobscha, Steven Krebs, Erin E. TI DOSE REDUCTION AND DISCONTINUATION OF LONG-TERM OPIOID THERAPY: A SYSTEMATIC REVIEW SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Krebs, Erin E.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Dobscha, Steven] Portland VA Med Ctr, Portland, OR USA. [Koenig, Christopher J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Koenig, Christopher J.] San Francisco Vet Affairs, San Francisco, CA USA. [Frank, Joseph W.] Univ Colorado, Sch Med, Aurora, CO USA. [Becker, William] VA Connecticut Healthcare Syst, West Haven, CT USA. [Frank, Joseph W.; Dischinger, Hannah R.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Morasco, Benjamin J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S200 EP S201 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600199 ER PT J AU Fuller, WS Long, J AF Fuller, William S. Long, Judith TI FACTORS PREDICTING IMPROVED GLYCEMIC CONTROL IN RESPONSE TO BEHAVIORAL SUPPORT INTERVENTIONS FOR POORLY CONTROLLED TYPE 2 DIABETES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Fuller, William S.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. [Long, Judith] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S224 EP S224 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600242 ER PT J AU Garg, M Mermel, L Hilliard, RW McNicoll, L AF Garg, Megha Mermel, Leonard Hilliard, Ross W. McNicoll, Lynn TI VAMPIRE MEDICINE: DO WE NEED ALL THESE BLOOD TESTS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Garg, Megha] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Mermel, Leonard; Hilliard, Ross W.; McNicoll, Lynn] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S921 EP S921 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603374 ER PT J AU Gelman, A Rosenfeld, EA Borrero, S AF Gelman, Amanda Rosenfeld, Elian A. Borrero, Sonya TI A QUALITATIVE ASSESSMENT OF ANTI-ABORTION ATTITUDES AMONG LOW-INCOME WOMEN UNDERGOING ABORTION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Gelman, Amanda] Univ Colorado, Sch Med, Denver, CO USA. [Borrero, Sonya] Univ Pittsburgh, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh, Pittsburgh, PA USA. [Rosenfeld, Elian A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S104 EP S105 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600037 ER PT J AU Giannitrapani, K Huynh, AK Schweizer, CA Hamilton, AB Hoggatt, KJ AF Giannitrapani, Karleen Huynh, Alexis K. Schweizer, Catherine A. Hamilton, Alison B. Hoggatt, Katherine J. TI PATIENT-CENTERED SUBSTANCE USE DISORDER TREATMENT FOR WOMEN VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Hamilton, Alison B.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Huynh, Alexis K.] Vet Affairs, Sepulveda, CA USA. [Giannitrapani, Karleen] Vet Hlth Adm, Menlo Pk, CA USA. [Schweizer, Catherine A.] Vet Hlth Adm, Los Angeles, CA USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hoggatt, Katherine J.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S328 EP S328 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601056 ER PT J AU Giannitrapani, K Ahluwalia, S McCaa, M Dobscha, S Krebs, EE Lorenz, K AF Giannitrapani, Karleen Ahluwalia, Sangeeta McCaa, Matthew Dobscha, Steven Krebs, Erin E. Lorenz, Karl TI BARRIERS TO UPTAKE OF NON-PHARMACOLOGIC PAIN MANAGEMENT STRATEGIES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Krebs, Erin E.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Dobscha, Steven] Portland VA Med Ctr, Portland, OR USA. [Ahluwalia, Sangeeta] RAND Corp, Encino, CA USA. [Giannitrapani, Karleen; McCaa, Matthew; Lorenz, Karl] Vet Hlth Adm, Menlo Pk, CA USA. [Lorenz, Karl] Stanford Univ, Stanford, CA 94305 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S133 EP S134 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600089 ER PT J AU Gupta, R Moriates, C Harrison, J Valencia, V Ong, M Clarke, R Steers, N Hays, RD Braddock, CH Wachter, RM AF Gupta, Reshma Moriates, Christopher Harrison, James Valencia, Victoria Ong, Michael Clarke, Robin Steers, Neil Hays, Ron D. Braddock, Clarence H. Wachter, Robert M. TI DEVELOPMENT OF A HIGH-VALUE CARE CULTURE SURVEY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Gupta, Reshma; Ong, Michael; Clarke, Robin; Steers, Neil; Hays, Ron D.; Braddock, Clarence H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Gupta, Reshma; Ong, Michael; Steers, Neil] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Syst, VA Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Moriates, Christopher; Harrison, James; Valencia, Victoria; Wachter, Robert M.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Moriates, Christopher] Univ Calif San Francisco, Ctr Healthcare Value, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S185 EP S186 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600177 ER PT J AU Gupta, R Schickedanz, A Arora, VM Braddock, CH AF Gupta, Reshma Schickedanz, Adam Arora, Vineet M. Braddock, Clarence H. TI COMPARING CLINICAL EXPERIENCES IN VALUE-BASED CARE AMONG INTERNAL MEDICINE RESIDENCY PROGRAMS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Gupta, Reshma; Braddock, Clarence H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Arora, Vineet M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Gupta, Reshma; Schickedanz, Adam] VA Greater Los Angeles Hlth Syst, VA UCLA Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Schickedanz, Adam] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S164 EP S164 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600140 ER PT J AU Helfrich, CD Simonetti, JA Clinton, WL Wood, GB Taylor, L Schectman, G Stark, R Fihn, SD Nelson, KM AF Helfrich, Christian D. Simonetti, Joseph A. Clinton, Walter L. Wood, Gordon B. Taylor, Leslie Schectman, Gordon Stark, Richard Fihn, Stephan D. Nelson, Karin M. TI PRIMARY CARE TEAM STAFFING AND TURNOVER HAVE STRONGER ASSOCIATION WITH BURNOUT THAN WORKLOAD AND PATIENT COMPLEXITY. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Helfrich, Christian D.; Simonetti, Joseph A.; Clinton, Walter L.; Wood, Gordon B.; Taylor, Leslie; Fihn, Stephan D.; Nelson, Karin M.] Dept Vet Affairs, Seattle, WA USA. [Stark, Richard] Dept Vet Affairs, Washington, DC USA. [Simonetti, Joseph A.] Univ Washington, Seattle, WA 98195 USA. [Fihn, Stephan D.; Nelson, Karin M.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. [Schectman, Gordon] Vet Affairs Cent Off, Milwaukee, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S366 EP S366 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601123 ER PT J AU Hoffman, EL Hariharan, J Lebduska, E Kohli, A AF Hoffman, Erika L. Hariharan, Jaishree Lebduska, Elena Kohli, Amar TI TEACHING POPULATION MANAGEMENT THROUGH A TEAM BASED HTN DISPARITY QI CURRICULUM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Kohli, Amar] UPMC, Mars, PA USA. [Hariharan, Jaishree; Lebduska, Elena] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Hoffman, Erika L.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hoffman, Erika L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S844 EP S845 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603247 ER PT J AU Hutt, E Jones, J Weber, M Albright, K Dischinger, HR O'Toole, T Doan, D Gruenewald, D AF Hutt, Evelyn Jones, Jacqueline Weber, Mary Albright, Karen Dischinger, Hannah R. O'Toole, Thomas Doan, Daniel Gruenewald, David TI ADDRESSINGTHE CHALLENGES OF PALLIATIVE CARE FOR HOMELESS VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Hutt, Evelyn] Denver VAMC, Denver, CO USA. [Jones, Jacqueline; Weber, Mary] Univ Colorado, AMC, Aurora, CO USA. [Dischinger, Hannah R.] Univ Colorado, Sch Med, Aurora, CO USA. [Hutt, Evelyn; Albright, Karen] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. [Albright, Karen] Univ Denver, Denver, CO USA. [O'Toole, Thomas] Providence VAMC, Providence, RI USA. [O'Toole, Thomas] Brown Univ, Providence, RI 02912 USA. [Doan, Daniel; Gruenewald, David] Seattle VAMC, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2470574 BP S113 EP S113 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600052 ER PT J AU Jensen, KM Campagna, EJ Juarez-Colunga, E McCabe, ER Prochazka, AV Runyan, DK AF Jensen, Kristin M. Campagna, Elizabeth J. Juarez-Colunga, Elizabeth McCabe, Edward R. Prochazka, Allan V. Runyan, Desmond K. TI ADHERENCE TO AGE-/GENDER-SPECIFIC PREVENTIVE CARE PATTERNS IN ADOLESCENTS AND ADULTS WITH DOWN SYNDROME SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Prochazka, Allan V.] Denver VAMC, Denver, CO USA. [Jensen, Kristin M.; Campagna, Elizabeth J.; Juarez-Colunga, Elizabeth] Univ Colorado, Aurora, CO USA. [Prochazka, Allan V.; Runyan, Desmond K.] Univ Colorado, Sch Med, Aurora, CO USA. [McCabe, Edward R.] March Dimes Fdn, White Plains, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2468686 BP S113 EP S114 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600053 ER PT J AU Jorgenson, J Prochazka, AV Gopal, RK AF Jorgenson, Joel Prochazka, Allan V. Gopal, Ravi K. TI SHOW ME THE DATA: WHERE IS THE NNT? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Prochazka, Allan V.; Gopal, Ravi K.] Denver VAMC, Denver, CO USA. [Jorgenson, Joel] Univ Colorado, Denver, CO 80202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S398 EP S398 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601186 ER PT J AU Kangovi, S Mitra, N Smith, RA Kulkarni, R Turr, LN Huo, HR Glanz, K Grande, D Long, J AF Kangovi, Shreya Mitra, Nandita Smith, Robyn A. Kulkarni, Raina Turr, Lindsey N. Huo, Hairong Glanz, Karen Grande, David Long, Judith TI DECISION-MAKING AND GOAL-SETTING IN A RANDOMIZED CONTROLLED TRIAL OF PATIENT-CENTERED SUPPORT FOR CHRONIC DISEASE MANAGEMENT SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Smith, Robyn A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Long, Judith] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Mitra, Nandita; Kulkarni, Raina; Turr, Lindsey N.; Huo, Hairong; Glanz, Karen; Grande, David; Long, Judith] Univ Penn, Philadelphia, PA 19104 USA. [Kangovi, Shreya] Univ Penn, Phialdelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S173 EP S174 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600157 ER PT J AU Karmo, S Clark, A Potoski, L Codario, R Hoffman, EL Rao, H AF Karmo, Stephanie Clark, Alexandra Potoski, Laura Codario, Ronald Hoffman, Erika L. Rao, Harsha TI EVALUATING THE EFFECTIVENESS OF A POLICY THAT ENCOURAGES CLINICAL REASONING BASED ON CLINICAL GUIDELINES IN THE DIAGNOSIS AND MANAGEMENT OF ANDROGEN DEFICIENCY IN THE VA PITTSBURGH HEALTHCARE SYSTEM (VAPHS). SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Karmo, Stephanie; Clark, Alexandra] UPMC, Pittsburgh, PA USA. [Hoffman, Erika L.] Univ Pittsburgh, VAPHS, Pittsburgh, PA USA. [Clark, Alexandra; Potoski, Laura; Rao, Harsha] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S215 EP S215 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600226 ER PT J AU Katz, DA Stewart, KR Paez, M Holman, J Adams, S Weg, MV Battaglia, C Joseph, A Titler, M Ono, SS AF Katz, David A. Stewart, Kenda R. Paez, Monica Holman, John Adams, Susan Weg, Mark Vander Battaglia, Catherine Joseph, Anne Titler, Marita Ono, Sarah S. TI NURSES' PERCEPTIONS IN IMPLEMENTING SMOKING CESSATION GUIDELINES FOR HOSPITALIZED VETERANS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Joseph, Anne] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Stewart, Kenda R.; Holman, John; Adams, Susan; Weg, Mark Vander] Dept Vet Affairs, Iowa City, IA USA. [Battaglia, Catherine] Eastern Colorado Healthcare Syst, Denver, CO USA. [Paez, Monica] Iowa City VA Hlth Care Syst, Iowa City, IA USA. [Katz, David A.] Univ Iowa, Iowa City, IA USA. [Ono, Sarah S.] Portland VA Med Ctr, CIVIC, Portland, OR USA. [Titler, Marita] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S314 EP S314 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601031 ER PT J AU Kennedy, AJ Sgro, G AF Kennedy, Amy J. Sgro, Gaetan TI BIRMINGHAM VOICES: DEVELOPING NARRATIVE COMPETENCY TO BETTER SERVE VULNERABLE POPULATIONS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Kennedy, Amy J.; Sgro, Gaetan] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Sgro, Gaetan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S806 EP S806 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603177 ER PT J AU Kertesz, S Kim, YI DeRussy, A Austin, EL Pollio, D Lukas, CV Holmes, S AF Kertesz, Stefan Kim, Young-il DeRussy, Aerin Austin, Erika L. Pollio, David Lukas, Carol VanDeusen Holmes, Sally TI POPULATION HEALTH AND ENDING HOMELESSNESS: CAN HOSPITALS RATIONALLY ALLOCATE SOCIAL BENEFITS? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Kertesz, Stefan; Kim, Young-il] Birmingham VA Med Ctr, Birmingham, AL USA. [Kertesz, Stefan; Kim, Young-il; Austin, Erika L.; Pollio, David] Univ Alabama Birmingham, Birmingham, AL USA. [DeRussy, Aerin; Lukas, Carol VanDeusen; Holmes, Sally] Boston VA Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S346 EP S346 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601089 ER PT J AU Kolehmainen, CJ Stahr, A Pribbenow, C Allard, CB Altman, L Baier, LM Brandt, C Gerber, MR Havens, K Haskell, SG Kerlikowske, K McNeil, M Moyer, R Phelan, CH Washington, DL Veet, L Carnes, M Yano, EM AF Kolehmainen, Christine J. Stahr, Anne Pribbenow, Christine Allard, Carolyn B. Altman, Lisa Baier, Linda M. Brandt, Cynthia Gerber, Megan R. Havens, Kathryn Haskell, Sally G. Kerlikowske, Karla McNeil, Melissa Moyer, Robin Phelan, Cynthia H. Washington, Donna L. Veet, Laure Carnes, Molly Yano, Elizabeth M. TI DEVELOPING A 'COMMUNITY OF PRACTICE' AMONG VA ADVANCED FELLOWSHIPS IN WOMEN'S HEALTH SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Gerber, Megan R.] Boston Univ, Jamaica Plain, MA USA. [Yano, Elizabeth M.] VA Greater Los Angeles HSR&D Ctr, Sepulveda, CA USA. [Haskell, Sally G.] Yale Univ, VA CT, Madison, CT USA. [Haskell, Sally G.] Yale Univ, VA Cent Off, Madison, CT USA. [Baier, Linda M.; Veet, Laure] Dept Vet Affairs, Washington, DC USA. [Kerlikowske, Karla] UCSF, San Francisco, CA USA. [McNeil, Melissa] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Pribbenow, Christine; Carnes, Molly] Univ Wisconsin, Madison, WI USA. [Stahr, Anne; Allard, Carolyn B.; Havens, Kathryn; Moyer, Robin] VA, Madison, WI USA. [Altman, Lisa; Washington, Donna L.] UCLA, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Kolehmainen, Christine J.; Phelan, Cynthia H.] William S Middleton Mem VA Hosptial, Madison, WI USA. [Brandt, Cynthia] VA Connecticut Healthcare Syst, West Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S815 EP S815 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603193 ER PT J AU Kryzhanovskaya, I Cohen, B Kohlwes, J AF Kryzhanovskaya, Irina Cohen, Beth Kohlwes, Jeff TI FACTORS ASSOCIATED WITH A CAREER IN PRIMARY CARE MEDICINE: RELATIONSHIPS MATTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Cohen, Beth] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco VA, San Francisco, CA 94143 USA. [Kryzhanovskaya, Irina] UCSF, San Francisco, CA USA. [Kohlwes, Jeff] UCSF, VAMC, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S222 EP S222 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600238 ER PT J AU Lam, C Sherbourne, C Tang, LQ Belin, TR Williams, P Young-Brinn, A Miranda, J Wells, KB AF Lam, Christine Sherbourne, Cathy Tang, Lingqi Belin, Thomas R. Williams, Pluscedia Young-Brinn, Angela Miranda, Jeanne Wells, Kenneth B. TI THE IMPACT OF COMMUNITY ENGAGEMENT ON HEALTH, SOCIAL, AND UTILIZATION OUTCOMES IN DEPRESSED IMPOVERISHED POPULATIONS: SECONDARY FINDINGS FROM A RANDOMIZED TRIAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Sherbourne, Cathy] RAND Corp, Santa Monica, CA USA. [Lam, Christine; Tang, Lingqi; Belin, Thomas R.; Miranda, Jeanne; Wells, Kenneth B.] Univ Calif Los Angeles, Los Angeles, CA USA. [Lam, Christine] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Williams, Pluscedia] Hlth African Amer Families II, Los Angeles, CA USA. [Williams, Pluscedia] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Young-Brinn, Angela] JD Pacada Fdn, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S421 EP S421 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601230 ER PT J AU Nelson, KM Taylor, L Silverman, JB Kiefer, MM Hebert, P Lessler, DS Krieger, J AF Nelson, Karin M. Taylor, Leslie Silverman, Julie B. Kiefer, Meghan M. Hebert, Paul Lessler, Daniel S. Krieger, Jim TI PEER SUPPORT FOR ACHIEVING INDEPENDENCE IN DIABETES (PEERAID): RESULTS OFA RANDOMIZED CONTROLLED TRIAL OF COMMUNITY HEALTH WORKER ASSISTED SELF-MANAGEMENT SUPPORT AMONG LOW-INCOME ADULTS WITH DIABETES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Nelson, Karin M.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. [Silverman, Julie B.] VA Puget Sound, Seattle, WA USA. [Taylor, Leslie; Hebert, Paul] VA HSR&D Seattle Denver Ctr Innovat Vet Ctr & Val, Seattle, WA USA. [Kiefer, Meghan M.; Lessler, Daniel S.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Krieger, Jim] Act Hlth Food, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S333 EP S334 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601066 ER PT J AU Nelson, KM Sylling, PW Taylor, L Helfrich, CD Rose, D Curtis, I Stark, R Schectman, G Fihn, SD AF Nelson, Karin M. Sylling, Philip W. Taylor, Leslie Helfrich, Christian D. Rose, Danielle Curtis, Idamay Stark, Richard Schectman, Gordon Fihn, Stephan D. TI IMPROVED TEAM FUNCTION ASSOCIATED WITH LOWER HEALTH CARE USE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Stark, Richard] Dept Veterans Affairs, Washington, DC USA. [Nelson, Karin M.; Fihn, Stephan D.] Univ Washington, VA Puget Sound, Seattle, WA USA. [Rose, Danielle] VA GLA Healthcare Syst, Sepulveda, CA USA. [Helfrich, Christian D.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Schectman, Gordon] Veterans Affairs Cent Off, Milwaukee, WI USA. [Sylling, Philip W.; Curtis, Idamay; Fihn, Stephan D.] Veterans Hlth Adm, Seattle, WA USA. [Taylor, Leslie] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S269 EP S269 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600327 ER PT J AU Nelson, KM Sylling, PW Taylor, L Curtis, I Rose, D Schectman, G Stark, R Fihn, SD AF Nelson, Karin M. Sylling, Philip W. Taylor, Leslie Curtis, Idamay Rose, Danielle Schectman, Gordon Stark, Richard Fihn, Stephan D. TI ELEMENTS OF THE PATIENT CENTERED MEDICAL HOME ASSOCIATED WITH CLINICAL QUALITY: EVIDENCE FOR ACCESS, CONTINUITY AND CARE COORDINATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Stark, Richard] Dept Vet Affairs, Washington, DC USA. [Nelson, Karin M.; Fihn, Stephan D.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA. [Rose, Danielle] VA GLA Healthcare Syst, Sepulveda, CA USA. [Schectman, Gordon] Vet Affairs Cent Off, Milwaukee, WI USA. [Sylling, Philip W.; Curtis, Idamay; Fihn, Stephan D.] Vet Hlth Adm, Seattle, WA USA. [Taylor, Leslie] VA Puget Sound, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S209 EP S210 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600216 ER PT J AU Ong, M Romano, PS Edgington, S Aronow, HU Auerbach, AD Black, JT De Marco, T Escarce, JJ Evangelista, LS Hanna, BH Ganiats, TG Greenberg, BH Greenfield, S Kaplan, SH Kimchi, A Liu, HH Lombardo, D Mangione, C Sadeghi, B Sadeghi, B Sarrafzadeh, M Tong, K Fonarow, G AF Ong, Michael Romano, Patrick S. Edgington, Sarah Aronow, Harriet U. Auerbach, Andrew D. Black, Jeanne T. De Marco, Teresa Escarce, Jose J. Evangelista, Lorraine S. Hanna, Barbara H. Ganiats, Theodore G. Greenberg, Barry H. Greenfield, Sheldon Kaplan, Sherrie H. Kimchi, Asher Liu, Honghu Lombardo, Dawn Mangione, Carol Sadeghi, Bahman Sadeghi, Banafsheh Sarrafzadeh, Majid Tong, Kathleen Fonarow, Gregg TI ADHERENCE TO REMOTE PATIENTMONITORING AFTER DISCHARGE OF HOSPITALIZED HEART FAILURE PATIENTS: THE BETTER EFFECTIVENESS AFTER TRANSITION - HEART FAILURE (BEAT-HF) RANDOMIZED CONTROLLED TRIAL SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Mangione, Carol; Fonarow, Gregg] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Romano, Patrick S.; Hanna, Barbara H.; Sadeghi, Banafsheh; Tong, Kathleen] Univ Calif Davis, Sacramento, CA USA. [Ong, Michael; Edgington, Sarah; Escarce, Jose J.; Liu, Honghu; Sadeghi, Bahman; Sarrafzadeh, Majid] Univ Calif Los Angeles, Los Angeles, CA USA. [Auerbach, Andrew D.] UCSF, Div Hosp Med, San Francisco, CA USA. [Ong, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Aronow, Harriet U.; Black, Jeanne T.; Kimchi, Asher] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [De Marco, Teresa] UC San Francisco, San Francisco, CA USA. [Evangelista, Lorraine S.; Greenfield, Sheldon; Kaplan, Sherrie H.; Lombardo, Dawn] UC Irvine, Irvine, CA USA. [Ganiats, Theodore G.; Greenberg, Barry H.] Univ Calif San Diego, La Jolla, CA USA. [Ganiats, Theodore G.] Univ Miami, Miami, FL USA. [Escarce, Jose J.] RAND, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2465761 BP S115 EP S115 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600056 ER PT J AU Patel, M Day, SC Small, D Zhu, JS Yang, L Honeywell, S Volpp, KG AF Patel, Mitesh Day, Susan C. Small, Dylan Zhu, Jingsan Yang, Lin Honeywell, Steven Volpp, Kevin G. TI USING ACTIVE CHOICE WITHIN THE ELECTRONIC HEALTH RECORD TO INCREASE COLORECTAL CANCER SCREENING RATES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Day, Susan C.; Small, Dylan; Zhu, Jingsan; Yang, Lin; Honeywell, Steven] Univ Penn, Philadelphia, PA 19104 USA. [Patel, Mitesh; Volpp, Kevin G.] Univ Penn, New York, NY USA. [Patel, Mitesh; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S455 EP S456 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601293 ER PT J AU Patel, M Volpp, KG Small, D Zhu, JS Yang, L Honeywell, S Day, SC AF Patel, Mitesh Volpp, Kevin G. Small, Dylan Zhu, Jingsan Yang, Lin Honeywell, Steven Day, Susan C. TI USING ACTIVE CHOICE WITHIN THE ELECTRONIC HEALTH RECORD TO INCREASE INFLUENZA VACCINATION RATES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Small, Dylan; Zhu, Jingsan; Yang, Lin; Honeywell, Steven; Day, Susan C.] Univ Penn, Philadelphia, PA 19104 USA. [Patel, Mitesh; Volpp, Kevin G.] Univ Penn, New York, NY USA. [Patel, Mitesh; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S456 EP S456 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601294 ER PT J AU Patel, M Day, SC Halpern, S Hanson, B Martinez, J Honeywell, S Volpp, KG AF Patel, Mitesh Day, Susan C. Halpern, Scott Hanson, Bill Martinez, Joseph Honeywell, Steven Volpp, Kevin G. TI CHANGE IN GENERIC MEDICATION PRESCRIBING RATES AFTER HEALTH SYSTEM-WIDE REDESIGN OF DEFAULT OPTIONS WITHIN THE ELECTRONIC HEALTH RECORD SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Day, Susan C.; Halpern, Scott; Hanson, Bill; Martinez, Joseph; Honeywell, Steven] Univ Penn, Philadelphia, PA 19104 USA. [Patel, Mitesh; Volpp, Kevin G.] Univ Penn, New York, NY USA. [Patel, Mitesh; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 MA 2467527 BP S148 EP S148 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600112 ER PT J AU Radomski, TR Zhao, XH Thorpe, CT Thorpe, JM Good, C Mor, M Fine, MJ Gellad, WF AF Radomski, Thomas R. Zhao, Xinhua Thorpe, Carolyn T. Thorpe, Joshua M. Good, Chester Mor, Maria Fine, Michael J. Gellad, Walid F. TI IS DUAL USE OF VA AND MEDICARE DIABETES SERVICES ASSOCIATED WITH ADVERSE HEALTH OUTCOMES? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Thorpe, Carolyn T.; Thorpe, Joshua M.] Univ Pittsburgh, Pittsburgh, PA USA. [Radomski, Thomas R.; Good, Chester; Fine, Michael J.; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Radomski, Thomas R.; Zhao, Xinhua; Thorpe, Carolyn T.; Thorpe, Joshua M.; Good, Chester; Mor, Maria; Fine, Michael J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S285 EP S286 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600356 ER PT J AU Reddy, A Huseman, T Canamucio, A Marcus, SC Asch, DA Volpp, KG Long, J AF Reddy, Ashok Huseman, Tiffany Canamucio, Anne Marcus, Steven C. Asch, David A. Volpp, Kevin G. Long, Judith TI EVALUATING INDIVIDUAL FEEDBACK AND PARTNER FEEDBACK TO IMPROVE STATIN MEDICATION ADHERENCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Huseman, Tiffany; Canamucio, Anne; Volpp, Kevin G.; Long, Judith] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Marcus, Steven C.; Asch, David A.] Univ Penn, Philadelphia, PA 19104 USA. [Reddy, Ashok] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S213 EP S213 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600222 ER PT J AU Robbins, JL McGinnis, KA Edelman, EJ Gordon, A Manhapra, A Fiellin, DA Moore, B Korthuis, PT Gaither, JR Gordon, KS Barry, D Crystal, S Justice, AC Kraemer, K AF Robbins, Jonathan L. McGinnis, Kathleen A. Edelman, E. J. Gordon, Adam Manhapra, Ajay Fiellin, David A. Moore, BrentA. Korthuis, Philip T. Gaither, J. R. Gordon, Kirsha S. Barry, Declan Crystal, Stephen Justice, Amy C. Kraemer, Kevin TI PREDICTORS OF INITIATING OPIOID AGONIST THERAPY IN A LARGE US COHORT OF HIV-INFECTED AND UNINFECTED PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Korthuis, Philip T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Robbins, Jonathan L.; Kraemer, Kevin] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Gordon, Adam] Univ Pittsburgh, Pittsburgh, PA USA. [McGinnis, Kathleen A.; Gordon, Adam] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fiellin, David A.; Gaither, J. R.] Yale Univ, New Haven, CT USA. [Justice, Amy C.] Yale Univ, West Haven, CT USA. [Edelman, E. J.; Barry, Declan] Yale Univ, Sch Med, New Haven, CT USA. [Manhapra, Ajay; Gordon, Kirsha S.] Yale Sch Med, New Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, New Brunswick, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S354 EP S354 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601104 ER PT J AU Rusiecki, J Schell, J Merriam, SB McNeil, M Spagnoletti, C AF Rusiecki, Jen Schell, Jane Merriam, Sarah B. McNeil, Melissa Spagnoletti, Carla TI AN INNOVATIVE SHARED DECISION MAKING CURRICULUM FOR INTERNAL MEDICINE RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Schell, Jane; Spagnoletti, Carla] Univ Pittsburgh, Pittsburgh, PA USA. [Rusiecki, Jen; Merriam, Sarah B.; McNeil, Melissa] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Rusiecki, Jen] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S803 EP S804 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603173 ER PT J AU Semere, W Agrawal, P Yun, K Di Bartolo, IM Annamalai, A Ross, JS AF Semere, Wagahta Agrawal, Pooja Yun, Katherine Di Bartolo, Isha M. Annamalai, Aniyizhai Ross, Joseph S. TI TIMING OF REFUGEE HEALTH ASSESSMENTS MAY BE ASSOCIATED WITH ACUTE HEALTHCARE UTILIZATION SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Semere, Wagahta] US Dept Vet Affairs, RWJF Clin Scholars Program, New Haven, CT USA. [Semere, Wagahta; Agrawal, Pooja; Di Bartolo, Isha M.; Annamalai, Aniyizhai; Ross, Joseph S.] Yale Univ, Sch Med, New Haven, CT USA. [Yun, Katherine] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S440 EP S440 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601264 ER PT J AU Shroff, S Jeong, K Rubio, D Donovan, AK Rosenfeld, EA Fischer, G AF Shroff, Swati Jeong, Kwonho Rubio, Doris Donovan, Anna K. Rosenfeld, Elian A. Fischer, Gary TI IMPROVING CHLAMYDIA SCREENING IN AN ACADEMIC PRIMARY CARE CLINIC SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Shroff, Swati; Jeong, Kwonho; Rubio, Doris; Donovan, Anna K.; Fischer, Gary] Univ Pittsburgh, Pittsburgh, PA USA. [Shroff, Swati; Rosenfeld, Elian A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S887 EP S888 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603320 ER PT J AU Shroff, S Bryk, J Fischer, G Simak, DM Wickline, D Peele, P Kapoor, WN AF Shroff, Swati Bryk, Jodie Fischer, Gary Simak, Deborah M. Wickline, Dennis Peele, Pamela Kapoor, Wishwa N. TI ENHANCED CARE PROGRAM, A MODEL FOR COMPLEX CARE MANAGEMENT: PRELIMINARY OUTCOMES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Shroff, Swati; Bryk, Jodie; Fischer, Gary; Simak, Deborah M.; Kapoor, Wishwa N.] Univ Pittsburgh, Pittsburgh, PA USA. [Shroff, Swati] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Wickline, Dennis; Peele, Pamela] UPMC Hlth Plan, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S877 EP S878 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603304 ER PT J AU Strewler, A Ewigman, N O'Brien, B Eng, JA Shunk, RL AF Strewler, Anna Ewigman, Nathan O'Brien, Bridget Eng, Jessica A. Shunk, Rebecca L. TI IMPLEMENTATION OF A TRAINEE-LED CASE CONFERENCE TO IMPROVE INTERPROFESSIONAL, TEAM-BASED CARE FOR HIGH COMPLEXITY PATIENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Ewigman, Nathan; O'Brien, Bridget; Eng, Jessica A.] SFVA UCSF, San Francisco, CA USA. [Strewler, Anna] San Francisco VA Med Ctr, San Bruno, CA USA. [Shunk, Rebecca L.] UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S795 EP S796 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603158 ER PT J AU Tcheung, LS Cordasco, K Danz, M Bell-Lewis, L Washington, DL AF Tcheung, Lueng S. Cordasco, KristinaM. Danz, Marjorie Bell-Lewis, LaShawnta Washington, Donna L. TI METHODS FOR MEASURING PRIMARY CARE PROVIDERS' QUALITY OF CARE FOR URINARY INCONTINENCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Tcheung, Lueng S.; Cordasco, KristinaM.; Danz, Marjorie; Bell-Lewis, LaShawnta; Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tcheung, Lueng S.; Cordasco, KristinaM.; Washington, Donna L.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA. [Danz, Marjorie] RAND, Santa Monica, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S302 EP S302 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601009 ER PT J AU Walk, TJ Sgro, G AF Walk, Thomas J. Sgro, Gaetan TI TRANSFORMING TRADITIONAL M&M INTO AN INTERACTIVE QI CONFERENCE SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Walk, Thomas J.] UPMC, Pittsburgh, PA USA. [Walk, Thomas J.; Sgro, Gaetan] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S852 EP S852 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603261 ER PT J AU Walker, M Jordan, L Caga-Anan, G Lan, C Von Marensdorff, H Bozkurt, B AF Walker, Megan Jordan, Lindsey Caga-Anan, Glynda Lan, Charlie Von Marensdorff, Hans Bozkurt, Biykem TI BUNDLED TRAINEE CENTERED INTERVENTIONS DRAMATICALLY IMPROVED ACUTE CARE LENGTH OF STAY IN A LARGE ACADEMIC TERTIARY CARE CENTER SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Walker, Megan; Jordan, Lindsey; Caga-Anan, Glynda; Lan, Charlie; Von Marensdorff, Hans; Bozkurt, Biykem] Baylor Coll Med, Houston, TX USA. [Jordan, Lindsey; Caga-Anan, Glynda] Michael E Debakey Med Ctr, Houston, TX USA. [Walker, Megan; Lan, Charlie; Von Marensdorff, Hans; Bozkurt, Biykem] Michael E DeBakey VA Med Ctr, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S866 EP S867 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603286 ER PT J AU Williams, DA AF Williams, David A. TI LEARN BEST THIS WAY! DEVELOPMENT AND IMPLEMENTATION OF A TEAM-BASED LEARNING CURRICULUM FOR INTERNAL MEDICINE CONTINUITY CLINIC RESIDENTS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Williams, David A.] Univ Colorado, Denver, CO 80202 USA. [Williams, David A.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S824 EP S824 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201603209 ER PT J AU Zuchowski, JL Hamilton, AB Washington, DL Gomez, AG Veet, L Cordasco, KM AF Zuchowski, Jessica L. Hamilton, Alison B. Washington, Donna L. Gomez, Arthur G. Veet, Laure Cordasco, Kristina M. TI WHAT DO WOMEN'S HEALTH PRIMARY CARE PROVIDERS NEED AND WANT TO KNOW?: LEARNING INTERESTS AND CONFIDENCE OF VA WOMEN'S HEALTH PCPS SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Veet, Laure] Dept Vet Affairs, Washington, DC USA. [Gomez, Arthur G.] Univ Calif Los Angeles, David Geffen Sch Med, Sepulveda, CA USA. [Zuchowski, Jessica L.] US Dept Vet Affairs, North Hills, CA USA. [Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare, Los Angeles, CA USA. [Cordasco, Kristina M.] Univ Calif Los Angeles, VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. [Veet, Laure] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S470 EP S471 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201601318 ER PT J AU Zuchowski, JL Chrystal, JG Hamilton, AB Zephyrin, LC Cordasco, KM AF Zuchowski, Jessica L. Chrystal, Joya G. Hamilton, Alison B. Zephyrin, Laurie C. Cordasco, Kristina M. TI COORDINATING VA-BASED CARE AND VA-PURCHASED CARE FOR GYNECOLOGIC MALIGNANCIES: CHALLENGES AND BEST PRACTICES SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT Meeting of the Society-of-General-Internal-Medicine (SGIM) CY MAY 11-14, 2015-2016 CL Hollywood, FL SP Soc Gen Internal Med C1 [Zephyrin, Laurie C.] US Dept Vet Affairs, Washington, DC USA. [Zuchowski, Jessica L.] US Dept Vet Affairs, North Hills, CA USA. [Chrystal, Joya G.; Hamilton, Alison B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cordasco, Kristina M.] Univ Calif Los Angeles, VA Greater Los Angles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2016 VL 31 SU 2 BP S168 EP S168 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EI0YL UT WOS:000392201600146 ER PT J AU Lo-Ciganic, W Gellad, WF Hiskamp, HA Choudhry, NK Zhang, R Chang, C Jones, BL Richards-Shubik, S Guclu, H Donohue, JM AF Lo-Ciganic, W. Gellad, W. F. Hiskamp, H. A. Choudhry, N. K. Zhang, R. Chang, C. Jones, B. L. Richards-Shubik, S. Guclu, H. Donohue, J. M. TI WHO WERE THE EARLY ADOPTERS OF DABIGATRAN? AN APPLICATION OF GROUP-BASED TRAJECTORY MODELS SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Lo-Ciganic, W.] Univ Arizona, Tucson, AZ USA. [Gellad, W. F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hiskamp, H. A.; Choudhry, N. K.] Harvard Med Sch, Boston, MA USA. [Choudhry, N. K.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Zhang, R.; Chang, C.; Guclu, H.; Donohue, J. M.] Univ Pittsburgh, Pittsburgh, PA USA. [Jones, B. L.] Carnegie Univ, Tuson, AZ USA. [Richards-Shubik, S.] Leigh Univ, Bethlehem, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2016 VL 19 IS 3 MA PCV106 BP A58 EP A58 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA DN2HZ UT WOS:000376886000320 ER PT J AU Basu, P Shah, NJ Kavali, L Aloysius, M Farhat, S AF Basu, Patrick Shah, Niraj J. Kavali, L. Aloysius, Mark Farhat, Sakina TI Low Titer Endomysial Antibody (EMA) in Non-Celiac Population Segregated From a Community With Immune Mediated Vasculitis. an Observational Study SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Aloysius, Mark] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. [Shah, Niraj J.] Univ N Carolina, Liver Transplant Ctr, Sch Med, Carolinas Med Ctr, Charlotte, NC USA. [Basu, Patrick] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Kavali, L.; Farhat, Sakina] Kings Cty Hosp Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Mo1361 BP AB469 EP AB469 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200343 ER PT J AU Hsieh, YH Binmoeller, K Leung, FW AF Hsieh, Yu-Hsi Binmoeller, Kenneth Leung, Felix W. TI Underwater Polypectomy: Heat-Sink Effect in an Experimental Model SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Hsieh, Yu-Hsi] Buddhist Dalin Tzu Chi Hosp, Dept Med, Div Gastroenterol, Chiayi, Taiwan. [Hsieh, Yu-Hsi] Buddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan. [Binmoeller, Kenneth] Calif Pacific Med Ctr, Intervent Endoscopy Serv, San Francisco, CA USA. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hill, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Su1664 BP AB385 EP AB385 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200134 ER PT J AU Woodward, ZJ Williams, JL Sonnenberg, A AF Woodward, Zibing J. Williams, Jeffrey L. Sonnenberg, Amnon TI Length of Work-Up in Gastrointestinal Bleeding SO GASTROINTESTINAL ENDOSCOPY LA English DT Meeting Abstract C1 [Woodward, Zibing J.; Sonnenberg, Amnon] OHSU, Gastroenterol, Portland, OR USA. [Williams, Jeffrey L.; Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAY PY 2016 VL 83 IS 5 SU S MA Mo1016 BP AB429 EP AB429 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EI5HF UT WOS:000392524200233 ER PT J AU Grudzen, CR Richardson, LD Johnson, PN Hu, M Wang, BH Ortiz, JM Kistler, EA Chen, A Morrison, S AF Grudzen, Corita R. Richardson, Lynne D. Johnson, Pauline N. Hu, Ming Wang, Binhuan Ortiz, Joanna M. Kistler, Emmett A. Chen, Angela Morrison, Sean TI Emergency Department-Initiated Palliative Care in Advanced Cancer A Randomized Clinical Trial SO JAMA ONCOLOGY LA English DT Article ID FUNCTIONAL ASSESSMENT; UNITED-STATES; CONSULTATION; COST; OUTCOMES; CAREGIVERS; CALIFORNIA; HOSPITALS; PROGRAMS; FATIGUE AB IMPORTANCE The delivery of palliative care is not standard of care within most emergency departments (EDs). OBJECTIVE To compare quality of life, depression, health care utilization, and survival in ED patients with advanced cancer randomized to ED-initiated palliative care consultation vs care as usual. DESIGN, SETTING, AND PARTICIPANTS A single-blind, randomized clinical trial of ED-initiated palliative care consultation for patients with advanced cancer vs usual care took place from June 2011 to April 2014 at an urban, academic ED at a quaternary care referral center. Adult patients with advanced cancer who were able to pass a cognitive screen, had never been seen by palliative care, spoke English or Spanish, and presented to the ED met eligibility criteria; 136 of 298 eligible patients were approached and enrolled in the ED and randomized via balanced block randomization. INTERVENTIONS Intervention participants received a comprehensive palliative care consultation by the inpatient team, including an assessment of symptoms, spiritual and/or social needs, and goals of care. MAIN OUTCOMES AND MEASURES The primary outcome was quality of life as measured by the change in Functional Assessment of Cancer Therapy-General Measure (FACT-G) score at 12 weeks. Secondary outcomes included major depressive disorder as measured by the Patient Health Questionnaire-9, health care utilization at 180 days, and survival at 1 year. RESULTS A total of 136 participants were enrolled, and 69 allocated to palliative care (mean [SD], 55.1 [13.1] years) and 67 were randomized to usual care (mean [SD], 57.8 [14.7] years). Quality of life, as measured by a change in FACT-G score from enrollment to 12 weeks, was significantly higher in patients randomized to the intervention group, who demonstrated a mean (SD) increase of 5.91 (16.65) points compared with 1.08 (16.00) in controls (P = .03 using the nonparametric Wilcoxon test). Median estimates of survival were longer in the intervention group than the control group: 289 (95% CI, 128-453) days vs 132 (95% CI, 80-302) days, although this did not reach statistical significance (P = .20). There were no statistically significant differences in depression, admission to the intensive care unit, and discharge to hospice. CONCLUSIONS AND RELEVANCE Emergency department-initiated palliative care consultation in advanced cancer improves quality of life in patients with advanced cancer and does not seem to shorten survival; the impact on health care utilization and depression is less clear and warrants further study. C1 [Grudzen, Corita R.; Johnson, Pauline N.; Hu, Ming; Wang, Binhuan; Ortiz, Joanna M.] NYU, Sch Med, New York, NY USA. [Richardson, Lynne D.; Kistler, Emmett A.; Morrison, Sean] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Chen, Angela] Rutgers Robert Wood Johnson Med Sch, Piscataway, NJ USA. [Morrison, Sean] James J Peters VA Med Ctr, Bronx, NY USA. RP Grudzen, CR (reprint author), NYU, 462 First Ave,Ste A345, New York, NY 10016 USA. EM corita.grudzen@nyumc.org OI Grudzen, Corita/0000-0003-3039-8497; Hu, Ming/0000-0002-6062-8794 FU Mentored Research Scholar Grant from the American Cancer Society; Mid-Career Investigator Award in Patient Oriented Research from the National Institute on Aging [K24 AG022345] FX The work was supported by a Mentored Research Scholar Grant from the American Cancer Society (Dr Grudzen) and by a Mid-Career Investigator Award in Patient Oriented Research (K24 AG022345) from the National Institute on Aging (Dr Morrison). NR 32 TC 8 Z9 9 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD MAY PY 2016 VL 2 IS 5 BP 591 EP 598 DI 10.1001/jamaoncol.2015.5252 PG 8 WC Oncology SC Oncology GA DW5KS UT WOS:000383684300008 ER PT J AU Kohli, P Ganz, P Ma, YF Scherzer, R Hur, S Weigel, B Grunfeld, C Deeks, S Wasserman, S Scott, R Hsue, PY AF Kohli, Payal Ganz, Peter Ma, Yifei Scherzer, Rebecca Hur, Sophia Weigel, Bernard Grunfeld, Carl Deeks, Steven Wasserman, Scott Scott, Rob Hsue, Priscilla Y. TI HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox" SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE hepatitis C virus; HIV; low-density lipoprotein cholesterol; proprotein convertase subtilisin kexin 9 ID HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; REACTIVE PROTEIN-LEVELS; CORONARY-HEART-DISEASE; MONOCLONAL-ANTIBODY; INFECTED PATIENTS; CARDIOVASCULAR-DISEASE; DRUG-INTERACTIONS; RANDOMIZED-TRIAL; ALCOHOL-PROBLEMS AB Background-Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population. HIV-infected individuals are at increased risk for cardiovascular events and have high rates of dyslipidemia and hepatitis C virus (HCV) coinfection, making PCSK9 inhibition a potentially attractive therapy. Methods and Results-We studied 567 participants from a clinic-based cohort to compare PCSK9 levels in patients with HIV/HCV coinfection (n=110) with those with HIV infection alone (n=385) and with uninfected controls (n=72). The mean age was 49 years, and the median LDL-C level was 100 mg/dL (IQR 77-124 mg/dL); 21% were taking statins. The 3 groups had similar rates of traditional risk factors. Total cholesterol, LDL-C, and high-density lipoprotein cholesterol levels were lower in coinfected patients compared with controls (P<0.001). PCSK9 was 21% higher in HIV/HCV-coinfected patients versus controls (95% CI 9-34%, P<0.001) and 11% higher in coinfected individuals versus those with HIV infection alone (95% CI 3-20%, P=0.008). After adjustment for cardiovascular risk factors, HIV/HCV coinfection remained significantly associated with 20% higher PCSK9 levels versus controls (95% CI 8-33%, P=0.001). Interleukin-6 levels increased in a stepwise fashion from controls (lowest) to HIVinfected to HIV/HCV-coinfected individuals (highest) and correlated with PCSK9 (r=0.11, P=0.018). Conclusions-Despite having lower LDL-C, circulating PCSK9 levels were increased in patients coinfected with HIV and HCV in parallel with elevations in the inflammatory, proatherogenic cytokine interleukin-6. Clinical trials should be conducted to determine the efficacy of targeted PCSK9 inhibition in the setting of HIV/HCV coinfection. C1 [Kohli, Payal; Ganz, Peter; Hur, Sophia; Weigel, Bernard; Hsue, Priscilla Y.] San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA 94110 USA. [Ma, Yifei; Scherzer, Rebecca; Grunfeld, Carl] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med UCSF, San Francisco, CA 94143 USA. [Deeks, Steven] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA. [Wasserman, Scott; Scott, Rob] Amgen Inc, Thousand Oaks, CA 91320 USA. RP Kohli, P (reprint author), San Francisco Gen Hosp, Div Cardiol, 1001 Potrero Ave, San Francisco, CA 94110 USA. EM payal.kohli.md@gmail.com FU San Francisco General Hospital; National Institutes of Health [K24AI112393]; Amgen, Inc. FX The study was sponsored by the San Francisco General Hospital and the National Institutes of Health (K24AI112393 to Dr Hsue) and funded by Amgen, Inc. NR 50 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD MAY PY 2016 VL 5 IS 5 AR e002683 DI 10.1161/JAHA.115.002683 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6BY UT WOS:000386711200006 ER PT J AU Glover, NG Sylvers, PD Shearer, EM Kane, MC Clasen, PC Epler, AJ Plumb-Vilardaga, JC Bonow, JT Jakupcak, M AF Glover, Natalie G. Sylvers, Patrick D. Shearer, Erika M. Kane, Mary-Catherine Clasen, Peter C. Epler, Amee J. Plumb-Vilardaga, Jennifer C. Bonow, Jordan T. Jakupcak, Matthew TI The Efficacy of Focused Acceptance and Commitment Therapy in VA Primary Care SO PSYCHOLOGICAL SERVICES LA English DT Article DE Acceptance and Commitment Therapy; efficacy; focused; primary care; VA ID STRESS SCALES DASS; FORM HEALTH SURVEY; PSYCHOMETRIC PROPERTIES; DEPRESSION ANXIETY; PHYSICAL-ACTIVITY; VALIDITY; QUESTIONNAIRE; METAANALYSIS AB Focused Acceptance & Commitment Therapy (FACT) is a brief intervention based on traditional Acceptance and Commitment Therapy (ACT). Although there is a growing body of research on the efficacy of ACT for a variety of populations and disorders, there is little research to date on the use of FACT in group settings. This project is 1 of the first of its kind, as it examines data on psychological flexibility, health and mental health status, and symptom reduction from a 4-week FACT group. Participants in this study were 51 patients who attended this group as part of routine clinical care in a VA integrated primary care and mental health setting. They completed pre- and posttreatment measures of well-being, depression, anxiety, stress, psychological flexibility, and perceptions of physical and mental health functioning. Pre-to posttreatment analyses of variance demonstrated large effects for quality of life, F(1,51) = 21.29, p < .001, eta(2) = 0.30, moderate effects for depressive symptoms, F(1, 51) = 11.47, p < .001, eta(2) = 0.08, and perceptions of mental health functioning (MCS scale), F(1, 51) = 9.67, p = .003, eta(2) = 0.11, and small effects for perceptions of perceived stress, F(1, 51) = 4.08, p = .04, eta(2) = 0.03, and physical health functioning (PCS scale), F(1, 51) = 6.60, p = .01, eta(2) = 0.08. There was a statistical trend for reductions in anxiety, F(1, 51) = 3.29, p = .07, eta(2) = 0.01, and a nonsignificant effect for psychological flexibility, F(1, 51) = 2.05, p = .16, eta(2) = 0.04. These data provide initial support for the implementation of a group-based FACT protocol within a VA primary care setting and help to lay a foundation for further, more controlled studies on Group FACT in future research. C1 [Glover, Natalie G.; Sylvers, Patrick D.; Shearer, Erika M.; Kane, Mary-Catherine; Epler, Amee J.; Plumb-Vilardaga, Jennifer C.; Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle, WA USA. [Sylvers, Patrick D.; Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Clasen, Peter C.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [Bonow, Jordan T.] VA Sierra Nevada Hlth Care Syst, Reno, NV USA. RP Glover, NG (reprint author), VA Puget Sound Amer Lake Div, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM natalie.glover@va.gov OI Glover, Natalie/0000-0002-3635-9176 NR 35 TC 1 Z9 1 U1 3 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD MAY PY 2016 VL 13 IS 2 SI SI BP 156 EP 161 DI 10.1037/ser0000062 PG 6 WC Psychology, Clinical SC Psychology GA DT8HB UT WOS:000381729600006 PM 27148950 ER PT J AU Saxon, AJ McCance-Katz, EF AF Saxon, Andrew J. McCance-Katz, Elinore F. TI Some Additional Considerations Regarding the American Society of Addiction Medicine National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use SO JOURNAL OF ADDICTION MEDICINE LA English DT Editorial Material DE buprenorphine; methadone; tobacco; treatment guidelines ID METHADONE-MAINTENANCE; RANDOMIZED-TRIAL; SERVICES; DEPENDENCE; STANDARD; DETOXIFICATION; BUPRENORPHINE; RETENTION; INDUCTION; IMPACT C1 [Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Ctr Excellence Subst Abuse Treatment & Educ, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [McCance-Katz, Elinore F.] Rhode Isl Dept Behav Hlth Dev Disabil & Hosp, Cranston, RI USA. RP Saxon, AJ (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Wy, Seattle, WA 98108 USA. EM asaxon@uw.edu NR 20 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2016 VL 10 IS 3 BP 140 EP 142 DI 10.1097/ADM.0000000000000219 PG 3 WC Substance Abuse SC Substance Abuse GA DS5RG UT WOS:000380839400003 PM 27223833 ER PT J AU Gordon, A Lo-Ciganic, WH Cochran, G Gellad, WF Cathers, T Donohue, JM AF Gordon, Adam Lo-Ciganic, Wei-Hsuan Cochran, Gerald Gellad, Walid F. Cathers, Terri Donohue, Julie M. TI Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow SO JOURNAL OF ADDICTION MEDICINE LA English DT Letter ID EPIDEMIC C1 [Gordon, Adam; Cochran, Gerald; Gellad, Walid F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Gordon, Adam; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam; Lo-Ciganic, Wei-Hsuan; Cochran, Gerald; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15260 USA. [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. [Cochran, Gerald] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15260 USA. [Cathers, Terri] Penn Dept Human Serv, Harrisburg, PA USA. [Gordon, Adam; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Gordon, A (reprint author), Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.; Gordon, A (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.; Gordon, A (reprint author), Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15260 USA. EM gordona@medschool.pitt.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2016 VL 10 IS 3 BP 210 EP 211 DI 10.1097/ADM.0000000000000210 PG 3 WC Substance Abuse SC Substance Abuse GA DS5RG UT WOS:000380839400016 PM 27223837 ER PT J AU Lamming, DW AF Lamming, Dudley W. TI Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE LA English DT Article ID LIFE-SPAN EXTENSION; GENETICALLY HETEROGENEOUS MICE; TERM CALORIC RESTRICTION; AMINO-ACID SUFFICIENCY; COMPLEX 2 MTORC2; DIETARY RESTRICTION; EXTENDS LIFE; MAMMALIAN TARGET; IN-VIVO; CAENORHABDITIS-ELEGANS AB Rapamycin is a Food and Drug Administration (FDA)-approved immunosuppressant and anticancer agent discovered in the soil of Easter Island in the early 1970s. Rapamycin is a potent and selective inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient signaling pathways. During the last decade, genetic and pharmaceutical inhibition of mTOR pathway signaling has been found to promote longevity in yeast, worms, flies, and mice. In this article, we will discuss the molecular biology underlying the effects of rapamycin and its physiological effects, evidence for rapamycin as an antiaging compound, mechanisms by which rapamycin may extend life span, and the potential limitations of rapamycin as an antiaging molecule. Finally, we will discuss possible strategies that may allow us to inhibit mTOR signaling safely while minimizing side effects, and reap the health, social, and economic benefits from slowing the aging process. C1 [Lamming, Dudley W.] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA. [Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Lamming, DW (reprint author), Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA.; Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu OI Lamming, Dudley/0000-0002-0079-4467 FU National Institutes of Health/National Institute of Aging (NIH/NIA) [K99/R00, AG041765] FX D.W.L. is supported in part by a K99/R00 Path-way to Independence Award from the National Institutes of Health/National Institute of Aging (NIH/NIA) (AG041765). This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 113 TC 2 Z9 2 U1 3 U2 8 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 2157-1422 J9 CSH PERSPECT MED JI Cold Spring Harb. Perspect. Med. PD MAY PY 2016 VL 6 IS 5 AR a025924 DI 10.1101/cshperspect.a025924 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DS0HT UT WOS:000380276900004 ER PT J AU Hamilton, JA Wu, Q Yang, P Luo, B Li, J Liu, SR Hsu, HC Mountz, JD AF Hamilton, Jennie A. Wu, Qi Yang, PingAr Luo, Bao Li, Jun liu, Shanrun Hsu, Hui-Chen Mountz, John D. TI Type I interferon signaling acts directly on transitional T2 B cells to promote RNP-Ag tolerance loss in BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Hamilton, Jennie A.; Wu, Qi; Yang, PingAr; Luo, Bao; Li, Jun; liu, Shanrun; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300246 ER PT J AU Hsu, HC Hamilton, JA Wu, Q Yang, PA Luo, B Xie, ST Liu, SR Li, J Mountz, JD AF Hsu, Hui-Chen Hamilton, Jennie A. Wu, Qi Yang, PingAr Luo, Bao Xie, Shutao Liu, Shanrun Li, Jun Mountz, John D. TI IL-17 receptor A signaling impedes NF-kappa B p50/p50 repressor and subverts B-cell anergy in BXD2 mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Hsu, Hui-Chen; Hamilton, Jennie A.; Wu, Qi; Yang, PingAr; Luo, Bao; Xie, Shutao; Liu, Shanrun; Li, Jun; Mountz, John D.] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302357 ER PT J AU Mountz, JD Hamilton, JA Wu, Q Yang, P Luo, B Liu, SR Li, J Hsu, HC AF Mountz, John D. Hamilton, Jennie Ann Wu, Qi Yang, PingAr Luo, Bao Liu, Shanrun Li, Jun Hsu, Hui-Chen TI Endogenous dsRNA and dsDNA sensing is increased in transitional B cells in BXD2 autoimmune-prone mice SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Mountz, John D.; Hamilton, Jennie Ann; Wu, Qi; Yang, PingAr; Luo, Bao; Liu, Shanrun; Li, Jun; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288300251 ER PT J AU Singh, I Samuvel, DJ Singh, AK Won, J AF Singh, Inderjit Samuvel, Devadoss J. Singh, Avtar K. Won, Jeseong TI Therapeutic efficacy of statins and AICAR in mitochondrial dysfunction in EAE SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Singh, Inderjit; Samuvel, Devadoss J.; Singh, Avtar K.; Won, Jeseong] Med Univ South Carolina, Charleston, SC USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302150 ER PT J AU Singh, RP Hahn, B Hossain, A AF Singh, Ram Pyare Hahn, Bevra Hossain, Awlad TI Expression of Interferon-inducible Genes is Influenced by Sex Hormones in SLE SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Singh, Ram Pyare; Hahn, Bevra; Hossain, Awlad] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Singh, Ram Pyare] VA Greater Los Angeles, Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 1 WC Immunology SC Immunology GA DS0LX UT WOS:000380288302359 ER PT J AU Won, J Saxena, N Samuvel, DJ Choi, S Singh, AK Singh, I AF Won, Jeseong Saxena, Nishant Samuvel, Devadoss J. Choi, Seungho Singh, Avtar K. Singh, Inderjit TI Novel mechanism in autoimmune regulation by S-nitrosoglutathione SO JOURNAL OF IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-of-Immunologists (AAI) CY MAY 13-17, 2016 CL Seattle, WA SP Amer Assoc Immunologists C1 [Won, Jeseong; Saxena, Nishant; Samuvel, Devadoss J.; Choi, Seungho; Singh, Avtar K.; Singh, Inderjit] Med Univ South Carolina, Charleston, SC USA. [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD MAY 1 PY 2016 VL 196 SU 1 PG 2 WC Immunology SC Immunology GA DS0LX UT WOS:000380288303083 ER PT J AU Dizon, M Linos, E Hills, N Chren, M AF Dizon, M. Linos, E. Hills, N. Chren, M. TI Quality of ambulatory skin cancer care at a fee-for-service practice and a Veterans Affairs clinic SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Dizon, M.; Linos, E.; Chren, M.] UCSF, Dermatol, San Francisco, CA USA. [Chren, M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Hills, N.] UCSF, Biostat & Epidemiol, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 140 BP S25 EP S25 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800140 ER PT J AU George, J Nihal, M Ndiaye, MA Ahmad, N AF George, J. Nihal, M. Ndiaye, M. A. Ahmad, N. TI SIRT3 manipulation affects tumor growth in vivo in NU/NU immunodeficient mice SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [George, J.; Nihal, M.; Ndiaye, M. A.; Ahmad, N.] Univ Wisconsin, Madison, WI USA. [Ahmad, N.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 635 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800635 ER PT J AU Karimkhani, C Wanga, V Coffeng, LE Naghavi, P Dellavalle, R Naghavi, M AF Karimkhani, C. Wanga, V. Coffeng, L. E. Naghavi, P. Dellavalle, R. Naghavi, M. TI Global burden of cutaneous leishmaniasis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Karimkhani, C.] Univ Hosp, Case Med Ctr, Dept Med, Cleveland, OH USA. [Wanga, V.; Coffeng, L. E.; Naghavi, P.; Naghavi, M.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Coffeng, L. E.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Rotterdam, Netherlands. [Dellavalle, R.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, R.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO USA. [Dellavalle, R.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 200 BP S35 EP S35 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800200 ER PT J AU Luo, Y Arcaroli, JJ Liu, S Kutty, LK Bagby, S Messersmith, W Fujita, M AF Luo, Y. Arcaroli, J. J. Liu, S. Kutty, L. K. Bagby, S. Messersmith, W. Fujita, M. TI CDK1 promotes tumor initiation by interacting with Sox2 and enhancing its function SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Luo, Y.; Liu, S.; Kutty, L. K.; Fujita, M.] Univ Colorado Denver, Dermatol, Aurora, CO USA. [Arcaroli, J. J.; Bagby, S.; Messersmith, W.] Univ Colorado Denver, Med, Aurora, CO USA. [Fujita, M.] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 617 BP S109 EP S109 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800617 ER PT J AU Pearson, DR Luo, Y Zhai, Z Couts, KL Azam, T Dinarello, CA Fujita, M AF Pearson, D. R. Luo, Y. Zhai, Z. Couts, K. L. Azam, T. Dinarello, C. A. Fujita, M. TI Alpha-1 antitrypsin suppresses melanoma growth by upregulating melanocyte differentiation antigens and enhancing T cell cytotoxicity SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Pearson, D. R.; Luo, Y.; Zhai, Z.; Couts, K. L.; Fujita, M.] Univ Colorado Denver SOM, Dept Dermatol, Aurora, CO USA. [Azam, T.; Dinarello, C. A.] Univ Colorado Denver SOM, Dept Med, Aurora, CO USA. [Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 611 BP S108 EP S108 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800611 ER PT J AU Rodriguez, CI Setaluri, V AF Rodriguez, C. I. Setaluri, V. TI Topical application of cyclic AMP modulators regulates melanoma tumor development and tumor growth SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Rodriguez, C. I.; Setaluri, V.] Univ Wisconsin, Dermatol, Madison, WI USA. [Rodriguez, C. I.; Setaluri, V.] Univ Wisconsin, Mol & Environm Toxicol, Madison, WI USA. [Setaluri, V.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 618 BP S110 EP S110 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800618 ER PT J AU Sendelweck, M Bell, E Ashack, K Pindyck, T Anderson, A Townley, C Dellavalle, R AF Sendelweck, M. Bell, E. Ashack, K. Pindyck, T. Anderson, A. Townley, C. Dellavalle, R. TI Indoor tanning associations with substance use among Colorado high school students SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Sendelweck, M.; Pindyck, T.] Univ Colorado, Denver, CO 80202 USA. [Dellavalle, R.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Bell, E.; Anderson, A.; Townley, C.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Ashack, K.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 203 BP S36 EP S36 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800203 ER PT J AU Wehner, MR Nead, KT Linos, E Chren, M AF Wehner, M. R. Nead, K. T. Linos, E. Chren, M. TI Body locations and gender differences in basal and squamous cell carcinoma of the skin SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Wehner, M. R.] Univ Penn, Dermatol, Philadelphia, PA 19104 USA. [Nead, K. T.] Univ Penn, Radiat Oncol, Philadelphia, PA 19104 USA. [Linos, E.; Chren, M.] Univ Calif San Francisco, Dermatol, San Francisco, CA 94143 USA. [Chren, M.] San Francisco VA Med Ctr, Dermatol, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 131 BP S24 EP S24 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800131 ER PT J AU Zhai, Z Liu, W Luo, Y Kaur, M Shellman, Y Norris, DA Dinarello, CA Spritz, R Fujita, M AF Zhai, Z. Liu, W. Luo, Y. Kaur, M. Shellman, Y. Norris, D. A. Dinarello, C. A. Spritz, R. Fujita, M. TI NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing caspase-3 activity in human melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology (SID) CY MAY 11-14, 2016 CL Scottsdale, AZ SP Soc Investigat Dermatol C1 [Zhai, Z.; Liu, W.; Luo, Y.; Kaur, M.; Shellman, Y.; Norris, D. A.; Fujita, M.] Univ Colorado Denver SOM, Dermatol, Aurora, CO USA. [Norris, D. A.; Fujita, M.] Denver VA Med Ctr, Denver, CO USA. [Dinarello, C. A.; Spritz, R.] Univ Colorado Denver SOM, Med, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD MAY PY 2016 VL 136 IS 5 SU 1 MA 647 BP S114 EP S114 PG 1 WC Dermatology SC Dermatology GA DR6RK UT WOS:000380028800647 ER PT J AU Sibila, O Garcia-Bellmunt, L Giner, J Rodrigo-Troyano, A Suarez-Cuartin, G Torrego, A Castillo, D Solanes, I Mateus, EF Vidal, S Sanchez-Reus, F Sala, E Cosio, BG Restrepo, MI Anzueto, A Chalmers, JD Plaza, V AF Sibila, Oriol Garcia-Bellmunt, Laia Giner, Jordi Rodrigo-Troyano, Ana Suarez-Cuartin, Guillermo Torrego, Alfons Castillo, Diego Solanes, Ingrid Mateus, Eder F. Vidal, Silvia Sanchez-Reus, Ferran Sala, Ernest Cosio, Borja G. Restrepo, Marcos I. Anzueto, Antonio Chalmers, James D. Plaza, Vicente TI Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Mucins are essential for airway defense against bacteria. We hypothesized that abnormal secreted airway mucin levels would be associated with bacterial colonization in patients with severe chronic obstructive pulmonary disease (COPD) Objectives: To investigate the relationship between mucin levels and the presence of potentially pathogenic micro-organisms in the airways of stable patients with severe COPD Methods: Clinically stable patients with severe COPD were examined prospectively. All patients underwent a computerized tomography scan, lung function tests, induced sputum collection, and bronchoscopy with bronchoalveolar lavage (BAL) and protected specimen brush. Patients with bronchiectasis were excluded. Secreted mucins (MUC2, MUC5AC, and MUC5B) and inflammatory markers were assessed in BAL and sputum by ELISA. Measurements and Main Results: Weenrolled 45 patients, with mean age (6SD) of 67 (68) years and mean FEV1 of 41 (610) % predicted. A total of 31% (n = 14) of patients had potentially pathogenic micro-organisms in quantitative bacterial cultures of samples obtained by protected specimen brush. Patients with COPD with positive cultures had lower levels of MUC2 both in BAL (P = 0.02) and in sputum (P = 0.01). No differences in MUC5B or MUC5AC levels were observed among the groups. Lower MUC2 levels were correlated with lower FEV1 (r = 0.32, P = 0.04) and higher sputum IL-6 (r = 20.40, P = 0.01). Conclusions: Airway MUC2 levels are decreased in patients with severe COPD colonized by potentially pathogenic micro-organisms. These findings may indicate one of the mechanisms underlying airway colonization in patients with severe COPD. C1 [Sibila, Oriol; Garcia-Bellmunt, Laia; Giner, Jordi; Rodrigo-Troyano, Ana; Suarez-Cuartin, Guillermo; Torrego, Alfons; Castillo, Diego; Solanes, Ingrid; Plaza, Vicente] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Serv Pneumol, Barcelona, Spain. [Sibila, Oriol; Garcia-Bellmunt, Laia; Giner, Jordi; Rodrigo-Troyano, Ana; Suarez-Cuartin, Guillermo; Torrego, Alfons; Castillo, Diego; Solanes, Ingrid; Mateus, Eder F.; Vidal, Silvia; Sanchez-Reus, Ferran; Plaza, Vicente] Inst Invest Biomed St Pau, Barcelona, Spain. [Mateus, Eder F.; Vidal, Silvia] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Expt Immunol Lab, Barcelona, Spain. [Sanchez-Reus, Ferran] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Microbiol Serv, Barcelona, Spain. [Sala, Ernest; Cosio, Borja G.] Hosp Son Espases, Inst Invest Sanitaria Palma, Serv Pneumol, Palma de Mallorca, Spain. [Sala, Ernest; Cosio, Borja G.] Ciber Enfermedades Resp, Madrid, Spain. [Restrepo, Marcos I.; Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Chalmers, James D.] Univ Dundee, Tayside Resp Res Grp, Dundee, Scotland. RP Sibila, O (reprint author), Hosp Santa Creu & Sant Pau, Serv Pneumol, C St Antoni M Claret 167, Barcelona 08025, Spain. EM osibila@santpau.cat OI Vidal, Silvia/0000-0002-3909-6682 FU Sociedad Espanola de Neumologia; Fundacio Catalana de Pneumologia; Instituto de Salud Carlos III [FIS PI 09/2567]; National Heart, Lung, and Blood Institute [K23HL096054] FX Supported by Sociedad Espanola de Neumologia, Fundacio Catalana de Pneumologia, and Instituto de Salud Carlos III grant FIS PI 09/2567; M.I.R. is partially funded by National Heart, Lung, and Blood Institute award K23HL096054. NR 0 TC 3 Z9 3 U1 1 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD MAY PY 2016 VL 13 IS 5 BP 636 EP 642 DI 10.1513/AnnalsATS.201512-797OC PG 7 WC Respiratory System SC Respiratory System GA DR7ST UT WOS:000380100700013 PM 26882402 ER PT J AU Moseson, EM Wiener, RS Golden, SE Au, DH Gorman, JD Laing, AD Deffebach, ME Slatore, CG AF Moseson, Erika M. Wiener, Renda Soylemez Golden, Sara E. Au, David H. Gorman, John D. Laing, Amber D. Deffebach, Mark E. Slatore, Christopher G. TI Patient and Clinician Characteristics Associated with Adherence A Cohort Study of Veterans with Incidental Pulmonary Nodules SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Many patients are diagnosed with small pulmonary nodules for which professional societies recommend subsequent imaging surveillance. Adherence to these guidelines involves many steps from both clinicians and patients but has not been well studied. Objectives: In a health care setting with a nodule tracking system, we evaluated the association of communication processes and distress with patient and clinician adherence to recommended follow up and Fleischner Society guidelines, respectively. Methods: We conducted a prospective, longitudinally assessed, cohort study of patients with incidentally detected nodules who received care at one Veterans Affairs Medical Center. We measured patient-centered communication with the Consultation Care Measure and distress with the Impact of Event Scale. We abstracted data regarding participant adherence to clinician recommendations (defined as receiving the follow-up scan within 30 d of the recommended date) and clinician adherence to Fleischner guidelines (defined as planning the follow-up scan within 30 d of the recommended interval) from the electronic medical record. We measured associations of communication and distress with adherence using multivariable-adjusted generalized estimating equations. Measurements and Main Results: Among 138 veterans, 39% were nonadherent at least once during follow up. Clinicians were nonadherent to Fleischner guidelines for 27% of follow-up scans. High-quality communication (adjusted odds ratio, 3.65; P = 0.02) and distress (adjusted odds ratio, 0.38; P = 0.02) were associated with increased and decreased participant adherence, respectively. Neither was associated with clinician adherence. Conclusions: Patients and clinicians often do not adhere to nodule follow-up recommendations. Interventions designed to improve communication quality and decrease distress may also improve patient adherence to nodule follow-up recommendations. C1 [Moseson, Erika M.] Legacy Hlth, Pulm & Crit Care Med, Portland, OR USA. [Moseson, Erika M.; Deffebach, Mark E.; Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02215 USA. [Golden, Sara E.; Slatore, Christopher G.] VA Portland Hlth Care Syst, Ctr Improve Vet Involvement Care, Portland, OR USA. [Gorman, John D.] VA Portland Hlth Care Syst, Dept Radiol, Portland, OR USA. [Laing, Amber D.; Deffebach, Mark E.; Slatore, Christopher G.] VA Portland Hlth Care Syst, Pulm & Crit Care Med Sect, Portland, OR USA. [Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Slatore, CG (reprint author), 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM christopher.slatore@va.gov OI Wiener, Renda/0000-0001-7712-2135; Slatore, Christopher/0000-0003-0958-8122 FU VA Health Services Research and Development Career Development Awards [CDA 09-025, CDP 11-227]; VA Portland Health Care System, Portland, Oregon; VA Puget Sound Healthcare System, Seattle, WA; Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts FX Supported by VA Health Services Research and Development Career Development Awards CDA 09-025 and CDP 11-227 (C.G.S.) and by resources from the VA Portland Health Care System, Portland, Oregon, the VA Puget Sound Healthcare System, Seattle, WA, and the Edith Nourse Rogers Memorial VA Hospital, Bedford, Massachusetts. The Department of Veterans Affairs did not have a role in the conduct of the study; in the collection, management, analysis, or interpretation of data; or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. Government. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD MAY PY 2016 VL 13 IS 5 BP 651 EP 659 DI 10.1513/AnnalsATS.201511-745OC PG 9 WC Respiratory System SC Respiratory System GA DR7ST UT WOS:000380100700015 PM 27144794 ER PT J AU Contrera, KJ Betz, J Deal, JA Choi, JS Ayonayon, HN Harris, T Helzner, E Martin, KR Mehta, K Pratt, S Rubin, SM Satterfield, S Yaffe, K Garcia, M Simonsick, EM Lin, FR AF Contrera, Kevin J. Betz, Josh Deal, Jennifer A. Choi, Janet S. Ayonayon, Hilsa N. Harris, Tamara Helzner, Elizabeth Martin, Kathryn R. Mehta, Kala Pratt, Sheila Rubin, Susan M. Satterfield, Suzanne Yaffe, Kristine Garcia, Melissa Simonsick, Eleanor M. Lin, Frank R. CA Hlth ABC Study TI Association of Hearing Impairment and Emotional Vitality in Older Adults SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Anxiety; Depression; Emotional vitality; Hearing; Mental health; Sensory impairment ID HEALTH; DEPRESSION; WOMEN; LIFE AB Objectives: To better understand the potential impact of hearing impairment (HI) and hearing aid use on emotional vitality and mental health in older adults. Method: We investigated the cross-sectional association of HI with emotional vitality in 1,903 adults aged 76-85 years in the Health ABC study adjusted for demographic and cardiovascular risk factors. Hearing was defined by the speech frequency pure tone average (no impairment < 25 dB, mild impairment 25-40 dB, and moderate or greater impairment > 40 dB). Emotional vitality was defined as having a high sense of personal mastery, happiness, low depressive symptomatology, and low anxiety. Results: Compared with individuals with no HI, participants with moderate or greater HI had a 23% lower odds of emotional vitality (odds ratio [OR] = 0.77; 95% confidence interval [CI]: 0.59-0.99). Hearing aid use was not associated with better emotional vitality (OR = 0.98; 95% CI: 0.81-1.20). Discussion: HI is associated with lower odds of emotional vitality in older adults. Further studies are needed to examine the longitudinal impact of HI on mental health and well-being. C1 [Contrera, Kevin J.; Choi, Janet S.; Pratt, Sheila] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Betz, Josh; Lin, Frank R.] Johns Hopkins Med Inst, Ctr Aging & Hlth, Baltimore, MD 21205 USA. [Deal, Jennifer A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Ayonayon, Hilsa N.; Rubin, Susan M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Harris, Tamara] NIA, Lab Epidemiol & Populat Sci, Baltimore, MD 21224 USA. [Helzner, Elizabeth] Suny Downstate Med Ctr, Dept Epidemiol & Biostat, Brooklyn, NY 11203 USA. [Martin, Kathryn R.] Univ Aberdeen, Inst Appl Hlth Sci, Sch Med & Dent, Aberdeen AB9 1FX, Scotland. [Mehta, Kala] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Pratt, Sheila] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Garcia, Melissa; Simonsick, Eleanor M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Lin, Frank R.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 2024 East Monument St,Suite 2-700, Baltimore, MD 21205 USA. RP Lin, FR (reprint author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, 2024 East Monument St,Suite 2-700, Baltimore, MD 21205 USA. EM flin1@jhmi.edu OI Betz, Joshua/0000-0003-4488-9799 FU NIH [K23DC011279]; Eleanor Schwartz Charitable Foundation; Triological Society; Johns Hopkins Institute for Clinical and Translational Research; NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; NIA Intramural Research Program FX This study was funded by the NIH grant K23DC011279; the Eleanor Schwartz Charitable Foundation; the Triological Society; the Johns Hopkins Institute for Clinical and Translational Research; the NIA contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; the NIA grant R01-AG028050; the NINR grant R01-NR012459; and the NIA Intramural Research Program. NR 22 TC 0 Z9 0 U1 8 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2016 VL 71 IS 3 BP 400 EP 404 DI 10.1093/geronb/gbw005 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA DR3PF UT WOS:000379814400002 PM 26883806 ER PT J AU McCrae, CS Dzierzewski, JM McNamara, JPH Vatthauer, KE Roth, AJ Rowe, MA AF McCrae, Christina S. Dzierzewski, Joseph M. McNamara, Joseph P. H. Vatthauer, Karlyn E. Roth, Alicia J. Rowe, Meredeth A. TI Changes in Sleep Predict Changes in Affect in Older Caregivers of Individuals with Alzheimer's Dementia: A Multilevel Model Approach SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES LA English DT Article DE Affect; Caregivers; Day-to-day relationships; Inconsistency; Mood; Sleep ID NEGATIVE AFFECT; ASSOCIATIONS; PERCEPTIONS; ADULTS AB Objectives: Understanding predictors of older dementia caregivers' mood could provide insight into potential treatments which may delay institutionalization of their care recipient. Research with older noncaregivers has shown that nights characterized by better subjective sleep were associated with days characterized by higher positive and lower negative affect, and vice versa. Examining daily relationships is important, as sleep and affect are state-like behaviors that fluctuate within individuals, across time. This study was a preliminary examination of whether a sample with a greater proportion of older dementia caregivers exhibits similar daily sleep/affect associations. Methods: Sleep diaries, actigraphy, and affect data were collected concurrently for 7 days in 55 community-dwelling, dementia caregivers (M = 62.80 years, SD = 12.21; 77.8% female). Sleep and affect were examined within- (day-to-day level) and between-persons (mean level). Results: Findings for older noncaregivers were replicated for negative affect only. Specifically, nights characterized by better subjective sleep were characterized by lower negative affect, and vice versa. Discussion: Examining older caregivers' daily sleep/affect association is important, because caregiving-related awakenings are unavoidable, often unpredictable, and can impact mood. Future research is needed to examine whether regularization in awakenings and/or negative affect represent important secondary, or even target, treatment outcomes for this vulnerable population. C1 [McCrae, Christina S.; Vatthauer, Karlyn E.; Roth, Alicia J.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA. [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [McNamara, Joseph P. H.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Rowe, Meredeth A.] Univ S Florida, Coll Nursing, Tampa, FL USA. RP McCrae, CS (reprint author), Univ Florida, Box 100165, Gainesville, FL 32610 USA. EM csmccrae@phhp.ufl.edu OI McCrae, Christina/0000-0003-4313-6867 FU National Institute of Nursing Research (NINR) at the National Institutes of Health [2R42 NR004952-02A2]; National Institute of Aging at the National Institutes of Health [R21 AG024459, L30 AG024875, F31 AG032802-0] FX This work was supported by the National Institute of Nursing Research (NINR) at the National Institutes of Health (2R42 NR004952-02A2 to M. A. Rowe); and the National Institute of Aging at the National Institutes of Health (R21 AG024459 and L30 AG024875 to C. S. McCrae, F31 AG032802-0 to J. M. Dzierzewski). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA and NINR. NR 16 TC 0 Z9 0 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5014 EI 1758-5368 J9 J GERONTOL B-PSYCHOL JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci. PD MAY PY 2016 VL 71 IS 3 BP 458 EP 462 DI 10.1093/geronb/gbu162 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology, Multidisciplinary SC Geriatrics & Gerontology; Psychology GA DR3PF UT WOS:000379814400009 PM 25429026 ER PT J AU Katz, PP Barton, J Trupin, L Schmajuk, G Yazdany, J Ruiz, PJ Yelin, E AF Katz, Patricia P. Barton, Jennifer Trupin, Laura Schmajuk, Gabriela Yazdany, Jinoos Ruiz, Pedro J. Yelin, Edward TI Poverty, Depression, or Lost in Translation? Ethnic and Language Variation in Patient-Reported Outcomes in Rheumatoid Arthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID VULNERABLE US HISPANICS; HEALTH LITERACY; DISEASE-ACTIVITY; DISPARITIES; DISABILITY; ASSOCIATION; PROFICIENCY; SEVERITY; MINORITY; SYMPTOMS AB Objective. Despite advances in therapies, disparities in outcomes have been documented for rheumatoid arthritis (RA) patients for both ethnicity and English language proficiency. The goals of these analyses were to compare differences in RA patient-reported outcomes, by both self-identification of ethnicity and English language proficiency, and to identify factors that might explain differences among groups. Methods. Data were collected through structured telephone interviews of a longitudinal cohort with physician-diagnosed RA (n=438); only women were included (n=335). Three groups were defined based on self-reported ethnicity and English proficiency: white/English (n=219), Hispanic/English (n=39), and Hispanic/Spanish (n=77). Outcomes examined were patient-reported physical functioning, pain, and presence of moderate or severe fatigue. Multivariate regression analyses compared outcomes among groups, adjusting for sociodemographic characteristics, health and disease factors, and depression. Results. Hispanic/Spanish women had worse function, pain, and fatigue than either English-proficient group. Depression was associated with all outcomes (P < 0.0001), and accounted for greater differentials in scores than ethnicity/language proficiency. In interaction analyses, differences between women who were and were not depressed were greater for Hispanic/English than for Hispanic/Spanish. Nondepressed Hispanic/Spanish scores were significantly worse than nondepressed Hispanic/English, i.e., the impact of depression was less for Hispanic/Spanish women because both depressed and nondepressed women in this group reported worse outcomes. After adjustment for sociodemographic factors and depression, language remained significantly associated with outcomes. Conclusion. Disparities in patient-reported outcomes may be driven less by ethnicity than by sociodemographic or psychological factors. Measurement instruments that are not culturally appropriate and equivalent may also hamper meaningful analyses of disparities. C1 [Katz, Patricia P.; Trupin, Laura; Schmajuk, Gabriela; Yazdany, Jinoos; Yelin, Edward] Univ Calif San Francisco, 3333 Calif St,Suite 270, San Francisco, CA 94143 USA. [Barton, Jennifer] Portland VA Med Ctr, Portland, OR USA. [Ruiz, Pedro J.] Calif Pacific Med Ctr, San Francisco, CA USA. RP Katz, PP (reprint author), Univ Calif San Francisco, 3333 Calif St,Suite 270, San Francisco, CA 94143 USA. EM patti.katz@ucsf.edu FU National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH [P-60-AR-053308]; Rosalind Russell Medical Research Center for Arthritis FX Supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH (P-60-AR-053308) and by the Rosalind Russell Medical Research Center for Arthritis. NR 31 TC 1 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2016 VL 68 IS 5 BP 621 EP 628 DI 10.1002/acr.22748 PG 8 WC Rheumatology SC Rheumatology GA DQ9UC UT WOS:000379553800007 PM 26414775 ER PT J AU de Lautour, H Taylor, WJ Adebajo, A Alten, R Burgos-Vargas, R Chapman, P Cimmino, MA Pinheiro, GDC Day, R Harrold, LR Helliwell, P Janssen, M Kerr, G Kavanaugh, A Khanna, D Khanna, PP Lin, C Louthrenoo, W McCarthy, G Vazquez-Mellado, J Mikuls, TR Neogi, T Ogdie, A Perez-Ruiz, F Schlesinger, N Schumacher, HR Scire, CA Singh, JA Sivera, F Slot, O Stamp, LK Tausche, AK Terkeltaub, R Uhlig, T van de Laar, M White, D Yamanaka, H Zeng, XJ Dalbeth, N AF de Lautour, Hugh Taylor, William J. Adebajo, Ade Alten, Rieke Burgos-Vargas, Ruben Chapman, Peter Cimmino, Marco A. Castelar Pinheiro, Geraldo da Rocha Day, Ric Harrold, Leslie R. Helliwell, Philip Janssen, Matthijs Kerr, Gail Kavanaugh, Arthur Khanna, Dinesh Khanna, Puja P. Lin, Chingtsai Louthrenoo, Worawit McCarthy, Geraldine Vazquez-Mellado, Janitzia Mikuls, Ted R. Neogi, Tuhina Ogdie, Alexis Perez-Ruiz, Fernando Schlesinger, Naomi Schumacher, H. Ralph Scire, Carlo A. Singh, Jasvinder A. Sivera, Francisca Slot, Ole Stamp, Lisa K. Tausche, Anne-Kathrin Terkeltaub, Robert Uhlig, Till van de Laar, Mart White, Douglas Yamanaka, Hisashi Zeng, Xuejun Dalbeth, Nicola TI Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises SO ARTHRITIS CARE & RESEARCH LA English DT Article ID OUTCOME DOMAINS; RESPONSE CRITERIA; CLINICAL-TRIALS; MANAGEMENT; PROGRESS; TOPHUS AB Objective. To establish consensus for potential remission criteria to use in clinical trials of gout. Methods. Experts (n=88) in gout from multiple countries were invited to participate in a web-based questionnaire study. Three rounds of Delphi consensus exercises were conducted using SurveyMonkey, followed by a discrete-choice experiment using 1000Minds software. The exercises focused on identifying domains, definitions for each domain, and the timeframe over which remission should be defined. Results. There were 49 respondents (56% response) to the initial survey, with subsequent response rates ranging from 57% to 90%. Consensus was reached for the inclusion of serum urate (98% agreement), flares (96%), tophi (92%), pain (83%), and patient global assessment of disease activity (93%) as measurement domains in remission criteria. Consensus was also reached for domain definitions, including serum urate (<0.36 mm), pain (<2 on a 10-point scale), and patient global assessment (<2 on a 10-point scale), all of which should be measured at least twice over a set time interval. Consensus was not achieved in the Delphi exercise for the timeframe for remission, with equal responses for 6 months (51%) and 1 year (49%). In the discrete-choice experiment, there was a preference towards 12 months as a timeframe for remission. Conclusion. These consensus exercises have identified domains and provisional definitions for gout remission criteria. Based on the results of these exercises, preliminary remission criteria are proposed with domains of serum urate, acute flares, tophus, pain, and patient global assessment. These preliminary criteria now require testing in clinical data sets. C1 [de Lautour, Hugh] Auckland Dist Hlth Board, Auckland, New Zealand. [Taylor, William J.] Univ Otago, Wellington, New Zealand. [Adebajo, Ade] Univ Sheffield, Sheffield, S Yorkshire, England. [Alten, Rieke] Charite, Schlosspk Klin, Berlin, Germany. [Burgos-Vargas, Ruben; Vazquez-Mellado, Janitzia] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Chapman, Peter] Christchurch Hosp, Christchurch, New Zealand. [Cimmino, Marco A.] Univ Genoa, Genoa, Italy. [Castelar Pinheiro, Geraldo da Rocha] Ernesto Univ Hosp, Rio De Janeiro, Brazil. [Day, Ric] Univ New S Wales, Sydney, NSW, Australia. [Day, Ric] St Vincents Hosp, Sydney, NSW, Australia. [Harrold, Leslie R.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Harrold, Leslie R.] Corrona LLC, Southborough, MA USA. [Helliwell, Philip] Leeds Inst Rheumat, Leeds, W Yorkshire, England. [Helliwell, Philip] Musculoskeletal Med, Leeds, W Yorkshire, England. [Janssen, Matthijs] Rijnstate Hosp, Arnhem, Netherlands. [Kerr, Gail] Georgetown Univ Hosp, Vet Affairs Med Ctr, Washington, DC 20007 USA. [Kerr, Gail] Howard Univ Hosp, Washington, DC 20007 USA. [Kavanaugh, Arthur] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Khanna, Dinesh; Khanna, Puja P.] Univ Michigan, Ann Arbor, MI 48109 USA. [Khanna, Puja P.] Ann Arbor VA Med Ctr, Ann Arbor, MI USA. [Lin, Chingtsai] Taichung Vet Gen Hosp, Taichung, Taiwan. [Louthrenoo, Worawit] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand. [McCarthy, Geraldine] Mater Misericordiae Univ Hosp, Dublin, Ireland. [McCarthy, Geraldine] Univ Coll, Dublin, Ireland. [Mikuls, Ted R.] Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Neogi, Tuhina] Boston Univ, Sch Med, Boston, MA 02118 USA. [Ogdie, Alexis; Schumacher, H. Ralph] Univ Penn, Philadelphia, PA 19104 USA. [Perez-Ruiz, Fernando] Hosp Univ Cruces, OSI EEC, Biscay, Spain. [Perez-Ruiz, Fernando] Biocruces Hlth Res Inst, Biscay, Spain. [Schlesinger, Naomi] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Scire, Carlo A.] Univ Pavia, IRCCS Policlin San Matteo Fdn, Pavia, Italy. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Sivera, Francisca] Hosp Gen Univ Elda, Elda, Spain. [Slot, Ole] Copenhagen Univ Hosp Glostrup, Glostrup, Denmark. [Stamp, Lisa K.] Univ Otago, Christchurch, New Zealand. [Tausche, Anne-Kathrin] Univ Hosp Carl Gustav Carus, Dresden, Germany. [Terkeltaub, Robert] Univ Calif San Diego, La Jolla, CA USA. [Terkeltaub, Robert] VA Med Ctr, La Jolla, CA USA. [Uhlig, Till] Diakonhjemmet Hosp, Natl Advisory Unit Rehabil Rheumatol, Oslo, Norway. [van de Laar, Mart] Univ Twente, Erschede, Netherlands. [White, Douglas] Univ Auckland, Waikato DHB, Hamilton, New Zealand. [White, Douglas] Univ Auckland, Waikato Clin Sch, Hamilton, New Zealand. [Yamanaka, Hisashi] Tokyo Womens Med Univ, Tokyo, Japan. [Zeng, Xuejun] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China. [Zeng, Xuejun] Peking Union Med Coll, Beijing, Peoples R China. [Dalbeth, Nicola] Univ Auckland, Auckland, New Zealand. [Dalbeth, Nicola] Auckland Dist Hlth Board, Auckland, New Zealand. RP de Lautour, H (reprint author), Auckland Dist Hlth Board, Auckland, New Zealand. EM hughdl@adhb.govt.nz OI Ogdie, Alexis/0000-0002-4639-0775; Perez-Ruiz, Fernando/0000-0002-5268-1894 FU AstraZeneca; Takeda; Pfizer; Ardea; Crealta; Novartis; Sobi; Savient; Regeneron; Merz; Bioiberica; Allergan; Horizon; Berlin Chemie Menarini; Ardea Bioscience; Relburn; Revive; Fonterra; Menarini; Metabolex; Cymabay; Teijin FX Dr. da Rocha Castelar Pinheiro has received consulting fees from AstraZeneca (less than $10,000). Dr. Harrold has received grants from AstraZeneca, Takeda, and Pfizer (less than $10,000 each). Dr. Kerr has received a grant from AstraZeneca (more than $10,000). Dr. D. Khanna has received consulting fees and/or grants from AstraZeneca and Takeda (less than $10,000 each). Dr. P. Khanna is the Principal Investigator on a study funded by AstraZeneca and on studies funded by Ardea and Crealta. Dr. Schlesinger has received grants and/or is on the advisory board for Takeda, AstraZeneca, Novartis, and Sobi (less than $10,000 each), and has received speaking fees from Novartis and Takeda (less than $10,000 each). Dr. Singh has received grants from Takeda (more than $10,000) and Savient (less than $10,000) and consulting fees from Savient, Takeda, Regeneron, Merz, Bioiberica, Crealta, and Allergan (less than $10,000 each), and is the Principal Investigator on a study funded by Horizon through a grant to DINORA (less than $10,000). Dr. Stamp has received speaking and/or consulting fees from AstraZeneca (less than $10,000). Dr. Tausche has received speaking fees and/or honoraria from Berlin Chemie Menarini, Novartis, Ardea Bioscience, AstraZeneca, and Savient (less than $10,000 each). Dr. Terkeltaub has received consulting fees from Ardea, AstraZeneca, Sobi, Takeda, Relburn, and Revive (less than $10,000 each). Dr. Uhlig has received honoraria from AstraZeneca, Novartis, and Sobi (less than $10,000 each). Dr. Dalbeth has received consulting fees, speaking fees, and/or grants from Ardea, AstraZeneca, Fonterra, Menarini, Metabolex, Pfizer, Savient, Cymabay, Takeda, and Teijin (less than $10,000 each). NR 18 TC 5 Z9 5 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAY PY 2016 VL 68 IS 5 BP 667 EP 672 DI 10.1002/acr.22741 PG 6 WC Rheumatology SC Rheumatology GA DQ9UC UT WOS:000379553800013 PM 26414176 ER PT J AU Curtius, K Wong, CJ Hazelton, WD Kaz, AM Chak, A Willis, JE Grady, WM Luebeck, EG AF Curtius, Kit Wong, Chao-Jen Hazelton, William D. Kaz, Andrew M. Chak, Amitabh Willis, Joseph E. Grady, William M. Luebeck, E. Georg TI A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID DNA METHYLATION; ULCERATIVE-COLITIS; CLONAL EXPANSION; CANCER; ADENOCARCINOMA; PROGRESSION; RISK; PREDICTORS; MUTATIONS; DYNAMICS AB Biomarkers that drift differentially with age between normal and premalignant tissues, such as Barrett's esophagus (BE), have the potential to improve the assessment of a patient's cancer risk by providing quantitative information about how long a patient has lived with the precursor (i.e., dwell time). In the case of BE, which is a metaplastic precursor to esophageal adenocarcinoma (EAC), such biomarkers would be particularly useful because EAC risk may change with BE dwell time and it is generally not known how long a patient has lived with BE when a patient is first diagnosed with this condition. In this study we first describe a statistical analysis of DNA methylation data (both cross-sectional and longitudinal) derived from tissue samples from 50 BE patients to identify and validate a set of 67 CpG dinucleotides in 51 CpG islands that undergo age-related methylomic drift. Next, we describe how this information can be used to estimate a patient's BE dwell time. We introduce a Bayesian model that incorporates longitudinal methylomic drift rates, patient age, and methylation data from individually paired BE and normal squamous tissue samples to estimate patient-specific BE onset times. Our application of the model to 30 sporadic BE patients' methylomic profiles first exposes a wide heterogeneity in patient-specific BE onset times. Furthermore, independent application of this method to a cohort of 22 familial BE (FBE) patients reveals significantly earlier mean BE onset times. Our analysis supports the conjecture that differential methylomic drift occurs in BE (relative to normal squamous tissue) and hence allows quantitative estimation of the time that a BE patient has lived with BE. C1 [Curtius, Kit; Kaz, Andrew M.; Grady, William M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA. [Curtius, Kit; Wong, Chao-Jen; Hazelton, William D.; Luebeck, E. Georg] Fred Hutchinson Canc Res Ctr, Program Computat Biol, 1124 Columbia St, Seattle, WA 98104 USA. [Kaz, Andrew M.; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA. [Chak, Amitabh; Willis, Joseph E.] Case Western Reserve Univ, Sch Med, Univ Hosp Case Med Ctr, Cleveland, OH USA. RP Curtius, K (reprint author), Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA.; Curtius, K (reprint author), Fred Hutchinson Canc Res Ctr, Program Computat Biol, 1124 Columbia St, Seattle, WA 98104 USA. EM kcurtius@medicine.washington.edu; gluebeck@fredhutch.org FU National Institutes of Health; National Cancer Institute [U01CA182940 (BG-U01), 5P30CA015704, 5U01CA152756, 5U54CA163060, NIH1P50CA150964-01A1] FX This research was supported by the National Institutes of Health (www.nih.gov) and the National Cancer Institute (www.cancer.gov) under grants U01CA182940 (BG-U01) (to EGL, CJW, WDH, WMG, and KC), 5P30CA015704 (to WMG and CJW), 5U01CA152756 (to WMG and CJW), 5U54CA163060 (to AC), and NIH1P50CA150964-01A1 (to JEW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 2 Z9 2 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD MAY PY 2016 VL 12 IS 5 AR e1004919 DI 10.1371/journal.pcbi.1004919 PG 20 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA DQ6XA UT WOS:000379348100025 PM 27168458 ER PT J AU Starker, LE Prieto, PA Liles, JS Cao, HST Grubbs, EG Lee, JE Perrier, ND Graham, PH AF Starker, Lee E. Prieto, Peter A. Liles, J. Spencer Cao, Hop S. Tran Grubbs, Elizabeth G. Lee, Jeffrey E. Perrier, Nancy D. Graham, Paul H. TI Endocrine incidentalomas SO CURRENT PROBLEMS IN SURGERY LA English DT Review ID FINE-NEEDLE-ASPIRATION; POSITRON-EMISSION-TOMOGRAPHY; PANCREATIC NEUROENDOCRINE TUMORS; 4TH INTERNATIONAL WORKSHOP; NEOPLASIA 1-RELATED HYPERPARATHYROIDISM; ROUTINE TRANSCERVICAL THYMECTOMY; REOPERATIVE PARATHYROID SURGERY; SUBCLINICAL CUSHINGS-SYNDROME; CLINICAL-PRACTICE GUIDELINES; NONPALPABLE THYROID-NODULES C1 [Starker, Lee E.; Prieto, Peter A.; Grubbs, Elizabeth G.; Perrier, Nancy D.; Graham, Paul H.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Liles, J. Spencer] Univ S Alabama, Mobile, AL USA. [Cao, Hop S. Tran] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Lee, Jeffrey E.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,Unit 1484, Houston, TX 77030 USA. RP Graham, PH (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,Unit 1484, Houston, TX 77030 USA. EM phgraham@mdanderson.org NR 147 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0011-3840 EI 1535-6337 J9 CURR PROB SURG JI Curr. Probl. Surg. PD MAY PY 2016 VL 53 IS 5 BP 219 EP 246 DI 10.1067/j.cpsurg.2016.04.001 PG 28 WC Surgery SC Surgery GA DQ1TD UT WOS:000378982400002 PM 27325542 ER PT J AU Pelluru, D Konadhode, RR Bhat, NR Shiromani, PJ AF Pelluru, Dheeraj Konadhode, Roda Rani Bhat, Narayan R. Shiromani, Priyattam J. TI Optogenetic stimulation of astrocytes in the posterior hypothalamus increases sleep at night in C57BL/6J mice SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE channelrhodopsin-2; melanin concentrating hormone; orexin; recombinant adenoassociated virus; REM sleep ID IN-VIVO; NEURAL ACTIVITY; VISUAL-CORTEX; MCH NEURONS; HOMEOSTASIS; ACTIVATION; RECEPTORS; ADENOSINE; SYNAPSES; MODULATION AB A distributed network of neurons regulates wake, non-rapid eye movement (NREM) sleep, and REM sleep. However, there are also glia in the brain, and there is growing evidence that neurons and astroglia communicate intimately to regulate behaviour. To identify the effect of optogenetic stimulation of astrocytes on sleep, the promoter for the astrocyte-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP) was used to direct the expression of channelrhodopsin-2 (ChR2) and the linked reporter gene, enhanced yellow fluorescent protein (EYFP), in astrocytes. rAAV-GFAP-ChR2 (H134R)-EYFP or rAAV-GFAP-EYFP was microinjected (750 nL) into the posterior hypothalamus (bilateral) of mice. Three weeks later baseline sleep was recorded (0 Hz) and 24 h later optogenetic stimulation applied during the first 6 h of the lights-off period. Mice with ChR2 were given 5, 10 or 30 Hz stimulation for 6 h (10-ms pulses; 1 mW; 1 min on 4 min off). At least 36 h elapsed between the stimulation periods (5, 10, 30 Hz) and although 0 Hz was always first, the order of the other three stimulation rates was randomised. In mice with ChR2 (n = 7), 10 Hz, but not 5 or 30 Hz stimulation increased both NREM and REM sleep during the 6-h period of stimulation. Delta power did not increase. In control mice (no ChR2; n = 5), 10 Hz stimulation had no effect. This study demonstrates that direct stimulation of astrocytes powerfully induces sleep during the active phase of the sleep-wake cycle and underlines the inclusion of astrocytes in network models of sleep-wake regulation. C1 [Pelluru, Dheeraj; Konadhode, Roda Rani; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Bhat, Narayan R.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Shiromani, PJ (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. EM shiroman@musc.edu FU Medical Research Service of the Department of Veterans Affairs; NIH [NS084477, NS079940, NS052287] FX We thank Drs Kumar Sambamurti, Carlos Blanco-Centurion and Meng Liu for helpful comments during the writing of the manuscript. We thank Dr Amanda LaRue for use of the confocal microscope. This study was supported by The Medical Research Service of the Department of Veterans Affairs and NIH grants NS084477, NS079940 and NS052287. NR 47 TC 2 Z9 2 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X EI 1460-9568 J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD MAY PY 2016 VL 43 IS 10 BP 1298 EP 1306 DI 10.1111/ejn.13074 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DP5UB UT WOS:000378562100008 PM 26369866 ER PT J AU Saxon, DR McDermott, MT Michels, AW AF Saxon, David R. McDermott, Michael T. Michels, Aaron W. TI Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID RESISTANCE; ANTIBODIES AB Context: Insulin autoimmune syndrome (IAS), or Hirata's disease, is a rare hypoglycemic disorder characterized by spontaneous hypoglycemia without evidence of exogenous insulin administration, a high serum concentration of total immunoreactive insulin, and the presence of insulin autoantibodies in high titer. The majority of cases occur in the Asian population, and treatment is generally successful with watchful waiting or steroids. Case Description: We report the case of a 71-year-old Caucasian man with severe hypoglycemia due to IAS that was refractory to a prolonged course of high-dose steroids. Type 1 diabetes prevention trials using rituximab have shown selective suppression of insulin autoantibodies, which are the pathogenic antibodies in IAS, and therefore we provided this therapy. Treatment with two doses of rituximab and daily use of a continuous glucose monitor resulted in disease remission. Conclusion: We present the first case where potentially life-threatening hypoglycemia due to IAS was successfully managed with rituximab and a continuous glucose monitor. We conclude that these treatment modalities are effective for the management of severe, refractory IAS. C1 [Saxon, David R.; McDermott, Michael T.] Univ Colorado, Div Endocrinol Metab & Diabet, Anschutz Med Campus, Aurora, CO 80045 USA. [Saxon, David R.] Denver Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA. [Michels, Aaron W.] Barbara Davis Ctr Childhood Diabet, Anschutz Med Campus, Aurora, CO 80045 USA. RP Saxon, DR (reprint author), Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, 12801 East 17th Ave,Mail Stop 8106, Aurora, CO 80045 USA. EM david.saxon@ucdenver.edu OI Michels, Aaron/0000-0003-3766-5244 NR 13 TC 3 Z9 3 U1 0 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 1931 EP 1934 DI 10.1210/jc.2016-1097 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700005 PM 26982011 ER PT J AU Tripathy, D Schwenke, DC Banerji, M Bray, GA Buchanan, TA Clement, SC Henry, RR Kitabchi, AE Mudaliar, S Ratner, RE Stentz, FB Musi, N Reaven, PD DeFronzo, RA AF Tripathy, Devjit Schwenke, Dawn C. Banerji, MaryAnn Bray, George A. Buchanan, Thomas A. Clement, Stephen C. Henry, Robert R. Kitabchi, Abbas E. Mudaliar, Sunder Ratner, Robert E. Stentz, Frankie B. Musi, Nicolas Reaven, Peter D. DeFronzo, Ralph A. TI Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PREVENTION PROGRAM OUTCOMES; LIFE-STYLE INTERVENTION; CONTROLLED-TRIAL; NATIONAL-HEALTH; MELLITUS; RISK; ROSIGLITAZONE; COMPLICATIONS; TROGLITAZONE; PREVALENCE AB Context: Thiazolidinediones have proven efficacy in preventing diabetes in high-risk individuals. However, the effect of thiazolidinediones on glucose tolerance after cessation of therapy is unclear. Objective: To examine the effect of pioglitazone (PIO) on incidence of diabetes after discontinuing therapy in ACT NOW. Design, Settings and Patients: Two-hundred ninety-three subjects (placebo [PLAC], n = 138; PIO, n = 152) completed a median followup of 11.7 mo after study medication was stopped. Results: Diabetes developed in 138 (12.3%) of PLAC vs 17 of 152 PIO patients (11.2%; P = not significant, PIO vs PLAC). However, the cumulative incidence of diabetes from start of study medication to end of washout period remained significantly lower in PIO vs PLAC (10.7 vs 22.3%; P < .005). After therapy was discontinued, 23.0% (35/152) of P10-treated patients remained normal glucose tolerant (NGT) vs 13.8% (19/138) of PLAC-treated patients (P = .04). Insulin secretion/insulin resistance index (I0-120/G(0-120) X Matsuda index) was markedly lower in subjects with impaired glucose tolerance (IGT) who converted to diabetes during followup vs those who remained IGT or NGT. The decline in-cell function (insulin secretion/insulin resistance index) was similar in subjects with IGT who developed diabetes, irrespective of whether they were treated with PIO or PLAC. Conclusions: 1) The protective effect of PIO on incidence of diabetes attenuates after discontinuation of therapy, 2) cumulative incidence of diabetes in individuals exposed to PIO remained significantly (56%) lower than PLAC and a greater number of P10-treated individuals maintained NGT after median followup of 11.4 mo, and 3) low insulin secretion/insulin resistance index is a strong predictor of future diabetes following PIO discontinuation. C1 [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] South Texas Vet Hlth Care Syst, Texas Diabet Inst, San Antonio, TX 78229 USA. [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Schwenke, Dawn C.; Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ 85012 USA. [Schwenke, Dawn C.] Arizona State Univ, Coll Nursing & Hlth Innovat, Tempe, AZ 85281 USA. [Banerji, MaryAnn] SUNY Hlth Sci Ctr Brooklyn, Brooklyn, NY 11203 USA. [Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA. [Buchanan, Thomas A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Clement, Stephen C.] Inova Fairfax Hosp, Falls Church, VA 22042 USA. [Henry, Robert R.; Mudaliar, Sunder] VA San Diego Healthcare Syst, San Diego, CA 92093 USA. [Henry, Robert R.; Mudaliar, Sunder] Univ Calif San Diego, San Diego, CA 92093 USA. [Kitabchi, Abbas E.; Stentz, Frankie B.] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN USA. [Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD 20782 USA. RP DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Med, 7703 Floyd Curl Dr,MSC7886, San Antonio, TX 78229 USA.; DeFronzo, RA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, 7703 Floyd Curl Dr,MSC7886, San Antonio, TX 78229 USA. EM albarado@uthscsa.edu FU GCRC at the University of Tennessee Health Science Center [MO1-RR00221]; Clinical and Translational Science Award [UL1TR000130]; South Texas Veterans Health Care System-Audie Murphy Division; Takeda Pharmaceuticals North America; South Texas Veterans Health Care System FX This work was supported in part by GCRC Grant MO1-RR00221 at the University of Tennessee Health Science Center, Clinical and Translational Science Award Grant UL1TR000130 to the University of Southern California, and the South Texas Veterans Health Care System-Audie Murphy Division. The study was supported by an investigator-initiated and unrestricted research grant from Takeda Pharmaceuticals North America. Takeda Pharmaceuticals played no role in the study design, data collection/analysis, or manuscript preparation/review. The salaries of D.T. and R.A.D. are in part supported by the South Texas Veterans Health Care System. NR 27 TC 4 Z9 4 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 2056 EP 2062 DI 10.1210/jc.2015-4202 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700020 PM 26982008 ER PT J AU Nielson, CM Jones, KS Chun, RF Jacobs, JM Wang, Y Hewison, M Adams, JS Swanson, CM Lee, CG Vanderschueren, D Pauwels, S Prentice, A Smith, RD Shi, TJ Gao, YQ Schepmoes, AA Zmuda, JM Lapidus, J Cauley, JA Bouillon, R Schoenmakers, I Orwoll, ES AF Nielson, Carrie M. Jones, Kerry S. Chun, Rene F. Jacobs, Jon M. Wang, Ying Hewison, Martin Adams, John S. Swanson, Christine M. Lee, Christine G. Vanderschueren, Dirk Pauwels, Steven Prentice, Ann Smith, Richard D. Shi, Tujin Gao, Yuqian Schepmoes, Athena A. Zmuda, Joseph M. Lapidus, Jodi Cauley, Jane A. Bouillon, Roger Schoenmakers, Inez Orwoll, Eric S. CA Osteoporotic Fractures Men MrOS TI Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BONE-MINERAL DENSITY; CLINICAL POPULATIONS; GENETIC-VARIANTS; D DEFICIENCY; HUMAN-SERUM; AFFINITY; METABOLITES; STATEMENT; AMERICANS; CALCIUM AB Context: Total 25-hydroxyvitamin D (25OHD) is a marker of vitamin D status and is lower in African Americans than in whites. Whether this difference holds for free 25OHOD (f25OHD) is unclear, considering reported genetic-racial differences in vitamin D binding protein (DBP) used to calculate f25OHD. Objectives: Our objective was to assess racial-geographic differences in f25OHD and to understand inconsistencies in racial associations with DBP and calculated f25OHD. Design: This study used a cross-sectional design. Setting: The general community in the United States, United Kingdom, and The Gambia were included in this study. Participants: Men in Osteoporotic Fractures in Men and Medical Research Council studies (N = 1057) were included. Exposures: Total 25OHD concentration, race, and DBP (GC) genotype exposures were included. Outcome Measures: Directly measured f25OHD, DBP assessed by proteomics, monoclonal and polyclonal immunoassays, and calculated f25OHD were the outcome measures. Results: Total 25OHD correlated strongly with directly measured f25OHD (Spearman r = 0.84). Measured by monoclonal assay, mean DBP in African-ancestry subjects was approximately 50% lower than in whites, whereas DBP measured by polyclonal DBP antibodies or proteomic methods was not lower in African-ancestry. Calculated f25OHD (using polyclonal DBP assays) correlated strongly with directly measured f25OHD (r = 0.80-0.83). Free 25OHD, measured or calculated from polyclonal DBP assays, reflected total 25OHD concentration irrespective of race and was lower in African Americans than in US whites. Conclusions: Previously reported racial differences in DBP concentration are likely from monoclonal assay bias, as there was no racial difference in DBP concentration by other methods. This confirms the poor vitamin D status of many African-Americans and the utility of total 25OHD in assessing vitamin D in the general population. C1 [Nielson, Carrie M.; Wang, Ying; Swanson, Christine M.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97239 USA. [Nielson, Carrie M.; Lapidus, Jodi] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97239 USA. [Jones, Kerry S.; Prentice, Ann; Schoenmakers, Inez] MRC, Human Nutr Res, Cambridge CB1 9NL, England. [Chun, Rene F.] Univ Calif Los Angeles, Dept Orthoped, Los Angeles, CA 90095 USA. [Jacobs, Jon M.; Smith, Richard D.; Shi, Tujin; Gao, Yuqian; Schepmoes, Athena A.] Pacific NW Natl Lab, Richland, WA 99354 USA. [Hewison, Martin] Univ Birmingham, Inst Metab & Syst Res, Birmingham B15 2TT, W Midlands, England. [Adams, John S.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Swanson, Christine M.; Lee, Christine G.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. [Lee, Christine G.] Portland VA Med Ctr, Portland, OR 97239 USA. [Vanderschueren, Dirk] Katholieke Univ Leuven, Lab Diagnost Med, B-3000 Leuven, Belgium. [Vanderschueren, Dirk; Bouillon, Roger] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, B-3000 Leuven, Belgium. [Pauwels, Steven] Katholieke Univ Leuven, Dept Cardiovasc Sci, B-3000 Leuven, Belgium. [Pauwels, Steven] Univ Hosp Leuven, Dept Lab Med, B-3000 Leuven, Belgium. [Prentice, Ann] MRC Keneba, Keneba, Gambia. [Zmuda, Joseph M.; Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Bouillon, R (reprint author), Katholieke Univ Leuven, Clin & Expt Endocrinol, O&NI Herestr 49,Box 902, B-3000 Leuven, Belgium. EM roger.bouillon@med.kuleuven.be RI Smith, Richard/J-3664-2012; Chun, Rene/A-9415-2010 OI Smith, Richard/0000-0002-2381-2349; Chun, Rene/0000-0002-0190-0807; Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health (NIH); National Institute on Aging; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences; NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; Medical Research Council [U105960371, U123261351, MC-A760-5QX00]; Department for International Development (DFID) under the MRC/DFID Concordat; Department of Energy [DE-AC05-76RL0 1830]; NIH [P41GM103493] FX The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health (NIH) funding. The following institutes provide support: the National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences, and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The research in the United Kingdom and The Gambia were funded by the Medical Research Council (program codes U105960371, U123261351, MC-A760-5QX00) and the Department for International Development (DFID) under the MRC/DFID Concordat agreement. Additionally, portions of the experimental work described herein were performed in the Environmental Molecular Sciences Laboratory, a national scientific user facility sponsored by the Department of Energy and located at Pacific Northwest National Laboratory, which is operated by Battelle Memorial Institute for the Department of Energy under Contract DE-AC05-76RL0 1830. Portions of this work were supported by NIH P41GM103493 (to R.D.S.). Free 25OHD assay provided by DIAsource ImmunoAssays SA (Belgium) and Future Diagnostics Solutions BV (Netherlands), an ELISA based on DIAsource patented monoclonal antibodies. NR 40 TC 18 Z9 18 U1 3 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAY PY 2016 VL 101 IS 5 BP 2226 EP 2234 DI 10.1210/jc.2016-1104 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP9MG UT WOS:000378819700041 PM 27007693 ER PT J AU Gilmore, AK Davis, MT Grubaugh, A Resnick, H Birks, A Denier, C Muzzy, W Tuerk, P Acierno, R AF Gilmore, Amanda K. Davis, Margaret T. Grubaugh, Anouk Resnick, Heidi Birks, Anna Denier, Carol Muzzy, Wendy Tuerk, Peter Acierno, Ron TI "Do you expect me to receive PTSD care in a setting where most of the other patients remind me of the perpetrator?": Home-based telemedicine to address barriers to care unique to military sexual trauma and veterans affairs hospitals SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Posttraumatic stress disorder; Clinical trial; Female veterans; Military sexual trauma; Home-based telemedicine; Prolonged exposure ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; COMBAT-RELATED PTSD; PROLONGED EXPOSURE; WOMEN VETERANS; MENTAL-HEALTH; DSM-IV; PSYCHOTHERAPY; THERAPY; ASSAULT AB Home-based telemedicine (HBT) is a validated method of evidence-based treatment delivery for posttraumatic stress disorder (PTSD), and justification for its use has centered on closing gaps related to provider availability and distance to treatment centers. However, another potential use of HBT may be to overcome barriers to care that are inherent to the treatment environment, such as with female veterans who have experienced military sexual trauma (MST) and who must present to VA Medical Centers where the majority of patients share features with perpetrator (e.g. gender, clothing) and may function as reminders of the trauma. Delivering evidence-based therapies to female veterans with MST-related PTSD via HBT can provide needed treatment to this population. This manuscript describes an ongoing federally funded randomized controlled trial comparing Prolonged Exposure (PE) delivered in-person to PE delivered via HBT. Outcomes include session attendance, satisfaction with services, and clinical and quality of life indices. It is hypothesized that based on intent-to-treat analyses, HBT delivery of PE will be more effective than SD at improving both clinical and quality of life outcomes at post, 3-, and 6-month follow-up. This is because 'dose received', that is fewer sessions missed, and lower attrition, will be observed in the HBT group. Although the current manuscript focuses on female veterans with MST-related PTSD, implications for other populations facing systemic barriers are discussed. (C) 2016 Elsevier Inc. All rights reserved. C1 [Gilmore, Amanda K.; Resnick, Heidi; Birks, Anna] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Davis, Margaret T.] Auburn Univ, Dept Psychol, Auburn, AL 36849 USA. [Grubaugh, Anouk; Birks, Anna; Denier, Carol; Tuerk, Peter; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, IL USA. [Muzzy, Wendy; Acierno, Ron] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Davis, Margaret T.] Univ Michigan, Dept Psychiat, VA Ann Arbor Hlth Care Syst, Ann Arbor, MI 48109 USA. RP Gilmore, AK (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC 861 2nd Floor,IOP South Bldg, Charleston, SC 29425 USA. FU Department of Defense [W81XWH-14-1-0264]; National Institute of Mental Health [T32 MH18869] FX Data collection and manuscript preparation was supported by grants from the Department of Defense (W81XWH-14-1-0264; PI: Acierno) and from the National Institute of Mental Health (T32 MH18869, PIs: Kilpatrick & Danielson). NR 46 TC 2 Z9 2 U1 3 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAY PY 2016 VL 48 BP 59 EP 64 DI 10.1016/j.cct.2016.03.004 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA DP4IF UT WOS:000378458900008 PM 26992740 ER PT J AU Brody, AA Guan, C Cortes, T Galvin, JE AF Brody, Abraham A. Guan, Carrie Cortes, Tara Galvin, James E. TI Development and testing of the Dementia Symptom Management at Home (DSM-H) program: An interprofessional home health care intervention to improve the quality of life for persons with dementia and their caregivers SO GERIATRIC NURSING LA English DT Article DE Interprofessional; Dementia; Home health care; Alzheimer's disease; Interdisciplinary; Geriatrics; Implementation science ID RANDOMIZED CONTROLLED-TRIAL; IMPLEMENTATION; OUTCOMES; DISSEMINATION; COMMUNICATION; DEPRESSION; KNOWLEDGE; EDUCATION; BELIEFS; NURSES AB Home health care agencies are increasingly taking care of sicker, older patients with greater comorbidities. However, they are unequipped to appropriately manage these older adults, particular persons living with dementia (PLWD). We therefore developed the Dementia Symptom Management at Home (DSM-H) Program, a bundled interprofessional intervention, to improve the care confidence of providers, and quality of care delivered to PLWD and their caregivers. We implemented the DSM-H with 83 registered nurses, physical therapists, and occupational therapists. Overall, there was significant improvement in pain knowledge (5.9%) and confidence (26.5%), depression knowledge (14.8%) and confidence (36.1%), and neuropsychiatric symptom general knowledge (16.8%), intervention knowledge (20.9%), attitudes (3.4%) and confidence (27.1%) at a statistical significance of (P < .0001). We also found significant differences between disciplines. Overall, this disseminable program proved to be implementable and improve clinician's knowledge and confidence in caring for PLWD, with the potential to improve quality of care and quality of life, and decrease costs. Published by Elsevier Inc. C1 [Brody, Abraham A.; Guan, Carrie; Cortes, Tara] NYU, Coll Nursing, Hartford Inst Geriatr Nursing, 433 First Ave,Room 504, New York, NY 10010 USA. [Brody, Abraham A.] James J Peters Bronx VA, GRECC, Bronx, NY USA. [Galvin, James E.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA. [Galvin, James E.] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL 33431 USA. RP Brody, AA (reprint author), NYU, Coll Nursing, Hartford Inst Geriatr Nursing, 433 First Ave,Room 504, New York, NY 10010 USA. EM Ab.Brody@nyu.edu OI Brody, Abraham/0000-0002-3405-7043 FU National Palliative Care Research Center FX The authors would like to thank the National Palliative Care Research Center for its generous funding of this study. NR 47 TC 0 Z9 0 U1 7 U2 19 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4572 EI 1528-3984 J9 GERIATR NURS JI Geriatr. Nurs. PD MAY-JUN PY 2016 VL 37 IS 3 BP 200 EP 206 DI 10.1016/j.gerinurse.2016.01.002 PG 7 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA DP3BC UT WOS:000378366400006 PM 26922312 ER PT J AU de Peralta, S Valente, S Emanuele, D AF de Peralta, Shelly Valente, Sharon Emanuele, Donna TI Measuring a veteran's quality of healthcare managed by a nurse practitioner in a VA facility using professional practice evaluation and core performance measures SO JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS LA English DT Article DE Nurse practitioner; quality of care; practice evaluation; performance measures; HEDIS performance measures; veterans' health care AB Purpose: Quality of care provided by nurse practitioners (NPs) has been measured for the last 40 years; however, no known program measuring quality of care in an NP practice on an ongoing basis was found in the published literature. The purpose of this article is to describe the implementation of an ongoing professional practice evaluation (OPPE) program at a Veterans Health Administration facility. Data sources: An evidence-based review was conducted to assess, evaluate, and report findings from outcomes research, systematic reviews, and meta-analyses, and interventions regarding standards and oversight of NP practice in the following databases: PubMed, Google (R), Cumulative Index of Nursing and Allied Health, Agency for Healthcare Research and Quality, Institute of Medicine, and ".gov" websites. Conclusions: NPs have established a reputation in the delivery of efficient, accessible, effective, and high-quality care. Researchers suggest episodic measurement of care. For NPs, an OPPE program provides oversight of quality of care, surveillance, education, and feedback while evaluating and validating an NP's quality of care on an ongoing basis. Implications for practice: The OPPE program provides a prototype for measuring and improving NP practice nationally. In providing validation and transparency, it reassures administrators and the public that NP practice meets strenuous national standards. C1 [de Peralta, Shelly] Greater Los Angeles Healthcare Syst, Adv Practice Registered Nurse Review Board, Vet Affairs, 11301 Wilshire Blvd, Los Alamos, CA 90073 USA. [Valente, Sharon] VA Greater Los Angeles Healthcare Syst, Res Educ, Los Alamos, NM USA. [Emanuele, Donna] Western Univ Hlth Sci, Coll Grad Nursing, Pomona, CA USA. RP de Peralta, S (reprint author), Greater Los Angeles Healthcare Syst, Adv Practice Registered Nurse Review Board, Vet Affairs, 11301 Wilshire Blvd, Los Alamos, CA 90073 USA. EM Shelly.deperalta@va.gov NR 18 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2327-6886 EI 2327-6924 J9 J AM ASSOC NURSE PRA JI J. Am. Assoc. Nurs. Pract. PD MAY PY 2016 VL 28 IS 5 BP 258 EP 268 DI 10.1002/2327-6924.12269 PG 11 WC Health Care Sciences & Services; Nursing SC Health Care Sciences & Services; Nursing GA DP2XQ UT WOS:000378357200005 PM 26042574 ER PT J AU Rosset, EM Bradshaw, AD AF Rosset, Emilie M. Bradshaw, Amy D. TI SPARC/osteonectin in mineralized tissue SO MATRIX BIOLOGY LA English DT Review DE Collagen; Mineral; Osteoblast; OSteoclast; Matricellular ID RECESSIVE OSTEOGENESIS IMPERFECTA; BINDING PROTEIN SPARC; EXTRACELLULAR-MATRIX; CROSS-LINKING; PLATELET OSTEONECTIN; BONE-FORMATION; MESSENGER-RNA; COLLAGEN; MICE; OSTEOBLASTS AB Secreted protein acidic and rich in cysteine (SPARC/osteonectin/BM40) is one of the most abundant non-collagenous protein expressed in mineralized tissues. This review will focus on elucidating functional roles of SPARC in bone formation building upon results from non-mineralized cells and tissues, the phenotype of SPARC-null bones, and recent discoveries of human diseases with either dysregulated expression of SPARC or mutations in the gene encoding SPARC that give rise to bone pathologies. The capacity of SPARC to influence pathways involved in extracellular matrix assembly such as procollagen processing and collagen fibril formation as well as the capacity to influence osteoblast differentiation and osteoclast activity will be addressed. In addition, the potential for SPARC to regulate cross-linking of extracellular matrix proteins by members of the transglutaminase family of enzymes is explored. Elucidating defined biological functions of SPARC in terms of bone formation and turnover are critical. Further insight into specific cellular mechanisms involved in the formation and homeostasis of mineralized tissues will lead to a better understanding of disease progression. (C) 2016 Elsevier B.V. All rights reserved. C1 [Rosset, Emilie M.; Bradshaw, Amy D.] Med Univ S Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Bradshaw, Amy D.] VA Med Ctr, Ralph H Johnson Vet Adm, Charleston, SC USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA.; Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.; Bradshaw, AD (reprint author), VA Med Ctr, Ralph H Johnson Vet Adm, Charleston, SC USA. FU NIH [T32DE017551]; VA merit award [BX001385] FX This work was supported by NIH T32DE017551 to EM and a VA merit award BX001385 to ADB. NR 54 TC 2 Z9 2 U1 3 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X EI 1569-1802 J9 MATRIX BIOL JI Matrix Biol. PD MAY-JUL PY 2016 VL 52-54 SI SI BP 78 EP 87 DI 10.1016/j.matbio.2016.02.001 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DP0PC UT WOS:000378190700007 PM 26851678 ER PT J AU Marinkovic, M Block, TJ Rakian, R Li, QH Wang, E Reilly, MA Dean, DD Chen, XD AF Marinkovic, Milos Block, Travis J. Rakian, Rubie Li, Qihong Wang, Exing Reilly, Matthew A. Dean, David D. Chen, Xiao-Dong TI One size does not fit all: developing a cell-specific niche for in vitro study of cell behavior SO MATRIX BIOLOGY LA English DT Article DE Cell culture; Extracellular matrix; Cell microenvironment; Niche; Mesenchymal stem cells (MSCs); Differentiation ID MESENCHYMAL STEM-CELLS; LEUCINE-RICH PROTEOGLYCANS; MARROW STROMAL CELLS; EXTRACELLULAR-MATRIX; BONE-MARROW; SURFACE-ENERGY; COLLAGEN-VI; EX-VIVO; DIFFERENTIATION; DECORIN AB For more than 100 years, cells and tissues have been studied in vitro using glass and plastic surfaces. Over the last 10-20 years, a great body of research has shown that cells are acutely sensitive to their local environment (extracellular matrix, ECM) which contains both chemical and physical cues that influence cell behavior. These observations suggest that modern cell culture systems, using tissue culture polystyrene (TCP) surfaces, may fail to reproduce authentic cell behavior in vitro, resulting in "artificial outcomes." In the current study, we use bone marrow (BM)- and adipose (AD)-derived stromal cells to prepare BM-ECM and AD-ECM, which are decellularized after synthesis by the cells, to mimic the cellular niche for each of these tissues. Each ECM was characterized for its ability to affect BM- and AD-mesenchymal stem cell (MSC) proliferation, as well as proliferation of three cancer cell lines (HeLa, MCF-7, and MDA-MB-231), modulate cell spreading, and direct differentiation relative to standard TCP surfaces. We found that both ECMs promoted the proliferation of MSCs, but that this effect was enhanced when the tissue-origin of the cells matched that of the ECM (i.e. BM-ECM promoted the proliferation of BM-MSCs over AD-MSCs, and vice versa). Moreover, BM- and AD-ECM were shown to preferentially direct MSC differentiation towards either osteogenic or adipogenic lineage, respectively, suggesting that the effects of the ECM were tissue-specific. Further, each ECM influenced cell morphology (i.e. circularity), irrespective of the origin of the MSCs, lending more support to the idea that effects were tissue specific. Interestingly, unlike MSCs, these ECMs did not promote the proliferation of the cancer cells. In an effort to further understand how these three culture substrates influence cell behavior, we evaluated the chemical (protein composition) and physical properties (architecture and mechanical) of the two ECMs. While many structural proteins (e.g. collagen and fibronectin) were found at equivalent levels in both BM- and AD-ECM, the architecture (i.e. fiber orientation; surface roughness) and physical properties (storage modulus, surface energy) of each were unique. These results, demonstrating differences in cell behavior when cultured on the three different substrates (BM- and AD-ECM and TCP) with differences in chemical and physical properties, provide evidence that the two ECMs may recapitulate specific elements of the native stem cell niche for bone marrow and adipose tissues. More broadly, it could be argued that ECMs, elaborated by cells ex vivo, serve as an ideal starting point for developing tissue-specific culture environments. In contrast to TCP, which relies on the "one size fits all" paradigm, native tissue-specific ECM may be a more rational model to approach engineering 3D tissue-specific culture systems to replicate the in vivo niche. We suggest that this approach will provide more meaningful information for basic research studies of cell behavior as well as cell-based therapeutics. Published by Elsevier B.V. C1 [Marinkovic, Milos; Block, Travis J.; Rakian, Rubie; Dean, David D.; Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Marinkovic, Milos; Block, Travis J.; Reilly, Matthew A.; Dean, David D.; Chen, Xiao-Dong] Univ Texas San Antonio, Dept Biomed Engn, San Antonio, TX USA. [Li, Qihong] Acad Mil Med Sci, Affiliated Hosp, Dept Stomatol, Beijing, Peoples R China. [Wang, Exing] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Chen, Xiao-Dong] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. RP Chen, XD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM chenx4@uthscsa.edu OI Reilly, Matthew/0000-0001-8029-0084; Dean, David/0000-0002-4512-9065 FU VA Merit Review [1I01BX002145-01]; NIH shared instrumentation grant [1 S10 RR021160-01] FX This study was supported by a VA Merit Review (1I01BX002145-01) to X-D Chen. We gratefully acknowledge Dr. Rong Li, Department of Molecular Medicine, University of Texas Health Science Center at San Antonio (UTHSCSA), for the kind gift of the HeLa, MCF7 and MDA-MB-231 cancer cell lines and guidance on their maintenance in culture. Mass spectrometry analyses were conducted in the UTHSCSA Institutional Mass Spectrometry Laboratory; the expert technical assistance of Kevin Hakala, M.S. is gratefully acknowledged. This work was supported in part by an NIH shared instrumentation grant (1 S10 RR021160-01) to Dr. Susan T. Weintraub, Director of the Mass Spectrometry Core Laboratory. NR 76 TC 5 Z9 5 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0945-053X EI 1569-1802 J9 MATRIX BIOL JI Matrix Biol. PD MAY-JUL PY 2016 VL 52-54 SI SI BP 426 EP 441 DI 10.1016/j.matbio.2016.01.004 PG 16 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA DP0PC UT WOS:000378190700034 PM 26780725 ER PT J AU Funk, LM Jolles, SA Greenberg, CC Schwarze, ML Safdar, N McVay, MA Whittle, JC Maciejewski, ML Voils, CI AF Funk, Luke M. Jolles, Sally A. Greenberg, Caprice C. Schwarze, Margaret L. Safdar, Nasia McVay, Megan A. Whittle, Jeffrey C. Maciejewski, Matthew L. Voils, Corrine I. TI Primary care physician decision making regarding severe obesity treatment and bariatric surgery: a qualitative study SO SURGERY FOR OBESITY AND RELATED DISEASES LA English DT Article DE Primary care physicians; Obesity treatment attitudes; Bariatric surgery ID Y GASTRIC BYPASS; MEDICAL THERAPY; OUTCOMES; TRENDS AB Background: Less than 1% of severely obese US adults undergo bariatric surgery annually. It is critical to understand the factors that contribute to its utilization. Objectives: To understand how primary care physicians (PCPs) make decisions regarding severe obesity treatment and bariatric surgery referral. Setting: Focus groups with PCPs practicing in small, medium, and large cities in Wisconsin. Methods: PCPs were asked to discuss prioritization of treatment for a severely obese patient with multiple co-morbidities and considerations regarding bariatric surgery referral. Focus group sessions were analyzed by using a directed approach to content analysis. A taxonomy of consensus codes was developed. Code summaries were created and representative quotes identified. Results: Sixteen PCPs participated in 3 focus groups. Four treatment prioritization approaches were identified: (1) treat the disease that is easiest to address; (2) treat the disease that is perceived as the most dangerous; (3) let the patient set the agenda; and (4) address obesity first because it is the common denominator underlying other co-morbid conditions. Only the latter approach placed emphasis on obesity treatment. Five factors made PCPs hesitate to refer patients for bariatric surgery: (1) wanting to "do no harm"; (2) questioning the long-term effectiveness of bariatric surgery; (3) limited knowledge about bariatric surgery; (4) not wanting to recommend bariatric surgery too early; and (5) not knowing if insurance would cover bariatric surgery. Conclusion: Decision making by PCPs for severely obese patients seems to underprioritize obesity treatment and overestimate bariatric surgery risks. This could be addressed with PCP education and improvements in communication between PCPs and bariatric surgeons. (Surg Obes Relat Dis 2016;12:893-902.) (C) 2016 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved. C1 [Funk, Luke M.; Jolles, Sally A.; Greenberg, Caprice C.; Schwarze, Margaret L.] Univ Wisconsin, Dept Surg, Wisconsin Surg Outcomes Res Program WiSOR, Madison, WI USA. [Funk, Luke M.; Jolles, Sally A.; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI USA. [McVay, Megan A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [McVay, Megan A.; Maciejewski, Matthew L.; Voils, Corrine I.] Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA. [Whittle, Jeffrey C.] Clement J Zablocki VA Med Ctr, Milwaukee, WI USA. [Maciejewski, Matthew L.; Voils, Corrine I.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Funk, LM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Surg, 600 Highland Ave H4-728 Clin Sci Ctr, Madison, WI 53792 USA. EM funk@surgery.wisc.edu FU ASMBS Research Grant; Clinical and Translational Science Award (CTSA) program through the National Institutes of Health National Center for Advancing Translational Sciences [UL1 TR000427] FX The research described in this manuscript was supported by a 2014 ASMBS Research Grant to Dr. Funk. This work was also supported by grant UL1 TR000427 from the Clinical and Translational Science Award (CTSA) program through the National Institutes of Health National Center for Advancing Translational Sciences and by resources from the Department of Veterans Affairs (DVA). The design and conduct of the study, data collection, management, analysis, approval of the manuscript, and decision to submit were made solely by the research team. NR 27 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1550-7289 EI 1878-7533 J9 SURG OBES RELAT DIS JI Surg. Obes. Relat. Dis. PD MAY PY 2016 VL 12 IS 4 BP 893 EP 901 DI 10.1016/j.soard.2015.11.028 PG 9 WC Surgery SC Surgery GA DP3AO UT WOS:000378365000029 PM 26948943 ER PT J AU Sevick, MA Piraino, BM St-Jules, DE Hough, LJ Hanlon, JT Marcum, ZA Zickmund, SL Snetselaar, LG Steenkiste, AR Stone, RA AF Sevick, Mary Ann Piraino, Beth M. St-Jules, David E. Hough, Linda J. Hanlon, Joseph T. Marcum, Zachary A. Zickmund, Susan L. Snetselaar, Linda G. Steenkiste, Ann R. Stone, Roslyn A. TI No Difference in Average Interdialytic Weight Gain Observed in a Randomized Trial With a Technology-Supported Behavioral Intervention to Reduce Dietary Sodium Intake in Adults Undergoing Maintenance Hemodialysis in the United States: Primary Outcomes of the BalanceWise Study SO JOURNAL OF RENAL NUTRITION LA English DT Article ID BLOOD-PRESSURE CONTROL; STAGE RENAL-DISEASE; MORTALITY; PHOSPHORUS; MORBIDITY; ADHERENCE; DIALYSIS; TRENDS; FOODS AB Objective: To evaluate the efficacy of behavioral counseling combined with technology-based self-monitoring for sodium restriction in hemodialysis (HD) patients. Design: Randomized clinical trial. Subjects: English literate adults undergoing outpatient, in-center intermittent HD for at least 3 months. Interventions: Over a 16-week period, both the intervention and the attention control groups were shown 6 educational modules on the HD diet. The intervention group also received social cognitive theory-based behavioral counseling and monitored their diets daily using handheld computers. Main Outcome Measures: Average daily interdialytic weight gain (IDWG(A)) was calculated for every week of HD treatment over the observation period by subtracting the post-dialysis weight at the previous treatment time (t-1) from the pre-dialysis weight at the current treatment time (t), dividing by the number of days between treatments. Three 24-hour dietary recalls were obtained at baseline, 8 weeks, and 16 weeks and evaluated using the Nutrient Data System for Research. Results: A total of 179 participants were randomized, and 160 (89.4%) completed final measurements. IDWGA did not differ significantly by treatment group at any time point considered (P > .79 for each). A significant differential change in dietary sodium intake observed at 8 weeks (-372 mg/day; P = .05) was not sustained at 16 weeks (-191 mg/day; P = .32). Conclusion: The BalanceWise Study intervention appeared to be feasible and acceptable to HD patients although IDWGA was unchanged and the desired behavioral changes observed at 8 weeks were not sustained. Unmeasured factors may have contributed to the mixed findings, and further research is needed to identify the appropriate patients for such interventions. (C) 2016 by the National Kidney Foundation, Inc. All rights reserved. C1 [Sevick, Mary Ann; St-Jules, David E.] NYU, Sch Med, Dept Populat Hlth, Ctr Healthful Behav Change, 227 E 30th St,6th Floor,Room 638, New York, NY 10016 USA. [Piraino, Beth M.; Hanlon, Joseph T.; Marcum, Zachary A.; Zickmund, Susan L.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Hough, Linda J.; Zickmund, Susan L.; Stone, Roslyn A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Snetselaar, Linda G.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA. [Steenkiste, Ann R.] Vet Res Fdn Pittsburgh, Pittsburgh, PA USA. [Stone, Roslyn A.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Sevick, MA (reprint author), NYU, Sch Med, Dept Populat Hlth, Ctr Healthful Behav Change, 227 E 30th St,6th Floor,Room 638, New York, NY 10016 USA. EM mary.sevick@nyumc.org FU National Institutes of Health (NIH) [NINR/R01-NR010135, NINR/NIDDk/NHLBI/NIA-K24-NR012226, NIA/R01-AG02717, NIA/P30-AG024827, NIA/K07-AG033174] FX The work of this article was supported by the following National Institutes of Health (NIH) grants: NINR/R01-NR010135, NINR/NIDDk/NHLBI/NIA-K24-NR012226, NIA/R01-AG02717, NIA/P30-AG024827 & NIA/K07-AG033174. The NIH played no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. NR 33 TC 2 Z9 2 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1051-2276 EI 1532-8503 J9 J RENAL NUTR JI J. Renal Nutr. PD MAY PY 2016 VL 26 IS 3 BP 149 EP 158 DI 10.1053/j.jrn.2015.11.006 PG 10 WC Nutrition & Dietetics; Urology & Nephrology SC Nutrition & Dietetics; Urology & Nephrology GA DO7SP UT WOS:000377983600006 PM 26868602 ER PT J AU Troxell, ML Gordon, NT Doggett, JS Ballard, M Vetto, JT Pommier, RF Naik, AM AF Troxell, Megan L. Gordon, Nicole T. Doggett, J. Stone Ballard, Morgan Vetto, John T. Pommier, Rodney F. Naik, Arpana M. TI Cystic Neutrophilic Granulomatous Mastitis Association With Gram-Positive Bacilli and Corynebacterium SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE Granulomatous mastitis; Gram-positive rods; Corynebacterium; IgG4; Cystic neutrophilic granulomatous mastitis ID BREAST ABSCESS; DISEASE; EXPERIENCE AB Objectives: To determine whether cystic neutrophilic granulomatous mastitis (CNGM) can be associated with Gram-positive bacilli and Corynebacterium Methods: We reviewed our experience with 35 granulomatous mastitis patients over a 10-year period, including histologic pattern, Gram stain and other microbiologic data, clinical presentation, treatment and outcome. Results: Biopsies from 19 patients demonstrated CNGM, while 16 patients had other patterns of granulomatous mastitis. Gram-positive organisms were seen within microcystic spaces in 16/19 CNGM, but 0/16 non-CNGM patients (P=.000). Culture or molecular studies demonstrated Corynebacterium species in three, all CNGM. Patients with CNGM were more likely to be younger, of Hispanic ethnicity, and born outside of the United States. Granulomatous mastitis resolved after a protracted course with widely variable treatment (antibiotics, surgery, steroids). Conclusions: Our data further support CNGM as an infectious disease; further study of Corynebacterium-directed therapy in CNGM is needed. C1 [Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Gordon, Nicole T.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA. [Vetto, John T.; Pommier, Rodney F.; Naik, Arpana M.] Oregon Hlth & Sci Univ, Dept Surg, Div Surg Oncol, Portland, OR 97201 USA. [Doggett, J. Stone] Portland VA Med Ctr, Div Infect Dis, Portland, OR USA. [Troxell, Megan L.; Ballard, Morgan] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA. RP Troxell, ML (reprint author), 3181 SW Sam Jackson Pk Rd,L471, Portland, OR 97239 USA. EM troxellm@ohsu.edu FU BLRD VA [IK2 BX002440] NR 29 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD MAY PY 2016 VL 145 IS 5 BP 635 EP 645 DI 10.1093/AJCP/AQW046 PG 11 WC Pathology SC Pathology GA DN7RQ UT WOS:000377275400007 PM 27247368 ER EF